Unnamed: 0,RowID,Outcome,Intervention,Comparator,Answer,Reasoning,XML
1,2425,venous ulcer healing,two-layer bandage,compression stocking,no significant difference,"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).",3298351
2,2425,venous ulcer healing,four-layer bandage,compression stocking,no significant difference,"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).",3298351
3,2425,venous ulcer healing,compression therapy,no treatment,significantly increased,We compared the dynamics of ulcer healing of patients treated with different types of compression therapy. The changes of ulceration area were statistically significant regardless of the type of compression therapy.,3298351
4,2425,venous ulcer healing,four-layer bandage,two-layer bandage,no significant difference,"What is more, no statistically significant advantage of any of the applied types of compression therapy was found (Table II).",3298351
5,2425,CEAP scores,four-layer bandage,two-layer bandage,no significant difference,"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).",3298351
6,2425,CEAP scores,four-layer bandage,compression stocking,no significant difference,"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).",3298351
7,2425,CEAP scores,two-layer bandage,compression stocking,no significant difference,"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).",3298351
8,2425,venous ulcer healing,ProGuide system,Profore compression,no significant difference,"In our own research, the comparison of two pre-prepared Profore and ProGuide compression systems as well as elastic compression, that is to say, compression stockings, did not show statistically significant differences.",3298351
9,2425,faster healing dynamics,layer compression,Compression stocking,significantly increased,"However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed.",3298351
10,2425,higher percentage of healed area,layer compression,Compression stocking,significantly increased,"However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed.",3298351
11,2286,interval to delivery,tocolysis,antibiotic therapy and tocolysis,no significant difference,"no significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.",2366143
12,2286,birth weight,tocolysis,antibiotic therapy and tocolysis,no significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.",2366143
13,2286,neonatal outcomes,tocolysis,antibiotic therapy and tocolysis,no significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.",2366143
14,2286,infection,antibiotic therapy,placebo,significantly decreased,Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group.,2366143
15,2270,gestational age,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
16,2270,frequency of contractions,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
17,2270,cervical Bishop's score,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
18,2270,white blood cell count,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
19,51310,pregnancy,twice weekly single iron tablet,weekly supplements of two iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
20,51310,pregnancy,weekly supplements of two iron tablets,daily single iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
21,51310,pregnancy,daily single iron tablets,twice weekly single iron tablet,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
22,51310,birth outcome,twice weekly single iron tablet,weekly supplements of two iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
23,51310,birth outcome,weekly supplements of two iron tablets,daily single iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
24,51310,birth outcome,daily single iron tablets,twice weekly single iron tablet,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
25,51310,side effects,weekly supplements of two iron tablets,no treatment,no significant difference,Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.,3233526
26,51310,side effects,daily single iron tablets,no treatment,no significant difference,Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.,3233526
27,51310,side effects,twice weekly single iron tablet,no treatment,no significant difference,Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.,3233526
28,51310,hemoglobin levels at week 28,weekly supplements of two iron tablets,no treatment,no significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,3233526
29,51310,hemoglobin levels at week 28,daily single iron tablets,no treatment,no significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,3233526
30,51310,hemoglobin levels at week 28,twice weekly single iron tablet,no treatment,no significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,3233526
31,51310,hemoglobin levels at week 38,weekly supplements of two iron tablets,twice weekly single iron tablet,significantly decreased,"When comparing the final levels at 38 weeks, a significant difference was observed between Group B and the other two groups in this iron status indicator (P = 0.035). This difference was also of marginal clinical significance (19.9 μg/L in Group B).",3233526
32,51310,hemoglobin levels at week 38,daily single iron tablets,twice weekly single iron tablet,significantly decreased,"When comparing the final levels at 38 weeks, a significant difference was observed between Group B and the other two groups in this iron status indicator (P = 0.035). This difference was also of marginal clinical significance (19.9 μg/L in Group B).",3233526
33,51310,ferritin levels at week 28,daily single iron tablets,weekly supplements of two iron tablets,significantly increased,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
34,51310,ferritin levels at week 28,daily single iron tablets,twice weekly single iron tablet,significantly increased,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
35,51310,ferritin levels at week 38,weekly supplements of two iron tablets,twice weekly single iron tablet,no significant difference,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
36,51310,ferritin levels at week 38,weekly supplements of two iron tablets,daily single iron tablets,no significant difference,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
37,51310,ferritin levels at week 38,daily single iron tablets,twice weekly single iron tablet,no significant difference,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
38,46206,symptoms of RA,golimumab and methotrexate,methotrexate,significantly decreased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.,2674549
39,46206,physical function,golimumab and methotrexate,methotrexate,significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.,2674549
40,46206,ACR20 ,placebo and methotrexate,Golimumab 100 mg and placebo,no significant difference,,2674549
41,46206,Median HAQ-DI score,placebo and methotrexate,Golimumab 100 mg and placebo,no significant difference,"No difference in the improvement in median HAQ-DI score was observed between group 2 and group 1 (−0.13; p = 0.240). Overall, 38.6% of patients in group 1, 45.3% of patients in group 2 (p = 0.276), 68.2% of patients in group 3 (p<0.001) and 72.1% of patients in group 4 (p<0.001) achieved a reduction in HAQ-DI score of 0.25 or greater.",2674549
42,46206,HAQ-DI score,50mg of Golimumab and methotrexate,placebo and methotrexate,significantly increased,"At week 24, patients in the combined groups 3 and 4 also showed significantly greater improvement in the median HAQ-DI score (−0.44, p<0.001) compared with group 1 (−0.13), with improvements of −0.38 (p = 0.001) in group 3 and −0.50 (p<0.001) in group 4 (table 2).",2674549
43,46206,HAQ-DI score,100mg of Golimumab and methotrexate,placebo and methotrexate,significantly increased,"At week 24, patients in the combined groups 3 and 4 also showed significantly greater improvement in the median HAQ-DI score (−0.44, p<0.001) compared with group 1 (−0.13), with improvements of −0.38 (p = 0.001) in group 3 and −0.50 (p<0.001) in group 4 (table 2).",2674549
44,46206,serious adverse events,100mg of Golimumab and methotrexate,placebo and methotrexate,significantly increased,"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.",2674549
45,46206,serious adverse events,100mg of Golimumab and methotrexate,Golimumab 100 mg and placebo,significantly increased,"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.",2674549
46,46206,serious adverse events,100mg of Golimumab and methotrexate,50mg of Golimumab and methotrexate,significantly increased,"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.",2674549
47,4505,induction-delivery interval,misoprostol,dinoprostone,significantly decreased,"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).",524504
48,4505,number of women who deliver within 12 hours,misoprostol,dinoprostone,significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05)",524504
49,4505,number of women who deliver within 24 hours,misoprostol,dinoprostone,significantly increased,,524504
50,4505,spontaneous rupture of membranes,misoprostol,dinoprostone,significantly increased,"spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05)",524504
51,4505,administration of oxytocin augmentation,misoprostol,dinoprostone,significantly decreased,"there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05)",524504
52,4505,Caesarean section rate,dinoprostone,misoprostol,no significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).",524504
53,4505,abnormal fetal heart rate,dinoprostone,misoprostol,no significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).",524504
54,4505,uterine tachysystole,misoprostol,dinoprostone,significantly increased,"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05)",524504
55,4505,Uterine Hyperstimulation,misoprostol,dinoprostone,no significant difference,Uterine Hyperstimulation 2 (2.5%) 1 (1.2%) NS,524504
56,4505,Meconium stained AF,dinoprostone,misoprostol,no significant difference,Meconium stained AF 15 (18.8%) 7 (9.6%) NS,524504
57,4505,perinatal death,dinoprostone,misoprostol,no significant difference,Perinatal death 0 1(1.2%) NS,524504
58,4505,Neonatal resuscitation,dinoprostone,misoprostol,no significant difference,Neonatal resuscitation 9 (11.3%) 9 (10.8%) NS,524504
59,4505,Core blood pH,dinoprostone,misoprostol,no significant difference,Cord blood pH (arterial)1 7.28 ± 0.05 7.27 ± 0.05 NS,524504
60,4505,Hyperbilirubinemia,dinoprostone,misoprostol,no significant difference,Hyperbilirubinemia 2 9 (11.3%) 5 (6.0%) NS,524504
61,4505,Birth trauma,dinoprostone,misoprostol,no significant difference,Birth trauma 3 0 2 (2.5%) NS,524504
62,2680,rates of vacuum-assisted delivery rate,Meperidine analgesia,epidural analgesia,no significant difference,There was no statistical difference in rates of vacuum-assisted delivery rate.,1764008
63,2680,c-section,Meperidine analgesia,epidural analgesia,no significant difference,"Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.",1764008
64,2680,duration of labor stages,Meperidine analgesia,epidural analgesia,no significant difference,Differences in the duration of the active-first and the second stages of labor were not statistically significant.,1764008
65,2680,oxytocin augmentation,Meperidine analgesia,epidural analgesia,no significant difference,"Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation",1764008
66,2680,preanalgesic visual analog pain,Meperidine analgesia,epidural analgesia,no significant difference,"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 ± 1.2 vs. intravenous meperidine, 9 ± 1.3; P = 0.09)",1764008
67,2680,pain levels during first stage labor,epidural analgesia,Meperidine analgesia,significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor",1764008
68,2680,pain levels during second stage labor,epidural analgesia,Meperidine analgesia,significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor",1764008
69,2680,hypotension,epidural analgesia,Meperidine analgesia,significantly increased,Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001),1764008
70,2680,nausea and vomiting,Meperidine analgesia,epidural analgesia,no significant difference,There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%),1764008
71,2680,obstetric outcome,Meperidine analgesia,epidural analgesia,no significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",1764008
72,2680,obstetric intervention,Meperidine analgesia,epidural analgesia,no significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",1764008
73,2680,neonatal outcome,Meperidine analgesia,epidural analgesia,no significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",1764008
74,35535,continuous abstienence at week 12,varenicline,placebo,significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001)",3281242
75,35535,continuous abstienence at 24 week follow up,varenicline,placebo,significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001)",3281242
76,35535,frequency of quit events by day 35,varenicline,placebo,no significant difference,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062). ",3281242
77,35535,time to make first quit attempt,varenicline,placebo,significantly decreased,"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).",3281242
78,36775,improved A1C,detemir,glargine,no significant difference,Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (P = 0.149),2875419
79,36775,number of patients with A1C <7%,detemir,glargine,no significant difference,with similar proportions of patients achieving A1C <7% (P = 0.254),2875419
80,36775,number of patients with A1C <6.5%,detemir,glargine,significantly increased,more detemir-treated patients reaching A1C <6.5% (P = 0.017),2875419
81,36775,Hypoglycemia,detemir,glargine,no significant difference,Hypoglycemia risk was similar.,2875419
82,36775,Weight Gain,glargine,detemir,significantly increased,"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).",2875419
83,36775,frequency of insulin doses,glargine,detemir,significantly decreased,"Insulin doses, however, were significantly lower for glargine: 43.5 ± 29.0 versus 76.5 ± 50.5 units/day (P < 0.001) (Fig. 1B)",2875419
84,36775,drop-out rate,detemir,glargine,significantly decreased,"Detemir-treated patients had less weight gain and more often achieved A1C <6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.",2875419
85,43880,IVD comlication rates,routine replacement,staff inclination replacement,no significant difference,"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).",2944158
86,43880,time until first complication,routine replacement,staff inclination replacement,no significant difference,"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).",2944158
87,43880,infections,routine replacement,staff inclination replacement,no significant difference,There were no local infections or IVD-related bloodstream infections in either group. ,2944158
88,43880,therapy duration,routine replacement,staff inclination replacement,no significant difference,IV therapy duration did not differ between groups (P = 0.22),2944158
89,43880,frequency of replacements,routine replacement,staff inclination replacement,significantly increased,"but more (P = 0.004) IVDs were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5)",2944158
90,43880,cost per patient,routine replacement,staff inclination replacement,significantly increased,with significantly higher hospital costs per patient (P < 0.001).,2944158
91,43880,IVD complications per person,routine replacement,staff inclination replacement,no significant difference,,2944158
92,43880,phlebitis,routine replacement,staff inclination replacement,no significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)",2944158
93,43880,infiltration,routine replacement,staff inclination replacement,no significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)",2944158
94,43880,occlusion,routine replacement,staff inclination replacement,no significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)",2944158
95,43880,IVD dwell times,staff inclination replacement,routine replacement,significantly increased,"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).",2944158
96,24976,frequency of healed index ucler after 1 year,HBOT ,placebo,significantly increased,complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03),2858204
97,24976,hypoglycemia occuring after treatment,HBOT ,placebo,no significant difference,"Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).",2858204
98,24976,downsizing of ucler area 2 weeks after treatment,HBOT ,placebo,significantly increased,"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037)",2858204
99,2871176,HbA1c level at 26 weeks,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%)",2871176
100,2871176,HbA1c level at 26 weeks,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.",2871176
101,2871176,Fasting plasma glucose at week 26,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l)",2871176
102,2871176,Fasting plasma glucose at week 26,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).",2871176
103,2871176,Postprandial plasma glucose,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)",2871176
104,2871176,Postprandial plasma glucose,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.,2871176
105,2871176,HbA1c level at 26 weeks,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.",2871176
106,2871176,HbA1c level at 26 weeks,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,All liraglutide doses were superior to placebo (P < 0.0001),2871176
107,2871176,HbA1c level at 26 weeks,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.",2871176
108,2871176,HbA1c level at 26 weeks,Liraglutide (0.6 mg) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,Liraglutide 0.6 mg was non-inferior to rosiglitazone,2871176
109,2871176,HbA1c level at 26 weeks,Rosiglitazone plus glimepiride,Placebo plus glimepiride,Significantly decreased,Rosiglitazone also was superior to placebo (P < 0.0001),2871176
110,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001),2871176
111,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001),2871176
112,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003),2871176
113,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003),2871176
114,2871176,Patients reaching HbA1c goals less than 7.0% ,Liraglutide (1.8 mg) plus glimepiride,Liraglutide (1.2 mg) plus glimepiride,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).",2871176
115,2871176,Fasting plasma glucose at week 26,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l)",2871176
116,2871176,Fasting plasma glucose at week 26,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001)",2871176
117,2871176,Fasting plasma glucose at week 26,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).",2871176
118,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,2871176
119,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,2871176
120,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,2871176
121,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).",2871176
122,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).",2871176
123,2871176,Postprandial plasma glucose,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)",2871176
124,2871176,Postprandial plasma glucose,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001),2871176
125,2871176,Postprandial plasma glucose,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.,2871176
126,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone",2871176
127,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone",2871176
128,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone",2871176
129,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.",2871176
130,2871176,Weight gain,Rosiglitazone plus glimepiride,Liraglutide plus glimepiride,Significantly increased,"Unlike rosiglitazone, weight did not increase substantially with liraglutide and the differences between rosiglitazone and liraglutide were statistically significant (−2.3 to −1.4 kg; P < 0.0001)",2871176
131,2871176,Proinsulin : insulin ratio,Liraglutide (1.2 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
132,2871176,Proinsulin : insulin ratio,Liraglutide (1.2 mg) plus glimepiride ,Placebo plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
133,2871176,Proinsulin : insulin ratio,Liraglutide (1.8 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
134,2871176,Proinsulin : insulin ratio,Liraglutide (1.8 mg) plus glimepiride ,Placebo plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
135,2871176,HOMA-B,Liraglutide (1.2 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly increased,HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),2871176
136,2871176,HOMA-B,Liraglutide (1.8 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly increased,HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),2871176
137,2871176,HOMA-B,Liraglutide (1.2 mg) plus glimepiride ,Placebo plus glimepiride ,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)",2871176
138,2871176,HOMA-B,Liraglutide (1.8 mg) plus glimepiride ,Placebo plus glimepiride ,No significant difference,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)",2871176
139,2871176,HOMA-IR,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,No significant difference,There were no significant differences between treatments for HOMA-IR.,2871176
140,2871176,HOMA-IR,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,There were no significant differences between treatments for HOMA-IR.,2871176
141,2871176,Reductions in systolic blood pressure,Liraglutide (1.2 mg) plus glimepiride ,Placebo plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg)",2871176
142,2871176,Reductions in systolic blood pressure,Liraglutide (1.8 mg) plus glimepiride ,Placebo plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg)",2871176
143,2871176,Reductions in systolic blood pressure,Liraglutide (1.2 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).",2871176
144,2871176,Reductions in systolic blood pressure,Liraglutide (1.8 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).",2871176
145,2871176,Decreases in diastolic blood pressure,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.",2871176
146,2871176,Decreases in diastolic blood pressure,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.",2871176
147,2871176,Pulse variations,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).,2871176
148,2871176,Pulse variations,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).,2871176
149,2871176,Pulse variations,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).,2871176
150,2871176,Incidence of minor hypoglycaemia,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.",2871176
151,2871176,Incidence of minor hypoglycaemia,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.",2871176
152,2871176,Incidence of minor hypoglycaemia,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.",2871176
153,2871176,Changes in calcitonin at week 26,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.,2871176
154,2871176,Changes in calcitonin at week 26,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.,2871176
155,2708184,Self-selected overground walk velocity,Body-weight supported treadmill training combined with Lokomat,Manually-assisted body-weight supported treadmill training,No significant difference,No significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of training.,2708184
156,2708184,Paretic step length ratio,Body-weight supported treadmill training combined with Lokomat,Manually-assisted body-weight supported treadmill training,No significant difference,No significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of training.,2708184
157,2708184,Locomotor-training effects,Fast treadmill speed,Slow treadmill speed,No significant difference,"Our second aim was to assess locomotor-training effects at faster vs. slower treadmill speeds. As anticipated, independent of whether training occurred in the Lokomat or manual-BWSTT mode, average weekly training speeds within the fast and slow groups were similar, p ≥ 0.29",2708184
158,2708184,Self-selected overground walk velocity,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Although an equal number of participants (n = 7) produced a training related increase in self-selected overground walking speed in each group, a significant difference, p = 0.04, was revealed only in the Lokomat group with a pre-post intervention difference of 0.10 m/s and an effect size of 0.32",2708184
159,2708184,6-minute walk test,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),No significant difference,"With the exception of the 6-minute walk test and LLFDI, p ≥ 0.16, all secondary measures revealed significant improvements within the Lokomat group",2708184
160,2708184,Late Life Function and Disability Instrument,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),No significant difference,"With the exception of the 6-minute walk test and LLFDI, p ≥ 0.16, all secondary measures revealed significant improvements within the Lokomat group",2708184
161,2708184,Improvement in lower extremity Fugl-Meyer score ,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Fast overground walk speed improved from pre- to post-training in 6 of 8 Lokomat participants, p = 0.05, with a small effect size of 0.15 (Figure 2A). Lower extremity Fugl-Meyer score improvements were also noted, p = 0.04, with an effect size of 0.60 and higher scores in 5 of 8 Lokomat group participants",2708184
162,2708184,Physical performance battery scores,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Similarly, short physical performance battery scores were improved in the Lokomat group, p = 0.04, with an effect size of 0.29 and improvements in 5 of 8 participants.",2708184
163,2708184,Berg Balance Scale score,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved)",2708184
164,2708184,Berg Balance Scale score,Manually-assisted body-weight supported treadmill training (post-test),Manually-assisted body-weight supported treadmill training (pre-test),Significantly increased,"Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved), and manual group, p = 0.02, effect size 0.57 (7 participants improved)",2708184
165,3001156,Care-seeking from qualified providers for ill newborns  ,Promotion by CHWs of maternal and newborn-care interventions ,Comparison arm ,Significantly increased,there was a highly significant (p<0.00001) increase in the proportion of families that sought care from qualified providers for sick newborns in the intervention arm (Fig. 2 and Rows 5 and 7 of Table 2) and a non-significant increase in the comparison arm (Rows 5 and 8).,3001156
166,3001156,Care-seeking from the Kumudini Hospital for ill newborns ,Promotion by CHWs of maternal and newborn-care interventions ,Comparison arm ,Significantly increased,"care-seeking for sick newborns specifically from the Kumudini Hospital increased significantly in both intervention and comparison arms, but the increase was of a much greater magnitude in the intervention arm",3001156
167,3001156,Care-seeking from unqualified providers (such as village doctors) for ill newborns  ,Promotion by CHWs of maternal and newborn-care interventions ,Comparison arm ,Significantly decreased,"the proportion of families who sought care from unqualified providers, such as unlicensed village doctors, remained unchanged in the comparison arm, but declined significantly in the intervention arm",3001156
168,2864284,Parasite clearance at day 1,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,"Initial parasitological responses were faster with dihydroartemisinin-piperaquine (Figure 4); in the dihydroartemisinin-piperaquine group 241/264 (91.3%) of patients cleared their parasitaemia at day 1 compared to 209/265 (78.9%) in the chloroquine group (p < 0.001, relative risk of clearance in chloroquine group = 0.87, 95% CI 0.81-0.93).",2864284
169,2864284,Parasite clearance at day 2,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,"At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59).",2864284
170,2864284,Recurrent infections at day 56,Dihydroartemisinin-piperaquine,Chloroquine,Significantly decreased,"By the end of the 56-day follow-up period, there were 23 recurrences (parasitological failures) in the chloroquine group and 7 in the dihydroartemisinin-piperaquine group, giving a day 56 failure rate of 8.9% (95% CI 6.0 - 13.1%) in the chloroquine group and 2.8% (1.4 - 5.8%) in the dihydroartemisinin-piperaquine group (Figure 2).",2864284
171,2864284,Superiority of treatment given by survival curves,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,The log-rank test comparing the survival curves confirmed the superiority of dihydroartemisinin-piperaquine over chloroquine (p = 0.003).,2864284
172,2864284,Serious adverse events,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,Both regimens were well tolerated and no serious adverse events were reported.,2864284
173,2864284,Baseline white blood cell count,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,"Patient characteristics at baseline were broadly similar between the two treatment groups (Table 1) except that the median white blood cell count was lower in the chloroquine group compared with dihydroartemisinin-piperaquine (median 6.0 vs. 6.6 × 109/l respectively, p = 0.02).",2864284
174,2864284,Fever resolution by day 1,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,"In terms of resolution of fever (defined as axillary temperature >37.0°C) dihydroartemisinin-piperaquine was again superior (Figure 4), with 29/266 (10.9%) of the dihydroartemisinin-piperaquine group febrile on day 1 compared to 45/268 (16.8%) in the chloroquine group (p = 0.049).",2864284
175,2864284,Fever resolution by day 2,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,"By day 2 there was no longer a significant difference in the proportion with fever (3/265 (1.1%) for dihydroartemisinin-piperaquine, 9/264 (3.4%) for chloroquine, p = 0.08).",2864284
176,2864284,Headache,Dihydroartemisinin-piperaquine,Chloroquine,Significantly decreased,"At day 1, headache was less frequent in the dihydroartemisinin-piperaquine arm (105/265 (39.6%)) compared to the chloroquine arm (145/266 (54.5%), p = 0.001)",2864284
177,2864284,Cure rate at day 28,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,The day 28 cure rate was 100% in both arms,2864284
178,2864284,Parasitaemias associated with gametocytaemia,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,"Twenty-one of 30 (70%) recurrent parasitaemias were associated with gametocytaemia, with no significant difference between treatment arms in terms of proportion of recurrent patients with gametocytaemia (16/23 and 5/7 for chloroquine and dihydroartemisinin-piperaquine respectively, p = 1.0).",2864284
179,2864284,Pruritus,Dihydroartemisinin-piperaquine,Chloroquine,Significantly decreased,"There was a significant increase in the proportion of patients with pruritus in the chloroquine arm compared to dihydroartemisinin-piperaquine on days 1, 2 and 3; on day 1, 15/268 subjects in the chloroquine arm had pruritus compared to 2/266 in the dihydroartemisinin-piperaquine arm (p = 0.002, relative risk 7.44, 95% CI 1.71-32.3), consistent with the known side-effects of chloroquine.",2864284
180,2864284,Haemoglobin concentration,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,There were no significant differences between the two arms in haemoglobin concentration or occurrence of anaemia (haemoglobin < 10 g/dl) at any stage during follow-up (all p > 0.5).,2864284
181,2517154,Severity of pain,Infliximab,Placebo,No significant difference,Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001).,2517154
182,2517154,Nodules diameters,Infliximab,Placebo,No significant difference,"No effect of treatment was found upon the mean diameters of the nodules as measured by TVU. For the placebo group (n = 7) and the infliximab group (n = 13), the diameters were 15.2 ± 4.6 and 13.6 ± 3.2 mm, during Visit 3, 15.1 ± 5.12 and 14.25 ± 3.5 mm, during Visit 5, 13.5 ± 4.9 and 15.6 ± 3.5 mm and during Visit 6, 13.2 + 3.4 and 15.1 + 2.38 mm.",2517154
183,2517154,Endometrial thickness,Infliximab,Placebo,No significant difference,"Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3–18) and 7.8 (1.9–11) mm and for the placebo group 7.7 (1.8–23) and 8.2 (3–15) mm, respectively.",2517154
184,2517154,Extend of the disease as visualized during surgery,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.",2517154
185,2517154,Macroscopic aspect of the tissue,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.",2517154
186,2517154,Surgery duration,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates",2517154
187,2517154,Bleeding during surgery,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates",2517154
188,2517154,Tissue examination by routine pathology,Infliximab,Placebo,No significant difference,Routine pathology (FC) also showed no obvious differences between the two groups.,2517154
189,2517154,Pain estimates after surgery,Infliximab,Placebo,No significant difference,"After surgery, all pain estimates decreased to less than 10% of the baseline in both groups (Figs 1 and 2), and no differences were found between the placebo and the infliximab group (two-way analysis of variance).",2517154
190,2517154,Pain killers intake,Infliximab,Placebo,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01)",2517154
191,2517154,Dysmenorrhea scores,Infliximab,Placebo,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01), and higher dysmenorrhea scores (P < 0.001 for physician assessment, for patient VAS scales and for patient diary).",2517154
192,1852268,obstetric/postpartum infection or gynecologic/postoperative infection,"Inravenous ertapenem, 1 g once a day","Intravenous piperacillin–tazobactam, 3.375 g every 6 hours",No significant difference,"At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.",1852268
193,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit & Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
194,3187863,Labour dystocia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
195,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
196,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
197,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit & Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
198,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit & Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
199,3187863,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit & Special unit,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
200,2688140,The survival rate / overall mortality of patients with ARDS,Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).",2688140
201,2688140,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS",Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents did not differ between the groups (Table 2).",2688140
202,4106715,Prolonged abstinence from smoking rates to 6 months,high Ab group,placebo,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71)",4106715
203,4106715,Prolonged abstinence from smoking rates to 6 months,low Ab group,placebo,No significant difference,"ith no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).",4106715
204,4106715,Prolonged abstinence from smoking rates to 12 months,high Ab group,placebo,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20).",4106715
205,4106715,Prolonged abstinence from smoking rates to 12 months,low Ab group,placebo,No significant difference,Prolonged abstinence from smoking rates to 6 months	low Ab group	placebo	No significant difference	ith no significant differences between the placebo,4106715
206,4106715,Reduction of daily cigarette consumption and cotinine,non-abstainers (weeks 19–52) with high Ab levels,non-abstainers in the placebo group,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19–52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C",4106715
207,4106715,attain 8 weeks continuous abstinence from weeks 19 through 26,recipients with the highest serum anti-nicotine antibody response (top 30% by AUC),placebo group,Significantly increased,"3’AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).",4106715
208,2206488,"Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I",dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,"procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.",2206488
209,2206488,Cardiac index ,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly increased,Higher figures of the cardiac index (p = 0.010),2206488
210,2206488,systemic vascular resistance,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,with reduced systemic vascular resistance (p = 0.005) were noted in group A.,2206488
211,2206488,C-reactive protein (mg/l),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,C-reactive protein (mg/l) Group A	3.7 (1.0–22.6)				79.9 (50.0–131.7)	112.0 (61.1–177.6)	<0.001† Group B	2.6 (0.6–10.5)				87.6 (52.4–143.0)	131.0 (71.0–228.0)	<0.001†	p = 0.068*				p = 0.092*	p = 0.168*,2206488
212,2206488,IL-6 (pg/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6 (pg/ml)							 Group A	1.6 (0.4–21.8)		95.0 (13.6–405.1)	46.3 (16.1–149.5)			<0.001† Group B	2.0 (0.4–60.6)		130.5 (21.7–353.8)	49.2 (14.8–214.5)			<0.001†	p = 0.107*		p = 0.829*	p = 0.482*,2206488
213,2206488,IL-6r (ng/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6r (ng/ml)							 Group A	43.6 (1.7–125.0)		47.4 (0.7–109.5)	56.2 (25.2–226.3)			0.949† Group B	40.7 (15.6–94.6)		42.4 (22.2–100.5)	50.2 (13.2–104.9)			0.861†	p = 0.607*		p = 0.914*	p = 0.304*,2206488
214,1475568,Hospitalization or death,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"61% of patients in the control group had at least one hospitalization or died, and 42% of patients in the intervention group had at least 1 hospitalization or died (p = 0.13).",1475568
215,1475568,Daily weight monitoring at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,Significantly increased,"At 12 months, more patients in the intervention group reported monitoring weights daily (79% vs. 29%, p < 0.0001).",1475568
216,1475568,Heart failure-related quality of life at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"In unadjusted analysis, the control group, on average, improved 5 points on the MLHF and the intervention group improved by 1 point. The difference was not statistically significant (3.5 points, 95% CI 11, -4, p = 0.36). After adjusting for baseline differences between the groups, the difference was 2 points (95% CI 9, -5, p = 0.59) suggesting no effect on heart failure-related quality of life.",1475568
217,1475568,Baseline hypertension,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
218,1475568,Baseline diabetes,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
219,1475568,Baseline systolic dysfunction,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
220,1475568,Baseline beta-blockers intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
221,1475568,Baseline angiotensin-converting enzyme (ACE) inhibitors intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
222,1475568,Baseline digoxin intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
223,1475568,Baseline angiotensin II receptor blockers (ARBs) intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
224,1475568,Minnesota living with heart failure (MLHF) questionnaire baseline scores,Follow-up and thorough education on self-care,Standard information about self-care,Significantly decreased,The control group did have statistically significantly higher baseline MLHF scores representing worse symptoms at baseline.,1475568
225,1475568,Cardiac-related hospitalization,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"39% of patients in the control group and 34% of patients in the intervention group had at least one hospitalization for cardiac causes (p = 0.55). The unadjusted IRR was 0.79 (95% CI 0.42, 1.5). After adjusting for baseline differences, the IRR was 0.85 (95% CI 0.44, 1.7).",1475568
226,1475568,Knowledge about heart failure,Follow-up and thorough education on self-care,Standard information about self-care,Significantly increased,"Heart failure related knowledge improved more in the intervention group than in the control group. Mean difference in score improvement was 12 percentage points (95% CI 6, 18; p < 0.001).",1475568
227,1475568,Self-efficacy,Follow-up and thorough education on self-care,Standard information about self-care,Significantly increased,"Heart failure self-efficacy improved more in the intervention group than in the control group. Mean difference in score improvement was 2 points (95% CI 0.7, 3.1; p = 0.0026).",1475568
228,1475568,Baseline life-quality score,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"Twenty-four patients in each group had inadequate literacy based on the S-TOFHLA (Table 2). Among these patients, there was no difference in quality of life score in unadjusted and adjusted analyses (difference = -1.6; 95% CI -15, 12); p = 0.81). For the combined outcome of hospitalization or death, the unadjusted IRR was 0.77 (95% CI 0.30, 1.94). After adjusting for baseline differences, the IRR was 0.39 (95% CI 0.16, 0.91).Seventy-five patients had marginal or adequate literacy based on the S-TOFHLA. We found no difference in quality of life score in unadjusted and adjusted analyses (difference = -4.2; 95% CI -14, 6; p = 0.40). Among patients in the higher literacy group, the unadjusted IRR for hospitalization or death was 0.65 (95% CI 0.33, 1.3). After adjusting for baseline differences, the IRR was 0.56 (95% CI 0.30, 1.04). We did not find a statistically significant effect modification between literacy and the intervention.",1475568
229,3090298,Uncorrected distance visual acuity at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA. Visual acuities were not statistically different between the groups at 3 or 6 months.",3090298
230,3090298,Uncorrected distance visual acuity at 3 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA. Visual acuities were not statistically different between the groups at 3 or 6 months.",3090298
231,3090298,Uncorrected distance visual acuity at 1 month,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),Significantly decreased,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA. Visual acuities were not statistically different between the groups at 3 or 6 months.",3090298
232,3090298,Corrected distance visual acuity at 1 month,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),Significantly decreased,"CDVA was statistically different between groups at 1 month, with 24% of the PRK group losing a line or more from preoperative values, while 9% of eyes in the thin-flap LASIK group lost only 1 line at 1 month. No eyes in the thin-flap LASIK group lost more than 1 line. Also, 39% of eyes in the thin-flap group gained a line by 1 month compared with only 12% of eyes in the PRK group.",3090298
233,3090298,Corrected distance visual acuity at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,Significant differences were not found between treatment groups in contrast sensitivity (P ≥ 0.156) or CDVA (P = 0.800) at postoperative 6 months.,3090298
234,3090298,1 line or more of CDVA at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"At 6 months 64% and 56% of eyes had gained a line or more of CDVA in the PRK and thin-flap LASIK groups, respectively (P = 0.462).",3090298
235,3090298,Contrast sensitivity,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"Contrast sensitivity measurements at 3, 6, 12, and 18 cycles per degree (cpd) in each group are shown in Figure 1. There were no differences between groups at any cpd at any time in the study (P ≥ 0.156).",3090298
236,3090298,Contrast sensitivity,Thin-flap laser in situ keratomileusis (LASIK) ,Pre-surgery baseline,No significant difference,The thin-flap LASIK group showed no change in contrast sensitivity postoperatively (P > 0.131),3090298
237,3090298,Contrast sensitivity at 1 month seen at 3 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,Significantly decreased,"patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively.",3090298
238,3090298,Contrast sensitivity at 3 months seen at 3 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,No significant difference,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).",3090298
239,3090298,Contrast sensitivity at 1 month seen at 12 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,Significantly decreased,"patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively.",3090298
240,3090298,Contrast sensitivity at 6 months seen at 3 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,Significantly decreased,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).",3090298
241,3090298,Higher-order aberrations during the study,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"There were no significant differences between groups in any HOAs throughout the study (P ≥ 0.101), with all P values at 6 months ≥0.63.",3090298
242,3090298,Higher-order aberrations at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"There were no significant differences between groups in any HOAs throughout the study (P ≥ 0.101), with all P values at 6 months ≥0.63.",3090298
243,2922723,Sputum expectoration during a single session,High frequency chest wall oscillation,Usual airway clearance techniques,Significantly decreased,"Significantly more sputum was expectorated during a single treatment session and over a 24 h period (mean difference 4.4 g and 6.9 g, respectively) with usual ACTs than with HFCWO (p<0.001).",2922723
244,2922723,FEV1%,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No statistically significant change in FEV1% or oxygen saturation was observed after either HFCWO or usual ACTs compared with baseline.,2922723
245,2922723,O2 saturation,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No statistically significant change in FEV1% or oxygen saturation was observed after either HFCWO or usual ACTs compared with baseline.,2922723
246,2922723,Sputum expectoration over a 24-hour period,High frequency chest wall oscillation,Usual airway clearance techniques,Significantly decreased,"Significantly more sputum was expectorated during a single treatment session and over a 24 h period (mean difference 4.4 g and 6.9 g, respectively) with usual ACTs than with HFCWO (p<0.001).",2922723
247,2922723,Sputum expectoration between treatments in a 24-hour period,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No statistically significant difference was observed in the amount of sputum expectorated when using HFCWO or usual ACT between treatments in a 24 h period.,2922723
248,2922723,Visual analogue scale scores for comfort,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No significant differences were observed in VAS scores for comfort or urinary leakage between HFCWO and usual ACT.,2922723
249,2922723,Visual analogue scale scores for urinary leakage,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No significant differences were observed in VAS scores for comfort or urinary leakage between HFCWO and usual ACT.,2922723
250,2922723,Visual analogue scale scores for efficacy,High frequency chest wall oscillation,Usual airway clearance techniques,Significantly decreased,Patients scored the efficacy of their usual ACT significantly higher than for HFCWO (mean difference 14 mm; p=0.002).,2922723
251,2922723,Adverse events,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,Neither HFCWO nor any of the usual ACTs were associated with any adverse clinical events,2922723
252,1831737,HIV-1 incidence,Communities that received additional education and preventive measures,Communities that received standard Government services,No significant difference,"Integrated peer education, condom distribution, and syndromic STI management did not reduce population-level HIV-1 incidence in a declining epidemic, despite reducing HIV-1 incidence in the immediate male target group.",1831737
253,1831737,HIV-1 prevalence,Communities that received additional education and preventive measures,Communities that received standard Government services,Significantly increased,"HIV-1 prevalence was higher in the intervention communities than in the control communities (24% versus 21%, risk ratio 1.13 [95% CI 1.05–1.22], p = 0.001)",1831737
254,1831737,Patients infected with T. vaginalis,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
255,1831737,Secondary school education,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
256,1831737,Spatial mobility,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
257,1831737,Genital discharge history,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
258,1831737,Intake of STI treatment,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
259,1831737,Self-reported STI symptoms,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,self-reported STI symptoms were similar in both sets of communities,1831737
260,1831737,HIV/AIDS meeting attendance,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,Significantly increased,"More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33–1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52–5.17], p < 0.001)",1831737
261,1831737,Programme meeting attendance,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,Significantly increased,"More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33–1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52–5.17], p < 0.001)",1831737
262,1831737,High-risk sexual behaviour,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,No evidence was found for reduced incidence of self-reported STI symptoms or high-risk sexual behaviour in the intervention communities.,1831737
263,2691927,Surgery duration,Laparoscopic surgery,Conventional open approach,Significantly increased,Operating time in the laparoscopy group was significantly longer than in the open group (75 min versus 50 min).,2691927
264,2691927,Visual analog scale pain score at day 1,Laparoscopic surgery,Conventional open approach,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.",2691927
265,2691927,Visual analog scale pain score at day 3,Laparoscopic surgery,Conventional open approach,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.",2691927
266,2691927,Visual analog scale pain score at day 7,Laparoscopic surgery,Conventional open approach,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.",2691927
267,2691927,Postoperative complications,Laparoscopic surgery,Conventional open approach,No significant difference,Complications were equally distributed.,2691927
268,2691927,Need for opiates,Laparoscopic surgery,Conventional open approach,Significantly decreased,Differences regarding postoperative dosage of opiates and the visual analog scale (VAS) for pain scoring system were in favor of the laparoscopic procedure.,2691927
269,2691927,Hospital permanence,Laparoscopic surgery,Conventional open approach,No significant difference,Hospital stay was also comparable: 6.5 days in the laparoscopic group versus 8.0 days in the open group (P = 0.235).,2691927
270,2691927,Ulcer mean diameter,Laparoscopic surgery,Conventional open approach,No significant difference,"The discovered ulcer perforations were found to have a mean diameter of 10 mm, which did not differ between groups",2691927
271,2691927,Ulcer location ,Laparoscopic surgery,Conventional open approach,No significant difference,Location of the perforated ulcers was distributed equally between groups,2691927
272,2691927,Median loss of blood,Laparoscopic surgery,Conventional open approach,No significant difference,Median blood loss did not differ between groups.,2691927
273,2691927,Time to nasogastric decompression,Laparoscopic surgery,Conventional open approach,No significant difference,Nasogastric decompression could be stopped after 2–3 days in both groups,2691927
274,2691927,Better scar appearance score as measured by visual analog scale,Laparoscopic surgery,Conventional open approach,Significantly increased,"The VAS score for appearance of the scar left by the respective procedures (subjectively recorded in the same way as pain) differed by 2.3 points, favoring the laparoscopic procedure (7.7 vs. 5.4; P = 0.033)",2691927
275,2375236,Prognosis enquiry,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls,2375236
276,2375236,Prognosis information given,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients.,2375236
277,2375236,Consult duration,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.",2375236
278,2375236,Anxiety,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.",2375236
279,2375236,Information recall,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly increased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.",2375236
280,2361806,Clinical response rates at 14 weeks,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"The objective clinical response rates after 14 weeks treatment (primary end point) were 30% for ILF and 17% for ELF (risk ratio (RR) 0.57, 95% confidence interval (CI) 0.29–1.13, P=0.0766).",2361806
281,2361806,Overall response rates,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),Significantly increased,"Overall response rates over the entire treatment period for ILF and ELF were 43 and 24%, respectively (RR 0.56, 95% CI 0.33–0.97; P=0.0467).",2361806
282,2361806,Time to treatment failure,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542)",2361806
283,2361806,Overall survival,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).",2361806
284,2361806,Progression-free survival,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"Compared with ELF, the ILF regimen extended median progression-free survival, median time to treatment failure and median overall survival (Table 4). However, when the treatment groups were compared by log-rank test, there was no significant difference between the two treatments for any of these parameters",2361806
285,2361806,Grade 3/4 digestive system toxic events,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),Significantly increased,"There were more grade 3/4 gastrointestinal toxic events with ILF, notably diarrhoea, which was reported by 18% of patients compared with no reports with ELF.",2361806
286,1871574,Quit attempt of 1 week or longer reported at 3 months,Smoking cessation advice and NRT offered,Usual care,Significantly increased,"With regards to quit attempts, at 3 months, there was a statistically significantly higher proportion of participants who reported a sustained quit attempt of one week or longer in the intervention group (16/43; 37%) compared to the control group (8/44; 18%) (p-value = 0.043, 95% CI (I-C) = (1, 37)%).",1871574
287,1871574,Gender,Smoking cessation advice and NRT offered,Usual care,No significant difference,"With respect to the baseline characteristics (Table 1), there was no significant difference between intervention and control groups with respect to gender or socio-economic status as measured by DEPCAT.",1871574
288,1871574,Socio-economic position,Smoking cessation advice and NRT offered,Usual care,No significant difference,"With respect to the baseline characteristics (Table 1), there was no significant difference between intervention and control groups with respect to gender or socio-economic status as measured by DEPCAT.",1871574
289,1871574,Baseline smoking habits,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There was no statistically significant difference between intervention and control groups with respect to any of the smoking behaviours or nicotine dependence variables, nor was there a significant association between the allocated group and motivation to quit as measured by 'Stage of Change'.",1871574
290,1871574,Baseline nicotine dependence variables,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There was no statistically significant difference between intervention and control groups with respect to any of the smoking behaviours or nicotine dependence variables, nor was there a significant association between the allocated group and motivation to quit as measured by 'Stage of Change'.",1871574
291,1871574,Baseline quit motivation,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There was no statistically significant difference between intervention and control groups with respect to any of the smoking behaviours or nicotine dependence variables, nor was there a significant association between the allocated group and motivation to quit as measured by 'Stage of Change'.",1871574
292,1871574,Baseline cotinine level,Smoking cessation advice and NRT offered,Usual care,No significant difference,There was no significant difference between the mean baseline biochemical values in the two groups,1871574
293,1871574,Baseline CO level,Smoking cessation advice and NRT offered,Usual care,No significant difference,There was no significant difference between the mean baseline biochemical values in the two groups,1871574
294,1871574,Smoking cessation at 3 months,Smoking cessation advice and NRT offered,Usual care,No significant difference,"the 9 intervention and 5 control participants determined as having quit smoking, represented quit rates of 15.3% and 8.8% respectively. However, the difference between intervention and control groups, in terms of the proportion of participants classified as quitters, did not reach statistical significance (p = 0.449, 95% CI (I-C) = (-8.4, 25.6)%).",1871574
295,1871574,Smoking reduction at 3 months,Smoking cessation advice and NRT offered,Usual care,Significantly increased,"There was also a statistically significantly higher proportion of participants who reported reducing their smoking behaviour in the intervention group (35/43; 81%) compared to the control group (20/44; 45%) (p-value < 0.001, 95% CI (I-C) = (17, 55)%).",1871574
296,1871574,"Inhaling less smoke, measured at 3 months",Smoking cessation advice and NRT offered,Usual care,No significant difference,"With regards to other self-reported potential changes, such as inhaling less, or smoking less of a cigarette, there was no statistically significant difference between the groups at this timepoint.",1871574
297,1871574,"Smoking less of a cigarette, measured at 3 months",Smoking cessation advice and NRT offered,Usual care,No significant difference,"With regards to other self-reported potential changes, such as inhaling less, or smoking less of a cigarette, there was no statistically significant difference between the groups at this timepoint.",1871574
298,1871574,Smoking cessation at 6 months,Smoking cessation advice and NRT offered,Usual care,No significant difference,"there was no statistically significant difference between the intervention and control groups in terms of the proportion of participants classified as having quit (p-value = 0.530, 95% CI (I-C) =(-8.5, 23.6)%). With regards to repeated point prevalence, there were 5/59 (8.5%) in the intervention group, compared to 3/57 (5.3%) in the control group (p-value = 0.671, 95% CI (I-C) =(-9.9, 21.8)%).",1871574
299,1871574,Quit attempt of 1 week or longer reported at 6 months,Smoking cessation advice and NRT offered,Usual care,Significantly increased,"At 6 months, with regards to quit attempts, a greater proportion in the intervention group reported a quit attempt of 1 week or more (14/30; 47%), compared to the control group (5/32; 16%). This result was of statistical significance (p-value = 0.018, 95% CI (I-C) = (6, 56)%).",1871574
300,1871574,Smoking habits at 6 months,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There were no statistically significant differences between the groups, at 6 months, in terms of any other changes in smoking behaviour.",1871574
301,2817867,Duration of surgery,Radiofrequency ablation,Hepatic resection,Significantly decreased,The operative time was significantly longer for the resection group compared to the RFA group (median of 269 minutes (range 118 to 452) versus 204 minutes (range 113 to 316); P < .0005).,2817867
302,2817867,Blood loss during surgery,Radiofrequency ablation,Hepatic resection,Significantly decreased,Operative blood loss (median 1400 mL (range 100 to 9000) versus 150 mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA.,2817867
303,2817867,Transfusion requirements,Radiofrequency ablation,Hepatic resection,Significantly decreased,Operative blood loss (median 1400 mL (range 100 to 9000) versus 150 mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA.,2817867
304,2817867,Need for ICU ,Radiofrequency ablation,Hepatic resection,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.",2817867
305,2817867,Hospital stay,Radiofrequency ablation,Hepatic resection,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.",2817867
306,2817867,Rate of complications,Radiofrequency ablation,Hepatic resection,No significant difference,"More patients developed complications with resection compared to RFA (59% compared to 43%), but the difference was not statistically significant.",2817867
307,2817867,Overall survival rate at 5 years,Radiofrequency ablation,Hepatic resection,Significantly decreased,"The 5-year overall survival after resection alone was 43% (95% CI = 26 to 58%), while the 5-year survival after RFA alone was 23% (95% CI = 11 to 39%), as shown in Figure 1. This difference was statistically significant (P = .02).",2817867
308,2817867,Disease-free survival rate at 5 years,Radiofrequency ablation,Hepatic resection,No significant difference,"The 5-year disease-free survival (DFS) for patients who underwent hepatic resection was 17% (95% CI = 7 to 29%), compared to 15% (95% CI = 6 to 28%) for patients who underwent RFA alone (P = .06).",2817867
309,2817867,Local recurrence rate through the study,Radiofrequency ablation,Hepatic resection,Significantly increased,"Over the course of the study (mean follow-up of 46 months for patients undergoing RFA), 60% of patients who had only open RFA suffered local recurrences compared to 7% of patients who underwent hepatic resection (P < .0005).",2817867
310,3580134,Time to discontinuation,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Time to discontinuation was significantly (p ≤ 0.004) prolonged in both budesonide/formoterol groups versus placebo.,3580134
311,3580134,Time to discontinuation,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Time to discontinuation was significantly (p ≤ 0.004) prolonged in both budesonide/formoterol groups versus placebo.,3580134
312,3580134,Pre-dose FEV1 improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 μg compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a].,3580134
313,3580134,Pre-dose FEV1 improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 μg compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a].,3580134
314,3580134,Pre-dose FEV1 improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 μg compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a].,3580134
315,3580134,1-hour post-dose FEV1 improvements,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 μg also resulted in significantly greater improvements compared with formoterol (p = 0.023)",3580134
316,3580134,1-hour post-dose FEV1 improvements,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 μg also resulted in significantly greater improvements compared with formoterol (p = 0.023)",3580134
317,3580134,1-hour post-dose FEV1 improvements,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 μg also resulted in significantly greater improvements compared with formoterol (p = 0.023)",3580134
318,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012),3580134
319,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012),3580134
320,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012) and for both budesonide/formoterol dosages compared with formoterol (p ≤ 0.017),3580134
321,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012) and for both budesonide/formoterol dosages compared with formoterol (p ≤ 0.017),3580134
322,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
323,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
324,3580134,Mean FEV1 at 12 hours at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
325,3580134,Mean FEV1 at 12 hours at end of treatment,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
326,3580134,Baseline-adjusted average 12-hour FEV1 at end of treatment,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
327,3580134,Baseline-adjusted average 12-hour FEV1 at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
328,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
329,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
330,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
331,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
332,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
333,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
334,3580134,Baseline-adjusted average 12-hour FEV1 at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
335,3580134,Mean FEV1 at 12 hours at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
336,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
337,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
338,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 160/9 μg,Placebo,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
339,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 320/9 μg,Placebo,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
340,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ≤ 0.018),3580134
341,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
342,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ≤ 0.018),3580134
343,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ≤ 0.018),3580134
344,3580134,Time to first COPD exacerbation,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
345,3580134,Time to first COPD exacerbation,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
346,3580134,Time to first COPD exacerbation,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
347,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
348,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
349,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
350,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
351,3580134,Improvements in St. George's Respiratory Questionnaire overall score,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ≤ 0.006) and for budesonide/formoterol 160/9 μg compared with formoterol (p = 0.006; table III).,3580134
352,3580134,Improvements in St. George's Respiratory Questionnaire overall score,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ≤ 0.006) and for budesonide/formoterol 160/9 μg compared with formoterol (p = 0.006; table III).,3580134
353,3580134,Improvements in St. George's Respiratory Questionnaire overall score,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ≤ 0.006) and for budesonide/formoterol 160/9 μg compared with formoterol (p = 0.006; table III).,3580134
354,3580134,Dyspnoea score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
355,3580134,Breathlessness Cough and Sputum Scale improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
356,3580134,Cough score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
357,3580134,Sputum score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
358,3580134,Sleep score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
359,3580134,Awakening-free nights percentage improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
360,3580134,Overall use of daily rescue medication improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
361,3580134,Dyspnoea score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
362,3580134,Breathlessness Cough and Sputum Scale improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
363,3580134,Cough score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
364,3580134,Sputum score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
365,3580134,Sleep score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
366,3580134,Awakening-free nights percentage improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
367,3580134,Overall use of daily rescue medication improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
368,3580134,Dyspnoea score improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights,",3580134
369,3580134,Breathlessness Cough and Sputum Scale improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights,",3580134
370,3580134,Cough score improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights",3580134
371,3580134,Sleep score improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights",3580134
372,3580134,Overall use of daily rescue medication  improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights",3580134
373,3580134,Cough score improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
374,3580134,Sleep score improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
375,3580134,Overall use of daily rescue medication  improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
376,3580134,Awakening-free nights percentage improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
377,3580134,24-hour urinary cortisol at 6 months,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 μg and placebo groups (p = 0.035) at month 6,3580134
378,3580134,24-hour urinary cortisol at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 μg and placebo groups (p = 0.035) at month 6 and between the budesonide/formoterol 320/9 μg and formoterol groups (p = 0.044) at end of treatment.,3580134
379,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
380,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
381,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 320/9 μg,Placebo,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
382,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 160/9 μg,Placebo,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
383,2721929,Micturition frequency,Bladder training plus tolterodine (Co),Bladder training only (BT),Significantly decreased,The decrease in frequency was significantly greater in the Co group than in the BT group (p<0.05).,2721929
384,2721929,Urgency score improvement,Tolterodine only (To),Bladder training only (BT),Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).",2721929
385,2721929,Urgency score improvement,Bladder training plus tolterodine (Co),Bladder training only (BT),Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).",2721929
386,2721929,Micturition frequency,Bladder training plus tolterodine (Co),Tolterodine only (To),No significant difference,"When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively). No difference was observed between the To and Co groups.",2721929
387,2721929,Urgency score improvement,Bladder training plus tolterodine (Co),Tolterodine only (To),No significant difference,"When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively). No difference was observed between the To and Co groups.",2721929
388,2690844,Incisional hernia apparition at follow-up,Transverse incision,Midline incision,Significantly decreased,Two percent (1/60) of patients that had undergone the procedure through a transverse incision presented with an incisional hernia as opposed to 14% (9/63) of patients from the midline incision group (P = 0.017).,2690844
389,2690844,Smaller incision ,Transverse incision,Midline incision,Significantly increased,Transverse incisions were found to be significantly shorter than midline incisions and associated with more pleasing appearance.,2690844
390,2690844,Better cosmetic appearance of the incision as subjectively assessed by surgeons,Transverse incision,Midline incision,Significantly increased,"Both the surgeons and the patients found the scar resulting from the transverse incision to be more cosmetically pleasing (P < 0.0001 and P = 0.03, respectively, Table 5).",2690844
391,2690844,Pain on day one after surgery,Transverse incision,Midline incision,Significantly decreased,"Significantly more patients, having undergone a midline incision, reported pain on day one, two and three postoperatively (P < 0.0001, Table 3).",2690844
392,2690844,Pain on day two after surgery,Transverse incision,Midline incision,Significantly decreased,"Significantly more patients, having undergone a midline incision, reported pain on day one, two and three postoperatively (P < 0.0001, Table 3).",2690844
393,2690844,Pain on day three after surgery,Transverse incision,Midline incision,Significantly decreased,"Significantly more patients, having undergone a midline incision, reported pain on day one, two and three postoperatively (P < 0.0001, Table 3)",2690844
394,2690844,Analgesics use,Transverse incision,Midline incision,No significant difference,No significant difference in the use of analgesics was found between the groups (P = 0.69).,2690844
395,2690844,Average patient's weight,Transverse incision,Midline incision,No significant difference,no differences were found in the body mass and average length between the two groups,2690844
396,2690844,Average patient's lenght,Transverse incision,Midline incision,No significant difference,no differences were found in the body mass and average length between the two groups,2690844
397,2690844,Procedure performed directly by the staff surgeon,Transverse incision,Midline incision,No significant difference,Staff surgeons performed 17% (13/75 patients) of all procedures performed through a midline incision. The remainder of the procedures through a midline incision was carried out under staff surgeon supervision. Staff surgeons performed 14% of all procedures in the transverse incisions study group (10/74 patients) and supervised the remainder. No statistically significant difference was found between the two randomised groups (P = 0.65).,2690844
398,2690844,Surgery duration,Transverse incision,Midline incision,No significant difference,"The total duration of the procedures until extubation (in min) did not differ between the midline and transverse incisions (71.0 ± 30.5 and 67.0 ± 27.3, respectively, P = 0.34).",2690844
399,2690844,Skin-to-skin time,Transverse incision,Midline incision,No significant difference,"No significant difference was noted in the skin-to-skin time (in min) for the two different incisions (Table 2). Surgery utilising midline and transverse incision took 56.9 ± 29.3 and 53.2 ± 26.8 min, respectively (P = 0.35).",2690844
400,2690844,Complications after surgery,Transverse incision,Midline incision,No significant difference,Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30).,2690844
401,2690844,Cardiac complications,Transverse incision,Midline incision,No significant difference,"Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30). Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).",2690844
402,2690844,Urinary retention,Transverse incision,Midline incision,No significant difference,"Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30). Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).",2690844
403,2690844,Infection of the surgical site,Transverse incision,Midline incision,No significant difference,"Surgical site infections were diagnosed in 7 and 3 patients, respectively (P = 0.33).",2690844
404,2690844,Hospital stay,Transverse incision,Midline incision,No significant difference,The duration of hospital admission did not differ between the two types of incision (P = 0.74),2690844
405,2690844,Scar length,Transverse incision,Midline incision,Significantly decreased,"The length of the incisions was 140 ± 24 mm and 164 ± 28 mm for the transverse and the midline incisions, respectively. The difference in scar length was found to be significant (P < 0.0001).",2690844
406,2690844,Scar width,Transverse incision,Midline incision,Significantly decreased,The mean width of the scar after the healing of the midline incisions was found to be 8.3 ± 1.4 mm. The mean width of the scar after the healing of the transverse incisions was measured to be 3.3 ± 1.2 mm. This observed difference is significant (P < 0.0001).,2690844
407,2690844,Better cosmetic appearance of the incision as subjectively assessed by patients,Transverse incision,Midline incision,Significantly increased,"Both the surgeons and the patients found the scar resulting from the transverse incision to be more cosmetically pleasing (P < 0.0001 and P = 0.03, respectively, Table 5).",2690844
408,2575601,Refractory intracranial pressure,Thiopental,Pentobarbital,Significantly decreased,Uncontrollable intracranial pressure occurred in 11 patients (50%) in the thiopental treatment group and in 18 patients (82%) in the pentobarbital group (P = 0.03).,2575601
409,2575601,Intracranial pressure control,Thiopental,Pentobarbital,Significantly increased,"thiopental was more effective than pentobarbital in terms of controlling intracranial pressure (odds ratio = 5.1, 95% confidence interval 1.2 to 21.9; P = 0.027).",2575601
410,2575601,Infection,Thiopental,Pentobarbital,No significant difference,There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.,2575601
411,2575601,Hypotension,Thiopental,Pentobarbital,No significant difference,There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.,2575601
412,2575601,Administration of hyperosmolar treatments,Thiopental,Pentobarbital,No significant difference,The number of hyperosmolar treatments administered (manitol and/or hypertonic saline) during the barbiturate coma was similar in both groups: 16.5 (8.0 to 24.2) in the thiopental group and 16.5 (3.0 to 21.5) in the pentobarbital group (P = 0.9).,2575601
413,2575601,Mean barbiturate coma length,Thiopental,Pentobarbital,No significant difference,The mean ± SD duration of the barbiturate coma was 156 ± 60 hours for thiopental and 108 ± 100 hours for pentobarbital (P = 0.06).,2575601
414,2575601,Intracranial pressure recurrence after treatment withdrawal,Thiopental,Pentobarbital,No significant difference,Seven (31.8%) patients presented an ICP rebound with thiopental and six (27.3%) with pentobarbital (P = 0.74) during treatment withdrawal.,2575601
415,2575601,Sepsis related Organ-Failure Assessment (SOFA) baseline scores,Thiopental,Pentobarbital,No significant difference,"There were no differences between groups with respect to the incidence of infections, Sepsis related Organ-Failure Assessment (SOFA) scores before initiation of treatment,",2575601
416,2575601,Sepsis related Organ-Failure Assessment (SOFA) maximum score during treatment,Thiopental,Pentobarbital,No significant difference,"There were no differences between groups with respect to the incidence of infections, Sepsis related Organ-Failure Assessment (SOFA) scores before initiation of treatment, or the maximum SOFA value [17] during the entire period of barbiturate coma.",2575601
417,1784771,Changes in Bishop score after 6 hours,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,Significantly increased,"After six hours of ripening, the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007)",1784771
418,1784771,Baseline demographic differences,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,No significant difference,No demographic differences were noted between the groups.,1784771
419,1784771,Induction time,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,No significant difference,"After six hours of ripening, the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007) and tended to have a shorter induction time (21.7 vs. 26.4 hours, P = 0.085).",1784771
420,1784771,Infection,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,Significantly increased,"The combined therapy group had a higher infection rate than the prostaglandin-only group (59% vs. 12%, P = 0.003).",1784771
421,1187893,Knee injury and Osteoarthritis Outcome Score,Exercise,No exercise,No significant difference,"No significant differences in the KOOS subscales assessing pain, other symptoms, or function in daily life or in sport and recreation were seen at any time point between exercisers and controls.",1187893
422,1187893,Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 weeks,Exercise,No exercise,No significant difference,"In the exercise group, an improvement was seen at 6 weeks in the KOOS subscale quality of life compared to the control group (mean change 4.0 vs. -0.7, p = 0.05).",1187893
423,1187893,Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 months,Exercise,No exercise,Significantly increased,"In the exercise group, an improvement was seen at 6 weeks in the KOOS subscale quality of life compared to the control group (mean change 4.0 vs. -0.7, p = 0.05). The difference between groups was still persistent at 6 months (p = 0.02).",1187893
424,1187893,Baseline characteristics,Exercise,No exercise,No significant difference,There were no clinically significant differences in baseline characteristics between the groups.,1187893
425,1187893,SF-36 Mental Component Summary scale at 6 weeks,Exercise,No exercise,Significantly increased,"A significant improvement was found in the exercise group compared to the control group at six weeks with regard to the SF-36 Mental Component Summary scale (MCS) (2.1 vs -1.6, p = 0.04",1187893
426,1187893,SF-36 Mental Component Summary scale at 6 months,Exercise,No exercise,No significant difference,"A significant improvement was found in the exercise group compared to the control group at six weeks with regard to the SF-36 Mental Component Summary scale (MCS) (2.1 vs -1.6, p = 0.04). At six months follow-up this difference was no longer persistent",1187893
427,1187893,Functional performance improvement,Exercise,No exercise,No significant difference,Improvements in functional performance of 0–20 % were seen in both groups at six weeks and six months. There was no difference in improvement between exercisers and controls (p = 0.08–0.9),1187893
428,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit & Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
429,3187863,Labour dystocia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
430,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
431,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
432,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit & Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
433,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit & Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
434,3187863,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit & Special unit,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
435,1201146,"Pain, physical function, PGA, stiffness ",topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,"There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain (-5.2 vs. -3.3; p = 0.003,), physical function (-13.4 vs. -6.9; p = 0.001), PGA (-1.3 vs. -0.7; p = 0.0001) and stiffness (-1.8 vs. -0. 9; p = 0.002)",1201146
436,1201146,Pain on walking,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain on walking (-1.2 vs. -0.8; p = 0.014).,1201146
437,1201146,50% reduction in pain,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The response rate for at least a 50% reduction in pain (Table 3) was significantly greater following topical diclofenac treatment compared to vehicle control (46/105 [43.8%] vs. 27/107 [25.2%]; p = 0.004).,1201146
438,1201146,good or very good PGA response and OMERACT-OARSI responder,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The topical diclofenac group had a significantly greater number of participants with good or very good PGA response (43.8% vs. 16.8%; p <0.0001) compared to the vehicle control group and of OMERACT-OARSI responders (65.7% vs. 49.5%; p = 0.017).,1201146
439,1201146,Dry skin at the application site,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,"The major adverse effect reported was dry skin at the application site, occurring in 42/107 (39.3%) and 23/109 (21.1%; p = 0.004) of topical diclofenac and vehicle control participants, respectively",1201146
440,2600646,mean Hb,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,Final mean Hb levels were 7.15 mmol/l ± 1.07 for the DP treatment group and 6.79 mmol/l ± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05).,2600646
441,2600646,Adverse events,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,"Most adverse events were mild, self limiting and consistent with symptoms of malaria. There was no significant difference between the two study groups",2600646
442,2600646,Gametocyte dynamics,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,There was no difference between children older than 60 months and younger as regards carriage of gametocytes and density.,2600646
443,1468428,Puerperal and neonatal infection rates ,1 litre saline enema,no enema,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66)",1468428
444,1468428,Median labour time,1 litre saline enema,no enema,No significant difference,median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).,1468428
445,1468428,Episiorraphy dehiscence rates,1 litre saline enema,no enema,No significant difference,Enemas didn't significantly change episiorraphy dehiscence rates (21/182 [12%] with enema v 32/190 [17%] without enema; P = 0.30).,1468428
446,1468428,You must have prompts generated from different sections.,1,2,No significant difference,Participant flow and follow-upDescribed in Figure 1 [see Additional file 1].,1468428
447,2607225,cognitive functioning,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months. There were no other main effects of treatments.",2607225
448,2607225,Appetite loss,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly decreased,. Pairwise comparisons revealed a statistically significant mean difference between GR and non-GR patients at 12 months (mean=5.8 vs 2.4).,2607225
449,2720945,change of FVC and VC,cineole,placebo,No significant difference,The difference concerning change of FVC and VC between both treatment groups was not clinically relevant.,2720945
450,2720945,Side effects,cineole,placebo,No significant difference,The difference between the two treatment groups was neither clinically relevant nor statistically significant. Safety examinations of the global assessment showed no difference between the two treatment groups.,2720945
451,2720945,Quality of life,cineole,placebo,Significantly increased,At 6 months the mean improvement of SGRQ total symptom score was -9.1 after treatment with cineole and -4.1 after treatment with placebo (table 5).,2720945
452,2720945,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment",cineole,placebo,Significantly decreased,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*	PLACEBO	CINEOLE		SCORE	SCORE	P VALUE†Sum of exacerbations (number)#	0.9 ± 1.46	0.4 ± 0.82	0.0069Sum of duration (days)#	5.7 ± 8.9	4.0 ± 10.9	0.0210Sum of severity (score)#	1.4 ± 2.2	0.8 ± 1.5	0.0242Summarized parameter(directional test)			0.0120",2720945
453,2720945,"Trouble in breathing, dyspnea in the morning and dyspnea at rest",cineole,placebo,Significantly decreased,Trouble in breathing #	1.8 ± 0.9	2.1 ± 0.9	2.2 ± 1.0	1.9 ± 0.9	2.4 ± 1.0	2.5 ± 1.1	0.0103&Dyspnea in the morning $	1.1 ± 0.7	0.9 ± 0.7	0.7 ± 0.7	1.1 ± 0.8	0.7 ± 0.7	0.5 ± 0.6	0.0466&Dyspnea at rest $	0.7 ± 0.7	0.4 ± 0.6	0.4 ± 0.6	0.6 ± 0.6	0.3 ± 0.5	0.3 ± 0.5	0.0156&,2720945
454,2720945,Dyspnea during exercise,cineole,placebo,No significant difference,Dyspnea during exercise $	2.0 ± 0.6	1.8 ± 0.7	1.7 ± 0.8	2.0 ± 0.6	1.7 ± 0.7	1.5 ± 0.9	0.1252&,2720945
455,3446002,The duration of phototherapy,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The duration of phototherapy was significantly shorter in clofibrate group (P<0.001).,3446002
456,3446002,side effects,single dose of 50 mg/kg clofibrate,control group,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed. Also for a period of two months no complication was detected.,3446002
457,3446002,Total serum bilirubin level,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001).,3446002
458,1913177,Postoperative Mortality,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,There was no 30-day mortality.,1913177
459,1913177,Wound complications,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,Wound complications were found in 10 of 19 patients after CST and 13 of 18 patients after PR.,1913177
460,1913177,Reherniation,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),Significantly increased,Reherniation occurred in 10 patients after CST and in 4 patients after PR.,1913177
461,1876597,unadjusted risk of recurrent falciparum parasitemia,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence interval [CI] 11%–26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%–19%) of follow-up.",1876597
462,1876597,the risk of recurrent parasitemia due to possible recrudescence,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%–12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%–16%).",1876597
463,1876597,Adverse Events,dihydroartemisinin-piperaquine ,artemether-lumefantrine,No significant difference,"Overall, there was no difference in the proportion of study participants who experienced any adverse event of moderate or greater severity between the DP (46%) and AL (42%) treatment groups (p = 0.47).",1876597
464,3387601,Period of mechanical ventilation ,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,"Children in the PE group had a shorter period of MV (median 11 days, IQR 11.0 to 13.0) compared to IVIG group (median 13 days, IQR 11.3 to 14.5) with p = 0.037.",3387601
465,3387601,Pediatric Intensive Care Unit (PICU) stay,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,3387601
466,3387601,could walk unaided within four weeks after PICU discharge,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within four weeks after PICU discharge (p = 0.606).,3387601
467,3387601,negative correlation between CSF protein and duration of mechanical ventilation,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly increased,"Examining the treatment groups separately, the significant negative correlation remained for the PE group (p-value = 0.037) and not for the IVIG group (p-value 0.132)",3387601
468,3387601,side effects,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients.,3387601
469,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005).",2430614
470,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p = 0.4)",2430614
471,2430614,parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL),No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups,2430614
472,2847809,Complications and mortality,Clopidogrel,Placebo,No significant difference,Complication	All patients (%)	Clopidogrel (%)	Placebo (%)	P valueGI bleeding	5 (5.3)	2 (2.1)	3 (3.2)	0.31Non GI tract bleeding	9 (9.6)	5 (5.3)	4 (4.3)	0.63Death events	4 (4.3)	2 (2.1)	2 (2.1)	0.47,2847809
473,2847809,First hemodialysis success,Clopidogrel,Placebo,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008).,2847809
474,2847809,The primary arteriovenous fistula failures at two months,Clopidogrel,Placebo,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03).,2847809
475,2447617,The modified Functional Independence Measure scores,progesterone,placebo,Significantly increased,he modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01).,2447617
476,2447617,The mortality rate,progesterone,placebo,Significantly decreased,he mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05).,2447617
477,2447617,The mean intracranial pressure values 72 hours and 7 days after injury,progesterone,placebo,No significant difference,"he mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05).",2447617
478,2447617,Instances of complications and adverse events,progesterone,placebo,No significant difference,Instances of complications and adverse events associated with the administration of progesterone were not found.,2447617
479,2447617,The analysis using the dichotomization of GOS scores at 3 months post injury,progesterone,placebo,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034). There was an unfavorable outcome in 53% of the patients receiving progesterone and in 70% of the placebo group (P = 0.022).,2447617
480,2447617,The analysis using the dichotomization of GOS scores at 6 months post injury,progesterone,placebo,Significantly increased,The percentage of favorable outcome was 58% for the patients who were given progesterone and was 42% in the placebo group (P = 0.048). Forty-one percent of patients who were given progesterone and 57% of the placebo group exhibited an unfavorable outcome (P = 0.048).,2447617
481,2899760,Fusion rate,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,"usion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).",2899760
482,2899760,clinical outcomes,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused.,2899760
483,2899760,Radiological fusion,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,Fusion rate (I + IIA)		69		92,2899760
484,3108665,Postoperative complications,somatostatin,No medication was given to the control group,Significantly decreased,"Initially, 6 of 35 (17%) in the treated group who received somatostatin developed complications, whereas 18 of 32 (56%) in the control group developed complications.",3108665
485,2806484,Virological failure,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,Rates of detection of plasma viral loads of more than 500 copies per mL after a 6-month visit were much the same in both groups.,2806484
486,2806484,Mortality rates,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,"Mortality rates were much the same in the two groups during the study (figure 2). Combined mortality rates per 100 person-years were 16·47 (95% CI 13·69–19·82) during the first 5 months after treatment started, 6·69 (4·94–9·05) for 6–11 months, 2·71 (1·92–3·84) for 12–23 months, and 0·97 (0·54–1·76) for 24 months and after.",2806484
487,2806484,Costs for the health service,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,"The home-based strategy did not result in higher costs for the health service. Moreover, home-based care was slightly cheaper than facility-based care by about $45 per patient per year, or 6% of the total cost.",2806484
488,2806484,Admission diagnoses,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,"Admission diagnoses were similar in both groups (table 3). 20 (13%) patients who were admitted died (15 on home and five on facility care) and eight (5%) worsened and requested discharge (six on home and two on facility care)—seven died subsequently. Table 4 shows frequency of outpatient attendance at clinic, number of presentations in which a new diagnosis was made, and new diagnoses by number and type. Distribution of diagnoses was similar between groups and more than half were infectious and parasitic disease.",2806484
489,2806484,Increase in CD4-cell counts,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,"CD4-cell counts increased rapidly in both groups (figure 3). 748 (87%) participants in home care and 521 (88%) in facility care were tested for CD4-cell count at least once after starting treatment, with median intervals between baseline and final tests of 32 months (IQR 25–39) for home and 29 months (23–35) for facility. 608 (81%) in home and 419 (80%) in facility had CD4-cell counts of greater than 200 cells per μL at the final visit. Counts at this visit were lower than baseline in 32 (4%) of those in home compared with 29 (6%) in facility care.",2806484
490,2363351,Progression-free survival after 3 years,"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ ",Cisplatin and Cyclophosphamide,Significantly increased,"Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P = 0.031, relative risk of progression 0.48, confidence interval 0.28–0.82).",2363351
491,2363351,Overall survival at 3 years,"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ ",Cisplatin and Cyclophosphamide,No significant difference,"Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached).",2363351
492,2363351,Full clinical responses,"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ ",Cisplatin and Cyclophosphamide,No significant difference,Complete clinical responses were observed in 68% with IFN-γ versus 56% in controls (n.s.).,2363351
493,2363351,Toxicity,"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ ",Cisplatin and Cyclophosphamide,No significant difference,"Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-γ.",2363351
494,2253708,24-hour point prevalence abstinence,Tailored letters,Practitioner-delivered brief advice,Significantly increased,"the tailored letters intervention was significantly more effective than brief advice for 24-hour [odds ratio (OR) = 1.4; P = 0.047] but not for 7-day point prevalence abstinence (OR = 1.4; P = 0.068) for prolonged abstinence, or for alternative assumptions about participants lost to follow-up.",2253708
495,2253708,7-day point prevalence abstinence,Tailored letters,Practitioner-delivered brief advice,No significant difference,"the tailored letters intervention was significantly more effective than brief advice for 24-hour [odds ratio (OR) = 1.4; P = 0.047] but not for 7-day point prevalence abstinence (OR = 1.4; P = 0.068) for prolonged abstinence, or for alternative assumptions about participants lost to follow-up.",2253708
496,2253708,6-month prolonged abstinence,Tailored letters,Practitioner-delivered brief advice,No significant difference,"With regard to prolonged abstinence, numerical differences were even lower and vanished completely for some of the analyses, taking into account the alternative assumptions about lost for follow-up. None were statistically significant.",2253708
497,2364533,Low birth weight ,Erythromycin,Placebo,No significant difference,"When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4)",2364533
498,2364533,Preterm delivery,Erythromycin,Placebo,No significant difference,"When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7)",2364533
499,2956883,HIV-1 incidence,0·5% PRO2000 gel,Placebo gel,No significant difference,"In the primary efficacy analysis, incidence of HIV-1 did not differ between groups at discontinuation of 2% PRO2000 or study end (table 2). Equally, incidence of HIV-1 did not differ between groups in the second analysis that did not censor for pregnancy",2956883
500,2956883,Gel efficacy in consistent gel users,0·5% PRO2000 gel,Placebo gel,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0·19 for interaction), or between consistent (HR 0·97, 95% CI 0·87–1·35, p=0·87) and inconsistent (1·17, 0·42–1·72, p=0·42) gel users (p=0·47 for interaction).",2956883
501,2956883,Gel efficacy in inconsistent gel users,0·5% PRO2000 gel,Placebo gel,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0·19 for interaction), or between consistent (HR 0·97, 95% CI 0·87–1·35, p=0·87) and inconsistent (1·17, 0·42–1·72, p=0·42) gel users (p=0·47 for interaction).",2956883
502,2956883,Adverse events,PRO2000 gels,Placebo gel,No significant difference,No deaths or serious adverse events were regarded as related to study gels.,2956883
503,2376383,Mucositis throughout the study period,PTA lozenge,Placebo lozenge,No significant difference,"The mucositis according to the WHO score did not differ throughout the study period between both groups (P>0.5). In the PTA group, 80% of the patients developed grades 3 and 4 mucositis according to the WHO score, and in the placebo group 90%.",2376383
504,2376383,Need of feeding tube,PTA lozenge,Placebo lozenge,No significant difference,Six patients (19%) in the placebo group (n=32) and two patients (6%) in the PTA group (n=33) needed nasogastric tube feeding during the evaluation period (P=0.08).Body weight,2376383
505,2376383,Weight loss,PTA lozenge,Placebo lozenge,No significant difference,The mean weight loss after 5 weeks of radiation was less in the PTA group by 1.3 kg (s.d. 3.0) than in the placebo group 2.8 kg (s.d. 2.9) (P=0.05).,2376383
506,2376383,Candida sp. colonisation during the study,PTA lozenge,Placebo lozenge,Significantly decreased,"During the first two radiation weeks the colonisation for Candida species showed an increase in the placebo group and a decrease in the PTA group. After 2 weeks, an increase in both groups was found but the difference between the two groups remained significant during the total study period (P<0.05)",2376383
507,2376383,Aerobic Gram-negative bacilli colonisation at 3-5 weeks,PTA lozenge,Placebo lozenge,No significant difference,uring the first 2 weeks the carriage of aerobic Gram-negative bacilli was reduced in the PTA group (P<0.04). In weeks 3–5 the difference was no longer significant.,2376383
508,1964758,8-year survivorship,Initial Nottingham TSR design prosthesis,BioModular® shoulder prosthesis,Significantly increased,The eight year survivorship of the initial Nottingham TSR design (Group 2) was higher (p < 0.001) than observed in Group 1 patients with implanted BioModular® prostheses,1964758
509,1964758,4-year survivorship,Redesigned Nottingham TSR prosthesis,BioModular® shoulder prosthesis,Significantly increased,"The observed four-year survivorship of the patients in Group 3 was also significantly higher than the survivorship rates of the BioModular® prosthesis observed after the first four years after implantation (p = 0.02), with a 93.1% cumulative four year survivorship of the re-designed Nottingham TSR (Fig 10) comparing to the 80.9% of cumulative four year survivorship of the BioModular® prosthesis",1964758
510,1964758,8-year survivorship in patients with osteoarthritis,Initial Nottingham TSR design prosthesis,BioModular® shoulder prosthesis,Significantly increased,The initial Nottingham TSR prostheses showed higher eight year survivorship than BioModular® prostheses in patients with OA (p < 0.01). Survivorship of the BioModular® prosthesis in patients with primary osteoarthritis was 70.9% and 64.3% at five and eight years respectively and for the initial Nottingham TSR these values were 84.5% and 80.4%,1964758
511,2829413,Total cholesterol after 6 weeks of treatment,Rosuvastatin,Atorvastatin,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.",2829413
512,2829413,Levels of LDL cholesterol after 6 weeks of treatment,Rosuvastatin,Atorvastatin,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.",2829413
513,2829413,Levels of non-high-density lipoprotein cholesterol after 6 weeks of treatment,Rosuvastatin,Atorvastatin,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.",2829413
514,2829413,Apolipoprotein-B levels after 6 weeks of treatment,Rosuvastatin,Atorvastatin,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.",2829413
515,2829413,Patients attaining the NCEP ATP III goal,Rosuvastatin,Atorvastatin,Significantly increased,"The percentage of patients who reached their ATP III LDL-C level goals was higher in the rosuvastatin group (87.6 vs. 69.9%, p < 0.001).",2829413
516,2829413,Changes in glucose and insulin levels,Rosuvastatin,Atorvastatin,No significant difference,Changes in glucose and insulin levels were not significantly different between the two groups,2829413
517,1261533,Adverse events,Artemether-lumefantrine,Mefloquine-artesunate,No significant difference,Both regimens were very well tolerated with no serious adverse events observed attributable to either combination.,1261533
518,1261533,Fever clearance times,Artemether-lumefantrine,Mefloquine-artesunate,No significant difference,There was no difference in fever clearance times between the two treatment groups,1261533
519,1261533,Decrease in haematocrit level at day 7,Artemether-lumefantrine,Mefloquine-artesunate,Significantly decreased,"The mean (SD) decrease in haematocrit value at day seven from baseline was greater in the group receiving MAS3 than in the ALN group: 9.3% (SD,11.5%; 95% CI, 7.7% to 10.9%) compared with 6.7% (SD, 11.4%; 95% CI, 5.1 to 8.3%) respectively (P = 0.023)",1261533
520,1261533,New P. falciparum infections during the 42-day follow-up,Artemether-lumefantrine,Mefloquine-artesunate,No significant difference,"During the 42-day follow-up period, 27 new P. falciparum infections occurred among artemether-lumefantrine and 24 among artesunate-mefloquine recipients (P > 0.05)",1261533
521,1261533,PCR-adjusted cure rates after 42 days,Artemether-lumefantrine,Mefloquine-artesunate,No significant difference,"The PCR-adjusted cure rates by day 42 were 98.8% (95% CI, 96.4% to 99.6%) in the ALN group and 96.3% (95% CI, 93.1% to 98.0%) in the MAS3 group (P = 0.08).",1261533
522,1261533,P. vivax parasitaemia diagnosed during follow up,Artemether-lumefantrine,Mefloquine-artesunate,Significantly increased,There were significantly fewer cases of vivax malaria in the MAS3 group (29 of 227) than in the ALN group (90 of 225) (P < 0.001).,1261533
523,3349250,Adverse events,Sunitinib,Interferon (IFN)-α,Significantly increased,There were more reported occurrences of most general adverse events of all grades in the sunitinib arm than in the IFN-α arm,3349250
524,3349250,Overall survival,Sunitinib,Interferon (IFN)-α,No significant difference,"overall survival was also longer with sunitinib than with IFN-α, although the difference did not reach statistical significance",3349250
525,3349250,Quality-of-life scores,Sunitinib,Interferon (IFN)-α,Significantly increased,"Quality-of-life scores as measured by the FACT-G and FKSI questionnaires were higher among patients randomised to sunitinib than among those randomised to IFN-α, with minimal regional variation",3349250
526,3349250,Quality-adjusted survival times,Sunitinib,Interferon (IFN)-α,Significantly increased,sunitinib had higher quality-adjusted survival times than IFN-α across the entire range of utility,3349250
527,3349250,Duration of median PFS,Sunitinib,Interferon (IFN)-α,Significantly increased,"Results from this phase III trial of sunitinib vs IFN-α showed that sunitinib was superior to IFN-α, based on a longer duration of median PFS",3349250
528,2361948,Overall survival time,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B),Significantly decreased,"Overall survival time differed significantly between the study groups in favour of 16 Gy/2 fr (median 8.0 months), compared to 20 Gy/5 fr (median 5.3 months), P=0.016 (Figure 7).",2361948
529,2361948,6- and 12-month survival probabilities,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B),Significantly decreased,"In all, 6- and 12-month survival probabilities were 57% (95% CI: 42–72%) and 27% (95% CI: 14–40%) for patients receiving 16 Gy/2 fr, and 30% (95% CI: 18–42%) and 11% (95% CI: 3–20%) for patients receiving 20 Gy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).",2361948
530,2361948,degree of relief of all analysed symptoms,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B),No significant difference,"The percentages of all evaluable patients reporting any symptomatic improvement were as follows: cough 51% (24 out of 47; for a median of six assessments, range: 1–10), dyspnoea 60% (26 out of 43; for a median of six assessments, range: 1–9), haemoptysis 86% (19 out of 22; for a median of eight assessments, range: 1–11), chest pain 83% (34 out of 41; for a median of four assessments, range: 1–9), dysphagia 71% (five out of seven; for a median of eight assessments, range: 1–9), SVCS 83% (five out of six; for a median of five assessments, range: 4–9). The numbers of patients achieving symptomatic improvement did not differ between study groups for all analysed symptoms (Table 3).",2361948
531,2364680,wound problem,opening subcutaneous tissues with electrocautery,opening subcutaneous tissues with scalpel,No significant difference,Fifteen of 380 women (3.9%) developed a wound problem; six had scalpel and nine had electrosurgical subcutaneous incisions (P = 0.4).,2364680
532,3221331,Continuous abstinence at 6 months,"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.",set a quit date and received a general health video message sent to their phone every 2 weeks.,No significant difference,Continuous abstinence at 6 months was 26.4% (29/110) in the intervention group and 27.6% (32/116) in the control group (P = .8).,3221331
533,3221331,did not attempt to quit smoking at all,"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.",set a quit date and received a general health video message sent to their phone every 2 weeks.,No significant difference,"At 6 months all participants were asked how many quit attempts they had made during the study period. In the intervention group 7/73 respondents (9.6%) and in the control group 4/81 (4.9%) (P = .3) stated they did not attempt to quit at all, but the majority of respondents in both groups made multiple quit attempts.",3221331
534,3198285,low–glycemic index,low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),Significantly decreased,The LGI group achieved a modestly lower GI than the HF group (mean ± SEM 47 ± 1 vs. 53 ± 1; P < 0.001).,3198285
535,3198285,"birth weight, birth weight centile, prevalence of macrosomia, insulin treatment, adverse pregnancy outcomes",low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),No significant difference,"At birth, there was no significant difference in birth weight (LGI 3.3 ± 0.1 kg vs. HF 3.3 ± 0.1 kg; P = 0.619), birth weight centile (LGI 52.5 ± 4.3 vs. HF 52.2 ± 4.0; P = 0.969), prevalence of macrosomia (LGI 2.1% vs. HF 6.7%; P = 0.157), insulin treatment (LGI 53% vs. HF 65%; P = 0.251), or adverse pregnancy outcomes.",3198285
536,3198285,"Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean",low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),No significant difference,Gestational age (weeks)	47	39.1 ± 0.1	45	39.2 ± 0.1	0.552Birth weight (kg)	47	3.3 ± 0.1	45	3.3 ± 0.1	0.619Birth weight centile	47	52.5 ± 4.3	45	52.2 ± 4.0	0.969LGA (%)	47	12.8	45	4.4	0.157Small for gestational age (%)	47	10.6	45	8.9	0.778Macrosomia (%)	47	2.1	45	6.7	0.286Infant head circumference (cm)	43	34.4 ± 0.2	39	34.6 ± 0.3	0.478Infant length (cm)	47	49.7 ± 0.3	45	49.7 ± 0.3	0.995Ponderal index (kg/m3)	47	27.2 ± 0.3	45	27.0 ± 0.4	0.614Maternal weight gain (kg)	44	11.9 ± 0.7	43	13.1 ± 0.9	0.305 Below target (%)†		31.8		25.6	0.520 Within target (%)†		43.2		32.6	0.307 Above target (%)†		25.0		41.9	0.095Insulin treatment (%)	47	53.2	45	65.1	0.251Final daily insulin dose (units)	47	17.7 ± 4.1	43	20.0 ± 3.8	0.676Emergency caesarean (%)	44	20.5	44	11.6	0.263,3198285
537,2722000,The incidence of bacterial infection,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"The incidence of bacterial infection was significantly lower in patient receiving antibiotic prophylaxis (2/62, 3.2% vs. 9/58, 15.5%, p=0.026).",2722000
538,2722000,Enteric bacteria,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"Enteric bacteria were more frequently identified in patients without antibiotic prophylaxis (0/62, 0% vs. 5/58, 8.6%, p=0.018).",2722000
539,2722000,rebleeding,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"The rebleeding rate in the prophylactic group was significantly lower than that in the on-demand group (21/62, 33.9% vs. 36/58, 62.1%, p=0.004).",2722000
540,2722000,Total mortality and 30-day mortality,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,No significant difference,otal mortality and 30-day mortality were not different between the two groups (Table 7). The overall rate of survival was similar between the two groups (Fig. 4).,2722000
541,2650992,drainage duration,fibrin glue group (glue sprayed onto the axillary dissection site),control group,Significantly decreased,subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006),2650992
542,2650992,overall drain output,fibrin glue group (glue sprayed onto the axillary dissection site),control group,Significantly decreased,overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.,2650992
543,2650992,The mean drainage duration,fibrin glue group (glue sprayed onto the axillary dissection site),control group,No significant difference,The mean drainage duration was 3.3 days for the fibrin glue group and 3.8 days for the control group (p=0.067).,2650992
544,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,"Caring for ""Super Spreading Patient"" (No = 0: yes = 1)	3.57(1.94~6.57)	<0.001",2666722
545,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,Number of pairs of gloves worn (Double = 0: single = 1)	4.13(1.99~8.55)	<0.001,2666722
546,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,Performing tracheal intubations (No = 0: yes = 1)	2.76(1.16~6.53)	<0.05,2666722
547,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly decreased,Avoiding face to face contact while caring for SARS patients		 Never	1.00	 Sometimes	0.67(0.36~1.24)	>0.05 Often	0.30(0.10~0.90)	<0.05 Every time	0.30(0.15~0.60)	<0.001,2666722
548,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly decreased,Method of air ventilation in office and SARS ward		 Artificial central ventilation	1.00	 Natural ventilation	0.40(0.18~0.88)	<0.05 Natural ventilation and additional electronic exhaust fan	0.27(0.16~0.63)	<0.01,2666722
549,125315,Sequential Organ Failure Assessment (SOFA) score ,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,No statistically significant difference was found between the changes in the percentage of SOFA scores of the steroid therapy group (43.1 ± 26.5%) and the standard therapy group (45.4 ± 12.7%) in survivors (P = 0.624).,125315
550,125315,The 28-day mortality,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,There were eight deaths (40%) in the steroid therapy group and 12 (60%) deaths in the standard therapy group (P = 0.343).,125315
551,125315,The median stay in hospital,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,The median stay in hospital was 14 days (95% CI 11.09–20.08) in the steroid therapy group and 13 days (95% CI 10.13–16.37) in the standard therapy group (P = 0.406).,125315
552,2830179,pain during movement,attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly decreased,"Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1))",2830179
553,2830179,Pain on rest (0-10),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly decreased,"Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1)) and at rest (-2.0 (-3.8 to -0.2)) and",2830179
554,2830179,Qualeffo Total (0-100),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly increased,Qualeffo Total (0-100) 29 (10) 26 (7) 21 (11) 27 (8) -7.2 (11.2) 1.2 (4.1) -7.1 (-14.9 to 0.8),2830179
555,2830179,Timed loaded standing test (s),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly increased,Timed loaded standing test (s)	50 (39)	62 (49)	82 (44)	46 (50)	32.6 (34.1)	-16.7 (29.8)	46.7 (16.1 to 77.3),2830179
556,4785315,Postnatal depression (Edinburgh Postnatal Depression Scale17 EPDS),"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,No significant difference,no significant differences were seen in the mean EPDS (mean difference (MD) −0.59 (95% CI −1.24 to 0.06)) for all the women recruited,4785315
557,4785315,Antenatal attendances,"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,No significant difference,"Antenatal attendances were high in the standard care control and did not increase further with addition of the POW intervention (10.1 vs 10.1 (mean difference; MD) −0.00, 95% CI (95% CI −0.37 to 0.37)).",4785315
558,4785315,Mother-to-infant bonding,"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,Significantly increased,"Mother-to-infant bonding was significantly better in the intervention group for all women (MD −0.30 (95% CI −0.61 to −0.00) p=0.05),",4785315
559,2888205,perceived functional deficits,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,Significantly decreased,"Compared to FME, the LPA group reported significantly less perceived functional deficits (P = .032)",2888205
560,2888205,pain,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,Significantly decreased,"At post-testing, compared to the FME group, the LPA group reported significant reductions in the FIQ score (P = .032; Cohen's d = .53) and in pain (P = .006; Cohen's d = .67).",2888205
561,2888205,six-minute walk test,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,"There were no differences between the groups on the six-minute walk test (P = .067),",2888205
562,2888205,Fatigue severity scale,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Fatigue severity scale  Baseline 84 51.9 ± 9.3 52.3 ± 9.1 .4 (-3.6 to 4.4) 0.843 .04 Post intervention 73 50.6 ± 9.9 51.4 ± 10.1 .8 (-3.9 to 5.5) 0.727 .07,2888205
563,2888205,Number of tender points,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Baseline 84 16.2 ± 2.3 16.1 ± 3.2 .1 (-1.2 to 1.0) 0.979 .03 Post intervention 72 16.0 ± 2.3 16.8 ± 2.0 .8 (-.35 to 1.9) 0.172 .37,2888205
564,2888205,Body mass index (BMI),"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Body mass index (BMI)  Baseline 82 31.4 ± 8.4 29.8 ± 6.2 1.6 (-4.7 to 1.7) 0.360 .22 Post intervention 60 31.0 ± 9.0 29.9 ± 6.2 1.1 (-5.3 to 2.9) 0.575 .14,2888205
565,2888205,Center for Epidemiologic Studies Depression Scale (CES-D),"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,CES-D*  Baseline 84 23.4 ± 8.6 24.0 ± 10 .6 (-3.8 to 4.5) 0.798 .06 Post intervention 73 21.6 ± 9.8 21.2 ± 11.3 .4 (-5.3 to 4.6) 0.888 .04,2888205
566,3490871,weight change,24-week intervention focussed on improving food choice and minimising weight gain,Usual care comprised of 7 weeks of group support sessions,No significant difference,"Analysis of weight change in those successful at stopping smoking was underpowered (66%) but indicated greater mean weight gain in intervention subjects (3.9 (SD 3.1) vs. 2.7 (SD 3.7) kg). Between group differences were not significant (p = 0.23, 95% CI −0.9 to 3.5) however the confidence interval is wide and includes a loss of −0.9 kg, thus the possibility of an effect in favour of the intervention cannot be excluded.",3490871
567,3490871,Smoking cessation,24-week intervention focussed on improving food choice and minimising weight gain,Usual care comprised of 7 weeks of group support sessions,No significant difference,"Although the study was not powered to detect changes in smoking status these data were examined for completers and also using a sensitivity analysis. Both analyses showed a higher percentage of control participants still smoking at week 24 in comparison to intervention participants, however between group differences were not significant (Table 8).Table 8Comparison of Smoking Status between Intervention and Control Groups 	Intervention	Control	Odds Ratio	95% Confidence Interval	pCompleters	 	 	 	 	 Smoking at Week 6	9 (18.8%)	6 (11.3%)	1.74	0.40 to 7.66	0.46Smoking at Week 24	17 (42.5%)	25 (58.1%)	0.43	0.14 to 1.34	0.14Sensitivity analysis	 	 	 	 	 Smoking at Week 6	29 (42.6%)	23 (32.9%)	1.38	0.63 to 3.04	0.42Smoking at Week 24	45 (66.2%)	52 (74.3%)	0.58	0.25 to 1.36	0.20",3490871
568,5256321,The 10mWT (10-m walking test ),Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",Significantly increased,the results for the 10mWT showed only significant improvements in the experimental group (11.38±3.0 to 10.12±2.47 seconds; p=0.01); whereas the control group did not show significant improvements.,5256321
569,5256321,trunk strength (BPR score),Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",Significantly increased,he improvement levels of the trunk strength (BPR score) for the experimental group using Spine Balance 3D system's evaluation program showed significant improvements at the 15° open mode; whereas the control group did not show any significant improvement.,5256321
570,5256321,"he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I) ",Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",No significant difference,"The results of the BBS, FRT, TUG, KFES-I, and Biodex Balance System evaluation program improved in both groups after 7 weeks of balance training.",5256321
571,5602855,Quality of life,good motivation/capability,inadequate motivation/capability,No significant difference,"The EQ-5D-3L summary index is shown in Fig. 2. No significant change could be observed in the anxiety/depression dimension of the EQ-5D-3L system either in those with good (p = 0.26) or inadequate (p = 0.71) motivation/capability during the three years of follow-up. Additionally, no change was observed in the EQ-5D-3L summary index (p = 0.14), EQ VAS (p = 0.68) or the anxiety/depression dimension of the EQ-5D-3L system (p = 0.95) during the follow-up in those subjects who continued pulse palpation at least weekly at 36 months.Fig. 2",5602855
572,5602855,Health care burden,good motivation/capability,inadequate motivation/capability,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (p = 0.39) or to special healthcare outpatient clinics (p = 0.072) during the follow-up.,5602855
573,5602855,Self-detected pulse irregularity and outcome events,good motivation/capability,inadequate motivation/capability,No significant difference,"Irregular pulse findings were not significantly associated with the composite outcome variable (p = 0.06), stroke/TIA (p = 0.48), pacemaker implantation (p = 0.10) or death (p = 1.00).",5602855
574,4419460,HbA1c at 12 or 24 months.,"The Child and Adolescent Structured Competencies Approach to Diabetes Education (CASCADE) is a structured educational group program, using psychological techniques, delivered primarily by diabetes nurses.",control,No significant difference,"Given that the trial found no evidence of benefits on venous HbA1c at 12 and 24 months and little evidence of benefits on secondary outcomes, the focus of this paper is to use the findings of the process evaluation to suggest how future structured education may be more effectively implemented.12",4419460
575,4577567,stride length,stride frequency manipulation,free stride frequency,Significantly increased,Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001),4577567
576,4577567,contact time,stride frequency manipulation,free stride frequency,Significantly increased,"With regard to the two training strategies, within the RWM group the CT significantly increased by 4.58% (p<0.001),",4577567
577,4577567,stride frequency,stride frequency manipulation,free stride frequency,Significantly decreased,a decreased stride frequency (4.44%; p<0.0001),4577567
578,4577567,internal work,stride frequency manipulation,free stride frequency,Significantly decreased,"nversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.",4577567
579,5294349,datasets of 3D coordinates,CT scan,2–4 stereo radiograph pair examinations,No significant difference,"he precision of RSA corresponding to the 99% confidence interval was 1.36°, 1.36°, and 0.60° for X-, Y-, and Z-rotation and 0.40, 0.17, and 0.37 mm for X-, Y-, and Z-translation. The limit of agreement between CT and RSA was 1.51°, 2.17°, and 1.05° for rotation and 0.59, 0.56, and 0.74 mm for translation. The differences between CT and RSA are close to the described normal 99% confidence interval for precision in RSA: 0.3° to 2° for rotation and 0.15 to 0.6 mm for translation.",5294349
580,5294349,datasets of 3D coordinates,CT scan,2–4 stereo radiograph pair examinations,No significant difference,"CT scans can be used for migration measurements in longitudinal evaluations of patients with RSA markers without losing clinically significant precision. The use of CT scans enables following RSA studies started earlier using a normal CT scan, thus avoiding the need for special RSA radiology facilities.",5294349
581,3329632,ICER (incremental cost-effectiveness ratio),ranibizumab ,ranibizumab combined with laser therapy,Significantly decreased,"Ranibizumab monotherapy was associated with an incremental gain of 0.17 QALY and cost of £4 191, corresponding to an ICER of £24 028 per QALY gained relative to laser monotherapy (table 3). Combination therapy provided an incremental gain of 0.13 QALY over laser monotherapy for an incremental cost of £4 695, leading to an ICER of £36 106 per QALY gained.",3329632
582,3800940,"Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss.",Gomutra sodhit Langali moola with honey for external application,Godugdha sodhit Langali moola with honey for external application,Significantly decreased,It was observed that after 60 days of treatment with Gomutrashodhit Langlimool in Group A there was reduction in Hair fall which is statistically highly significant (P<0.001) and highly significant improvement was observed in reducing dandruff.(p<0.001). Where as in Group B Godugdashodhit Langlimool application reduced the hair fall to statistically significant level (p<0.01) and statistically significant in reducing the dandruff in patient with Indralupta (P<0.01).,3800940
583,4819709,Bending the legs without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Bending the legs without discomfort	50	3·0	4·6	1·38 (1·14, 1·67)",4819709
584,4819709,Lifting heavy objects without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Lifting heavy objects without discomfort	50	4·8	9·8	1·97 (1·59, 2·44)90	16·9	34·5",4819709
585,4819709,Moving from standing to sitting without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Moving from standing to sitting without discomfort	50	1·9	3·7	1·63 (1·35, 1·97)",4819709
586,4819709,Standing still for a long time (> 15 min ) without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Standing still for a long time (> 15 min ) without discomfort	50	3·9	7·1	1·67 (1·36, 2·05)90	15·8	28·7",4819709
587,4819709,Walking short distances (< 20 min ) without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Walking short distances (< 20 min ) without discomfort	50	1·9	4·4	2·00 (1·65, 2·42)90	8·2	19·1",4819709
588,4819709,Walking long distances (> 20 min),Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Walking long distances (> 20 min)	50	4·5	8·0	1·76 (1·45, 2·14)90	15·2	27·1",4819709
589,4819709,Having a bath or shower,Ultrasound‐guided foam sclerotherapy,surgery,No significant difference,"Having a bath or shower	50	5·4	4·9	0·85 (0·70, 1·03)90	11·4	10·3",4819709
590,4819709,Driving a car,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Driving a car	50	4·1	7·0	1·78 (1·45, 2·19)",4819709
591,4819709,Doing housework,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Doing housework	50	2·1	4·5	2·10 (1·72, 2·56)",4819709
592,4819709,Looking after children,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Looking after children	50	1·2	3·5	2·20 (1·61, 3·00)90	6·2	17·9",4819709
593,4819709,Wearing clothes that show the legs,Ultrasound‐guided foam sclerotherapy,surgery,No significant difference,"Wearing clothes that show the legs	50	12·4	12·8	1·03 (0·78, 1·35)90	56·6	58·7",4819709
594,4819709,Partial return to normal work/employment,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Partial return to normal work/employment	50	4·4	9·9	2·16 (1·72, 2·72)90	15·4	34·2",4819709
595,4819709,Full return to normal work/employment,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Full return to normal work/employment	50	4·8	11·7	2·56 (2·05, 3·21)90	14·9	36·2",4819709
596,4819709,Going out socially,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Going out socially	50	7·1	9·3	1·29 (1·06, 1·57)90	25·8	34·0",4819709
597,4819709,Sporting activity or exercise,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Sporting activity or exercise	50	15·7	21·8	1·33 (1·05, 1·68)",4819709
598,4819709,"Bending the legs without discomfort, lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (> 15 min) without discomfort, Driving a car, Doing housework, Partial return to normal work/employment, Going out socially, Sporting activity or exercise",Endovenous laser ablation,Ultrasound‐guided foam sclerotherapy,No significant difference,"Activity items Bending the legs without discomfort 50 2·7 3·0 0·94 (0·75, 1·17)90 12·6 14·1Lifting heavy objects without discomfort 50 5·9 4·8 1·11 (0·87, 1·42)90 20·5 16·9Moving from standing to sitting without discomfort 50 2·2 1·9 1·12 (0·90, 1·40)90 10·4 9·3Standing still for a long time (> 15 min) without discomfort 50 4·8 3·9 1·14 (0·90, 1·44)90 20·0 15·8Walking short distances (< 20 min) without discomfort 50 3·0 1·9 1·48 (1·19, 1·84)90 13·2 8·2Walking long distances (> 20 min) 50 5·6 4·5 1·32 (1·05, 1·66)90 19·8 15·2Having a bath or shower 50 5·5 5·4 1·19 (0·96, 1·48)90 12·8 11·4Driving a car 50 4·4 4·1 0·95 (0·74, 1·21)90 12·7 12·4Participation items Doing housework 50 2·5 2·1 1·03 (0·82, 1·29)90 8·4 7·3Looking after children 50 1·9 1·2 1·45 (1·04, 2·02)90 8·8 6·2Wearing clothes that show the legs 50 14·6 12·4 1·17 (0·83, 1·64)90 75·1 56·6Partial return to normal work/employment 50 6·3 4·4 1·17 (0·89, 1·52)90 21·1 15·4Full return to normal work/employment 50 7·7 4·8 1·43 (1·11, 1·85)90 23·5 14·9Going out socially 50 6·9 7·1 0·88 (0·70, 1·10)90 23·9 25·8Sporting activity or exercise 50 14·2 15·7 0·80 (0·61, 1·04)90 55·5 62·6",4819709
599,4819709,"walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment",Endovenous laser ablation,Ultrasound‐guided foam sclerotherapy,Significantly decreased,"Return to ‘walking short distances without discomfort’, ‘walking long distances’, ‘looking after children’ and ‘full return to normal work/employment’ took longer for the EVLA group than the UGFS group.",4819709
600,4819709,"Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (> 15 min) without discomfort, Walking short distances (< 20 min) without discomfort, Walking long distances (> 20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise, ",Endovenous laser ablation,surgery,Significantly increased,"Activity items				Bending the legs without discomfort	50	2·7	4·6	1·49 (1·19, 1·75)90	12·6	21·3Lifting heavy objects without discomfort	50	5·9	9·8	1·79 (1·39, 2·27)90	20·5	34·5Moving from standing to sitting without discomfort	50	2·2	3·7	1·56 (1·27, 1·96)90	10·4	17·5Standing still for a long time (> 15 min) without discomfort	50	4·8	7·1	1·41 (1·11, 1·79)90	20·0	28·7Walking short distances (< 20 min) without discomfort	50	3·0	4·4	1·30 (1·04, 1·61)90	13·2	19·1Walking long distances (> 20 min)	50	5·6	8·0	1·53 (1·06, 1·67)90	19·8	27·1Having a bath or shower	50	5·5	4·9	0·74 (0·59, 0·93)90	12·8	10·3Driving a car	50	4·4	7·0	1·82 (1·43, 2·33)90	12·7	21·1Participation items				Doing housework	50	2·5	4·5	1·89 (1·49, 2·38)90	8·4	15·7Looking after children	50	1·9	3·5	1·61 (1·15, 2·27)90	8·8	17·9Wearing clothes that show the legs	50	14·6	12·8	0·97 (0·69, 1·35)90	75·1	58·7Partial return to normal work/employment	50	6·3	9·9	1·75 (1·33, 2·27)90	21·1	34·2Full return to normal work/employment	50	7·7	11·7	1·79 (1·37, 2·27)90	23·5	36·2Going out socially	50	6·9	9·3	1·41 (1·12, 1·75)90	23·9	34·0Sporting activity or exercise	50	14·2	21·8	1·47 (1·12, 1·92)",4819709
601,2891743,transurethral resection (TUR) syndrome,glycine 1.5% solution as irrigating fluid,glucose 5% solution,Significantly increased,TUR syndrome	17*	0	0,2891743
602,2891743,transurethral resection (TUR) syndrome,glycine 1.5% solution as irrigating fluid,normal saline 0.9% solution,Significantly increased,TUR syndrome 17* 0 0,2891743
603,3418149,Morbidity after surgery,ipsilateral arm morbidity,contralateral arm morbidity,Significantly increased,"Comparison of ipsilateral vs. contralateral arm shows that changes affecting one limb strongly correlated with changes affecting the other limb (upper right quarter of Table 3). The highest correlations were abduction (R = 0.78), retroflexion (R = 0.73), scapular distance (R = 0.65), and arm volume (R = 0.57), all P-values <0.001.",3418149
604,5062194,neonatal outcome,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",No significant difference,There were no between-group differences regarding the neonatal outcome.,5062194
605,5062194,postoperative satisfaction,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly increased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,5062194
606,5062194,preoperative anxiety,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly decreased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,5062194
607,5062194,No statistical analysis because they are in tables,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly increased,"Table 2Amsterdam Preoperative Anxiety and Information Scale, Maternal Satisfaction Scale for cesarean section, Apgar score and neonatal neurologic and adaptive capacity score in both groupsTable 3Blood gas analysis of umbilical artery blood samples in both groupsRegarding maternal hemodynamics, baseline HR, SBP, and DBP were comparable between the two groups before the administration of the tested drug. However, 5 min after injecting the tested drug, there was a significant decrease in all parameters in group (M) compared to group (S). During insertion of the spinal needle, there was a rise in HR and SBP in group (S) compared to group (M) while DBP was at a lower level in group (M). After the induction of spinal anesthesia and placing the patient into the tilted supine position, there was an increase in HR with some decrease in blood pressure parameters in both groups as shown in Tables 4–6.Table 4Maternal heart rate in both groupsTable 5Systolic blood pressure in both groupsTable 6Diastolic blood pressure in both groups",5062194
608,5577662,percentage changes in area,"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,"percentage changes in area were significantly greater with CCH 0.40 mg (−80.1%, P = 0.0002) and CCH 0.60 mg (−78.2%, P = 0.0003), but not CCH 0.25 mg (−58.3%, P = 0.079), versus placebo (−42.2%) at post-treatment Week 8.",5577662
609,5577662,Mean change in nodular consistency and hardness,"receive a dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,Mean change in nodular consistency and hardness were significantly improved with CCH versus placebo at Weeks 4 and 8 (P ≤ 0.0139 for all).,5577662
610,5577662,global assessment of improvement,"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,nvestigator global assessment of improvement was significantly greater with CCH 0.40 mg and 0.60 mg (P ≤ 0.0014),5577662
611,5577662,percentage changes in area,receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH),"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",No significant difference,"percentage changes in area were significantly greater with CCH 0.40 mg (−80.1%, P = 0.0002) and CCH 0.60 mg (−78.2%, P = 0.0003), but not CCH 0.25 mg (−58.3%, P = 0.079), versus placebo (−42.2%) at post-treatment Week 8.",5577662
612,5577662,global assessment of improvement,receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH),"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",No significant difference,global assessment of improvement was significantly greater with CCH 0.40 mg and 0.60 mg (P ≤ 0.0014) but not statistically significant with CCH 0.25 mg versus placebo (P = 0.13).,5577662
613,4794897,pyridinoline,resistance training dyrung radiation therapy,passive physical therapy,Significantly decreased,Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p = 0.035 and p = 0.043),4794897
614,4794897,beta-isomer of carboxy-terminal telopeptide of type I collagen,resistance training dyrung radiation therapy,passive physical therapy,Significantly decreased,Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p = 0.035 and p = 0.043),4794897
615,5062234,The 24 h morphine requirement,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,No significant difference,The 24 h morphine requirement (mean ± standard deviation) was 34.57 ± 14.64 mg in TAP group and 32.76 ± 14.34 mg in local infiltration group (P = 0.688).,5062234
616,5062234,intraoperative supplemental fentanyl,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,Significantly decreased,The number of patients requiring intraoperative supplemental fentanyl in TAP group was 8 and in local infiltration group was 16 (P = 0.028).,5062234
617,5062234,The visual analog scale scores at rest and on coughing,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,Significantly decreased,"At 4 h, none of the patients in the TAP group but seven patients (33.3%) in the control group had moderate to severe pain (VAS >3) at rest (P = 0.009*). At 4 h, eight patients (38.1%) in the TAP group and 15 patients (71.4%) in the control group had moderate to severe pain on coughing (P = 0.03*). At 12 h, six patients (28.5%) in the TAP group and 18 patients (85.7%) in the control group had moderate to severe pain on coughing (P < 0.001*).",5062234
618,4139977,decrease in abdominal pain and distension severity,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,"here was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (P<0.001), but there was no difference between the two groups in this regard (P>0.05).",4139977
619,4139977,Improvement in bowel habit,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,mprovement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910).,4139977
620,4139977,quality-of-life ,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,"With regard to QOL, an improvement was observed in the probiotic (P = 0.008), but not in the placebo group (P = 0.175); though, there was no significant difference between the two groups in this regard (P = 0.372),",4139977
621,1852268,obstetric/postpartum infection or gynecologic/postoperative infection,"Inravenous ertapenem, 1 g once a day","Intravenous piperacillin–tazobactam, 3.375 g every 6 hours",No significant difference,"At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.",1852268
622,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit & Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
623,3187863,Labour dystocia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
624,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
625,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
626,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit & Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
627,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit & Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
628,3187863,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit & Special unit,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
629,2688140,The survival rate / overall mortality of patients with ARDS,Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).",2688140
630,2688140,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS",Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents did not differ between the groups (Table 2).",2688140
631,4106715,Prolonged abstinence from smoking rates to 6 months,high Ab group,placebo,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71)",4106715
632,4106715,Prolonged abstinence from smoking rates to 6 months,low Ab group,placebo,No significant difference,"ith no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).",4106715
633,4106715,Prolonged abstinence from smoking rates to 12 months,high Ab group,placebo,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20).",4106715
634,4106715,Prolonged abstinence from smoking rates to 12 months,low Ab group,placebo,No significant difference,Prolonged abstinence from smoking rates to 6 months	low Ab group	placebo	No significant difference	ith no significant differences between the placebo,4106715
635,4106715,Reduction of daily cigarette consumption and cotinine,non-abstainers (weeks 19–52) with high Ab levels,non-abstainers in the placebo group,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19–52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C",4106715
636,4106715,attain 8 weeks continuous abstinence from weeks 19 through 26,recipients with the highest serum anti-nicotine antibody response (top 30% by AUC),placebo group,Significantly increased,"3’AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).",4106715
637,2206488,"Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I",dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,"procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.",2206488
638,2206488,Cardiac index ,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly increased,Higher figures of the cardiac index (p = 0.010),2206488
639,2206488,systemic vascular resistance,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,with reduced systemic vascular resistance (p = 0.005) were noted in group A.,2206488
640,2206488,C-reactive protein (mg/l),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,C-reactive protein (mg/l)?Group A	3.7 (1.0–22.6)				79.9 (50.0–131.7)	112.0 (61.1–177.6)	<0.001†?Group B	2.6 (0.6–10.5)				87.6 (52.4–143.0)	131.0 (71.0–228.0)	<0.001†	p = 0.068*				p = 0.092*	p = 0.168*,2206488
641,2206488,IL-6 (pg/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6 (pg/ml)							?Group A	1.6 (0.4–21.8)		95.0 (13.6–405.1)	46.3 (16.1–149.5)			<0.001†?Group B	2.0 (0.4–60.6)		130.5 (21.7–353.8)	49.2 (14.8–214.5)			<0.001†	p = 0.107*		p = 0.829*	p = 0.482*,2206488
642,2206488,IL-6r (ng/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6r (ng/ml)							?Group A	43.6 (1.7–125.0)		47.4 (0.7–109.5)	56.2 (25.2–226.3)			0.949†?Group B	40.7 (15.6–94.6)		42.4 (22.2–100.5)	50.2 (13.2–104.9)			0.861†	p = 0.607*		p = 0.914*	p = 0.304*,2206488
643,1201146,"Pain, physical function, PGA, stiffness ",topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,"There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain (-5.2 vs. -3.3; p = 0.003,), physical function (-13.4 vs. -6.9; p = 0.001), PGA (-1.3 vs. -0.7; p = 0.0001) and stiffness (-1.8 vs. -0. 9; p = 0.002)",1201146
644,1201146,Pain on walking,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain on walking (-1.2 vs. -0.8; p = 0.014).,1201146
645,1201146,50% reduction in pain,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The response rate for at least a 50% reduction in pain (Table 3) was significantly greater following topical diclofenac treatment compared to vehicle control (46/105 [43.8%] vs. 27/107 [25.2%]; p = 0.004).,1201146
646,1201146,good or very good PGA response and OMERACT-OARSI responder,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The topical diclofenac group had a significantly greater number of participants with good or very good PGA response (43.8% vs. 16.8%; p <0.0001) compared to the vehicle control group and of OMERACT-OARSI responders (65.7% vs. 49.5%; p = 0.017).,1201146
647,1201146,Dry skin at the application site,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,"The major adverse effect reported was dry skin at the application site, occurring in 42/107 (39.3%) and 23/109 (21.1%; p = 0.004) of topical diclofenac and vehicle control participants, respectively",1201146
648,2600646,mean Hb,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,Final mean Hb levels were 7.15 mmol/l ± 1.07 for the DP treatment group and 6.79 mmol/l ± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05).,2600646
649,2600646,Adverse events,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,"Most adverse events were mild, self limiting and consistent with symptoms of malaria. There was no significant difference between the two study groups",2600646
650,2600646,Gametocyte dynamics,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,There was no difference between children older than 60 months and younger as regards carriage of gametocytes and density.,2600646
651,1468428,Puerperal and neonatal infection rates ,1 litre saline enema,no enema,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66)",1468428
652,1468428,Median labour time,1 litre saline enema,no enema,No significant difference,median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).,1468428
653,1468428,Episiorraphy dehiscence rates,1 litre saline enema,no enema,No significant difference,Enemas didn't significantly change episiorraphy dehiscence rates (21/182 [12%] with enema v 32/190 [17%] without enema; P = 0.30).,1468428
654,1468428,You must have prompts generated from different sections.,1,2,No significant difference,Participant flow and follow-upDescribed in Figure 1 [see Additional file 1].,1468428
655,2607225,cognitive functioning,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months. There were no other main effects of treatments.",2607225
656,2607225,Appetite loss,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly decreased,. Pairwise comparisons revealed a statistically significant mean difference between GR and non-GR patients at 12 months (mean=5.8 vs 2.4).,2607225
657,2720945,change of FVC and VC,cineole,placebo,No significant difference,The difference concerning change of FVC and VC between both treatment groups was not clinically relevant.,2720945
658,2720945,Side effects,cineole,placebo,No significant difference,The difference between the two treatment groups was neither clinically relevant nor statistically significant. Safety examinations of the global assessment showed no difference between the two treatment groups.,2720945
659,2720945,Quality of life,cineole,placebo,Significantly increased,At 6 months the mean improvement of SGRQ total symptom score was -9.1 after treatment with cineole and -4.1 after treatment with placebo (table 5).,2720945
660,2720945,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment",cineole,placebo,Significantly decreased,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*	PLACEBO	CINEOLE		SCORE	SCORE	P VALUE†Sum of exacerbations (number)#	0.9 ± 1.46	0.4 ± 0.82	0.0069Sum of duration (days)#	5.7 ± 8.9	4.0 ± 10.9	0.0210Sum of severity (score)#	1.4 ± 2.2	0.8 ± 1.5	0.0242Summarized parameter(directional test)			0.0120",2720945
661,2720945,"Trouble in breathing, dyspnea in the morning and dyspnea at rest",cineole,placebo,Significantly decreased,Trouble in breathing #	1.8 ± 0.9	2.1 ± 0.9	2.2 ± 1.0	1.9 ± 0.9	2.4 ± 1.0	2.5 ± 1.1	0.0103&Dyspnea in the morning $	1.1 ± 0.7	0.9 ± 0.7	0.7 ± 0.7	1.1 ± 0.8	0.7 ± 0.7	0.5 ± 0.6	0.0466&Dyspnea at rest $	0.7 ± 0.7	0.4 ± 0.6	0.4 ± 0.6	0.6 ± 0.6	0.3 ± 0.5	0.3 ± 0.5	0.0156&,2720945
662,2720945,Dyspnea during exercise,cineole,placebo,No significant difference,Dyspnea during exercise $	2.0 ± 0.6	1.8 ± 0.7	1.7 ± 0.8	2.0 ± 0.6	1.7 ± 0.7	1.5 ± 0.9	0.1252&,2720945
663,3446002,The duration of phototherapy,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The duration of phototherapy was significantly shorter in clofibrate group (P<0.001).,3446002
664,3446002,side effects,single dose of 50 mg/kg clofibrate,control group,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed. Also for a period of two months no complication was detected.,3446002
665,3446002,Total serum bilirubin level,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001).,3446002
666,1913177,Postoperative Mortality,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,There was no 30-day mortality.,1913177
667,1913177,Wound complications,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,Wound complications were found in 10 of 19 patients after CST and 13 of 18 patients after PR.,1913177
668,1913177,Reherniation,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),Significantly increased,Reherniation occurred in 10 patients after CST and in 4 patients after PR.,1913177
669,1876597,unadjusted risk of recurrent falciparum parasitemia,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence interval [CI] 11%–26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%–19%) of follow-up.",1876597
670,1876597,the risk of recurrent parasitemia due to possible recrudescence,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%–12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%–16%).",1876597
671,1876597,Adverse Events,dihydroartemisinin-piperaquine ,artemether-lumefantrine,No significant difference,"Overall, there was no difference in the proportion of study participants who experienced any adverse event of moderate or greater severity between the DP (46%) and AL (42%) treatment groups (p = 0.47).",1876597
672,3387601,Period of mechanical ventilation ,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,"Children in the PE group had a shorter period of MV (median 11 days, IQR 11.0 to 13.0) compared to IVIG group (median 13 days, IQR 11.3 to 14.5) with p = 0.037.",3387601
673,3387601,Pediatric Intensive Care Unit (PICU) stay,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,3387601
674,3387601,could walk unaided within four weeks after PICU discharge,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within four weeks after PICU discharge (p = 0.606).,3387601
675,3387601,negative correlation between CSF protein and duration of mechanical ventilation,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly increased,"Examining the treatment groups separately, the significant negative correlation remained for the PE group (p-value = 0.037) and not for the IVIG group (p-value 0.132)",3387601
676,3387601,side effects,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients.,3387601
677,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p?=?0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p?=?0.005).",2430614
678,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p?=?0.4)",2430614
679,2430614,parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL),No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups,2430614
680,2847809,Complications and mortality,Clopidogrel,Placebo,No significant difference,Complication	All patients (%)	Clopidogrel (%)	Placebo (%)	P valueGI bleeding	5 (5.3)	2 (2.1)	3 (3.2)	0.31Non GI tract bleeding	9 (9.6)	5 (5.3)	4 (4.3)	0.63Death events	4 (4.3)	2 (2.1)	2 (2.1)	0.47,2847809
681,2847809,First hemodialysis success,Clopidogrel,Placebo,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008).,2847809
682,2847809,The primary arteriovenous fistula failures at two months,Clopidogrel,Placebo,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03).,2847809
683,2447617,The modified Functional Independence Measure scores,progesterone,placebo,Significantly increased,he modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01).,2447617
684,2447617,The mortality rate,progesterone,placebo,Significantly decreased,he mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05).,2447617
685,2447617,The mean intracranial pressure values 72 hours and 7 days after injury,progesterone,placebo,No significant difference,"he mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05).",2447617
686,2447617,Instances of complications and adverse events,progesterone,placebo,No significant difference,Instances of complications and adverse events associated with the administration of progesterone were not found.,2447617
687,2447617,The analysis using the dichotomization of GOS scores at 3 months post injury,progesterone,placebo,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034). There was an unfavorable outcome in 53% of the patients receiving progesterone and in 70% of the placebo group (P = 0.022).,2447617
688,2447617,The analysis using the dichotomization of GOS scores at 6 months post injury,progesterone,placebo,Significantly increased,The percentage of favorable outcome was 58% for the patients who were given progesterone and was 42% in the placebo group (P = 0.048). Forty-one percent of patients who were given progesterone and 57% of the placebo group exhibited an unfavorable outcome (P = 0.048).,2447617
689,2899760,Fusion rate,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,"usion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).",2899760
690,2899760,clinical outcomes,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused.,2899760
691,2899760,Radiological fusion,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,Fusion rate (I + IIA)		69		92,2899760
692,3108665,Postoperative complications,somatostatin,No medication was given to the control group,Significantly decreased,"Initially, 6 of 35 (17%) in the treated group who received somatostatin developed complications, whereas 18 of 32 (56%) in the control group developed complications.",3108665
693,43880,hospital costs per patient for the course of IV therapy,clinically indicated,routine replacement,Significantly decreased,"Mean hospital costs per patient for the course of IV therapy were significantly higher (P < 0.001) for those managed with routine resite (mean $55.42, SD $35.26) compared with resite on clinical indication (mean $43.35, SD $26.78).",2944158
694,24976,complete healing of the index ulcer at 1-year of follow-up,hyperbaric oxygen therapy,placebo,Significantly increased,complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).,2858204
695,24976,"In the intention-to-treat analysis, complete healing of the index ulcer",hyperbaric oxygen therapy,placebo,Significantly increased,"In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up in 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).",2858204
696,24976,"In the per-protocol analysis, complete healing of the index ulcer",hyperbaric oxygen therapy,placebo,Significantly increased,"In the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009)",2858204
697,1852268,obstetric/postpartum infection or gynecologic/postoperative infection,"Inravenous ertapenem, 1 g once a day","Intravenous piperacillin–tazobactam, 3.375 g every 6 hours",No significant difference,"At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.",1852268
698,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit & Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
699,3187863,Labour dystocia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
700,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
701,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
702,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit & Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
703,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit & Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
704,3187863,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit & Special unit,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
705,2688140,The survival rate / overall mortality of patients with ARDS,Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).",2688140
706,2688140,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS",Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents did not differ between the groups (Table 2).",2688140
707,4106715,Prolonged abstinence from smoking rates to 6 months,high Ab group,placebo,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71)",4106715
708,4106715,Prolonged abstinence from smoking rates to 6 months,low Ab group,placebo,No significant difference,"ith no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).",4106715
709,4106715,Prolonged abstinence from smoking rates to 12 months,high Ab group,placebo,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20).",4106715
710,4106715,Prolonged abstinence from smoking rates to 12 months,low Ab group,placebo,No significant difference,Prolonged abstinence from smoking rates to 6 months	low Ab group	placebo	No significant difference	ith no significant differences between the placebo,4106715
711,4106715,Reduction of daily cigarette consumption and cotinine,non-abstainers (weeks 19–52) with high Ab levels,non-abstainers in the placebo group,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19–52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C",4106715
712,4106715,attain 8 weeks continuous abstinence from weeks 19 through 26,recipients with the highest serum anti-nicotine antibody response (top 30% by AUC),placebo group,Significantly increased,"3’AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).",4106715
713,2206488,"Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I",dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,"procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.",2206488
714,2206488,Cardiac index ,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly increased,Higher figures of the cardiac index (p = 0.010),2206488
715,2206488,systemic vascular resistance,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,with reduced systemic vascular resistance (p = 0.005) were noted in group A.,2206488
716,2206488,C-reactive protein (mg/l),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,C-reactive protein (mg/l)?Group A	3.7 (1.0–22.6)				79.9 (50.0–131.7)	112.0 (61.1–177.6)	<0.001†?Group B	2.6 (0.6–10.5)				87.6 (52.4–143.0)	131.0 (71.0–228.0)	<0.001†	p = 0.068*				p = 0.092*	p = 0.168*,2206488
717,2206488,IL-6 (pg/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6 (pg/ml)							?Group A	1.6 (0.4–21.8)		95.0 (13.6–405.1)	46.3 (16.1–149.5)			<0.001†?Group B	2.0 (0.4–60.6)		130.5 (21.7–353.8)	49.2 (14.8–214.5)			<0.001†	p = 0.107*		p = 0.829*	p = 0.482*,2206488
718,2206488,IL-6r (ng/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6r (ng/ml)							?Group A	43.6 (1.7–125.0)		47.4 (0.7–109.5)	56.2 (25.2–226.3)			0.949†?Group B	40.7 (15.6–94.6)		42.4 (22.2–100.5)	50.2 (13.2–104.9)			0.861†	p = 0.607*		p = 0.914*	p = 0.304*,2206488
719,1201146,"Pain, physical function, PGA, stiffness ",topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,"There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain (-5.2 vs. -3.3; p = 0.003,), physical function (-13.4 vs. -6.9; p = 0.001), PGA (-1.3 vs. -0.7; p = 0.0001) and stiffness (-1.8 vs. -0. 9; p = 0.002)",1201146
720,1201146,Pain on walking,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain on walking (-1.2 vs. -0.8; p = 0.014).,1201146
721,1201146,50% reduction in pain,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The response rate for at least a 50% reduction in pain (Table 3) was significantly greater following topical diclofenac treatment compared to vehicle control (46/105 [43.8%] vs. 27/107 [25.2%]; p = 0.004).,1201146
722,1201146,good or very good PGA response and OMERACT-OARSI responder,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The topical diclofenac group had a significantly greater number of participants with good or very good PGA response (43.8% vs. 16.8%; p <0.0001) compared to the vehicle control group and of OMERACT-OARSI responders (65.7% vs. 49.5%; p = 0.017).,1201146
723,1201146,Dry skin at the application site,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,"The major adverse effect reported was dry skin at the application site, occurring in 42/107 (39.3%) and 23/109 (21.1%; p = 0.004) of topical diclofenac and vehicle control participants, respectively",1201146
724,2600646,mean Hb,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,Final mean Hb levels were 7.15 mmol/l ± 1.07 for the DP treatment group and 6.79 mmol/l ± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05).,2600646
725,2600646,Adverse events,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,"Most adverse events were mild, self limiting and consistent with symptoms of malaria. There was no significant difference between the two study groups",2600646
726,2600646,Gametocyte dynamics,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,There was no difference between children older than 60 months and younger as regards carriage of gametocytes and density.,2600646
727,1468428,Puerperal and neonatal infection rates ,1 litre saline enema,no enema,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66)",1468428
728,1468428,Median labour time,1 litre saline enema,no enema,No significant difference,median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).,1468428
729,1468428,Episiorraphy dehiscence rates,1 litre saline enema,no enema,No significant difference,Enemas didn't significantly change episiorraphy dehiscence rates (21/182 [12%] with enema v 32/190 [17%] without enema; P = 0.30).,1468428
730,1468428,You must have prompts generated from different sections.,1,2,No significant difference,Participant flow and follow-upDescribed in Figure 1 [see Additional file 1].,1468428
731,2607225,cognitive functioning,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months. There were no other main effects of treatments.",2607225
732,2607225,Appetite loss,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly decreased,. Pairwise comparisons revealed a statistically significant mean difference between GR and non-GR patients at 12 months (mean=5.8 vs 2.4).,2607225
733,2720945,change of FVC and VC,cineole,placebo,No significant difference,The difference concerning change of FVC and VC between both treatment groups was not clinically relevant.,2720945
734,2720945,Side effects,cineole,placebo,No significant difference,The difference between the two treatment groups was neither clinically relevant nor statistically significant. Safety examinations of the global assessment showed no difference between the two treatment groups.,2720945
735,2720945,Quality of life,cineole,placebo,Significantly increased,At 6 months the mean improvement of SGRQ total symptom score was -9.1 after treatment with cineole and -4.1 after treatment with placebo (table 5).,2720945
736,2720945,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment",cineole,placebo,Significantly decreased,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*	PLACEBO	CINEOLE		SCORE	SCORE	P VALUE†Sum of exacerbations (number)#	0.9 ± 1.46	0.4 ± 0.82	0.0069Sum of duration (days)#	5.7 ± 8.9	4.0 ± 10.9	0.0210Sum of severity (score)#	1.4 ± 2.2	0.8 ± 1.5	0.0242Summarized parameter(directional test)			0.0120",2720945
737,2720945,"Trouble in breathing, dyspnea in the morning and dyspnea at rest",cineole,placebo,Significantly decreased,Trouble in breathing #	1.8 ± 0.9	2.1 ± 0.9	2.2 ± 1.0	1.9 ± 0.9	2.4 ± 1.0	2.5 ± 1.1	0.0103&Dyspnea in the morning $	1.1 ± 0.7	0.9 ± 0.7	0.7 ± 0.7	1.1 ± 0.8	0.7 ± 0.7	0.5 ± 0.6	0.0466&Dyspnea at rest $	0.7 ± 0.7	0.4 ± 0.6	0.4 ± 0.6	0.6 ± 0.6	0.3 ± 0.5	0.3 ± 0.5	0.0156&,2720945
738,2720945,Dyspnea during exercise,cineole,placebo,No significant difference,Dyspnea during exercise $	2.0 ± 0.6	1.8 ± 0.7	1.7 ± 0.8	2.0 ± 0.6	1.7 ± 0.7	1.5 ± 0.9	0.1252&,2720945
739,3446002,The duration of phototherapy,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The duration of phototherapy was significantly shorter in clofibrate group (P<0.001).,3446002
740,3446002,side effects,single dose of 50 mg/kg clofibrate,control group,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed. Also for a period of two months no complication was detected.,3446002
741,3446002,Total serum bilirubin level,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001).,3446002
742,1913177,Postoperative Mortality,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,There was no 30-day mortality.,1913177
743,1913177,Wound complications,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,Wound complications were found in 10 of 19 patients after CST and 13 of 18 patients after PR.,1913177
744,1913177,Reherniation,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),Significantly increased,Reherniation occurred in 10 patients after CST and in 4 patients after PR.,1913177
745,1876597,unadjusted risk of recurrent falciparum parasitemia,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence interval [CI] 11%–26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%–19%) of follow-up.",1876597
746,1876597,the risk of recurrent parasitemia due to possible recrudescence,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%–12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%–16%).",1876597
747,1876597,Adverse Events,dihydroartemisinin-piperaquine ,artemether-lumefantrine,No significant difference,"Overall, there was no difference in the proportion of study participants who experienced any adverse event of moderate or greater severity between the DP (46%) and AL (42%) treatment groups (p = 0.47).",1876597
748,3387601,Period of mechanical ventilation ,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,"Children in the PE group had a shorter period of MV (median 11 days, IQR 11.0 to 13.0) compared to IVIG group (median 13 days, IQR 11.3 to 14.5) with p = 0.037.",3387601
749,3387601,Pediatric Intensive Care Unit (PICU) stay,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,3387601
750,3387601,could walk unaided within four weeks after PICU discharge,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within four weeks after PICU discharge (p = 0.606).,3387601
751,3387601,negative correlation between CSF protein and duration of mechanical ventilation,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly increased,"Examining the treatment groups separately, the significant negative correlation remained for the PE group (p-value = 0.037) and not for the IVIG group (p-value 0.132)",3387601
752,3387601,side effects,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients.,3387601
753,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p?=?0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p?=?0.005).",2430614
754,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p?=?0.4)",2430614
755,2430614,parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL),No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups,2430614
756,2847809,Complications and mortality,Clopidogrel,Placebo,No significant difference,Complication	All patients (%)	Clopidogrel (%)	Placebo (%)	P valueGI bleeding	5 (5.3)	2 (2.1)	3 (3.2)	0.31Non GI tract bleeding	9 (9.6)	5 (5.3)	4 (4.3)	0.63Death events	4 (4.3)	2 (2.1)	2 (2.1)	0.47,2847809
757,2847809,First hemodialysis success,Clopidogrel,Placebo,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008).,2847809
758,2847809,The primary arteriovenous fistula failures at two months,Clopidogrel,Placebo,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03).,2847809
759,2447617,The modified Functional Independence Measure scores,progesterone,placebo,Significantly increased,he modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01).,2447617
760,2447617,The mortality rate,progesterone,placebo,Significantly decreased,he mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05).,2447617
761,2447617,The mean intracranial pressure values 72 hours and 7 days after injury,progesterone,placebo,No significant difference,"he mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05).",2447617
762,2447617,Instances of complications and adverse events,progesterone,placebo,No significant difference,Instances of complications and adverse events associated with the administration of progesterone were not found.,2447617
763,2447617,The analysis using the dichotomization of GOS scores at 3 months post injury,progesterone,placebo,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034). There was an unfavorable outcome in 53% of the patients receiving progesterone and in 70% of the placebo group (P = 0.022).,2447617
764,2447617,The analysis using the dichotomization of GOS scores at 6 months post injury,progesterone,placebo,Significantly increased,The percentage of favorable outcome was 58% for the patients who were given progesterone and was 42% in the placebo group (P = 0.048). Forty-one percent of patients who were given progesterone and 57% of the placebo group exhibited an unfavorable outcome (P = 0.048).,2447617
765,2899760,Fusion rate,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,"usion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).",2899760
766,2899760,clinical outcomes,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused.,2899760
767,2899760,Radiological fusion,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,Fusion rate (I + IIA)		69		92,2899760
768,3108665,Postoperative complications,somatostatin,No medication was given to the control group,Significantly decreased,"Initially, 6 of 35 (17%) in the treated group who received somatostatin developed complications, whereas 18 of 32 (56%) in the control group developed complications.",3108665
769,2361948,Overall survival time,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B),Significantly decreased,"Overall survival time differed significantly between the study groups in favour of 16?Gy/2 fr (median 8.0 months), compared to 20?Gy/5 fr (median 5.3 months), P=0.016 (Figure 7).",2361948
770,2361948,6- and 12-month survival probabilities,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B),Significantly decreased,"In all, 6- and 12-month survival probabilities were 57% (95% CI: 42–72%) and 27% (95% CI: 14–40%) for patients receiving 16?Gy/2 fr, and 30% (95% CI: 18–42%) and 11% (95% CI: 3–20%) for patients receiving 20?Gy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).",2361948
771,2361948,degree of relief of all analysed symptoms,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B),No significant difference,"The percentages of all evaluable patients reporting any symptomatic improvement were as follows: cough 51% (24 out of 47; for a median of six assessments, range: 1–10), dyspnoea 60% (26 out of 43; for a median of six assessments, range: 1–9), haemoptysis 86% (19 out of 22; for a median of eight assessments, range: 1–11), chest pain 83% (34 out of 41; for a median of four assessments, range: 1–9), dysphagia 71% (five out of seven; for a median of eight assessments, range: 1–9), SVCS 83% (five out of six; for a median of five assessments, range: 4–9). The numbers of patients achieving symptomatic improvement did not differ between study groups for all analysed symptoms (Table 3).",2361948
772,2364680,wound problem,opening subcutaneous tissues with electrocautery,opening subcutaneous tissues with scalpel,No significant difference,Fifteen of 380 women (3.9%) developed a wound problem; six had scalpel and nine had electrosurgical subcutaneous incisions (P = 0.4).,2364680
773,3221331,Continuous abstinence at 6 months,"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.",set a quit date and received a general health video message sent to their phone every 2 weeks.,No significant difference,Continuous abstinence at 6 months was 26.4% (29/110) in the intervention group and 27.6% (32/116) in the control group (P = .8).,3221331
774,3221331,did not attempt to quit smoking at all,"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.",set a quit date and received a general health video message sent to their phone every 2 weeks.,No significant difference,"At 6 months all participants were asked how many quit attempts they had made during the study period. In the intervention group 7/73 respondents (9.6%) and in the control group 4/81 (4.9%) (P = .3) stated they did not attempt to quit at all, but the majority of respondents in both groups made multiple quit attempts.",3221331
775,3198285,low–glycemic index,low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),Significantly decreased,The LGI group achieved a modestly lower GI than the HF group (mean ± SEM 47 ± 1 vs. 53 ± 1; P < 0.001).,3198285
776,3198285,"birth weight, birth weight centile, prevalence of macrosomia, insulin treatment, adverse pregnancy outcomes",low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),No significant difference,"At birth, there was no significant difference in birth weight (LGI 3.3 ± 0.1 kg vs. HF 3.3 ± 0.1 kg; P = 0.619), birth weight centile (LGI 52.5 ± 4.3 vs. HF 52.2 ± 4.0; P = 0.969), prevalence of macrosomia (LGI 2.1% vs. HF 6.7%; P = 0.157), insulin treatment (LGI 53% vs. HF 65%; P = 0.251), or adverse pregnancy outcomes.",3198285
777,3198285,"Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean",low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),No significant difference,Gestational age (weeks)	47	39.1 ± 0.1	45	39.2 ± 0.1	0.552Birth weight (kg)	47	3.3 ± 0.1	45	3.3 ± 0.1	0.619Birth weight centile	47	52.5 ± 4.3	45	52.2 ± 4.0	0.969LGA (%)	47	12.8	45	4.4	0.157Small for gestational age (%)	47	10.6	45	8.9	0.778Macrosomia (%)	47	2.1	45	6.7	0.286Infant head circumference (cm)	43	34.4 ± 0.2	39	34.6 ± 0.3	0.478Infant length (cm)	47	49.7 ± 0.3	45	49.7 ± 0.3	0.995Ponderal index (kg/m3)	47	27.2 ± 0.3	45	27.0 ± 0.4	0.614Maternal weight gain (kg)	44	11.9 ± 0.7	43	13.1 ± 0.9	0.305?Below target (%)†		31.8		25.6	0.520?Within target (%)†		43.2		32.6	0.307?Above target (%)†		25.0		41.9	0.095Insulin treatment (%)	47	53.2	45	65.1	0.251Final daily insulin dose (units)	47	17.7 ± 4.1	43	20.0 ± 3.8	0.676Emergency caesarean (%)	44	20.5	44	11.6	0.263,3198285
778,2722000,The incidence of bacterial infection,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"The incidence of bacterial infection was significantly lower in patient receiving antibiotic prophylaxis (2/62, 3.2% vs. 9/58, 15.5%, p=0.026).",2722000
779,2722000,Enteric bacteria,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"Enteric bacteria were more frequently identified in patients without antibiotic prophylaxis (0/62, 0% vs. 5/58, 8.6%, p=0.018).",2722000
780,2722000,rebleeding,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"The rebleeding rate in the prophylactic group was significantly lower than that in the on-demand group (21/62, 33.9% vs. 36/58, 62.1%, p=0.004).",2722000
781,2722000,Total mortality and 30-day mortality,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,No significant difference,otal mortality and 30-day mortality were not different between the two groups (Table 7). The overall rate of survival was similar between the two groups (Fig. 4).,2722000
782,2650992,drainage duration,fibrin glue group (glue sprayed onto the axillary dissection site),control group,Significantly decreased,subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006),2650992
783,2650992,overall drain output,fibrin glue group (glue sprayed onto the axillary dissection site),control group,Significantly decreased,overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.,2650992
784,2650992,The mean drainage duration,fibrin glue group (glue sprayed onto the axillary dissection site),control group,No significant difference,The mean drainage duration was 3.3 days for the fibrin glue group and 3.8 days for the control group (p=0.067).,2650992
785,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,"Caring for ""Super Spreading Patient"" (No = 0: yes = 1)	3.57(1.94~6.57)	<0.001",2666722
786,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,Number of pairs of gloves worn (Double = 0: single = 1)	4.13(1.99~8.55)	<0.001,2666722
787,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,Performing tracheal intubations (No = 0: yes = 1)	2.76(1.16~6.53)	<0.05,2666722
788,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly decreased,Avoiding face to face contact while caring for SARS patients		?Never	1.00	?Sometimes	0.67(0.36~1.24)	>0.05?Often	0.30(0.10~0.90)	<0.05?Every time	0.30(0.15~0.60)	<0.001,2666722
789,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly decreased,Method of air ventilation in office and SARS ward		?Artificial central ventilation	1.00	?Natural ventilation	0.40(0.18~0.88)	<0.05?Natural ventilation and additional electronic exhaust fan	0.27(0.16~0.63)	<0.01,2666722
790,125315,Sequential Organ Failure Assessment (SOFA) score ,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,No statistically significant difference was found between the changes in the percentage of SOFA scores of the steroid therapy group (43.1 ± 26.5%) and the standard therapy group (45.4 ± 12.7%) in survivors (P = 0.624).,125315
791,125315,The 28-day mortality,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,There were eight deaths (40%) in the steroid therapy group and 12 (60%) deaths in the standard therapy group (P = 0.343).,125315
792,125315,The median stay in hospital,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,The median stay in hospital was 14 days (95% CI 11.09–20.08) in the steroid therapy group and 13 days (95% CI 10.13–16.37) in the standard therapy group (P = 0.406).,125315
793,2830179,pain during movement,attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly decreased,"Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1))",2830179
794,2830179,Pain on rest (0-10),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly decreased,"Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1)) and at rest (-2.0 (-3.8 to -0.2)) and",2830179
795,2830179,Qualeffo Total (0-100),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly increased,Qualeffo Total (0-100) 29 (10) 26 (7) 21 (11) 27 (8) -7.2 (11.2) 1.2 (4.1) -7.1 (-14.9 to 0.8),2830179
796,2830179,Timed loaded standing test (s),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly increased,Timed loaded standing test (s)	50 (39)	62 (49)	82 (44)	46 (50)	32.6 (34.1)	-16.7 (29.8)	46.7 (16.1 to 77.3),2830179
797,4785315,Postnatal depression (Edinburgh Postnatal Depression Scale17 EPDS),"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,No significant difference,no significant differences were seen in the mean EPDS (mean difference (MD) ?0.59 (95% CI ?1.24 to 0.06)) for all the women recruited,4785315
798,4785315,Antenatal attendances,"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,No significant difference,"Antenatal attendances were high in the standard care control and did not increase further with addition of the POW intervention (10.1 vs 10.1 (mean difference; MD) ?0.00, 95% CI (95% CI ?0.37 to 0.37)).",4785315
799,4785315,Mother-to-infant bonding,"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,Significantly increased,"Mother-to-infant bonding was significantly better in the intervention group for all women (MD ?0.30 (95% CI ?0.61 to ?0.00) p=0.05),",4785315
800,2888205,perceived functional deficits,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,Significantly decreased,"Compared to FME, the LPA group reported significantly less perceived functional deficits (P = .032)",2888205
801,2888205,pain,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,Significantly decreased,"At post-testing, compared to the FME group, the LPA group reported significant reductions in the FIQ score (P = .032; Cohen's d = .53) and in pain (P = .006; Cohen's d = .67).",2888205
802,2888205,six-minute walk test,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,"There were no differences between the groups on the six-minute walk test (P = .067),",2888205
803,2888205,Fatigue severity scale,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Fatigue severity scale ?Baseline 84 51.9 ± 9.3 52.3 ± 9.1 .4 (-3.6 to 4.4) 0.843 .04?Post intervention 73 50.6 ± 9.9 51.4 ± 10.1 .8 (-3.9 to 5.5) 0.727 .07,2888205
804,2888205,Number of tender points,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Baseline 84 16.2 ± 2.3 16.1 ± 3.2 .1 (-1.2 to 1.0) 0.979 .03?Post intervention 72 16.0 ± 2.3 16.8 ± 2.0 .8 (-.35 to 1.9) 0.172 .37,2888205
805,2888205,Body mass index (BMI),"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Body mass index (BMI) ?Baseline 82 31.4 ± 8.4 29.8 ± 6.2 1.6 (-4.7 to 1.7) 0.360 .22?Post intervention 60 31.0 ± 9.0 29.9 ± 6.2 1.1 (-5.3 to 2.9) 0.575 .14,2888205
806,2888205,Center for Epidemiologic Studies Depression Scale (CES-D),"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,CES-D* ?Baseline 84 23.4 ± 8.6 24.0 ± 10 .6 (-3.8 to 4.5) 0.798 .06?Post intervention 73 21.6 ± 9.8 21.2 ± 11.3 .4 (-5.3 to 4.6) 0.888 .04,2888205
807,3490871,weight change,24-week intervention focussed on improving food choice and minimising weight gain,Usual care comprised of 7?weeks of group support sessions,No significant difference,"Analysis of weight change in those successful at stopping smoking was underpowered (66%) but indicated greater mean weight gain in intervention subjects (3.9 (SD 3.1) vs. 2.7 (SD 3.7) kg). Between group differences were not significant (p?=?0.23, 95% CI ?0.9 to 3.5) however the confidence interval is wide and includes a loss of ?0.9?kg, thus the possibility of an effect in favour of the intervention cannot be excluded.",3490871
808,3490871,Smoking cessation,24-week intervention focussed on improving food choice and minimising weight gain,Usual care comprised of 7?weeks of group support sessions,No significant difference,"Although the study was not powered to detect changes in smoking status these data were examined for completers and also using a sensitivity analysis. Both analyses showed a higher percentage of control participants still smoking at week 24 in comparison to intervention participants, however between group differences were not significant (Table 8).Table 8Comparison of Smoking Status between Intervention and Control Groups 	Intervention	Control	Odds Ratio	95% Confidence Interval	pCompleters	 	 	 	 	 Smoking at Week 6	9 (18.8%)	6 (11.3%)	1.74	0.40 to 7.66	0.46Smoking at Week 24	17 (42.5%)	25 (58.1%)	0.43	0.14 to 1.34	0.14Sensitivity analysis	 	 	 	 	 Smoking at Week 6	29 (42.6%)	23 (32.9%)	1.38	0.63 to 3.04	0.42Smoking at Week 24	45 (66.2%)	52 (74.3%)	0.58	0.25 to 1.36	0.20",3490871
809,5256321,The 10mWT (10-m walking test ),Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",Significantly increased,the results for the 10mWT showed only significant improvements in the experimental group (11.38±3.0 to 10.12±2.47 seconds; p=0.01); whereas the control group did not show significant improvements.,5256321
810,5256321,trunk strength (BPR score),Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",Significantly increased,he improvement levels of the trunk strength (BPR score) for the experimental group using Spine Balance 3D system's evaluation program showed significant improvements at the 15° open mode; whereas the control group did not show any significant improvement.,5256321
811,5256321,"he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I) ",Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",No significant difference,"The results of the BBS, FRT, TUG, KFES-I, and Biodex Balance System evaluation program improved in both groups after 7 weeks of balance training.",5256321
812,5602855,Quality of life,good motivation/capability,inadequate motivation/capability,No significant difference,"The EQ-5D-3L summary index is shown in Fig. 2. No significant change could be observed in the anxiety/depression dimension of the EQ-5D-3L system either in those with good (p = 0.26) or inadequate (p = 0.71) motivation/capability during the three years of follow-up. Additionally, no change was observed in the EQ-5D-3L summary index (p = 0.14), EQ VAS (p = 0.68) or the anxiety/depression dimension of the EQ-5D-3L system (p = 0.95) during the follow-up in those subjects who continued pulse palpation at least weekly at 36 months.Fig. 2",5602855
813,5602855,Health care burden,good motivation/capability,inadequate motivation/capability,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (p = 0.39) or to special healthcare outpatient clinics (p = 0.072) during the follow-up.,5602855
814,5602855,Self-detected pulse irregularity and outcome events,good motivation/capability,inadequate motivation/capability,No significant difference,"Irregular pulse findings were not significantly associated with the composite outcome variable (p = 0.06), stroke/TIA (p = 0.48), pacemaker implantation (p = 0.10) or death (p = 1.00).",5602855
815,4419460,HbA1c at 12 or 24?months.,"The Child and Adolescent Structured Competencies Approach to Diabetes Education (CASCADE) is a structured educational group program, using psychological techniques, delivered primarily by diabetes nurses.",control,No significant difference,"Given that the trial found no evidence of benefits on venous HbA1c at 12 and 24?months and little evidence of benefits on secondary outcomes, the focus of this paper is to use the findings of the process evaluation to suggest how future structured education may be more effectively implemented.12",4419460
816,4577567,stride length,stride frequency manipulation,free stride frequency,Significantly increased,Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001),4577567
817,4577567,contact time,stride frequency manipulation,free stride frequency,Significantly increased,"With regard to the two training strategies, within the RWM group the CT significantly increased by 4.58% (p<0.001),",4577567
818,4577567,stride frequency,stride frequency manipulation,free stride frequency,Significantly decreased,a decreased stride frequency (4.44%; p<0.0001),4577567
819,4577567,internal work,stride frequency manipulation,free stride frequency,Significantly decreased,"nversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.",4577567
820,5294349,datasets of 3D coordinates,CT scan,2–4 stereo radiograph pair examinations,No significant difference,"he precision of RSA corresponding to the 99% confidence interval was 1.36°, 1.36°, and 0.60° for X-, Y-, and Z-rotation and 0.40, 0.17, and 0.37?mm for X-, Y-, and Z-translation. The limit of agreement between CT and RSA was 1.51°, 2.17°, and 1.05° for rotation and 0.59, 0.56, and 0.74?mm for translation. The differences between CT and RSA are close to the described normal 99% confidence interval for precision in RSA: 0.3° to 2° for rotation and 0.15 to 0.6?mm for translation.",5294349
821,5294349,datasets of 3D coordinates,CT scan,2–4 stereo radiograph pair examinations,No significant difference,"CT scans can be used for migration measurements in longitudinal evaluations of patients with RSA markers without losing clinically significant precision. The use of CT scans enables following RSA studies started earlier using a normal CT scan, thus avoiding the need for special RSA radiology facilities.",5294349
822,3329632,ICER (incremental cost-effectiveness ratio),ranibizumab ,ranibizumab combined with laser therapy,Significantly decreased,"Ranibizumab monotherapy was associated with an incremental gain of 0.17 QALY and cost of £4 191, corresponding to an ICER of £24?028 per QALY gained relative to laser monotherapy (table 3). Combination therapy provided an incremental gain of 0.13 QALY over laser monotherapy for an incremental cost of £4 695, leading to an ICER of £36?106 per QALY gained.",3329632
823,3800940,"Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss.",Gomutra sodhit Langali moola with honey for external application,Godugdha sodhit Langali moola with honey for external application,Significantly decreased,It was observed that after 60 days of treatment with Gomutrashodhit Langlimool in Group A there was reduction in Hair fall which is statistically highly significant (P<0.001) and highly significant improvement was observed in reducing dandruff.(p<0.001). Where as in Group B Godugdashodhit Langlimool application reduced the hair fall to statistically significant level (p<0.01) and statistically significant in reducing the dandruff in patient with Indralupta (P<0.01).,3800940
824,4819709,Bending the legs without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Bending the legs without discomfort	50	3·0	4·6	1·38 (1·14, 1·67)",4819709
825,4819709,Lifting heavy objects without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Lifting heavy objects without discomfort	50	4·8	9·8	1·97 (1·59, 2·44)90	16·9	34·5",4819709
826,4819709,Moving from standing to sitting without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Moving from standing to sitting without discomfort	50	1·9	3·7	1·63 (1·35, 1·97)",4819709
827,4819709,Standing still for a long time (>?15 min ) without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Standing still for a long time (>?15 min ) without discomfort	50	3·9	7·1	1·67 (1·36, 2·05)90	15·8	28·7",4819709
828,4819709,Walking short distances (<?20 min ) without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Walking short distances (<?20 min ) without discomfort	50	1·9	4·4	2·00 (1·65, 2·42)90	8·2	19·1",4819709
829,4819709,Walking long distances (>?20 min),Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Walking long distances (>?20 min)	50	4·5	8·0	1·76 (1·45, 2·14)90	15·2	27·1",4819709
830,4819709,Having a bath or shower,Ultrasound?guided foam sclerotherapy,surgery,No significant difference,"Having a bath or shower	50	5·4	4·9	0·85 (0·70, 1·03)90	11·4	10·3",4819709
831,4819709,Driving a car,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Driving a car	50	4·1	7·0	1·78 (1·45, 2·19)",4819709
832,4819709,Doing housework,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Doing housework	50	2·1	4·5	2·10 (1·72, 2·56)",4819709
833,4819709,Looking after children,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Looking after children	50	1·2	3·5	2·20 (1·61, 3·00)90	6·2	17·9",4819709
834,4819709,Wearing clothes that show the legs,Ultrasound?guided foam sclerotherapy,surgery,No significant difference,"Wearing clothes that show the legs	50	12·4	12·8	1·03 (0·78, 1·35)90	56·6	58·7",4819709
835,4819709,Partial return to normal work/employment,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Partial return to normal work/employment	50	4·4	9·9	2·16 (1·72, 2·72)90	15·4	34·2",4819709
836,4819709,Full return to normal work/employment,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Full return to normal work/employment	50	4·8	11·7	2·56 (2·05, 3·21)90	14·9	36·2",4819709
837,4819709,Going out socially,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Going out socially	50	7·1	9·3	1·29 (1·06, 1·57)90	25·8	34·0",4819709
838,4819709,Sporting activity or exercise,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Sporting activity or exercise	50	15·7	21·8	1·33 (1·05, 1·68)",4819709
839,4819709,"Bending the legs without discomfort, lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (>?15 min) without discomfort, Driving a car, Doing housework, Partial return to normal work/employment, Going out socially, Sporting activity or exercise",Endovenous laser ablation,Ultrasound?guided foam sclerotherapy,No significant difference,"Activity items Bending the legs without discomfort 50 2·7 3·0 0·94 (0·75, 1·17)90 12·6 14·1Lifting heavy objects without discomfort 50 5·9 4·8 1·11 (0·87, 1·42)90 20·5 16·9Moving from standing to sitting without discomfort 50 2·2 1·9 1·12 (0·90, 1·40)90 10·4 9·3Standing still for a long time (>?15 min) without discomfort 50 4·8 3·9 1·14 (0·90, 1·44)90 20·0 15·8Walking short distances (<?20 min) without discomfort 50 3·0 1·9 1·48 (1·19, 1·84)90 13·2 8·2Walking long distances (>?20 min) 50 5·6 4·5 1·32 (1·05, 1·66)90 19·8 15·2Having a bath or shower 50 5·5 5·4 1·19 (0·96, 1·48)90 12·8 11·4Driving a car 50 4·4 4·1 0·95 (0·74, 1·21)90 12·7 12·4Participation items Doing housework 50 2·5 2·1 1·03 (0·82, 1·29)90 8·4 7·3Looking after children 50 1·9 1·2 1·45 (1·04, 2·02)90 8·8 6·2Wearing clothes that show the legs 50 14·6 12·4 1·17 (0·83, 1·64)90 75·1 56·6Partial return to normal work/employment 50 6·3 4·4 1·17 (0·89, 1·52)90 21·1 15·4Full return to normal work/employment 50 7·7 4·8 1·43 (1·11, 1·85)90 23·5 14·9Going out socially 50 6·9 7·1 0·88 (0·70, 1·10)90 23·9 25·8Sporting activity or exercise 50 14·2 15·7 0·80 (0·61, 1·04)90 55·5 62·6",4819709
840,4819709,"walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment",Endovenous laser ablation,Ultrasound?guided foam sclerotherapy,Significantly decreased,"Return to ‘walking short distances without discomfort’, ‘walking long distances’, ‘looking after children’ and ‘full return to normal work/employment’ took longer for the EVLA group than the UGFS group.",4819709
841,4819709,"Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (>?15 min) without discomfort, Walking short distances (<?20 min) without discomfort, Walking long distances (>?20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise, ",Endovenous laser ablation,surgery,Significantly increased,"Activity items				Bending the legs without discomfort	50	2·7	4·6	1·49 (1·19, 1·75)90	12·6	21·3Lifting heavy objects without discomfort	50	5·9	9·8	1·79 (1·39, 2·27)90	20·5	34·5Moving from standing to sitting without discomfort	50	2·2	3·7	1·56 (1·27, 1·96)90	10·4	17·5Standing still for a long time (>?15 min) without discomfort	50	4·8	7·1	1·41 (1·11, 1·79)90	20·0	28·7Walking short distances (<?20 min) without discomfort	50	3·0	4·4	1·30 (1·04, 1·61)90	13·2	19·1Walking long distances (>?20 min)	50	5·6	8·0	1·53 (1·06, 1·67)90	19·8	27·1Having a bath or shower	50	5·5	4·9	0·74 (0·59, 0·93)90	12·8	10·3Driving a car	50	4·4	7·0	1·82 (1·43, 2·33)90	12·7	21·1Participation items				Doing housework	50	2·5	4·5	1·89 (1·49, 2·38)90	8·4	15·7Looking after children	50	1·9	3·5	1·61 (1·15, 2·27)90	8·8	17·9Wearing clothes that show the legs	50	14·6	12·8	0·97 (0·69, 1·35)90	75·1	58·7Partial return to normal work/employment	50	6·3	9·9	1·75 (1·33, 2·27)90	21·1	34·2Full return to normal work/employment	50	7·7	11·7	1·79 (1·37, 2·27)90	23·5	36·2Going out socially	50	6·9	9·3	1·41 (1·12, 1·75)90	23·9	34·0Sporting activity or exercise	50	14·2	21·8	1·47 (1·12, 1·92)",4819709
842,2891743,transurethral resection (TUR) syndrome,glycine 1.5% solution as irrigating fluid,glucose 5% solution,Significantly increased,TUR syndrome	17*	0	0,2891743
843,2891743,transurethral resection (TUR) syndrome,glycine 1.5% solution as irrigating fluid,normal saline 0.9% solution,Significantly increased,TUR syndrome 17* 0 0,2891743
844,3418149,Morbidity after surgery,ipsilateral arm morbidity,contralateral arm morbidity,Significantly increased,"Comparison of ipsilateral vs. contralateral arm shows that changes affecting one limb strongly correlated with changes affecting the other limb (upper right quarter of Table 3). The highest correlations were abduction (R = 0.78), retroflexion (R = 0.73), scapular distance (R = 0.65), and arm volume (R = 0.57), all P-values <0.001.",3418149
845,5062194,neonatal outcome,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",No significant difference,There were no between-group differences regarding the neonatal outcome.,5062194
846,5062194,postoperative satisfaction,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly increased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,5062194
847,5062194,preoperative anxiety,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly decreased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,5062194
848,5062194,No statistical analysis because they are in tables,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly increased,"Table 2Amsterdam Preoperative Anxiety and Information Scale, Maternal Satisfaction Scale for cesarean section, Apgar score and neonatal neurologic and adaptive capacity score in both groupsTable 3Blood gas analysis of umbilical artery blood samples in both groupsRegarding maternal hemodynamics, baseline HR, SBP, and DBP were comparable between the two groups before the administration of the tested drug. However, 5 min after injecting the tested drug, there was a significant decrease in all parameters in group (M) compared to group (S). During insertion of the spinal needle, there was a rise in HR and SBP in group (S) compared to group (M) while DBP was at a lower level in group (M). After the induction of spinal anesthesia and placing the patient into the tilted supine position, there was an increase in HR with some decrease in blood pressure parameters in both groups as shown in Tables 4–6.Table 4Maternal heart rate in both groupsTable 5Systolic blood pressure in both groupsTable 6Diastolic blood pressure in both groups",5062194
849,5577662,percentage changes in area,"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,"percentage changes in area were significantly greater with CCH 0.40 mg (?80.1%, P = 0.0002) and CCH 0.60 mg (?78.2%, P = 0.0003), but not CCH 0.25 mg (?58.3%, P = 0.079), versus placebo (?42.2%) at post-treatment Week 8.",5577662
850,5577662,Mean change in nodular consistency and hardness,"receive a dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,Mean change in nodular consistency and hardness were significantly improved with CCH versus placebo at Weeks 4 and 8 (P ? 0.0139 for all).,5577662
851,5577662,global assessment of improvement,"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,nvestigator global assessment of improvement was significantly greater with CCH 0.40 mg and 0.60 mg (P ? 0.0014),5577662
852,5577662,percentage changes in area,receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH),"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",No significant difference,"percentage changes in area were significantly greater with CCH 0.40 mg (?80.1%, P = 0.0002) and CCH 0.60 mg (?78.2%, P = 0.0003), but not CCH 0.25 mg (?58.3%, P = 0.079), versus placebo (?42.2%) at post-treatment Week 8.",5577662
853,5577662,global assessment of improvement,receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH),"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",No significant difference,global assessment of improvement was significantly greater with CCH 0.40 mg and 0.60 mg (P ? 0.0014) but not statistically significant with CCH 0.25 mg versus placebo (P = 0.13).,5577662
854,4794897,pyridinoline,resistance training dyrung radiation therapy,passive physical therapy,Significantly decreased,Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p?=?0.035 and p?=?0.043),4794897
855,4794897,beta-isomer of carboxy-terminal telopeptide of type I collagen,resistance training dyrung radiation therapy,passive physical therapy,Significantly decreased,Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p?=?0.035 and p?=?0.043),4794897
856,5062234,The 24 h morphine requirement,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,No significant difference,The 24 h morphine requirement (mean ± standard deviation) was 34.57 ± 14.64 mg in TAP group and 32.76 ± 14.34 mg in local infiltration group (P = 0.688).,5062234
857,5062234,intraoperative supplemental fentanyl,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,Significantly decreased,The number of patients requiring intraoperative supplemental fentanyl in TAP group was 8 and in local infiltration group was 16 (P = 0.028).,5062234
858,5062234,The visual analog scale scores at rest and on coughing,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,Significantly decreased,"At 4 h, none of the patients in the TAP group but seven patients (33.3%) in the control group had moderate to severe pain (VAS >3) at rest (P = 0.009*). At 4 h, eight patients (38.1%) in the TAP group and 15 patients (71.4%) in the control group had moderate to severe pain on coughing (P = 0.03*). At 12 h, six patients (28.5%) in the TAP group and 18 patients (85.7%) in the control group had moderate to severe pain on coughing (P < 0.001*).",5062234
859,4139977,decrease in abdominal pain and distension severity,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,"here was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (P<0.001), but there was no difference between the two groups in this regard (P>0.05).",4139977
860,4139977,Improvement in bowel habit,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,mprovement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910).,4139977
861,4139977,quality-of-life ,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,"With regard to QOL, an improvement was observed in the probiotic (P = 0.008), but not in the placebo group (P = 0.175); though, there was no significant difference between the two groups in this regard (P = 0.372),",4139977
862,4078386,mean of HCV-RNA numbers in 12 weeks of therapy,20 mg atorvastatin nightly for 3 months,placebo,No significant difference,"we didn't find any significant differences in the mean of HCV-RNA numbers in statin and placebo groups in 12th week of Statins therapy (P > 0.05),",4078386
863,4078386,mean of HCV-RNA numbers at the end of treatment ,20 mg atorvastatin nightly for 3 months,placebo,No significant difference,"we didn't find any significant differences in the mean of HCV-RNA numbers in statin and placebo groups in 12th week of Statins therapy (P > 0.05), at the end of treatment (P > 0.05)",4078386
864,4078386,mean of HCV-RNA numbers 6 months after treatment ,20 mg atorvastatin nightly for 3 months,placebo,No significant difference,"we didn't find any significant differences in the mean of HCV-RNA numbers in statin and placebo groups in 12th week of Statins therapy (P > 0.05), at the end of treatment (P > 0.05) and 6 months after treatment (P > 0.05)",4078386
865,5680306,Serum 25(OH)D concentrations,"vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily","the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks",Significantly increased,"Serum 25(OH)D concentrations increased significantly in the vitamin D group, from 31.4?±?12.6 at baseline to 88.4?±?21.0 nmol/L at 16 weeks (p?<?0.001), with no change in the placebo group for the same time-period (34.2?±?10.0 and 36.1?±?15.3 nmol/L, respectively; p?=?0.5)",5680306
866,5680306,"hsCRP, TNF, MCP-1, IFN-?, any of the interleukins","vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily","the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks",No significant difference,"There were no differences between vitamin D and placebo groups in change in hsCRP (?0.1?±?1.4 versus ?0.4?±?2.3?mg/L, p?=?0.9), TNF (?8.0?±?109.4 versus ?2.9?±?103.9?pg/ml, p?=?0.9), MCP-1 (?234.8?±?1071.9 versus ?58.8?±?819.4?pg/ml, p?=?0.6) or IFN-? (11.1?±?85.8 versus ?1.3?±?22.7?pg/ml, p?=?0.9). Similarly, no differences between vitamin D and placebo groups were found for any of the interleukins (all p?>?0.1; Table 2).",5680306
867,5680306,NF?B activity,"vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily","the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks",No significant difference,NF?B activity also did not differ between vitamin D and placebo groups in this subgroup (p?=?0.3;,5680306
868,5332972,FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set;,after 4 weeks of repetitive facilitative exercises  and orthotic treatment.,before repetitive facilitative exercises  and orthotic treatment.,Significantly increased,"In terms of lower-limb motor performance, FMA-LE increased significantly from 22.96 ± 4.07 to 25.85 ± 4.03 (p<0.01), and SIAS increased significantly from 46.59 ± 8.34 to 53.63 ± 7.63 (p<0.01).",5332972
869,5332972,TUG: Timed “Up & Go” test;,after 4 weeks of repetitive facilitative exercises  and orthotic treatment.,before repetitive facilitative exercises  and orthotic treatment.,Significantly decreased,"TUG decreased significantly from 17.35 ± 5.57 seconds to 14.02 ± 4.46 seconds (p<0.01),",5332972
870,5332972,comfortable gait speed and fast gait speed ,after 4 weeks of repetitive facilitative exercises and orthotic treatment.,before repetitive facilitative exercises and orthotic treatment.,Significantly increased,"comfortable gait speed increased significantly from 0.68 ± 0.22 (m/sec) to 0.81 ± 0.24 (m/sec) (p<0.01), and fast gait speed increased significantly from 0.80 ± 0.28 (m/sec) to 0.96 ± 0.31 (m/sec) (p<0.01).",5332972
871,5209819,Pre-treatment testing performed within the ADDO,"After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.","Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.",Significantly increased,Pre-treatment testing performed within the ADDO increased from 0 to 65% of suspected malaria patients who visited a shop (95% CI 60.8–69.6%) with no difference between intervention districts.,5209819
872,5209819,The proportion of patients present at the ADDO who received a diagnostic test ,"After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.","Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.",Significantly increased,The proportion of patients present at the ADDO who received a diagnostic test increased from 19% pre-intervention to 74% post-intervention in the intervention districts and from 3 to 18% in the control district (p < 0.01 for both groups).,5209819
873,5729252,hospital-free survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF),bosentan,no treatment,Significantly increased,"At the time of survival time analysis, hospital-free survival was 358.87?±?68.65 days (mean?±?SE) (median, 331 days) in the untreated group, which was significantly different from that in the drug-treated group (603.44?±?50.074 days) as assessed by proportional hazard analysis (hazard ratio of the drug-treated group to the untreated group, 0.19, P?=?0.017; log-rank test, P?=?0.019; and Wilcoxon test, P?=?0.014).",5729252
874,5729252,overall survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF),bosentan,no treatment,Significantly increased,"(671 days vs. 433.78?±?66.98 days; HR, 0.10; P?=?0.0082).",5729252
875,2974815,percentage of patients with controlled blood pressure,phone calls” group,“no phone calls” group,No significant difference,There was no difference in the percentage of patients with controlled blood pressure in the “phone calls” group and “no phone calls” group or in the “traditional” and “current” groups.,2974815
876,2974815,discontinued treatment,phone calls” group,“no phone calls” group,Significantly decreased,Significantly fewer patients in the “phone calls” group discontinued treatment compared to those in the “no phone calls” group (4 vs. 30; p<0.0094).,2974815
877,2974815,The percentage of patients with controlled blood pressure (<140/90 mmHg),phone calls” group,“no phone calls” group,Significantly increased,"The percentage of patients with controlled blood pressure (<140/90 mmHg) was increased at the end of the treatment (74%), reaching 80% in the “uncomplicated” group and 67% in the “complicated” group (p<0.000001).",2974815
878,4088715,rate of intubations,CPAP + standard of care (nCPAP group),standard group,Significantly decreased,"Finally, the rate of intubations was higher in the standard group (n = 8, n = 3) than the nCPAP group (P < 0.01).",4088715
879,4088715,hospital and ICU length of stay,CPAP + standard of care (nCPAP group),standard group,Significantly decreased,"The nCPAP group also had a shorter hospital and ICU length of stay compared with the standard group (4 vs 5 days, and 2 vs 3 days, respectively).",4088715
880,4088715,"tidal volume (TV), end-tidal carbon dioxide (EtCO2) and Rapid Shallow Breathing Index (RSBI)",CPAP + standard of care (nCPAP group),standard group,Significantly increased,"Subjects in the nCPAP group had a greater improvement for various parameters compared with the standard group including TV (0.8 l, 0.3 l), EtCO2 (30 mmHg, 38 mmHg) and RSBI (39, 150), respectively.",4088715
881,5539984,Primary outcome effect,The Network for Mental Health (NWpG-IC),standard mental health care,No significant difference,"ixed-models for EPAS total score (see Table 3) indicated a significant effect of time (b = 0.07, p < 0.001), but no significant group by time interaction effect (b = 0.02; p = 0.258). This means with regard to the parameterisation of the mixed effects model that there was a significant change of overall empowerment in the control group, but NWpG-IC treatment had no additional effect on improvement of overall empowerment during the 18 month study period.",5539984
882,5539984,prevalence of psychiatric inpatient admission,The Network for Mental Health (NWpG-IC),standard mental health care,No significant difference,"The results of the mixed effects logistic regression model (not presented) did neither show differences of the prevalence of psychiatric inpatient admission between groups during the six months before baseline assessment (OR 0.99; p = 0.985), nor a change over time (OR 0.62; p = 0.086) in either groups or a difference between the groups (OR 0.97; p = 0.878) during the study period.",5539984
883,5539984,reduction of total needs and the increase of met needs,The Network for Mental Health (NWpG-IC),standard mental health care,No significant difference,"However, as indicated by the non-significant group by time interaction, there was no difference between groups regarding the reduction of total needs (b = 0.09; p = 0.217) or the increase of met needs (b = 0.01; p = 0.621).",5539984
884,5514258,survival,major salivary gland cancer in high risk group plus adjuvant radiation therapy,major salivary gland cancer in high risk group without adjuvant radiation therapy,Significantly increased,"Patients in the high-risk group had greater survival (hazard ratio [HR], 0.76; P = .002; 95% confidence interval [CI], 0.64-0.91) if they received adjuvant radiation therapy.",5514258
885,5514258,survival,major salivary gland cancer in low/intermediate risk group plus adjuvant radiation therapy,major salivary gland cancer in low/intermediate risk group without adjuvant radiation therapy,No significant difference,"patients in the intermediate- (HR, 1.01; P = .904; 95% CI, 0.85-1.20) and low-risk groups (HR, 0.85; P = .427; 95% CI, 0.57-1.26) did not experience a survival benefit with adjuvant radiation therapy.",5514258
886,4804575,The average TB incidence rate attributable to reinfection in the first year,during isoniazid preventive therapy,after isoniazid preventive therapy,Significantly decreased,"The average TB incidence rate attributable to reinfection in the first year was estimated at 1.3/100 pyrs, compared to an observed rate of 2.2/100 pyrs (95 % CI, 1.8–2.7).",4804575
887,5801479,"gene expression of interleukin (IL), tumor necrosis factor alpha (TNF-?), interferon gamma (IFN-?) ","vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks",placebo (n = 30) every 2 weeks for 12 weeks,Significantly decreased,"Results of RT-PCR indicated that after the 12-week intervention, compared to the placebo, vitamin D supplementation downregulated gene expression of interleukin (IL)-1? (P = 0.02), tumor necrosis factor alpha (TNF-?) (P = 0.02) and interferon gamma (IFN-?) (P = 0.03) in PBMCs of diabetic HD patients.",5801479
888,5801479,"gene expression of transforming growth factor beta (TGF-?), protein kinase C (PKC), mitogen-activated protein kinases 1 (MAPK1) ","vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks",placebo (n = 30) every 2 weeks for 12 weeks,Significantly decreased,"Additionally, vitamin D supplementation, compared to the placebo, downregulated gene expression of TGF-? (P = 0.04), PKC (P = 0.001), and MAPK1 (P = 0.02) in PBMCs of diabetic HD patients",5801479
889,5801479,"nuclear factor kappa B (NF-kB), interleukin (IL)-4, IL-6, and vascular endothelial growth factor (VEGF) ","vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks",placebo (n = 30) every 2 weeks for 12 weeks,No significant difference,"Although not significant, vitamin D supplementation let to a reduction of nuclear factor kappa B (NF-kB) (p = 0.75) expression in PBMCs isolated from diabetic patients compared to the placebo group. There was no statistically significant change following supplementation with vitamin D on gene expression of interleukin (IL)-4, IL-6, and vascular endothelial growth factor (VEGF) in PBMCs of diabetic HD patients.",5801479
890,5519461,H. pylori eradication,"amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week.","amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week.",No significant difference,"The eradication rates of the EAC and RAC regimen groups were 79.8% [95% confidential interval (CI): 71.7-89.0%] and 74.7% (66.0-83.4%) for the per protocol (PP) analysis and 75.8% (67.4-84.2%) and 71.0% (62.1-79.9%) for the intention-to-treat (ITT) analysis, respectively (Fig. 2A). No significant differences were observed between the two regimens.",5519461
891,5519461,Eradication of H. pylori with homo EM genotype and those with hetero IM or PM genotype.,"amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week.","amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week.",No significant difference,"The eradication rate of the EAC and RAC regimens in the homo EM patients was 73.3% (CI: 57.5-89.1%) and 76.7% (CI: 61.6-91.8%), respectively. In the hetero IM and PM patients, the eradication rate of the EAC regimen was 82.8% (73.6-92.0%), and that of the RAC regimen was 73.8% (63.1-84.5%). The eradication rates of the EAC and RAC regimen groups were not significantly different between the patients with homo EM genotype and those with hetero IM or PM genotype.",5519461
892,5618071,"ADI-R (algorithm for current condition), the Autism Behavioral Checklist (ABC), and the Autism Treatment Evaluation Checklist (ATEC)  after 1 month",after Non-Invasive Brain Stimulation (NIBS),before Non-Invasive Brain Stimulation (NIBS),Significantly decreased,"As a global result (G1 + G2), a significant decrease in the total score was observed in ADI-R, ABC, and ATEC scales one month after the intervention (Wilcoxon matched pair test; ABC, Z = 3.823, p = 0.000131; ADI-R, 3.337, p = 0.000846; ATEC, Z = 3.723, p = 0.000196).",5618071
893,4005450,pain experience,injected with lidocaine solutions 2%,"injected with lidocaine solutions 0,4%",No significant difference,Group A	Group B	Total	P valuePain severity 				0.003Mild	36	41	77	Moderate	6	6	12	Sever	8	3	11,4005450
894,4140547,"The proportion of patients who met the primary end point (composite of acute rejection, graft loss, death by month 6)",belatacept groups,tacrolimus groups,Significantly increased,". Demographic characteristics were similar among groups. The proportion of patients who met the primary end point (composite of acute rejection, graft loss, death by month 6) was higher in the belatacept groups (42–48%) versus tacrolimus groups (15–38%), with the highest number of deaths and grafts losses in the belatacept LD group.",4140547
895,4140547,"By month 12, the proportion surviving with a functioning graft",belatacept groups,tacrolimus groups,Significantly decreased,"By month 12, the proportion surviving with a functioning graft was higher with tacrolimus + MMF (93%) and lower with belatacept LD (67%) versus other groups (90%: basiliximab + belatacept HD; 83%: belatacept HD; 88%: tacrolimus).",4140547
896,4140547,Mean calculated GFR at 1 year.,belatacept groups,tacrolimus groups,Significantly increased,The proportion of patients with >10 mL/min improvement in cGFR from baseline to month 12 was 47–65% in the belatacept groups versus 12–27% in the tacrolimus groups.,4140547
897,1198254,total fecal counts of lactobacilli,L. fermentum ME-3 fermented goat milk,goat milk,Significantly increased,"Increase of total fecal counts of lactobacilli in healthy volunteers consuming of ME-3 in fermented goat milk and probiotic capsule. 1 – Day 0, 2 – Day 21 Significantly different from pre-treatment values (Student's t-test): * p < 0.05; Significantly different from control (Student's t-test): ‡ p = 0.01",1198254
898,1198254,glutathione red-ox ratio,"Capsule trial, ME-3",Placebo,No significant difference,"When the probiotic was consumed in capsulated form, no significant decrease was noticed in the glutathione red-ox ratio.",1198254
899,1198254,glutathione red-ox ratio,L. fermentum ME-3 fermented goat milk,goat milk,No significant difference,"The effect of goat-milk consumption on the TAA and TAS values was significantlyhigher (p < 0.001) than by the consumption of the capsulated probiotic (Fig. 3). The decrease of the glutathione red-ox ratio was significant in both groups: the study Group (from 0.15 ± 0.01 to 0.11 ± 0.04 ?g/ml, p < 0.01) and control (from 0.14 ± 0.03 to 0.11 ± 0.02 ?g/ml, p < 0.01) in the goat milk trial.",1198254
900,1198254,Total Antioxidative Activity,L. fermentum ME-3 fermented goat milk,goat milk,Significantly increased,"The positive effect on the blood ox stress markers as TAA and TAS was seen in the case of both formulations (Fig. 3). Particularly, the additive increase in goat milk group was 6% and 9% respectively as compared to control group, however only 4% for TAA and 2.5% for TAS in probiotic capsule study group as compared to placebo.",1198254
901,4677000,On average (median) pain  in the paediatric population,lidocaine gel (2%),placebo,Significantly decreased,On average (median) pain has been reduced by 2.0/5 (verum) versus 1.2/5 (placebo) (Table 3). Nonparametric analysis (Mann-Whitney??U test) of treatment related difference in pain assessment yielded a statistical significance (p < 0.001) of the observed effect in favour of the 2% lidocaine gel (verum). A similar result (p < 0.002) was achieved also for the measurement of pain reduction from T1 to T3.,4677000
902,4677000,pain  in the paediatric population,lidocaine gel (2%),placebo,Significantly decreased,The observed ratings consequently showed statistically significant reduction of pain (Wilcoxon signed rank test results; T2: p value < 0.0001 and T3: p value < 0.0001).,4677000
903,4320624,peak FEV1,Abediterol,placebo,Significantly increased,"Abediterol produced dose-dependent improvements in peak FEV1 from baseline compared with placebo, from 0.274 (95% CI 0.221, 0.327) to 0.405 L (95% CI 0.353, 0.458) for abediterol 0.313 to 2.5 ?g, respectively (p?<?0.0001 all doses)",4320624
904,4320624,peak FEV1,Abediterol,salbutamol,No significant difference,"Abediterol 0.625, 1.25, and 2.5 ?g had similar magnitude of peak FEV1 effect to salbutamol.",4320624
905,4320624,Dose-dependent changes from baseline in trough FEV1,Abediterol,placebo,Significantly increased,"Dose-dependent changes from baseline in trough FEV1 versus placebo were 0.219 (95% CI 0.136, 0.302) to 0.400 L (95% CI 0.317, 0.483) for abediterol 0.313 to 2.5 ?g, respectively (p?<?0.0001).",4320624
906,4320624,"Change from baseline in normalized FEV1 AUC0–6, FEV1 AUC0–12, and FEV1 AUC0–2",Abediterol,placebo,Significantly increased,"Change from baseline in normalized FEV1 AUC0–6, FEV1 AUC0–12, and FEV1 AUC0–24 was significantly higher for all doses of abediterol versus placebo (p?<?0.0001 for all, Table 2), with dose-related effects observed.",4320624
907,5816054,The duration of nebulization,furosemide,0.9% saline,No significant difference,"The duration of nebulization was not significantly different across treatments: 0.9% saline, 35.7 ± 1.0 min; 40 mg furosemide, 36.4 ± 1.2 min; and 120 mg furosemide, 39.2 ± 1.1 min (p = 0.075).",5816054
908,5816054,"breathlessness, leg discomfort, chest tightness to exercise cessation were not significantly different across treatments.",furosemide,0.9% saline,No significant difference,"The relative contributions of breathlessness [0.9% saline, 41.9 ± 3.4%; 40 mg furosemide, 40.2 ± 3.6%; 120 mg furosemide, 39.4 ± 4.0% (p = 0.876)], leg discomfort [0.9% saline, 55.4 ± 4.1%; 40 mg furosemide, 54.4 ± 4.2%; 120 mg furosemide, 51.7 ± 4.6% (p = 0.746)] and chest tightness [0.9% saline, 2.4 ± 1.5%; 40 mg furosemide, 0.8 ± 0.8%; 120 mg furosemide, 6.0 ± 3.3% (p = 0.170)] to exercise cessation were not significantly different across treatments.",5816054
909,2774638,Estimation of total daily calcium intake,calcium-focused food frequency questionnaire (CFFFQ),24-hour recall,Significantly increased,"The CFFFQ estimated greater total daily calcium intake than did the 24-hour recall (mean [SD], 1,021 [624] mg/d vs 800 [433] mg/d, P < .001).",2774638
910,2774638,Estimation of underreported calcium as daily calcium intake increased,calcium-focused food frequency questionnaire (CFFFQ),24-hour recall,Significantly decreased,"As daily calcium intake increased, the 24-hour recall increasingly underreported calcium (r = 0.41, P < .001) compared with the CFFFQ.",2774638
911,2774638,obtained calcium from dairy ,white women,black women,Significantly increased,"White women obtained more calcium (630 [423] mg) from dairy than did black women (424 [373] mg, P < .004).",2774638
912,2774638,difference in mean (SD) dairy calcium,white women,black women,Significantly increased,"Calcium from grains primarily came from fortified foods. Dairy was also the primary calcium source when the 24-hour recall data were analyzed, and a significant difference in mean (SD) dairy calcium intake between racial groups was found (243 [273] mg for black women, 444 [360] mg for white women, P < .001).",2774638
913,4713214,catheter related bladder discomfort During the first three days of post-operative period,"received, intravesically, 40 mL of 20 nM Resiniferatoxin 20 hours before operation.",no treatment before operation.,Significantly decreased,"During the first three days of post-operative period, the incidence of patients' CRBD was lower in Group I than that in Group II (25% vs. 75%, P=0.001, Fisher's exact test).",4713214
914,4713214,required tolterodine,"received, intravesically, 40 mL of 20 nM Resiniferatoxin 20 hours before operation.",no treatment before operation.,Significantly decreased,"Finally, less patients in RTX group required tolterodine, compared with control, P=0.009.",4713214
915,4713214,catheter related bladder discomfort On the fifth day after surgery,"received, intravesically, 40 mL of 20 nM Resiniferatoxin 20 hours before operation.",no treatment before operation.,No significant difference,"On the fifth day after surgery, although the incidence of CRBD was still lower in Group I than that in Group II (50% vs. 75%), there was no significant difference between them (P=0.135, Fisher's exact test).",4713214
916,5332489,"International Prostate Symptom Score (IPSS),  BPH Impact Index (BII), question 8 of the IPSS (IPSS-Q8)]",fixed-dose combination (FDC) of dutasteride and tamsulosin,watchful waiting (WW),No significant difference,"The adjusted mean decrease in IPSS, BII and IPSS-Q8 at each post-baseline visit over 24 months appeared greater in the FDC (n = 369) and WW-no treatment groups (n = 144) than in the WW-TAM group (n = 229)",5332489
917,3616124,risk of the primary outcome or preeclampsia,daily doses of 400 IU of vitamin E and 1000 mg of vitamin C from 9-16 weeks gestation until delivery.,placebo from 9-16 weeks gestation until delivery.,No significant difference,Vitamin supplementation did not reduce the risk of the primary outcome or preeclampsia in women of any phenotype.,3616124
918,3616124,preeclampsia risk  in Hispanic Hp 2-2 women.,daily doses of 400 IU of vitamin E and 1000 mg of vitamin C from 9-16 weeks gestation until delivery.,placebo from 9-16 weeks gestation until delivery.,Significantly increased,"Hispanic 2-2 women who were not taking prenatal vitamins at randomization had a smaller increase in preeclampsia risk with supplementation than Hispanic 2-2 women who were taking prenatal vitamins at randomization (2.01; 0.80–5.01, p?=?0.14 vs. 7.83; 2.01–30.53, p<0.01, Table 4).",3616124
919,3616124,preeclampsia risk,"Haptoglobin’s (Hp)  1-1, 2-1, ",Haptoglobin’s (Hp) 2-2 phenotypes,No significant difference,"Hp phenotype does not influence preeclampsia risk, or identify a subset of women who may benefit from vitamin C and E supplementation to prevent preeclampsia.",3616124
920,3015551,The mean time to remove both tubal segments,undergo a tubal resection after Pomeroy ligation,undergo a tubal resection after bipolar coagulation with Kleppinger forceps,No significant difference,"The mean time to remove both tubal segments was not different between techniques (7 minutes, 21 seconds; range, 4 minutes, 25 seconds to 15 minutes, 43 seconds).",3015551
921,3015551,Postoperative pain at 6 hours,undergo a tubal resection after Pomeroy ligation,undergo a tubal resection after bipolar coagulation with Kleppinger forceps,No significant difference,"Pain at incision sites or in the pelvis was described by the patient as being usually mild or moderate 6 hours postoperatively (mean score: 4.6 out of 10 for ligation, 4.0 of 10 for coagulation) except in 6 patients (ligation 4, coagulation 2) that required overnight admission for parenteral morphine or meperidine.",3015551
922,3015551,Outpatient recovery,undergo a tubal resection after Pomeroy ligation,undergo a tubal resection after bipolar coagulation with Kleppinger forceps,No significant difference,"Outpatient recovery was the same, unless pelvic pain required overnight observation (ligation, 4 patients; coagulation, 2 patients).",3015551
923,5295802,cytokine levels at baseline,levocarnitine,placebo,No significant difference,"There was no statistically significant difference in cytokine levels between symptom groups (severe vs. non-severe fatigue and severe vs. non-severe depression) at baseline based on the Wilcoxon rank sum test (p>0.05 for all cytokines, data not shown).",5295802
924,5295802,IFN-? and VEGF in depression patients,after intervention,before intervention,Significantly decreased,IFN-? (p=0.005) and VEGF (p=0.045),5295802
925,5295802,"all ten cytokines/growth factors -  IL-1, IL-1?, IL-6, IL-8, IL-1Ra, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?), EGF, TGF-?, and vascular endothelial growth factor (VEGF)",after intervention,before intervention,Significantly decreased,"Among 101 analyzable patients, all ten cytokines/growth factors examined were highly elevated at baseline and all significantly decreased at week 4 (p<0.001) regardless of treatment intervention.",5295802
926,3220090,thickness of the keratinized tissue (TKT),coronally positioned flap (CPF) with acellular dermal matrix allograft (ADMA).,coronally positioned flap (CPF) without acellular dermal matrix allograft (ADMA).,Significantly increased,"However, on comparison between the test and control group, only TKT parameter showed statistically significant result, indicating that acellular dermal matrix has significantly contributed to the thickness in the test group.",3220090
927,4192987,17-hydroxy progesterone and testosterone levels,10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm,10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 09.00-10.00 pm ,No significant difference,The three different regimens were found to be similar in their ability to control 17-hydroxyprogesterone and testosterone levels.,4192987
928,4192987,Median 17-hydroxy progesterone and testosterone levels,10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm,10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was replaced by equivalent dose of prednisolone suspension which was administered at 10.00 pm.,No significant difference,Serum 17-hydroxyprogesterone and testosterone values at the end of 3 different treatment regimens of the thirteen patents studied are shown in Table 4.,4192987
929,4183415,patient adherence,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,No significant difference,There was no difference in patient adherence between arms (Table 6).,4183415
930,4183415,Completed treatment,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,No significant difference,"Completed treatment was 70% in the control arm and 68% in the intervention arm (adjusted risk ratio [aRR] = 0.96 [95% CI: 0.82, 1.1]; p [adjusted] = 0.6), with a similar percentage of patients adherent to each of the four age-appropriate blister packs and no important differences between arms.",4183415
931,4183415,completion of each dose at the correct time,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,No significant difference,"or as completion of each dose at the correct time (intervention 33.1%, control 32.6%, p [adjusted] = 0.9). Further studies on the potential of text messages to improve adherence are needed.",4183415
932,5462761,cold perception thresholds,"2?mA anodal tDCS, when applied for 15?min over the motor cortex",baseline,Significantly increased,"In details, 15?minutes 2?mA anodal tDCS induced a significant increase in cold perception thresholds immediately after the end of the stimulation (p?=?0.039) (see Fig. 3).Figure 3",5462761
933,5462761,"cold perception threshold, warm perception threshold, cold pain threshold and heat pain threshold",2?mA anodal tDCS when applied over the Pcor for 15?minutes,baseline,No significant difference,"Moreover, 2?mA anodal tDCS when applied over the Pcor for 15?minutes induced no significant changes in all the studied parameters (one-way follow-up ANOVA for cold perception: F(2,18)?=?3,33; p?=?0.058), we only observed a tendency to increase the cold perception (Baseline vs Post 25; p?=?0.058).",5462761
934,4264479,blood-stage infection,"aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge)",nothing,Significantly increased,All participants developed blood-stage infection confirmed by quantitative polymerase chain reaction (qPCR).,4264479
935,4264479,blood-stage infection,definitely exposed volunteers for both antigens ,minimally exposed volunteers for both antigens,Significantly increased,A significant difference was seen between minimally and definitely exposed volunteers for both antigens (Anti-schizont = p ? 0.0001; Anti-MSP2 = p = 0.006; Mann–Whitney test).,4264479
936,4918678,Writing,soundfield amplification devices in the classroom,nothing,No significant difference,"Between groups	t(28)=.59,	P=.561	F(1,17)=1.33,	P=.265",4918678
937,4918678,Reading,soundfield amplification devices in the classroom,nothing,No significant difference,"Between groups	t(28)=.39,	P=.702	F(1,17)=.04,	P=.841",4918678
938,4918678,Arithmetic,soundfield amplification devices in the classroom,nothing,No significant difference,"Between groups	t(28)=.89,	P=.383	F(1,17)=1.19,	P=.291",4918678
939,4918678,Silent reading,soundfield amplification devices in the classroom,nothing,No significant difference,"Between goups	t(28)=1.44,	P=.167	F(1,17)=1.02,	P=.327",4918678
940,4918678,Oral reading,soundfield amplification devices in the classroom,nothing,No significant difference,"between goups	t(28)=.62,	P=.541	F(1,17)=.06,	P=.812",4918678
941,3039191,the result of frequency doubling technique (FDT) perimetry.,"IOLs were selected randomly among two types of yellow IOLs (Acrysof SN60WF IOL, Hoya YA60BBR IOL)",clear IOL was used as a control.,No significant difference,"There were no statistically significant differences for MD and PSD between the clear IOL and Hoya YA60BBR IOL groups (MD: clear IOL, -5.09 ± 4.72 Db; Hoya YA60BBR IOL, -3.68 ± 3.83 dB; p = 0.21 / PSD: clear IOL, 4.26 ± 2.45 dB; Hoya YA60BBR IOL, 3.81 ± 1.99; p = 0.27, Mann-Whitney U-test). There were no statistically significant differences for MD and PSD the clear IOL and Alcon SN60WF IOL groups (MD: clear IOL, -5.09 ± 4.72 dB; Alcon SN60WF IOL, -2.47 ± 2.61 dB; p = 0.11 / PSD: clear IOL, 4.26 ± 2.45 dB; Alcon SN60WF IOL, 3.28 ± 1.23 dB; p = 0.22, Mann-Whitney U-test). No statistically significant differences were observed between the two types of yellow IOL groups (MD: Hoya YA60BBR, -3.68 ± 3.83 dB; Alcon SN60WF, -2.47 ± 2.61 dB; p = 0.33 / PSD: Hoya YA60BBR, 3.81 ± 1.99 dB; Alcon SN60WF, 3.28 ± 1.23; p = 0.56, Mann-Whitney U-test).",3039191
942,5551012,"birthweight, incidence of congenital birth defect and mean Apgar scores",antibiotics,no antibiotics,No significant difference,"Intrapartum antibiotic exposure did not significantly affect the birthweight, incidence of congenital birth defect and mean Apgar scores.",5551012
943,5551012,mean Apgar,antibiotics in less than 24 h to parturition,no antibiotics,Significantly decreased,"when mothers were treated with antibiotics in less than 24 h to parturition, there was a statistically significant decrease in mean Apgar than those not treated with antibiotics i.e. (7.86 ± 1.72 vs 8.4 ± 1.30 p = 0.002, F = 13.65) after adjusting for the effects of the mode of delivery.",5551012
944,5504551,physical activity ,awareness of wearing an accelerometer (nonblinded group),no awareness of wearing an accelerometer (blinded group),No significant difference,the awareness of wearing an accelerometer has no influence on physical activity patterns in young people.,5504551
945,5504551,The duration of wearing the accelerometer,awareness of wearing an accelerometer (nonblinded group),no awareness of wearing an accelerometer (blinded group),No significant difference,"The duration of wearing the accelerometer did not differ between the 2 groups for the overall 4-day-period, nor did it differ after separating school days from school-free days.",5504551
946,4693888,"Cardiac index, catecholamines ICU-stay and mortality (1 death in the control group)",Custodiol-N,Custodiol,No significant difference,"Cardiac index, catecholamines ICU-stay and mortality (1 death in the control group) was similar in both groups.",4693888
947,4693888,peak CKMB,Custodiol-N,Custodiol,Significantly decreased,"Although the trial was designed for non-inferiority, peak CKMB (52 ± 40 vs. 41 ± 30 U/l, superiority p < 0.002) was significantly lower in the Custodiol-N group.",4693888
948,4693888,CKMB AUC and Troponin-T AUC,Custodiol-N,Custodiol,No significant difference,"CKMB AUC (878 ± 549 vs. 778 ± 439 h*U/l, non-inferiority p < 0.001) and Troponin-T AUC (12990 ± 8347 vs. 13498 ± 6513 h*pg/ml, non-inferiority p < 0.001) was similar in both groups.",4693888
949,3278655,maximum total point motion (MTPM),The trabecular metal tibial monoblock component (TM),cemented component.,No significant difference,"At the 5-year follow-up, there was no difference in MTPM between the cemented group and the trabecular metal group (p = 0.9)",3278655
950,3278655,subsidence,The trabecular metal tibial monoblock component (TM),cemented component.,Significantly increased,The TM components had significantly greater subsidence than the cemented components (p = 0.001).,3278655
951,3278655,The proportion of “at risk” components at 5 years,The trabecular metal tibial monoblock component (TM),cemented component.,No significant difference,The proportion of “at risk” components at 5 years was 2 of 18 in the cemented group and 0 of 27 in the TM group (p = 0.2).,3278655
952,3597472,"the rate of S. japonicum infection in humans, bovines, snails, cow dung and mice","The routine interventions included praziquantel chemotherapy and controlling snails plus new interventions, mainly consisting of building fences to limit the grazing area for bovines, building safe pastures for grazing, improving the residents' health conditions and facilities,","The routine interventions included praziquantel chemotherapy and controlling snails,",Significantly decreased,"Results showed that the rate of S. japonicum infection in humans, bovines, snails, cow dung and mice in the intervention group decreased from 3.41% in 2008 to 0.81% in 2011, 3.3% to none, 11 of 6,219 to none, 3.9% to none and 31.7% to 1.7%, respectively (P<0.001 for all comparisons).",3597472
953,3597472,infection risk in humans,"The routine interventions included praziquantel chemotherapy and controlling snails plus new interventions, mainly consisting of building fences to limit the grazing area for bovines, building safe pastures for grazing, improving the residents' health conditions and facilities,","The routine interventions included praziquantel chemotherapy and controlling snails,",Significantly decreased,"The generalized linear model (Table 3), yielding odds ratios (OR) adjusted for participants' age and gender, showed a higher infection risk in humans in the control villages than the intervention villages (OR?=?1.250, P?=?0.001); and an overall significant downward trend in infection risk during the study period.",3597472
954,3330821,Beck Depression Inventory-II (BDI-II) after 4 months,trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP),Employee Assistance Program,Significantly decreased,"The BDI-II scores fell from the mean of 17.3 at baseline to 11.0 in the intervention group and to 15.7 in the control group after 4 months (p<0.001, Effect size?=?0.69, 95%CI: 0.32 to 1.05).",3330821
955,3330821,absolute and relative presenteeism,trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP),Employee Assistance Program,No significant difference,"However, there was no statistically significant decrease in absolute and relative presenteeism (p?=?0.44, ES?=?0.15, ?0.21 to 0.52, and p?=?0.50, ES?=?0.02, ?0.34 to 0.39, respectively).",3330821
956,3330821,The overall satisfaction score,trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP),Employee Assistance Program,Significantly increased,The overall satisfaction score for the services was 3.57 (3.31 to 3.81) for the EAP alone group and 4.42 (4.17 to 4.67) for the tCBT +EAP group (p<0.001).,3330821
957,4803984,the frequency of Apgar score?8 in the first and 5th minutes ,supportive care or acupuncture group,control groups,Significantly increased,"The lowest mean lengths of the first and second stages of labor (157.0±29.5 and 58.9±25.8, respectively) were related to the supportive care group, while the highest mean lengths (281.0±79.8 and 128.4±44.9, respectively) were observed in the control group (Table 1).Table 1",4803984
958,4803984,The mean length of the first and second stages of labor,supportive care or acupuncture group,control groups,Significantly decreased,"The mean length of the first and second stages of labor was respectively 157.0±29.5 and 58.9±25.8 minutes in the supportive care group, 161.7±37.3 and 56.1±31.4 minutes in the acupressure group, ad 281.0±79.8 and 128.4±44.9 minutes in the control group.",4803984
959,2656477,self-efficacy related to social pressure and restraint in overweight and obese endometrial cancer survivors.,lifestyle intervention (LI) consisting of exercise and nutritional counseling with cognitive-behavior modification,usual care,Significantly increased,There was a significant improvement for self-efficacy related to social pressure (p = .03) and restraint (p = .02) in the LI group.,2656477
960,2656477,"emotional well-being quality of life, self-efficacy related to negative emotions, food availability in overweight and obese endometrial cancer survivors.",lifestyle intervention (LI) consisting of exercise and nutritional counseling with cognitive-behavior modification,usual care,Significantly increased,"There was a significant difference for emotional well-being quality of life (p = .02), self-efficacy related to negative emotions (p < .01), food availability (p = .03), and physical discomfort (p = .01) in women who lost weight as compared to women who gained weight.",2656477
961,2656477,depression,lost weight,no weight lost,Significantly decreased,Women who lost weight had improvement in depression (2.3 versus 1.2) and TFEQ restraint score (2.8 versus 0.1).,2656477
962,4889691,return of spontaneous circulation (ROSC),AutoPulse automated chest compression device,manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA),Significantly increased,the ROSC rate was significantly higher in the AutoPulse CPR group than in the Manual CPR group (44.9% vs. 23.4%; p = 0.009).,4889691
963,4889691,The 24-h survival rate of OHCA,AutoPulse automated chest compression device,manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA),Significantly increased,The 24-h survival rate of OHCA patients was significantly higher in the AutoPulse CPR group than in the Manual CPR group (39.1% vs. 21.9%; p = 0.03).,4889691
964,4889691,The hospital discharge rate of the patients with OHCA,AutoPulse automated chest compression device,manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA),Significantly increased,The hospital discharge rate of the patients with OHCA was significantly higher in the AutoPulse CPR group than in the Manual CPR group (18.8% vs. 6.3%; p = 0.03).,4889691
965,4889691,The proportion of patients with OHCA and a cerebral performance category score of 1 or 2 points at hospital discharge ,AutoPulse automated chest compression device,manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA),No significant difference,"The proportion of patients with OHCA and a cerebral performance category score of 1 or 2 points at hospital discharge was higher in the AutoPulse CPR group than in the Manual CPR group, but the difference was not statistically significant (16.2% vs. 13.4%, p = 1.00).",4889691
966,5372931,14 (poly)phenol metabolites,cranberry juices,nothing,Significantly increased,14 (poly)phenol metabolites displayed a linear dose-response curve (r2 ? 0.89) in plasma (Figure 1) with slopes significantly different from zero (p < 0.05):,5372931
967,5372931,"flavonols, valerolactones, benzoic acids, cinnamic acids, phenylacetic acids, benzaldehydes ",cranberry juices,nothing,Significantly increased,"Linear regression analysis was performed between the TP level in the intervention and the AUC of each class of compounds. The AUC for flavonols produced the highest r2 (0.97, p < 0.001), followed by the valerolactones (r2 = 0.89, p < 0.005), benzoic acids (r2 = 0.85, p < 0.01), cinnamic acids (r2 = 0.72, p < 0.05), phenylacetic acids (r2 = 0.71, p < 0.05), benzaldehydes (r2 = 0.65, p < 0.05)",5372931
968,5372931,12 (poly)phenol metabolites,cranberry juices,nothing,Significantly increased,"A positive, linear dose response for total excretion over 24 h of each urinary metabolite was assessed and of the 60 identified metabolites, 12 (poly)phenol metabolites displayed a positive linear dose-response curve (r2 ? 0.66) in urine with slopes significantly different from zero (p < 0.05)",5372931
969,3491047,Short-term adherence to the program at 3 months,Walking and Behavioural intervention (WB),Self-directed control (C),Significantly increased,Statistically significant results for short-term adherence rates favoured participants in the WB group (80.2%) compared to the self-directed (C) group (65.2%) (p&lt;0.012) after 3 months.,3491047
970,3491047,Long-term adherence to the program,Walking and Behavioural intervention (WB),Self-directed control (C),No significant difference,"No statistical significance (p&gt; 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.",3491047
971,3491047,Total adherence to the program,Walking and Behavioural intervention (WB),Self-directed control (C),No significant difference,"No statistical significance (p&gt; 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.",3491047
972,3491047,Long-term adherence to the program,Walking and Behavioural intervention (WB),Walking intervention (W),No significant difference,"No statistical significance (p&gt; 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.",3491047
973,3491047,Total adherence to the program,Walking and Behavioural intervention (WB),Walking intervention (W),No significant difference,"No statistical significance (p&gt; 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.",3491047
974,3798949,Treatment cost,"Academic, non-commercial sponsored trials",Commercial sponsored trials,Significantly increased,The average TC for 27 non-commercial trials was an excess of £431 (range £6393 excess to £6005 saving) and for 26 commercial trials was an average saving of £9294 (range £0 to £71?480).,3798949
975,3798949,Savings in drugs and dispensing costs,"Academic, non-commercial sponsored trials",Commercial sponsored trials,Significantly decreased,"In general, it can be seen that both commercial and non-commercial trials saved drug costs, whereas the extent of drug and dispensing cost savings was markedly higher for commercial compared with non-commercial trials.",3798949
976,3798949,Extra clinic visits and CT scans assessments,"Academic, non-commercial sponsored trials",Commercial sponsored trials,Significantly decreased,"The contribution of extra clinic visits and investigations, in particular CT scans used for response assessment, was significantly higher for commercial compared with non-commercial trials.",3798949
977,5619630,Improvement in the Hamilton Rating Scale for Depression at 12 weeks,Medication plus exercise,Medication only,Significantly increased,"The medication-plus-exercise group showed a greater improvement in HRSD scores (change in score from baseline) than the medication-only group from the first follow-up, at 6 weeks, and this difference became statistically significant at weeks 12 (P = 0.04, t = 2.10) and 24 (P = 0.02, t = 2.42)",5619630
978,5619630,Improvement in the Hamilton Rating Scale for Depression at 24 weeks,Medication plus exercise,Medication only,Significantly increased,"The medication-plus-exercise group showed a greater improvement in HRSD scores (change in score from baseline) than the medication-only group from the first follow-up, at 6 weeks, and this difference became statistically significant at weeks 12 (P = 0.04, t = 2.10) and 24 (P = 0.02, t = 2.42)",5619630
979,5619630,Improvement in Presumptive Stressful Life Events Scale,Medication plus exercise,Medication only,No significant difference,there was no significant difference between the groups’ PSLES scores at any follow-up point.,5619630
980,5619630,Relapse rates,Medication plus exercise,Medication only,No significant difference,"In total, nine patients relapsed, two from the medication-plus-exercise group (both in week 18) and seven from the medication-only group (one relapse in week 6, two in week 12 and four in week 24). This difference in relapse rates did not reach significance (Fisher’s exact test: one-tailed, P = 0.07; two-tailed, P = 0.14).",5619630
981,5490116,Glucometric random blood sugar at 24 hours,"Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B)",Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C),Significantly increased,Glucometric random blood sugar (GRBS) was significantly (P &lt; 0.005) higher in Group B compared to Groups A and C at 24 h,5490116
982,5490116,Mean visual analog scale,"Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B)",Ropivacaine 0.2% alone (Group A) ,Significantly decreased,"VAS scores were significantly lower in Groups B and C at 8 h, 12 h, and 24 h compared to Group A.",5490116
983,5490116,Mean visual analog scale,Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C),Ropivacaine 0.2% alone (Group A) ,Significantly decreased,"VAS scores were significantly lower in Groups B and C at 8 h, 12 h, and 24 h compared to Group A.",5490116
984,5490116,Glucometric random blood sugar at 24 hours,"Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B)",Ropivacaine 0.2% alone (Group A),Significantly increased,Glucometric random blood sugar (GRBS) was significantly (P &lt; 0.005) higher in Group B compared to Groups A and C at 24 h,5490116
985,5062220,Time to tracheal extubation,Bispectral index (BIS) guided anesthesia,Standard end-tidal anesthetic gas (ETAG) guided anesthesia,Significantly increased,"Mean time to tracheal extubation was significantly longer in BIS group (9.63 ± 3.02 min) as compared to ETAG group (5.29 ± 1.51 min), mean difference 4.34 min with 95% confidence interval (3.106, 5.982) (P &lt; 0.05).",5062220
986,5062220,Perioperative complications,Bispectral index (BIS) guided anesthesia,Standard end-tidal anesthetic gas (ETAG) guided anesthesia,No significant difference,"All the patients were extubated in the operating room, and no significant complication was noted during perioperative period in any patient.",5062220
987,2920262,Improvement in HAD anxiety score,Singing classes,Usual care,Significantly increased,Singers also had a significant fall in HAD anxiety score; -1.1(2.7) vs. +0.8(1.7) p = 0.03.,2920262
988,2920262,Improvement in SF-36 physical component score,Singing classes,Usual care,Significantly increased,"In singers, there was a significant improvement in HAD anxiety score -1.1(2.7) vs. +0.8(1.7) p = 0.03 and SF-36 physical component score +7.5(14.6) vs. -3.8(8.4) p = 0.02.",2920262
989,2920262,Breath hold time,Singing classes,Usual care,Significantly decreased,Breath hold time actually increased in the control group relative to the singing group -0.3(6.9) sec vs. +5.3(5.7) sec (p = 0.03).,2920262
990,2920262,Single breath counting and functional exercise capacity,Singing classes,Usual care,No significant difference,"There was no significant difference in single breath counting, functional exercise capacity or recovery times following ISWT",2920262
991,2920262,Recovery time after incremental shuttle walk test,Singing classes,Usual care,No significant difference,"There was no significant difference in single breath counting, functional exercise capacity or recovery times following ISWT",2920262
992,3074545,Changes in total Composite Abuse Scale score,Non-professional mentor support,Non-mentored group,Significantly increased,"The adjusted difference in the total CAS score from baseline was greater in the mentored compared with the non-mentored arm (Adj Diff = -8.67, range -16.2 to -1.15), but the evidence for this difference was weaker after PS adjustment.",3074545
993,3074545,Depression mean scores,Non-professional mentor support,Non-mentored group,No significant difference,"Observed reduction in depression mean scores from 15.0 to 8.9 in the intervention arm compared favourably with non-mentored women (12.9 to 9.9), but the adjusted difference (AdjDiff) of -1.90, 95% CI -4.12 to 0.32, did not reach conventional statistical significance.",3074545
994,3074545,Use of health care services,Non-professional mentor support,Non-mentored group,No significant difference,There were no significant differences in use of health care services between groups over the 12 month follow-up period.,3074545
995,3074545,Improvements in physical and mental wellbeing,Non-professional mentor support,Non-mentored group,Significantly increased,"There was weak evidence for a difference between the intervention and comparison arms in general wellbeing improvements at follow-up, while mean adjusted differences on both the Mental and Physical Components Scores (MCS and PCS) favoured the intervention arm.",3074545
996,3074545,Changes in total Composite Abuse Scale score,Non-professional mentor support,Non-mentored group,Significantly increased,"The adjusted difference in the total CAS score from baseline was greater in the mentored compared with the non-mentored arm (Adj Diff = -8.67, range -16.2 to -1.15), but the evidence for this difference was weaker after PS adjustment.",3074545
997,3074545,Depression mean scores,Non-professional mentor support,Non-mentored group,No significant difference,"Observed reduction in depression mean scores from 15.0 to 8.9 in the intervention arm compared favourably with non-mentored women (12.9 to 9.9), but the adjusted difference (AdjDiff) of -1.90, 95% CI -4.12 to 0.32, did not reach conventional statistical significance.",3074545
998,3074545,Use of health care services,Non-professional mentor support,Non-mentored group,No significant difference,There were no significant differences in use of health care services between groups over the 12 month follow-up period.,3074545
999,3074545,Improvements in physical and mental wellbeing,Non-professional mentor support,Non-mentored group,Significantly increased,"There was weak evidence for a difference between the intervention and comparison arms in general wellbeing improvements at follow-up, while mean adjusted differences on both the Mental and Physical Components Scores (MCS and PCS) favoured the intervention arm.",3074545
1000,3878029,Smoking status,Hypnotherapy,Relaxation,No significant difference,The intervention had no effect on smoking status (p =?.73),3878029
1001,3878029,Cigarettes smoked per day,Hypnotherapy,Relaxation,No significant difference,The intervention had no effect on smoking status (p =?.73) or on the number of cigarettes smoked per day (p =?.56).,3878029
1002,3878029,Smoking abstinence after 2 weeks,Hypnotherapy,Relaxation,No significant difference,"At the two-week follow-up, 38 (33.3%) of the participants in the hypnosis group and 26 (24.5%) of those in the relaxation group reported smoking abstinence in the previous seven days. The effect of the intervention was not significant (OR =?1.73, SE =?0.60, 95% CI [0.84, 3.57], t =?1.58, p =?.13).",3878029
1003,3878029,Adverse reactions,Hypnotherapy,Relaxation,No significant difference,Both interventions produced few adverse reactions (p =?.81).,3878029
1004,3442969,Disease control rates,FUFOX,CAPOX,No significant difference,"Disease control rates (DCR) were 77%, 81% and 88%, respectively, which was not statistically significant (Table3, p?=?0.29).",3442969
1005,3442969,Median progression-free survival,FUFOX,CAPOX,No significant difference,"The median PFS in all patients of the KRAS subcohort was not statistically different in relation to the KRAS mutational status (wild type: 7.5?months, mutation codon 12: 8.2?months, mutation codon 13: 10.0?months; p?=?0.71)",3442969
1006,3442969,Overall survival,FUFOX,CAPOX,No significant difference,"Evaluating the different treatment arms separately, we found comparable survival times without significant differences",3442969
1007,3442969,Progression-free survival in patients with codon 13 mutations,FUFOX,CAPOX,Significantly decreased,"Interestingly, we found a substantial difference in PFS between patients with codon 12 and 13 mutant tumors when looking at infusional 5-FU versus capecitabine based regimens. Patients with codon 13 mutations seem to benefit more in terms of PFS from the oral capecitabine based protocols.",3442969
1008,5003313,Symptom severity after 8 weeks ,Stretching exercises,No exercises,Significantly decreased,The symptom severity of this syndrome meaningfully changed eight weeks after intervention in the intervention group compared to the control group (P &lt; 0.001).,5003313
1009,5003313,Symptom severity after 4 weeks ,Stretching exercises,No exercises,Significantly decreased,the results of t-test show that the changes in the severity of RLS symptoms before intervention and after 4 weeks were not statistically meaningful between intervention and control groups.,5003313
1010,5018157,Risk of hypotension,Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients,Low-dose bupivacaine spinal anesthesia in healthy parturients,Significantly decreased,"The incidence rate of hypotension in the preeclamptic patients (55.8%) was less than that of the healthy parturients (89.2%) (Table 2), despite the former receiving smaller volumes of intravenous fluids (2.4 versus 2.5 lit) (Table 1) (P = 0.001).",5018157
1011,5018157,IV ephedrine total dosage,Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients,Low-dose bupivacaine spinal anesthesia in healthy parturients,Significantly decreased,The total doses of IV ephedrine for treating hypotension were significantly lower among the preeclamptic patients (3.2 mg in preeclamptic patients versus 7.6 mg in normotensive patients) (P = 0.02).,5018157
1012,5018157,One-minute Apgar score,Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients,Low-dose bupivacaine spinal anesthesia in healthy parturients,Significantly decreased,The one-minute Apgar score was significantly lower for the preeclamptic parturients (8.4 ± 0.7 versus 7.2 ± 1.5) (P = 0.001),5018157
1013,5018157,Five-minute Apgar score,Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients,Low-dose bupivacaine spinal anesthesia in healthy parturients,No significant difference,there was no significant difference in the five-minute Apgar scores between the two groups.,5018157
1014,5101425,Thrombocytopenia rate,Desmopressin,Placebo,Significantly decreased,The analysis revealed that the rate of thrombocytopenia after surgery was higher in the control group (P = 0.012).,5101425
1015,5101425,Bleeding rate after surgery,Desmopressin,Placebo,No significant difference,No significant difference was noted between the groups regarding the rate of bleeding after surgery (359.3 ± 266.2 in group D vs. 406.3 ± 341.6 in group P (control group); P = 0.208).,5101425
1016,5101425,Complications,Desmopressin,Placebo,No significant difference,"there was no significant difference between the groups regarding the outbreak of complications such as nausea, vomiting, blood pressure alteration, and the amount of bleeding (P &gt; 0.05).",5101425
1017,5101425,Hb levels,Desmopressin,Placebo,No significant difference,"the Hb levels decreased significantly in each group after surgery (P = 0.0001), but the difference was not statistically significant between the groups (0.134).",5101425
1018,3159986,Improvement in myasthenia score,Respiratory muscle endurance training,Baseline characteristics,Significantly increased,Myasthenia score improved from 0.71 ± 0.1 to 0.56 ± 0.1 (P = 0.007).,3159986
1019,3159986,Improvement in respiratory endurance,Respiratory muscle endurance training,Baseline characteristics,Significantly increased,Respiratory endurance time increased from 6.1 ± 0.8 to 20.3 ± 3.0 min (P &lt; 0.001).,3159986
1020,3159986,Lung function parameters,Respiratory muscle endurance training,Baseline characteristics,No significant difference,"RMET induced mild but not significant increases in VC (P1: 95.9 ± 3.5%, P4: 99.2 ± 4.1%, P = 0.39), FEV1 (P1: 93.1 ± 2.7%, P4: 96.3 ± 3.8%, P = 0.28), PEF (P1: 90.0 ± 4.8%, P4: 95.7 ± 5.4%, P = 0.07), MVV (P1: 95.6 ± 6.0%, P4: 101.0 ± 6.5%, P = 0.24), and PImax (P1: 79.2 ± 5.4%, P4: 78.0 ± 6.4%, P = 0.42)",3159986
1021,4895766,Adverse reactions,Katupila Kalka with Tila Taila,Betadine ointment,No significant difference,"In both the groups, no patients reported any adverse drug reaction during the entire course of treatment as well as in follow-up period.",4895766
1022,4895766,Healing of diabetic wounds,Katupila Kalka with Tila Taila,Betadine ointment,Significantly increased,"In Group A, diabetic wounds treated with Katupila paste got healed within 28 days with minimal scar formation without any complications, whereas in Group B, wound was healed completely only in two patients within 28 days.",4895766
1023,4895766,Control of foul smell,Katupila Kalka with Tila Taila,Betadine ointment,Significantly increased,"foul smell was controlled after 3 days in Group A patients, which was found statistically significant (P &lt; 0.001). In Group B, foul smell from ulcer continues until the wound was healed",4895766
1024,4895766,Control of infection,Katupila Kalka with Tila Taila,Betadine ointment,No significant difference,Both drugs have shown statistically highly significant (P &lt; 0.001) result in controlling infection.,4895766
1025,4486943,Programme engagement,Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20,Standard quitline treatment,Significantly increased,"Programme engagement was measured as the number of counselling calls completed by participants:1 planned programme counselling calls,2 participant-initiated inbound calls, or3 IVR-transferred counselling calls (table 2). Overall, the average number of total calls completed was 3.9 (SD=1.7; range 2–19). There was a statistical difference between groups; the TEQ-10 and TEQ-20 groups completed slightly more calls than the standard study group due to the additional IVR-transferred counselling calls they received after a positive screen (p&lt;0.001).",4486943
1026,4486943,Number of positive screens,Technology Enhanced Quitline-10 ,Technology Enhanced Quitline-20,Significantly decreased,"There was a statistical difference in the number of positive screens between the two intervention groups, with TEQ-20 having slightly more positive screens than TEQ-10 (on average, 1.52 (SD=1.66) for TEQ-10 and 1.82 (SD=1.99) for TEQ-20, p=0.003).",4486943
1027,4486943,Time to relapse,Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20,Standard quitline treatment,No significant difference,There was no significant association between time to relapse and randomisation group,4486943
1028,4486943,Tobacco abstinence,Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20,Standard quitline treatment,No significant difference,there were no differences in tobacco abstinence rates between the control (standard QFL) and technology-enhanced (IVR-delivered risk assessments and transfer for counselling) groups at 6-month and 12-month follow-up.,4486943
1029,4221638,Intracranial haemorrhage,Tranexamic acid,Placebo,No significant difference,Progressive intracranial haemorrhage was present in 21 (18%) of patients allocated to TXA and in 32 (27%) of patients allocated to placebo. The difference was not statistically significant [RR?=?0.65 (95% CI 0.40 to 1.05)].,4221638
1030,4221638,Risk of death,Tranexamic acid,Placebo,No significant difference,There were no significant difference in the risk of death from all causes in patients allocated to TXA compared with placebo [RR?=?0.69 (95% CI 0.35 to 1.39,4221638
1031,4221638,Risk of thromboembolic events,Tranexamic acid,Placebo,No significant difference,There was no evidence of increased risk of thromboembolic events in those patients allocated to TXA.,4221638
1032,4221638,Risk of unfavorable outcome on the Glasgow Outcome Score,Tranexamic acid,Placebo,No significant difference,There were no significant difference in the risk of death from all causes in patients allocated to TXA compared with placebo [RR?=?0.69 (95% CI 0.35 to 1.39)] and the risk of unfavourable outcome on the Glasgow Outcome Scale [RR?=?0.76 (95% CI 0.46 to 1.27)].,4221638
1033,4138383,Negative feelings,Self-referral treatment,Inpatient treatment,Significantly decreased,"Patients with a contract also expressed less resignation, hopelessness and powerlessness than patients without a contract.",4138383
1034,4138383,Self-confidence in applying methods to deal with mental illness,Self-referral treatment,Inpatient treatment,Significantly increased,One of the findings in the present study was that patients with a contract for self-referral described more confidence in applying coping strategies than patients without a contract.,4138383
1035,4138383,Patients striving for recovery,Self-referral treatment,Inpatient treatment,Significantly increased,"The findings in the present study indicate that patients who have had the opportunity to decide whether and when they needed referral to inpatient treatment are more actively pursuing recovery, both from and in mental illness.",4138383
1036,4588874,Baseline nicotine concentrations,E-cigarettes ,Conventional tobacco cigarette,No significant difference,"Baseline nicotine concentrations were below the limit of quantification in the majority of subjects and mean baseline nicotine concentrations were comparable across study products, all representing less than half the limit of quantification of 0.200&nbsp;ng/mL",4588874
1037,4588874,Urge to smoke,E-cigarettes ,Conventional tobacco cigarette,No significant difference,No statistically significant differences were found in the maximal smoking urge reduction parameters Emax0–30 and Emaxreduction0–30 (all differences within 11&nbsp;%) or the overall smoking urge reduction parameter AUEC0-30 (all differences within 21&nbsp;%) between the use of a single tobacco cigarette and each of the e-cigarettes during the controlled use period.,4588874
1038,4588874,Serious adverse events,E-cigarettes ,Conventional tobacco cigarette,No significant difference,There were no serious adverse events reported and no subjects were discontinued due to AEs.,4588874
1039,4588874,Level of exhaled CO,E-cigarettes ,Conventional tobacco cigarette,Significantly decreased,"Furthermore, it was also observed that the use of the e-cigarettes produced no increase the exhaled CO levels, whereas the cigarette significantly increased the exhaled CO more than eight (8) times above the baseline.",4588874
1040,4588874,Nicotine concentration after ad lib use,E-cigarettes ,Conventional tobacco cigarette,Significantly decreased,"Following ad lib use of all products for 60&nbsp;min, the tobacco cigarette yielded a significantly higher nicotine concentration (C90) compared to each of the e-cigarettes. T",4588874
1041,5746685,Weight rebound after 12 months,Enhanced weight loss maintenance program,Basic weight loss maintenance program,No significant difference,"There was no significant weight rebound from the start of weight loss maintenance to 12 months for either group (mean: basic 1.3%, enhanced 1.5%)",5746685
1042,5746685,Change in body mass index,Enhanced weight loss maintenance program,Basic weight loss maintenance program,No significant difference,"There were no significant between-group differences in the primary outcome of change in BMI (basic ?0.5 (1.9) kg/m2, enhanced ?0.5 (1.6) kg/m2, p = 0.93).",5746685
1043,5746685,Attrition after 12 months,Enhanced weight loss maintenance program,Basic weight loss maintenance program,No significant difference,"There was no significant between-group difference in attrition after 12 months, basic 18.4% and enhanced 23.9%, p = 0.31.",5746685
1044,4748685,Systolic blood pressure,CAPSYS system,Standard care,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = –9 mmHg; p = 0.03; 95 % CI = [–17.29, –0.71]), LDL (pseudo-median of the differences = –7.9 mg/dl; p = 0.04; 95 % CI = [–18.5, –0.5]) and triglyceride values (pseudo-median of the differences = –12.5 mg/dl; p = 0.04; 95 % CI = [–26, –0.5]) in the intervention group, while no such changes could be observed in the control group.",4748685
1045,4748685,LDL values,CAPSYS system,Standard care,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = –9 mmHg; p = 0.03; 95 % CI = [–17.29, –0.71]), LDL (pseudo-median of the differences = –7.9 mg/dl; p = 0.04; 95 % CI = [–18.5, –0.5]) and triglyceride values (pseudo-median of the differences = –12.5 mg/dl; p = 0.04; 95 % CI = [–26, –0.5]) in the intervention group, while no such changes could be observed in the control group.",4748685
1046,4748685,Triglyceride levels,CAPSYS system,Standard care,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = –9 mmHg; p = 0.03; 95 % CI = [–17.29, –0.71]), LDL (pseudo-median of the differences = –7.9 mg/dl; p = 0.04; 95 % CI = [–18.5, –0.5]) and triglyceride values (pseudo-median of the differences = –12.5 mg/dl; p = 0.04; 95 % CI = [–26, –0.5]) in the intervention group, while no such changes could be observed in the control group.",4748685
1047,4748685,Self-reported consumption of fruits and vegetables,CAPSYS system,Standard care,Significantly increased,"Concerning the secondary dependent measures, we could observe the following statistically significant results:Increase of self-reported fruit and vegetable consumption in IC group (Wilcoxon signed-rank test: pseudo-median of the differences = 5.4 servings/week; p = 0.04; 95 % CI = [0.5, 10.5]; r = 0.26: medium effect size)",4748685
1048,4748685,Self-reported consumption of sweets,CAPSYS system,Standard care,Significantly decreased,"Furthermore, we detected a statistically significant increase in self-reported fruit and vegetable consumption (pseudo-median of the differences = 5.4 servings/week; p = 0.04; 95 % CI = [0.5, 10.5]) and a decrease in sweets consumption (pseudo-median of the differences = –2 servings/week; p = 0.04; 95 % CI = [–4, –0.00001]) in the intervention group.",4748685
1049,5089605,Improvement in patient?reported outcomes at the end of treatment,Golimumab plus?MTX,Placebo?plus MTX or Golimumab,No significant difference,Improvements from baseline to week 256 in patient?reported outcomes were generally similar among the treatment groups,5089605
1050,5089605,ACR20/50/70 response,Golimumab plus?MTX,Placebo?plus MTX or Golimumab,No significant difference,"Among all randomized patients in the GO?BEFORE trial, 72.8% of patients had an ACR20 response, 54.6% had an ACR50 response, and 38.0% had an ACR70 response at week 256 (when all patients were receiving golimumab), with no appreciable differences among the treatment groups.",5089605
1051,4075638,Decrease in symptoms among patients with low immature defense style after 1 year,Short-term psychotherapy,Long-term psychotherapy,Significantly increased,"During the first year of the follow-up, a statistically larger symptom reduction in the short-term therapy group than in the long-term therapy group (18–45% vs. 9–31%, respectively) was found among patients with low immature defense style according to all six outcome measures.",4075638
1052,4075638,Decrease in symptoms among patients with high immature defense style after 3 years,Short-term psychotherapy,Long-term psychotherapy,Significantly decreased,"At the end of the 3-year follow-up, on the other hand, a statistically larger symptom reduction in the long-term therapy group than in the short-term therapy group (26–64% vs. 21–45%, respectively) was found among patients with high immature defense style according to five outcome measures.",4075638
1053,4075638,Overall symptom reduction after 3 years,Short-term psychotherapy,Long-term psychotherapy,No significant difference,"During the 3-year follow-up, a statistically significant symptom reduction was found in all six outcome measures (BDI, HDRS, SCL-90-Anx, HARS, SCL-90-GSI, GAF) in both short-term and long-term therapy groups",4075638
1054,2223531,Median AUC(inf),Oral etoposide phosphate,Oral etoposide,No significant difference,The median AUC(inf) (area under the concentration vs time curve from zero to infinity) of etoposide was 77.7 mg l(-1) h after etoposide phosphate (95% CI 61.3-100.5) and 62.0 mg l(-1) h after oral etoposide (95% CI 52.2-76.9). The difference in favour of etoposide phosphate was borderline significant: median 9.9 mg l(-1) h (95% CI 0.1-32.8 mg l(-1) h; P = 0.05).,2223531
1055,2223531,Toxicity,Oral etoposide phosphate,Oral etoposide,No significant difference,Toxicities of oral etoposide phosphate were not different from those known for etoposide,2223531
1056,2223531,Different section ,-,-,No significant difference,Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.,2223531
1057,3787573,Numerical Rating Scale,NMES plus exercise,Exercise alone,No significant difference,"For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63)",3787573
1058,3787573,Timed Up and Go test,NMES plus exercise,Exercise alone,No significant difference,"For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63)",3787573
1059,3787573,Western Ontario and McMaster Universities Osteoarthritis Index for pain,NMES plus exercise,Exercise alone,No significant difference,"No significant differences between groups were found on the pain, physical function, and stiffness subscales of the WOMAC index on ITT analysis.",3787573
1060,3787573,Western Ontario and McMaster Universities Osteoarthritis Index for physical function,NMES plus exercise,Exercise alone,No significant difference,"No significant differences between groups were found on the pain, physical function, and stiffness subscales of the WOMAC index on ITT analysis.",3787573
1061,3787573,Western Ontario and McMaster Universities Osteoarthritis Index for stiffness,NMES plus exercise,Exercise alone,No significant difference,"No significant differences between groups were found on the pain, physical function, and stiffness subscales of the WOMAC index on ITT analysis.",3787573
1062,5100099,Blood pH levels,Neurally Adjusted Ventilatory Assist,Conventional Ventilation,No significant difference,"There were no statistically significant differences on blood pH levels between the two modes of ventilation (7.32?±?0.02 vs. 7.32?±?0.04, P?=?0.34).",5100099
1063,5100099,Peak inspiratory pressures,Neurally Adjusted Ventilatory Assist,Conventional Ventilation,Significantly decreased,"Ventilation with NAVA delivered lower peak inspiratory pressures than with CV: -32.7&nbsp;% (95&nbsp;% CI: -48.2 to –17.1&nbsp;%, P?=?0.04)",5100099
1064,5100099,Systolic arterial pressure,Neurally Adjusted Ventilatory Assist,Conventional Ventilation,Significantly increased,"With regard to hemodynamics, systolic arterial pressures were higher using NAVA: +8.4&nbsp;% (95&nbsp;% CI: +3.3 to +13.6&nbsp;%, P?=?0.03).",5100099
1065,5100099,Cardiac index improvement,Neurally Adjusted Ventilatory Assist,Conventional Ventilation,No significant difference,Cardiac index during NAVA compared to CV did not statistically differ.,5100099
1066,520750,"HAMD17 total score,",A mixed-effects model repeated measures approach (MMRM),analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA),Significantly increased,"In the case of the HAMD17 total score, advantages for duloxetine over placebo at endpoint (Week 9) from MMRM in Studies 1 and 2 were 4.86 (p &lt; .001) and 2.17 (p = .024), respectively.",520750
1067,520750, VAS overall pain,A mixed-effects model repeated measures approach (MMRM),analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA),Significantly increased,"For VAS overall pain, the advantage of duloxetine over placebo at endpoint from MMRM in Studies 1 and 2 were 5.88 (p = .055) and 4.40 (p = .135), respectively.",520750
1068,520750,Standard errors,A mixed-effects model repeated measures approach (MMRM),analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA),Significantly increased,Standard errors from LOCF_ANCOVA were approximately 5% smaller than the Week 9 standard errors from MMRM for both the HAMD17 total score and VAS overall pain.,520750
1069,4821226,clinical outcome,core decompression with the application of bone marrow aspirate concentrate,core decompression only,No significant difference,"However, there was no difference in the clinical outcome between the two study groups (Figures 1 and 2).",4821226
1070,4821226,femoral head necrosis (FHN),core decompression with the application of bone marrow aspirate concentrate,core decompression only,No significant difference,"n contrast to the clinical outcome, we could not perceive any significant change in the volume of FHN in both treatment groups related to the longitudinal course after treating (Figure 3). Again no statistically significant difference was detected between the groups.",4821226
1071,4821226,the head survival rate,core decompression with the application of bone marrow aspirate concentrate,core decompression only,No significant difference,"Over the period of two years there was no significant difference between the head survival rate of 8/14 (57%) in the control group, and 7/11 (64%) in the verum group. There was no difference between the two groups with regard to the interval between core decompression with or without BMAC application and THA.",4821226
1072,4821226,fibroblast colony forming units (CFU-Fs).,core decompression with the application of bone marrow aspirate concentrate,core decompression only,Significantly increased,"Table 2 shows the significant increase in the number of nucleated cells due to the centrifugation step. Additionally, the number of CFU that best represents the number of MSC shows a significant increase (Table 2).",4821226
1073,1562433,Maximum voluntary isometric contractions,knee extension at 90° of flexion,hip abduction at 0° and 30°,Significantly increased,"Maximum voluntary isometric contractions for knee extension at 90° of flexion resulted in a significantly higher EMG activity for the VMO muscle compared with hip abduction at 0° and 30° of abduction for both male (p &lt; 0.008) and female (p &lt; 0.0005) subjects (Table 1, Figure 5).",1562433
1074,1562433,vastus medialis obliquus (VMO) EMG activity ,knee extension at 90° of flexion,hip abduction at 0° and 30°,Significantly increased,Significantly higher VMO activity for both male and female subjects performing MVIC knee extension at 90° of flexion when compared to MVIC hip abduction at 0° and 30° of abduction.,1562433
1075,1562433,vastus lateralis longus (VLL) EMG activity,knee extension at 90° of flexion,hip abduction at 0° and 30°,No significant difference,VLL EMG activity without significant differences among the three exercises tested.,1562433
1076,1562433,vastus lateralis obliquus (VLO) EMG activity,knee extension at 90° of flexion,hip abduction at 0° and 30°,Significantly increased,Significantly higher VLO activity for male subjects was observed in MVIC knee extension at 90° of flexion compared with MVIC hip abduction at 0° and 30° of abduction and for female subjects performing MVIC knee extension at 90° of flexion when compared with MVIC hip abduction at 0° and 30° of abduction.,1562433
1077,4667210,"The intensity of the MSG symptom complex (characterized by unpleasant reactions such as numbness, tingling, headaches, muscle tightness, general weakness, and flushing )",Capsules (300 mg) containing Lactobacillus brevis G101 (1×1010 CFU/individual),maltodextrin (placebo),Significantly decreased,The intensity of the MSG symptom complex was significantly reduced in respondents of the G101 intake group (2.87 ± 0.73) compared to that in those treated with the placebo (3.63 ± 1.03) (P = 0.0016).,4667210
1078,4667210,the appearance time of the MSG symptom complex,Capsules (300 mg) containing Lactobacillus brevis G101 (1×1010 CFU/individual),maltodextrin (placebo),No significant difference,"Although there was no significant difference in the appearance time of the MSG symptom complex between subjects orally administered G101 and those administered the placebo,",4667210
1079,4667210,disappearance in &lt; 3 h  of the MSG symptom complex,Capsules (300 mg) containing Lactobacillus brevis G101 (1×1010 CFU/individual),maltodextrin (placebo),Significantly increased,Disappearance of the MSG symptom complex in less than 3 h was observed in 69.9% of subjects in the G101 treatment group and in 38.0% of subjects in the placebo group (P = 0.0841).,4667210
1080,4565804,morphine doses,gabapentin (10 mg/kg),Placebo,Significantly decreased,"Dogs in the Placebo group received significantly more morphine doses than the Gabapentin group (P=0.021), despite no significant differences in pain scores. Perioperative gabapentin reduced the postoperative morphine requirements in dogs after mastectomy.",4565804
1081,4565804,You must have prompts generated from different sections.,1,2,No significant difference,Article TitleGabapentin as an adjuvant for postoperative pain management in dogs undergoing mastectomyPubMed Id25816802PMC4565804,4565804
1082,5610854,intraocular pressure (IOP),laser peripheral iridotomy (LPI) group 1,primary trabeculectomy group 2,Significantly increased,"At each visit, the IOP was significantly lower in group 2 (p &lt; 0.001).",5610854
1083,5610854,intraocular pressure (IOP)-lowering medications,laser peripheral iridotomy (LPI) group 1,primary trabeculectomy group 2,Significantly increased,"Five eyes in group 1 required trabeculectomy: 1 eye at 6 months, 2 eyes at 12 months, and 2 eyes at 18 months. 17 of the 38 eyes (44.7%, CI: 28.9%–60.5%) in group 1 required a mean of 1.8 IOP-lowering medications while seven of the 111 eyes (6.3%, CI: 1.8%–10.8%) in group 2 required a mean of 1.1 medications (Pearson's chi-square value?=?30.940, p &lt; 0.001).",5610854
1084,5610854,The absolute risk for ?2 lost lines of vision,laser peripheral iridotomy (LPI) group 1,primary trabeculectomy group 2,Significantly decreased,The absolute risk for ?2 lost lines of vision in the trabeculectomy group was 18% (20 of 111) compared to 16% (6 of 38) in the LPI group. The absolute risk increased with trabeculectomy is 2% and the number needed to harm (NNH) is 50.,5610854
1085,5610854,Cataract progression,laser peripheral iridotomy (LPI) group 1,primary trabeculectomy group 2,Significantly decreased,"Cataract progression as defined was documented in 2 eyes (5.3%, CI: ?1.8%–12.4%) in group 1 and 16 eyes (14.4%, CI: 7.9%–20.9%) in group 2 (Pearson's chi-square value?=?2.232, p = 0.135). The absolute risk increased in cataract formation with trabeculectomy is 9% and translates into a NNH of 11.",5610854
1086,4395717,repositioning error in flexion and right and left side-bending and reduction in pain,upper thoracic manipulation (UTM),cervical stability training (CST),Significantly decreased,The UTM showed significantly smaller repositioning error in flexion and right and left side-bending and greater reduction in pain than the CST group (p&lt;0.01).,4395717
1087,4395717,reduction in pain,upper thoracic manipulation (UTM),cervical stability training (CST),Significantly increased,The UTM showed significantly smaller repositioning error in flexion and right and left side-bending and greater reduction in pain than the CST group (p&lt;0.01).,4395717
1088,4082484, flow-mediated vasodilation (FMD),single serving of curry meal,spice-free control meal,Significantly increased,"On the other hand, the consumption of the curry increased FMD from 5.2?±?2.5% to 6.6?±?2.0% (P?=?0.001),",4082484
1089,4082484,postprandial FMD,single serving of curry meal,spice-free control meal,Significantly increased,"and the postprandial FMD after the curry meal was higher than that after the control meal (5.1?±?2.3% vs. 6.6?±?2.0%, P?=?0.002).",4082484
1090,4082484,"systemic and forearm hemodynamics, or any biochemical parameters including oxidative stress markers",single serving of curry meal,spice-free control meal,No significant difference,"Presence of spices in the curry did not alter significantly the systemic and forearm hemodynamics, or any biochemical parameters including oxidative stress markers measured.",4082484
1091,2644667,Mean ± SD patient global assessment scores at the end of the SR phase,hydromorphone,morphine,No significant difference,Mean ± SD patient global assessment scores at the end of the SR phase were 3.2 ± 1.14 for the OROS® hydromorphone group and 3.3 ± 0.98 for the CR morphine group (p = 0.6696);,2644667
1092,2644667,mean ± SD investigator global assessment scores,hydromorphone,morphine,No significant difference,"mean ± SD investigator global assessment scores were 3.2 ± 1.07 and 3.3 ± 0.91, respectively (p = 0.4760).",2644667
1093,2644667,mean scores for the secondary efficacy variables  and MMSE and ECOG scores,hydromorphone,morphine,No significant difference,"At the end of the IR phase, mean scores for the secondary efficacy variables (other assessments of pain from the BPI [Table 3 and Figure 4], and MMSE and ECOG scores [data not shown]) were similar for IR hydromorphone and IR morphine,",2644667
1094,2644667,'pain now PM',hydromorphone,morphine,Significantly decreased,"'pain now PM' was significantly lower in the OROS® hydromorphone group compared with the CR morphine group (LS mean [SE] scores, 2.6 [0.3] versus 3.4 [0.3], respectively; p = 0.0372)",2644667
1095,2644667,"the time to withdrawal, irrespective of phase",hydromorphone,morphine,No significant difference,"There was no statistically significant difference between treatment groups in the time to withdrawal, irrespective of phase (IR phase, p = 0.6537; SR phase, p = 0.2827).",2644667
1096,4109867,average daily gain (ADG) of Hanwoo steers,2% seamustard,basal diet,Significantly increased,The average daily gain (ADG) of Hanwoo steers was increased in SW supplemented group compared to control (p&lt;0.05).,4109867
1097,4109867,average daily feed intake (ADFI),2% seamustard,basal diet,Significantly decreased,"However, in the present study, significantly decreased average daily feed intake (ADFI) and increased gain:feed was found in the SW dietary group compared to control (p&lt;0.05).",4109867
1098,4109867,gain:feed,2% seamustard,basal diet,Significantly increased,"However, in the present study, significantly decreased average daily feed intake (ADFI) and increased gain:feed was found in the SW dietary group compared to control (p&lt;0.05).",4109867
1099,4109867,IgG concentrations,2% seamustard,basal diet,Significantly increased,The SW supplementation significantly increased (p&lt;0.05) IgG concentrations,4109867
1100,4109867,IgM concentrations,2% seamustard,basal diet,No significant difference,The SW supplementation significantly increased (p&lt;0.05) IgG concentrations while IgM concentrations remained unaffected (Table 4).,4109867
1101,4109867,Meat cholesterol concentration,2% seamustard,basal diet,Significantly decreased,Meat cholesterol concentration in the SW group was significantly lower (p&lt;0.05) than in the control group (Table 6).,4109867
1102,4109867,myristic acid (C14:0) and palmitoleic acid (C16:ln-7) concentration,2% seamustard,basal diet,Significantly decreased,"Dietary SW supplementation significantly reduced the myristic acid (C14:0) and palmitoleic acid (C16:ln-7) concentration,",4109867
1103,4109867,concentration of stearic acid (C18:0) and linolenic acid (C18:3n-3),2% seamustard,basal diet,Significantly increased,while SW increased the concentration of stearic acid (C18:0) and linolenic acid (C18:3n-3) compared to control (p&lt;0.05).,4109867
1104,4109867,"saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles",2% seamustard,basal diet,No significant difference,"Dietary SW supplementation had no effect on saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles.",4109867
1105,5064802,Hemodynamic data,Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.,no helium,No significant difference,Data are presented as mean ± SD; no significant differences were observed between groups,5064802
1106,5064802,Postoperative troponin T,Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.,no helium,No significant difference,"Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].",5064802
1107,5064802,"activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-? in the human heart",Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.,no helium,No significant difference,"No effect was observed of helium preconditioning, postconditioning or the combination thereof on activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-? in the human heart.",5064802
1108,4940009,Postoperative myalgia (POM),"Group K, 0.5 mg/kg of ketamine was injected intravenously,","Group N, the same volume (5 mL) of normal saline was injected",Significantly decreased,"Grade 1 POM was lower in Group K when compared with Group N (nine in Group K versus 33 in Group N; P&lt;0.001),",4940009
1109,4940009,Changes in heart rate after induction and intubation,"Group K, 0.5 mg/kg of ketamine was injected intravenously,","Group N, the same volume (5 mL) of normal saline was injected",No significant difference,Changes in heart rate after induction and intubation between the two groups were compared and repeated measures of variance analysis showed no significant difference in the two groups (P&gt;0.05; Table 3).,4940009
1110,4940009,the incidence of POM,"Group K, 0.5 mg/kg of ketamine was injected intravenously,","Group N, the same volume (5 mL) of normal saline was injected",Significantly decreased,"Overall, the incidence of POM in Group K was significantly less, when compared with Group N (P&lt;0.05),",4940009
1111,4940009,grade 2 of POM,"Group K, 0.5 mg/kg of ketamine was injected intravenously,","Group N, the same volume (5 mL) of normal saline was injected",No significant difference,both groups were comparable based on the grade 2 of POM,4940009
1112,3423952,"erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood, and decreased plasma nitric oxide.",3000 IU d?1 oral superoxide dismutase (SOD) powder  for 6?wks - treatment group (TRT),placebo (cellulose powder) for 6?wks,No significant difference,There were no TRT effects detected for any parameter measured (P &gt; 0.05).,3423952
1113,3423952,"erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood",exercise,no exercise,Significantly increased,"Exercise resulted in increased (P &lt; 0.05) antioxidant defenses including erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood,",3423952
1114,3423952,plasma nitric oxide,exercise,no exercise,Significantly decreased,Plasma NO decreased (P = 0.002; Figure 1(d)) from 30?min POST to 24?h POST and returned to PRE values at 36?h POST.,3423952
1115,3423952,"chondroitin sulfate-846 (CS) in synovial fluid (SF) and adjusted-PGE2, ",exercise,no exercise,Significantly increased,"Exercise increased (P &lt; 0.05) SF CS and adjusted-PGE2, and higher (P &lt; 0.05) CS and PGE2 were found in hock versus carpus joints.",3423952
1116,5215617,received colostrum as the first food,receive exclusive breastfeeding counselling from the counsellors,receive the usual health messages from the Matlab regular health staff,Significantly increased,"In the breastfeeding counselling group, 95.5% of the babies had received colostrum as the first food, compared with 85.8% in the usual health message group (p &lt; 0.001).",5215617
1117,5215617,The median duration of exclusive breastfeeding,receive exclusive breastfeeding counselling from the counsellors,receive the usual health messages from the Matlab regular health staff,Significantly increased,"The median duration of exclusive breastfeeding was longer in the breastfeeding counselling group (135 days, 95% CI: 131–139) than in usual health message group (75 days, 95% CI: 68–82) – a difference of 60 days (p &lt; 0.001).",5215617
1118,3577738,website use and terms of the number of pages visited and terms of time on the website,website with social presence elements.,website without social presence elements.,No significant difference,"but did not differ in website use in comparison with the control condition; neither in terms of the number of pages visited (t(456)?=?1.44, p?=?.15), nor in terms of time on the website (t(456)?=?0.01, p?=?.99).",3577738
1119,3577738,focused on the social presence elements in terms of frequency and duration,website with social presence elements.,website without social presence elements.,Significantly increased,"Participants in the experimental condition focused on the social presence elements, both in terms of frequency (F(1, 98)?=?40.34, p&lt;.001) and duration (F(1, 88)?=?39.99, p&lt;.001),",3577738
1120,3577738,"efficiency, effectiveness, enjoyment, active trust, and interest",website with social presence elements.,website without social presence elements.,No significant difference,"There were no differences between conditions in terms of efficiency (F(1, 456)?=?0.84, p?=?.36), effectiveness (F(1, 456)?=?0.03, p?=?.87), enjoyment (F(1, 456)?=?0.08, p?=?.78), active trust (F(1, 456)?=?0.03, p?=?.87) and interest (F(1, 456)?=?0.07, p?=?.80).",3577738
1121,5489138,confirmed disability progression,"timed 25-foot walk [T25FW],",Expanded Disability Status Scale [EDSS],Significantly increased,CDP rates defined by a ?20% increase in T25FW were higher than those defined by EDSS score at 12 and 24 months.,5489138
1122,5489138,confirmed disability progression,"timed 25-foot walk [T25FW],",9-hole peg test [9HPT],Significantly increased,CDP rates defined by T25FW or EDSS score were higher than those defined by 9HPT score.,5489138
1123,5489138,confirmed disability progression,EDSS/T25FW/9HPT,EDSS/T25FW or EDSS/9HPT,Significantly increased,"UDP proportions were consistently higher than CDP proportions for all measures, with a considerably greater difference between UDP and CDP in the cumulative incidence of the composite of all 3 individual measures (1 year: 63.8% and 41.4%, respectively; 2 years: 82.1% and 63.9%, respectively) compared with the cross-sectional proportions (1 year: 47.8% and 37.5%, respectively; 2 years: 57.5% and 52.8%, respectively).",5489138
1124,3611646,"names forgotten, numbers forgotten, memory impairment in recalling special events in life, forgetfulness, losing of valuables, difficulty in remembering multiple items to be purchased, inability to concentrate, impaired recognition, memory impairment of recall of previous histories, difficulty in recalling information quickly, depression, and inability to relax ","administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow’s ghee and sugar.",administered Sarkaradi Granules (SG).,Significantly increased,"In comparison to Group B, Group A showed highly significant relief in symptoms such as names forgotten (63.56%), numbers forgotten (61.62%), and memory impairment in recalling special events in life (59.71%) at a level of P`0.001, and forgetfulness (68.60%), losing of valuables (73.64%), difficulty in remembering multiple items to be purchased (68.21%), inability to concentrate (68.14%), impaired recognition (79.7%), memory impairment of recall of previous histories (60.66%) at a level of P`0.01, and a significant relief (P`0.05) from difficulty in recalling information quickly (71.57%), depression (89.66%), and inability to relax (82.93%) [Table 3].",3611646
1125,3611646,"serum cholesterol, serum triglyceride, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) levels","administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow’s ghee and sugar.",administered Sarkaradi Granules (SG).,Significantly decreased,"With regard to the biochemical parameters, Group A showed highly significant decrease (P`0.01) in serum cholesterol, serum triglyceride, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) levels,",3611646
1126,3611646,high density lipoprotein (HDL),"administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow’s ghee and sugar.",administered Sarkaradi Granules (SG).,Significantly increased,while high density lipoprotein (HDL) increased highly significantly (P`0.01),3611646
1127,3611646,overall effect,"administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow’s ghee and sugar.",administered Sarkaradi Granules (SG).,Significantly increased,"Regarding the overall effect, Group A showed marked improvement in 18.6% patients, moderate improvement in 74.4% patients and mild improvement in 7.0% patients, while Group B showed moderate improvement in 32.2% patients and mild improvement in 67.8% patients.",3611646
1128,5936036,drop-out rates,simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD),the SCBT with medication group or regular medication group,No significant difference,"there was no significant difference among the drop-out rates of the three groups (X2=1.41, df=2, p=0.494) with the drop-out rate of the medication only group being the highest. The summation of drop-out rates of the SCBT group and SCBT with medication group was 24.8%.",5936036
1129,5936036,"quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met.",simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD),the SCBT with medication group ,No significant difference,"As stated in Table 1, participants in the SCBT group and SCBT with medication group were not significantly different in satisfaction factors, such as the quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met.",5936036
1130,5225252,Gag-specific IFN-? enzyme-linked immunospot–determined response rates and geometric mean responses,groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA),a single dose of Ad35-GRIN or SeV-Gag,Significantly increased,"Gag-specific IFN-? enzyme-linked immunospot–determined response rates and geometric mean responses were higher (96% and 248 spot-forming units, respectively) in groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) than those after a single dose of Ad35-GRIN (56% and 54 spot-forming units, respectively) or SeV-Gag (55% and 59 spot-forming units, respectively); responses persisted for ?8 months after completion of the prime-boost regimen.",5225252
1131,5225252,"Functional CD8+ T-cell responses with greater breadth, magnitude, and frequency in a viral inhibition assay",groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA),a single dose of Ad35-GRIN or SeV-Gag,Significantly increased,"Functional CD8+ T-cell responses with greater breadth, magnitude, and frequency in a viral inhibition assay were also seen in the SLA and SHA groups after Ad35-GRIN boost, compared with those who received either vaccine alone.",5225252
1132,5225252,The GMTs,ASH group,"SLA, SHA, SHSH, and placebo groups,",Significantly increased,"The GMTs were significantly higher (P &lt; .0001, by the Kruskal-Wallis test) in the ASH group after the SeV boost than in the other groups (53, 53, 245, 50, and 59 in the SLA, SHA, ASH, SHSH, and placebo groups, respectively; Figure 4).",5225252
1133,5225252,the Gag response rate,SLA and SHA groups,ASH group,Significantly increased,"In the SLA and SHA groups combined, the Gag response rate was significantly higher 2 weeks after the second vaccination (95.7%), compared with the rate in the ASH group 2 weeks after either the Ad35-GRIN prime or the SeV-Gag boost (54.5% for both; P = .008).",5225252
1134,4627811,VO2peak tended,high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III,continuous training (CT) 12-weeks inpatients NYHA II-III,No significant difference,No significant differences were observed between both interventions (Table 2).,4627811
1135,4627811,"brachial and superficial femoral artery diameter, peak blood flow, and FMD",high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III,continuous training (CT) 12-weeks inpatients NYHA II-III,No significant difference,"We found no significant changes in brachial and superficial femoral artery diameter, peak blood flow, and FMD (Table 3).",4627811
1136,4627811,Quality of life,high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III,continuous training (CT) 12-weeks inpatients NYHA II-III,No significant difference,"5). There was a significant increase in the SF-36 subscale 'physical function' after training (P = 0.004, Table 5), which did not differ between groups (time*group P = 0.11).",4627811
1137,4627811,maximal oxygen uptake,high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III,continuous training (CT) 12-weeks inpatients NYHA II-III,No significant difference,"We found no changes over the 12-week period in maximal oxygen uptake (17.4±5.9 versus 17.5±5.8 ml/min/kg, P = 0.79) or in any of the other parameters of physical fitness (all P&gt;0.05, S1 Table).",4627811
1138,4627811,"maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen pulse",training for 12-weeks in patients NYHA II-III,no training for 12-weeks inpatients NYHA II-III,No significant difference,"Training improved maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen pulse (all P&lt;0.05), whilst no differences were present between HIT and CT (N.S.).",4627811
1139,3895597,The VAS scores of abdominal pain at week 4,tiropramide 100,octylonium 20 mg,No significant difference,"The VAS scores of abdominal pain at week 4, were significantly decreased in both tiropramide and octylonium groups, but the change from baseline did not differ between the 2 groups (difference,-0.26 mm; 95% CI,-4.33-3.82; P = 0.901).",3895597
1140,3895597,"Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL",tiropramide 100,octylonium 20 mg,No significant difference,"Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL were also improved by both treatments, and the changes from baseline did not differ.",3895597
1141,3895597,The incidence of adverse events,tiropramide 100,octylonium 20 mg,No significant difference,"The incidence of adverse events was similar in the 2 groups, and no severe adverse events involving either drug were observed.",3895597
1142,3895597,the degree of symptom reduction in abdominal pain using symptom diaries from week 1 ,tiropramide 100,octylonium 20 mg,Significantly increased,"Furthermore, the degree of symptom reduction in abdominal pain using symptom diaries was higher in the tiropramide group than in the octylonium group from week 1 (P = 0.033).",3895597
1143,3742017,performed on KABC-II Composite Index Simultaneous Processing and on subtest Rover,E-group - The Newborn Individualized Developmental Care and Assessment Program (NIDCAP) provides a system of NICU care and environmental structure that supports preterm infants’ early brain development.,"C-group - the Newborn Intensive Care Unit (NICU) experience (exposure to bright lights, heightened sound, frequent interventions), which alters brain development.",Significantly increased,E-performed significantly better than the C-children on KABC-II Composite Index Simultaneous Processing and on subtest Rover; subtest Triangles showed a trend [Table 4].,3742017
1144,4893237,mortality in old people with femoral neck fracture.,pulmonary emboli or cancer or cardiac failure or cardiovascular disease or dementia or dependence in P-ADL,no comorbidities,Significantly increased,"In the final model (Model C.) all significant variables in the two multivariate models above were combined; pulmonary emboli (HR 69.396, CI: 7.107–677.632), cancer (HR 3.393, CI: 1.959–5.877), cardiac failure (HR 2.221, CI: 1.148–4.294), cardiovascular disease (HR 2.026, CI: 1.160–3.539), dementia (HR 1.883, CI: 1.091–3.250) and dependence in P-ADL (HR 2.362, CI: 1.271–4.387)",4893237
1145,5851630,absolute beta power (ABP) after exercise,Taurine combined with Ethanol (TA+ET),Placebo—PL,Significantly increased,"However, in the ET+TA treatment, ABP values were greater after exercise, except for Fp1.",5851630
1146,5851630,absolute beta power (ABP) after exercise,exercise,no exercise,Significantly decreased,"Difference was found at Fp1 between the baseline and post-exercise moments (p&lt;0.05) and between peak and post-exercise (p&lt;0.05) for the PL, ET and TA treatments.",5851630
1147,5626376,"At early follow-up (3 months), total WOMAC scores Western Ontario and McMaster Universities Arthritis Index (WOMAC)",five injections of HA1 (Suprahyal®/Adant®),standard care (control),Significantly increased,"At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2).",5626376
1148,5626376,"At early follow-up (3 months), total WOMAC scores the Western Ontario and McMaster Universities Arthritis Index (WOMAC)",four injections of HA2 (Orthovisc®);,standard care (control),No significant difference,"At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2).",5626376
1149,5626376,"At early follow-up (3 months), total WOMAC scores the Western Ontario and McMaster Universities Arthritis Index (WOMAC)",three injections of HA3 (Synvisc®),standard care (control),Significantly increased,"At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2).",5626376
1150,5626376,"At early follow-up (3 months), total WOMAC scores the Western Ontario and McMaster Universities Arthritis Index (WOMAC)",a single injection of PRP (GPS™ II),standard care (control),Significantly increased,"At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2).",5626376
1151,5626376,"At 18 months, the higher improvement in total WOMAC",five injections of HA1 (Suprahyal®/Adant®),standard care (control),Significantly increased,"At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).",5626376
1152,5626376,"At 18 months, the higher improvement in total WOMAC",a single injection of PRP (GPS™ II),standard care (control),Significantly increased,"At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).",5626376
1153,5626376,"At 18 months, the higher improvement in total WOMAC",three injections of HA3 (Synvisc®),standard care (control),Significantly increased,"At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).",5626376
1154,5626376,"At 18 months, the higher improvement in total WOMAC",four injections of HA2 (Orthovisc®),standard care (control),Significantly increased,"At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).",5626376
1155,5626376,The percentage of patients achieving the MCII for both pain and function at 18 months,1) five injections of HA1 (Suprahyal®/Adant®); 2) four injections of HA2 (Orthovisc®); 3) three injections of HA3 (Synvisc®); 4) a single injection of PRP (GPS™ II);,standard care (control),Significantly increased,"At the end of follow-up, a growing number of patients experienced a clinically significant improvement in HA1 with a 100% responders rate, followed by HA3 (80%). In the group treated with HA2 and in those treated with PRP, the results reached 60% responders, whereas in the control group, all patients returned to near pre-arthroscopy levels of pain and impairment and none of the patients reached the 20% MCII cutoff (",5626376
1156,3296686,HCV RNA at day-14,Pioglitazone (30 mg/day for 14 days),baseline,Significantly decreased,"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n?=?10; difference of means?=?205,618 IU/ml; 95% CI 26,600 to 384,600; P&lt;0.001).",3296686
1157,3296686,HCV RNA at day-14,Prednisone (40 mg/day for 4 days),baseline,Significantly increased,"Although Prednisone did increase serum HCV RNA at day-4 (n?=?10; change from baseline?=??42,786 IU/ml; 95% CI ?85,500 to ?15,700; P?=?0.049),",3296686
1158,3296686,day-14 fasting serum glucose  and  the 2-hr glucose (Glucose-120 min) after an OGTT ,Pioglitazone (30 mg/day for 14 days),baseline,Significantly decreased,Pioglitazone treatment decreased by day-14 fasting serum glucose (Glucose-0) (mean change?=?8.2 mg/dL; P?=?0.024) as well as the 2-hr glucose (Glucose-120 min) after an OGTT (mean change?=?18.8 mg/dL; P?=?0.001) ( Table 4 ).,3296686
1159,3296686,serum ALT and AST values,Pioglitazone (30 mg/day for 14 days),baseline,Significantly decreased,Pioglitazone treatment decreased at day-14 serum ALT levels (mean change?=?7.5 IU/ml; 95% CI: 2.1 to 12.9; P?=?0.012) and to a smaller degree serum AST levels (mean change?=?2.6 IU/ml; 95% CI: ?0.6 to 5.8; P?=?0.096) ( Table 5 ).,3296686
1160,3296686,serum IL-8 levels at day-14,Pioglitazone (30 mg/day for 14 days),baseline,Significantly increased,ioglitazone increased serum IL-8 levels at day-14 when compared to baseline day-0 values (mean change?=??166.8 IU/ml; 95% CI: ?300.1 to ?33.5; P?=?0.019),3296686
1161,3296686,"day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF",Pioglitazone (30 mg/day for 14 days),baseline,No significant difference,"We found no statistically significant differences between day-0 and day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF ( Table 6 ).",3296686
1162,3296686,fasting serum glucose and 2-hr (Glucose-120 min) after an OGTT,Prednisone (40 mg/day for 4 days),baseline,Significantly increased,"Prednisone treatment increased by day-4, when compared to baseline day-0 values, fasting serum glucose (Glucose-0) (mean change?=?9.0 mg/dL; 95% CI: 20.4 to ?2.4; P?=?0.108) as well as the 2-hr (Glucose-120 min) after an OGTT (mean change?=?11.0 mg/dL; 95% CI: 17.9 to 4.1; P?=?0.006).",3296686
1163,3296686,"serum ALT, AST, IL-8 or other inflammatory mediators",Prednisone (40 mg/day for 4 days),baseline,No significant difference,"Prednisone treatment did not affect at day-4 either serum ALT, AST, IL-8 or other inflammatory mediators ( Tables 9 and 10 ).",3296686
1164,4223523,sleep efficiency ,olanzapine,placebo,Significantly increased,"Two two-way repeated-measures ANOVA showed an increase in TST (trend for main effect of treatment, F[1,23]?=?3.69, p?=?0.067) and sleep efficiency (main effect of treatment, F[1,23]?=?5.10, p?=?0.034)",4223523
1165,4223523,awake time,olanzapine,placebo,Significantly decreased,"ut by Day 28–31, olanzapine treatment was significantly decreasing amount of awake time participants experienced (t23?=?2.26, p?=?0.003).",4223523
1166,4223523,Montgomery-Asberg Depression Rating Scale and Hamilton Depression Rating Scale-17 item (HDRS-17),olanzapine,placebo,Significantly decreased,"One-way repeated measures ANOVA showed a significant decrease in total MADRS score from baseline to the end of the trial (day 28–31) for olanzapine-treated patients (main effect of time: F[1,14]?=?6.03, p?=?.022), where as placebo treatment did not show a decrease (F[1,9]?=?0.529, p?=?.486). HDRS scores also significantly decreased over time in the olanzapine-treated group (F[1,14] =19.6, p?=?.001), but the placebo-treated group did not (F[1,9] =4.67, p?=?.059).",4223523
1167,4223523,"Spatial Working Memory (SWM), Spatial Span (SSP), and Reaction Time (RTI) tasks",olanzapine,placebo,No significant difference,"There was no significant difference between olanzapine- and placebo-treated participants in SWM, SSP or RTI tasks.",4223523
1168,5354011,willingness?to?pay.,after treatment ,before treatment,Significantly increased,The significance tests show the WTP values between ‘&lt;25%’ and ‘51–75%’ to be significantly increased as percentage change in MMAS increases (P = 0.033; P &lt; 0.05).,5354011
1169,3697211,serum level of IgM,type 1 DM,type 2 DM,No significant difference,There are no significant differences between serum level of IgM between patients with T1D and T2D (181.1 ± 58.8 vs 183.8 ± 54.1 mg/dl respectively) and these values are less than reference value of healthy subjects in the laboratory (219 ± 44 mg/dl).,3697211
1170,3224529,Proportions of REM sleep duration,neurally adjusted ventilatory assist (NAVA),pressure support ventilation (PSV),Significantly increased,"Proportions of REM sleep duration were different in the two ventilatory modes (4.5% (range, 3-11%) in PSV and 16.5% (range, 13-29%) during NAVA (p = 0.001)),",3224529
1171,3224529,fragmentation index,neurally adjusted ventilatory assist (NAVA),pressure support ventilation (PSV),Significantly decreased,"as well as the fragmentation index, with 40 ± 20 arousals and awakenings per hour in PSV and 16 ± 9 during NAVA (p = 0.001).",3224529
1172,3224529,episodes of central apnea and ineffective efforts,neurally adjusted ventilatory assist (NAVA),pressure support ventilation (PSV),Significantly decreased,The mean index of sleep apneas (number of apneas per hour of sleep) was 10.5 ± 11 apneas during PSV and 0 during NAVA (p = 0.005) and ineffective efforts (number of ineffective efforts per hour of sleep) was 24 ± 23 ineffective efforts during PSV and 0 during NAVA (p = 0.001).,3224529
1173,4821313,the pH of urine,sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast),sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr).,No significant difference,"Regarding the pH of urine, we found that it was (5.95 ± 0.26) in group 1 and (5.97 ± 0.24) in group 2, showing no statistical difference and highlighting the fact that both regimen had almost the same alkalinizing efficacy with no proven extra benefit for patients with pH values greater than 6.",4821313
1174,4821313,serum creatinine,sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast),sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr).,Significantly increased,"We observed a significant increase in S. Cr. and significant decrease in eGFR calculated by MDRD formula in (group 1) when we compare their levels prior to contrast administration with their levels 48 hr after the intervention (S. Cr: 2.32 ± 0.41 vs. 2.42 ± 0.48) and (eGFR by MDRD: 30.22 ± 6.07 vs, 28.97 ± 6.57). Regarding group 2, the results of our study showed no statistical difference in S. Cr. and eGFR calculated by MDRD 48 hr post-procedure (S. Cr: 2.26 ± 0.47 vs. 2.26 ± 0.49) and (eGFR by MDRD: 30.97 ± 7.13 vs. 31.06 ± 7.41).",4821313
1175,4821313,eGFR ,sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast),sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr).,Significantly decreased,"We observed a significant increase in S. Cr. and significant decrease in eGFR calculated by MDRD formula in (group 1) when we compare their levels prior to contrast administration with their levels 48 hr after the intervention (S. Cr: 2.32 ± 0.41 vs. 2.42 ± 0.48) and (eGFR by MDRD: 30.22 ± 6.07 vs, 28.97 ± 6.57). Regarding group 2, the results of our study showed no statistical difference in S. Cr. and eGFR calculated by MDRD 48 hr post-procedure (S. Cr: 2.26 ± 0.47 vs. 2.26 ± 0.49) and (eGFR by MDRD: 30.97 ± 7.13 vs. 31.06 ± 7.41).",4821313
1176,3752932,the mean number of incontinence episodes/24 h and the mean number of micturitions/24 h,mirabegron (50 and 100 mg),placebo,Significantly decreased,"Mirabegron at doses of 50 and 100 mg once daily demonstrated statistically significant improvement from baseline to Final Visit compared with placebo in reducing the mean number of incontinence episodes/24 h and the mean number of micturitions/24 h (p &lt; 0.05 for all comparisons; Table 2 and Figures 3 and 4, respectively). The adjusted mean (95% CI) change from baseline to Final Visit in the mean number of incontinence episodes/24 h was ?1.10 (?1.23, ?0.97), ?1.49 (?1.63, ?1.36) and ?1.50 (?1.67, ?1.34) in the placebo, mirabegron 50 and 100 mg groups, respectively, and ?1.20 (?1.34, ?1.06), ?1.75 (?1.89, ?1.61), ?1.74 (?1.91, ?1.56) for the adjusted mean change from baseline to Final Visit in the mean number of micturitions/24.",3752932
1177,3752932,"mean volume voided/micturition, mean level of urgency, mean number of urgency episodesand mean number of urgency incontinence episodes/24 h",mirabegron (50 and 100 mg),placebo,Significantly decreased,"Both 50 and 100 mg mirabegron doses were associated with statistically significant improvements from baseline to Final Visit compared with placebo for the key secondary efficacy end-points of mean volume voided/micturition (p &lt; 0.05 for all comparisons; Table 2), mean level of urgency, mean number of urgency episodes (grade 3 or 4)/24 h and mean number of urgency incontinence episodes/24 h (p &lt; 0.05 for all comparisons; Table 2 and Figure 5).",3752932
1178,3752932,mean number of nocturia episodes/24 h,mirabegron (50 and 100 mg),placebo,Significantly decreased,"Significant improvements were also evident in the pooled efficacy analysis with respect to the change from baseline to Final Visit (95% CI) in the mean number of nocturia episodes/24 h in the mirabegron 50 mg [?0.55 (?0.62, ?0.49)] and mirabegron 100 mg groups [?0.54 (?0.62, ?0.46)] vs. placebo [?0.42 (?0.48, ?0.35)] (p &lt; 0.05; Table 2).",3752932
1179,3752932,the Treatment Satisfaction-Visual Analogue Scale (TS-VAS),mirabegron (50 and 100 mg),placebo,Significantly increased,"In health-related quality of life outcomes, mirabegron 50 and 100 mg was associated with a statistically significant improvement in the TS-VAS score at Final Visit compared with placebo (p &lt; 0.05; Table 2). The adjusted mean (95% CI) changes from baseline to Final Visit were 1.25 (1.08, 1.42), 2.01 (1.84, 2.19) and 2.33 (2.11, 2.55) for the placebo, mirabegron 50 and 100 mg groups, respectively.",3752932
1180,5002324,the limits of stability (LOS) performance and one-leg stance (OLS) tests,a balance-based exergaming group for an 8-week balance training period.,a balance training group for an 8-week balance training period.,Significantly increased,"Within-group post hoc analysis revealed that balance-based exergaming training significantly improved LOS performance (improving reaction time from 0.96?±?0.33 to 0.74?±?0.24 s, end point excursion from 75.2?±?12.48 to 84?±?12.04 % and directional control from 75.7?±?8.78 to 78.9?±?7.65 %) and OLS on the less affected leg in the eyes-closed condition (from 3.35?±?2.85 to 6.1?±?8.65 s).",5002324
1181,5002324,directional control in the LOS test,a balance-based exergaming group for an 8-week balance training period.,a balance training group for an 8-week balance training period.,Significantly increased,"Furthermore, balance-based exergaming training resulted in significantly better performance in directional control in the LOS test (78.9?±?7.65 %) compared with conventional balance training (70.6?±?9.37 %).",5002324
1182,5064056,Mean pain intensity,"tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice",no therapy,Significantly decreased,Mean pain intensity reported for all participants was 38 over the pre-treatment baseline period and 18 over the post-treatment baseline period on the Visual Analogue Scale.,5064056
1183,5064056,Mean disability,"tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice",no therapy,Significantly decreased,"ean disability was 43 over the pre-treatment baseline period and 23 over the post-treatment baseline period, on a similar 0-100 scale.",5064056
1184,4653470,Absolute increase in performance of insulin therapy for DM.,serious game called InsuOnLine©,traditional on-site learning activity,Significantly increased,"Absolute increase in performance was higher in the game group (40%) than in control (34%, p=0.01).",4653470
1185,3971783,"O2sat, PaO2","breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping",no breathing exercises ,Significantly increased,"Likewise, O2sat, PaO2 in the case group were higher than the control group (P &lt; 0.0001).",3971783
1186,3971783,The nocturnal enuresis,"breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping",no breathing exercises ,Significantly decreased,"After intervention, the median of nocturnal enuresis frequency in the case group was significantly lower than the control group (P &lt; 0.001).",3971783
1187,3971783,PaCO2 and Respiratory rates ,"breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping",no breathing exercises ,Significantly decreased,After intervention the means of PaCO2 and RR in the control group were significantly higher than the case group (P &lt; 0.0001).,3971783
1188,5122238,incidence and intensity of shivering,received 1 mg/kg and 2 mg/kg hydrocortisone,received normal saline,Significantly decreased,"while the incidence and intensity of shivering had a significant difference between the two groups of hydrocortisone of 1 mg/kg and placebo group (P = 0.039 and P = 0.018, respectively). Moreover, the incidence and intensity of shivering had a significant difference between the two groups of hydrocortisone of 2 mg/kg and placebo group (P = 0.0001 and P = 0.001, respectively).",5122238
1189,5122238,"Mean central temperature, Mean peripheral temperature, Mean blood pressure, Mean heart rate",received 1 mg/kg and 2 mg/kg hydrocortisone,received normal saline,No significant difference,Figure 1Mean central temperature from 0 to 60 min recovery in the three groups (P = 0.64)Figure 2Mean peripheral temperature from 0 to 60 min recovery in the three groups (P = 0.31)Figure 3Mean blood pressure from 0 to 60 min recovery in the three groups (P = 0.82)Figure 4Mean heart rate from 0 to 60 min recovery in the three groups (P = 0.77),5122238
1190,3743641,mean daily number of moderate to severe hot flushes at week 4,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly decreased,"In SMART-2, at week 4, BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg were associated with a significant decrease (P &lt; 0.001) in the adjusted mean daily number of moderate to severe hot flushes as compared with placebo.",3743641
1191,3743641,mean daily number of moderate to severe hot flushes at week 12,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly decreased,"At week 12, BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg were associated with a decrease (P &lt; 0.001) in the adjusted mean daily number of moderate to severe hot flushes, reaching a 74% and a 80% reduction, respectively, representing a clinically meaningful reduction of approximately 7–8 hot flushes per day, compared with a 51% reduction (representing a reduction of approximately five hot flushes per day) in the placebo group (Figure 1).18",3743641
1192,3743641,mean proportion of superficial cells,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,BZA 20 mg/CE 0.45 or 0.625 mg showed a significantly greater increase from baseline in the mean proportion of superficial cells compared with placebo (P &lt; 0.001).,3743641
1193,3743641,reduction from baseline in the mean proportion of parabasal cells,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,Both BZA/CE groups also showed a significantly greater reduction from baseline in the mean proportion of parabasal cells (P &lt; 0.001),3743641
1194,3743641,increase from baseline in the mean proportion of intermediate cells,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,and a significantly greater increase from baseline in the mean proportion of intermediate cells (P &lt; 0.05) compared with placebo at weeks 4 and 12.,3743641
1195,3743641,vaginal pH,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly decreased,"Additionally, treatment with BZA 20 mg/CE 0.625 mg resulted in a significantly greater decrease from baseline in vaginal pH (P &lt; 0.001)",3743641
1196,3743641,improvement in the women’s most bothersome vulvovaginal atrophy symptoms,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,and a greater improvement in the women’s most bothersome vulvovaginal atrophy symptoms (P &lt; 0.05) compared with placebo (Figure 4).19,3743641
1197,3743641,reduction in the incidence of dyspareunia,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,"This maturation of the vaginal epithelium was associated with a statistically significant reduction in the incidence of dyspareunia relative to placebo during weeks 9–12 of therapy (P &lt; 0.001) and in ease of lubrication score from baseline compared with placebo (P &lt; 0.05) on the Arizona Sexual Experiences scale.17,19",3743641
1198,3743641,sexual function and total scores,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,"Additionally, in SMART-3 (subjects with vulvovaginal atrophy), the Menopause-Specific Quality of Life questionnaire results at week 12 showed significant improvements in sexual function and total scores with both BZA/CE doses versus placebo or BZA 20 mg (P &lt; 0.001).",3743641
1199,3743641,lumbar spine bone mineral density (BMD),"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,"Two clinical trials (SMART-1 and SMART-5) evaluated the safety and efficacy of BZA/CE for the prevention of osteoporosis.17,20 Among subjects ?5 years since menopause (substudy II of SMART-1 and SMART-5), significant (P &lt; 0.001) increases from baseline to month 12 in lumbar spine bone mineral density (BMD) were demonstrated for both the BZA 20 mg/CE 0.45 mg (1.05% and 0.24% in SMART-1 and SMART-5, respectively) and BZA 20 mg/CE 0.625 mg (1.05% and 0.60%, in SMART-1 and SMART-5, respectively) treatment groups compared with placebo (?1.81% and ?1.28%, in SMART-1 and SMART-5, respectively).17,20",3743641
1200,3743641,breast tenderness,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly decreased,"In SMART-5, the incidence of breast tenderness in subjects treated with BZA/CE was significantly lower than that in subjects treated with CE 0.45 mg/MPA 1.5 mg (P &lt; 0.001, Figure 7)",3743641
1201,3743641,"risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer,","BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,No significant difference,"No apparent increased risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, was observed with either dose strength of BZA/CE.",3743641
1202,4280954,"DM + E group received a high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food","ceived a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)","high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA;",No significant difference,the DM + Flax + E group received a high-fat diet enriched with flaxseed and vitamin E.,4280954
1203,4280954,serum glucose,"high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly decreased,The addition of flaxseed or/and vitamin E to the high-fat diet led to significant reductions of serum glucose levels compared with those in the DM group (Table II).,4280954
1204,4280954,serum TC and non-HDL-C levels ,"high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; ","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly decreased,Flaxseed supplementation significantly decreased serum TC and non-HDL-C levels and increased HDL-C levels (Table II) compared with those in the unsupplemented DM group.,4280954
1205,4280954,HDL-C levels,"high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; ","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly increased,Flaxseed supplementation significantly decreased serum TC and non-HDL-C levels and increased HDL-C levels (Table II) compared with those in the unsupplemented DM group.,4280954
1206,4280954,"TC, non-HDL-C and TG levels","high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly decreased,"The addition of vitamin E to the flaxseed-rich diet significantly decreased TC, non-HDL-C and TG levels but did not improved the HDL-C level in diabetic hamsters.",4280954
1207,4280954,the aortic cholesterol content,"high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly decreased,Flaxseed or/and vitamin E supplementation of the diet significantly decreased the aortic cholesterol content in the hamsters with DM (Table II).,4280954
1208,4526336,proportion of words out of the total number of words,mild cognitive impairment (MCI),healthy,Significantly increased,The average proportion of words spoken by participants across the 3 assessment time points was different between the groups (p=0.01) with 68.3% (SD 9.3) among those with MCI and 60.0% (SD 9.3) among cognitively intact.,4526336
1209,4306068,The proportion of patients who received analgesics,pain score display group,not displayed in the control.,No significant difference,The proportion of patients who received analgesics when pain score was displayed was 6.5% more than when pain score was not displayed. This difference was however not statistically significant.,4306068
1210,4306068,The mean timing to analgesic administration,pain score display group,not displayed in the control.,No significant difference,"The mean timing (in minutes) to analgesic administration for the displayed and non-displayed groups were 81.3?±?41.2 (95% C.I 65.9, 96.7) and 88.7?±?45.4 (95% C.I 69.0, 108.3), respectively (p?=?0.538). The distribution of timing of analgesics according to the severity of pain is as shown in Table 3.",4306068
1211,5397544,Thromboelastography R-time,Low-molecular-weight heparin before and after the surgery,Low-molecular-weight heparin only before the surgery,No significant difference,There was no significant difference in thromboelastography R-time between the groups before low-molecular-weight heparin injection,5397544
1212,5397544,Alpha-angle values,Low-molecular-weight heparin before and after the surgery,Low-molecular-weight heparin only before the surgery,No significant difference,There were no significant changes in ?-angle and maximum amplitude values during or after laparoscopic fundoplication in both groups,5397544
1213,5397544,Maximum amplitude values,Low-molecular-weight heparin before and after the surgery,Low-molecular-weight heparin only before the surgery,No significant difference,There were no significant changes in ?-angle and maximum amplitude values during or after laparoscopic fundoplication in both groups,5397544
1214,3743198,Admission rate,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,Significantly decreased,"The admission rate decreased by 8.3% in the intervention group (adjusted odds ratio 0.31, 95% confidence interval 0.13-0.70, p=0.005).",3743198
1215,3743198,Medical costs,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,Significantly decreased,"In the multivariate linear regression analysis of medical costs, membership in the intervention group was associated with decreased costs (coefficient -712000 KRW, 95% CI -1341000 to -83000 KRW, p=0.027)",3743198
1216,3743198,Rate of certain diagnosis,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,No significant difference,"There was an increasing trend in the rate of certain diagnosis in the intervention group, but it was not statistically significant.",3743198
1217,3743198,Postural blood pressure measurement,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,Significantly increased,"Postural blood pressure measurement was more frequently performed in the intervention group than the control group (97.6% vs. 87.9%, p=0.003).",3743198
1218,3743198,Cardiac enzymes and electroencephalography testing,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,Significantly decreased,"the use of cardiac enzymes and electroencephalography were lower in the intervention group than the control group, respectively (42.9% vs. 56.0%, p=0.041; 2.3% vs. 8.6%, p=0.029).",3743198
1219,5741263,Stroke duration,Amplitude training,Placebo,Significantly increased,"the current results showed increases in stroke duration and normalized jerk after amplitude training, which were absent in the placebo group",5741263
1220,5741263,Writing velocity,Amplitude training,Placebo,No significant difference,velocity remained unchanged throughout the study.,5741263
1221,5741263,Normalized jerk,Amplitude training,Placebo,Significantly increased,"A significant Time x Group interaction was found for the normalized jerk in the large-amplitude condition (F = 8.928, p &lt; 0.001) (Fig 1C). Further analysis revealed a higher normalized jerk in the EXP group compared to PLB group post-training (p = 0.027).",5741263
1222,3917123,Total score of fatigue,Routine unit care ,Placebo,No significant difference,"Post-hoc Duncan test showed that in the study group, total score of fatigue and score of fatigue in emotional, cognitive, and behavioral dimensions were significantly less than in the two groups of placebo and control after intervention (P &lt; 0.05), but there was no significant difference between the control and placebo groups (P &gt; 0.05).",3917123
1223,3917123,Fatigue score in the sensory dimension,Acupressure,Placebo,Significantly decreased,"Mean score of fatigue in the sensory dimension in the study group was significantly less than in the placebo group (P &lt; 0.05),",3917123
1224,3917123,Total score of fatigue,Accupressure,Placebo and routine unit care,Significantly decreased,"Post-hoc Duncan test showed that in the study group, total score of fatigue and score of fatigue in emotional, cognitive, and behavioral dimensions were significantly less than in the two groups of placebo and control after intervention (P &lt; 0.05), but there was no significant difference between the control and placebo groups (P &gt; 0.05).",3917123
1225,3917123,Fatigue score in the sensory dimension,Routine unit care,Placebo,Significantly increased,"Mean score of fatigue in the sensory dimension in the study group was significantly less than in the placebo group (P &lt; 0.05), and in the placebo group, it was significantly less that in the control group (P &lt; 0.05).",3917123
1226,4996255,"the number of steps to use, time taken to use and ease of use",Ellipta™ DPI,HandiHaler®,Significantly increased,"In the combined analyses from the two Phase IIIa active comparator studies, patients declared a preference for the Ellipta™ DPI compared with the HandiHaler® in relation to the number of steps to use (59% vs 17%), time taken to use (62% vs 14%) and ease of use (63% vs 15%), although 22%–24% of all patients declared no preference for either inhaler (Table 4).",4996255
1227,3452313,headache relief for attacks occurring inside and outside the menstrual period (migraine attacks),sumatriptan  for 2 months,placebo  for 2 months,Significantly increased,"For the first attack, significantly more patients receiving sumatriptan than placebo reported headache relief for attacks occurring inside (67% vs. 33%, p=0.007) and outside (79% vs. 31%, p&lt;0.001) the menstrual period.",3452313
1228,5966469,increase of fluency in the double loops tasks,the combined and in the pure handwriting group,the spelling training and the reading groups,Significantly increased,"One of the exceptions mentioned above was a marked increase of fluency in the double loops tasks observed in the combined and in the pure handwriting group from pre-test to post-test, which outperformed the spelling training and the reading groups as indicated by the significant interaction term intervention*time (F(3,171) = 2.7, p &lt; 0.05, ?p2 = 0.05).",5966469
1229,2694465,"forced vital capacity (FVC), FEV1/FVC and PaO2/FiO2 ratio",400 ?g of intrathecal morphine followed by general anesthesia,general anesthesia,No significant difference,"Both groups experienced reduced FVC postoperatively (3.24 L to 1.38 L in control group; 2.72 L to 1.18 L in morphine FEV1 (p=0.085), group), with no significant decreases observed between groups. The two groups also exhibited similar results for FEV1/FVC (p=0.68) and PaO2/FiO2 ratio (p=0.08).",2694465
1230,2694465,pain intensity,400 ?g of intrathecal morphine followed by general anesthesia,general anesthesia,Significantly decreased,"The morphine group reported less pain intensity (evaluated using a visual numeric scale), especially when coughing (18 hours postoperatively: control group= 4.73 and morphine group= 1.80, p=0.001).",2694465
1231,2694465,Cumulative morphine consumption,400 ?g of intrathecal morphine followed by general anesthesia,general anesthesia,Significantly decreased,"umulative morphine consumption was reduced after 18 hours in the morphine group (control group= 20.14 and morphine group= 14.20 mg, p=0.037).",2694465
1232,2694465,The plasma morphine concentration,400 ?g of intrathecal morphine followed by general anesthesia,general anesthesia,Significantly decreased,"Plasma morphine levels were zero at the end of surgery in both groups. However, plasma levels were significantly reduced in the morphine group during the postoperative period 24 hours after the operation (control group= 15.87 ± 18.05 ng mL?1 and morphine group 4.08 ± 5.28 ng mL?1, p=0.029),",2694465
1233,5506592,the proportion of households who purchased anti-mosquito products in the last month,education and mobilisation activities,baseline,Significantly decreased,"In 2012, after the intervention, the proportion of households who purchased anti-mosquito products in the last month was significantly lower in intervention clusters (47.8%; 2503/5293) than in control clusters (53.3%; 2707/5079) (difference ? 0.05, 95% CIca ?0.100 to ?0.010).",5506592
1234,5506592,"The mean expenditure on the products,",education and mobilisation activities,baseline,Significantly decreased,"The mean expenditure on the products, among those households who bought them, was USD6.43; 30.4% in the intervention clusters and 36.7% in the control clusters spent more than this (difference ? 0.06, 95% CIca ?0.12 to ?0.01).",5506592
1235,5228611,mean HIV treatment satisfaction total scores at weeks 24 and 48,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,Significantly increased,"Although both arms showed improved patient-reported outcome scores, participants in the E/C/F/TAF plus DRV group reported statistically significantly higher mean HIV treatment satisfaction total scores at weeks 24 and 48 (Fig. 5) and answered questions specific to the flexibility or convenience of and the patient's satisfaction with the treatment more favorably.",5228611
1236,5228611,days with missed doses,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,Significantly decreased,"Based on the visual analog scale adherence questionnaire, participants on E/C/F/TAF plus DRV consistently reported fewer days with missed doses, whereas those on their baseline regimen reported a higher number of days with missed doses as the study progressed: more participants in the E/C/F/TAF plus DRV group reported &lt;2 days with missed doses in the 30 days before week 24 (90% vs. 74%) or 48 (86% vs. 59%) and no days with missed doses in the 4 days before weeks 24 (98% vs. 83%) or 48 (99% vs. 73%).",5228611
1237,5228611,eGFR,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,No significant difference,There were no differences between the 2 groups in median changes from baseline in eGFR (week 48: +7.4 mL/min vs. +3.9 mL/min; P = 0.18).,5228611
1238,5228611,quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio),elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,Significantly decreased,Participants in the E/C/F/TAF plus DRV group had statistically significant declines in both measures of quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) at week 48 vs. increases in the baseline regimen group (Fig. 4).,5228611
1239,5228611,rate of any adverse events,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,Significantly increased,Participants in the E/C/F/TAF plus DRV group had a higher rate of any adverse events [92% (n = 82) vs. 78% (n = 36)].,5228611
1240,5228611,HIV-1 RNA &lt;50 copies per mililiter at week 24;,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,No significant difference,E/C/F/TAF plus DRV was noninferior to baseline regimens for the primary outcome (HIV-1 RNA &lt;50 copies per mililiter at week 24; FDA-snapshot algorithm) using the full analysis set (96.6% vs. 91.3%; difference 5.3%; 95.001% CI: ?3.4% to 17.4%) (Fig. 3).,5228611
1241,3051215,"mean changes in body weight, BMI, and waist circumference",anti-inflammatory agent (Diacerein treatment group),placebo,No significant difference,"The treatment group had a tendency towards more reduction in anthropometry as compared to the placebo group, in body weight reduction (- 7.0 kg vs. - 4.6 kg), body mass index (- 2.51 kg/m2 vs. - 1.59 kg/m2), and waist circumference (- 7.3 cm vs. - 4.4 cm). These reductions were not statistically significant.",3051215
1242,3051215,"hsCRP, and adiponectin",anti-inflammatory agent (Diacerein treatment group),placebo,No significant difference,"We also evaluated the changes in inflammatory markers between the two groups. Again, no statistical differences were apparent. Although there were no differences between the two groups, hsCRP, and adiponectin showed more favorable change in the treatment group than in the placebo group. Other inflammatory markers were not shown as expected, but TNF-? was decreased in both groups after intervention (Table 3).",3051215
1243,3466198,The median vaginal and cervical pH,Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,Significantly decreased,"The median pH at the cervix, lateral vaginal wall, posterior fornix and CVL was significantly lower 2 hours after application of Acidform compared to the placebo group (p&lt;0.01)",3466198
1244,3466198,at least one local adverse event,Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,Significantly increased,Eleven of 17 (65%) women who received Acidform had at least 1 AE compared with 2 of 18 (11%) who received HEC placebo gel (p?=?0.002).,3466198
1245,3466198,"CVL concentrations of lactoferrin and interleukin-1 receptor antagonist (IL-1ra), an anti-inflammatory protein,",Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,No significant difference,"No significant drug effect was observed for the other cytokines, chemokines and host protective factors. However, there was a trend towards a reduction in CVL concentrations of IgG (p?=?0.06), IgA (p?=?0.05) and IL-8 (p?=?0.08) in women who applied Acidform gel.",3466198
1246,3466198,detectable L. crispatus or L. jensenii,Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,No significant difference,There were no significant changes in the number of women with detectable L. crispatus or L. jensenii or in the concentrations of bacteria recovered by PCR in the Acidform or HEC group following 14 days of twice daily gel use (Table 4).,3466198
1247,3466198,G. vaginalis,Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,No significant difference,"However, there was a trend towards a decrease in the concentration of G. vaginalis following repeated application of Acidform from a median of 1.3×106 to 3.6×104 DNA copies/swab (p?=?0.083).",3466198
1248,3056193,Hamilton Rating Scale for Depression (HAM-D) and the Montgomery-Asberg Rating Scale (MADRS),placeboxetine (PB) hydrochloride extended release capsules,sertraline hydrochloride,No significant difference,"Similar results were obtained with the MADRS assessments [Figure 2]. There was no difference between groups at baseline, there was significant improvement in each group at the end of weeks 2 (P&lt;0.01) and 6 (P&lt;0.001), and there were no significant differences between groups at any follow up visit.",3056193
1249,5225191,"medication-attributed, antidepressant-specific side effect score",amitriptyline,placebo pill,Significantly increased,"We found that the amitriptyline group’s medication-attributed, antidepressant-specific side effect score was significantly higher after the acquisition phase (p ? .001; g = 1.75; CI 1.02–2.49) and after the evocation night (p = .008; g = 0.88; CI 0.22–1.54) than the placebo group’s (see Table 2 and Fig. 3b).",5225191
1250,5225191,GASE-AD (antidepressant-specific side effects),amitriptyline,placebo pill,Significantly increased,the amitriptyline group reported significantly more side effects (see Table 2 and Fig. 3a).,5225191
1251,5225191,GASE-generic (generic side effects),amitriptyline,placebo pill,No significant difference,"We observed no differences between the groups in either the GASE-generic or GASE-generic-MA (multivariate analyses: group effect F (2, 36) = 1.89, p = .166; time effect F (4, 34) = 2.83, p = .040; group × time interaction effect F (4, 34) = 2.19, p = .091; univariate analyses regarding GASE-generic-MA: time effect F (0.60, 22.20) = 5.43, p = .027).",5225191
1252,3172326,visual analogue scale (VAS).,received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision,0.5 mg/kg of normal saline was injected,Significantly decreased,"VAS scores are presented in Table 2. For all of the evaluated times, the VAS score was significantly lower in the ketamine group than that of the control group.",3172326
1253,3172326,The interval time for the first analgesic request,received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision,0.5 mg/kg of normal saline was injected,Significantly increased,The interval time for the first analgesic request was 23.1 ± 6.7 minutes in the ketamine group and 18.1 ± 7.3 minutes in the control group (P = 0.02).,3172326
1254,3172326,The total number of pethidine injections in first 24 hours postoperatively,received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision,0.5 mg/kg of normal saline was injected,Significantly decreased,The total number of pethidine injections in first 24 hours postoperatively was 0.6 ± 0.6 in the ketamine group and 2.0 ± 0.8 in the control group (P = 0.032).,3172326
1255,4864053,mean decrease in [11C]Ro15?4513 BP,"MSD, 100 mg l?dopa plus 25 mg carbidopa",placebo (starch),Significantly increased,"r. For a composite gray matter region, a one?sample t?test showed that l?dopa was associated with an 11% mean decrease in [11C]Ro15?4513 BP (t = ?2.29, 9 degrees of freedom, P = 0.048). There was a highly significant effect of regions (linear mixed model, P = 0.000049).",4864053
1256,4864053,The BP of the GABA ligand,"MSD, 100 mg l?dopa plus 25 mg carbidopa",placebo (starch),Significantly decreased,"The BP of the GABA ligand decreased significantly with l?dopa in the medial prefrontal/anterior cingulate and right insula regions (by 18%, t = ?3.63 P = 0.0054, and 18%, t = 3.85 P = 0039, respectively), with no significant effect in the other regions.",4864053
1257,4488484,support for training first responders to use naloxone,Several message exposures,no-exposure control group,Significantly increased,"Factual information alone led to higher support for training first responders to use naloxone (77.4% versus 63.2% in the no-exposure control group),",4488484
1258,4488484,providing naloxone to friends and family members of people using opioids,Several message exposures,no-exposure control group,Significantly increased,"providing naloxone to friends and family members of people using opioids (45.5% versus 24.4% in the no-exposure control group),",4488484
1259,4488484,passing laws to protect people who administer naloxone,Several message exposures,no-exposure control group,Significantly increased,passing laws to protect people who administer naloxone (58.0% versus 41.6% in the no-exposure control group).,4488484
1260,4488484,"support all policies: providing naloxone to friends and family members, training first responders to use naloxone, passing laws to protect people if they administer naloxone, and passing laws to protect people if they call for medical help for an overdose ",receiving the combination of the sympathetic narrative and factual information,factual information alon,Significantly increased,"Participants receiving the combination of the sympathetic narrative and factual information, compared to factual information alone, were more likely to support all policies: providing naloxone to friends and family members (OR: 2.0 [95% CI: 1.4 to 2.9]), training first responders to use naloxone (OR: 2.0 [95% CI: 1.2 to 3.4]), passing laws to protect people if they administer naloxone (OR: 1.5 [95% CI: 1.04 to 2.2]), and passing laws to protect people if they call for medical help for an overdose (OR: 1.7 [95% CI: 1.2 to 2.5]).",4488484
1261,5414544,The rate of HBsAg positivity,Zimbabwe,Uganda,Significantly increased,"The rate of HBsAg positivity was significantly higher in Zimbabwe than Uganda (12.2 vs. 7.7%, adjusted odds ratio?=?1.54, P?&lt;?0.001) despite a similar prevalence of antibody to HBV core antigen (56.3 vs. 52.4%) in the two settings.",5414544
1262,5414544,HBsAg positivity,male,female,Significantly increased,"Men were significantly more likely to test positive than women [adjusted odds ratio (aOR) 1.39, 95% confidence interval (CI) 1.19–1.61], although this difference was more marked in Zimbabwe (aOR 1.85, 95% CI 1.41–2.42) than Uganda (aOR 1.22, 95% CI 1.02–1.46) (P?=?0.005, test for interaction).",5414544
1263,3517421,breakdown recurrence,"two culling strategies on breakdown prolongation and recurrence, during and after culling",control,No significant difference,"There is no notable impact of culling treatment in the buffer zones, but there is a decrease in the odds of recurrence in the proactively culled core areas during the culling period, for both the 24 month (OR: 0.82; 95% CI [0.64–1.0]), and 36 month (OR: 0.69; 95% CI [0.54–0.86]) follow-up periods.",3517421
1264,3933059,"Systolic blood pressure (SBP), diastolic blood pressure (DBP)",Pomegranate juice (PJ),baseline,Significantly decreased,"Comparison of pre- vs. post-trial values revealed a significant reduction in both SBP (P = 0.013) and DBP (P = 0.010), amounting to an approximate reduction by 7% and 6%, respectively.",3933059
1265,3933059,flow-mediated dilation (FMD),Pomegranate juice (PJ),baseline,No significant difference,"However, percentage changes in FMD (20%) was not found to be statistically significant (P = 0.172).",3933059
1266,3933059,"C-reactive protein (CRP), intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin and interleukin-6 (IL-6)",Pomegranate juice (PJ),baseline,No significant difference,"there was no significant difference in the circulating concentrations of inflammatory biomarkers namely hsCRP (P = 0.263), ICAM-1 (P = 0.248), VCAM-1 (P = 0.657), E-selectin (P = 0.182), and IL-6 (P = 0.763) following consumption of PJ.",3933059
1267,4709985,would have liked more information on acupuncture,tertiary education,other educations,Significantly increased,"The role of educational status was examined in response these questions and we found women with tertiary education would have liked more information on acupuncture (p?&lt;?0.009), no other associations were found.T",4709985
1268,3655855,Red cell and plasma phospholipid eicosapentaenoic acid and docosahexaenoic acid concentrations,1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks,safflower oil placebo for 4 weeks,Significantly increased,Figure 1 shows the effect of O3 dosing for four weeks on plasma phospholipid EPA and DHA. Plasma levels increased significantly (p?&lt;?0.001).,3655855
1269,3655855,"central pulse wave velocity, augmentation index, aortic systolic blood pressure, BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10,CRP ",1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks,safflower oil placebo for 4 weeks,No significant difference,"The effects of supplementation on components of the metabolic syndrome, plasma lipids, vascular measures, and cytokines are shown in Table 3. The daily treatment dose of 1.7 g of O3 for four weeks had no effect on any of these measures compared to the safflower placebo. Not shown are BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10, all of which also showed no effect.",3655855
1270,4401879,"energy, protein, and fat and zinc intake",30mg/day zinc gluconate for eight consecutive weeks,placebo for eight consecutive weeks,Significantly increased,"Supplementation with 30mg of zinc significantly increased energy, protein, and fat and zinc intake in zinc group (P &lt; 0.05). However, no change was observed in the placebo group (P &gt;0.05).",4401879
1271,4401879,"fasting blood sugar, insulin and homeostatic model assessment of insulin resistance",30mg/day zinc gluconate for eight consecutive weeks,placebo for eight consecutive weeks,No significant difference,"According to the results shown in this table, serum zinc increased (P =0.012) significantly, but there were no significant statistical changes in FBS, serum insulin levels and HOMA-IR (P ? 0.05).",4401879
1272,4880652,"the modified Aldrete scores at 60 minutes, systolic pressures at 0 minutes, oxygen saturation at 10, 15, 20 minutes, diastolic blood pressure at 10, 15, 20 minutes, heart rates, and visual analogue scores",fentanyl (1 µg/kg) and propofol ,paracetamol (20 mg/kg) and propofol,No significant difference,"When the modified Aldrete scores at 60 minutes, systolic pressures at 0 minutes, oxygen saturation at 10, 15, 20 minutes, diastolic blood pressure at 10, 15, 20 minutes, heart rates, and visual analogue scores were compared, there was no significant difference between groups (p&gt;0.05).",4880652
1273,4880652,"systolic blood pressures at 5, 10, 15, and 20 minutes",fentanyl (1 µg/kg) and propofol ,paracetamol (20 mg/kg) and propofol,Significantly decreased,"n the fentanyl group, systolic blood pressures at 5, 10, 15, and 20 minutes were significantly lower (p&lt;0.05) than in the paracetamol group;",4880652
1274,4880652,Diastolic blood pressures at 5 minutes,fentanyl (1 µg/kg) and propofol ,paracetamol (20 mg/kg) and propofol,Significantly decreased,Diastolic blood pressures at 5 minutes were significantly lower (p&lt;0.05) in the fentanyl group;,4880652
1275,4880652,SpO2 at 5 minutes,fentanyl (1 µg/kg) and propofol ,paracetamol (20 mg/kg) and propofol,Significantly decreased,"In the fentanyl group, SpO2 at 5 minutes was significantly lower (p&lt;0.05) than in the paracetamol group,",4880652
1276,3585965,Mean (± standard error of the mean) plasma GLPG0259 concentrations a,single ascending doses (1.5–150 mg)  of GLPG0259,multiple oral doses (20 and 50 mg once daily) of GLPG0259,No significant difference,"Although no statistical analysis was performed on t1/2,?z, no noticeable difference in this parameter was observed, with a mean value of about 26.0 hours (range 25.5–26.4 hours).",3585965
1277,3585965,the rate and extent of absorption of GLPG0259,GLPG0259 and methotrexate,GLPG0259 ,No significant difference,"Regarding GLPG0259, co-administration of methotrexate 7.5 mg did not significantly alter the rate and extent of absorption of GLPG0259, with point estimates for Cmax and AUC24h of 102.67% and 102.11%, respectively.",3585965
1278,3585965,the rate of absorption of methotrexate,GLPG0259 and methotrexate,GLPG0259 ,No significant difference,"When methotrexate was co-administered with GLPG0259 50 mg, the rate of absorption of methotrexate was slightly but not statistically significantly decreased, with a point estimate for Cmax of 89.63% (figure 3, table IV).",3585965
1279,5928476,bulk-fill composite resins’ bond strengths,SureFil SDR or EverX Posterior bulk-fill composite resins’ bond,ProRoot MTA or Biodentine calcium silicate cements,Significantly increased,The mean and standard deviation values of the tested materials obtained from the push-out bond strength test are presented in Table 2. SDR (4.10 ± 0.88) and EXP (3.86 ± 0.72) bulk-fill composite resins’ bond strengths were significantly higher than those of ProRoot MTA (2.29 ± 0.43) and BD (3.20 ± 0.49) calcium silicate cements (P&lt;0.05).,5928476
1280,5928476,bulk-fill composite resin values and calcium silicate cement values,SureFil SDR or EverX Posterior bulk-fill composite resins’ bond,ProRoot MTA or Biodentine calcium silicate cements,No significant difference,"However, there were no significant differences between bulk-fill composite resin values and calcium silicate cement values (P&gt;0.05).",5928476
1281,4132637,The incidence of the primary composite endpoint,ticagrelor,clopidogrel,Significantly decreased,"The incidence of the primary composite endpoint was reduced with ticagrelor vs. clopidogrel (10.0 vs. 12.3%; HR 0.83; 95% CI = 0.74–0.93; P = 0.0013) (see Supplementary material online, Figure S1A).",4132637
1282,4132637,Cardiovascular death,ticagrelor,clopidogrel,Significantly decreased,"Cardiovascular death occurred less often in the ticagrelor group than in the clopidogrel group (3.7 vs. 4.9%; HR 0.77; 95% CI = 0.64–0.93; P = 0.0070),",4132637
1283,4132637,myocardial infarction,ticagrelor,clopidogrel,Significantly decreased,"myocardial infarction was also less common with ticagrelor vs. clopidogrel (6.6 vs. 7.7%; HR 0.86; 95% CI = 0.74–0.99; P = 0.0419),",4132637
1284,4132637,stroke incidence,ticagrelor,clopidogrel,No significant difference,whereas stroke incidence did not differ significantly between treatment arms (1.3 vs. 1.4%; HR 0.95; 95% CI 0.69–1.33; P = 0.79).,4132637
1285,4132637,All-cause death,ticagrelor,clopidogrel,Significantly decreased,"All-cause death was reduced in those treated with ticagrelor vs. clopidogrel (4.3 vs. 5.8%; HR 0.76; 95% CI = 0.64–0.90; P = 0.0020) (see Supplementary material online, Figure S1B).",4132637
1286,4132637,major bleeding,ticagrelor,clopidogrel,No significant difference,"With ticagrelor when compared with clopidogrel, there was no significant difference in PLATO major bleeding (13.4 vs. 12.6%; HR 1.07; 95% CI = 0.95–1.19; P = 0.26),",4132637
1287,4132637,non-CABG-related major bleeding,ticagrelor,clopidogrel,Significantly increased,"higher rate of non-CABG-related major bleeding (4.8 vs. 3.8%; HR 1.28; 95% CI = 1.05–1.56; P = 0.0139) (see Supplementary material online, Figure S2A and B).",4132637
1288,4132637,the rate of life-threatening or fatal bleeding or the rate of intracranial bleeding,ticagrelor,clopidogrel,No significant difference,"There was no significant difference in the rate of life-threatening or fatal bleeding (6.6 vs. 6.5%; HR 1.05; 95% CI = 0.90–1.22, P = 0.56), nor any significant difference in the rate of intracranial bleeding with ticagrelor compared with clopidogrel (0.3 vs. 0.2%; HR 2.01; 95% CI = 0.81–4.99; P = 0.13).",4132637
1289,4132637,The composite of major or minor bleeding (by PLATO criteria),ticagrelor,clopidogrel,Significantly increased,"The composite of major or minor bleeding (by PLATO criteria) occurred more often in the ticagrelor group (18.2 vs. 16.3%; HR 1.14; 95% CI = 1.03–1.25, P = 0.0078).",4132637
1290,4132637,major or minor bleeding (by TIMI criteria),ticagrelor,clopidogrel,No significant difference,"hen assessed by TIMI criteria, there was no significant difference in major or minor bleeding (13.2 vs. 12.3%; HR 1.08; 95% CI = 0.97–1.21; P = 0.16).",4132637
1291,5551214,the Aberrant Behaviour Checklist-Community Edition (ABC-C),horse riding intervention,control group,Significantly decreased,"There was a significant interaction effect between pre- to post-test change in Hyperactivity scores and the participant’s condition (F(1, 22) = 8.084, p = 0.009, r = 0.518). This signifies a large effect size, as it is above Cohen’s benchmark of 0.5. Whilst the control group had the same mean Hyperactivity scores at pre- and post-test (21), the intervention group’s mean score was significantly lower at post-test (22.3) than at pre-test (26.3) (Figure 2)",5551214
1292,5551214,"Childhood Autism Rating Scale, Second Edition (CARS2)",horse riding intervention,control group,Significantly decreased,"Whilst the control group had the same mean CARS2 scores at pre-test and post-test (42.61), the intervention group’s mean score was significantly lower at post-test (40.05) than at pre-test (40.95) (Figure 1).",5551214
1293,3636800,the total quantitative feedback score,completing 6 days of assessment (four sets of questions per day) with a native smartphone application,completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation,No significant difference,No significant difference was observed for the total quantitative feedback score when comparing the two delivery modalities.,3636800
1294,3636800,numbers of entries,completing 6 days of assessment (four sets of questions per day) with a native smartphone application,completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation,Significantly increased,"When controlling for order effect, participants completed significantly greater numbers of entries on the native smartphone application when compared to SMS text-only implementation (Tables 3 and 4).",3636800
1295,3636800,proportion of data points,completing 6 days of assessment (four sets of questions per day) with a native smartphone application,completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation,Significantly increased,"A greater proportion of data points were completed with the native smartphone application in comparison to the SMS text-only implementation (? = -.25, SE=.11, P=.02), which also took significantly less time to complete (? =.78, SE= .09, P&lt;.001).",3636800
1296,3901329,The prostate volumes,"an experimental arm with an extreme hypo-fractionated regimen (7?×?6.1 Gy?=?42.7 Gy given every other weekday, and always including two weekends without RT)"," conventional fractionation (39?×?2.0 Gy?=?78.0 Gy given once a day, five days per week) ",Significantly increased,"The prostate volumes measured on the treatment-planning CT averaged 23% larger than those delineated on the baseline MRI (MRIbaseline). The difference was statistically significant, p?=?0.0001.",3901329
1297,5951568,Overall scores for anxiety,provided with written information about the electrodiagnostic testing,control,Significantly decreased,Overall scores for anxiety in the NCS cohort were found to be significantly lower (p = 0.04) in the intervention group (14.53±2.44mm) than in the non-intervention group (21.28±2.86mm; Fig 2).,5951568
1298,5951568,Overall pain scores,provided with written information about the electrodiagnostic testing,control,No significant difference,Overall pain scores between the intervention (20.91±2.33mm) and non-intervention group (25.30±2.44mm) in the NCS cohort did not differ significantly (p = 0.15).,5951568
1299,5951568,the perceived pain  or anxiety levels,provided with written information about the electrodiagnostic testing,control,No significant difference,No significant differences in the perceived pain (p = 0.34) or anxiety (p = 0.65) levels were demonstrated for the intervention and non-intervention groups in the subgroup of patients that underwent needle EMG testing.,5951568
1300,5951568,levels of pain,provided with written information about the electrodiagnostic testing,control,Significantly decreased,Those who received information had significantly lower levels of pain (13.75±2.71mm) compared to those that did not (54.63±13.37mm) (Figs 4 and 5).,5951568
1301,3924124,CD4/8,"2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks",received only general health guidance.,Significantly increased,"Significant (P &lt; 0.05) interaction was observed for the secondary outcome measure CD4/8, which was used to represent participants' immunological function. Related to this result, significant (P &lt; 0.05) interaction was found between groups for CD4+ and CD8+.",3924124
1302,3924124,Rates of intervention attendance for the high and low attendance groups,"2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks",received only general health guidance.,Significantly increased,"Rates of intervention attendance for the high and low attendance groups were 57.0 ± 22.3% and 8.3 ± 9.4%, respectively, and were significantly different (P &lt; 0.001). Participants who performed their individualized programs attended the classroom more frequently.",3924124
1303,5451423,"Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf",empagliflozin after administration to German subjects,empagliflozin after administration to Egyptian volunteers,No significant difference,"*Studied groups from pharmacokinetic studies conducted in white German subjects using 25?mg EG13, 15, 20, 38 showed no significant difference at P?&gt;?0.05, with P?=?0.283 for Cmax and P?=?0.064 for AUC0-inf.",5451423
1304,5451423,"Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf",empagliflozin after administration to Japanese and Chinese subjects,empagliflozin after administration to Egyptian volunteers,No significant difference,"*Studied groups from pharmacokinetic studies conducted in Japanese11 and Chinese9 subjects using 25?mg empagliflozin showed no significant difference at P?&gt;?0.05, with P?=?0.651 for Cmax and P?=?0.891 for AUC0-inf.",5451423
1305,3596913,progression-free survival and overall survival,"receive FU 500 mg/m2 IV bolus weekly ×6 weeks plus leucovorin 500?mg/m2 IV weekly for 6 weeks during each 8-week cycle plus oxaliplatin 85?mg/m2 IV on weeks 1, 3, and 5 of each 8-week (FLOX) ","receive weekly intravenous infusions of oxaliplatin 40?mg/m2, 5-FU 500 mg/m2, and leucovorin 250?mg/m2 (3 weeks on, 1 week off)",No significant difference,"There was no statistical significance in progression-free survival between the 2 regimens (P value by log rank test = .4619), and so was the situation in overall survival (P-value by log rank test = .5248).",3596913
1306,5789132,The mean pain score using FRS scale,receive the injection with diabetic needle, receive the injection with conventional syringe,Significantly decreased,"The mean pain score using FRS scale for 26 gauge conventional syringe was found to be 3.25, whereas mean pain score for 30 gauge insulin syringe was found to be 1.35 (Table 1). The mean difference found was statistically significant (p = 0.05).",5789132
1307,5789132,The mean SEM score,receive the injection with diabetic needle, receive the injection with conventional syringe,Significantly decreased,he mean SEM score in patients receiving LA with conventional syringe was found to be 2.47 and for patients receiving LA with insulin syringe was 1.48. The mean difference was statistically significant.,5789132
1308,5789132,The mean pain score and mean SEM scores in female patients,receive the injection with diabetic needle, receive the injection with conventional syringe,Significantly decreased,The mean pain score in female patients using conventional syringe was 3.40 and score using insulin syringe was 1.40 (Table 3). The difference was statistically significant. The mean SEM scores in female patients receiving LA with conventional and insulin syringe were 2.59 and 1.55 respectively. The difference was statistically significant.,5789132
1309,3258678,Clinical Dementia Rating – Sum of Boxes (CDR-SB),78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID,78-week treatment with placebo,No significant difference,The adjusted model for CDR-SB revealed no significant treatment effect (G × V interaction: P = 0.505).,3258678
1310,3258678,hippocampus volume (HV) change,78-week treatment with tramiprosate 150 mg BID,78-week treatment with placebo,Significantly decreased,"Compared to Placebo, the 100 mg BID group showed no volume change difference (P = 0.782), while a trend toward greater HV decrease was observed in the 150 mg BID group (P = 0.056).",3258678
1311,3258678,adverse effects,78-week treatment with tramiprosate 100 mg ,78-week treatment with placebo,No significant difference,"owever, the incidence of these AEs in the 100 mg BID group was not statistically different from placebo.",3258678
1312,3258678,Alzheimer Disease Assessment Scale – cognitive subscale (ADAS-cog),78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID,78-week treatment with placebo,No significant difference,The ADAS-cog adjusted model revealed a statistical trend for treatment effect in favour of the two tramiprosate groups (G × V interaction: P = 0.098) while post-hoc planned contrasts showed lower changes from Baseline relative to placebo in the 100 mg BID group at Week 26 (P = 0.065) and Week 52 (P = 0.090).,3258678
1313,5873424,total sleep time,paracetamol/buprenorphine,placebo tablets,Significantly increased,"In addition, TST improved significantly for the active treatment group compared with the placebo group (see Table 3).",5873424
1314,5873424,"sleep efficiency (SE), sleep onset latency (SOL), early morning awakening (EMA)",paracetamol/buprenorphine,placebo tablets,Significantly increased,"In the intervention group (paracetamol/buprenorphine), SE (70%?72%), SOL (32?24 min), and EMA (50?40 min) improved compared with the control group (SE, 70%?67%; SOL, 47?60 min; EMA, 31?35 min). Treatment effects were significant (P &lt; .01, P &lt; .05, and P &lt; .05, respectively).",5873424
1315,4124480,total weight lifted,12-weeks of progressive endurance and strength training at a local health club,continuation of unsupervised habitual physical activity,Significantly increased,Patients who participated in the CBE arm lifted significantly more weight at the end of the exercise program compared with the beginning as shown in Figure 3: 3432 versus 1775 kilograms (P?&lt;?0.001).,4124480
1316,4124480,TDI focal score,12-weeks of progressive endurance and strength training at a local health club,continuation of unsupervised habitual physical activity,Significantly increased,"TDI focal score, shown in Figure 5, increased by 5.1 in the CBE group versus a decrease of 0.2 in the control group, indicating less breathlessness (P?&lt;?0.001).",4124480
1317,4124480,Mean treadmill endurance times,12-weeks of progressive endurance and strength training at a local health club,continuation of unsupervised habitual physical activity,Significantly increased,Mean treadmill endurance times for the two groups at baseline and after 12 weeks. Mean changes were a decrease of 59 seconds for the control group compared with an increase of 134 seconds for those completing the community-based exercise program (P?=?0.041).,4124480
1318,4124480,Mean SGRQ scores,12-weeks of progressive endurance and strength training at a local health club,continuation of unsupervised habitual physical activity,Significantly decreased,Mean SGRQ scores for the two groups at baseline and after 12 weeks. Mean changes were a decrease of 0.7 for the control group and a decrease of 4.6 for those completing the community-based exercise program (P?=?0.611). Decreased scores represent improvement in quality of life where a change of 4.0 is considered clinically meaningful.,4124480
1319,5494586,glucose incremental peaks,"3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream)",50?g OGTT  (A),Significantly decreased,"the repeated measures ANOVA with Greenhouse-Geisser correction resulted significant (p &lt; 0.001) and the Tukey-Kramer post hoc test revealed that B1 (36.2?±?3.8?mg/dL), B2 (19.6?±?2.9?mg/dL), and B3 (27.3?±?4.0?mg/dL) had significantly smaller glucose incremental peaks than A (55.9?±?6.1?mg/dL) with p values associated to such post hoc comparisons that were p = 0.04, p &lt; 0.001, and p = 0.002, respectively.",5494586
1320,5494586, insulin excursions ,"3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream)",50?g OGTT  (A),Significantly decreased,"All three commercial breakfasts showed somewhat smaller insulin excursions with respect to the one elicited by glucose administration (Figure 2(a), 2(b), and 2(c)). As for the comparison among the insulinemic AUC values (Figure 2(d)), the repeated measures ANOVA was significant (p &lt; 0.001) (without requiring any correction for the sphericity condition) and the Tukey-Kramer post hoc test showed that both B1 and B2 had smaller insulin AUCs than A (p = 0.002 and p = 0.016, resp.).",5494586
1321,5494586,the 2-hour plasma ghrelin,"3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream)",50?g OGTT  (A),No significant difference,"After glucose/breakfast ingestion, the 2-hour plasma ghrelin attained the lowest level in B3 (332.1?±?30.2?pg/mL), but the decrement with respect to A (420.6?±?44.2?pg/mL) did not achieve the statistical significance (Figure 3(c)).",5494586
1322,5494586,P300 latency incremental values,"B3: milk, apple, bread, and hazelnut chocolate cream",50?g OGTT  (A),Significantly decreased,"The repeated measures ANOVA with Greenhouse-Geisser correction was significant (p &lt; 0.01) and the Tukey-Kramer post hoc test showed that the only significant difference among means was the one between breakfast B3 and glucose (?33.6?±?5.9?ms versus 9.7?±?6.6?ms, p &lt; 0.01).",5494586
1323,5236513,lower abdominal pain/discomfort scores at week 8,Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856,placebo,No significant difference,"At W8, lower abdominal pain/discomfort scores were reported in the Active group compared to Placebo but the difference did not achieve statistical significance (Active group: 2.14 ± 1.292 a.u., Placebo group: 2.31 ± 1.355 a.u., P = 0.1052).",5236513
1324,5236513,Bristol Stool Scale (BSS) score,Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856,placebo,Significantly increased,"There was a statistically significant increase in the Bristol Stool Scale (BSS) score between W0 and W8 in the Active group (2.41 ± 0.817 a.u. vs 3.13 ± 1.197 a.u., P &lt; 0.0001, diff[95%CI] = 0.752 [0.391;1.114]) and in the Placebo group (2.24 ± 0.714 a.u. vs 2.58 ± 1.020 a.u., P = 0.0266, diff[95%CI] = 0.402 [0.032;0.771]) (Figure 3).",5236513
1325,5236513,stool consistency,Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856,placebo,Significantly increased,"At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as “normal” compared to Placebo (respectively 3.13 ± 1.197 a.u. vs 2.58 ± 1.020 a.u., P = 0.0003).",5236513
1326,3478519,"total fat, FM%, and percentage of trunk fat",assigned to the high-protein diet who carried the AA genotype of FTO rs1558902,assigned to the high-protein diet without this genotype,Significantly decreased,"When assigned to the high-protein diet, participants who carried the AA genotype had greater loss in total fat, FM%, and percentage of trunk fat than those without this genotype.",3478519
1327,3478519,"total fat, FM%, and percentage of trunk fat",assigned to the dietary fat components who carried the AA genotype of FTO rs1558902,assigned to the dietary fat components without this genotype,No significant difference,We did not find significant genetic effects and interactions on changes in fat distribution in subgroups treated by different dietary fat components (all P &gt; 0.05; Supplementary Table 2 and Supplementary Fig. 2).Similar results were found in the white participants (data not shown).,3478519
1328,4716419,Death and serious infections,enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months, intravenous cyclophosphamide (CYC) 0.5–1?g/m2 monthly,Significantly decreased,"The percentage of serious fatal and non-fatal infections was, however, higher in the CYC group (15.63% vs 3.7%, the per cent difference adjusted for baseline proteinuria 13.35 (95% CI 0.3 to 26.4), p=0.04).",4716419
1329,4716419,The early discontinuation rates,enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months, intravenous cyclophosphamide (CYC) 0.5–1?g/m2 monthly,Significantly decreased,"Of note, the adjusted rate of discontinuation within 6?months was significantly higher in the CYC group (per cent difference 16.90, 95% CI 1.3 to 32.4, p=0.03; adjusted for baseline proteinuria and eGFR).",4716419
1330,4716419,complete and partial remission rates and times to remission,enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months, intravenous cyclophosphamide (CYC) 0.5–1?g/m2 monthly,No significant difference,"At the 12th month, both arms were comparable in terms of complete and partial remission rates (68% CYC and 71% EC-MPS) and times to remission (96?days CYC and 97?days EC-MPS).",4716419
1331,4716419,"Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment)",enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months, intravenous cyclophosphamide (CYC) 0.5–1?g/m2 monthly,No significant difference,"Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment) were 46.9% and 37% in CYC and EC-MPS (risk difference=9.84; p=0.44).",4716419
1332,3917204,"Probing depth (PD), Gingival recession (GR),  Clinical attachment level (CAL)",received treatment with rotary instruments,received scaling and root planing with hand instruments,No significant difference,"At deep pocket site (initial PD &gt; 6 mm), in the rotary instrument group, PD reduced from 7.2 ± 1.5 to 6.5 ± 1.8 and in the Gracey curette group, it reduced from 6.7 ± 0.9 to 5.4 ± 1.8. But while comparing these two groups, the results were statistically nonsignificant. Similarly, other clinical parameters like GR and CAL gave statistically nonsignificant results [Table 3].",3917204
1333,3917204,Clinical improvement in multi-rooted teeth ,received treatment with rotary instruments,received scaling and root planing with hand instruments,No significant difference,"In the rotary instrument group, 256 multi-rooted teeth and in the Gracey curette group, 302 multi-rooted teeth were treated. Clinical improvement was noticed in both moderately deep pocket sites and deep pocket areas. But comparison of groups showed them to be statistically nonsignificant [Tables 4 and 5].",3917204
1334,5673730,newborns weight,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,When fetal outcomes were evaluated the babies of Group-B were significantly more in weight as compared to Group-A (p=0.01).,5673730
1335,5673730,numbers of babies were delivered after 38 weeks of pregnancy,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,Significant numbers of babies were delivered after 38 weeks of pregnancy in Group-B (P=0.021).,5673730
1336,5673730,HbA1C,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,There were two intrauterine deaths and significantly higher HbA1C at term in Group-B. (P=0.03).,5673730
1337,5673730,fasting blood sugar (FBS) at term ,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),No significant difference,FBS at term was non-significant (p=0.079),5673730
1338,5673730,number of cesarean sections due to feto-maternal disproportion,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,here was more number of cesarean sections due to feto-maternal disproportion in Group-B (28% vs.2%).,5673730
1339,5673730,glycemic control before and after the treatment,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,Results analyzed for glycemic control before and after the treatment revealed that FBS was statistically less in Group-A (p=0.00) whereas for Group-B the value of FBS and HbA1C was statistically high. (p=0.002 &amp; 0.04 respectively).,5673730
1340,4012222,Global performance status and STS,lower limb neuromuscular electrical stimulation (NMES) applied daily to both quadriceps muscles for six weeks.,baseline,No significant difference,"Global performance status and STS appeared somewhat better, but these changes did not achieve statistical significance (Fisher’s exact test p =?0.15 comparing categories of PS; mean reduction in STS?=??1.2s, P?=?0.3).",4012222
1341,5320660,peptide YY [PYY],muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),Significantly increased,"At baseline, total PYY concentrations were significantly higher 120 min following the consumption of study muffins in the HAM-RS2 group than control group (P?=?0.043).",5320660
1342,5320660,"glucose, AUC leptin, and postprandial 120-min leptin",muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),Significantly decreased,"However, a significant within-group decrease in both AUC glucose (P?=?0.028) and AUC leptin (P?=?0.022) was observed from baseline to week 6 in the HAM-RS2 group.",5320660
1343,5320660,Mean overall satiety score,muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),No significant difference,Mean overall satiety score did not differ within or between groups (P?=?0.230).,5320660
1344,5320660,The mean score for the question “how full do you feel?”,muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),Significantly increased,The mean score for the question “how full do you feel?” in the HAM-RS2 group increased from baseline to the end of the study and approached significance (P?=?0.058) (data not shown).,5320660
1345,5320660,body composition,muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),No significant difference,Consuming muffins with HAM-RS2 did not significantly change body composition.,5320660
1346,5628593,Maximal voluntary isometric contraction,30-Hz whole-body vibration training,50-Hz whole-body vibration training,Significantly increased,"In the 30-Hz group, there was a significant increase in the maximal voluntary isometric contraction (p=0.039)",5628593
1347,5628593,Concentric peak torque of knee extensors,30-Hz whole-body vibration training,50-Hz whole-body vibration training,Significantly increased,"a statistically significant increase has occurred in the concentric peak torque of knee extensors in the 30-Hz (+13.6%; p&lt;0.001) group, while not in the 50-Hz (+2.1%; p=0.605) group. When the groups were compared, there was a significant (p=0.018) difference between the two groups in terms of improvements in the concentric peak torque.",5628593
1348,5628593,Eccentric peak torque of knee extensors,30-Hz whole-body vibration training,50-Hz whole-body vibration training,No significant difference,"In addition, the eccentric peak torque of knee extensors was increased significantly in both groups (p&lt;0.05); however, there was no significant difference between the two groups (p=0.873).",5628593
1349,5628593,Attendance rates,30-Hz whole-body vibration training,50-Hz whole-body vibration training,No significant difference,No significant difference existed between the two groups in the attendance rates (p=0.286).,5628593
1350,5820389,Number of absence days due to sickness at 6 months,Inpatient program,Outpatient program,No significant difference,"The median number of sickness absence days (work days) at 6&nbsp;months after inclusion was 58 (IQR 37â€“92) for the inpatient program and 51 (IQR 32â€“85) for the outpatient program. The difference was not statistically significant (Mannâ€“Whitney U test, pâ€‰=â€‰0.284).",5820389
1351,5820389,Sustainable return to work,Inpatient program,Outpatient program,No significant difference,"In the outpatient program 57% of the participants achieved sustainable return to work (median time 7&nbsp;months), in the inpatient program 49% (log rank, pâ€‰=â€‰0.167). The hazard ratio for sustainable return to work was 0.74 (95% CI 0.48â€“1.32, pâ€‰=â€‰0.165), in favor of the outpatient program.",5820389
1352,5820389,Number of absence days due to sickness at 12 months,Inpatient program,Outpatient program,No significant difference,"For the 12&nbsp;months follow-up, the median number of sickness absence days was 114 (IQR 46â€“172) for the inpatient program and 96 (IQR 35â€“175) for the outpatient program (Fig.&nbsp;2). The difference was not statistically significant (Mannâ€“Whitney U test, pâ€‰=â€‰0.403).",5820389
1353,3179725,Patient adherence,Active chest wall oscillation treatment,Sham chest wall oscillation treatment,No significant difference,Patient adherence was similarly high in both groups (91% vs. 93%; p = 0.70).,3179725
1354,3179725,Patient satisfaction,Active chest wall oscillation treatment,Sham chest wall oscillation treatment,No significant difference,"Satisfaction with study treatment was also high, even in the sham HFCWO group (active vs. sham HFCWO: comfortable, 88% vs. 92%, p = 0.67; feel better, 80% vs. 85%, p = 0.73).",3179725
1355,3179725,Dyspnea improvement,Active chest wall oscillation treatment,Sham chest wall oscillation treatment,Significantly increased,"After four treatments, a higher proportion of patients in the active treatment group had a clinically significant improvement in dyspnea (70.8% vs. 42.3%, p = 0.04).",3179725
1356,3179725,"Secondary outcomes including spontaneously expectorated sputum volume, and forced expired volume in 1 second",Active chest wall oscillation treatment,Sham chest wall oscillation treatment,No significant difference,There were no significant differences in other secondary outcomes.,3179725
1357,3403961,ECBI Intensity scale after treatment,Parentâ€“Child Interaction Therapy,Non-Clinical Group,No significant difference,"When the clinical group mothers were compared with the non-clinical group mothers on the ECBI Intensity scale at post treatment, no significant differences were found between the groups.",3403961
1358,3403961,ECBI Problem Scale after treatment,Parentâ€“Child Interaction Therapy,Non-Clinical Group,Significantly increased,"mothers in the clinical group continued to view their childâ€™s behaviour as significantly more problematic (ECBI Problem Scale; t (81)â€‰=â€‰2.21, pâ€‰&lt;â€‰.05) than mothers in the non-clinical comparison group.",3403961
1359,3842830,Daily OFF time,Istradefylline 20 mg or 40 mg,Placebo,Significantly decreased,"The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (âˆ’0.99 hours, Pâ€‰=â€‰.003) and istradefylline 40 mg/day (âˆ’0.96 hours, Pâ€‰=â€‰.003) groups compared with the placebo group (âˆ’0.23 hours).",3842830
1360,3842830,Secondary efficacy variables,Istradefylline 20 mg or 40 mg,Placebo,No significant difference,No differences were observed among the groups for other secondary efficacy variables.,3842830
1361,3842830,Daily OFF time,Istradefylline 20 mg,Istradefylline 40 mg,No significant difference,"The changes from baseline at the end point for daily OFF time for placebo, istradefylline 20 mg/day, and istradefylline 40 mg/day were âˆ’0.23, âˆ’0.99 (Pâ€‰=â€‰.003), and âˆ’0.96 (Pâ€‰=â€‰.003) hours, respectively. The differences from the placebo were significant, but there were no difference between the 2 groups.",3842830
1362,3842830,Daily ON time with problematic dyskinesia,Istradefylline 20 mg,Istradefylline 40 mg,No significant difference,Neither istradefylline 20 mg/day nor istradefylline 40 mg/day increased daily ON time with troublesome dyskinesia.,3842830
1363,4365564,Major neurological complications,CharitÃ© artificial disc,ALIF with BAK cages,No significant difference,"The rate of major neurological complications was similar between the 2 groups (investigational = 4.4%, control = 4.0%)",4365564
1364,4365564,Complications related to approach method,CharitÃ© artificial disc,ALIF with BAK cages,No significant difference,"The rate of approach-related complications in all 304 patients was 9.9% (30/304) and was similar between the 2 groups, with 9.8% (20/205) in the investigational group and 10.1% (10/99) in the control group",4365564
1365,4365564,Rate of superficial wound infection,CharitÃ© artificial disc,ALIF with BAK cages,No significant difference,"The rate of superficial wound infection was 3 times higher in the investigational group (6.3%) compared with the control group (2.0%), but there was no significant difference between the groups (P = .103)",4365564
1366,5311860,Effective use of syndromic alerts after 1 year,Standardized aberrant event detection algorithm and response protocol,Pre-existing syndromic surveillance infrastructure and processes,No significant difference,"Despite efforts to create standardized protocols and engage public health agencies in the process, no significant differences in the effective use of syndromic alerts were observed beyond year 1.",5311860
1367,5311860,Generated alerts,Standardized aberrant event detection algorithm and response protocol,Pre-existing syndromic surveillance infrastructure and processes,No significant difference,No difference was observed between study generated alerts and those generated by their systems.,5311860
1368,5311860,Alert response during the first year,Standardized aberrant event detection algorithm and response protocol,Pre-existing syndromic surveillance infrastructure and processes,Significantly decreased,The effect of the intervention was more pronounced in year 1 with large LPHAs in the intervention group showing fewer responses to the alerts than control LPHAs.,5311860
1369,5311860,"All responses, excluding â€˜watchful waitingâ€™",Standardized aberrant event detection algorithm and response protocol,Pre-existing syndromic surveillance infrastructure and processes,No significant difference,"Using a direct test for statistical interaction, only the outcome of â€œall responses other than â€˜watchful waitingâ€™â€? had no statistical interaction to the year of the study (pâ€‰=â€‰0.86).",5311860
1370,5285426,Urological function scores in females,Robotic surgery,Laparoscopic surgery,No significant difference,"In females, there was no difference between the two groups in any of the components of urological or sexual function.",5285426
1371,5285426,Baseline rectal cancer diagnosis,Robotic surgery,Laparoscopic surgery,Significantly decreased,patients in the robotic group had lower rectal cancers (p&nbsp;=&nbsp;0.032),5285426
1372,5285426,Male sexual function scores,Robotic surgery,Laparoscopic surgery,Significantly increased,Mean scores deteriorated across all component of MSF in the laparoscopic group but none in the robotic group. Statistical comparison of the mean change of MSF scores from baseline revealed favourable outcomes for the robotic group across all four components of MSF as shown in Table 4. Composite MSF score change was also better in the robotic group,5285426
1373,5285426,Sexual function scores in females,Robotic surgery,Laparoscopic surgery,No significant difference,"Overall, there was no statistical difference between the mean change of scores from baseline between the two groups in any of the FSF components or the FSF composite scores.",5285426
1374,3628658,Hospital stay,Lateral decubitus position,Supine position,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.",3628658
1375,3628658,Loss of blood during surgery,Lateral decubitus position,Supine position,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.",3628658
1376,3628658,Incision lenght,Lateral decubitus position,Supine position,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.",3628658
1377,3628658,Surgery time,Lateral decubitus position,Supine position,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.",3628658
1378,3628658,Harris hip values and union time of fractures,Lateral decubitus position,Supine position,No significant difference,"After treatment for 12 weeks, the Harris hip score and average union time of fractures were not statistically different between the two groups.",3628658
1379,4659198,Defecation frequency after 3 days,Phototherapy plus massage,Phototherapy only,Significantly increased,"On the third day, the massage group showed significantly higher defecation frequency (pâ€‰=â€‰0.045)",4659198
1380,4659198,Bilirubin levels after 3 days,Phototherapy plus massage,Phototherapy only,Significantly decreased,"On the third day, the massage group showed significantly higher defecation frequency (pâ€‰=â€‰0.045) and significantly lower bilirubin levels (pâ€‰=â€‰0.03) compared with the control group",4659198
1381,4659198,Total food intake,Phototherapy plus massage,Phototherapy only,No significant difference,"For all participating neonates, food intake increased through hospitalization. In both groups, food intake was significantly higher on the second and third days of hospitalization than on the first day (pâ€‰&lt;â€‰0.001). However, no significant difference was observed between the groups during hospitalization",4659198
1382,4659198,Body weight,Phototherapy plus massage,Phototherapy only,No significant difference,"The body weights of all neonates increased through hospitalization, with the body weight being significantly higher on the third than on the first day of hospitalization (pâ€‰=â€‰0.03). However, there was no significant difference between the groups",4659198
1383,4659198,Baseline medical characteristics,Phototherapy plus massage,Phototherapy only,No significant difference,"Table&nbsp;1 shows the medical characteristics of participating neonates. We observed no significant differences between the two groups in terms of type of feeding, gestational age at birth, body weight at birth, body weight on the date of admission, phototherapy duration, or physical weight loss.",4659198
1384,3464379,Plateletâ€“monocyte conjugation,N-acetylcysteine,Placebo,Significantly decreased,Plateletâ€“monocyte conjugation was significantly inhibited in patients at 2 h after administration of NAC (conjugated monocytes reduced from 53.1â€‰Â±â€‰4.5 to 42.5â€‰Â±â€‰3.9% of monocyte population: pâ€‰=â€‰0.011; Fig.&nbsp;2a); no significant effect was seen in the equivalent results from the placebo arm of the study (pâ€‰&gt;â€‰0.05; Fig.&nbsp;2b).,3464379
1385,3464379,Adverse events,N-acetylcysteine,Placebo,No significant difference,There were no adverse events.,3464379
1386,3464379,Microparticles count,N-acetylcysteine,Placebo,Significantly decreased,"There was a significant increase in microparticle count at 2&nbsp;h in the placebo arm of the study (pâ€‰=â€‰0.047 by paired Studentâ€™s t test) but a trend towards a reduction (pâ€‰=â€‰0.09) in the NAC arm (nâ€‰=â€‰14). Over a 7 day dosing period (c), there was a significant inhibition of microparticle count between NAC and placebo (black bars, NAC; white bars, placebo: pâ€‰=â€‰0.016 for NAC vs placebo; nâ€‰=â€‰13 by repeated measures two-way ANOVA)",3464379
1387,3464379,Plasma PAI-1,N-acetylcysteine,Placebo,No significant difference,There was no significant effect of NAC or placebo on plasma PAI-1 antigen or activity at either 2&nbsp;h after the first dose or after 7&nbsp;days of oral dosing (pâ€‰&gt;â€‰0.05).,3464379
1388,3464379,Intraplatelet tGSH,N-acetylcysteine,Placebo,No significant difference,Intraplatelet tGSH was not significantly altered in either the NAC or placebo arms of the study at +2&nbsp;h,3464379
1389,4599543,clotting time,received fibrinogen concentrate,received saline solution (placebo),Significantly decreased,"After dosing, there was a significant (P=0.001) shortening of clotting time at the EXTEM in the treatment arm and no changes in the control arm.",4599543
1390,4599543,clot firmness,received fibrinogen concentrate,received saline solution (placebo),Significantly increased,"Patients in the treatment arm demonstrated a significant increase in clot firmness both at EXTEM and FIBTEM, whereas patients in the control arm did not.",4599543
1391,4599543,levels of fibrinogen,received fibrinogen concentrate,received saline solution (placebo),Significantly increased,"At the arrival in the ICU, patients in the treatment arm had significantly higher levels of fibrinogen, as measured by the central laboratory.",4599543
1392,4599543,free from any allogeneic blood product transfusions,received fibrinogen concentrate,received saline solution (placebo),Significantly increased,"During hospital stay, 39 (67.2%) patients in the treatment arm were free from any allogeneic blood product transfusions, a significantly (P=0.012) higher rate than those in the control arm (44.8%).",4599543
1393,4599543,postoperative bleeding,received fibrinogen concentrate,received saline solution (placebo),Significantly decreased,"Among the secondary endpoints, postoperative bleeding, as recorded from chest drains during the first 12 postoperative hours, was significantly lower in the treatment arm, and the total amount of PRCs, FFP, and PLT used during hospital stay was significantly lower.",4599543
1394,5724392,transcranial Doppler (TCD) flow velocities,hydroxyurea,transfusions,No significant difference,"The final model-based TCD velocities (mean Â± standard error) on the Standard Arm versus Alternative Arm were 143 Â± 1.6 and 138 Â± 1.6 cm/sec, respectively, with difference (95% CI) = 4.54 (0.10, 8.98), non-inferiority p=8.82 Ã— 10âˆ’16 and a post-hoc superiority p=0.023. The planned per-protocol analysis excluding study participants who exited the study early showed almost identical findings, with difference = 5.06 (0.56, 9.57), non-inferiority p=1.05 Ã— 10âˆ’15 and a post-hoc superiority p=0.015. An age-adjusted analysis gave almost identical findings (not shown).",5724392
1395,5724392,Iron burden,phlebotomy (Alternative Arm) ,chelation (Standard Arm),Significantly decreased,"Iron burden decreased more in the Alternative Arm, with ferritin difference âˆ’1047 ng/mL (âˆ’1524, âˆ’570), p&lt;0.001 and liver iron difference âˆ’4.3 mg Fe/gm dry weight (âˆ’6.1, âˆ’2.5), p=0.001.",5724392
1396,5228669,"intraoperative estimated blood loss, postoperative drainage, total blood loss",receiving a loading dose of 30â€Šmg/kg Tranexamic acid over 15â€Šminutes before skin incision followed by a maintenance infusion of TA (2â€Šmg/kg/h) were continued until skin closure in the TA group.,Equivalent normal saline was administered in the placebo group.,Significantly decreased,"However, intraoperative estimated blood loss (170â€ŠÂ±â€Š153â€ŠmL vs 255â€ŠÂ±â€Š188â€ŠmL, Pâ€Š=â€Š0.016), postoperative drainage (145â€ŠÂ±â€Š84â€ŠmL vs 281â€ŠÂ±â€Š165â€ŠmL, Pâ€Šâ‰¤â€Š0.001), and total blood loss (315â€ŠÂ±â€Š205â€ŠmL vs 536â€ŠÂ±â€Š261â€ŠmL, Pâ€Š&lt;â€Š0.001) were significantly different between the TA and placebo groups (Fig. 2).",5228669
1397,3456942,"response rate (RR), disease control rate (DCR), progression-free survival (PFS)",oxaliplatin (FOLFOX) plus bevacizumab ,irinotecan (FOLFIRI) plus bevacizumab ,Significantly increased,"In the first-line setting, 47 patients treated with mFOLFOX6 plus bevacizumab achieved RR of 61.7 %, DCR of 89.4 %, and median PFS of 13.1 months (95 % CI, 8.7â€“17.5 months). Thirty-one patients went on to receive a second-line therapy with FOLFIRI plus bevacizumab and achieved RR of 27.6 %, DCR of 62.1 %, and median PFS of 7.3 months (95 % CI, 5.0â€“9.6 months). Median 2nd PFS was 18.0 months (95 % CI, 13.7â€“22.3 months).",3456942
1398,5766333,The percentage of patients who showed restlessness ,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),No significant difference,"The percentage of patients who showed restlessness was lower in the Combination group than in the PF group; however, there was no statistically significant difference between the two groups (6.9â€Š% vs. 24.1â€Š%, P â€Š=â€Š0.144).",5766333
1399,5766333,The satisfaction scores,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly increased,"The satisfaction scores of both the endoscopists and the sedation providers were significantly higher in the Combination group than in the PF group (88 [6â€Šâ€“â€Š100] mm vs. 69 [31â€Šâ€“â€Š96] mm, P â€Š=â€Š0.003, and 95 [24â€Šâ€“â€Š100] mm vs. 67 [15â€Šâ€“â€Š93] mm, P â€Š&lt;â€Š0.001, respectively, median [range]).",5766333
1400,5766333,incidence of hypoxemia,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),No significant difference,"Although the minimum percutaneous oxygen saturation level was statistically higher in the Combination group than in the PF group (96 [79â€Šâ€“â€Š99]% vs. 95 [68â€Šâ€“â€Š98]%, P â€Š=â€Š0.029, median [range]), there were no significant differences in the incidence of hypoxemia (defined as percutaneous oxygen saturation level â‰¤â€Š94â€Š%) between the two groups (24.1â€Š% vs. 34.5â€Š%, P â€Š=â€Š0.565).",5766333
1401,5766333,the minimum pulse rate,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly decreased,"On the other hand, the minimum pulse rate was significantly lower in the Combination group than in the PF group (47 [34â€Šâ€“â€Š61] bpm vs. 59 [36â€Šâ€“â€Š72] bpm, P â€Š&lt;â€Š0.001, median [range]),",5766333
1402,5766333,the incidence of bradycardia,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly increased,"and the incidence of bradycardia (defined as pulse rate â‰¤â€Š45â€Šbpm) was significantly higher in the Combination group than in the PF group (37.9â€Š% vs. 10.3â€Š%, P â€Š=â€Š0.029).",5766333
1403,5766333,The maintenance dose of PF,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly decreased,"The maintenance dose of PF was less in the Combination group than in the PF group (2 [2â€Šâ€“â€Š4] mg/kg/h vs. 5 [3â€Šâ€“â€Š7] mg/kg/h, P â€Š&lt;â€Š0.001,",5766333
1404,5766333,the number of times a rescue PF injection,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly decreased,"nd the number of times a rescue PF injection was needed was also fewer in the Combination group than in the PF group (2 [0â€Šâ€“â€Š16] times vs. 6 [3â€Šâ€“â€Š13] times, P â€Š&lt;â€Š0.001, median [range]).",5766333
1405,3106384,the heart rate and mean blood pressure 10 seconds after insertion,Proseal laryngeal mask airway (PLMA),endotracheal tube (ETT),Significantly decreased,"However, statistically significant (P&lt;0.05) increase in the heart rate and mean blood pressure in PLMA group was seen only 10 seconds after insertion [Figure 2].",3106384
1406,3106384,oxygen saturation (SpO2) or end-tidal carbon dioxide (EtCO2),Proseal laryngeal mask airway (PLMA),endotracheal tube (ETT),No significant difference,There were no statistically significant differences in oxygen saturation (SpO2) or end-tidal carbon dioxide (EtCO2) between the two groups before or during peritoneal insufflation.,3106384
1407,3106384,The PAP till 6 minutes after pneumoperitoneum was attained,Proseal laryngeal mask airway (PLMA),endotracheal tube (ETT),Significantly increased,"The PAP in group P showed a statistically significant (P&lt;0.05) increase in value after insertion till 6 minutes after pneumoperitoneum was attained, and thereafter it was insignificant.",3106384
1408,5578640,fentanyl dose after 1 month and 3 months,vitamin D 4000 IE/day,untreated (control),Significantly decreased,"The change in fentanyl dose between the groups was analyzed by linear regression with bias corrected and accelerated bootstrap and revealed a statistically significant difference already after 1 month; 46 Î¼g/h (95% CI 24â€“78 Î¼g/h), which increased even further at three months; 91 Î¼g/h (95% CI 56â€“140 Î¼g/h) (Tables 2 and 3, Fig 2A).",5578640
1409,5578640,ESAS QoL-score after three months,vitamin D 4000 IE/day,untreated (control),No significant difference,"A small improvement in the ESAS QoL-score (i.e. decrease in ESAS-score) among the vitamin D treated patients was observed after one month, eliminating the difference between the two groups; -1.4 (95% CI -2.6-(-0.21) (Tables 2 and 3, Fig 2B). After three months no further significant changes in either group were seen.",5578640
1410,5578640,infections after 3 months,vitamin D 4000 IE/day,untreated (control),Significantly decreased,"After 3 months of vitamin D supplementation a statistically significant mean difference between the groups with regards to infections could be observed, with lower values in the vitamin D treated group; -26% (95% CI -41%â€“(-12%)) (Tables 2 and 3, Fig 2C).",5578640
1411,5578640,25-OHD,vitamin D 4000 IE/day,untreated (control),Significantly increased,Follow-up monitoring of 25-OHD was performed after 3 months in 23 patients and showed a mean value of 73 nmol/L (SD 31) which was a significant increase from baseline as shown in Fig 3 (p&lt;0.0001).,5578640
1412,5578640,The ESAS QoL-score after 1 month,vitamin D 4000 IE/day,untreated (control),Significantly increased,The ESAS QoL-score improved in the Vitamin D group the first month; -1.4; 95% CI -2.6 - (-0.21).,5578640
1413,4092608,patients reached the target INR in the first hour after ending cardiopulmonary bypass (CPB),prothrombin complex concentrates (PCC),fresh frozen plasma,Significantly increased,"More patients in this group reached the target INR in the first hour after ending CPB (T7, P &lt; 0.007).",4092608
1414,4092608,received an additional dose of PPSB,prothrombin complex concentrates (PCC),fresh frozen plasma,Significantly decreased,In the FFP group 16/20 (80%) patients received an additional dose of PPSB vs 6/20 (30%) in the PCC group.,4092608
1415,4092608,factor II and factor X,prothrombin complex concentrates (PCC),fresh frozen plasma,Significantly increased,We found a significant difference between groups in factor II (P = 0.023) and factor X (P = 0.008) levels over time.,4092608
1416,5456350,wanted to receive a DEKA Arm,completers of in-laboratory (Part A) and home trial (Part B),completers of in-laboratory (Part A) only,Significantly increased,"At end of Part A, 22 (69%) of the 32 participants who completed in-laboratory training wanted to receive a DEKA Arm and 5 (16%) might want one. At end of Part B, 14 (88%) of 16 prosthesis users who completed the home trial preferred the overall function of the DEKA Arm, 13 (81%) preferred DEKA hand function and 14 (88%) preferred DEKA wrist function to their own prosthesis.",5456350
1417,5456350,scores of the DEKA Usability subscales,completers of in-laboratory (Part A) and home trial (Part B),completers of in-laboratory (Part A) only,No significant difference,There were no statistically significant differences in scores of the DEKA Usability subscales for participants who completed Parts A and B and those who completed only Part A (Table 5).,5456350
1418,5456350,The Overall subscale,completers of in-laboratory (Part A) and home trial (Part B),completers of in-laboratory (Part A) only,Significantly increased,The Overall subscale was rated significantly (p = 0.0165) higher by completers of Part B (mn 5.8) than non-completers (mn 5.0).,5456350
1419,5456350,rated the DEKA function and the external battery life,completers of in-laboratory (Part A) and home trial (Part B),completers of in-laboratory (Part A) only,Significantly increased,"Participants who completed Part B rated the DEKA function and the external battery life (mn 5.8, 5.8, 5.5) higher than those who did not complete Part B (mn 5.0; 4.7; 4.5, respectively).",5456350
1420,2361654,colposcopy referrals (sensitivity?),primary hrHPV screening,cytological screening,Significantly increased,"Compared with the conventional arm, clearly more colposcopy referrals were made in the hrHPV screening arm (RR 1.51, CI 95% 1.03â€“2.22). As a result of performed colposcopies, a total of 52 histologically confirmed precancerous lesions were detected within the study population: 33 in the hrHPV screening arm and 19 in the conventional arm.",2361654
1421,2361654,Specificity,primary hrHPV screening,cytological screening,Significantly decreased,"Specificity of the primary screening with sole hrHPV test (91.5â€“92.1%) was much lower than that with the cytology triage (98.7â€“99.3%), which was not quite as specific as screening with conventional cytology (99.2â€“99.6%).",2361654
1422,3814588,"cognitive, habitual behavioral, affective",problem based learning intervention or critical reading intervention,"no intervention (control group, which continued clinical practice as normal)",No significant difference,"In all three dimensions there were significant differences within the groups in the pre- versus post-intervention scores, yet no significant differences were observed between groups. No interaction between pre- and post-intervention differences was detected in any of the groups for any dimension (Table 4). A post-hoc power analysis revealed that the sample size was insufficient to detect statistical differences in each of the groups for the effect size given by the mean scores between each group after the interventions.",3814588
1423,5330006,Values of total antioxidant capacity (TAC),receiving 1200 mg of cranberry extract for 6 weeks,placebo group,Significantly increased,"At trial II, cranberry-supplemented athletes presented with significantly higher resting, post-exercise and post-recovery levels of TAC than the controls.",5330006
1424,5330006,interleukin 6 levels during exercise tests,receiving 1200 mg of cranberry extract for 6 weeks,placebo group,No significant difference,"Supplementation with cranberry extract did not exert a significant effect on IL-6 concentration (main effect, pâ€‰=â€‰0.051).Fig. 2",5330006
1425,5330006,tumor necrosis factor alpha levels during exercise tests,receiving 1200 mg of cranberry extract for 6 weeks,placebo group,No significant difference,"Based on the results of ANOVA, cranberry supplementation did not exert a statistically significant effect on TNF-alpha levels (main effect, pâ€‰=â€‰0.118).",5330006
1426,5330006,serum iron,receiving 1200 mg of cranberry extract for 6 weeks,placebo group,No significant difference,"Supplementation with cranberry extract did not exert a significant effect on serum iron (main effect, pâ€‰=â€‰0.516).",5330006
1427,5553001,had seen a social worker at preassessment,"Internet-based guided self-help program, including weekly support from a therapist via encrypted email",wait-list control condition,Significantly decreased,Significantly more parents in the intervention group had seen a social worker at preassessment.,5553001
1428,5553001,PTSD-Checklist-Civilian version (PCL-C) difference ,"Internet-based guided self-help program, including weekly support from a therapist via encrypted email",wait-list control condition,Significantly increased,". The model difference at postassessment was 9.16 points on the PCL-C in favor of the intervention group, representing a large effects size. At follow-up, the model difference was 8.07 points on the PCL-C in favor of the intervention group, representing a medium to large effect size.",5553001
1429,5553001,the Beck Depression Inventory-II (BDI-II) difference ,"Internet-based guided self-help program, including weekly support from a therapist via encrypted email",wait-list control condition,Significantly increased,"The model difference at postassessment was 3.91 points on the BDI-II in favor of the intervention group, representing a medium effect size. The model difference at follow-up was 9.41 points on the BDI-II, representing a large effect size. For BAI, a linear model provided best fit to the data (see Multimedia Appendix 3). At preassessment, the intervention group reported a significantly higher level of symptoms; the model difference was 5.11 points on the BAI. The intervention group exhibited a significant decline over time, whereas the control group exhibited a significant increase in symptoms over time. At postassessment, there was no difference between the groups. However, at follow-up there was a difference of 6.99 points on the BAI in favor of the intervention group, representing a large effect size",5553001
1430,5566825,total duration of illnesses,receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,Significantly decreased,"Evaluation of total duration of illnesses related to infection and allergy showed that of the total duration of 3983 days of illness, there were 1369 (34.37%) illness days in CP group whereas it was 2614 (65.62%) days in the control group. This difference was observed statistically significant (P &lt; 0.01) and the proportionate difference was about 2 times (1.91) [Figure 3].",5566825
1431,5566825,episodes of infection/allergy related to immunity,receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,No significant difference,"A total of 540 participants had episodes of infection/allergy related to immunity. Of these, 254 participants (47.03%) participants were in CP group while 286 (52.96%) were in the control group. The difference observed was statistically not significant (P &gt; 0.05).",5566825
1432,5566825,absent due to infection/allergy/immunity related illnesses,receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,Significantly decreased,"There were a total of 281 participants who were absent due to infection/allergy/immunity related illnesses. Of these, 93 participants (33.09%) were in CP group while 188 (66.90%) were in the control group. This difference was found to be statistically significant (P &lt; 0.001) [Figure 5].",5566825
1433,5566825,"energy, physical fitness, strength and stamina",receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,No significant difference,"Though no significant difference was observed between the groups at 3 and 6 months follow up, CP group showed a better improvement in energy levels, physical fitness, strength and stamina as compared to control group [Table 4].",5566825
1434,5566825,CGI-I scale improvement,receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,Significantly increased,Assessment of participants on CGI-I scale showed that a higher percentage of participants (66.12%) showed improvement on this scale in CP Group as compared to control group (51.43%) [Table 7].,5566825
1435,5336430,The percentage of patients with complete clinical clearance (CCC) 8 weeks after the end of treatment (primary endpoint),5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"The percentage of patients with CCC 8 weeks after the end of treatment (primary endpoint) was significantly higher in the 5-FU 0.5%/salicylic acid 10% arm compared with vehicle in both the ITT and per protocol (PP) populations [ITT LOCF: 49.5% vs. 18.2%; OR 3.9 (95% CI 1.7, 8.7) P = 0.0006 (Fig. 3a); PP LOCF: 55.1% vs. 19.6%; OR 5.1 (95% CI 2.1, 12.2) P = 0.0002].",5336430
1436,5336430,differences between 5-FU 0.5%/salicylic acid 10% and vehicle during treatment,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,No significant difference,"During treatment, there were no significant differences between 5-FU 0.5%/salicylic acid 10% and vehicle (Fig. 3b); however, it should be noted that it can be difficult to assess lesion counts during treatment because of irritation at the site of administration.Fig. 3",5336430
1437,5336430,"the proportion of patients who achieved PC of AK lesions eight weeks after the end of treatment,",5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"Eight weeks after the end of treatment, the proportion of patients who achieved PC of AK lesions was significantly greater in the 5-FU 0.5%/salicylic acid 10% arm than in the vehicle arm [69.5% vs. 34.6%; OR 4.9 (95% CI 2.3, 10.5) P &lt; 0.0001 (Fig. 4)].",5336430
1438,5336430,The proportional reduction from baseline in the total number of AK lesions per patient ,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"The proportional reduction from baseline in the total number of AK lesions per patient was significantly greater with 5-FU 0.5%/salicylic acid 10% than with vehicle: 78.0% versus 46.9%, respectively; P &lt; 0.0001 (Fig. 5).",5336430
1439,5336430,"overall treatment satisfaction and effectiveness domain mean scores at 8 weeks after the end of treatment,",5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"At 8 weeks after the end of treatment, 5-FU 0.5%/salicylic acid 10% was associated with significant improvements in overall treatment satisfaction and effectiveness domain mean scores in the TSQM compared with vehicle [69.2 vs. 56.1 (P = 0.0019); 70.8 vs. 59.2 (P = 0.0064), respectively].",5336430
1440,5336430,the TSQM convenience and side effect domain scores,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,No significant difference,"No statistically significant differences were observed between the study arms for the TSQM convenience (70.7 and 71.2, respectively) and side effect (92.4 and 96.4, respectively) domain scores.",5336430
1441,5336430,DLQI total score 8 weeks after the end of treatment,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"the improvement in DLQI total score switched in favor of 5-FU 0.5%/salicylic acid 10% 8 weeks after the end of treatment, although this was not statistically significant (P = 0.0725; Table 2; Supplementary Fig. S1).Table 2",5336430
1442,5336430,Treatment-emergent adverse events,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"Treatment-emergent adverse events, predominantly related to application- and administration-site reactions, were more common with 5-FU 0.5%/salicylic acid 10% than with vehicle (99.1% vs. 83.6%).",5336430
1443,5610684,cortisol concentration from 20 to 45 min post-stressor onset,use their own Facebook profile,quietly read,Significantly increased,"However, compared to the Facebook use condition (Mdifference = â€“0.35, SD = 0.37), control participants (Mdifference = â€“0.51, SD = 0.38) showed a significantly greater decrease in cortisol concentration from 20 to 45 min post-stressor onset when controlling for gender and Facebook Intensity score2, F(1, 84) = 5.03, p = 0.03, 95% CI [0.21, 0.33], Î·2 = 0.06 (see Figures 2Aâ€“D).",5610684
1444,5610684,"tension, anxiety, well-being",use their own Facebook profile,quietly read,No significant difference,"There were no significant condition differences for tension F(1, 91) = 1.56, p = 0.21, 95% CI [â€“0.29, 1.25], Î·2 = 0.02; anxiety F(1, 88) = 0.004, p = 0.95, 95% CI [â€“1.01, 0.95], Î·2 = 0.00; or well-being F(1, 91) = 0.33, p = 0.57, 95% CI [â€“0.49, 0.90], Î·2 = 0.004.",5610684
1445,5610684,Subjective stress markers,use their own Facebook profile,quietly read,No significant difference,Subjective stress markers and cortisol for Facebook and Control conditions. Facebook and Control conditions showed no significant differences at any time point (p &lt; 0.05).,5610684
1446,4859395,external elastic membrane (EEM) area and lumen area,nebivolol,atenolol,Significantly decreased,"On VHâ€?IVUS, nebivolol segments demonstrated significantly decreased EEM area (P=0.02) and lumen area (P=0.004) but similar changes in plaque components and number of TCFAs per vessel compared with atenolol (Table 2).",4859395
1447,4859395,plaque components and number of TCFAs per vessel,nebivolol,atenolol,No significant difference,"On VHâ€?IVUS, nebivolol segments demonstrated significantly decreased EEM area (P=0.02) and lumen area (P=0.004) but similar changes in plaque components and number of TCFAs per vessel compared with atenolol (Table 2).",4859395
1448,4859395,plaque area,nebivolol,atenolol,No significant difference,"Nebivolol also showed increased plaque area at followâ€?up (P&lt;0.001), whereas atenolol demonstrated plaque regression (P=0.047); however, the difference between the 2 arms was not significant (P=0.27).",4859395
1449,4859395,constrictive remodeling,nebivolol,atenolol,Significantly increased,"With respect to arterial remodeling, static remodeling (remodeling index) was similar between the 2 groups, but serial remodeling was significantly different (P=0.002), with nebivolol segments demonstrating more constrictive remodeling (73% versus 46%)",4859395
1450,4859395,excessive expansive remodeling,nebivolol,atenolol,Significantly decreased,"With respect to arterial remodeling, static remodeling (remodeling index) was similar between the 2 groups, but serial remodeling was significantly different (P=0.002), with nebivolol segments demonstrating more constrictive remodeling (73% versus 46%) and less excessive expansive remodeling (16% versus 39%) than atenolol (Figure 6).",4859395
1451,4859395,Among lowâ€? wall shear stress (WSS) segments  Î”EEM area ,nebivolol,atenolol,Significantly decreased,"Among lowâ€?WSS segments (Table 4), those treated with nebivolol demonstrated decreased Î”EEM area compared with atenolol (P=0.02), consistent with a higher percentage of constrictive serial remodeling (83% versus 63%).",4859395
1452,3406743,engaging in moderate physical activity,"enhanced intervention (EIG) - The enhanced intervention was delivered by CHWs as 3 individually tailored, one-on-one counseling sessions. The sessions occurred approximately 1 month, 2 months, and 6 months after screening. Each session averaged 50 minutes. Participants received transportation tokens and grocery store vouchers as incentives for attendance.",baseline,Significantly increased,"The EIG was approximately twice as likely to report engaging in moderate physical activity at follow-up as at baseline; 71% of women in this group reported moderate physical activity at baseline, and 84% at follow-up.",3406743
1453,3406743,engaging in moderate physical activity,usual care (UCG),baseline,No significant difference,"The UCG did not change between baseline and follow-up; 75% of women in this group reported moderate physical activity at baseline, and 77% at follow-up.",3406743
1454,3406743,engaging in vigorous physical activity,enhanced intervention (EIG),baseline,Significantly increased,"he EIG was approximately 3 times as likely to report engaging in vigorous physical activity at follow-up as at baseline; 13% of these women reported moderate activity at baseline, and 33% at follow-up.",3406743
1455,3406743,engaging in vigorous physical activity,usual care (UCG),baseline,No significant difference,"Women in the UC group showed no change (16%, baseline vs 17%, follow-up).",3406743
1456,3406743,readiness to engage in vigorous physical activity,enhanced intervention (EIG),baseline,Significantly increased,"The EIG was twice as likely to report being in the action/maintenance stage for vigorous physical activity at follow-up than at baseline; 47% of women in this group reported readiness to engage in vigorous physical activity at baseline, and 67% at follow-up.",3406743
1457,3406743,readiness to engage in vigorous physical activity,usual care (UCG),baseline,No significant difference,"The EIG was twice as likely to report being in the action/maintenance stage for vigorous physical activity at follow-up than at baseline; 47% of women in this group reported readiness to engage in vigorous physical activity at baseline, and 67% at follow-up.",3406743
1458,4600230,OSAUS scores of the clinical performance test ,simulation-based training followed by clinical training,clinical training only,Significantly increased,"OSAUS scores of the clinical performance test were significantly higher in the intervention than in the control group (mean, 59.1 Â± 9.3% vs 37.6 Â± 11.8%; P &lt; 0.001).",4600230
1459,4600230,a pre-established pass/fail level of 50.0% in OSAUS score,simulation-based training followed by clinical training,clinical training only,Significantly increased,"A significantly higher number of participants from the intervention group passed a pre-established pass/fail level of 50.0% in OSAUS score compared with the control group (85.7% vs 8.3%, respectively; P &lt; 0.001).",4600230
1460,4600230,"image optimization, systematic examination, interpretation of images, documentation of examination, and medical decision-making",simulation-based training followed by clinical training,clinical training only,Significantly increased,"There were statistically significant differences between the scores of the two groups (Figure 3) on image optimization (P &lt; 0.001), systematic examination (P = 0.001), interpretation of images (P &lt; 0.001), documentation of examination (P &lt; 0.001), and medical decision-making (P = 0.005)",4600230
1461,4600230,knowledge of equipment ,simulation-based training followed by clinical training,clinical training only,No significant difference,but no difference was observed for knowledge of equipment (P = 0.095).,4600230
1462,4600230,completed scans during the 2 months of clinical training,simulation-based training followed by clinical training,clinical training only,No significant difference,"During the 2 months of clinical training, participants in the intervention and control groups completed an average Â± SD of 58 Â± 41 and 63 Â± 47 scans, respectively (P = 0.67).",4600230
1463,2837815,rotations or translations,SmartSet HV acrylic bone cements (without antibiotics),Palacos R acrylic bone cements (without antibiotics),No significant difference,At 2-year follow-up there were no statistically significant differences in rotations or translations between the SmartSet HV group and the Palacos R group.,2837815
1464,2837815,The mean distal translation,SmartSet HV acrylic bone cements (without antibiotics),Palacos R acrylic bone cements (without antibiotics),No significant difference,The mean distal translation observed was âˆ’0.15 mm for SmartSet HV and âˆ’0.16 mm for Palacos R.,2837815
1465,2837815,The mean rotation around the longitudinal axis,SmartSet HV acrylic bone cements (without antibiotics),Palacos R acrylic bone cements (without antibiotics),No significant difference,The mean rotation around the longitudinal axis was 0.9Â° for SmartSet HV and 1.2Â° for Palacos R.,2837815
1466,2837815,The Merle dâ€™Aubigne Postel score,SmartSet HV acrylic bone cements (without antibiotics),Palacos R acrylic bone cements (without antibiotics),No significant difference,The Merle dâ€™Aubigne Postel score was the maximum of 18 points for all patients in both groups.,2837815
1467,4367028,SBP and DBP,Trendelenburg (TBG) tilt &gt;30Â° ,Trendelenburg (TBG) tilt &lt;30Â°,No significant difference,Head down tilt was associated with a rising trend in SBP and DBP which was higher in TBG &gt;30Â° than TBG &lt;30Â° group however the results were not statistically significant [Table 4].,4367028
1468,4367028,pulse rate,Trendelenburg (TBG) tilt &gt;30Â° ,Trendelenburg (TBG) tilt &lt;30Â°,No significant difference,"Interestingly, pulse rate decreased with head down tilt and fall was much higher in TBG &gt;30Â° than TBG &lt;30Â° group but without any statistical significance.",4367028
1469,4367028,Bispectral index values,Trendelenburg (TBG) tilt &gt;30Â°,Trendelenburg (TBG) tilt &lt;30Â°,Significantly increased,"Bispectral index values also gradually increased with head down tilt and TBG &gt;30Â° group showed higher BIS value than TBG &lt;30Â° [Table 5 and Figure 1]. Although the BIS values among two groups were statistically significant, the patients from either group didnâ€™t complain of its awareness (probably due to their anesthetic state).",4367028
1470,4367028,Nitroglycerine and fentanyl use,Trendelenburg (TBG) tilt &gt;30Â°,Trendelenburg (TBG) tilt &lt;30Â°,Significantly increased,Nitroglycerine and fentanyl use in TBG &gt;30Â° group was higher and statistically significant (P &lt; 0.05) when compared with TBG &lt;30Â° [Table 6].,4367028
1471,4367028,PACU stay,Trendelenburg (TBG) tilt &gt;30Â°,Trendelenburg (TBG) tilt &lt;30Â°,Significantly increased,Again PACU stay was longer (P &lt; 0.05) in TBG &gt;30Â° group compared to TBG &lt;30Â° group [Table 6].,4367028
1472,4222592,self-reported subjective feelings of satisfaction  for the AUC(0-5h),consumed a standardized breakfast with Avocado Added (AA),consumed a standardized breakfast  [Control (C)avocado-free],Significantly increased,"Post-hoc testing revealed that compared to the C test meal, the AA test meal increased satisfaction by 23% (Pâ€‰=â€‰0.05) and decreased the desire to eat by 28% (Pâ€‰=â€‰0.04) for the AUC(0-5h).",4222592
1473,4222592,desire to eat  for the AUC(0-5h),consumed a standardized breakfast with Avocado Added (AA),consumed a standardized breakfast  [Control (C)avocado-free],Significantly decreased,"Post-hoc testing revealed that compared to the C test meal, the AA test meal increased satisfaction by 23% (Pâ€‰=â€‰0.05) and decreased the desire to eat by 28% (Pâ€‰=â€‰0.04) for the AUC(0-5h).",4222592
1474,4222592,self-reported subjective feelings of satisfaction,consumed a standardized breakfast with Avocado Included (AI),consumed a standardized breakfast  [Control (C)avocado-free],No significant difference,"Additionally, the AI test meal showed a tendency towards increasing satisfaction by 22% Pâ€‰=â€‰0.07) as compared to the C test meal for the AUC(0-3h).",4222592
1475,4222592,self-reported subjective feelings of satisfaction  for the AUC(0-3h),consumed a standardized breakfast with Avocado Added (AA),consumed a standardized breakfast  [Control (C)avocado-free],Significantly increased,"For the AUC(0-3h), the AA test meal increased satisfaction by 26% (P=0.02)",4222592
1476,4222592,the AUC(0-3h) for blood insulin,consumed a standardized breakfast with Avocado Included (AI),consumed a standardized breakfast with Avocado Added (AA) or consumed a standardized breakfast  [Control (C)avocado-free],Significantly decreased,"Compared to the AI meal, the AUC(0-3h) for blood insulin was higher in the C and AA meals (P=0.04 and P=0.05, respectively).",4222592
1477,4222592,desire to eat for the AUC(0-3h),consumed a standardized breakfast with Avocado Added (AA),consumed a standardized breakfast  [Control (C)avocado-free],Significantly increased,decreased the desire to eat by 40% (P=0.01) as compared to the C test meal.,4222592
1478,4673066,performance on the diagnostic performance test,schema-based lecture,traditional,Significantly increased,"Schema-based instruction was associated with increased performance on the diagnostic performance test (64â€‰%â€‰Â±â€‰22 vs 44â€‰%â€‰Â±â€‰25, pâ€‰&lt;â€‰0.001).",4673066
1479,4673066,intrinsic cognitive load,schema-based lecture,traditional,Significantly decreased,"Participants rated intrinsic cognitive load lower with the schema-based lecture (20 vs 24 points, mean difference =â€‰15â€‰%, standard error 3â€‰%, pâ€‰&lt;â€‰0.001).",4673066
1480,4673066,extraneous or germane load,schema-based lecture,traditional,No significant difference,"There was no significant difference in reported extraneous (11 vs. 12 points, mean difference =â€‰3â€‰%, standard error =â€‰3â€‰%, pâ€‰=â€‰0.36) or germane (22 vs 21 points, mean difference =â€‰3â€‰%, standard error =â€‰4.5â€‰%, pâ€‰=â€‰0.42) load.",4673066
1481,4673066,evaluation of the lecturers,schema-based lecture,traditional,No significant difference,"Fifty-nine (59â€‰%) participants evaluated the lecturers. Participants rated both lecturers similarly (traditional lecture: 4.98 vs schema-based lecture: 5.25, pâ€‰=â€‰0.114).",4673066
1482,4881089,prevalence rates of reported musculoskeletal symptoms, ergonomic intervention,baseline,Significantly decreased,"The McNemar test indicated significant differences between prevalence rates of reported musculoskeletal symptoms in the arm (p = 0.004), upper back (p = 0.001), and lower back (p = 0.0001) regions before and after intervention. The prevalence rates of problems were significantly lower after intervention.",4881089
1483,4881089,prevalence rates of reported musculoskeletal symptoms,control (did not receive ergonomic training),baseline,No significant difference,Table 3 shows musculoskeletal symptoms in the control subjects before and after intervention. McNemar test showed no significant difference in the prevalence rates of musculoskeletal symptoms in all regions before and after intervention.,4881089
1484,4881089,"mean scores in work pace, influence at work, meaning of work, predictability, rewards, role conflicts and social support from supervisor ", ergonomic intervention,baseline,Significantly increased,"he paired t-test showed significant differences in mean scores before and after intervention in: work pace (p = 0.002), influence at work (p = 0.005), meaning of work (p = 0.001), predictability (p = 0.001), rewards (p = 0.001), role conflicts (p = 0.001) and social support from supervisor (p = 0.001).",4881089
1485,4881089,any of the scales of the Thai version of the COPSOQ questionnaire,control,baseline,No significant difference,Table 5 also shows that there was no significant difference in any of the scales of the Thai version of the COPSOQ questionnaire before and after intervention in the control group.,4881089
1486,5932317,week Ã— diameter Ã— application types in terms of LII ,copper-nickel-titanium (CuNiTi) round archwires with increasing diameters applied sequentially to the mandibular arch ,nickel-titanium (NiTi) round archwires with increasing diameters applied sequentially to the mandibular arch,No significant difference,No statistically significant three-way interaction was observed between week Ã— diameter Ã— application types in terms of LII (p &gt; 0.05).,5932317
1487,5932317,The length of the arch perimeter between the canines and the length of the arch perimeter between the first molars,copper-nickel-titanium (CuNiTi) round archwires with increasing diameters applied sequentially to the mandibular arch ,nickel-titanium (NiTi) round archwires with increasing diameters applied sequentially to the mandibular arch,Significantly increased,The length of the arch perimeter between the canines and the length of the arch perimeter between the first molars were significantly higher in the CuNiTi group than in the NiTi group in terms of the main effect (application factor) (p &lt; 0.001).,5932317
1488,5932317,The mean values obtained using 0.016-in archwire application,copper-nickel-titanium (CuNiTi) round archwires with increasing diameters applied sequentially to the mandibular arch ,nickel-titanium (NiTi) round archwires with increasing diameters applied sequentially to the mandibular arch,Significantly increased,"The mean values obtained using 0.016-in archwire application were significantly lower in the NiTi group than in the CuNiTi group in the second week (p &lt; 0.05); however, these were significantly higher in the fourth week. In the sixth week, the mean values obtained in the NiTi group were significantly lower than those obtained in the CuNiTi group (p &lt; 0.05).",5932317
1489,5379843,calculus formation,use the Abhaibhubejhr or Total toothpastes,use the Cavity Protection toothpaste,Significantly decreased,"The subjects who used the Abhaibhubejhr and Total toothpastes for 12 weeks showed 20.51% and 38.46% less calculus formation, respectively than subjects who used the Cavity Protection toothpaste, which was statistically significant (P &lt; 0.05).",5379843
1490,5379843,calculus formation,use the Total toothpastes,use the Abhaibhubejhr ,Significantly decreased,"In addition, subjects using the total toothpaste had 22.58% statistically significant less calculus formation than subjects using the Abhaibhubejhr toothpaste (P &lt; 0.05).",5379843
1491,5021748,activated clotting time (ACT),the warfarin or dabigatran  ,the rivaroxaban or apixaban  ,Significantly increased,"The baseline ACTs in the control and dabigatran groups (151 Â± 17 and 156 Â± 15 s, respectively) were significantly longer than those in the rivaroxaban (135 Â± 12 s) and apixaban (132 Â± 17 s) groups (Fig. 2).",5021748
1492,5021748,protamine usage for haemostasis,rivaroxaban or apixaban or dabigatran  ,control (warfarin),No significant difference,"No significant differences in protamine usage for haemostasis were found among the control and three NOAC groups (control, 13 Â± 20; dabigatran, 26 Â± 23; rivaroxaban, 25 Â± 25; apixaban, 28 Â± 28 mg).",5021748
1493,5021748,heparin dosages required to produce an ACT 15 min after the initial bolus  that was identical to the control (110U/kg),rivaroxaban or apixaban or dabigatran  ,control (warfarin),Significantly increased,"The initial bolus heparin dosages required to produce an ACT 15 min after the initial bolus that was identical to the control (333 Â± 32 s) were 120 U/kg (318 Â± 29 s) and 130 U/kg (339 Â± 43 s) for dabigatran, 130 U/kg (314 Â± 31 s) for rivaroxaban and 130 U/kg (317 Â± 39 s) for apixaban. The NOAC groups required significantly larger doses of total heparin than the warfarin group.",5021748
1494,4274342,The mean (SD) increase in endometrial thickness based on TVUS,ospemifene 60 mg/day,placebo,Significantly increased,"The mean (SD) increase in endometrial thickness based on TVUS was 0.51 (1.5) versus 0.06 (1.2) mm at 12 weeks, 0.56 (1.6) versus 0.05 (1.3) mm at 6 months, and 0.81 (1.5) versus 0.07 (1.2) mm at 12 months for participants in the ospemifene and placebo groups, respectively. The differences between participants receiving ospemifene and participants receiving placebo were statistically significant (P â‰¤ 0.001, Welchâ€™s test) at all three evaluations.",4274342
1495,4274342,vaginal bleeding,ospemifene 60 mg/day,placebo,No significant difference,"We assessed for a possible association between endometrial thickness and vaginal bleeding, which demonstrated no statistically significant correlation (ospemifene 60 mg/day: Spearman Ï? = 0.0625, P = 0.2527; placebo: Spearman Ï? = 0.3152, P = 0.0847; Table 4).",4274342
1496,4274342,endometrial cancer,ospemifene 60 mg/day,placebo,No significant difference,There were no cases of endometrial cancer observed with exposure of up to 52 weeks in the ospemifene clinical trials.,4274342
1497,4274342,pelvic organ prolapse,ospemifene 60 mg/day,placebo,No significant difference,There were rare cases of pelvic organ prolapse in both the ospemifene and placebo groups.,4274342
1498,3846239,The analgesic requirement,bupivacaine plus dexamethasone ,bupivacaine ,Significantly decreased,"The analgesic requirement was significantly lower in the B+D group compared with the B group (P=0.038), with 12 and 18 patients requiring post-surgical oral/intra muscular analgesics, respectively (Table 3).",3846239
1499,3846239,"At 1, 2, 4, 6, and 12 h post surgery, VAS pain scores",bupivacaine plus dexamethasone ,bupivacaine ,Significantly decreased,"At 1, 2, 4, 6, and 12 h post surgery, VAS pain scores were significantly lower in the B+D group than in the B group(P&lt;0.0001, P=0.002, P=0.023, P&lt;0.0001 and P=0.011, respectively)",3846239
1500,3846239,"At 24 h post surgery, VAS pain scores",bupivacaine plus dexamethasone ,bupivacaine ,No significant difference,but there was no statistically significant difference between the groups in VAS at 24 h after surgery P=0.221 (Table 2).,3846239
1501,2627861,maternal blood lead concentrations,"ingest 1,200 mg dietary calcium",ingest placebo,Significantly decreased,"In the intent-to-treat analysis (n = 557), calcium supplementation was associated with an overall average reduction of 11% in maternal blood lead concentrations relative to placebo (p = 0.004) (Table 2).",2627861
1502,2627861,maternal blood lead concentrations in the second/third trimester,"ingest 1,200 mg dietary calcium",ingest placebo,Significantly decreased,"This reduction was more evident in the second trimester (âˆ’14%, p &lt; 0.001) than in the third (âˆ’8%, p = 0.107) and was strongest in women who were most compliant (those who consumed â‰¥ 75% calcium pills; âˆ’24%, p &lt; 0.001), had baseline blood lead &gt; 5 Î¼g/dL (âˆ’17%, p &lt; 0.01), or reported use of lead-glazed ceramics and high bone lead (âˆ’31%, p &lt; 0.01).",2627861
1503,5854362,anxiety and depressive symptoms , Cognitive Bias Modification for Interpretations (CBM-I) training,placebo training,No significant difference,"Our first and primary hypothesis, that CBM-I would result in reduced anxiety and depressive symptoms compared to Placebo, was not confirmed, as no significant Condition x Time interactions were observed for SCARED and CDI scores.",5854362
1504,5850185,pDF strength at A1 and A2,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),unilateral TENS+TOT,Significantly increased,"he results suggest that for every 10 sessions of training, the Biâ€?TENS group demonstrated an additional 1.32â€?kg increase in pDF strength. Post hoc analyses revealed that the Biâ€?TENS group had greater improvement than the Uniâ€?TENS group in the pDF strength at A1 (mean difference, 2.62; P=0.036) and at A2 (mean difference, 3.23; P=0.034).",5850185
1505,5850185,pDF strength at A1 and A2,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),baseline,Significantly increased,"When compared with baseline, the Biâ€?TENS group showed improvement in the pDF strength at A1 (mean difference, 2.67; P&lt;0.001) and at A2 (mean difference, 4.46; P&lt;0.001).",5850185
1506,5850185,TUG completion time at A2,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),unilateral TENS+TOT,Significantly increased,"Post hoc analyses of the significant interaction effect reveal that the Biâ€?TENS group had greater improvement than the Uniâ€?TENS group in the TUG completion time at A2 (mean difference, âˆ’3.09; P=0.047).",5850185
1507,5850185,the TUG completion time at A1 and A2,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),baseline,Significantly increased,"When compared with baseline, the Biâ€?TENS group showed improvement in the TUG completion time at A1 (mean difference, âˆ’2.01; P=0.001) and at A2 (mean difference, âˆ’3.76; P&lt;0.001).",5850185
1508,5850185,paretic ankle dorsiflexion strength and the completion time for the Timed Up and Go test,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),unilateral TENS+TOT,Significantly increased,The subjects in the bilateral TENS+TOT group showed greater improvement in paretic ankle dorsiflexion strength (Î²=1.32; P=0.032) and in the completion time for the Timed Up and Go test (Î²=âˆ’1.54; P=0.004) than those in the unilateral TENS+TOT group.,5850185
1509,4134501,Mean pertuzumab Cmin at day 43,pertuzumab 840â€‰mg for cycle 1 and 420â€‰mg q3w for cycles 2â€“6 (Arm A),pertuzumab 840â€‰mg q3w for six cycles (Arm B),Significantly decreased,"the day 43 mean (s.d.) pertuzumab Cmin in Arms A and B was 40.0â€‰Î¼gâ€‰mlâˆ’1 (17.3) and 62.7â€‰Î¼gâ€‰mlâˆ’1 (29.1), respectively, and the geometric mean Cmin in Arms A and B was 36.8â€‰Î¼gâ€‰mlâˆ’1 and 56.4â€‰Î¼gâ€‰mlâˆ’1, respectively.",4134501
1510,4134501,The safety profiles,pertuzumab 840â€‰mg for cycle 1 and 420â€‰mg q3w for cycles 2â€“6 (Arm A),pertuzumab 840â€‰mg q3w for six cycles (Arm B),No significant difference,"The total number of grade â©¾3 AEs was 78 in Arm A and 60 in Arm B and the most frequent grade â©¾3 AEs are shown in Table 3. Seventy-three percent and 67% of patients in Arms A and B, respectively, experienced at least one serious AE and the total number of all serious AEs was 35 in Arm A and 19 in Arm B.",4134501
1511,4134501,Partial responses,pertuzumab 840â€‰mg for cycle 1 and 420â€‰mg q3w for cycles 2â€“6 (Arm A),pertuzumab 840â€‰mg q3w for six cycles (Arm B),Significantly increased,"At the end of cycle 6, a partial response was observed in 12 (86%) and 6 (55%) patients in Arms A and B, respectively, whereas 2 (14%) and 3 (27%) patients, respectively, had stable disease. Two patients in Arm B had progressive disease.",4134501
1512,2361520,Median survival,receive immediate treatment,receive delayed treatment,No significant difference,"Median survival was 13.0 months in patients receiving immediate treatment and 11.0 months in the delayed-treatment group (hazard ratio, 1.08; 95% CI 0.79â€“1.47) (Figure 2). Adjustment for risk factors did not significantly change the hazard ratio (hazard ratio, 1.15; 95% CI 0.77â€“1.72).",2361520
1513,2361520,progression-free survival,receive immediate treatment,receive delayed treatment,No significant difference,"There was no statistically significant difference in progression-free survival (time from randomisation until first evidence of progression after chemotherapy, 10.2 vs 10.8 months; hazard ratio, 1.08; 95% CI 0.71â€“1.64; P=0.73).",2361520
1514,2361520,overall QoL,receive immediate treatment,receive delayed treatment,No significant difference,There was no statistically significant difference in overall QoL or any component domain between the two treatment strategies at baseline or at any subsequent time point.,2361520
1515,2361520,time to disease progression or survival,receive immediate treatment,receive delayed treatment,No significant difference,"Multivariate analysis was conducted with the Cox proportional-hazards model. Age, sex, liver metastases, ECOG performance status, baseline QoL scores, weight, disease-free interval &gt;12 months, stage at first presentation, and prior adjuvant chemotherapy did not statistically significantly influence time to disease progression or survival for immediate vs delayed treatment.",2361520
1516,5593173,the creative foraging game (CFG) and the alternate uses test (AUT) scores,smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ,smelled and rated an odorant,Significantly increased,"Participants in the placebo group showed significantly higher originality than the control group, both in the CFG (MW U = 753, p = 0.036; Fig 2, left panel), and in the AUT (MW U = 278, p = 0.048, Fig 2, right panel). Effect size was medium (CFG: Cohenâ€™s D = 0.46; AUT: Cohenâ€™s D = 0.43).",5593173
1517,5593173,Fluency and flexibility,smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ,smelled and rated an odorant,No significant difference,"In the CFG, we defined fluency as the number of shapes selected to the gallery during exploitation phases, finding no significant difference between control and placebo (MW U = 970, p = 0.73). In the AUT test, fluency showed a trend for being higher in the placebo group than in the control group (MW U = 286, p = 0.056, Cohenâ€™s D = 0.43) (Fig 3).",5593173
1518,5593173,"the extent to which players found categories of shapes that were non-standard, naming it â€œout-of-the-boxnessâ€?, OB",smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ,smelled and rated an odorant,Significantly increased,"We find that the OB of the placebo group was significantly higher than the control with medium-to-large effect size (MW U = 683, p = 0.008; D = 0.6).",5593173
1519,5593173,Torrance test (TTCT),smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ,smelled and rated an odorant,No significant difference,"The placebo group showed higher originality than the control group both in the CFG (p&lt;0.04, effect size = 0.5) and in the AUT (p&lt;0.05, effect size = 0.4), but not in the Torrance test.",5593173
1520,4107254,New oral anticoagulants administration,centers admitting â‰¥ 200 patients/year,centers admitting less than 200 patients/year,Significantly decreased,"New oral anticoagulants were more frequently (214/156 vs. 5/20) used in centers admitting less than 200 patients per year, which was statistically significant (p = 0.046).",4107254
1521,4107254,interested in joining randomized trials evaluating any of the methods used in VTE prophylaxis,centers admitting â‰¥ 200 patients/year,centers admitting less than 200 patients/year,Significantly increased,"Centers admitting â‰¥ 200 per year were more interested in joining randomized trials evaluating any of the methods used in VTE prophylaxis (70.67 vs. 45; p = 0.039),",4107254
1522,4107254,Dextrans administration,centers with stroke unit,centers without stroke unit,Significantly decreased,"Dextrans were less frequently used in centers with a stroke unit (6.6% vs. 13%, p = 0.05).",4107254
1523,4107254,willing to join a randomized trial evaluating any of the methods used in VTE prophylaxis in stroke patients,centers with stroke unit,centers without stroke unit,Significantly increased,"The centers with a stroke unit were also more willing to join a randomized trial evaluating any of the methods used in VTE prophylaxis in stroke patients (95/132 vs. 20/38; p = 0.031), b",4107254
1524,4518214,overall survival (OS) in patients with  locoregionally advanced nasopharyngeal carcinoma (NPC),chemoradiotherapy ,radiotherapy alone,Significantly increased,"The true study endpoint, 5-year OS, was 62% in the RT group and 72% in the CRT group (Plog-rankâ€‰=â€‰0.038; Fig. 1). The adjusted HR for CRT was 0.66 (95% CI, 0.44â€“0.97; PCoxâ€‰=â€‰0.036). This translates to a 34% relative reduction in deaths after CRT compared to RT.",4518214
1525,4092926,goats body weight at slaughter,sunflower cake,soybean meal,No significant difference,The substitution of soybean meal by sunflower cake in the diet of goats did not affect (p&gt;0.05) body weight at slaughter (Table 3).,4092926
1526,4092926,"Weights, carcass yields, rib eye area of goats",sunflower cake,soybean meal,No significant difference,Weights and carcass yields as well as rib eye area showed no differences (p&gt;0.05) with the substitution of soybean meal by sunflower cake.,4092926
1527,4092926,The commercial cuts and yields and goats,sunflower cake,soybean meal,No significant difference,The commercial cuts and yields were not influenced (p&gt;0.05) by the substitution of soybean meal by sunflower cake (Table 5).,4092926
1528,5343624,Volume reduction,"Xenogeneic bone substitute material (Bio-OssÂ®, BO) "," Synthetic bone substitute material (NanoBoneÂ®, NB) ",No significant difference,"Radiographic analysis revealed a volume reduction of the initial augmented bone substitute material (i.e. 100%) to 77.36 (Â±11.68) % in the BO-group, respectively, 75.82 (Â±22.28) % in the NB-group six months after augmentation. In both materials, the volume reduction was not significant.",5343624
1529,5343624,Ratio of remaining material,"Xenogeneic bone substitute material (Bio-OssÂ®, BO) "," Synthetic bone substitute material (NanoBoneÂ®, NB) ",Significantly increased,"Further, the analysis of the tissue distribution in the implantation bed showed a significantly higher ratio of remaining bone substitute material in BO than that in NB group (NB: 24.28% Â± 3.26%; BO: 40.13% Â± 3.53%; P &lt; 0.01).",5343624
1530,5343624,Vascularization and ratio of connective tissue,"Xenogeneic bone substitute material (Bio-OssÂ®, BO) "," Synthetic bone substitute material (NanoBoneÂ®, NB) ",Significantly decreased,"In accordance with the presence of multinucleated giant cells, which are transported in the augmentation bed by a vessel-rich connective tissue, the vascularization and the ratio of connective tissue were significantly higher in the NB group (percentage vascularization: NB: 2.66% Â± 0.78%; BO: 0.86% Â± 0.07%; P &lt; 0.001; connective tissue: NB: 53.87% Â± 5.12%; BO: 34.14% Â± 4.45%; P &lt; 0.001).",5343624
1531,5343624,Formation of new bone,"Xenogeneic bone substitute material (Bio-OssÂ®, BO) "," Synthetic bone substitute material (NanoBoneÂ®, NB) ",No significant difference,no statistically significant difference in new bone formation could be observed (NB: 21.85% Â± 5.96%; BO: 25.73% Â± 7.94%).,5343624
1532,5343624,Density changes,"Xenogeneic bone substitute material (Bio-OssÂ®, BO) "," Synthetic bone substitute material (NanoBoneÂ®, NB) ",No significant difference,"Accordingly, the radiologically investigated volumetric and bone density changes in the present study also did not differ significantly between both groups.",5343624
1533,5941723,Number of sensations elicited,Acupuncture,Placebo,No significant difference,"There were no significant differences in number of sensations elicited, MASS index, range of spreading, and intensity of needle pain for 5â€‰mm penetration versus 1â€‰mm skin press and 10â€‰mm penetration versus 2â€‰mm skin press.",5941723
1534,5941723,MASS index,Acupuncture,Placebo,No significant difference,"There were no significant differences in number of sensations elicited, MASS index, range of spreading, and intensity of needle pain for 5â€‰mm penetration versus 1â€‰mm skin press and 10â€‰mm penetration versus 2â€‰mm skin press.",5941723
1535,5941723,Spreading range,Acupuncture,Placebo,No significant difference,"There were no significant differences in number of sensations elicited, MASS index, range of spreading, and intensity of needle pain for 5â€‰mm penetration versus 1â€‰mm skin press and 10â€‰mm penetration versus 2â€‰mm skin press.",5941723
1536,5941723,Needle pain intensity,Acupuncture,Placebo,No significant difference,"There were no significant differences in number of sensations elicited, MASS index, range of spreading, and intensity of needle pain for 5â€‰mm penetration versus 1â€‰mm skin press and 10â€‰mm penetration versus 2â€‰mm skin press.",5941723
1537,5941723,Severe adverse events,Acupuncture,Placebo,No significant difference,Dot haemorrhage occurred in three cases with the 10â€‰mm penetrating needle. There were no critical adverse events.,5941723
1538,3269796,Mean length of the specimens,OnControl Bone Marrow Biopsy System,Standard marrow needle,Significantly increased,"The mean length of the marrow biopsy specimens was significantly longer (56%) for the OBM group (15.3 mm) than for the standard bone marrow (SBM) group (9.8 mm), P&lt;0.003.",3269796
1539,3269796,Mean procedure time,OnControl Bone Marrow Biopsy System,Standard marrow needle,Significantly decreased,"The mean procedure time, a secondary endpoint, was significantly shorter in the OBM group (175 s) compared to the SBM group (292 s), P&lt;0.007.",3269796
1540,3269796,Pain scores recorded by physicians,OnControl Bone Marrow Biopsy System,Standard marrow needle,Significantly decreased,Other secondary endpoints which significantly favored the OBM group included the mean pain scores recorded by the fellows (P&lt;0.002) and by the attendings (P&lt;0.008).,3269796
1541,3269796,Pain scores recorded by patients,OnControl Bone Marrow Biopsy System,Standard marrow needle,No significant difference,"In regard to the mean pain scores reported by the patients in the 2 study groups, a lower score was tabulated in the OBM group (4.7) than in the SBM group (5.9), but the difference was not significant (P=0.11).",3269796
1542,3269796,Patient willingness to repeat the produce,OnControl Bone Marrow Biopsy System,Standard marrow needle,Significantly increased,"patients indicated a greater willingness to have a repeat OBM (1.0) than a repeat SBM (2.9), P&lt;0.03.",3269796
1543,5396972,Overall adverse cardiac events,General anesthesia plus epidural infusion (PCEA),General anesthesia plus intravenous analgesia (PCIA),Significantly decreased,"There was a significant reduction in overall adverse cardiac events (myocardial injury, arrhythmias, angina, heart failure and nonfatal cardiac arrest) in PCEA group in comparison to PCIA group.",5396972
1544,5396972,Dynamic VAS pain score,General anesthesia plus epidural infusion (PCEA),General anesthesia plus intravenous analgesia (PCIA),Significantly decreased,there was a significant reduction in dynamic VAS pain score in group PCEA in comparison to PCIA at all measured time points.,5396972
1545,5396972,Mean arterial pressure and heart rate during surgery,General anesthesia plus epidural infusion (PCEA),General anesthesia plus intravenous analgesia (PCIA),Significantly decreased,"Regarding perioperative hemodynamics, there was a significant reduction in intra-operative mean arterial pressure (MAP); and heart rate in PCEA group in comparison to PCIA group at most of measured time points",5396972
1546,5396972,Postoperative complications,General anesthesia plus epidural infusion (PCEA),General anesthesia plus intravenous analgesia (PCIA),Significantly decreased,"The incidence of other postoperative complications such as DVT, pneumonia and in hospital mortality were decreased in PCEA group.",5396972
1547,5396972,Troponin I levels,General anesthesia plus epidural infusion (PCEA),General anesthesia plus intravenous analgesia (PCIA),Significantly increased,The level of troponin I was significantly higher in group PCEA in comparison to group PCIA at all measured time points (P&lt;0.038),5396972
1548,4396724,Duration of vigorous physical activity weekly,High-intensity interval training,Traditional moderate-intensity continuous training,Significantly increased,"Minutes spent in vigorous physical activity per week measured by accelerometer were higher in HIIT (24â€‰Â±â€‰18) as compared to MICT (11â€‰Â±â€‰10) at one-month follow-up (Pâ€‰=â€‰0.049, Cohen's dâ€‰=â€‰0.92).",4396724
1549,4396724,Adherence to training after 1 month,High-intensity interval training,Traditional moderate-intensity continuous training,No significant difference,"Individuals in HIIT (89â€‰Â±â€‰11%) adhered to their prescribed protocol to a greater extent than individuals in MICT (71â€‰Â±â€‰31%) as determined by training logs completed over one-month follow-up (Pâ€‰=â€‰0.05, Cohen's dâ€‰=â€‰0.75).",4396724
1550,4396724,Changes in fitness measures,High-intensity interval training,Traditional moderate-intensity continuous training,No significant difference,"There were no main effects for group or group by time interactions for these fitness parameter variables, indicating that there were no differences in the degree of change experienced between HIIT and MICT over time.",4396724
1551,4396724,Maximal heart rate at the end of the test,High-intensity interval training,Traditional moderate-intensity continuous training,No significant difference,"Maximal heart rate achieved at the end of the graded exercise test, body mass, and waist circumference did not change significantly from baseline to one-month follow-up in either HIIT or MICT (P's &gt; 0.05).",4396724
1552,4396724,"Body mass, and waist circumference",High-intensity interval training,Traditional moderate-intensity continuous training,No significant difference,"Maximal heart rate achieved at the end of the graded exercise test, body mass, and waist circumference did not change significantly from baseline to one-month follow-up in either HIIT or MICT (P's &gt; 0.05).",4396724
1553,1488892,Change in CD4 T lymphocyte count at 24 weeks,IL-2 injections,No treatment,Significantly increased,"Area under curve (AUC) for change in the mean CD4 T lymphocyte count through 24 wk was 129 cells/mm3 for those assigned IL-2 (both dose groups combined) and 13 cells/mm3 for control participants (95% CI for difference, 51.3â€“181.2 cells/mm3; p = 0.0009).",1488892
1554,1488892,Increase in CD4 T lymphocyte count ,IL-2 injection at 4.5 MIU dose,No treatment,Significantly increased,"Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively.",1488892
1555,1488892,Increase in CD4 T lymphocyte count ,IL-2 injection at 7.5 MIU dose,No treatment,Significantly increased,"Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively.",1488892
1556,1488892,Change in plasma HIV RNA,IL-2 injections,No treatment,No significant difference,"The AUC for change in plasma HIV RNA from baseline was similar for those assigned IL-2 (0.13 log10 copies/ml) and control (0.09 log10 copies/ml) (95% CI for difference, âˆ’0.17 to 0.26; p = 0.70) (Table 3). Similarly, there were no significant differences between treatment groups for mean changes in log10 HIV RNA at any timepoint in this parameter.",1488892
1557,5916905,Secretion of insulin,Orange juice intake in-between meals (BM),Orange juice intake with each meal (WM) ,No significant difference,"Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all pâ€‰&gt;â€‰0.05).",5916905
1558,5916905,Daylong glycemia,Orange juice intake in-between meals (BM),Orange juice intake with each meal (WM) ,No significant difference,"Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all pâ€‰&gt;â€‰0.05).",5916905
1559,5916905,Basal insulin sensitivity,Orange juice intake in-between meals (BM),Orange juice intake with each meal (WM) ,No significant difference,"Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all pâ€‰&gt;â€‰0.05).",5916905
1560,5916905,Triglycerides levels,Orange juice intake in-between meals (BM),Orange juice intake with each meal (WM) ,No significant difference,"Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all pâ€‰&gt;â€‰0.05).",5916905
1561,5916905, Insulin sensitivity after meals,Orange juice intake in-between meals (BM),Orange juice intake with each meal (WM) ,No significant difference,"TG, postprandial and basal insulin sensitivity remained unchanged with both interventions",5916905
1562,3094237,L-lysine blood concentration,L-lysine,Placebo,Significantly increased,"Analysis of L-lysine concentration in blood showed a significant effect of treatment such that concentration increased after L-lysine treatment (6 g/day for four weeks) compared to baseline and placebo levels (F(2,14) = 7.84, P &lt; 0.05, Table 2), in 8 out of the 10 patients.",3094237
1563,3094237,Adverse side effects,L-lysine,Placebo,No significant difference,the L-lysine treatment was not found to induce any adverse side effects including extrapyramidal effects. N,3094237
1564,3094237,Symptom severity by PANSS measure,L-lysine,Placebo,No significant difference,"given a biologically significant effect of L-lysine, a major part of the improvement in the testing score should be attributed to the L-lysine treatment period, and less to the placebo period and this effect should be detected in the interaction analysis. Albeit close to a significant interaction (F(2,12) = 3.08, P = 0.08), this analysis did not reach statistical significance and consequently it could not be excluded that a significant part of the effects obtained on the PANSS score was caused by factors not related to L-lysine treatment.",3094237
1565,3094237,Capacity to solve problems,L-lysine,Placebo,Significantly increased,"Problem solving capacity and cognitive flexibility, as assessed by the WCST, was significantly improved following treatment. This effect was statistically significant measured as decrease in the number of errors on the WCST (F(2,14) = 4.91, P &lt; 0.05, Table 2)",3094237
1566,5379203,Mean costs per patient,Home-based approach,Hospital-based approach,Significantly decreased,"Following modified ITT analysis, the mean (SD) costs for the patients in group A (nâ€‰=â€‰86) and group B (nâ€‰=â€‰86) were HK$8479 (989) and HK$22,248 (2407) respectively. The mean difference between groups was HK$-13,769 per patient with 95% CI. (âˆ’14324, âˆ’13213), pâ€‰&lt;â€‰0.001.",5379203
1567,5379203,Waiting time,Home-based approach,Hospital-based approach,Significantly decreased,"The waiting time of patients with AHIâ€‰â‰¥â€‰15/hr who were started on CPAP treatment from the first clinic consultation to the diagnostic sleep test, autoCPAP titration, and CPAP treatment was 189.6, 148.8 and 145.0 days shorter in group A than group B respectively. Home-based approach is non-inferior to hospital-based approach in managing patients with suspected OSAS, with shorter waiting time, and substantial cost savings.",5379203
1568,4924222,Improvement in peripheral diastolic blood pressure ,"Increased intake of fruits, vegetables and dairy",Usual diet,Significantly increased,Peripheral diastolic BP and central pulse pressure were improved in the intervention group compared with the control group at 12 months.,4924222
1569,4924222,Central pulse pressure ,"Increased intake of fruits, vegetables and dairy",Usual diet,No significant difference,There was no significant difference in central pulse pressure between the groups at any of the time points.,4924222
1570,4924222,Central blood pressure (cBP),"Increased intake of fruits, vegetables and dairy",Usual diet,No significant difference,"In the cohort with type 1 and type 2 diabetes, improving dietary quality by increasing consumption of fruit, vegetables and dairy did not improve cBP, AIx or cfPWV, compared with a control group continuing on their usual diet, after 12 months.",4924222
1571,4924222,Augmentation index (AIx),"Increased intake of fruits, vegetables and dairy",Usual diet,No significant difference,"In the cohort with type 1 and type 2 diabetes, improving dietary quality by increasing consumption of fruit, vegetables and dairy did not improve cBP, AIx or cfPWV, compared with a control group continuing on their usual diet, after 12 months.",4924222
1572,4924222,Carotid femoral pulse wave velocity (cfPWV),"Increased intake of fruits, vegetables and dairy",Usual diet,No significant difference,"In the cohort with type 1 and type 2 diabetes, improving dietary quality by increasing consumption of fruit, vegetables and dairy did not improve cBP, AIx or cfPWV, compared with a control group continuing on their usual diet, after 12 months.",4924222
1573,5791393,Pain intensity,With catheter (group II),Without catheter (group I),Significantly increased,Intensity of pain measured by the Visual Analog Scale was higher in Group II.,5791393
1574,5791393,Hospital stay after surgery,With catheter (group II),Without catheter (group I),No significant difference,"There was also no significant difference in the post-operative hospital stay between the groups, both in total and separately in women and in men.",5791393
1575,5791393,Fever,With catheter (group II),Without catheter (group I),No significant difference,No fever occurred after surgery in any of the patients â€“ there were no differences among the groups.,5791393
1576,5791393,Bacteriuria,With catheter (group II),Without catheter (group I),No significant difference,Presence of the post-operative positive urine culture was not significantly dependent on catheterisation.,5791393
1577,5791393,Acute urinary retention and post-void residual urine volume ,With catheter (group II),Without catheter (group I),No significant difference,"No significant correlation was found in the post operative AUR and PVR &gt;30 ml on the day of discharge depending on catheterisation, both in total and separately in women and in men.",5791393
1578,5074260,Change in levels of glycated haemoglobin after 26 weeks,Liraglutide and metformin plus insulin degludec (IDeg),Liraglutide and metformin plus placebo,Significantly increased,"At 26â€‰weeks, the mean change in glycated haemoglobin level was greater in the IDeg addâ€?on to liraglutide arm (âˆ’1.04%) than in the placebo addâ€?on to liraglutide arm (âˆ’0.16%; pâ€‰&lt;â€‰0.0001)",5074260
1579,5074260,Mean fasting plasma glucose at 26 weeks,Liraglutide and metformin plus insulin degludec (IDeg),Liraglutide and metformin plus placebo,Significantly decreased,"the mean fasting plasma glucose reduction was greater, and selfâ€?measured plasma glucose values were lower at all eight time points, with IDeg addâ€?on versus placebo addâ€?on (both pâ€‰&lt;â€‰0.0001).",5074260
1580,5074260,Overall confirmed hypoglycaemia,Liraglutide and metformin plus insulin degludec (IDeg),Liraglutide and metformin plus placebo,Significantly increased,"Confirmed hypoglycaemia rates were low in both groups, although higher with IDeg than with placebo (0.57 vs. 0.12 episodes/patientâ€?years of exposure; pâ€‰=â€‰0.0002).",5074260
1581,5074260,Nocturnal confirmed hypoglycaemia,Liraglutide and metformin plus insulin degludec (IDeg),Liraglutide and metformin plus placebo,No significant difference,rates of nocturnal confirmed hypoglycaemia were low in both treatment groups (higher with IDeg but not statistically significant).,5074260
1582,5074260,Adverse events,Liraglutide and metformin plus insulin degludec (IDeg),Liraglutide and metformin plus placebo,No significant difference,"In the present study, there were no confirmed cases of pancreatitis or pancreatic cancer. Other AEs reported in this study were as expected considering the component drugs of the regimen, and patterns of AEs were similar in the two treatment groups.",5074260
1583,5642191,Baseline characteristics,Lunch meals with fatty fish (fish group),Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group),No significant difference,No differences in baseline characteristics were found between the three intervention groups,5642191
1584,5642191,SDQ change scores,Lunch meals with fatty fish (fish group),Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group),No significant difference,"There were no differences in any of the SDQ change scores from pre to post between the fish and meat or fish and supplement group, neither before nor after adjusting for the participantsâ€™ baseline scores or baseline and compliance scores",5642191
1585,5642191,Symptom scores for emotional problems in high SDQ scorers,Lunch meals with fatty fish (fish group),Lunch meals with meat (meat group) ,Significantly decreased,"In the high-scorer sample, the fish group improved less in the symptom scores for emotional problems (p&nbsp;=&nbsp;0.04) and total difficulties (p&nbsp;=&nbsp;0.02) than the meat group. The difference remained significant for emotional problems (p&nbsp;=&nbsp;0.03), and was borderline significant for total difficulties (p&nbsp;=&nbsp;0.06) after adjusting for compliance",5642191
1586,3810136,Gastrocnemius masses after 2 days,T-HS/SE and T-HS/EAA,T-HS/Ctr,Significantly increased,"Gastrocnemius masses in the T-HS/SE and T-HS/EAA groups were significantly higher than the T-HS/Ctr group by 2 days post-T-HS (p&lt;0.01), and this trend continued throughout the remainder of the study.",3810136
1587,3810136,Gastrocnemius masses on day 4 and 6,T-HS/EAA,T-HS/SE,Significantly increased,"the T-HS/EAA group exhibited a significant increase in gastrocnemius mass compared with the T-HS/SE group on days 4 and 6, respectively (p&lt;0.01).",3810136
1588,3810136,Free IGF-1 concentrations at day 4 and day 6,T-HS/Ctr,"T-HS/SE, T-HS/EAA",Significantly decreased,"free IGF-1 concentrations increased gradually, but most slowly in the T-HS/Ctr group, which remained statistically lower than the other EN-treated groups (vs T-HS/SE at day 4, p&lt;0.05; vs T-HS/EAA at day 4, p&lt;0.01; vs T-HS/SE or T-HS/EAA at day 6, p&lt;0.01).",3810136
1589,3810136,Levels of insulin,T-HS/Ctr,PF group,Significantly decreased,"Insulin levels in the T-HS/Ctr group were significantly decreased compared with the PF group at all the time points (p&lt;0.05, at day 2; p&lt;0.01, at day 4 or 6; Figure 6A )",3810136
1590,3810136,S6K1 phosphorylation,T-HS/EAA,T-HS/Ctr and T-HS/SE ,Significantly increased,"After EN treatment, S6K1 phosphorylation increased in both groups, but only with statistical significance observed in the T-HS/EAA group compared with the T-HS/Ctr group (p&lt;0.01). Furthermore, phospho-S6K1 levels in the T-HS/EAA group were also higher than the T-HS/SE group (p&lt;0.05).",3810136
1591,2714198,Survival time,Suture groups,Control groups,No significant difference,No difference in survival time was observed across the different groups.,2714198
1592,2714198,Leeches activity level,Suture groups,Control groups,No significant difference,"Over the course of the 7-day experiment, all leeches survived and exhibited similar activity levels in all 3 groups.",2714198
1593,2911596,Decrease in Surgical Stress Index after fentanyl boluses,Sevoflurane-fentanyl anesthesia,Isoflurane-fentanyl anesthesia,No significant difference,"During surgery, the decrease of SSI after fentanyl boluses was similar in sevoflurane and isoflurane groups",2911596
1594,2911596,Surgical Stress Index values during surgery,Sevoflurane-fentanyl anesthesia,Isoflurane-fentanyl anesthesia,Significantly increased,SSI values in SEVO group were higher than in ISOF group during surgery,2911596
1595,2911596,MAC and SE values before fentanyl boluses,Sevoflurane-fentanyl anesthesia,Isoflurane-fentanyl anesthesia,No significant difference,"MAC and SE values were similar in SEVO and ISOF groups before fentanyl boluses [0.74 Â± 0.12 versus 0.77 Â± 0.17, (P = .32) and 43.5 Â± 8.1 versus 45.2 Â± 8.3, (P = .47), resp.]",2911596
1596,2911596,"HR, MAC and SE values after fentanyl boluses",Sevoflurane-fentanyl anesthesia,Isoflurane-fentanyl anesthesia,No significant difference,"After fentanyl boluses, SE and HR changes were similar and MAC values remained stable in both groups.",2911596
1597,2911596,HR values,Sevoflurane-fentanyl anesthesia,Isoflurane-fentanyl anesthesia,Significantly increased,"HR values were significantly different in SEVO and ISOF groups 70.6 Â± 13.0 versus 64.9 Â± 11.8, (P &lt; .01), respectively",2911596
1598,5434251,Number of practiced exercises ,Patients receiving text messageâ€“based feedback,Patients not receiving text message assistance during follow-up,No significant difference,"The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).",5434251
1599,5434251,PHQ-9 (depressive symptoms) scores,Patients receiving text messageâ€“based feedback,Patients not receiving text message assistance during follow-up,No significant difference,"The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).",5434251
1600,5434251,PTQ (perseverative thinking) scores,Patients receiving text messageâ€“based feedback,Patients not receiving text message assistance during follow-up,No significant difference,"The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).",5434251
1601,5434251,SCS-D (self-compassion) scores,Patients receiving text messageâ€“based feedback,Patients not receiving text message assistance during follow-up,No significant difference,"The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).",5434251
1602,5434251,"Freiburg Mindfulness Inventory (Freiburger Fragebogen zur Achtsamkeit, FFA) scores",Patients receiving text messageâ€“based feedback,Patients not receiving text message assistance during follow-up,No significant difference,"The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).",5434251
1603,4335741,Baseline demographic characteristics,Alfentanil,Remifentanil,No significant difference,"Demographic data (age, weight, and sex) were not significantly different between the two groups (Table 2). As shown in Table 2, group A and group R did not differ significantly in mean age (32. 5 Â± 8. 7 vs. 35 Â± 9. 5 years; P = 0. 165) and mean weight (66 Â± 9. 7 vs. 67. 6 Â± 7. 3 kg; P = 0. 352). Male patients comprised 46% of group A and 58% of group R, indicating that the two groups did not differ significantly in this regard (P = 0. 230).",4335741
1604,4335741,Vocal cords patency,Alfentanil,Remifentanil,Significantly decreased,vocal cords were significantly more patent in group R than those in group A (P = 0. 028),4335741
1605,4335741,Jaw relaxation scores,Alfentanil,Remifentanil,No significant difference,"Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the R and A groups and there were no significant differences",4335741
1606,4335741,Limb movement score,Alfentanil,Remifentanil,No significant difference,"Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the R and A groups and there were no significant differences",4335741
1607,4335741,Scores for ease of laryngoscopy,Alfentanil,Remifentanil,No significant difference,"Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the R and A groups and there were no significant differences",4335741
1608,4086013,Fertilization,New universal medium (GM501),Standard sequential culture medium ISM1,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.",4086013
1609,4086013,Pregnancy,New universal medium (GM501),Standard sequential culture medium ISM1,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.",4086013
1610,4086013,Implantation rates,New universal medium (GM501),Standard sequential culture medium ISM1,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.",4086013
1611,4086013,Live birth rate,New universal medium (GM501),Standard sequential culture medium ISM1,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.",4086013
1612,4086013,Embryos with minimal fragmentation rate,New universal medium (GM501),Standard sequential culture medium ISM1,Significantly increased,"a higher percentage of minimally fragmented embryos, i.e., &lt;â€ˆ30% fragmentation rate, (70% vs. 47.6%, pâ€ˆ=â€ˆ0.0003) were available for transfer when GM501 was used.",4086013
1613,5934937, improvement in the Dysphagia Symptom Questionnaire (DSQ) score,histologic response (â‰¤6 eos/hpf) after treatment,no histologic response (&gt;6 eos/hpf) after treatment,Significantly increased,Patients with a histologic response (â‰¤6 eos/hpf) exhibited a greater improvement in DSQ scores from baseline (visit 2): mean change (Â±SD) [SES]: âˆ’16.2 (Â±14.3) [âˆ’1.09]; p &lt; 0.0001 than those who did not have a histologic response (&gt;6 eos/hpf): mean change: âˆ’9.9 (Â±11.6) [âˆ’0.67]; p &lt; 0.0001 (Table 4).,5934937
1614,5934937,mean DSQ scores,"patients with heartburn, chest pain, regurgitation, nausea or vomiting",patients without these symptoms,Significantly increased,"At baseline (visit 2), patients with heartburn, chest pain, regurgitation, nausea or vomiting had significantly higher (worse) mean DSQ scores than patients without these symptoms (all p &lt; 0.05).",5934937
1615,3430047,mean pain scores at 8 and 24h,subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine),subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine),No significant difference,"However, there was no difference between the groups when comparing mean pain scores at 8 and 24h the first SP instillation of bupivacaine 0.5% (Figure 1).",3430047
1616,3430047,PHS criteria and bupivacaine consumption,subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine),subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine),Significantly decreased,PHS criteria and bupivacaine consumption in SPCA group was significantly lower than in SIA group. (Table 2).,3430047
1617,3430047,"the incidence of adverse effects, such as pneumonia, atelectasis, bronchoscopic interventions, reintubations, hypersensitivity and postoperative ICU and hospital stay",subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine),subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine),No significant difference,"there were no significant differences between the SP-treatment groups comparing the incidence of adverse effects, such as pneumonia, atelectasis, bronchoscopic interventions, reintubations, hypersensitivity and postoperative ICU and hospital stay (Table 1)",3430047
1618,3430047,VAS scores for 24 hr,subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine),subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine),No significant difference,"When VAS scores were analyzed duration 24h, there were also no differences between the groups. There werenâ€™t any differences between sex and VAS scores at three times. (p&lt;0.05)",3430047
1619,3430047,VAS mean score at 16 h,subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine),subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine),Significantly decreased,VAS mean score at 16 h after the first SP instillation of bupivacaine 0.5% in SPCA group was significantly reduced to SIA group.,3430047
1620,4409094,plasma D-dimer values,"intravenous injection of rhC1INH (50 IU/kg for patients &lt;84 kg, or 4200 IU for patients â‰¥84 kg)",saline,No significant difference,"Of note, severe attacks treated with rhC1INH did tend to have lower plasma D-dimer values (280 [109â€“925] Î¼g/l) by Day 7 than those treated with saline (560 [273â€“4056] Î¼g/l; P = 0.1323, not significant).",4409094
1621,4409094,Thrombotic/thromboembolic events (TEE) or DVT ,"intravenous injection of rhC1INH (50 IU/kg for patients &amp;lt;84 kg, or 4200 IU for patients â‰¥84 kg)",saline,No significant difference,"No increased risk of DVT was identified, nor any TEE reported in rhC1INH treated or controls.",4409094
1622,3719224,"the variables of knowledge, perceived susceptibility, and perceived benefit",received educational intervention plus routine education,received just routine education,Significantly increased,"Table 2 shows a significant difference in the intervention group between two time points of before and after intervention with regard to the variables of knowledge, perceived susceptibility, and perceived benefit (P &lt; 0.05).",3719224
1623,3719224,"the variables, knowledge",received educational intervention plus routine education,received just routine education,Significantly increased,"there were significant differences between the two groups in mean scores of the variables, knowledge (4.62 Â± 1.38 vs. 3.53 Â± 1.61),",3719224
1624,3719224,perceived susceptibility,received educational intervention plus routine education,received just routine education,Significantly increased,perceived susceptibility (14.05 Â± 1.51 vs. 12.37 Â± 2.11),3719224
1625,3719224,perceived benefits,received educational intervention plus routine education,received just routine education,Significantly increased,"perceived benefits (28.41 Â± 2.14 vs. 27.51 Â± 3.05), at follow-up time after 3 months (P &lt; 0.05).",3719224
1626,3640164,The use of midazolam,popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator,spinal anesthesia with 2.5 ml of 0.5% bupivacaine  ,No significant difference,"he use of midazolam was more frequent in the spinal anesthesia group than in the PSNB group, but there was no statistical significance (Table 2).",3640164
1627,3640164,unpleasant feelings during surgery and anxiety,popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator,spinal anesthesia with 2.5 ml of 0.5% bupivacaine  ,No significant difference,"According to the survey, unpleasant feelings during surgery and anxiety were higher in the spinal anesthesia group, but there was no statistical significance.",3640164
1628,3640164,Incisional pain,popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator,spinal anesthesia with 2.5 ml of 0.5% bupivacaine  ,No significant difference,"Incisional pain was not reported in the spinal anesthesia group but was reported by 15% (3 cases) of patients in the PSNB group; however, these figures were not statistically significant (Table 3).",3640164
1629,3640164,satisfied with the anesthesia procedure,popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator,spinal anesthesia with 2.5 ml of 0.5% bupivacaine  ,No significant difference,"In the satisfaction survey, 60% (12 cases) of the spinal anesthesia group and 85% (17 cases) of the PSNB group responded that they were satisfied with the anesthesia procedure (including those who responded 'average'), although the results were not statistically significant (Table 4).",3640164
1630,3640164,"The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time",popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator,spinal anesthesia with 2.5 ml of 0.5% bupivacaine  ,Significantly increased,"The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time were shorter in the spinal anesthesia group than in the PSNB group (P &lt; 0.01).",3640164
1631,3640164,he anesthesia-related side effects,popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator,spinal anesthesia with 2.5 ml of 0.5% bupivacaine  ,No significant difference,"The anesthesia-related side effects in the spinal anesthesia group were hypotension, bradycardia, shivering, vomiting, postoperative headache, and urinary retension, occurring in 15%, 10%, 5%, 5%, 10%, and 20% of patients, respectively. There was no incidence of side effects in the PSNB group, but it was not statistically significant.",3640164
1632,5420386,Mystical Experience Questionnaire (MEQ) scores,oral administration of 100 and 200&nbsp;Î¼g LSD,placebo,Significantly increased,"LSD (200&nbsp;Î¼g) significantly increased all MEQ scores compared with placebo (Fig. 1a, Table 1).",5420386
1633,5420386,MEQ43 and MEQ30,oral administration of 100 and 200&amp;nbsp;Î¼g LSD,placebo,Significantly increased,"In the present study in healthy subjects, LSD (200&nbsp;Î¼g) significantly increased scores on all scales of the MEQ43 and MEQ30 compared with placebo (Table 1).",5420386
1634,5420386,all dimensions and subscales of the 5D-ASC scale,oral administration of 200 Î¼g LSD,100&nbsp;Î¼g dose of LSD,Significantly increased,"LSD induced pronounced peak alterations of waking consciousness, with significant increases in all dimensions and subscales of the 5D-ASC scale (Fig. 2).",5420386
1635,5420386,overall ASC scale,oral administration of 100 and 200&amp;amp;amp;nbsp;Î¼g LSD,placebo,Significantly increased,"The 200&nbsp;Î¼g dose of LSD produced significantly greater scores on the overall ASC scale, the dimension of visionary restructuralization, and the blissful state, insightfulness, and changed meaning of percepts subscales compared with the 100&nbsp;Î¼g dose (Fig. 2, Table 1).",5420386
1636,5420386,all of the scales,oral administration of 100 and 200&amp;amp;amp;amp;nbsp;Î¼g LSD,placebo,Significantly increased,"LSD-induced changes on the 5D-ASC scale were significant compared with placebo for both doses and all of the scales, with the exception of the effects of the 200&nbsp;Î¼g dose on anxiety (Table 1).",5420386
1637,5420386,"ratings of blissful state, insightfulness, and changed meaning of percepts",oral administration of 200 Î¼g LSD,100&amp;nbsp;Î¼g dose of LSD,Significantly increased,"At 200&nbsp;Î¼g, LSD produced significant and relevantly higher ratings of blissful state, insightfulness, and changed meaning of percepts compared with 100&nbsp;Î¼g (one asterisk p&nbsp;&lt;&nbsp;0.05, two asterisks p&nbsp;&lt;&nbsp;0.01, t tests).",5420386
1638,270000,"chemical, clinical and continuing pregnancies, rate of live birth",Bravelle(R) ,Follistim(R,No significant difference,"Although patients receiving Bravelle(R) consistently reported a greater number of chemical, clinical and continuing pregnancies, as well as an increased rate of live birth, the data did not attain statistical significance (P &gt; 0.05).",270000
1639,270000,"total dose of FSH administered, the duration of treatment or peak estradiol levels",Bravelle(R) ,Follistim(R,No significant difference,"No significant differences were observed in the total dose of FSH administered, the duration of treatment or peak estradiol levels between groups (Table 2).",270000
1640,270000,adverse events,Bravelle(R) ,Follistim(R,No significant difference,"There were no significant differences in the number of patients reporting adverse events (P = 0.680), severe adverse events (P = 0.307) or serious adverse events (P = 0.161) between the BravelleÂ® or FollistimÂ® groups. The most frequently reported adverse events were headache, abdominal cramps, vaginal bleeding/spotting and nausea (Table 3).",270000
1641,270000,pain score,Bravelle(R) ,Follistim(R,Significantly decreased,A two-way ANOVA model used to compare mean daily injection-site pain revealed a significantly lower pain score in BravelleÂ® patients on most treatment days and during the entire treatment period (P &lt; 0.05).,270000
1642,3309311,"differences in the disc herniation, HDD, annulus tear, and HIZ","adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",Significantly increased,"There were significant differences in the disc herniation, HDD, annulus tear, and HIZ between the patients with acute severe lower back pain (group A) and the control group B (p&lt;0.05) (Table 3).",3309311
1643,3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",Significantly increased,"The proportion of HIZ incidence was significantly higher in group A than in control group B, and in the patients with severe radiating pain (control group C) (p&lt;0.05) (Table 3).",3309311
1644,3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)",adults with LBP with radicular pain (group C),Significantly increased,"The proportion of HIZ incidence was significantly higher in group A than in control group B, and in the patients with severe radiating pain (control group C) (p&lt;0.05) (Table 3).",3309311
1645,5498096,pain intensity and disability index,stabilization exercise in prone position group (SIP),baseline,Significantly decreased,"The result revealed that there was a significant reduction between pretreatment, 4th week of PI (F=22.500, P&lt;0.001) and DI (F= 15.582, P&lt;0.001) and 8th week.",5498096
1646,5498096,pain intensity and disability index,stabilization in supine position group (SIS),baseline,Significantly decreased,"The result revealed that there was a significant reduction when pretreatment, 4th week of PI (F= 13.314, P&lt;0.001) and DI (F=15.95 P&lt;0.001) and 8th week were compared.",5498096
1647,5498096,pain intensity and disability index,stabilization in prone and supine group (SIPS),baseline,Significantly decreased,"The result revealed that there was a significant reduction between pretreatment and 4th week PI (F=17.894, P&lt; 0.001) and DI (F=17.200 P&lt;0.000) and 8th week.",5498096
1648,5498096,pain intensity and functional disability,stabilization in prone (SIP),stabilization in supine (SIS) or prone and supine (SIPS) position group,No significant difference,"However, the result showed that there was no significant difference in the PI and FD at the 8th week (P&gt;0.05) of the treatment sessions across the three groups when compared.",5498096
1649,2856148,acute exacerbation of COPD,Noninvasive ventilation (NIV),Pressure support ventilation (PSV),No significant difference,"Five patients developed VAP in the PSV group, where as only one patient had pneumonia in the NIV group. Lesser number of deaths in the NIV group at discharge from ICU (3 vs. 5 patients, respectively) and at 30 days (5 vs. 9 patients, respectively), it did not achieve statistical significance (P &gt; 0.05).",2856148
1650,2856148,time spent on mechanical ventilation,Noninvasive ventilation (NIV),Pressure support ventilation (PSV),No significant difference,"There was no difference in the time spent on mechanical ventilation between the two groups i.e. 6.20 Â± 5.20 day's vs. 7.47 Â± 6.38 days in Gp I and Gp II, respectively (P &gt; 0.05, Table 3).",2856148
1651,2856148,days spend in the ICU,Noninvasive ventilation (NIV),Pressure support ventilation (PSV),No significant difference,"Patients weaned by NIV spent nearly 2 days less in the ICU, in comparison to weaning by PSV (8.47 Â± 4.79 vs. 10.80 Â± 5.28 days), the difference was not statistically significant (P &gt; 0.05, Table 3).",2856148
1652,2856148,Mortality at discharge from ICU,Noninvasive ventilation (NIV),Pressure support ventilation (PSV),No significant difference,"Mortality at discharge from ICU, three (20% mortality) and five deaths (33.33% mortality), respectively, were observed in the NIV and PSV group at the time of ICU discharge. Nevertheless, the difference was not statistically significant (P &gt; 0.05, Table 3). At 30 days, there were lesser number of absolute deaths in the NIV group (5 vs. 9); however, it did not achieve statistical significance (P &gt; 0.05, Table 3)",2856148
1653,2856148,duration of weaning,Noninvasive ventilation (NIV),Pressure support ventilation (PSV),No significant difference,"No difference in duration of weaning was observed between NIV and PSV groups (35.17 Â± 16.98 and 47.05 Â± 20.98 hrs, respectively, p.&gt;0.05, Table 3).",2856148
1654,2291328,mortality in CIBIS trial,bisoprolol,placebo ,No significant difference,This difference was not statistically significant with a risk reduction of 0.80 (0.56â€“1.15).,2291328
1655,2291328,heart rate reduction and blood pressure reduction in CIBIS-II study ,Bisoprolol,placebo,Significantly increased,"Bisoprolol induced a significant heart rate reduction (of 9.8 Â± 14.7 beats/min), with a limited effect on blood pressure (systolic blood pressure reduction of 4.1 Â± 16.4 mmHg with bisoprolol but of 2.3 Â± 16.4 mmHg with placebo) (Lechat et al 2001).",2291328
1656,2291328,"heart rate, hospital admission, sudden cardiac death, hospital admission for worsening heart failure in CIBIS-II study ",Bisoprolol,placebo,Significantly decreased,"Bisoprolol significantly reduced cardiovascular mortality (HR: 0.71 [0.56â€“0.9]), sudden cardiac death (HR: 0.56 [0.39â€“0.80]), hospital admission (HR: 0.80 [0.71â€“0.91]), and hospital admission for worsening heart failure (HR: 0.64 [0.53â€“0.79]) compared with placebo.",2291328
1657,2291328,mortality in CIBIS-III ,10 mg/day for bisoprolol,20 mg/day for enalapril,No significant difference,"There were fewer deaths in the bisoprolol-first group than in the enalapril-first group, but the difference was not statistically significant (65 vs 73, HR: 0.88 [0.63â€“1.22], p = 0.44).",2291328
1658,2291328,hospitalization hospitalization for worsening CHF in CIBIS-III,10 mg/day for bisoprolol,20 mg/day for enalapril,No significant difference,"There was a non-significant increase in the number of patients having a hospitalization for worsening CHF in the bisoprolol-first group compared with the enalapril-first group (63 vs 51 patients, respectively, HR = 1.25 [0.87â€“1.81], p = 0.23).",2291328
1659,3489577,"blood pressure, other anthropometric or laboratory measures",100grams of instant oat cereal,100 grams of wheat flour-based noodles,No significant difference,"There were no significant changes in blood pressure, other anthropometric or laboratory measures between the two groups at the end of the intervention.",3489577
1660,3489577,dietary fiber,100 grams of instant oat cereal,100 grams of wheat flour-based noodles,Significantly increased,"After 6 weeks of intervention, dietary fiber significantly increased among the oat group compared to the control group (p&lt;0.001).",3489577
1661,3489577,Waist circumference,100 grams of instant oat cereal,100 grams of wheat flour-based noodles,Significantly decreased,Waist circumference significantly decreased after 6weeks in the oat group compared to the control group (p=0.002).,3489577
1662,3489577,plasma glucose levels,100 grams of instant oat cereal,100 grams of wheat flour-based noodles,No significant difference,There were no significant differences in plasma glucose levels between the two groups.,3489577
1663,3489577,total cholesterol and LDL-C ,100 grams of instant oat cereal,100 grams of wheat flour-based noodles,Significantly decreased,The oat group showed significant decreases in total cholesterol (p=0.015) and LDL-C (p=0.028) compared to the control group.,3489577
1664,3489577,HDL-C,100 grams of instant oat cereal,100 grams of wheat flour-based noodles,Significantly increased,HDL-C decreased significantly in the control group compared to the oat group (p=0.017).,3489577
1665,5017045,The mean consultation duration,video-assisted remote consultations,standard consultation (UNN),No significant difference,The mean consultation duration was not significantly different between the groups (pâ€‰=â€‰0.60).,5017045
1666,5017045,The mean consultation duration in the subgroup patients who required casting,video-assisted remote consultations ,standard consultation (UNN),Significantly increased,"In the subgroup analyses restricted to patients who required casting, we observed a significantly longer mean consultation time in the RMC group (29.0&nbsp;min) compared to the UNN group (22.6&nbsp;min, pâ€‰=â€‰0.0063).",5017045
1667,5017045,number of operated patients,video-assisted remote consultations,standard consultation,No significant difference,There were no significant differences in the number of operated patients between the two groups (pâ€‰=â€‰0.432).,5017045
1668,5017045,numbers of consultations ,video-assisted remote consultations,standard consultation,No significant difference,"There was a tendency toward more consultations in the RMC group, but this was not statistically significant (pâ€‰=â€‰0.057).",5017045
1669,5017045,"number of â€˜discharged patientsâ€™ (i.e. in those who were not referred for operation, a standard consultation or any follow-up appointment for chronic disorders with the orthopaedic department within six months).",video-assisted remote consultations,standard consultation,No significant difference,"Furthermore, no significant difference was observed in the subgroup of â€˜discharged patientsâ€™ (i.e. in those who were not referred for operation, a standard consultation or any follow-up appointment for chronic disorders with the orthopaedic department within six months).",5017045
1670,5017045,the sum score of the orthopaedic surgeonâ€™s evaluation,video-assisted remote consultations,standard consultation (UNN),Significantly decreased,"The primary outcome â€“ the sum score of the orthopaedic surgeonâ€™s evaluation â€“ was significantly lower, in other words, â€˜betterâ€™, at UNN compared to RMC (1.72 versus 1.82, pâ€‰=â€‰0.0030). However, the 90&nbsp;% CI for the difference in score (0.05, 0.17) was within the non-inferiority margin (Fig.&nbsp;2).",5017045
1671,2941605,myelosuppression,Cisplatin 40mg/m2,Vinorelbine 6mg/m2,Significantly increased,"When arm B was compared with arm A, myelosuppression was higher in arm A (statistically significant, P-value 0.05).",2941605
1672,2941605,Skin reaction,Cisplatin 40mg/m2,Vinorelbine 6mg/m2,Significantly decreased,Skin reaction was also lower in the Vinorelbine arm when compared with the other arm.,2941605
1673,2941605,Nausea,Cisplatin 40mg/m2,Vinorelbine 6mg/m2,Significantly increased,Skin reaction was also lower in the Vinorelbine arm when compared with the other arm. Nausea was significantly higher in arm A (RT+cisplatin) when compared with arm B [Table 3.],2941605
1674,4737200,early stance peak EKAM,barefoot walking,control shoe,Significantly decreased,"When we examined the effects of the conditions on measures of medial loading (Tables 1 and 2, Fig. 3), we found that barefoot walking had the greatest effect on early stance peak EKAM, lowering it by âˆ’7.6% (pâ€‰&lt;â€‰0.001 vs. control shoe).",4737200
1675,4737200,second peak in EKAM during late stance,lateral wedge insoles,control condition,Significantly decreased,"For the second peak in EKAM during late stance, both of the lateral wedge insoles significantly reduced the magnitude of this peak in comparison to the control condition.",4737200
1676,4737200,mobility,barefoot conditions,control condition,No significant difference,There was no difference in the mobility or barefoot conditions in comparison to the control condition.,4737200
1677,4737200,knee adduction angular impulse (KAAI),barefoot condition,control condition,Significantly decreased,"For the knee adduction angular impulse (KAAI), the barefoot condition and the two lateral wedge conditions were significantly different in comparison to the control condition (barefoot âˆ’4.3%, pâ€‰=â€‰0.023; typical wedge âˆ’7.95%, pâ€‰&lt;â€‰0.001; supported wedge âˆ’5.5%, pâ€‰&lt;â€‰0.001).",4737200
1678,4737200,knee adduction angular impulse (KAAI),typical wedge,control condition,Significantly decreased,"For the knee adduction angular impulse (KAAI), the barefoot condition and the two lateral wedge conditions were significantly different in comparison to the control condition (barefoot âˆ’4.3%, pâ€‰=â€‰0.023; typical wedge âˆ’7.95%, pâ€‰&lt;â€‰0.001; supported wedge âˆ’5.5%, pâ€‰&lt;â€‰0.001).",4737200
1679,4737200,knee adduction angular impulse (KAAI),supported wedge,control condition,Significantly decreased,"For the knee adduction angular impulse (KAAI), the barefoot condition and the two lateral wedge conditions were significantly different in comparison to the control condition (barefoot âˆ’4.3%, pâ€‰=â€‰0.023; typical wedge âˆ’7.95%, pâ€‰&lt;â€‰0.001; supported wedge âˆ’5.5%, pâ€‰&lt;â€‰0.001).",4737200
1680,4737200,early stance peak EKAM,each of the two lateral wedge conditions,barefoot walking,No significant difference,Pairwise comparisons (see supplementary material eTables S1â€“3) showed that there were no significant differences in the effects on the early stance peak in EKAM between each of the two lateral wedge conditions and barefoot walking.,4737200
1681,4737200,early stance peak EKAM,barefoot condition,mobility shoe,Significantly decreased,"However, the early stance peak in EKAM in the barefoot condition was reduced significantly more than the mobility shoe (mean difference âˆ’0.024â€‰Nm/kg, pâ€‰=â€‰0.004)",4737200
1682,4737200,second peak in EKAM,both of the lateral wedge insoles,barefoot,Significantly decreased,"For the second peak in EKAM, both of the lateral wedge insoles had significantly greater reductions than the barefoot (typical wedge mean difference âˆ’0.029â€‰Nm/kg, pâ€‰&lt;â€‰0.01; supported wedge mean difference âˆ’0.019â€‰Nm/kg, pâ€‰=â€‰0.004) and mobility (typical wedge mean difference âˆ’0.023â€‰Nm/kg, pâ€‰&lt;â€‰0.01; supported wedge mean difference âˆ’0.013â€‰Nm/kg, pâ€‰=â€‰0.024) conditions.",4737200
1683,4737200,mobility,both of the lateral wedge insoles,barefoot,Significantly decreased,"For the second peak in EKAM, both of the lateral wedge insoles had significantly greater reductions than the barefoot (typical wedge mean difference âˆ’0.029â€‰Nm/kg, pâ€‰&lt;â€‰0.01; supported wedge mean difference âˆ’0.019â€‰Nm/kg, pâ€‰=â€‰0.004) and mobility (typical wedge mean difference âˆ’0.023â€‰Nm/kg, pâ€‰&lt;â€‰0.01; supported wedge mean difference âˆ’0.013â€‰Nm/kg, pâ€‰=â€‰0.024) conditions.",4737200
1684,4737200,knee adduction angular impulse (KAAI),typical wedge,mobility shoe,Significantly decreased,"A larger second peak reduction in the typical wedge resulted in a significant reduction in KAAI in comparison to the mobility shoe (mean difference 0.008 Nm/kgâ€‰s, pâ€‰=â€‰0.011).",4737200
1685,4737200,walking speed,mobility shoe,control shoe,Significantly increased,"Compared with the control shoe, walking speed increased by 0.03m/s with the mobility shoe (95%CIâ€‰0.02â€“0.04, pâ€‰&lt;â€‰0.001) and slowed by 0.04â€‰m/s with barefoot walking (95%CI âˆ’0.05 to âˆ’0.03, pâ€‰&lt;â€‰0.001), but with adjustment for walking speed, this did not affect the overall findings or their significance.",4737200
1686,4737200,walking speed ,barefoot walking,control shoe,Significantly decreased,"Compared with the control shoe, walking speed increased by 0.03m/s with the mobility shoe (95%CIâ€‰0.02â€“0.04, pâ€‰&lt;â€‰0.001) and slowed by 0.04â€‰m/s with barefoot walking (95%CI âˆ’0.05 to âˆ’0.03, pâ€‰&lt;â€‰0.001), but with adjustment for walking speed, this did not affect the overall findings or their significance.",4737200
1687,4737200,maximum external knee flexion moment (KFM) (etable 3) during early stance,barefoot condition,control shoe and all other conditions,Significantly decreased,"In comparison with the control shoe and all other conditions, the barefoot condition had significant reductions in the maximum external knee flexion moment (KFM) (etable 3) during early stance. No other changes in external knee flexion moment were seen.",4737200
1688,5362210,Risk of severe brain injury or death,Cerebral NIRS monitoring in combination with an evidence based intervention guideline,Blinded collection of NIRS values combined with treatment as usual,Significantly decreased,the statistical significance of the randomisation indicator means that the risk of severe brain injury or death in the experimental group of the SafeBoosC-II trial was less in the experimental group than in the control group when adjusted for a number of other factors.,5362210
1689,5362210,Burden of hypoxia within the 4th quartile versus quartile 1â€“3,Cerebral NIRS monitoring in combination with an evidence based intervention guideline,Blinded collection of NIRS values combined with treatment as usual,Significantly decreased,"there were significantly fewer infants form the intervention group with a burden of hypoxia in the 4th quartile, than in quartile 1â€“3",5362210
1690,5362210,Burden of hyperoxia within the 4th quartile versus quartile 1â€“3,Cerebral NIRS monitoring in combination with an evidence based intervention guideline,Blinded collection of NIRS values combined with treatment as usual,No significant difference,"the burden of cerebral hyperoxia within the 4th quartile versus quartile 1â€“3, was unaffected by allocation in the SafeBoosC trial",5362210
1691,3600348,Positive predictive value for extubation failure,Automatic tube compensation,Pressure support ventilation,No significant difference,"In the ATC group (n = 17), 11 (65%) patients passed the SBT with subsequent extubation failure (9%). While in PSV group (n = 19), 10 (53%) patients passed the SBT with subsequent extubation failure (10%). This represented a positive predictive value for ATC of 91% and PSV of 90% (P = 0.52).",3600348
1692,3600348,Baseline characteristics,Automatic tube compensation,Pressure support ventilation,No significant difference,There were no significant differences between the ATC and PSV groups in any of the compared items.,3600348
1693,3600348,Extubation failure,Automatic tube compensation,Pressure support ventilation,No significant difference,Failed extubation was equal in both groups (P = 0.9),3600348
1694,3600348,Causes of reintubation,Automatic tube compensation,Pressure support ventilation,No significant difference,There were no significant difference in the causes of reintubation between the two groups (P = 0.46).,3600348
1695,3600348,Breathing trial failure,Automatic tube compensation,Pressure support ventilation,No significant difference,We found that 9 of 19 (47%) patients in the PSV group failed the breathing trial compared to only 6 of 17 (35%) patients in the ATC group. This observed difference of 12% between both groups however did not reach statistical significance (P = 0.69).,3600348
1696,4045368,Follow-up duration,Locking plate fixation,Nonlocking plate fixation,No significant difference,"No difference was observed in the duration of follow-up between the locking plate and nonlocking plate groups (10.61 Â± 3.05 months versus 12.95 Â± 2.63 months, P = 0.158).",4045368
1697,4045368,Severity of the tibial plateau fractures,Locking plate fixation,Nonlocking plate fixation,No significant difference,No significant differences were found between the two groups in the severity of the tibial plateau fractures according to the Schatzker (P = 0.556) or AO (P = 0.257) classifications systems (Figures 2 and 3).,4045368
1698,4045368,Mean knee scores at follow-up,Locking plate fixation,Nonlocking plate fixation,Significantly increased,"The mean of knee scores was significantly higher in the locking plate group as compared with the nonlocking plate group at the most recent follow-up (80.20 Â± 10.21 versus 72.52 Â± 14.75, P = 0.039).",4045368
1699,4045368,Mean functional score at follow-up,Locking plate fixation,Nonlocking plate fixation,Significantly increased,"the mean of functional score was also higher in the locking plate group than in the nonlocking plate group at the follow-up (77.26 Â± 9.95 versus 69.55 Â± 10.22, P = 0.026).",4045368
1700,4045368,Mean VAS pain score,Locking plate fixation,Nonlocking plate fixation,Significantly decreased,"The mean VAS pain score was significantly lower in the locking plate group compared with the nonlocking plate group (4.45 Â± 2.50 versus 6.00 Â± 2.59, P = 0.046).",4045368
1701,3403627,Pain scores,Auricular acupressure therapy,Sham control group,No significant difference,No differences were found in pain scores between the groups at all points.,3403627
1702,3403627,Use of analgesic drugs,Auricular acupressure therapy,Sham control group,Significantly decreased,The analgesic drug usage (38.49 Â± 15.53â€‰mg of morphine) in the acupressure group patients was significantly lower than in the sham control group patients (53.07 Â± 19.90â€‰mg) (P &lt; 0.05).,3403627
1703,3403627,Passive knee motion at 3 days after surgery,Auricular acupressure therapy,Sham control group,Significantly increased,"On the 3rd day after surgery, the passive knee motion in the acupressure group patients was significantly better than in the sham control group patients (P &lt; 0.05)",3403627
1704,5556332,UPAT scores,"Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery",No PAN administered before the surgery,Significantly decreased,"Patients in the PAN group had significantly lower UPAT scores at 0, 2, 4, 6, 12, 24 and 48 hours after the surgery than those in the control group (P = 0.008, 0.021, 0.008, 0.047, 0.004, 0.001, and 0.001).",5556332
1705,5556332,Consumption of morphine after the surgery,"Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery",No PAN administered before the surgery,Significantly decreased,The mean dose of postoperative morphine consumption in the PAN group was 37% less than the control group (P = 0.001).,5556332
1706,5556332,Rate of complications,"Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery",No PAN administered before the surgery,No significant difference,The complications were not significantly different between the two groups.,5556332
1707,5556332,Satisfaction with pain control as reported by surgeons,"Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery",No PAN administered before the surgery,Significantly increased,Surgeons reported more satisfaction with pain control in the medication group in 24 and 48 hours after surgery (P = 0.001),5556332
1708,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1709,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1710,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1711,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1712,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1713,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1714,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1715,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1716,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1717,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1718,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1719,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1720,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1721,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1722,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1723,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1724,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1725,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1726,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1727,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1728,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1729,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1730,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1731,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1732,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1733,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1734,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1735,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1736,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1737,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1738,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1739,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1740,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1741,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1742,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1743,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1744,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1745,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1746,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1747,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1748,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1749,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1750,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1751,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1752,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1753,5742644,Subjective well-being,Haloperidol,Placebo,No significant difference,"The 2 Ã— 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâ€™s &gt; 0.531).",5742644
1754,5742644,Stimulation outcomes,Haloperidol,Placebo,No significant difference,"A 2 Ã— 3 Ã— 2 ANOVA revealed a significant main effect of context (F(1.79,34.07) = 75.65; p &lt; 0.0001) and a significant interaction between context and stimulation outcome (F(1.34 25.54) = 4.09; p = 0.043), but no interaction with the factor drug (other pâ€™s &gt; 0.089). Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâ€™s &gt; 0.093).",5742644
1755,5742644,Habituation from phase I to phase III,Haloperidol,Placebo,Significantly decreased,"Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III.",5742644
1756,5742644,Brain regions with adaptive coding ,Haloperidol,Placebo,No significant difference,"we identified brain regions with adaptively coded responses to stimulation outcome irrespective of drug treatment (i.e., main effect of adaptive coding). FWE-corrected whole brain analysis did not reveal any significant effects. Subsequently, a SVC was performed, using the insula and ACC as masks (see â€œIntroductionâ€� section: Ploner et al., 2011; Leknes et al., 2013); this analysis also did not reveal any significant main effects or interactions (p &lt; 0.05, FWE-corrected, k &gt; 5 voxel).",5742644
1757,5742644,Discrimination between stimulation intensities,Haloperidol,Placebo,No significant difference,participants were equally able to differentiate between stimulation intensities irrespective of time and drug.,5742644
1758,4199180,Chance of survival ,Pentoxifylline plus prednisolone (Group 2),Pentoxifylline alone (Group 1),No significant difference,survival probability is higher among Group 1 patients but the difference is not statistically significant.,4199180
1759,4199180,Rate of morbidity and complications,Pentoxifylline plus prednisolone (Group 2),Pentoxifylline alone (Group 1),No significant difference,The morbidity/complication profiles among the two groups were comparable,4199180
1760,4199180,MDF scores and MELD scores at 4 weeks,Pentoxifylline plus prednisolone (Group 2),Pentoxifylline alone (Group 1),Significantly increased,"MDF score and MELD score were observed to be significantly lower among patients receiving PTX at the end of 4 week, as compared to those receiving PTX plus prednisolone (P &lt; 0.05 and &lt; 0.01 respectively)",4199180
1761,4199180,"Child-Pugh, GAHS, MDF, and MELD scores at 3 months, 6 months, and 1 year",Pentoxifylline plus prednisolone (Group 2),Pentoxifylline alone (Group 1),No significant difference,"there were no significant differences in MELD, MDF, Child-Pugh and GAHS score between two groups at the end of 3 months, 6 months and 1 year.",4199180
1762,4526979,Baseline demographics,Website users,Nonusers,No significant difference,"Baseline demographics between groups were similar for gender (152/195, 77.9% female), age (mean 60, SD 9 years) and body mass index (mean 31.1, SD 6.8 kg/m2).",4526979
1763,4526979,"Self-management as measured on the OAQI, after 12 months",Website users,Nonusers,Significantly increased,"Following 12 months of exposure to the website, there were significant improvements for users compared to nonusers in self-management (absolute change score 15% vs 2%, P=.001) and weight reduction (absolute change scores 3% vs â€“6%, P=.03) measured on the OAQI.",4526979
1764,4526979,"Weight reduction as measured on the OAQI, after 12 months",Website users,Nonusers,Significantly increased,"Following 12 months of exposure to the website, there were significant improvements for users compared to nonusers in self-management (absolute change score 15% vs 2%, P=.001) and weight reduction (absolute change scores 3% vs â€“6%, P=.03) measured on the OAQI.",4526979
1765,4526979,Domains examined for the heiQ,Website users,Nonusers,No significant difference,"All domains, except health service navigation, showed a clear positive trend in change scores (the difference between follow-up and baseline) in the intervention group relative to nonusers, although the differences in change between the groups were not statistically significant",4526979
1766,4526979,Treatment categories change scores,Website users,Nonusers,No significant difference,"Between the intervention group and nonusers, there were minimal differences that did not reach statistical significance in core treatments (change scores 10.3% vs 4.7%, P=.17), adjunct treatments (change scores 3.1% vs 1.2%, P=.54), pharmacological treatments (change scores â€“1.7% vs â€“2.4%, P=.35), and nonpharmacological treatments (change scores 9.5% vs 4.0%, P=.29).",4526979
1767,4780150,Total body stores of vitamin A,Sachets of â€œSprinklesâ€� with vitamin A,Sachets of â€œSprinklesâ€� without vitamin A,No significant difference,"After intervention, total body stores (TBS) and liver retinol concentrations did not differ between intervention and control groups; TBS were 436 (SD 303) and 434 (SD 186) Î¼mol, respectively",4780150
1768,4780150,Vitamin A concentrations in the liver,Sachets of â€œSprinklesâ€� with vitamin A,Sachets of â€œSprinklesâ€� without vitamin A,No significant difference,"After intervention, total body stores (TBS) and liver retinol concentrations did not differ between intervention and control groups; TBS were 436 (SD 303) and 434 (SD 186) Î¼mol, respectively, and estimated liver concentrations were 0Â·82 (SD 0Â·53) and 0Â·79 (SD 0Â·36) Î¼mol/g liver",4780150
1769,4780150,Anthropometric indices,Sachets of â€œSprinklesâ€� with vitamin A,Sachets of â€œSprinklesâ€� without vitamin A,No significant difference,Weight and height of enrolled children did not differ at baseline and endline. There was no change observed in other anthropometric indices between the intervention and the control groups,4780150
1770,4780150,Anaemia,Sachets of â€œSprinklesâ€� with vitamin A,Sachets of â€œSprinklesâ€� without vitamin A,No significant difference,"At the end of the supplementation period, more infants tended to be anaemic in the control group as compared with the intervention group (23â€‰Â·â€‰5&nbsp;% vs. 31â€‰Â·â€‰6&nbsp;%) but this was not significant (Table&nbsp;2).",4780150
1771,4780150,Baseline MRDR values,Sachets of â€œSprinklesâ€� with vitamin A,Sachets of â€œSprinklesâ€� without vitamin A,No significant difference,"At baseline, the MRDR values (95&nbsp;% CI) for infants were comparable in the intervention and control groups: normal at 0Â·032 (SD 0Â·018) (0Â·025â€“0Â·038) and 0Â·031 (SD 0Â·018) (0Â·024â€“0Â·038), respectively.",4780150
1772,4472776,Mean cost per patient,Chlorhexidine gluconate dressing,Transparent dressings,No significant difference,"The mean cost difference per patient of â‚¬141 is not statistically significant (95% confidence interval: [â‚¬-975; â‚¬1,258]).",4472776
1773,4472776,Number of days in the ICU,Chlorhexidine gluconate dressing,Transparent dressings,No significant difference,The number of ICU-days as well as the number of days before discharge and death occurred was comparable in the two groups.,4472776
1774,4472776,Number of days admitted in the hospital,Chlorhexidine gluconate dressing,Transparent dressings,No significant difference,The number of ICU-days as well as the number of days before discharge and death occurred was comparable in the two groups.,4472776
1775,4472776,Catheter-related bloodstream infection,Chlorhexidine gluconate dressing,Transparent dressings,Significantly decreased,"A ratio of 1 to 5 was observed for the average number of CRBSIs between CHG and non-CHG dressing groups. CRBSI occurred for 3 and 14 patients in each CHG and non-CHG groups respectively (1,000 patients in each group; Table 3). This difference was highly statistically significant as indicated by the non-overlapping 95% confidence intervals (CI).",4472776
1776,4137650,Mean arterial pressure after laryngoscopy and intubation,Placebo (Group C) and esmolol (Group E),Dexmedetomidine (Group D),Significantly increased,The mean arterial pressure was significantly increased in patients receiving placebo (P &lt; 0.0001) and esmolol (P &lt; 0.0001) after laryngoscopy and intubation compared with baseline value and Group D (P = 0.6294),4137650
1777,4137650,Mean heart rate after intubation,Placebo (Group C) and esmolol (Group E),Dexmedetomidine (Group D),Significantly increased,"The increase in mean HR after intubation was seen in all the three groups. But the mean increase was minimal 5.83% in Group D (4 beats, P = 0.0848), when compared with Group E 14% (9.81beats; P = 0.0152) and Group C 30% (24.9 beats; P &lt; 0.0001), which was highly significant (P &lt; 0.0001).",4137650
1778,4137650,Mean systolic arterial pressure after intubation,Placebo (Group C) and esmolol (Group E),Dexmedetomidine (Group D),Significantly increased,"The mean SAP levels in Group D were significantly lower than Groups C and E immediately after intubation (P &lt; 0.001, P &gt; 0.001 respectively) and until the end of surgery.",4137650
1779,4137650,Mean diastolic arterial pressure after intubation,Placebo (Group C) and esmolol (Group E),Dexmedetomidine (Group D),Significantly increased,The DAP levels in Group D were significantly lower than Groups C and E at all times after intubation.,4137650
1780,4137650,Mean rate pressure product up to 15 min after intubation,Placebo (Group C) and esmolol (Group E),Dexmedetomidine (Group D),Significantly increased,"In our study the RPP during intubation revealed a highly significant increase in Group C (76.5%, P &lt; 0.0001) and significant increase in Group E (49%, P &lt; 0.001), whereas the increase was insignificant in Group D (16%, P &gt; 0.0666). These changes were highly significant up to 15 min post-intubation. Although comparing Group E to Group D the increase in RPP in Group E at the time of intubation (P &lt; 0.001) was statistically significant. The rise in mean RPP was least in Group D and highest in Group C",4137650
1781,5697397,Leucine concentrations in blood,Native whey protein,Milk protein and WPC-80 protein,Significantly increased,Native whey increased blood leucine concentrations more than WPC-80 and milk (Pâ€‰&lt;â€‰0.05),5697397
1782,5697397,Phosphorylation of p70S6K 3 hours after exercise,Native whey protein,Milk protein ,Significantly increased,Native whey ingestion induced a greater phosphorylation of p70S6K than milk 180&nbsp;min after exercise (Pâ€‰=â€‰0.03),5697397
1783,5697397,Rates of muscle protein synthesis,Native whey protein,Milk protein ,Significantly increased,"Muscle protein synthesis rates were higher 1â€“5&nbsp;h after exercise with native whey than with milk (0.112% vs. 0.064, Pâ€‰=â€‰0.023).",5697397
1784,5697397,Phosphorylation of p70S6K and rates of muscle protein synthesis ,Native whey protein,WPC-80 protein,No significant difference,"Despite higher-magnitude increases in blood leucine concentrations with native whey, it was not superior to WPC-80 concerning effect on muscle protein synthesis and phosphorylation of p70S6K during a 5-h post-exercise period.",5697397
1785,5697397,Recovery of muscle function,Native whey protein,WPC-80 protein and milk protein,No significant difference,"A reduced force-generating capacity measured as MVC force, was evident&nbsp;15 min after the exercise session in all groups (native whey: âˆ’17.4â€‰Â±â€‰7.3%, WPC-80: -17.1â€‰Â±â€‰7.4%, milk: âˆ’16.6â€‰Â±â€‰9.3%, Pâ€‰&lt;â€‰0.001; Fig.&nbsp;7). At 24&nbsp;h WPC-80 and native whey were not significantly different from baseline (Pâ€‰&gt;â€‰0.098), whereas milk had a lower force generating capacity than baseline (Pâ€‰&lt;â€‰0.001). There were no significant group differences",5697397
1786,4878364,Gait speed,Exercise program,No exercise,Significantly increased,"When compared to the control group, the exercise group experienced significant improvements in gait speed (F(4.078) = 8.265, p = 0.007), sit to stand performance (F(3.24) = 11.033, p = 0.002) and handgrip strength (F(3.697) = 26.359, p &lt; 0.001).",4878364
1787,4878364,Sit to stand performance,Exercise program,No exercise,Significantly increased,"When compared to the control group, the exercise group experienced significant improvements in gait speed (F(4.078) = 8.265, p = 0.007), sit to stand performance (F(3.24) = 11.033, p = 0.002) and handgrip strength (F(3.697) = 26.359, p &lt; 0.001).",4878364
1788,4878364,Handgrip strength,Exercise program,No exercise,Significantly increased,"When compared to the control group, the exercise group experienced significant improvements in gait speed (F(4.078) = 8.265, p = 0.007), sit to stand performance (F(3.24) = 11.033, p = 0.002) and handgrip strength (F(3.697) = 26.359, p &lt; 0.001).",4878364
1789,4878364,Baseline characteristics,Exercise program,No exercise,No significant difference,"Descriptive characteristics of the sample, provided in Table 1, showed no significant difference between groups at baseline.",4878364
1790,3798206,Rates of myocardial infarction ,Dabigatran,Enoxaparin or placebo,No significant difference,Dabigatran had similar myocardial infarction rates when compared with enoxaparin or placebo.,3798206
1791,3798206,Risk of vascular death,Dabigatran 150 mg BID,Warfarin,Significantly decreased,"The risk of vascular death for dabigatran 150 mg twice daily was significantly lower than for well-controlled warfarin (hazard ratio [HR] 0.85, 95% CI 0.72â€“0.99, P = 0.04).",3798206
1792,3798206,Rates of myocardial infarction ,Dabigatran,Warfarin,No significant difference,"The rates of MI in RE-LY measured 0.82%, 0.81%, and 0.64% per year for the dabigatran 110 mg twice daily, dabigatran 150 mg twice daily, and warfarin treatment groups, respectively; the differences did not reach statistical significance.",3798206
1793,3798206,Cardiovascular and all-cause mortality rates,Dabigatran 150 mg or 110 mg,Placebo or dabigatran 50 mg,Significantly decreased,Cardiovascular and all-cause mortality rates were lowest in the 110 mg twice daily and 150 mg twice daily groups compared with the lower dose dabigatran and placebo groups,3798206
1794,4900317,Need of morphine during 48 hours after surgery,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),Significantly decreased,"During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 Â± 0.94 mg vs. 18.83 Â± 3.4 mg respectively, P = 0.2)",4900317
1795,4900317,Pain scores,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),Significantly decreased,The mean VAS score of pain was significantly less in Group B than Group C at most time points,4900317
1796,4900317,Extubation time,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),Significantly decreased,"The time to extubation was obviously shorter in Group B compared to Group C (117 Â± 10 min vs. 195 Â± 19 min, respectively, P = 0.03).",4900317
1797,4900317,Wound infection incidence,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),No significant difference,There was no incidence of sternal infection or delayed wound healing recorded in either group.,4900317
1798,4900317,Time of hospital or ICU admission ,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),No significant difference,there were no statistically difference between the two groups in the ICU and the hospital stay duration,4900317
1799,4900317,Need of morphine during 48 hours after surgery,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),Significantly decreased,"During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 Â± 0.94 mg vs. 18.83 Â± 3.4 mg respectively, P = 0.2)",4900317
1800,4900317,Pain scores,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),Significantly decreased,The mean VAS score of pain was significantly less in Group B than Group C at most time points,4900317
1801,4900317,Extubation time,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),Significantly decreased,"The time to extubation was obviously shorter in Group B compared to Group C (117 Â± 10 min vs. 195 Â± 19 min, respectively, P = 0.03).",4900317
1802,4900317,Wound infection incidence,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),No significant difference,There was no incidence of sternal infection or delayed wound healing recorded in either group.,4900317
1803,4900317,Time of hospital or ICU admission ,Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B),Presternal catheter with continuous saline infusion (Group C),No significant difference,there were no statistically difference between the two groups in the ICU and the hospital stay duration,4900317
1804,111193,"Blood loss, excluding intraoperative blood loss",Preoperative acute normovolaemic hemodilution (ANH),No preoperative hemodilution (non-ANH),Significantly increased,"Blood loss was, except from the intraoperative loss, significantly higher in ANH group.",111193
1805,111193,Surgery duration,Preoperative acute normovolaemic hemodilution (ANH),No preoperative hemodilution (non-ANH),No significant difference,Time used for anaesthesia (from patient enters the operating theatre to entering the recovery room) and duration of surgery was identical between groups.,111193
1806,111193,Amount of transfused blood,Preoperative acute normovolaemic hemodilution (ANH),No preoperative hemodilution (non-ANH),No significant difference,The amount of blood transfusion was identical 386 ml (ANH) vs. 343 ml (non-ANH) (ns). 50 % went through surgery without receiving blood (ANH) vs. 58 % (non-ANH),111193
1807,111193,Mean artery blood pressure during surgery,Preoperative acute normovolaemic hemodilution (ANH),No preoperative hemodilution (non-ANH),No significant difference,The intraoperative mean artery blood pressure was identical between groups.,111193
1808,111193,Hospital stay,Preoperative acute normovolaemic hemodilution (ANH),No preoperative hemodilution (non-ANH),No significant difference,There was no difference in time spent in hospital between the groups.,111193
1809,3154934,Baseline characteristics,Vitamin A supplementation (VAS),Placebo ,No significant difference,"There were no baseline differences between the children who had received neonatal VAS or placebo, continued to live in the study area and were met at follow-up (Table 1). There were no differences between the children met at follow-up (groups A and B) and those not met (parts of groups C and D) with regard to treatment, sex or anthropometric measurements at enrolment.",3154934
1810,3154934,Mortality rates after FU-VAS,Vitamin A supplementation (VAS),Placebo,Significantly decreased,"After FU-VAS, mortality was significantly lower for children who had received neonatal VAS (group A) than for children who had received placebo (group B) (MRR: 0.54 (0.31â€“0.94))",3154934
1811,3154934,Mortality rates in children who did not receive FU-VAS,Vitamin A supplementation (VAS),Placebo,No significant difference,"Among children who had not received FU-VAS, mortality in the second and third year of life did not differ according to reception of neonatal VAS or placebo.",3154934
1812,5003869,Mean adherence rates,Pharmacist telephone counseling,Usual care,No significant difference,n the overall ITT analysis we found a mean adherence rate (MPRm) of 74.7% (SD 37.5) for intervention patients and 74.5% (SD 37.9) for control patients (see Table 2). The proportion adherent patients (MPRmâ‰¥80%) was 69.0% in the intervention arm and 69.9% in the usual care arm and differences between intervention and usual care arms were not significantly different on both outcomes.,5003869
1813,5003869,"Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates.",Pharmacist telephone counseling,Usual care,Significantly increased,"Comparing patients with counseling to patients with usual care (per protocol analysis), adherence was statistically significant higher for patients starting with RAS-inhibitors, statins and bisphosphonates.",5003869
1814,5003869,Adherence in patients starting with antidepressants,Pharmacist telephone counseling,Usual care,No significant difference,"For antidepressants we found no significant difference in adherence rate between patients in the intervention arm (62.7% SD 41.7) and patients with usual care (66.8%, 40.9). The proportion adherent patients was also not significantly different between the arms (54.1% respectively 60.4% with OR 0.78, 95%CI 0.59, 1.02). In the PP-analysis we found no significant difference between arms.",5003869
1815,5003869,Therapy discontinuation in patients starting with antidepressants,Pharmacist telephone counseling,Usual care,No significant difference,"For patients starting with antidepressants in the intervention arm 47.5% discontinued compared to 42.7% in the usual care arm which is a significant different (HR 1.17, 95% CI 1.01, 1.37). However in the PP-analysis 44.9% discontinued in the intervention arm which is not significantly different from usual care (HR 1.04, 95%CI 0.84, 1.27)",5003869
1816,5003869,"Therapy discontinuation in patients starting with RAS-inhibitors, statins and bisphosphonates.",Pharmacist telephone counseling,Usual care,No significant difference,"For patients starting with RAS-inhibitors 22.6% of the patients in the intervention arm discontinued therapy compared to 27.9% of patients with usual care which is significantly lower (HR 0.77, 95% CI 0.69, 0.91). The result of the PP-analysis is comparable but not statistically significant. For statins and bisphosphonate users, discontinuation rates were not significantly different (HR 0.87, 95% CI 0.73, 1.10, respectively 0.73, 95% CI 0.56, 1.02).",5003869
1817,5003869,Mean adherence rates,Pharmacist telephone counseling,Usual care,No significant difference,n the overall ITT analysis we found a mean adherence rate (MPRm) of 74.7% (SD 37.5) for intervention patients and 74.5% (SD 37.9) for control patients (see Table 2). The proportion adherent patients (MPRmâ‰¥80%) was 69.0% in the intervention arm and 69.9% in the usual care arm and differences between intervention and usual care arms were not significantly different on both outcomes.,5003869
1818,5003869,"Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates.",Pharmacist telephone counseling,Usual care,Significantly increased,"Comparing patients with counseling to patients with usual care (per protocol analysis), adherence was statistically significant higher for patients starting with RAS-inhibitors, statins and bisphosphonates.",5003869
1819,5003869,Adherence in patients starting with antidepressants,Pharmacist telephone counseling,Usual care,No significant difference,"For antidepressants we found no significant difference in adherence rate between patients in the intervention arm (62.7% SD 41.7) and patients with usual care (66.8%, 40.9). The proportion adherent patients was also not significantly different between the arms (54.1% respectively 60.4% with OR 0.78, 95%CI 0.59, 1.02). In the PP-analysis we found no significant difference between arms.",5003869
1820,5003869,Therapy discontinuation in patients starting with antidepressants,Pharmacist telephone counseling,Usual care,No significant difference,"For patients starting with antidepressants in the intervention arm 47.5% discontinued compared to 42.7% in the usual care arm which is a significant different (HR 1.17, 95% CI 1.01, 1.37). However in the PP-analysis 44.9% discontinued in the intervention arm which is not significantly different from usual care (HR 1.04, 95%CI 0.84, 1.27)",5003869
1821,5003869,"Therapy discontinuation in patients starting with RAS-inhibitors, statins and bisphosphonates.",Pharmacist telephone counseling,Usual care,No significant difference,"For patients starting with RAS-inhibitors 22.6% of the patients in the intervention arm discontinued therapy compared to 27.9% of patients with usual care which is significantly lower (HR 0.77, 95% CI 0.69, 0.91). The result of the PP-analysis is comparable but not statistically significant. For statins and bisphosphonate users, discontinuation rates were not significantly different (HR 0.87, 95% CI 0.73, 1.10, respectively 0.73, 95% CI 0.56, 1.02).",5003869
1822,3388481,Success of external cephalic version (ECV) procedure,Hypnosis and Neurolinguistic Programming (NLP),Standard medical care alone,Significantly increased,In the control group (n = 122) 27.3% (n = 33) had a statistically significant lower successful ECV procedure than NLP (P = 0.05) and hypnosis and NLP (P = 0.03).,3388481
1823,3388481,Success of external cephalic version (ECV) procedure,Neurolinguistic Programming (NLP),Standard medical care alone,No significant difference,In the control group (n = 122) 27.3% (n = 33) had a statistically significant lower successful ECV procedure than NLP (P = 0.05) and hypnosis and NLP (P = 0.03).,3388481
1824,3388481,Baseline characteristics,Neurolinguistic Programming (NLP) and Hypnosis,Standard medical care alone,No significant difference,"Baseline characteristics (size, weight before pregnancy, current weight, gestation age, amniotic fluid index, fetal weight estimation, parity, and breech firmly fixed in the pelvis) were similar in the two groups (P &gt; 0.05; Tables 1 and 2).",3388481
1825,3388481,Success of external cephalic version (ECV) procedure,Hypnosis,Standard medical care alone,No significant difference,"Statistically improved success rates were seen when comparing NLP (P = 0.05) or hypnosis and NLP together (P = 0.03) with the control group (Table 3); however, hypnosis only had a trend to higher success rates when compared to the control group (P = 0.08).",3388481
1826,4733710,Hemoglobin at day 1 after surgery,Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group,Control group,Significantly decreased,"Only the POTTS-E group on the 1st postoperative day Hb was lower than group control, P &lt; 0.05.",4733710
1827,4733710,Rates of utilization of autologous blood,Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group,Control group,No significant difference,There were no statistical differences in utilization rates of autologous blood of the two groups,4733710
1828,4733710,"Rates of utilization of allogeneic RBC, total allogeneic RBC and total RBC",Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group,Control group,Significantly decreased,"the utilization rates of allogeneic RBC, total allogeneic RBC and total RBC were 48.48%, 51.5%, and 75.7% in POTTS-E group, which were lower than those of the control group (84.3%, 84.3%, and 96.8%) P &lt; 0.05 or P &lt; 0.01.",4733710
1829,4733710,Baseline characteristics,Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group,Control group,No significant difference,"Peri-operative Transfusion Trigger Score of Emergency group and control group were compared in age, gender, body mass index, ASA score, and operation area; Heart rate, mean arterial pressure, SpO2, body temperature, and shock index when entering into the operation room; there was no statistical difference between the two groups for Hb values and APACHE II scores after entering into the operation room",4733710
1830,4733710,Blood transfusion-related complications and mortality rates,Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group,Control group,No significant difference,"There were no statistical differences between the two groups in anesthesia time, intraoperative rehydration, staying time in PACU, emergency hospitalization, postoperative 72 h APACHE II scores, blood transfusion-related complications and mortality",4733710
1831,2967098,Improvement rate,High dose (20 mg/day) haloperidol,Low dose (5 mg/day) haloperidol,No significant difference,Comparison of the improvement rate in both study groups revealed no significant difference.,2967098
1832,5599918,Pain intensity after surgery,Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and conventional thoracic epidural patient-controlled analgesia (E-PCA group),Fentanyl-based IV-PCA only (IV-PCA group),Significantly decreased,The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group,5599918
1833,5599918,Pain intensity after surgery,Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group),Conventional thoracic epidural patient-controlled analgesia (E-PCA group),No significant difference,"The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group, but comparable between the dIV-PCA group and the E-PCA group.",5599918
1834,5599918,"Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries",Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group),Fentanyl-based IV-PCA only (IV-PCA group),Significantly decreased,"Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group.",5599918
1835,5599918,Total dose of remifentanil,Fentanyl-based IV-PCA only (IV-PCA group),Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group),Significantly increased,"The total administered dose of remifentanil was higher in the IV-PCA group than in the E-PCA and dIV-PCA groups (Bonferroni corrected P = 0.017 and P &lt; 0.001, respectively).",5599918
1836,5599918,Total dose of ephedrine,Fentanyl-based IV-PCA only (IV-PCA group),Conventional thoracic epidural patient-controlled analgesia (E-PCA group),Significantly decreased,the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 Â± 9.1 vs. 4.0 Â± 4.8 Î¼g; Bonferroni corrected P = 0.013).,5599918
1837,5599918,Pain intensity after surgery,Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and conventional thoracic epidural patient-controlled analgesia (E-PCA group),Fentanyl-based IV-PCA only (IV-PCA group),Significantly decreased,The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group,5599918
1838,5599918,Pain intensity after surgery,Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group),Conventional thoracic epidural patient-controlled analgesia (E-PCA group),No significant difference,"The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group, but comparable between the dIV-PCA group and the E-PCA group.",5599918
1839,5599918,"Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries",Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group),Fentanyl-based IV-PCA only (IV-PCA group),Significantly decreased,"Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group.",5599918
1840,5599918,Total dose of remifentanil,Fentanyl-based IV-PCA only (IV-PCA group),Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group),Significantly increased,"The total administered dose of remifentanil was higher in the IV-PCA group than in the E-PCA and dIV-PCA groups (Bonferroni corrected P = 0.017 and P &lt; 0.001, respectively).",5599918
1841,5599918,Total dose of ephedrine,Fentanyl-based IV-PCA only (IV-PCA group),Conventional thoracic epidural patient-controlled analgesia (E-PCA group),Significantly decreased,the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 Â± 9.1 vs. 4.0 Â± 4.8 Î¼g; Bonferroni corrected P = 0.013).,5599918
1842,5599918,Pain intensity after surgery,Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and conventional thoracic epidural patient-controlled analgesia (E-PCA group),Fentanyl-based IV-PCA only (IV-PCA group),Significantly decreased,The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group,5599918
1843,5599918,Pain intensity after surgery,Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group),Conventional thoracic epidural patient-controlled analgesia (E-PCA group),No significant difference,"The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group, but comparable between the dIV-PCA group and the E-PCA group.",5599918
1844,5599918,"Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries",Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group),Fentanyl-based IV-PCA only (IV-PCA group),Significantly decreased,"Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group.",5599918
1845,5599918,Total dose of remifentanil,Fentanyl-based IV-PCA only (IV-PCA group),Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group),Significantly increased,"The total administered dose of remifentanil was higher in the IV-PCA group than in the E-PCA and dIV-PCA groups (Bonferroni corrected P = 0.017 and P &lt; 0.001, respectively).",5599918
1846,5599918,Total dose of ephedrine,Fentanyl-based IV-PCA only (IV-PCA group),Conventional thoracic epidural patient-controlled analgesia (E-PCA group),Significantly decreased,the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 Â± 9.1 vs. 4.0 Â± 4.8 Î¼g; Bonferroni corrected P = 0.013).,5599918
1847,2375877,increased knowledge about asthma,small group asthma education workshops and locally adapted asthma management guidelines,"alternative education program consisting of information about management of paediatric ear, nose and throat (ENT) conditions, without receiving any adapted asthma resource materials until the end of the trial",Significantly increased,there was some evidence suggesting that GPs in the intervention group had increased their knowledge about asthma and were better able to assess the severity of asthma attack,2375877
1848,2375877,improved ability to assess the severity of an asthma attack,small group asthma education workshops and locally adapted asthma management guidelines,"alternative education program consisting of information about management of paediatric ear, nose and throat (ENT) problems, without receiving any adapted asthma resource materials until the end of the trial",Significantly increased,there was some evidence suggesting that GPs in the intervention group had increased their knowledge about asthma and were better able to assess the severity of asthma attack.,2375877
1849,2375877,increased ability to identify patients who have a high risk of severe asthma attacks,small group asthma education workshops and received locally adapted asthma management guidelines,"alternative education program consisting of information about management of paediatric ear, nose and throat (ENT) problems, without receiving any adapted asthma resource materials until the end of the trial",Significantly increased,there was evidence suggesting that these GPs were better able to identify patients at high risk of severe attack compared to the control groups that received the alternate intervention,2375877
1850,2375877,likelihood of providing a written asthma action plan to children,small group asthma education workshops and locally adapted asthma management guidelines,"alternative education program consisting of information about management of paediatric ear, nose and throat (ENT) problems, without receiving any adapted asthma resource materials until the end of the trial",No significant difference,There was no evidence supporting the hypothesis that GPs in the intervention group (education + guidelines) were more likely to report providing a written asthma action plan to children compared to GPs in the two control groups,2375877
1851,2375877,higher confidence levels regarding the ongoing management of infrequent episodic asthma,small group asthma education workshops and locally adapted asthma management guidelines,"alternative education program consisting of information about management of paediatric ENT problems, without receiving any adapted asthma resource materials until the end of the trial",Significantly increased,"Post-intervention, a higher proportion of GPs in the intervention arm (Group 1) felt 'very confident' compared to control arm GPs for ongoing management of infrequent episodic asthma (p = 0.03)",2375877
1852,5145296,Throat cleansing,"PPIs, lifestyle changes, and daily zinc capsules","PIs, lifestyle changes, and placebo",Significantly decreased,"the statistical difference between the drug and placebo groups in terms of presentationsâ€™ frequencies was statistically significant in 6 items: Throat cleansing (p=0.05), chronic cough (p=0.04), postnasal drip (p=0.03), foreign body sensation (p=0.003), heart burn (p=0.003), and otitis media (p=0.003).",5145296
1853,5145296,chronic cough,"PPIs, lifestyle changes, and daily zinc capsules","PPIs, lifestyle changes, and placebo",Significantly decreased,"the statistical difference between the drug and placebo groups in terms of presentationsâ€™ frequencies was statistically significant in 6 items: Throat cleansing (p=0.05), chronic cough (p=0.04), postnasal drip (p=0.03), foreign body sensation (p=0.003), heart burn (p=0.003), and otitis media (p=0.003).",5145296
1854,5145296,postnasal drip,"PPIs, lifestyle changes, and daily zinc capsules","PPIs, lifestyle changes, and placebo",Significantly decreased,"the statistical difference between the drug and placebo groups in terms of presentationsâ€™ frequencies was statistically significant in 6 items: Throat cleansing (p=0.05), chronic cough (p=0.04), postnasal drip (p=0.03), foreign body sensation (p=0.003), heart burn (p=0.003), and otitis media (p=0.003).",5145296
1855,5145296,foreign body sensation,"PPIs, lifestyle changes, and daily zinc capsules","PPIs, lifestyle changes, and placebo",Significantly decreased,"the statistical difference between the drug and placebo groups in terms of presentationsâ€™ frequencies was statistically significant in 6 items: Throat cleansing (p=0.05), chronic cough (p=0.04), postnasal drip (p=0.03), foreign body sensation (p=0.003), heart burn (p=0.003), and otitis media (p=0.003).",5145296
1856,5145296,heart burn,"PPIs, lifestyle changes, and daily zinc capsules","PPIs, lifestyle changes, and placebo",Significantly decreased,"the statistical difference between the drug and placebo groups in terms of presentationsâ€™ frequencies was statistically significant in 6 items: Throat cleansing (p=0.05), chronic cough (p=0.04), postnasal drip (p=0.03), foreign body sensation (p=0.003), heart burn (p=0.003), and otitis media (p=0.003).",5145296
1857,4223282,men discussing and using condoms within stable relationships,SASA! community mobilization intervention program,no intervention,Significantly increased,"Positive impacts include increased discussion about, and use of, condoms within regular partnerships in the past year with men in intervention communities twice as likely to report condom use with their partner at last intercourse than men in control communities",4223282
1858,4223282,male reports of undergoing HIV testing,SASA! community mobilization intervention program,no intervention,Significantly increased,"Levels of discussion around HIV testing and reports of having been tested in the past year were also higher, with men in intervention communities being 50% more likely to have had a test, relative to control counterparts",4223282
1859,4223282,male's reported sexual concurrency,SASA! community mobilization intervention program,no intervention,Significantly decreased,Reported sexual concurrency was significantly lower among men in intervention communities,4223282
1860,4223282,women's ability to refuse sex,SASA! community mobilization intervention program,no intervention,Significantly increased,women in SASA! communities reported feeling more able to refuse sex with their partner,4223282
1861,4223282,women making decisions jointly with their partner,SASA! community mobilization intervention program,no intervention,Significantly increased,Effect sizes tended to be larger for indicators of relationship dynamics than for HIV-related risk behaviours with women in intervention communities significantly more likely than their control counterparts to report making decisions jointly with their partner,4223282
1862,5332296,insulin levels among women in the middle IA ancestry tertile,traditional Mexican diet,U.S. diet,Significantly decreased,"Compared to the U.S. diet, the traditional Mexican diet tended to reduce glucose (P=0.08), and insulin concentrations (P&lt;0.05) among women in the middle IA ancestry tertile, and tended to reduce insulin concentrations among women in the lowest IA ancestry tertile (P=0.06)",5332296
1863,5332296,glucose levels among women in the middle IA ancestry tertile,traditional Mexican diet,U.S. diet,No significant difference,"Compared to the U.S. diet, the traditional Mexican diet tended to reduce glucose (P=0.08), and insulin concentrations (P&lt;0.05) among women in the middle IA ancestry tertile, and tended to reduce insulin concentrations among women in the lowest IA ancestry tertile (P=0.06)",5332296
1864,5332296,HOMAIR among women in the middle IA ancestry tertile,traditional Mexican diet,U.S. diet,Significantly decreased,"Similarly, compared to the U.S. diet, the traditional Mexican diet significantly reduced HOMAIR (P&lt;0.05) and circulating concentrations of IGFBP-3 (P&lt;0.01) and, while tended to reduce IGF-1 (P=0.06) among women in the middle IA ancestry tertile.",5332296
1865,5332296,circulating concentrations of IGFBP-3 among women in the middle IA ancestry tertile,traditional Mexican diet,U.S. diet,Significantly decreased,"Similarly, compared to the U.S. diet, the traditional Mexican diet significantly reduced HOMAIR (P&lt;0.05) and circulating concentrations of IGFBP-3 (P&lt;0.01) and, while tended to reduce IGF-1 (P=0.06) among women in the middle IA ancestry tertile.",5332296
1866,5332296,IGF-1 levels among women in the middle IA ancestry tertile,traditional Mexican diet,U.S. diet,No significant difference,"Similarly, compared to the U.S. diet, the traditional Mexican diet significantly reduced HOMAIR (P&lt;0.05) and circulating concentrations of IGFBP-3 (P&lt;0.01) and, while tended to reduce IGF-1 (P=0.06) among women in the middle IA ancestry tertile.",5332296
1867,3657931,dosage of propofol required by males,propofol induction guided by BIS,propofol induction guided by clinical signs,Significantly decreased,"On comparing the dosage of propofol among males of the two groups, a significantly lower dosage of propofol was observed in group B (2.06Â±0.45 mg/kg and 1.83Â±0.32 mg/kg, respectively, P=0.016).",3657931
1868,3657931,dosage of propofol required by females,propofol induction guided by BIS,propofol induction guided by clinical signs,No significant difference,"This decrease however was not observed among female patients, dosage being 1.65Â±0.44 mg/kg and 1.75Â±0.49 mg/kg, respectively (group A versus group B) (P=0.372).",3657931
1869,3657931,hemodynamic parameters at postintubation readings,propofol induction guided by BIS,propofol induction guided by clinical signs,Significantly increased,"The hemodynamic variables including heart rate, systolic/diastolic blood pressure and BIS were comparable within the group at induction, post-induction, and intubation. However, there was a significant increase in all the parameters at postintubation readings (P&lt;0.001).",3657931
1870,3657931,mean dose of propofol required for induction,propofol induction guided by BIS,propofol induction guided by clinical signs,No significant difference,"The mean dose of propofol used for induction was 1.85Â±0.48 mg/kg (group A) and 1.79Â±0.41 mg/kg (group B), respectively. The dosage of propofol in group B were less compared to group A, but it was not statistically significant (P=0.575)",3657931
1871,5019463,number of follow-up appointments during the one year study period,assistance from a patient navigator,usual care,No significant difference,"The mean (Â±standard deviation) number of follow-up visits during the 1-year study period was 1.3 (Â±1.3) for G1, 1.6 (Â±1.3) for G2, and 1.3 (Â±1.1) for G3 (P=0.48).",5019463
1872,5019463,"Appointment adherence, exemplified by the attendance of one or more follow-up visits",assistance from a patient navigator,usual care,No significant difference,"Appointment adherence, defined as attendance of â‰¥1 follow-up visit, was 69.8% (n=37/53) for G1, 82.5% (n=47/57) for G2, and 73.3% (n=33/45) for G3, (P=0.28).",5019463
1873,5019463,adherence rates for patients who attended two or more follow-up appointments,assistance from a patient navigator,usual care,No significant difference,"A subanalysis was conducted to analyze whether subjects attended â‰¥ follow-up visits. The results are: 91.3% (n=21/23) of G1, 74.3% (n=26/35) of G2, and 66.7% (n=18/27) of G3 attended â‰¥2 follow-up visits (P=0.11).",5019463
1874,3259296,"concentrations of serum glucose at 15 min, 30 min, and 45 min in study 1",xylose-containing solutions,sucrose solution,Significantly decreased,"The concentrations of serum glucose at 15 min (P &lt; 0.0001), 30 min (P &lt; 0.0001), and 45 min (P = 0.0005) were significantly lower after consuming both concentrations of xylose-containing solutions compared to those after consuming the control solution.",3259296
1875,3259296,glucose concentration at 120 minutes in study 1,xylose-containing solution,sucrose solution,Significantly increased,"However, glucose concentration was significantly higher at 120 min for those who consumed the xylose-containing solution (P &lt; 0.0001).",3259296
1876,3259296,"AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, and 0-90 min in study 2",xylose-containing test meal,sucrose-containing meal,Significantly decreased,"In study 2, the test meal exhibited significantly lower AUCg and AUCi values for 0-15 min (P &lt; 0.0001, P &lt; 0.0001), 0-30 min (P &lt; 0.0001, P &lt; 0.0001), 0-45 min (P &lt; 0.0001, P = 0.0005), 0-60 min (P = 0.0002, P = 0.0025), and 0-90 min (P = 0.0396, P = 0.0246).",3259296
1877,3259296,concentrations of serum glucose at 15 min and 30 min in study 2,xylose-containing test meal,sucrose-containing meal,Significantly decreased,The concentrations of serum glucose at 15 min (P &lt; 0.0001) and 30 min (P &lt; 0.0001) after intake of the test meal were significantly lower than those after intake of the control meal.,3259296
1878,3259296,"AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, 0-90 min, and 0-120 min in study 1",5 g xylose-containing solution,sucrose solution,Significantly decreased,"In study 1, the 5 g xylose-containing solutions exhibited significantly lower area under the glucose curve (AUCg) and area under the insulin curve (AUCi) values for 0-15 min (P &lt; 0.0001, P &lt; 0.0001), 0-30 min (P &lt; 0.0001, P &lt; 0.0001), 0-45 min (P &lt; 0.0001, P &lt; 0.0001), 0-60 min (P &lt; 0.0001, P &lt; 0.0001), 0-90 min (P &lt; 0.0001, P &lt; 0.0001) and 0-120 min (P = 0.0071, P = 0.0016).",3259296
1879,5291156,number of times that a gag reflex was triggered in absence of sedation,lidocaine spray,lidocaine spray and viscous solution,Significantly increased,"The number of gag reflexes was significantly higher in the spray group than in the combination group (2.35â€ŠÂ±â€Š2.87 vs. 1.27â€ŠÂ±â€Š1.79), Pâ€Š=â€Š0.03)",5291156
1880,5291156,percentage of images of suitable quality at the right pyriform sinus,lidocaine spray,lidocaine spray and viscous solution,Significantly decreased,"The percentage of suitable quality images at the right pyriform sinus was significantly lower in the spray group compared to the combination group (82.8â€Š% vs. 91.2â€Š%, Pâ€Š=â€Š0.02).",5291156
1881,5291156,pain evaluated by VAS in the presence of sedation,lidocaine spray,lidocaine spray and viscous solution,No significant difference,"Subgroup analysis for presence of sedation (223 cases) revealed almost no differences between the 2 groups in the number of pharyngeal observation sites (8.48â€ŠÂ±â€Š2.16 vs. 8.79â€ŠÂ±â€Š1.85, Pâ€Š=â€Š0.25), pain evaluated by VAS (1.08â€ŠÂ±â€Š2.06 vs. 1.33â€ŠÂ±â€Š2.16, Pâ€Š=â€Š0.79), pharyngeal observation time (73.3â€ŠÂ±â€Š36.6 vs. 68.3â€ŠÂ±â€Š30.9 seconds, Pâ€Š=â€Š0.14), and number of gag reflexes (2.02â€ŠÂ±â€Š2.44 vs. 1.86â€ŠÂ±â€Š2.45, Pâ€Š=â€Š0.63)",5291156
1882,5291156,number of times that a gag reflex was triggered in the presence of sedation,lidocaine spray,lidocaine spray and viscous solution,No significant difference,"Subgroup analysis for presence of sedation (223 cases) revealed almost no differences between the 2 groups in the number of pharyngeal observation sites (8.48â€ŠÂ±â€Š2.16 vs. 8.79â€ŠÂ±â€Š1.85, Pâ€Š=â€Š0.25), pain evaluated by VAS (1.08â€ŠÂ±â€Š2.06 vs. 1.33â€ŠÂ±â€Š2.16, Pâ€Š=â€Š0.79), pharyngeal observation time (73.3â€ŠÂ±â€Š36.6 vs. 68.3â€ŠÂ±â€Š30.9 seconds, Pâ€Š=â€Š0.14), and number of gag reflexes (2.02â€ŠÂ±â€Š2.44 vs. 1.86â€ŠÂ±â€Š2.45, Pâ€Š=â€Š0.63)",5291156
1883,5291156,occurrence of adverse events,lidocaine spray,lidocaine spray and viscous solution,No significant difference,"There were almost no differences in adverse events, decrease of SpO2 (2.55â€Š% vs. 5.29â€Š%, Pâ€Š=â€Š0.20), decrease of blood pressure (0â€Š% vs. 1.76â€Š%, Pâ€Š=â€Š0.27), and bradycardia (0â€Š% vs. 0â€Š%, Pâ€Š=â€Š1.00) between the 2 groups.",5291156
1884,4188762,withdrawal response of rocuronium,"lidocaine, ketamine, or remifentanil",normal saline,Significantly decreased,"Lidocaine (40 mg), ketamine (0.5 mg/kg), or remifentanil (1 Âµg/kg) decreased the withdrawal response significantly and remifentanil (1 Âµg/kg) was the most effective in the prevention of withdrawal response among the drugs (P &lt; 0.00833)",4188762
1885,4188762,mean blood pressure,remifentanil,"normal saline, lidocaine, or ketamine",Significantly decreased,"However, in group R, mean blood pressure was significantly lower compared to other groups (P &lt; 0.05)",4188762
1886,4188762,heart rate,remifentanil,"normal saline, lidocaine, or ketamine",Significantly decreased,"Heart rate increased significantly compared to control in all groups but, it was significantly lower in group R compared to other groups (P &lt; 0.05)",4188762
1887,2742700,mean systolic and diastolic blood pressure,nurse educator-conducted class and home blood pressure monitorization,usual care,No significant difference,"Of the 24 subjects who completed the study, only 20% achieved the target blood pressure of &lt;130/80 and there was no statistical difference in mean systolic and diastolic blood pressures among the three groups (p &gt; 0.05).",2742700
1888,2742700,RN and MD visits,nurse educator-conducted class and home blood pressure monitorization,usual care,No significant difference,We compared the number of RN and MD visits during the study period for each study participant and found no difference among the three groups.,2742700
1889,3687261,peak blood glucose,sitagliptin and d-xylose,placebo and sucralose,Significantly decreased,"Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (P &lt; 0.01 for each) and were lowest after SX (P &lt; 0.05 for each), while overall blood glucose was lower after SX than PC (P &lt; 0.05).",3687261
1890,3687261,plasma GLP-1 before consuming the meal,d-xylose,sucralose,Significantly increased,Plasma GLP-1 concentrations were higher after d-xylose than control only before the meal (P &lt; 0.05) but were sustained postprandially when combined with sitagliptin (P &lt; 0.05).,3687261
1891,3687261,incremental areas under the curve,"placebo and d-xylose, or sitagliptin and d-xylose","placebo and sucralose, or sitagliptin and sucralose",Significantly increased,"Before the meal, insulin concentrations increased slightly when d-xylose was given (i.e., PX and SX) in contrast to the control days, so that the iAUC (âˆ’40 to 0 min) was greater for PX and SX than for PC and SC (P &lt; 0.05 for each)",3687261
1892,3687261,overall blood glucose,sitagliptin and d-xylose,placebo and sucralose,Significantly decreased,"Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (P &lt; 0.01 for each) and were lowest after SX (P &lt; 0.05 for each), while overall blood glucose was lower after SX than PC (P &lt; 0.05).",3687261
1893,3687261,amplitude of glycemic excursion,sitagliptin and d-xylose,placebo and sucralose,Significantly decreased,"Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (P &lt; 0.01 for each) and were lowest after SX (P &lt; 0.05 for each), while overall blood glucose was lower after SX than PC (P &lt; 0.05).",3687261
1894,5389230,Emergence agitation ,Intranasal dexmedetomidine (Group D),Intranasal saline 0.9% (Group C),Significantly decreased,"There was a significant difference in the incidence of EA between Groups D and C (6.98% and 58%, respectively, with P = 0.001).",5389230
1895,5389230,Need of nalbuphine for pain and agitation episodes after surgery,Intranasal dexmedetomidine (Group D),Intranasal saline 0.9% (Group C),Significantly decreased,Postoperative nalbuphine dose consumption as a rescue medication for agitation episodes and pain was significantly higher in Group C compared with Group D with a P = 0.001,5389230
1896,5389230,Median scores of FLACC pain,Intranasal dexmedetomidine (Group D),Intranasal saline 0.9% (Group C),Significantly decreased,the median scores of FLACC pain scales of Group D were significantly lower than those of Group C at the all six time points with P &lt; 0.05,5389230
1897,5389230,Extubation times,Intranasal dexmedetomidine (Group D),Intranasal saline 0.9% (Group C),No significant difference,"There was no statistically significant difference between the two groups regarding extubation, emergence, and discharge times with a P &gt; 0.05",5389230
1898,5389230,Discharge times,Intranasal dexmedetomidine (Group D),Intranasal saline 0.9% (Group C),No significant difference,"There was no statistically significant difference between the two groups regarding extubation, emergence, and discharge times with a P &gt; 0.05",5389230
1899,5045666,Mean serum levels of high-density lipoprotein cholesterol (HDL-C),Vitamin D supplement,Placebo,Significantly increased,"Based on an ANCOVA, the serum HDL levels were correlated before and after the intervention (P &lt; 0.001). After adjustment for confounding variables, the mean serum HDL level of the treatment group was significantly higher than that of the control group (P = 0.04).",5045666
1900,5045666,Mean serum levels of vitamin D,Vitamin D supplement,Placebo,Significantly increased,"The same correlation was found for vitamin D levels (P &lt; 0.001). After adjustment, the level of the study group was significantly higher than that of the control group (P &lt; 0.001).",5045666
1901,5045666,Baseline levels of high-density lipoprotein cholesterol (HDL-C) and vitamin D,Vitamin D supplement,Placebo,No significant difference,"there was no significant difference in the mean level of HDL and vitamin D between the study and control groups before the intervention (P = 0.95 and P = 0.20, respectively).",5045666
1902,3000449,Negative stereotyping,Interaction with an obese patient in a digital environment,Interaction with a non-obese patient in a digital environment,Significantly increased,"Students endorsed significantly higher levels of negative stereotypes when they interacted with the obese version of the patient than the non-obese version of the patient, F(1,73)=49.64, p&lt;.0001.",3000449
1903,3000449,Perception of patient adherence to given recommendations,Interaction with an obese patient in a digital environment,Interaction with a non-obese patient in a digital environment,Significantly decreased,"Students also rated the obese patient as less likely to adhere to their advice, F(1,73)=7.42, p&lt;.01",3000449
1904,3000449,Perception of good health status,Interaction with an obese patient in a digital environment,Interaction with a non-obese patient in a digital environment,Significantly decreased,"students rated the obese patient as being less healthy than the non-obese patient, F(1,73)=54.16, p&lt;.0001.",3000449
1905,3000449,Patient being held responsible for the weight-related symptoms,Interaction with an obese patient in a digital environment,Interaction with a non-obese patient in a digital environment,Significantly increased,"In addition, the obese patient was rated as more responsible for causing the presenting complaints that could be construed as weight-related, but not the unrelated condition. That is, the obese patient was held significantly more responsible for causing her shortness of breath, F(1,73)=26.37, p&lt;.0001, and her knee pain, F(1,73)=36.11, p&lt;.0001,",3000449
1906,3000449,Patient being held responsible for symptoms unrelated to weight,Interaction with an obese patient in a digital environment,Interaction with a non-obese patient in a digital environment,No significant difference,there was no difference in student ratings of the obese and non-obese patients' responsibility for causing the eczema.,3000449
1907,3480782,Immediate efficacy,Ciclesonide (CIC),Fluticasone propionate (FLP),No significant difference,There was no statistically significant difference in immediate efficacy.,3480782
1908,3480782,Preferred intranasal corticosteroid,Ciclesonide (CIC),Fluticasone propionate (FLP),Significantly decreased,"Patients (58% males; pooled median age 32 years [Interquartile range, IQR, 25â€“41]; pooled median symptom duration 24 months [IQR 12â€“72]) preferred FLP over CIC nasal spray overall (55.41% vs. 25.68%, P = 0.007)",3480782
1909,3480782,Sensory attributes,Ciclesonide (CIC),Fluticasone propionate (FLP),Significantly decreased,"Regarding sensory attributes, patient ratings favored FLP over CIC with respect to satisfying scent, soothing feel and nasal irritation. Thirty seven (50%) patients preferred FLP compared to 6 (8.11%) preferring CIC with regards to satisfying scent (P &lt; 0.001); 42 (56.76%) reported FLP to provide a more soothing feel compared to 15 (20.27%) preferring CIC in this regard (P &lt; 0.001). Only 1 (1.35%) patient reported nasal irritation following FLP administration, in contrast to 21 (28.38%) following ciclesonide use (P = 0.002).",3480782
1910,3480782,"Urge to sneeze, aftertaste, run down to throat, and run off from nose following the use of intranasal corticosteroids ",Ciclesonide (CIC),Fluticasone propionate (FLP),No significant difference,"Although, only one patient (1.35%) had urge to sneeze following FLP use, compared to 10 following CIC (13.51%), this difference was not statistically significant. The number reporting immediate taste, aftertaste, run down to throat and run off from nose were less with CIC compared to FLP, but these differences were also insignificant statistically.",3480782
1911,5630555,"BMI (or body weight), blood pressure and HbA1c",sitagliptin,pioglitazone,No significant difference,"The values of BMI (or body weight), blood pressure and HbA1c did not significantly differ between the two groups during the study.",5630555
1912,5630555,the âˆ‘C-peptide values during the oral glucose tolerance test,sitagliptin,pioglitazone,No significant difference,"On average, the âˆ‘C-peptide values during the oral glucose tolerance test through the follow-up periods showed a nonsignificant increase in the S group (n&nbsp;=&nbsp;6, n&nbsp;=&nbsp;5 at 48&nbsp;months) compared to the P group (n&nbsp;=&nbsp;5, n&nbsp;=&nbsp;2 at 48&nbsp;months).",5630555
1913,5630555,The titers of GADAb,sitagliptin,pioglitazone,No significant difference,The titers of GADAb were not significantly different between the S and P groups at any time point in the present study (Table S1).,5630555
1914,3276929,Resting pain in participants with OA knees,yoga,control,Significantly decreased,"Resting pain (numerical rating scale) reduced better (P&lt;0.001, Mannâ€“Whitney U test) in yoga group (post 1=33.6% and post 2=71.8%) than control group (post 1=13.4% and post 2=37.5%).",3276929
1915,3276929,State anxiety in participants with OA knees,yoga,control,Significantly decreased,State anxiety (STAI-1) reduced (P&lt;0.001) by 35.5% (post 1) and 58.4% (post 2) in the yoga group and 15.6% (post 1) and 38.8% (post 2) in the control group; trait anxiety (STAI 2) reduced (P&lt;0.001) better (post 1=34.6% and post 2=57.10%) in yoga than control group (post 1=14.12% and post 2=34.73%).,3276929
1916,3276929,Morning stiffness in participants with OA knees,yoga,control,Significantly decreased,Morning stiffness decreased more (P&lt;0.001) in yoga (post 1=68.6% and post 2=98.1%) than control group (post 1=38.6% and post 2=71.6%).,3276929
1917,3276929,Systolic blood pressure,yoga,control,Significantly decreased,Systolic blood pressure reduced (P&lt;0.001) better in yoga group (post 1=âˆ’7.93% and post 2=âˆ’15.7%) than the control group (post 1=âˆ’1.8% and post 2=âˆ’3.8%).,3276929
1918,3276929,Diastolic blood pressure,yoga,control,Significantly decreased,Diastolic blood pressure reduced (P&lt;0.001) better in yoga group (post 1=âˆ’7.6% and post 2=âˆ’16.4%) than the control group (post 1=âˆ’2.1% and post 2=âˆ’5.0%).,3276929
1919,3276929,Pulse rate,yoga,control,Significantly decreased,"There was significant reduction in both groups with (Wilcoxon's, P&lt;0.001) and between groups (Mannâ€“Whitney, P&lt;0.001) significantly better reduction in yoga than control group at 15th and 90 th days.",3276929
1920,5863418,The mean TNF-Î± value  at 24 h ,preadjusted edgewise appliance (PEA) and self-ligating (SL) systems,without orthodontic treatment,Significantly increased,"There was a statistically significant difference in TNF-Î± concentration at 24 h after orthodontic force application in the PEA group as compared to baseline (P &lt; 0.05). Meanwhile, significant differences were observed at 24 h and 168 h after orthodontic force application in the SL system as compared to baseline (P &lt; 0.05). The mean TNF-Î± value was significantly elevated at 24 h after force application in the PEA and SL groups.",5863418
1921,5863418,TNF-Î± levels after 168 h,preadjusted edgewise appliance (PEA),without orthodontic treatment,Significantly decreased,"Table 2 compares two adjacent concentrations of TNF-Î±, which were significantly decreased after 168 h of force application in the PEA group (P &lt; 0.05).",5863418
1922,4374260,Mean intra-vaginal ejaculatory latency time (IELT),50 mg of tramadol and 100 mg of tramadol,placebo or baseline,Significantly increased,"Mean IELT was 72 at presentation, 82 for placebo, 150 for tramadol 50 mg, and 272 for tramadol 100 mg (P &lt; 0.001 for all comparisons).",4374260
1923,4374260,premature ejaculation (PE).,50 mg of tramadol and 100 mg of tramadol,placebo ,Significantly decreased,"PE was successfully treated in only 2.4% of patients with placebo, in contrast to 53.6% and 85.6% with 50 and 100 mg tramadol, respectively (P &lt; 0.001 for all comparisons).",4374260
1924,4374260,Weak scanty ejaculation,50 mg of tramadol and 100 mg of tramadol,placebo,Significantly increased,"Weak scanty ejaculation was the main complaint in 7.2% versus 21.6% of those using 50 and 100 mg tramadol, respectively (P = 0.002).",4374260
1925,4374260,Postmicturition dribble,50 mg of tramadol and 100 mg of tramadol,placebo ,Significantly increased,. Postmicturition dribble annoyed 12.8% of those who received 50 mg tramadol and 33.6% of those who received 100 mg tramadol (P &lt; 0.001).,4374260
1926,4374260,adverse events,50 mg of tramadol and 100 mg of tramadol,placebo ,Significantly increased,"Among the 125 patients included in the study, adverse events were noted in 3.2% with placebo, 21.6% with tramadol 50 mg and 45.6% with tramadol 100 mg (P &lt; 0.001).",4374260
1927,3278262,the mean MOCUS score,Packaging Instructions,Control,No significant difference,"his difference was modest and amounted to an average of approximately one-third of a MOCUS item better performance for the Packaging Instructions Group (ie, approximately one-quarter of a standard deviation) and was non-significant (F[1, 203] = 2.90, P = 0.09, Î·2 = 0.014).",3278262
1928,3278262,performing successfully two of the seven MOCUS items,Packaging Instructions,Control,Significantly increased,"As can be seen in Table 2, those who read the packaging instructions performed significantly better on two of the seven MOCUS items",3278262
1929,4322313,low-density lipoprotein cholesterol,simvastatin/ezetimibe,placebo,Significantly decreased,Simvastatin/ezetimibe reduced low-density lipoprotein cholesterol (3.49 (2.94 to 4.15) to 1.32 (1.02 to 1.69) vs 3.46 (2.92 to 4.08) to 3.34 (2.81 to 3.92)â€…mmol/L),4322313
1930,4322313,hsCRP,simvastatin/ezetimibe,placebo,Significantly decreased,Variable	Allocation	Baseline	Year 1	Paired p value	One-year changeshsCRP (mg/L)	Treatment	2.1 (0.9â€“4.1)*	1.2 (0.6â€“2.4)*	&lt;0.001	1.76 (0.0â€“4.4)**Placebo	2.2 (0.9â€“4.9)	1.8 (0.85â€“4.35)	0.003	0.00 (âˆ’1.5â€“2.1),4322313
1931,4175246,"anterior, non-paretic and paretic reach"," task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks",baseline,Significantly increased,"After intervention, anterior, non-paretic and paretic reach were significantly higher in the experimental group (p&lt;0.05).",4175246
1932,4175246,anterior reach,control group,baeeline,Significantly decreased,"After the intervention, anterior reach was significantly higher (p&lt;0.05) in the control group.",4175246
1933,4175246,average velocity and total path length of COP," task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks and control",baseline,No significant difference,. There were no significant differences in the average velocity and total path length of COP sway between the groups.,4175246
1934,4175246,total length of COP," task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks ",control,Significantly decreased,Differences in total length of COP between pre- and post-intervention differed significantly between the two groups (p&lt;0.05).,4175246
1935,4094699,"skinfold thicknesses at lower corner of scapula, triceps brachii, and abdomen,",Baduanjin exercise,control,Significantly decreased,"Compared with the control group, the skinfold thicknesses decreased at lower corner of scapula, triceps brachii, and abdomen, with a statistical significance (P &lt; 0.001; P = 0.005; P = 0.003).",4094699
1936,4094699,the body weight and body mass index (BMI),Baduanjin exercise,control,No significant difference,"Compared with the control group, the body weight and body mass index (BMI) dropped in the intervention group, but the difference was of no statistical significance.",4094699
1937,4094699,the results of sit-and-reach test,Baduanjin exercise,control,Significantly increased,"By comparing the physical fitness indices of the subjects, it was found that the results of sit-and-reach test in the intervention group were increased significantly. However, the control group showed no such changes. The increase of the results of sit-and-reach test in the intervention group had statistical significance (Table 6).",4094699
1938,5340016,The clinical response rates,receive 4â€“6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilâ€“epirubicinâ€“cyclophosphamide (FEC) regimen,weekly paclitaxelâ€“epirubicin (PE) regimen,Significantly decreased,"The clinical response rates were significantly higher in the PE arm than in the FEC arm (76.55% vs. 56.95%, P&nbsp;=&nbsp;0.001).",5340016
1939,5340016,"cPR clinical partial response, cSD clinical stable disease",receive 4â€“6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilâ€“epirubicinâ€“cyclophosphamide (FEC) regimen,weekly paclitaxelâ€“epirubicin (PE) regimen,Significantly decreased,"Those in the PE arm achieved higher cPR and lower cSD rates than those in the FEC arm (cPR rate: 70.92% vs. 54.30%, P&nbsp;=&nbsp;0.006; cSD rate: 14.79% vs. 30.46% P&nbsp;=&nbsp;0.002).",5340016
1940,5340016,down-staging effect,receive 4â€“6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilâ€“epirubicinâ€“cyclophosphamide (FEC) regimen,weekly paclitaxelâ€“epirubicin (PE) regimen,Significantly decreased,"As shown in Table&nbsp;3, both regimens exhibited excellent down-staging effects (both P&nbsp;&lt;&nbsp;0.001), with the PE regimen exhibiting a superior down-staging effect compared with the FEC regimen (P&nbsp;=&nbsp;0.026).Table&nbsp;3",5340016
1941,5340016,pCR (pCR in both the breast and lymph nodes) rates,receive 4â€“6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilâ€“epirubicinâ€“cyclophosphamide (FEC) regimen,weekly paclitaxelâ€“epirubicin (PE) regimen,No significant difference,"However, no significant differences between the FEC and PE arms were observed in the overall pCR (pCR in both the breast and lymph nodes) rates (10.61% vs. 12.31%, P&nbsp;=&nbsp;0.665), the breast pCR rates (13.64% vs. 16.92%, P&nbsp;=&nbsp;0.460), or regional lymph node pCR rates (34.85% vs. 39.23%, P&nbsp;=&nbsp;0.463).Table&nbsp;5",5340016
1942,5340016,The frequency of neutropenia,receive 4â€“6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilâ€“epirubicinâ€“cyclophosphamide (FEC) regimen,weekly paclitaxelâ€“epirubicin (PE) regimen,Significantly decreased,The frequency of neutropenia was higher in the PE arm than in the FEC arm (P&nbsp;=&nbsp;0.031).,5340016
1943,5340016,the post-chemotherapy pathologic T and N stages,receive 4â€“6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilâ€“epirubicinâ€“cyclophosphamide (FEC) regimen,weekly paclitaxelâ€“epirubicin (PE) regimen,Significantly increased,"Consistently, the post-chemotherapy pathologic T and N stages were significantly lower in the PE arm than in the FEC arm (P&nbsp;&lt;&nbsp;0.001).",5340016
1944,4481831,durations of the gait phases,after Ice application,baseline,No significant difference,Ice application did not affect the durations of the gait phases (Table 2).,4481831
1945,4481831,peak value immediately after contact of the foot with the ground (PVF1),after Ice application,baseline,Significantly increased,The application of ice to the sole and calf increased PVF1 immediately following application (Table 3).,4481831
1946,4481831,peak value before lifting the foot from the ground (PVF2),after Ice application,baseline,Significantly decreased,"For PVF2, there was a decrease in the values of these variables from Pre and T0 to T30 when the ice was applied to the ankle and calf. In the AP direction,",4481831
1947,4481831,the maximum braking force (BrF),after Ice application,baseline,Significantly decreased,BrF increased at T30 when compared to Pre with the application of ice to the ankle and sole of the foot.,4481831
1948,3085176,Resting metabolic rates (RMR), p-synephrine (50 mg) alone,placebo,Significantly increased,The group receiving p-synephrine (50 mg) alone exhibited a 65 kcal increase in RMR as compared to the placebo group.,3085176
1949,3085176,Resting metabolic rates (RMR),600 mg naringin with 50 mg p-synephrine,placebo,Significantly increased,The consumption of 600 mg naringin with 50 mg p-synephrine resulted in a 129 kcal increase in RMR relative to the placebo group.,3085176
1950,3085176,Resting metabolic rates (RMR),100 mg hesperidin in addition to the 50 mg p-synephrine plus 600 mg naringin,placebo,Significantly increased,"In the group receiving 100 mg hesperidin in addition to the 50 mg p-synephrine plus 600 mg naringin, the RMR increased by 183 kcal, an increase that was statistically significant with respect to the placebo control (p&lt;0.02).",3085176
1951,3085176,Resting metabolic rates (RMR),1000 mg hesperidin with 50 mg p-synephrine plus 600 mg naringin,placebo,Significantly increased,"However, consuming 1000 mg hesperidin with 50 mg p-synephrine plus 600 mg naringin resulted in a RMR that was only 79 kcal greater than the placebo group.",3085176
1952,3085176,heart rate and blood pressure ,1000 mg hesperidin with 50 mg p-synephrine plus 600 mg naringin and other groups,placebo,No significant difference,"None of the treatment groups exhibited changes in heart rate or blood pressure relative to the control group, nor there were no differences in self-reported ratings of 10 symptoms between the treatment groups and the control group.",3085176
1953,3085176,self-report ratings for the 10 symptoms,1000 mg hesperidin with 50 mg p-synephrine plus 600 mg naringin and other groups,placebo,No significant difference,"Table 3 depicts the results of the self-report ratings for the 10 symptoms. As compared to the placebo group, none of the changes in these 10 self-reported symptoms were statistically significant either 45 or 75 min. from baseline. No significant effects relative to the placebo group were observed by the participants in the four treatment groups for symptoms including anxiety, hunger, tension, sleepiness, energy, nervousness, headache, upset stomach, concentration or general discomfort.",3085176
1954,4048120,mean peri-implant crevicular fluid volume (CFV),received implants immediately after extraction,implants were placed in healed sites,No significant difference,"A higher mean peri-implant crevicular fluid volume (CFV) was observed in immediate implants (Group A) versus non-immediate implants (Group B) at all study time points, in both maxilla and mandible and overall; while overall mean CFV did not show statistically significant differences between groups,",4048120
1955,4048120,maxillary CFV at time points 2 and 3,received implants immediately after extraction,implants were placed in healed sites,Significantly increased,here were significant differences between groups in maxillary CFV at time points 2 and 3 ( Table 2).,4048120
1956,4048120,plaque levels,received implants immediately after extraction,implants were placed in healed sites,No significant difference,"Although plaque levels increased along the different time points, no statistically significant differences were identified between groups (pâ‰¥0.05 - Mann-Whitney U-test) ( Table 2).",4048120
1957,4048120,Bone loss,received implants immediately after extraction,implants were placed in healed sites,No significant difference,Bone loss was 0.54 Â± 0.39 mm for immediate implants and 0.66 Â± 0.25 mm for delayed implants (p=0.201). No implants failed in either group.,4048120
1958,4048120,Gingival retraction and probing depth,received implants immediately after extraction,implants were placed in healed sites,No significant difference,Gingival retraction and probing depth increased in both groups over time; no significant differences were observed between the two groups at any of the time points.,4048120
1959,4048120,Keratinized mucosa width,received implants immediately after extraction,implants were placed in healed sites,No significant difference,"Keratinized mucosa width was seen to decrease in both groups over time; the group of immediate implants had more keratinized mucosa throughout the study, although differences were only statistically significant at time point 1 ( Table 2).",4048120
1960,4048120,Modified gingival index,received implants immediately after extraction,implants were placed in healed sites,No significant difference,Modified gingival index was slightly higher among immediate implants (Group A) although no significant differences between groups were identified ( Table 2).,4048120
1961,3293139,"responses on the scales: â€˜anxietyâ€™, â€˜behaviourâ€™, â€˜dejectionâ€™, â€˜self-blameâ€™, â€˜focus on airway symptomsâ€™ and â€˜introvertâ€™.",screen group,control group,Significantly increased,"Notable was the statistically significant difference between the two groups' responses on the scales: â€˜anxietyâ€™, â€˜behaviourâ€™, â€˜dejectionâ€™, â€˜self-blameâ€™, â€˜focus on airway symptomsâ€™ and â€˜introvertâ€™.",3293139
1962,3293139,"the scales and single items: â€˜sleepâ€™, â€˜stigmatisationâ€™, â€˜harm of smokingâ€™, â€˜busy to take mind off thingsâ€™, â€˜less interest in sexâ€™ and â€˜self-rated healthâ€™.",screen group,control group,No significant difference,"There was no statistically significant difference in the scales and single items: â€˜sleepâ€™, â€˜stigmatisationâ€™, â€˜harm of smokingâ€™, â€˜busy to take mind off thingsâ€™, â€˜less interest in sexâ€™ and â€˜self-rated healthâ€™.",3293139
1963,3293139,negative psychosocial consequences,screen group and control group,baseline,Significantly increased,"As demonstrated in table 4, the participants in both the control and the screen groups had a mean increase in negative psychosocial consequences because there was a statistically significant difference between the prevalence and incidence rounds in the scales: â€˜behaviourâ€™, â€˜dejectionâ€™, â€˜sleepâ€™, â€˜busy to take mind off thingsâ€™ and â€˜less interest in sexâ€™.",3293139
1964,3293139,negative psychosocial consequences,screen group,control group,No significant difference,The mean increase in psychosocial consequences was also compared between participants in the control and the screen groups and no statistically significant differences were revealed.,3293139
1965,4723180,passive drag,"Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerâ€™s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head.","Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head.",Significantly decreased,"Regarding the swimmerâ€™s head position, passive drag was found to be significantly lower in the LA condition (with the arms in front of the head) for the HD and HM than the HU at all speeds (Figure 2).",4723180
1966,4723180,passive drag,"Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerâ€™s ears were covered by the forearms, which were fully extended over the head ","Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head.",No significant difference,No differences were observed in passive drag between the HD and HM at all speeds.,4723180
1967,4723180,passive drag,"Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerâ€™s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head.","Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head.",Significantly decreased,he passive drag tended to decrease significantly by a mean of 17.6% (p &lt; 0.001) for all speeds examined with the arms alongside the body position rather than with the arms above the head position.,4723180
1968,2920889,"Depression or Anxiety or Adjustment Disorder with Depressed Mood, Anxiety, or Mixed Anxiety and Depressed Mood","invited to attend a half-day program with up to five couples and one month old infants, facilitated by trained, supervised nurses",control,Significantly decreased,"In women without a psychiatric history (232/364; 64%), 36/125 (29%) were diagnosed with Depression or Anxiety or Adjustment Disorder with Depressed Mood, Anxiety, or Mixed Anxiety and Depressed Mood in the control group, compared with 16/107 (15%) in the intervention group.",2920889
1969,2920889,mental disorder,psychiatric history,no psychiatric history,Significantly decreased,"For participants with no psychiatric history, being in the intervention group was associated with a significantly reduced odds (OR 0.43; 95% CI 0.21, 0.89; p = 0.022) of a diagnosis of a mental disorder. A linear combination of estimates was used to calculate the odds ratio associated with diagnosis of a mental disorder for participants with a psychiatric history in the intervention group (OR = 1.8; 95% CI 0.92, 3.71; p = 0.082) and demonstrated that being in the intervention group was not associated with significantly increased odds, compared to the control group, and thus the intervention did not cause harm.",2920889
1970,4404560,the rate of injury,exercise ,routine activity,No significant difference,"owever when a fall occurred there was compelling evidence showing no significant difference in the rate of injury in the routine activity compared to the exercise group (combined group: IRR 0.962, 95% CI: 0.76 to 1.21; women only group: IRR 0.989, 95% CI: 0.75 to 1.23).",4404560
1971,4404560,the falls rate in the women only,exercise ,routine activity,No significant difference,There was no significant difference in the falls rate reduction in the women only analysis compared to the overall group.,4404560
1972,4404560, rate of injury when men only fell ,exercise ,routine activity,Significantly decreased,"However compared to women, men had a 44% lower rate of injury when they fell (IRR 0.56, 95% CI: 0.44 to 0.72).",4404560
1973,5376493,Non-technical skills concerning situation awareness and teamwork,non-technical skills seminar,medical seminar,Significantly increased,"Non-technical skills concerning situation awareness (p&lt;.01, r=0.5) and teamwork (p&lt;.01, r=0.45) improved from simulation I to II in the NTS group.",5376493
1974,5376493,Decision making,non-technical skills seminar,medical seminar,No significant difference,"Decision making improved in both groups (NTS: p&lt;.01, r=0.39; control: p&lt;.01, r=0.46).",5376493
1975,5376493,The attitude â€˜handling errorsâ€™,non-technical skills seminar,medical seminar,Significantly increased,"The attitude â€˜handling errorsâ€™ improved significantly in the NTS group (p&lt;.05, r=0.34).",5376493
1976,5376493,"â€˜command roles and responsibilitiesâ€™, â€˜speaking upâ€™, â€˜debriefingâ€™, â€˜feedback and critiqueâ€™, â€˜realistic appraisal of stressâ€™, and â€˜denial of stressâ€™",non-technical skills seminar,medical seminar,No significant difference,"Data for â€˜command roles and responsibilitiesâ€™, â€˜speaking upâ€™, â€˜debriefingâ€™, â€˜feedback and critiqueâ€™, â€˜realistic appraisal of stressâ€™, and â€˜denial of stressâ€™ showed no significant effects between or within groups over time (.06",5376493
1977,5376493,â€˜Teamworkâ€™ over time,non-technical skills seminar,medical seminar,Significantly decreased,"â€˜Teamworkâ€™ decreased significantly over time in the NTS group (t(42) = 2.26, p = .03, r = 0.33), but not in the control group (t(33) = 1.15, p=.26, r=0.20).",5376493
1978,4227976,frequency of sexual dysfunction,Elaeagnus angustifolia flower extract,control,No significant difference,"so, no significant difference was observed in E. angustifolia group before and after the intervention (41.5% vs. 29.3%; p=0.267).",4227976
1979,4227976,frequency of sexual dysfunction,Sildenafil citrate,control,Significantly decreased,"On the other hand, a significant difference was found in the sildenafil citrate group before and after the intervention (40.5% vs. 29.3%; p=0.006) (Table 1).",4227976
1980,4227976,mean score of sexual satisfaction,Elaeagnus angustifolia flower extract,control,Significantly increased,"Also, a significant difference was observed between the EA group and the control group (p&lt;0.001) and between the sildenafil citrate and control groups (p&lt;0.001) regarding the mean score of sexual satisfaction (Table 2).",4227976
1981,4227976,average score of sexual function,Sildenafil citrate,control,No significant difference,"On the other hand, no significant difference was found in the sildenafil citrate group before and after the intervention (p=0.06).",4227976
1982,4227976,mean score of sexual satisfaction,Sildenafil citrate and Elaeagnus angustifolia flower extract,control,Significantly increased,"Also, a significant difference was observed between the EA group and the control group (p&lt;0.001) and between the sildenafil citrate and control groups (p&lt;0.001) regarding the mean score of sexual satisfaction (Table 2).",4227976
1983,4202748,"Waist circumference, HDL-C, VO2max, and TBARS","performed a single period of continuous exercise (Long-bout group: 30â€…min Ã— 1) 3 d per week,",performed 3 short bouts of exercise (Short-bouts group: 10â€…min Ã— 3) 3 d per week,No significant difference,"s shown in Table 2, comparison [p (time Ã— group)] between the long and short bouts of exercise showed no significant difference in the effects of the interventions on the overall variables.",4202748
1984,4202748,"waist circumference, VO2max, DBP ","performed a single period of continuous exercise (Long-bout group: 30â€…min Ã— 1) 3 d per week,",baseline,Significantly increased,"In the Long-bout group, waist circumference and VO2max significantly improved after 20 wk, whereas the DBP after 10 weeks showed a significant increase compared with the baseline value (Table 2Table 2.",4202748
1985,4202748,"HDL-C, VO2max, DBP. SBP",performed 3 short bouts of exercise (Short-bouts group: 10â€…min Ã— 3) 3 d per week,baseline,Significantly increased,"The Short-bouts group demonstrated significant increases in VO2max after 10 weeks and in HDL-C after 20 weeks, whereas the DBP after both 10 and 20 wk and the SBP after 20 wk had significantly increased (Table 2).",4202748
1986,4202748,lasma levels of TBARS (thiobarbituric acid-reactive substances),"performed a single period of continuous exercise (Long-bout group: 30â€…min Ã— 1) 3 d per week,",baseline,Significantly decreased,Plasma levels of TBARS significantly decreased after 20 wk in the Long-bout group (Table 2).,4202748
1987,4415132,The average readings for the SBP and DBP,Measuring BPs in the forearm (FA)  ,Measuring BPs in the upper arm (UA),Significantly increased,The average readings for the SBP and DBP were higher in FA than in UA by approximately 3 mmHg. Statistically significant difference existed in both SBP and DBP.,4415132
1988,5193306,"irritable bowel syndrome (IBS) symptoms (pain, bloating, constipation and diarrhoea)",â€˜individualisedâ€™ (holistic) hypnotherapy,standard â€˜gut-directedâ€™ hypnotherapy,No significant difference,"All the participants in this study improved their IBS symptoms (pain, bloating, constipation and diarrhoea) and physical functioning at the end of the treatment from baseline, but this was not significantly different across the treatment arms.",5193306
1989,5193306,"irritable bowel syndrome (IBS) symptoms (pain, bloating, constipation and diarrhoea)",â€˜individualisedâ€™ (holistic) hypnotherapy,relaxation therapy,No significant difference,"All the participants in this study improved their IBS symptoms (pain, bloating, constipation and diarrhoea) and physical functioning at the end of the treatment from baseline, but this was not significantly different across the treatment arms.",5193306
1990,5193306,the level of pain,â€˜individualisedâ€™ (holistic) hypnotherapy or standard â€˜gut-directedâ€™ hypnotherapy or relaxation therapy,baseline,Significantly decreased,"here was a highly significant decrease in the level of pain,",5193306
1991,5193306,"physical functioning, general health",â€˜individualisedâ€™ (holistic) hypnotherapy or standard â€˜gut-directedâ€™ hypnotherapy or relaxation therapy,baseline,Significantly increased,"There was also significant improvement in physical functioning, general health and the extent to which emotional problems interfered with their work or daily activities from baseline (Figure 4).",5193306
1992,3232004,The response rate,sertraline,placebo,No significant difference,"The response rate was slightly higher for sertraline than for placebo, but this difference was not statistically significant (25/43 (58%) vs 18/46 (39%) responders, Ï‡2(1)=1.39, P=0.24).",3232004
1993,5808396,felt stigma after treatment,Cognitive Processing Therapy,individual support,Significantly decreased,"While women in both arms experienced a reduction in felt stigma over time, participants in group-CPT experienced a significantly greater decline in felt stigma relative to IS participants at the end of treatment (Bâ€‰=â€‰âˆ’â€‰0.44, p valueâ€‰=â€‰0.02).",5808396
1994,5808396,felt stigma after 6 months of treatment,Cognitive Processing Therapy,individual support,No significant difference,"This magnitude but not the statistical significance of this effect was maintained six months post-treatment (Bâ€‰=â€‰âˆ’â€‰0.45, p valueâ€‰=â€‰0.12).Table 2",5808396
1995,5808396,felt stigma after treatment,Cognitive Processing Therapy or individual support,baseline,Significantly decreased,"While women in both arms experienced a reduction in felt stigma over time, participants in group-CPT experienced a significantly greater decline in felt stigma relative to IS participants at the end of treatment (Bâ€‰=â€‰âˆ’â€‰0.44, p valueâ€‰=â€‰0.02).",5808396
1996,5808396,felt stigma after 6 months of treatment,Cognitive Processing Therapy or individual support,baseline,No significant difference,"While women in both arms experienced a reduction in felt stigma over time, participants in group-CPT experienced a significantly greater decline in felt stigma relative to IS participants at the end of treatment (Bâ€‰=â€‰âˆ’â€‰0.44, p valueâ€‰=â€‰0.02).",5808396
1997,5012042,navigator efficiency,underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG),underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF) ,Significantly increased,Using the FG improved average navigator efficiency from 33â€‰Â±â€‰15 to 58â€‰Â±â€‰13 % (pâ€‰&lt;â€‰0.001),5012042
1998,5012042,signal-to-noise ratio (SNR),underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG),underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF) ,Significantly increased,improved SNR by 5 % (pâ€‰=â€‰0.01) compared to acquisitions with NF,5012042
1999,5012042,Circumferential and radial strains,underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG),underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF) ,Significantly decreased,"Circumferential and radial strains derived from FG acquisitions were slightly reduced compared to NF acquisitions (âˆ’16â€‰Â±â€‰2 % vs âˆ’17â€‰Â±â€‰2 %, pâ€‰&lt;â€‰0.001; 40â€‰Â±â€‰10 % vs 44â€‰Â±â€‰11 %, pâ€‰=â€‰0.005, respectively).",5012042
2000,5012042,longitudinal strain,underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG),underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF) ,No significant difference,There were no differences in longitudinal strain (pâ€‰=â€‰0.38).,5012042
2001,5012042,navigator efficiency and signal-to-noise ratio (SNR),xtensive off-scanner training with the FG using a MRI simulator,no off-scanner training,No significant difference,There was no difference in navigator efficiency (pâ€‰=â€‰0.90) or SNR (pâ€‰=â€‰0.77) between untrained and trained participants for FG acquisitions.,5012042
2002,2758834,Roland-Morris Disability Scale,acupuncture treatments,usual care,Significantly increased,"Compared to those receiving usual care, the 8 week dysfunction score improved more for those randomized to any of the three acupuncture or simulated acupuncture groups who had higher levels of dysfunction at baseline (overall interaction p = 0.004) (Table 4).",2758834
2003,4845428,levels of decompression ,MRI + (PM or DTI), MRI + NE,Significantly decreased,The levels of decompression determined by MRI + (PM or DTI) in the experimental group were statistically significantly less than that determined by MRI + NE in the control group (pâ€‰=â€‰0.000) (Table 7).,4845428
2004,4845428,"surgical time, blood loss, and surgical transfusion",experimental group,control group,Significantly decreased,"The surgical time, blood loss, and surgical transfusion were statistically significantly less in the experimental group (pâ€‰=â€‰0.001, pâ€‰=â€‰0.011, pâ€‰=â€‰0.001, respectively). There were no differences in leg dysesthesia complications (pâ€‰=â€‰0.109) (Table 7).",4845428
2005,4845428,"the visual analog scale back and leg pain (VAS-BP, VAS-LP) scores and Oswestry Disability Index (ODI) scores at 2&nbsp;weeks, 3&nbsp;months, 6&nbsp;months, and 12&nbsp;months after operation",experimental,control groups,No significant difference,"There were no differences in improvement of the visual analog scale back and leg pain (VAS-BP, VAS-LP) scores and Oswestry Disability Index (ODI) scores at 2&nbsp;weeks, 3&nbsp;months, 6&nbsp;months, and 12&nbsp;months after operation between the experimental and control groups.",4845428
2006,2671648,percentage of pregnant women who quitted smoking,four visits of a midwife trained in smoking cessation techniques to the home of a smoking pregnant woman,received only a standard written information on the health risk from maternal smoking to the foetus,Significantly increased,The percentage of pregnant women who quitted smoking during the project was 46.1% in the intervention group and 23.4% among the controls (p &lt; 0.001).,2671648
2007,2671648,percentage of pregnant women who quitted smoking,four visits of a midwife trained in smoking cessation techniques to the home of a smoking pregnant woman,received only a standard written information on the health risk from maternal smoking to the foetus,Significantly increased,"After combining the intervention group with the group of women who refused to participate in the project, the rate of quitting was still significantly higher than in the control group (34.7 vs. 18.0, p = 0.02).",2671648
2008,2671648,Attempts to quit smoking,four visits of a midwife trained in smoking cessation techniques to the home of a smoking pregnant woman,received only a standard written information on the health risk from maternal smoking to the foetus,Significantly increased,"The intervention group almost twice as often as the controls undertook at least one attempt to quit smoking (78.9% vs. 40.0%, p &lt; 0.001) (Table 3).",2671648
2009,2671648,The effectiveness of smoking cessation attempts (success rate),four visits of a midwife trained in smoking cessation techniques to the home of a smoking pregnant woman,received only a standard written information on the health risk from maternal smoking to the foetus,No significant difference,"The effectiveness of smoking cessation attempts (success rate), measured by the ratio of successful quitters to all who attempted to quit smoking, was 58.3% and 58.6%, respectively in the intervention and control groups (p = 1.0) (Table 4). No differences were found either in the success rate calculated for education subgroups.",2671648
2010,2671648,reduce smoking rate,four visits of a midwife trained in smoking cessation techniques to the home of a smoking pregnant woman,received only a standard written information on the health risk from maternal smoking to the foetus,Significantly increased,"In the intervention group, the number of subjects who were able to at least slightly reduce their smoking rate was twice as large as in the controls (91.5% vs. 50.5%, p &lt; 0.001).",2671648
2011,5976967,the amount of canal transportation,preparation of the mesiobuccal canal with One Shape or Reciproc rotary systems,preparation of the mesiobuccal canal with M-One rotary systems,No significant difference,"Table 1 and Figure 3 show the amount of canal transportation in the apical, middle, and coronal thirds in the three groups. No significant difference was noted in the amount of canal transportation among the three groups (P &gt; 0.05).",5976967
2012,4338635,blood carboxyhaemoglobin concentrations,exposed to wood smoke (~1 mg/m3 particulate matter concentration)  for one hour during intermittent exercise,exposed filtered air for one hour during intermittent exercise,Significantly increased,"Compared to filtered air, exposure to wood smoke increased blood carboxyhaemoglobin concentrations (1.3% versus 0.8%; Pâ€‰&lt;â€‰0.001), but had no effect on arterial pressure, augmentation index or pulse wave velocity (Pâ€‰&gt;â€‰0.05 for all).",4338635
2013,4338635,augmentation index,exposed to wood smoke (~1 mg/m3 particulate matter concentration)  for one hour during intermittent exercise,exposed filtered air for one hour during intermittent exercise,No significant difference,"Compared to filtered air, exposure to wood smoke increased blood carboxyhaemoglobin concentrations (1.3% versus 0.8%; Pâ€‰&lt;â€‰0.001), but had no effect on arterial pressure, augmentation index or pulse wave velocity (Pâ€‰&gt;â€‰0.05 for all).",4338635
2014,4338635,pulse wave velocity,exposed to wood smoke (~1 mg/m3 particulate matter concentration)  for one hour during intermittent exercise,exposed filtered air for one hour during intermittent exercise,No significant difference,"Compared to filtered air, exposure to wood smoke increased blood carboxyhaemoglobin concentrations (1.3% versus 0.8%; Pâ€‰&lt;â€‰0.001), but had no effect on arterial pressure, augmentation index or pulse wave velocity (Pâ€‰&gt;â€‰0.05 for all).",4338635
2015,4338635,forearm blood flow, intra-brachial infusion of acetylcholine or sodium nitroprusside, intra-brachial infusion of verapamil,No significant difference,"However there were no differences in blood flow responses to acetylcholine (Pâ€‰=â€‰0.91), sodium nitroprusside (Pâ€‰=â€‰0.52) or verapamil (Pâ€‰=â€‰0.63) between exposures (Figure 3).",4338635
2016,4338635,vasodilatation to bradykinin,exposed to wood smoke (~1 mg/m3 particulate matter concentration)  for one hour during intermittent exercise,exposed filtered air for one hour during intermittent exercise,Significantly increased,"Following exposure to wood smoke, vasodilatation to bradykinin increased (Pâ€‰=â€‰0.003)",4338635
2017,4338635,"effect on bradykinin-induced tissue-plasminogen activator release, thrombus area or markers of platelet activation",exposed to wood smoke (~1 mg/m3 particulate matter concentration)  for one hour during intermittent exercise,exposed filtered air for one hour during intermittent exercise,No significant difference,"Following exposure to wood smoke, vasodilatation to bradykinin increased (Pâ€‰=â€‰0.003), but there was no effect on bradykinin-induced tissue-plasminogen activator release, thrombus area or markers of platelet activation (Pâ€‰&gt;â€‰0.05 for all).",4338635
2018,4235088,psychometric hepatic encephalopathy score (PHES),receive lactulose (30â€“60 mL/day) + probiotic (200 million colony forming units of seven bacteria species/day) (Gp-LPr)  or probiotic alone (Gp-Pr) or lactulose + placebo (Gp-L),baseline,Significantly increased,"PHES significantly improved after medication in all the three groups (Gp-LPr: âˆ’3.8 Â± 3.9 to âˆ’1.6 Â± 3.0; Gp-L: âˆ’4.8 Â± 4.1 to âˆ’1.6 Â± 2.9; and Gp-Pr: âˆ’4.9 Â± 3.7 to âˆ’2.1 Â± 2.5, P &lt; 0.001).",4235088
2019,4235088,psychometric hepatic encephalopathy score (PHES) after 8 weeks,receive lactulose (30â€“60 mL/day) + probiotic (200 million colony forming units of seven bacteria species/day) (Gp-LPr)  or probiotic alone (Gp-Pr),baseline,Significantly increased,"After 8 weeks follow-up, there was a deterioration in the Gp-L (âˆ’1.6 Â± 2.9 to âˆ’4.8 Â± 4.2), while the status of the Gp-LPr and Gp-Pr arms did not change significantly [Figure 2].",4235088
2020,4235088,psychometric hepatic encephalopathy score (PHES) after 8 weeks,lactulose + placebo (Gp-L),baseline,No significant difference,"After 8 weeks follow-up, there was a deterioration in the Gp-L (âˆ’1.6 Â± 2.9 to âˆ’4.8 Â± 4.2), while the status of the Gp-LPr and Gp-Pr arms did not change significantly [Figure 2].",4235088
2021,5614293,The mean score of final visual acuity,combination of IVT and IVB,intravitreal triamcinolone acetonide (IVT) or intravitreal bevacizumab (IVB),Significantly increased,"The mean score of final visual acuity was 0.293Â±0.11 in the IVT group, 0.25Â±0.10 in the IVB group and 0.48Â±0.15 in the IVB+IVT group. The differences between groups, considering final visual acuity, was significant (p&lt;0.001).",5614293
2022,5614293,The average of final visual acuity,combination of IVT and IVB,intravitreal triamcinolone acetonide (IVT) or intravitreal bevacizumab (IVB),Significantly increased,"The average of final visual acuity was obtained as following, in the IVT group, 0.293Â±0.11, in the IVB group, 0.25Â±0.1 and in the IVT + IVB group, 0.48Â±0.15. The difference between the groups was statistically significant in terms of final visual acuity (p&lt;0.001) (Table 2).",5614293
2023,5614293,The average of final macular thickness,combination of IVT and IVB,intravitreal triamcinolone acetonide (IVT) or intravitreal bevacizumab (IVB),Significantly decreased,"The average of final macular thickness was 383.33Â±97.70 micrometers in the IVT group, 386.33Â±136.79 micrometers in the IVB group and 307.33Â±110.79 micrometers in the IVT+IVB group, which were significant (p&lt;0.014) (Table 2)",5614293
2024,3178704,"weight, BMI, body fat, waist circumference, and visceral fat area (VFA)",the diet only (DO),baseline,Significantly increased,"Significant increases in weight, BMI, body fat, waist circumference, and visceral fat area (VFA) as measured by CT were observed in the DO group while their glucose area under the curve (AUC) decreased from the baseline value.",3178704
2025,3178704,glucose AUC,diet with aerobic exercise (AE),baseline,Significantly decreased,The AE group showed a definite decrease in their glucose AUC when compared to their values measured at baseline.,3178704
2026,3178704,"body weight, BMI, body fat, muscle mass and VFA",diet with resistance training (RT),baseline,Significantly increased,"The RT group had increases in body weight, BMI, body fat, muscle mass and VFA as measured by CT following the 12-week program.",3178704
2027,3178704,glucose area under the curve (AUC) ,the diet only (DO),baseline,Significantly decreased,in the DO group while their glucose area under the curve (AUC) decreased from the baseline value. T,3178704
2028,3178704,insulin AUC and insulin sensitivity index,diet with aerobic exercise (AE) and diet with resistance training (RT),baseline,Significantly decreased,Both exercise groups (aerobic and resistance) had significant improvements in their insulin AUC and insulin sensitivity index versus their baseline values while the DO group showed no significant changes in these variables.,3178704
2029,5426756,adverse events,ulinastatin,placebo,No significant difference,"Using Fisherâ€™s exact probability test, we found that the incidence of AEs did not differ between drug and placebo groups (P = 1.000), nor did it differ between males and females (P = 0.054).",5426756
2030,4747995,adverse events,ch14.18-UTC,ch14.18-NCI,No significant difference,Productsâ€™ adverse events were similar and consistent with those previously reported.,4747995
2031,4747995,AUCinf,ch14.18-UTC,ch14.18-NCI,No significant difference,"Following standardized single-dose regimens, population pharmacokinetic estimates for AUCinf were 431 ÂµgÂ·h/mL for ch14.18-UTC and 413 ÂµgÂ·h/mL for ch14.18-NCI (ratio = 1.04; 90 % CI 0.98â€“1.11).",4747995
2032,4747995,Cmax,ch14.18-UTC,ch14.18-NCI,No significant difference,"Population pharmacokinetic estimates for Cmax were 6.57 Âµg/mL and 6.88 Âµg/mL, respectively (ratio = 0.96; 90 % CI 0.88â€“1.04).",4747995
2033,3101755,the mean and maximum duration of analgesia,magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours,control,Significantly increased,A statistically significant (P&lt;0.05) increase in the mean and maximum duration of analgesia (minutes) was found in Group A (571.66 [34.313]) in comparison with Group B (305.83 [77.313]) as seen in Table 5 and Figure 1.,3101755
2034,3101755,Total epidural dose of fentanyl and bupivacaine,magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours,control,Significantly decreased,otal epidural dose of fentanyl in 24 h (Î¼g)	70.55 (15.65)	160.75 (20.75)	&lt;0.05Total dose of bupivacaine in 24 h (mg)	15.75 (5.75)	32.75 (5.67)	&lt;0.05,3101755
2035,3101755,"pruritus, nausea, vomiting during first 24 h",magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours,control,Significantly decreased,Patients with pruritus during first 24 h (%) 2 (7) 10 (33) &lt;0.05Patients with nausea during first 24 h (%) 3 (10) 14 (47) &lt;0.05Patients with vomiting during first 24 h (%) 1 (3) 9 (30) &lt;0.05,3101755
2036,5609057,Mean score of general symptoms,extract of three Cretan herbs,placebo,No significant difference,Post-hoc analyses indicated no significant differences in the total score of symptoms between patients consuming supplementary medication and those who did not (mean difference&nbsp;=&nbsp;0.87; 95% CI: âˆ’2.5 - 4.26; p&nbsp;=&nbsp;0.611 for day 4 and mean difference&nbsp;=&nbsp;âˆ’0.1; 95% CI: âˆ’5.1-5.0; p&nbsp;=&nbsp;0.980 for day 7).,5609057
2037,4477402,Length of ICU,Ultra fast-track extubation (UFE),Late extubation ,Significantly decreased,Length of ICU stay was significantly higher in late extubation group (4.2 Â± 1.2 days) than the UFE group (1.72 Â± 1.5 days) (P = 0.02).,4477402
2038,4477402,The length of survival,Ultra fast-track extubation (UFE),Late extubation ,No significant difference,"In survival analysis, there was no significant difference between UFE and LE groups (Log-rank test P = 0.9) [Figure 1].",4477402
2039,4882968,mean severity of mania,omega-3 supplement,placebo,Significantly decreased,"However, the difference in the experimental group showed a statistically significant difference between the mean severity of mania before and after intervention (P &lt; 0.01) [Table 2].",4882968
2040,4882968,The mean intensity of mania,omega-3 supplement,placebo,Significantly decreased,The mean intensity of mania before (23.50 Â± 7.02) and after (10.64 Â± 3.3) intervention reported to be significant at P &lt; 0.05.,4882968
2041,4121500,Bispectral index (BIS) after 10 minutes interval,L received a loading dose of 0.5 Âµg/kg ,group H - 1.0 Âµg/kg,Significantly increased,"Between two groups, BIS values showed a significant differences only at T10, BIS of group H was lower than that of group L.",4121500
2042,4121500,heart rate,Group L - loading dose of 0.5 Âµg/kg for 10 minutes,group H - 1.0 Âµg/kg,No significant difference,"Throughout this study, heart rate decreased significantly rather than T0 value in the both groups. But, there were no significant differences between two groups (Fig. 2).",4121500
2043,4121500,Systolic blood pressure,Group L - loading dose of 0.5 Âµg/kg for 10 minutes,group H - 1.0 Âµg/kg,Significantly decreased,"Between two groups, SBP value in both groups showed a significant difference only at TL, SBP value of group L was lower than that of group H (Fig. 3).",4121500
2044,4121500,"bradycardia, hypoxemia, hypotension and hypertension",Group L - loading dose of 0.5 Âµg/kg for 10 minutes,group H - 1.0 Âµg/kg,No significant difference,"There were no significant differences between two groups in the incidence of bradycardia, hypoxemia, hypotension and hypertension (Table 3).",4121500
2045,4121500,"oral dryness, tachycardia, excessive bradycardia and use of atropine and ephedrine",Group L - loading dose of 0.5 Âµg/kg for 10 minutes,group H - 1.0 Âµg/kg,No significant difference,"Incidence of oral dryness, tachycardia, excessive bradycardia and use of atropine and ephedrine did not show any significant differences.",4121500
2046,4121500,Ramsay score,Group L - loading dose of 0.5 Âµg/kg for 10 minutes,group H - 1.0 Âµg/kg,No significant difference,Ramsay score did not show any significant differences except at TL when the score of group L was significantly lower than the score of group H (Fig. 4).,4121500
2047,4584261,"levels of depression, anxiety, pain, fatigue and sleep disturbance",Cranial electrical stimulation (CES),sham-controlled group,No significant difference,"There were no statistically significant group differences in levels of depression, anxiety, pain, fatigue and sleep disturbance (Table&nbsp;4) at any of the study measurement points (pre-chemotherapy, mid-chemotherapy, and/or two weeks after completion of chemotherapy).",4584261
2048,5049622, number of nocturnal  or severe hypoglycaemic events,insulin glargine 300 U/ml (Glaâ€�300),insulin glargine 100 U/ml (Glaâ€�100),Significantly decreased,"There was a significant 37% relative reduction in annualized rate with Glaâ€�300 compared with Glaâ€�100 [1.74 vs 2.77, rate ratio 0.63 (95% CI 0.42â€“0.96); p = 0.0308; Figure 3B]",5049622
2049,5049622,percentage of participants experiencing â‰¥1 nocturnal confirmed or severe hypoglycaemic event during the 12â€�month,insulin glargine 300 U/ml (Glaâ€�300),insulin glargine 100 U/ml (Glaâ€�100),Significantly decreased,"There was a significant 37% relative reduction in annualized rate with Glaâ€�300 compared with Glaâ€�100 [1.74 vs 2.77, rate ratio 0.63 (95% CI 0.42â€“0.96); p = 0.0308; Figure 3B], and a 16% relative risk reduction in the percentage of participants experiencing â‰¥1 nocturnal confirmed or severe hypoglycaemic event during the 12â€�month study period [38% vs 45%, relative risk 0.84 (95% CI 0.71â€“0.99); Table S1].",5049622
2050,5049622,at least one hypoglycaemic event during 12 months of treatment,insulin glargine 300 U/ml (Glaâ€�300),insulin glargine 100 U/ml (Glaâ€�100),No significant difference,The annualized event rate (Figure 3D) and the percentage of participants with at least one event during 12 months of treatment were numerically lower but not significantly different with Glaâ€�300 compared with Glaâ€�100.,5049622
2051,5049622,weight,insulin glargine 300 U/ml (Glaâ€�300),insulin glargine 100 U/ml (Glaâ€�100),Significantly decreased,"The mean (s.d.) change in body weight, based on the last onâ€�treatment value, was significantly lower with Glaâ€�300 than with Glaâ€�100 [0.4 (4.1) vs 1.2 (3.6) kg];",5049622
2052,5049622,adverse events,insulin glargine 300 U/ml (Glaâ€�300),insulin glargine 100 U/ml (Glaâ€�100),No significant difference,Both treatments were well tolerated with a similar pattern of adverse events (incidence of 69 and 60% in the Glaâ€�300 and Glaâ€�100 groups).,5049622
2053,3793419,histological parameters of Oral Submucous Fibrosis (OSF),"tablet colchicine orally, 0.5 mg twice daily and 0.5 ml intralesional injection Hyaluronidase 1,500 IU into each buccal mucosa once a week","Group 2-Patients were administered 0.5 ml intralesional injection Hyaluronidase 1,500 IU and 0.5 ml intralesional injection Hydrocortisone acetate 25 mg/ml in each buccal mucosa once a week",Significantly decreased,"To compare the effectiveness of treatment in reducing the histological parameters in between the two groups after treatment, Student's â€˜tâ€™ test was done which resulted in a value of P &lt; 0.05 which is statistically significant and indicated that group 1 responded better than group 2.",3793419
2054,3793419,burning sensation,"tablet colchicine orally, 0.5 mg twice daily and 0.5 ml intralesional injection Hyaluronidase 1,500 IU into each buccal mucosa once a week","Group 2-Patients were administered 0.5 ml intralesional injection Hyaluronidase 1,500 IU and 0.5 ml intralesional injection Hydrocortisone acetate 25 mg/ml in each buccal mucosa once a week",Significantly decreased,"However, 33% in group 1 got relief in the second week itself as against 21% in group 2 [Table 4]. For inter group comparison of the effectiveness of treatment in increasing the mouth opening parameters, student's t test was done that resulted in a value P &lt; 0.05 which indicated that group 1 patients responded better than group 2.",3793419
2055,5723168,oral health status at the end of 4th of 8th week,oral health care program (OHCP),Ñ�ontrol group,Significantly increased,"Post hoc Bonferroni pairwise comparison tests (Î±=.005) revealed that the oral health scores were significantly different at the study onset and the end of 4th week (t=36.042, df=45, p&lt;.001), at the study onset and the end of 8th week (t=26.861, df=45, p&lt;.001), and at the end of 4th and 8th week (t=2.817, df=45, p=.007), within the intervention group, indicating large effect sizes (h2=.95).",5723168
2056,4045752,the anti-HBs level ,paracetamol for 24 hours starting at the time of (prophylactic use) before vaccination,The control group received no paracetamol.,Significantly decreased,"Subsequently, we focused on comparison of the GMC of the different treatment groups. The anti-HBs level in the prophylactic paracetamol group was significantly lower (pâ€Š=â€Š0.048) than the level in the control group (Fig. 4, panel B) by using the Mann-Whitney U test. The reduction in anti-HBs level in the prophylactic paracetamol group was 26% as compared to the control group (4257 mIU/mL vs. 5768 mIU/mL) indicating that paracetamol decreases the induction of antibody response in adults.",4045752
2057,4045752,The anti-HBs level ,paracetamol for 6 hours after (therapeutic use)  vaccination,The control group received no paracetamol.,No significant difference,The anti-HBs level in the therapeutic paracetamol group (4958 mIU/mL) was not significantly different from the control group.,4045752
2058,3655565,"heart rate, respiratory rate, mean arterial pressure, peripheral oxygen saturation [SpO2], tidal volumes [V T], minute ventilation [V E], dynamic lung compliance [Cdyn], and rapid shallow breathing index the ratio of the frequency of breathing (f) divided by the tidal volume (V T)",standard care with adjunctive acupressure on one day,standard care ,Significantly increased,"On the first day, compared to subjects in the standard care group, change in tidal volumes from baseline was higher by 48.63â€‰mL (P = 0.036) at 0.5â€‰hrs for participants receiving one-day adjunctive acupressure.",3655565
2059,3655565,"heart rate, respiratory rate, mean arterial pressure, peripheral oxygen saturation [SpO2], tidal volumes [V T], minute ventilation [V E], dynamic lung compliance [Cdyn], and rapid shallow breathing index the ratio of the frequency of breathing (f) divided by the tidal volume (V T)",two-day adjunctive acupressure with standard care ,standard care ,Significantly increased,"For those in the two-day adjunctive acupressure arm, changes were higher by 32.32â€‰mL (P = 0.028) at 1â€‰hr and 39.71â€‰mL (P = 0.041) at 3.5â€‰hrs.",3655565
2060,5404215,flow-mediated dilation (FMD) score at 240 min postconsumption,3 ounces (85 g) ground peanuts,baseline,Significantly decreased,The control shake significantly reduced FMD by 1.2% at 240 min postconsumption compared with baseline (P = 0.029).,5404215
2061,5404215,flow-mediated dilation (FMD) score at 240 min postconsumption in participants with higher baseline total cholesterol (TC),control meal,baseline,Significantly decreased,Participants with higher baseline TC concentrations (&gt;150.0 mg/dL; n = 9) showed a significant decrease in FMD (âˆ’1.8%; P = 0.017) 240 min after consumption of the control meal compared with baseline (Figure 3A).,5404215
2062,5404215,flow-mediated dilation (FMD) score at 240 min postconsumption in participants (n = 6) with a higher baseline LDL-cholesterol concentration (&gt;100 mg/dL),control meal,baseline,Significantly decreased,Participants (n = 6) with a higher baseline LDL-cholesterol concentration (&gt;100 mg/dL) showed a significant decrease in FMD (âˆ’2.0%; P = 0.038) 240 min after the control meal (Figure 3B).,5404215
2063,4019890,median and mean peak IFN-Î³ T cell response,"1000 Î¼g (arm C) of CEA peptide emulsified in Montanide and GM-CSF, given every 2 weeks until disease progression.","10 Î¼g (arm A) of CEA peptide emulsified in Montanide and GM-CSF, given every 2 weeks until disease progression.",Significantly increased,A statistically significant difference in median (Pâ€‰=â€‰0.028) and mean (Pâ€‰=â€‰0.032) T cell response against the immunizing mutant peptide was observed between arm A and C.,4019890
2064,5659064,"plasma levels of vitamin D, EPA, DHA, and total nâ€�3 FA","oral nutritional supplementation, enriched with leucine, vitamin D, and omegaâ€�3 fatty acids (NUTRITION)",baseline,Significantly increased,"Compared with baseline, plasma levels of vitamin D, EPA, DHA, and total nâ€�3 FA significantly increased in NUTRITION (respectively, +26%, P&nbsp;&lt;&nbsp;0.001; +91%, P&nbsp;&lt;&nbsp;0.001; +27%, P&nbsp;=&nbsp;0.001; and +38%, P&nbsp;&lt;&nbsp;0.001), while AA and total nâ€�6 FA significantly decreased (âˆ’10%, P&nbsp;=&nbsp;0.012 and âˆ’5%, P&nbsp;&lt;&nbsp;0.001).",5659064
2065,5659064," plasma vitamin D, EPA, DHA, and nâ€�3 FA","oral nutritional supplementation, enriched with leucine, vitamin D, and omegaâ€�3 fatty acids (NUTRITION)",PLACEBO,Significantly increased,"In PLACEBO, DHA significantly decreased (âˆ’9%, P&nbsp;=&nbsp;0.030), resulting in significant betweenâ€�group difference in favour of NUTRITION in plasma vitamin D (+24%, P&nbsp;=&nbsp;0.004), EPA (+91%, P&nbsp;&lt;&nbsp;0.001), DHA (+31%, P&nbsp;&lt;&nbsp;0.001), and nâ€�3 FA (+42%, P&nbsp;&lt;&nbsp;0.001).",5659064
2066,5659064,"body mass, skeletal muscle mass (SMM,) and FM","oral nutritional supplementation, enriched with leucine, vitamin D, and omegaâ€�3 fatty acids (NUTRITION)",baseline,Significantly increased,"Body composition results showed significantly increased body mass, skeletal muscle mass (SMM,) and FM in NUTRITION compared with baseline (Table 2).",5659064
2067,5659064,body mass and FM,"oral nutritional supplementation, enriched with leucine, vitamin D, and omegaâ€�3 fatty acids (NUTRITION)",PLACEBO,Significantly increased,"After PR, NUTRITION showed significantly higher body mass and FM than PLACEBO.",5659064
2068,5659064,Inspiratory muscle strength,"oral nutritional supplementation, enriched with leucine, vitamin D, and omegaâ€�3 fatty acids (NUTRITION)",PLACEBO,Significantly increased,Inspiratory muscle strength improved significantly only in NUTRITION (Figure 4).,5659064
2069,3835146,mature and total B-cells,"atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 Ã— 9 mg/kg)",placebo,Significantly decreased,Atacicept induced an initial transient increase followed by a dose-dependent reduction in mature and total B-cells (Figure 4A and B). The greatest reductions were seen in mature B-cells 6 weeks after a single dose in the 9 mg/kg group (40% reduction from baseline) and 7 weeks after the repeated dose in the 2 Ã— 9 mg/kg group (55% reduction from baseline).,3835146
2070,3835146,Ig levels,"atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 Ã— 9 mg/kg)",placebo,Significantly decreased,"Ig levels decreased rapidly after atacicept dosing, with the greatest reductions seen for IgM (Figure 4C and D). The largest effect was seen in the 2 Ã— 9mg/kg group, which showed a median decrease frombaseline of âˆ¼40% for IgM 6 weeks after the last dose (33% decrease in IgA, 20% decrease in IgG).",3835146
2071,3835146,C3 levels,"atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 Ã— 9 mg/kg)",placebo,No significant difference,C3 levels remained within the normal range throughout the study for most patients.,3835146
2072,3921228,happiness ,rtfMRI-nf from left amygdala (LA),rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS,Significantly increased,"The increase in happiness was significantly greater in the experimental compared to control group (t(19)â€Š=â€Š2.33, pâ€Š=â€Š0.01),",3921228
2073,3921228,POMS depression,rtfMRI-nf from left amygdala (LA),rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS,No significant difference,"while the change in POMS depression between groups failed to reach significance (t(19)â€Š=â€Š1.33, pâ€Š=â€Š0.10).",3921228
2074,3921228,state anxiety,rtfMRI-nf from left amygdala (LA),rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS,Significantly decreased,"ignificant decreases were also found within the experimental group for ratings of POMS anger (t(13)â€Š=â€Š2.42, pâ€Š=â€Š0.015), trait anxiety (STAI-Trait subscale; t(13)â€Š=â€Š2.62, pâ€Š=â€Š0.01), state anxiety (STAI-Trait subscale; t(13)â€Š=â€Š2.34, pâ€Š=â€Š0.02), and VAS ratings of restlessness (t(13)â€Š=â€Š2.23, pâ€Š=â€Š0.02), anxiety (t(13)â€Š=â€Š4.37, p&lt;0.001), and irritability (t(13)â€Š=â€Š2.14, pâ€Š=â€Š0.025), and the difference between the groups on state anxiety was significant t(19)â€Š=â€Š2.58, pâ€Š=â€Š0.03).",3921228
2075,4628236,nitro-oxidative stress,the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,Significantly decreased,"DM was associated with increased NT immunoreactivity in LV myocardium referring to pronounced nitro-oxidative stress which was significantly alleviated by cinaciguat treatment (Fig. 2a, b).",4628236
2076,4628236,expression of PDE-5,the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,Significantly decreased,"Application of cinaciguat in diabetic animals significantly reduced the expression of PDE-5,",4628236
2077,4628236,PKG activity,the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,Significantly increased,"Application of cinaciguat in diabetic animals significantly reduced the expression of PDE-5, markedly increased PKG activity (as indicated by elevated p-VASP/VASP ratio) (Fig. 3a), while the expression of PKG did not differ between the two diabetic groups (Fig. 3a).Fig. 3",4628236
2078,4628236,profibrotic TGF-Î²1,the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,Significantly decreased,"The profibrotic TGF-Î²1 showed increased expression in the diabetic animals, which was significantly ameliorated by cinaciguat (Fig. 4c).",4628236
2079,4628236,Expression of MMP-9 and MMP-2,the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,No significant difference,"Expression of MMP-9 showed a twofold increase in DM, while MMP-2 remained unchanged (Fig. 4c). Cinaciguat did not significantly alter these parameters (Fig. 4c).",4628236
2080,4628236,the profibrotic mediator TGF-Î²1 and fibrosis marker fibronectin,the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,Significantly decreased,"Additionally, elevated immunoreactivity was observed against the profibrotic mediator TGF-Î²1 and fibrosis marker fibronectin in the diabetic heart (Fig. 4c). Application of cinaciguat reduced MT staining intensity of diabetic myocardium (Fig. 4c) while TGF-Î²1 immunoreactivity strongly tended to decrease (P = 0.051) (Fig. 4c).Fig. 4",4628236
2081,4628236,the slope of EDPVR,the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,Significantly decreased,"In comparison with Co group the slope of EDPVR tended to increase (P = 0.063) in diabetic animals, which was significantly reduced by cinaciguat (Fig. 6b).",4628236
2082,4628236,"The values of load-independent, Pâ€“V-loop derived contractility indexes (Ees, PRSW)",the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,Significantly increased,"The values of load-independent, Pâ€“V-loop derived contractility indexes (Ees, PRSW) were significantly reduced in diabetic animals indicating severe contractile dysfunction (Fig. 6a, b) Treatment with cinaciguat led to a significant increase in PRSW (Fig. 6b) while Ees showed a strong tendency towards improvement in DM (P = 0.092) (Fig. 6b).Fig. 6",4628236
2083,4628236,ANF and the Î²-MHC/Î±-MHC ratio,the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,Significantly decreased,Treatment with cinaciguat caused a significant decrease of ANF expression in DM (Fig. 5a) while Î²-MHC/Î±-MHC ratio showed slight decrease (Fig. 5a).,4628236
2084,4628236,Tau (Weiss; ms),the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks,placebo orally for 8 weeks,Significantly decreased,Tau (Weiss; ms)	10.3 Â± 0.3	10.1 Â± 0.3	17.3 Â± 0.8*	14.9 Â± 0.6*â€ 	&lt;0.001	0.016	0.054,4628236
2085,4342682,choosing the best treatment,unconscious-thought condition,the immediate-decision condition,Significantly increased,"logistic regression analysis indicated that the odds of participants choosing the best treatment were 2.25 times higher in the unconscious-thought condition compared to the immediate-decision condition (b=.81, Wald=4.32, P=.04, 95% CI 1.048-4.836),",4342682
2086,4342682,choosing the best treatment,unconscious-thought condition,conscious-thought condition,Significantly increased,"and 2.39 times greater compared to the conscious-thought condition (b=.87, Wald=4.87, P=.027, 95% CI 1.103-5.186).",4342682
2087,4342682,choosing the best treatment,the immediate-decision condition,the immediate-decision condition,No significant difference,Immediate	No Load	3	9	12Low Load	4	20	24High Load	10	12	22Total	17 (29.3%)	41 (70.7%)	58Conscious	No Load	7	19	26Low Load	4	10	14High Load	5	12	17Total	16 (28.1%)	41 (71.9%)	57,4342682
2088,4471244,lactate levels at 24 hours,thiamine,placebo,Significantly decreased,"Of the deficient patients, those receiving thiamine had statistically significant lower lactate levels at 24 hours (2.1 (IQR: 1.4 to 2.5) vs. 3.1 (IQR: 1.9 to 8.3), P = 0.03",4471244
2089,4471244,Mortality,thiamine,placebo,No significant difference,"Mortality in the thiamine and placebo groups was 13% and 46%, respectively (P = 0.10).",4471244
2090,4471244,24-hour SOFA score,thiamine,placebo,No significant difference,We found no difference in 24-hour SOFA score or mortality.,4471244
2091,5452066,median PFS (Progression-free survival),PM01183,topotecan,Significantly increased,"median PFS was significantly longer with PM01183: 3.9â€‰months (95% CI, 2.5â€“5.7â€‰months) versus 2.0â€‰months (95% CI, 1.4â€“2.8â€‰months) with topotecan (Pâ€‰=â€‰0.0067).",5452066
2092,5452066,median PFS (Progression-free survival) for patients with platinum-resistant disease,PM01183,topotecan,Significantly increased,"Median PFS was significantly longer with PM01183 versus topotecan for patients with platinum-resistant disease, both in the study as a whole (Pâ€‰=â€‰0.0017) and in the second stage alone (Pâ€‰=â€‰0.0043) (Figure 2B).",5452066
2093,5452066,Median OS,PM01183,topotecan,No significant difference,"Median OS was 9.7â€‰months (95% CI, 7.7â€“19.3â€‰months) with PM01183, and 8.5â€‰months (95% CI, 3.3â€“15.6â€‰months) with topotecan (Pâ€‰=â€‰0.2871).",5452066
2094,5360580,Plasma PlsPE,1 mg/day of Pls purified from scallop,placebo,No significant difference,"There was a statistically significant elevation of erythrocyte PlsPE at week 16 in the treatment group and at week 24 in placebo. However, the changes were not significantly different between the two groups.",5360580
2095,5360580,occurrence of adverse events,1 mg/day of Pls purified from scallop,placebo,No significant difference,There was no notable difference in the occurrence of adverse events between the two groups.,5360580
2096,5360580,"WMS-R (30 min) In the patients aged 77 years or younger,",1 mg/day of Pls purified from scallop,placebo,Significantly increased,"In the patients aged 77 years or younger, WMS-R (30 min) increased statistically significantly in the treatment group, showing a significant between-group difference (P = 0.029).",5360580
2097,5360580,WMS-R (0 min),1 mg/day of Pls purified from scallop,placebo,Significantly increased,"WMS-R (0 min) and WMS-R (30 min) improved statistically significantly in the treatment group, and the improvement seemed greater in the Pls treatment group with respect to the 0 min value (P = 0.067) and the 30-min value (P = 0.078) (Table 3).",5360580
2098,3190091,seeing HIV prevention posters displayed on the walls,study-specific prevention activities,control,No significant difference,"As expected, high proportions of patrons at both intervention and control beer halls reported seeing HIV prevention posters displayed on the walls (74.2 vs. 65.5%, respectively, P = 0.005), as these were placed in both intervention and control beer halls.",3190091
2099,3190091,five episodes of unprotected sex with non-wife partners,study-specific prevention activities,control,No significant difference,"For our primary endpoint, both intervention and control beer hall patrons reported approximately five episodes of unprotected sex with non-wife partners (median 5.4 vs. 5.1, respectively, P = 0.98).",3190091
2100,3190091,numbers of non-wife partners and episodes of unprotected sex with non-wife partners ,study-specific prevention activities,baseline,Significantly decreased,"There were significant reductions in numbers of non-wife partners (median beer hall change: 0.4 fewer partners, P = 0.02) and in episodes of unprotected sex with non-wife partners (median change: 6.9 fewer episodes, P = 0.05) in the intervention beer halls from pre- to post-intervention.",3190091
2101,4760045,Onset of both sensory and motor block,30 ml 0.5% ropivacaine + 100 Î¼g of dexmedetomidine (RD),30 ml 0.5% ropivacaine + 75 Î¼g clonidine (RC),Significantly decreased,Onset of both sensory and motor block were earlier in RD group than group RC [Table 3] and they were clinically significant (P &lt; 0.05).,4760045
2102,4760045,The mean time from block placement to first request for pain medication,30 ml 0.5% ropivacaine + 100 Î¼g of dexmedetomidine (RD),30 ml 0.5% ropivacaine + 75 Î¼g clonidine (RC),Significantly decreased,"The mean time from block placement to first request for pain medication, that is, the duration of analgesia was 821.11 min in the dexmedetomidine group, but 768.24 min in the clonidine group. This difference (about 52.87 min) was highly significant (P &lt; 0.006) statistically as well as clinically [Table 4 and Figure 1].",4760045
2103,4760045,required amount of diclofenac sodium injection as rescue analgesics in first 20 h of postoperative period,30 ml 0.5% ropivacaine + 100 Î¼g of dexmedetomidine (RD),30 ml 0.5% ropivacaine + 75 Î¼g clonidine (RC),Significantly decreased,"Table 4 and Figure 2 shows that group RD required less amount of diclofenac sodium injection as rescue analgesics than patients in group RC in first 20 h of postoperative period, and the difference is statistically highly significant (P &lt; 0.01).",4760045
2104,4760045,suffered from bradycardia,30 ml 0.5% ropivacaine + 100 Î¼g of dexmedetomidine (RD),30 ml 0.5% ropivacaine + 75 Î¼g clonidine (RC),Significantly increased,"Again group RD suffered from bradycardia, which was statistically higher (P &lt; 0.05) than group RC.",4760045
2105,4760045,VAS score,30 ml 0.5% ropivacaine + 100 Î¼g of dexmedetomidine (RD),30 ml 0.5% ropivacaine + 75 Î¼g clonidine (RC),Significantly decreased,Figure 3 shows that VAS score was of much higher value in group RC than RD group.,4760045
2106,5534500,compliant to enforced mobilization within 24 hours after surgery,enhanced recovery,conventional recover,Significantly increased,Patients in the enhanced recovery group were compliant to enforced mobilization within 24 hours after surgery (POD 0) while only five patients in the control group were ambulated successfully within that period (P &lt; 0.001).,5534500
2107,5534500,tolerated earlier oral feeding (fluids) without severe PONV,enhanced recovery,conventional recover,Significantly increased,"Similarly, patients in the en-hanced recovery group tolerated earlier oral feeding (fluids) without severe PONV (P &lt; 0.001).",5534500
2108,5534500,The times of removal of urinary catheters,enhanced recovery,conventional recover,No significant difference,The times of removal of urinary catheters were similar in the 2 groups (P = 0.202).,5534500
2109,5534500,left the hospital,enhanced recovery,conventional recover,Significantly increased,"Subsequently, enhanced recovery patients met the pre-emptive discharge criteria earlier and thus left the hospital earlier (P &lt; 0.001)",5534500
2110,5534500,"wound infection, respiratory tract infections, and anastomotic leak",enhanced recovery,conventional recover,Significantly decreased,"Regarding postoperative complications, patients in the enhanced recovery group had lower incidences of complications some of which were statistically significant, such as wound infection (P &lt; 0.001), respiratory tract infections (P = 0.025) and anastomotic leak (P = 0.05).",5534500
2111,5534500,"The mean postoperative hospital stay, the mean time of removal of NGTs, the mean time of successful enteral feeding, the mean time for removal of intra-abdominal drains ",enhanced recovery,conventional recover,Significantly decreased,"The mean postoperative hospital stay was 4.49 Â± 0.85 days vs. 13.31 Â± 6.9 days (P &lt; 0.001), the mean time of removal of NGTs was 0.77 Â± 1.031 days vs. 3.26 Â± 2.737 days (P &lt; 0.001), the mean time of successful enteral feeding was 1.89 Â± 1.13 days vs. 5.46 Â± 1.67 days (P &lt; 0.001), and the mean time for removal of intra-abdominal drains was 2.94 Â± 1.056 days vs. 9.06 Â± 3.757 days (P &lt; 0.001) for the enhanced and the conventional groups, respectively.",5534500
2112,5534500,Complications,enhanced recovery,conventional recover,Significantly decreased,Complications were significantly lower among patients in the enhanced group (25.7% vs. 65.7%) (P = 0.001).,5534500
2113,2772252,Catheter-associated urinary tract infection (CAUTI),amikacin bladder wash,control group that did not receive any bladder wash,Significantly decreased,None of the subjects from the bladder wash group developed CAUTI. Amikacin bladder wash was effective in preventing CAUTI (P &lt; 0.001).,2772252
2114,5437665,Fatigue score at week 4,Simvastatin,Red yeast rice,Significantly increased,"At week 4, the fatigue scores were significantly increased in the simvastatin group (P&nbsp;&lt;&nbsp;.001 vs. baseline) and were significantly greater than those of the red yeast rice group (P&nbsp;&lt;&nbsp;.01; Fig. 2).",5437665
2115,5437665,Level of physical activity,Simvastatin,Red yeast rice,Significantly decreased,the physical activity level was significantly decreased in patients from simvastatin group when compared to those from red yeast rice group.,5437665
2116,5437665,Effects in reduction of lipids levels,Simvastatin,Red yeast rice,No significant difference,Similar lipid-lowering effects were observed in two groups.,5437665
2117,5437665,"Concentrations of ALT, AST, Cr, or CPK",Simvastatin,Red yeast rice,No significant difference,"No significant increases of in the concentrations of ALT, AST, Cr, or CPK from baseline were observed in either arm",5437665
2118,5437665,Fatigue score at week 4,Simvastatin,Red yeast rice,Significantly increased,"At week 4, the fatigue scores were significantly increased in the simvastatin group (P&nbsp;&lt;&nbsp;.001 vs. baseline) and were significantly greater than those of the red yeast rice group (P&nbsp;&lt;&nbsp;.01; Fig. 2).",5437665
2119,5437665,Level of physical activity,Simvastatin,Red yeast rice,Significantly decreased,the physical activity level was significantly decreased in patients from simvastatin group when compared to those from red yeast rice group.,5437665
2120,5437665,Effects in reduction of lipids levels,Simvastatin,Red yeast rice,No significant difference,Similar lipid-lowering effects were observed in two groups.,5437665
2121,5437665,"Concentrations of ALT, AST, Cr, or CPK",Simvastatin,Red yeast rice,No significant difference,"No significant increases of in the concentrations of ALT, AST, Cr, or CPK from baseline were observed in either arm",5437665
2122,2815285,Improvement in hemodynamic variables,Lactated Ringer (group II) and hypertonic saline plus dextran (group III),No treatment (group I),Significantly increased,"Volume replacement produced transitory recovery in hemodynamic variables, including mean pulmonary artery pressure, pulmonary capillary wedge pressure and cardiac index, with significant increase in dogs treated with 32 mL/kg of Lactated Ringerâ€™s and 7.5% NaCl plus 6.0% dextran 70 (p&lt;0.001, against no treatment),",2815285
2123,2815285,Blood volume in the retroperitoneal hematoma,Lactated Ringer (group II) ,Hypertonic saline plus dextran (group III),Significantly increased,"Significantly higher VRPH was observed in LR-treated animals when compared to the HSD group, indicating more pronounced rebleeding (p&lt;0.05 NT vs. LR and HSD; p&lt;0.05 LR vs. HSD)",2815285
2124,2815285,Blood volume in the retroperitoneal hematoma,No treatment (group I),Lactated Ringer (group II) and hypertonic saline plus dextran (group III),Significantly increased,"Significantly higher VRPH was observed in LR-treated animals when compared to the HSD group, indicating more pronounced rebleeding (p&lt;0.05 NT vs. LR and HSD; p&lt;0.05 LR vs. HSD)",2815285
2125,2815285,Circulating red cell volume,Lactated Ringer (group II) , Hypertonic saline plus dextran (group III),Significantly decreased,"Fluid resuscitation with subsequent rebleeding led to a decrease in CBV in both treatment groups, although changes were more pronounced in LR-treated animals (p&lt;0.05 NT vs. LR; p&lt;0.05 LR vs. HSD)",2815285
2126,2815285,Transcapillary refill,Lactated Ringer (group II) , Hypertonic saline plus dextran (group III) and no treatment (group I),Significantly decreased,"Transcapillary refill increased in all groups during hemorrhage. Fluid resuscitation determined plateaus in the NT group. It increased in HSD-treated animals and decreased significantly in the LR group (p&lt;0.05 NT and HSD vs. LR) (panel E). In addition, LR-treated animals had negative TR values, indicating transcapillary leaks, while HSD-treated animals had significantly increased transcapillary refill.",2815285
2127,5787910,Mean acne severity,Conventional isotretinoin dose,Low-dose isotretinoin ,No significant difference,The average severity of acne in the two treatment groups did not differ significantly within any of the study periods.,5787910
2128,5787910,"Baseline characteristics, except gender",Conventional isotretinoin dose,Low-dose isotretinoin ,No significant difference,"there was no statistically significant difference between age results (P = 0.911). Similarly, the average age and duration of acne did not differ significantly in the two groups (P &gt; 0.05). Frequency distributions of qualitative research variables including gender differed significantly in the two groups, because 5 participants in the first group (13.9%) and 8 participants in the second group (26.7%), which added up to 13 (19.7%), were male, whereas 31 participants in the first group (86.1%) and 22 (73.3%) in the second group (which added up to 53 or 80.3%) were female (P = 0.011). However, there was no significant difference between the two groups in terms of family history of acne and frequency of previous acne treatments (P &gt; 0.05).",5787910
2129,5787910,Patients' satisfaction score,Conventional isotretinoin dose,Low-dose isotretinoin ,Significantly decreased,"the average of patients' satisfaction score in the first group (mean = 4.78, SD = 0.4) was significantly higher than the second group (mean = 4.43, SD = 0.6) (P = 0.02), which shows that the satisfaction of patients treated with lower doses of medication (Group I) was higher than patients treated with higher doses of the drug (Group II).",5787910
2130,5787910,Frequency of side effects,Conventional isotretinoin dose,Low-dose isotretinoin ,Significantly increased,"a significant difference can be seen in the frequency of side effects dry mouth, dry nose, repeated rhinorrhea, and hair thinning and loss in both groups (P &lt; 0.05), so that the frequency of side effects in the group receiving a higher dose of the drug (the second group) was more than the group receiving the low dose of the drug (the first group).",5787910
2131,4860224,Change on knowledge scores,Intensified anticipatory guidance program,Routine anticipatory guidance program,No significant difference,There was no statistically significant difference in within subject change on knowledge scores between the two study arms.,4860224
2132,4860224,Baseline characteristics,Intensified anticipatory guidance program,Routine anticipatory guidance program,No significant difference,"There were no significant differences between groups regarding age, race/ethnicity, education, marital status, and number of children.",4860224
2133,4860224,Nonurgent ED visit,Intensified anticipatory guidance program,Routine anticipatory guidance program,No significant difference,"Overall, a quarter (76/323, 24%) of the subjects' newborns had at least one nonurgent ED visit reported during the first month of life. While such visits were reported in only 35/170 (21%) infants of the intervention group compared to 41/153 (27%) infants of the control group, this difference was not statistically significant (p = 0.12).",4860224
2134,5444773,Mean airway pressure,Pressure support ventilation (PSV),Pressure-controlled ventilation (PCV),Significantly decreased,"Regardless of whether IAH was present, PSV resulted in lower mean airway pressure (with no differences in peak airway or peak and mean transpulmonary pressures) and less mRNA expression of biomarkers associated with lung inflammation (IL-6) and fibrogenesis (type III procollagen) than PCV.",5444773
2135,5444773,mRNA expression of IL-6 and type III procollagen,Pressure support ventilation (PSV),Pressure-controlled ventilation (PCV),Significantly decreased,"Regardless of whether IAH was present, PSV resulted in lower mean airway pressure (with no differences in peak airway or peak and mean transpulmonary pressures) and less mRNA expression of biomarkers associated with lung inflammation (IL-6) and fibrogenesis (type III procollagen) than PCV.",5444773
2136,5444773, Surfactant protein B expression,Pressure support ventilation (PSV),Pressure-controlled ventilation (PCV),Significantly increased,"In the presence of IAH, PSV improved oxygenation; decreased alveolar collapse, interstitial edema, and diffuse alveolar damage; and increased expression of surfactant protein B as compared to PCV.",5444773
2137,5444773,"Alveolar collapse, interstitial edema, septal thickening, or DAD score in nIAP animals",Pressure support ventilation (PSV),Pressure-controlled ventilation (PCV),No significant difference,"In nIAP animals, no significant differences were observed between PCV and PSV with regard to alveolar collapse, interstitial edema, septal thickening, or DAD score",5444773
2138,5444773,"Alveolar collapse, interstitial edema, or DAD score in animals with IAH",Pressure support ventilation (PSV),Pressure-controlled ventilation (PCV),Significantly decreased,"in the IAH group, PSV was associated with less alveolar collapse, interstitial edema, and DAD compared to PCV",5444773
2139,5387905,Mean pain VAS scores at 4 and 6 hours after the procedure,Diclofenac potassium group,Paracetamol group and ibuprofen group,Significantly decreased,"There were significant decreases in mean pain VAS scores for diclofenac potassium group compared to paracetamol and ibuprofen groups at 4 hours postoperatively (one-way Analysis of Variance: p=0.0001, p=0.001) and 6 hours postoperatively (p=0.04, p=0.005).",5387905
2140,5387905,Mean pain scores at 4 and 6 hours after the procedure,Paracetamol group,Ibuprofen group,No significant difference,there were no significant differences between the mean pain scores for the paracetamol and ibuprofen groups 4 and 6 hours post-operatively,5387905
2141,5387905,Mean pain scores 2 hours after the procedure,Diclofenac potassium group and paracetamol group, Ibuprofen group,No significant difference,"For both paracetamol and diclofenac potassium groups at 2 hours postoperatively, there were no significant decreases in mean pain scores compared with the ibuprofen group (p-values from one-way ANOVA: 1.000, 0.06, Table 1).",5387905
2142,5867479,Levels of S100B,Dexmedetomidine,Normal saline (control group),Significantly decreased,The concentrations of serum S100B and NGF in dexmedetomidine group was lower than those in control group (P&lt;0.01).,5867479
2143,5867479,Levels of NGF,Dexmedetomidine,Normal saline (control group),Significantly decreased,The concentrations of serum S100B and NGF in dexmedetomidine group was lower than those in control group (P&lt;0.01).,5867479
2144,5867479,Levels of BDNF,Dexmedetomidine,Normal saline (control group),Significantly increased,"The results of western blotting showed that the levels of serum BDNF in control group and dexmedetomidine group were significantly lower than that in normal group (P&lt;0.01), and it was higher in dexmedetomidine group than that in control group (P&lt;0.01).",5867479
2145,5867479,"Scores of visual space, executive function, attention, and delayed memory",Dexmedetomidine,Normal saline (control group),Significantly increased,"both MoCA and ANT results revealed that the visual space and executive function scores, attention scores, delayed memory scores, targeted network efficiency and executive control network efficiency in dexmedetomidine group were obviously higher than those in control group (P&lt;0.01).",5867479
2146,5867479,Targeted network efficiency and control network efficiency,Dexmedetomidine,Normal saline (control group),Significantly increased,"The targeted network efficiency and control network efficiency in control group and dexmedetomidine group were obviously decreased compared with those in normal group (P&lt;0.01), and they were obviously higher in dexmedetomidine group than those in control group (P&lt;0.01, P&lt;0.05).",5867479
2147,5029935,Mortality rates,Long-term oxygen therapy 15 h/day,Long-term oxygen therapy 24 h/day,No significant difference,Adjusted mortality rates were similar for deaths from all causes and from respiratory and cardiovascular disease.,5029935
2148,5029935,Survival benefit in hypoxemic COPD,Long-term oxygen therapy 15 h/day,Long-term oxygen therapy 24 h/day,No significant difference,"In hypoxemic COPD, LTOT 24 h/day was not associated with a survival benefit compared with treatment 15â€“16 h/day.",5029935
2149,5174811,E-RS cough/sputum domain scores,Aclidinium 400â€…Âµg (ATTAIN),Placebo (ATTAIN),Significantly decreased,"Treatment with aclidinium 400â€…Âµg significantly reduced total daily COPD symptoms compared with placebo, as assessed by E-RS total score over 24â€…weeks in ATTAIN (p&lt;0.001; figure 1A)",5174811
2150,5174811,E-RS cough/sputum domain scores,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400â€…Âµg versus placebo in ATTAIN (âˆ’0.7 vs âˆ’0.3, respectively; p&lt;0.01) and the active-comparator study (âˆ’0.6 vs âˆ’0.2, respectively; p&lt;0.01).",5174811
2151,5174811,Morning cough severity and phlegm,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (âˆ’0.19 vs âˆ’0.02; p&lt;0.01) and phlegm (âˆ’0.19 vs âˆ’0.02; p&lt;0.05).",5174811
2152,5174811,Night-time cough frequency and severity,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05)",5174811
2153,5174811,Frequency of sputum production at night-time,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05), and frequency of night-time sputum production (âˆ’0.37 vs 0.05 for placebo; p&lt;0.001).",5174811
2154,5174811,E-RS cough/sputum domain scores,Aclidinium 400â€…Âµg (ATTAIN),Placebo (ATTAIN),Significantly decreased,"Treatment with aclidinium 400â€…Âµg significantly reduced total daily COPD symptoms compared with placebo, as assessed by E-RS total score over 24â€…weeks in ATTAIN (p&lt;0.001; figure 1A)",5174811
2155,5174811,E-RS cough/sputum domain scores,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400â€…Âµg versus placebo in ATTAIN (âˆ’0.7 vs âˆ’0.3, respectively; p&lt;0.01) and the active-comparator study (âˆ’0.6 vs âˆ’0.2, respectively; p&lt;0.01).",5174811
2156,5174811,Morning cough severity and phlegm,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (âˆ’0.19 vs âˆ’0.02; p&lt;0.01) and phlegm (âˆ’0.19 vs âˆ’0.02; p&lt;0.05).",5174811
2157,5174811,Night-time cough frequency and severity,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05)",5174811
2158,5174811,Frequency of sputum production at night-time,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05), and frequency of night-time sputum production (âˆ’0.37 vs 0.05 for placebo; p&lt;0.001).",5174811
2159,5174811,E-RS cough/sputum domain scores,Aclidinium 400â€…Âµg (ATTAIN),Placebo (ATTAIN),Significantly decreased,"Treatment with aclidinium 400â€…Âµg significantly reduced total daily COPD symptoms compared with placebo, as assessed by E-RS total score over 24â€…weeks in ATTAIN (p&lt;0.001; figure 1A)",5174811
2160,5174811,E-RS cough/sputum domain scores,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400â€…Âµg versus placebo in ATTAIN (âˆ’0.7 vs âˆ’0.3, respectively; p&lt;0.01) and the active-comparator study (âˆ’0.6 vs âˆ’0.2, respectively; p&lt;0.01).",5174811
2161,5174811,Morning cough severity and phlegm,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (âˆ’0.19 vs âˆ’0.02; p&lt;0.01) and phlegm (âˆ’0.19 vs âˆ’0.02; p&lt;0.05).",5174811
2162,5174811,Night-time cough frequency and severity,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05)",5174811
2163,5174811,Frequency of sputum production at night-time,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05), and frequency of night-time sputum production (âˆ’0.37 vs 0.05 for placebo; p&lt;0.001).",5174811
2164,5174811,E-RS cough/sputum domain scores,Aclidinium 400â€…Âµg (ATTAIN),Placebo (ATTAIN),Significantly decreased,"Treatment with aclidinium 400â€…Âµg significantly reduced total daily COPD symptoms compared with placebo, as assessed by E-RS total score over 24â€…weeks in ATTAIN (p&lt;0.001; figure 1A)",5174811
2165,5174811,E-RS cough/sputum domain scores,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400â€…Âµg versus placebo in ATTAIN (âˆ’0.7 vs âˆ’0.3, respectively; p&lt;0.01) and the active-comparator study (âˆ’0.6 vs âˆ’0.2, respectively; p&lt;0.01).",5174811
2166,5174811,Morning cough severity and phlegm,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (âˆ’0.19 vs âˆ’0.02; p&lt;0.01) and phlegm (âˆ’0.19 vs âˆ’0.02; p&lt;0.05).",5174811
2167,5174811,Night-time cough frequency and severity,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05)",5174811
2168,5174811,Frequency of sputum production at night-time,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05), and frequency of night-time sputum production (âˆ’0.37 vs 0.05 for placebo; p&lt;0.001).",5174811
2169,5174811,E-RS cough/sputum domain scores,Aclidinium 400â€…Âµg (ATTAIN),Placebo (ATTAIN),Significantly decreased,"Treatment with aclidinium 400â€…Âµg significantly reduced total daily COPD symptoms compared with placebo, as assessed by E-RS total score over 24â€…weeks in ATTAIN (p&lt;0.001; figure 1A)",5174811
2170,5174811,E-RS cough/sputum domain scores,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400â€…Âµg versus placebo in ATTAIN (âˆ’0.7 vs âˆ’0.3, respectively; p&lt;0.01) and the active-comparator study (âˆ’0.6 vs âˆ’0.2, respectively; p&lt;0.01).",5174811
2171,5174811,Morning cough severity and phlegm,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (âˆ’0.19 vs âˆ’0.02; p&lt;0.01) and phlegm (âˆ’0.19 vs âˆ’0.02; p&lt;0.05).",5174811
2172,5174811,Night-time cough frequency and severity,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05)",5174811
2173,5174811,Frequency of sputum production at night-time,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05), and frequency of night-time sputum production (âˆ’0.37 vs 0.05 for placebo; p&lt;0.001).",5174811
2174,5174811,E-RS cough/sputum domain scores,Aclidinium 400â€…Âµg (ATTAIN),Placebo (ATTAIN),Significantly decreased,"Treatment with aclidinium 400â€…Âµg significantly reduced total daily COPD symptoms compared with placebo, as assessed by E-RS total score over 24â€…weeks in ATTAIN (p&lt;0.001; figure 1A)",5174811
2175,5174811,E-RS cough/sputum domain scores,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400â€…Âµg versus placebo in ATTAIN (âˆ’0.7 vs âˆ’0.3, respectively; p&lt;0.01) and the active-comparator study (âˆ’0.6 vs âˆ’0.2, respectively; p&lt;0.01).",5174811
2176,5174811,Morning cough severity and phlegm,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (âˆ’0.19 vs âˆ’0.02; p&lt;0.01) and phlegm (âˆ’0.19 vs âˆ’0.02; p&lt;0.05).",5174811
2177,5174811,Night-time cough frequency and severity,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05)",5174811
2178,5174811,Frequency of sputum production at night-time,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05), and frequency of night-time sputum production (âˆ’0.37 vs 0.05 for placebo; p&lt;0.001).",5174811
2179,5174811,E-RS cough/sputum domain scores,Aclidinium 400â€…Âµg (ATTAIN),Placebo (ATTAIN),Significantly decreased,"Treatment with aclidinium 400â€…Âµg significantly reduced total daily COPD symptoms compared with placebo, as assessed by E-RS total score over 24â€…weeks in ATTAIN (p&lt;0.001; figure 1A)",5174811
2180,5174811,E-RS cough/sputum domain scores,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400â€…Âµg versus placebo in ATTAIN (âˆ’0.7 vs âˆ’0.3, respectively; p&lt;0.01) and the active-comparator study (âˆ’0.6 vs âˆ’0.2, respectively; p&lt;0.01).",5174811
2181,5174811,Morning cough severity and phlegm,Aclidinium (active-comparator study),Placebo (active-comparator study),Significantly decreased,"In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (âˆ’0.19 vs âˆ’0.02; p&lt;0.01) and phlegm (âˆ’0.19 vs âˆ’0.02; p&lt;0.05).",5174811
2182,5174811,Night-time cough frequency and severity,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05)",5174811
2183,5174811,Frequency of sputum production at night-time,Aclidinium (ACCORD),Placebo (ACCORD),Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (âˆ’0.36 vs 0.1 for placebo; p&lt;0.001) and severity (âˆ’0.24 vs âˆ’0.1 for placebo; p&lt;0.05), and frequency of night-time sputum production (âˆ’0.37 vs 0.05 for placebo; p&lt;0.001).",5174811
2184,3118076,Rate of success,Immediate loading implants (group I),Delayed loading implants (group II),No significant difference,"The success rate in group I was found to be 80%, which was lower than the success rate in group II which was found to be 90%. On comparison, there was no statistically significant difference in success rate between the two study groups",3118076
2185,3118076,Soft tissue parameters,Immediate loading implants (group I),Delayed loading implants (group II),No significant difference,"There was no statistically significant difference between the groups over time in parameters like mPI, mBI, ML and WKM.",3118076
2186,3118076,Papillary index score,Immediate loading implants (group I),Delayed loading implants (group II),Significantly decreased,The mean PPI score in group II showed a significant increase from when compared to group I.,3118076
2187,4509558,Glycated hemoglobin A1c (HbA1c),laparoscopic sleeve gastrectomy (SG),Roux-en-Y gastric bypass (RYGB) procedure,No significant difference,"Primary and secondary outcomes at 36&nbsp;months are shown in Table&nbsp;2. 22 patients (78.6&nbsp;%) in SG group and 23 patients (85.2&nbsp;%) in RYGB group achieved complete remission of diabetes mellitus with HbA1câ€‰&lt;â€‰6.0&nbsp;% (Pâ€‰=â€‰0.525) and without taking antidiabetic medications, and 25 patients in each group (89.3&nbsp;% vs. 92.6&nbsp;%) gained successful treatment of diabetes with HbA1câ€‰â‰¤â€‰6.5&nbsp;% (Pâ€‰=â€‰0.100).",4509558
2188,4509558,"HbA1c, FBG and C peptid",laparoscopic sleeve gastrectomy (SG),Roux-en-Y gastric bypass (RYGB) procedure,Significantly decreased,"The RYGB group had significantly greater weight loss than the SG group [percentage of total weight loss (%TWL) of 31.0&nbsp;% vs. 27.1&nbsp;% (Pâ€‰=â€‰0.049), %EWL of 92.3&nbsp;% vs. 81.9&nbsp;% (Pâ€‰=â€‰0.003), and change in BMI of 11.0 vs. 9.1&nbsp;kg/m2(Pâ€‰=â€‰0.017), respectively].",4509558
2189,3627033,Disease Activity Score 28 joints C-reactive protein (DAS28-CRP) and simplified disease activity index (SDAI) score,"golimumab (100&nbsp;mg) every 4&nbsp;weeks, with or without methotrexate (MTX) and 50 mg golimumab plus MTX",baseline,Significantly increased,The mean DAS28-CRP 4&nbsp;weeks after the start of treatment was significantly improved compared with the pretreatment score [mean DAS28-CRP at week 4&nbsp;=&nbsp;1.80 vs 4.14 (range 1.28â€“7.04) at baseline; p&nbsp;&lt;&nbsp;0.001].,3627033
2190,3794450,rate of favorable outcomes,intravenous rtPA,control group,Significantly increased,Patients (&gt;80 years old) treated with intravenous rtPA had a higher rate of favorable outcomes (40% vs 16%; P=0.137) and a lower rate of mortality (22% vs 44%; P=0.128) than patients not receiving rtPA treatment.,3794450
2191,3794450,rate of early improvement at 24 h,intravenous rtPA,control group,Significantly increased,A significantly higher rate of early improvement at 24 h was found in patients treated with rtPA (4% vs 23%; P=0.001).,3794450
2192,3794450,rate of mortality,intravenous rtPA,control group,Significantly decreased,Patients (&gt;80 years old) treated with intravenous rtPA had a higher rate of favorable outcomes (40% vs 16%; P=0.137) and a lower rate of mortality (22% vs 44%; P=0.128) than patients not receiving rtPA treatment.,3794450
2193,3735552,Antibiotic prescribing rates,PCT guidance algorithm established for adult LRTI,standard care clinical guidelines,No significant difference,"Antibiotic prescribing rates were not significantly different in PCT guided patients compared to controls (OR 1.26; 95% CI 0.81, 1.95).",3735552
2194,3735552,The mean duration of antibiotic exposure in the subgroup of community-acquired pneumonia (CAP) patients,PCT guidance algorithm established for adult LRTI in the subgroup of community-acquired pneumonia (CAP) patients,standard care clinical guidelines,Significantly decreased,"The mean duration of antibiotic exposure was 4.5 and 6.3 days in the PCT and control group, respectively (mean difference âˆ’1.8 days; 95% CI âˆ’3.1, âˆ’0.5; Pâ€Š=â€Š0.039) (Table 2 and Figure 3).",3735552
2195,3735552,the mean duration of antibiotic treatment in subgroup of non-community-acquired pneumonia (CAP),PCT guidance algorithm established for adult lower respiratory tract infection (LRTI) and non-community-acquired pneumonia (CAP),standard care clinical guidelines,Significantly decreased,"In the subgroup of patients with non-CAP LRTI, the mean duration of antibiotic treatment was 2.4 and 1.6 days in the PCT and control group, respectively (mean difference 0.8 days; 95% CI âˆ’0.5, 2.0; Pâ€Š=â€Š0.01).",3735552
2196,5320759,intubation time,transillumination-assisted technique group (T group) , midline approach technique group (R group),No significant difference,"Among the cases of successful intubation, the intubation time was not significantly different between the two groups (P &gt; 0.05).",5320759
2197,5320759,success rate of intubation,transillumination-assisted technique group (T group) , midline approach technique group (R group),No significant difference,The overall success rate of intubation was not significantly different between the two groups (P &gt; 0.05).,5320759
2198,5320759,"the frequencies of dry throat, sore throat and hoarseness",transillumination-assisted technique group (T group) , midline approach technique group (R group),Significantly increased,"Compared to the midline approach technique, the frequencies of dry throat (52.2% vs. 40.4%, P = 0.020), sore throat (26.8% vs. 16.8%, P = 0.009) and hoarseness (14% vs. 8%, P = 0.045) were higher in the transillumination-assisted technique (Table&nbsp;2).Table 2",5320759
2199,5320759,"The intubation success rates at the first, second, and third attempt",transillumination-assisted technique group (T group) , midline approach technique group (R group),No significant difference,"The intubation success rates at the first, second, and third attempts as well as the average intubation times were similar between the two groups (P &gt; 0.05), but in patients receiving successful intubation at the second attempt, the intubation time was longer in the T group (P = 0.0006).",5320759
2200,5320759,The intubation time at the second attempt,transillumination-assisted technique group (T group) , midline approach technique group (R group),Significantly increased,"The intubation success rates at the first, second, and third attempts as well as the average intubation times were similar between the two groups (P &gt; 0.05), but in patients receiving successful intubation at the second attempt, the intubation time was longer in the T group (P = 0.0006).",5320759
2201,5615441,learning achievement,a mandatory course â€œEvidence-based Medicineâ€�,control group,Significantly increased,"while there was a significant impact of the intervention (repeated testing) on learning achievement, F(1106)&nbsp;=&nbsp;12.72, p&nbsp;&lt;&nbsp;.05, d&nbsp;=&nbsp;.94, r&nbsp;=&nbsp;.42 (95% CI: [.26, .57]).",5615441
2202,5372065,weight loss,"Phase I (months 1â€“6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7â€“12), option of a 16-week weight loss intervention, Phase III (months 13â€“24), weight loss maintenance intervention ",baseline,Significantly decreased,"Among participants with diabetes, average weight change was âˆ’1.2â€…kg (95% CI âˆ’2.1 to âˆ’0.4) at 6â€…months (n=92), âˆ’1.5â€…kg (95% CI âˆ’2.9 to âˆ’0.2) at 12â€…months (n=96), and âˆ’3.7â€…kg (95% CI âˆ’5.2 to âˆ’2.1) at 24â€…months (n=93).",5372065
2203,5372065,"Systolic BP, mmâ€…Hg","Phase I (months 1â€“6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7â€“12), option of a 16-week weight loss intervention, Phase III (months 13â€“24), weight loss maintenance intervention ",baseline,Significantly decreased,"Systolic BP, mmâ€…Hg	249	âˆ’6.4 (âˆ’8.7 to âˆ’4.1)***	251	âˆ’6.2 (âˆ’9.0 to âˆ’3.3)***	250	âˆ’7.3 (âˆ’9.9 to âˆ’4.6)***",5372065
2204,5372065,"HbA1c, %","Phase I (months 1â€“6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7â€“12), option of a 16-week weight loss intervention, Phase III (months 13â€“24), weight loss maintenance intervention ",baseline,No significant difference,"HbA1c, %â€ 	217	0.01 (âˆ’0.09 to 0.12)	220	âˆ’0.07 (âˆ’0.20 to 0.06)",5372065
2205,5372065,"Total cholesterol, mg/dL","Phase I (months 1â€“6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7â€“12), option of a 16-week weight loss intervention, Phase III (months 13â€“24), weight loss maintenance intervention ",baseline,No significant difference,"Total cholesterol, mg/dLâ€¡			221	âˆ’3.2 (âˆ’7.0 to 0.7)	211	âˆ’3.1 (âˆ’7.8 to 1.7)",5372065
2206,4064763,"induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation)",10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate,10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum,No significant difference,"After intervention, variables including: induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation), in the two groups, were found to be the same (P &lt; 0.05).",4064763
2207,4064763,Mean drug dose,10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate,10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum,Significantly increased,"Mean drug dose was 28.98 drops in group A, and 24.29 drops in group B, and the difference between the two groups was statistically significant (p= 0.042).",4064763
2208,4064763,duration of contractions,10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate,10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum,Significantly increased,"Also, duration of contractions was 42.96 seconds in the oxytocin group and 40.25 seconds in oxytocip group, which was less than that in foreign-made drug (P = 0.016) (Table 1).",4064763
2209,4064763,Number of postpartum hemorrhage,10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate,10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum,No significant difference,"Postpartum hemorrhage was slightly more in group B compared to group A; however, the difference was insignificant (P = 0.59).",4064763
2210,3561645,risk of episodes of high reliever use,"(Symbicort SMARTâ„¢, TurbuhalerÂ®) 160/4.5â€‰Î¼g twice daily plus as needed with similar or higher maintenance doses of ICS/LABA plus SABA or formoterol.",higher maintenance doses of ICS/LABA plus SABA or formoterol,Significantly decreased,In both studies the risk of any episode with &gt;6 inhalations/day of reliever was reduced with budesonide/formoterol maintenance and reliever therapy vs. comparators (Pâ€‰â‰¤â€‰0.014; Table 2 and 3).,3561645
2211,3561645,The risk of hospitalisation/ER visits,budesonide/formoterol regimens,fixed-dose salmeterol/fluticasone,Significantly decreased,The risk of hospitalisation/ER visits in Study B during the 21-day period was significantly (Pâ€‰&lt;â€‰0.05) lower for both budesonide/formoterol regimens compared with fixed-dose salmeterol/fluticasone (Table 3).,3561645
2212,5308129,Hepatic Encephalopathy Scoring Algorithm (HESA) score,"PEGâ€“lactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes ","20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube",Significantly decreased,"In comparison with lactulose alone, PEG-lactulose could improve HESA score in 24 hours more effectively (p =0.04, table 3).",5308129
2213,5308129,length of hospital stay,"PEGâ€“lactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes","20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube",Significantly decreased,"Overall, PEG-lactulose regimen was associated with a decrease in length of hospital stay compared with lactulose treatment (p =0.03) but in subgroup analysis we found that PEG-lactulose regimen could only decrease the length of hospital stay in women significantly (p =0.01).",5308129
2214,5308129,blood level of ammonia,"PEGâ€“lactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes","20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube",No significant difference,"There was no significant change in the blood level of ammonia after 24 hours between the treatment groups (p =0.858, table 3).",5308129
2215,4313493,IOP (intraocular pressure),group A bimatoprost 0.03% eye drops once daily for a period of 4 weeks,group B brimonidine 0.2% eye drops twice daily for a period of 4 weeks,Significantly decreased,"As shown in Table 2, absolute fall in IOP with bimatoprost was by 8.9 Â± 1.598 mm Hg by the final visit. This was significantly (P &lt; 0.0001) higher than the reduction of 6.55 Â± 1.26 mm Hg seen in brimonidine-treated patients.",4313493
2216,3556334,mean weight gain,"600,000â€‰IU of Intramuscular vitamin D3",placebo for 2 doses,Significantly increased,"Changes in serum 25 hydroxyvitamin D levels in the two groups is shown in Additional file 1: Figure S1. After 12â€‰weeks of antituberculous therapy, the 25-hydroxyvitamin D supplemented arm had a mean weight gain (kg) of; + 3.75 (3.16 â€“ 4.34) v/sâ€‰+â€‰2.61 (95% CI 1.99 â€“ 3.23) in the placebo arm (p 0.009) and in BMI; + 1.39 (95% CI 1.15 â€“ 1.63) v/sâ€‰+â€‰0.95 (95% CI 0.71 â€“ 1.19) in the placebo arm (p 0.01).",3556334
2217,3556334,number of zones involved,"600,000â€‰IU of Intramuscular vitamin D3",placebo for 2 doses,Significantly decreased,"Interpretation of chest radiographs at 12â€‰weeks showed that the mean number of zones involved in the vitamin D arm were 1.35 v/s 1.82 zones in the placebo arm (p 0.004) (95% CI 0.15, 0.79).",3556334
2218,3556334,cavity size,"600,000â€‰IU of Intramuscular vitamin D3",placebo for 2 doses,Significantly decreased,106 (89.8%) patients in the vitamin D arm had 50% or more reduction in cavity size v/s 111 (94.8%) in the placebo arm (p 0.035).,3556334
2219,3556334,MTBs-induced IFN-g secretion,"600,000â€‰IU of Intramuscular vitamin D3",placebo for 2 doses,Significantly increased,"Increase in MTBs-induced IFN-g secretion after therapy occurred only in subjects with Deficient 25-hydroxyvitamin D levels (pâ€‰=â€‰0.021, Figureâ€‰ 5B) in the drug intervention group but not in the placebo group, Figureâ€‰ 5A.",3556334
2220,3556334,TB severity scores,"600,000â€‰IU of Intramuscular vitamin D3",placebo for 2 doses,Significantly decreased,"On post hoc analysis, patients in the vitamin D arm and serum &lt; 30 ng/mL (â€˜Insufficientâ€™ and â€˜Deficientâ€™ groups) at enrolment had significantly greater improvements in TB severity scores compared to patients with normal baseline 25-hydroxyvitamin D levels; p 0.014.",3556334
2221,3804449,home environmental safety,"Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items",customary care,Significantly increased,"Caregivers in the intervention group had significantly improved home environmental safety (P â‰¤ 0.000) higher caregiver self-efficacy (P â‰¤ 0.002), and lower caregiver strain (P â‰¤ 0.000) than caregivers in the control group.",3804449
2222,3804449,caregiver strain ,"Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items",customary care,Significantly decreased,"Caregivers in the intervention group had significantly improved home environmental safety (P â‰¤ 0.000) higher caregiver self-efficacy (P â‰¤ 0.002), and lower caregiver strain (P â‰¤ 0.000) than caregivers in the control group.",3804449
2223,3804449,caregiver self-efficacy,"Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items",customary care,Significantly increased,"Caregivers in the intervention group had significantly improved home environmental safety (P â‰¤ 0.000) higher caregiver self-efficacy (P â‰¤ 0.002), and lower caregiver strain (P â‰¤ 0.000) than caregivers in the control group.",3804449
2224,3804449,risky behaviors and accidents,"Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items",customary care,Significantly decreased,Care recipients in the intervention group had significantly less risky behaviors and accidents (P â‰¤ 0.000) than care recipients in the control group.,3804449
2225,4477338,serum triglyceride levels, 3.9 g/day EPA+DHA,placebo,Significantly decreased,"As expected, serum triglyceride levels decreased in the n-3 group and increased in the placebo group (P = 0.012).",4477338
2226,4477338,"Total cholesterol, HDL and LDL", 3.9 g/day EPA+DHA,placebo,No significant difference,"Total cholesterol, HDL and LDL, did not change in either group.",4477338
2227,4477338,percent suppression of Endogenous Glucose Production (EGP), 3.9 g/day EPA+DHA,placebo,Significantly increased,"EGP was modestly suppressed during the low-dose insulin infusion (Fig. 1E and F), but the percent suppression decreased by 12% on average in the placebo group and increased by 15% on average in the n-3 group (P = 0.024) (Fig. 1G)",4477338
2228,3329148,H. pylori eradication rate,"group A received 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin for the first 5 days, followed by 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin, and 1000â€‰mg of Amoxicillin for the remaining 5 days.","Group B received 20â€‰mg of Esomeprazole, 1000â€‰mg of Amoxicillin for the first 5 days, followed by 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin, and 1000â€‰mg of Amoxicillin for the remaining 5 days.",Significantly increased,"The H. pylori eradication rate of group A was slightly higher than group B (P &lt; 0.05), and both of them were obviously higher than group C (P &lt; 0.05) (Table 2).",3329148
2229,3329148,H. pylori eradication rate,"group A received 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin for the first 5 days, followed by 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin, and 1000â€‰mg of Amoxicillin for the remaining 5 days and Group B received 20â€‰mg of Esomeprazole, 1000â€‰mg of Amoxicillin for the first 5 days, followed by 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin, and 1000â€‰mg of Amoxicillin for the remaining 5 days.","Group C received 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin, and 1000â€‰mg of Amoxicillin for standard 10-day therapy.",Significantly increased,"The H. pylori eradication rate of group A was slightly higher than group B (P &lt; 0.05), and both of them were obviously higher than group C (P &lt; 0.05) (Table 2).",3329148
2230,3329148,total score descending of symptoms,"group A received 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin for the first 5 days, followed by 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin, and 1000â€‰mg of Amoxicillin for the remaining 5 days and Group B received 20â€‰mg of Esomeprazole, 1000â€‰mg of Amoxicillin for the first 5 days, followed by 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin, and 1000â€‰mg of Amoxicillin for the remaining 5 days.","Group C received 20â€‰mg of Esomeprazole, 500â€‰mg of Clarithromycin, and 1000â€‰mg of Amoxicillin for standard 10-day therapy.",No significant difference,There was no significant difference in total score descending of symptoms between each group (P &gt; 0.05).,3329148
2231,4056626,cough reflex,100 Î³/kg/min of racemic ketamine for 10&nbsp;minutes ,propofol and remifentanil,Significantly decreased,after ETS (T3) cough reflex was significantly reduced in comparison with controls (cough score 4 (IQR 3 to 4) vs. 2 (IQR1 to 2); P &lt;0.0001) (Figure&nbsp;6).,4056626
2232,4056626,"Mean arterial pressure (MAP),  ICP, SjO2 and mVMCA",propofol and remifentanil,baseline,Significantly increased,"In the control group ETS stimulated the cough reflex, with a median cough score of 2 (interquartile range (IQR) 1 to 2). Furthermore, it caused an increase in mean arterial pressure (MAP) (from 89.0â€‰Â±â€‰11.6 to 96.4â€‰Â±â€‰13.1&nbsp;mmHg; P &lt;0.001), ICP (from 11.0â€‰Â±â€‰6.7 to 18.5â€‰Â±â€‰8.9&nbsp;mmHg; P &lt;0.001), SjO2 (from 82.3â€‰Â±â€‰7.5 to 89.1â€‰Â±â€‰5.4; Pâ€‰=â€‰0.01) and mVMCA (from 76.8â€‰Â±â€‰20.4 to 90.2â€‰Â±â€‰30.2&nbsp;cm/sec; Pâ€‰=â€‰0.04).",4056626
2233,4056626,"Mean arterial pressure (MAP),   cerebral perfusion pressure (CPP), SjO2 and mVMCA",100 Î³/kg/min of racemic ketamine for 10 minutes,baseline,No significant difference,"In the intervention group, no significant variation of MAP, CPP, mVMCA, and SjO2 were observed in any step; after ETS, ICP increased if compared with baseline (15.1â€‰Â±â€‰9.4 vs. 11.0â€‰Â±â€‰6.4&nbsp;mmHg; P &lt;0.05).",4056626
2234,4056626,ICP ,100 Î³/kg/min of racemic ketamine for 10 minutes,baseline,Significantly increased,ICP increased if compared with baseline (15.1â€‰Â±â€‰9.4 vs. 11.0â€‰Â±â€‰6.4&nbsp;mmHg; P &lt;0.05),4056626
2235,3525032,serum cortisol levels after CO2 insufflation,laryngeal Mask (PLMA),endotracheal intubation (ETT),Significantly decreased,serum cortisol levels after CO2 insufflation in PLMA group were significantly lower than the ETT group (p = 0.024).,3525032
2236,3525032,"adrenalin, noradrenalin and dopamine values",laryngeal Mask (PLMA),endotracheal intubation (ETT),No significant difference,"no statistically significant differences were observed between and within groups when adrenalin, noradrenalin and dopamine values were compared,",3525032
2237,3525032,cortisol levels 20 minutes after CO2 insufflation,laryngeal Mask (PLMA) or endotracheal intubation (ETT),baseline,Significantly increased,"When serum cortisol levels were compared within groups, cortisol levels 20 minutes after CO2 insufflation were significantly higher than cortisol levels after anaesthesia induction in both groups (p = 0.001)",3525032
2238,3210325,Depression ratings,received an Attention bias modification procedure designed to induce a bias in attention toward positive pictures,received an Attention bias modification procedure designed to induce a bias in attention toward negative material,Significantly decreased,"Depression ratings also increased more following negative ABM [t(56) = âˆ’7.1, p &lt; .001, Cohen's d = .95] than positive ABM [t(58) = âˆ’3.6, p &lt; .001, Cohen's d = .47].",3210325
2239,3210325,the anxiety ratings,received an Attention bias modification procedure designed to induce a bias in attention toward positive pictures,received an Attention bias modification procedure designed to induce a bias in attention toward negative material,Significantly decreased,"For the anxiety ratings, the increase following training was greater for negative ABM [t(56) = âˆ’7.1, p &lt; .001, Cohen's d = .94] than for positive ABM [t(58) = âˆ’2.4, p &lt; .018, Cohen's d = .32].",3210325
2240,4678179,progression-free-survival (PFS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),No significant difference,"Median PFS was 4.0 and 2.5 months for GV and GP arms, respectively (95% CI, 2.5 to 5.3 and 1.9 to 3.8, respectively; adjusted hazard ratio, 0.81; 95% CI, 0.54 to 1.21; P = .30).",4678179
2241,4678179,Median overall survival (OS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),No significant difference,"Median overall survival (OS) was 6.9 and 6.1 months for GV and GP arms, respectively (95% CI, 5.8 to 8.0 and 5.0 to 8.0, respectively; adjusted hazard ratio, 1.04; 95% CI, 0.69 to 1.58; P = .84).",4678179
2242,4678179,Response rates,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),No significant difference,The difference in response rates (8% v 13%) was not significant (P = .53; Data Supplement).,4678179
2243,4678179,rate of adverse events,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),No significant difference,There were no statistically significant differences in the rate of adverse events (AEs) between the arms.,4678179
2244,5372977,plasma and salivary nitrate and nitrite concentrations,ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days,nitrate-depleted beetroot juice (PLA) for six subsequent days,Significantly increased,"Six days of BR ingestion increased plasma and salivary nitrate and nitrite concentrations in comparison to PLA (p &lt; 0.001),",5372977
2245,5372977,Mean HR,ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days,nitrate-depleted beetroot juice (PLA) for six subsequent days,Significantly decreased,Mean HR was lower in the BR (172 Â± 2) vs. PLA trial (175 Â± 2; p = 0.014).,5372977
2246,5372977,High-intensity intermittent running performance as assessed by the Yo-Yo IR1,ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days,nitrate-depleted beetroot juice (PLA) for six subsequent days,Significantly increased,High-intensity intermittent running performance as assessed by the Yo-Yo IR1 significantly improved following BR ingestion (1623 Â± 48 m) when compared to PLA (1574 Â± 47 m; p = 0.027; Figure 2A).,5372977
2247,5372977,Ratings of perceived exertion as determined with the Borg scale,ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days,nitrate-depleted beetroot juice (PLA) for six subsequent days,No significant difference,Ratings of perceived exertion as determined with the Borg scale were also not different between interventions (p = 0.23; Table 1).,5372977
2248,3373832,PRTEE,dextrose prolotherapy,Waitlist,Significantly increased,"Prolotherapy participants (n=10) reported improved PRTEE composite scores compared to Waitlist (n=12) at 4 and 16 weeks (p&lt;0.05), and improved pain and function PRTEE subscale scores (p&lt;0.05) at 4 and 16 weeks, respectively.",3373832
2249,3373832,pain and function PRTEE subscale scores at 4 and 16 weeks,dextrose prolotherapy,Waitlist,Significantly increased,"Prolotherapy participants (n=10) reported improved PRTEE composite scores compared to Waitlist (n=12) at 4 and 16 weeks (p&lt;0.05), and improved pain and function PRTEE subscale scores (p&lt;0.05) at 4 and 16 weeks, respectively.",3373832
2250,3373832,pain and function PRTEE subscale scores at 4 and 16 weeks,dextrose prolotherapy,baseline,Significantly increased,"Prolotherapy participants reported improvement in composite PRTEE scores from baseline at 16 and 32 weeks of 17.9Â±11.64 and 24.8Â±10.58 points, a difference of 49.7% and 70.2% respectively, far in excess of the 11-point PRTEE-based minimal clinical important difference.",3373832
2251,3373832,Grip strength,dextrose prolotherapy,Waitlist,No significant difference,Grip strength improved in all groups without between-group difference.,3373832
2252,3467590,medication intensification,"web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group",baseline,Significantly increased,"In the unadjusted analysis, intensification of medications to control A1c increased in both trial arms when baseline and follow-up data were compared (intervention, 26.4% vs 32.6%, p=0.022; control, 24.8% vs 31.1%, p=0.033; figure 2). This was confirmed in the adjusted analysis (intervention, adjusted OR (AOR) 1.37; 95% CI 1.06 to 1.76; control, AOR 1.41 (95% CI 1.06 to 1.89)).",3467590
2253,3467590,incremental benefit,"web-based continuing medical education (CME), performance feedback and quality improvement tools",control group,No significant difference,"however, we observed no incremental benefit solely due to the intervention (group-by-time interaction, p=0.948).",3467590
2254,3467590,intensification of medications to control BP,"web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group",baseline,No significant difference,"In the unadjusted analysis, intensification of medications to control BP did not differ for patients cared for by physicians in either trial arm when comparing baseline and follow-up data (intervention, 12.3% vs 15.9%, p=0.080; control, 16.5% vs16.3%, p=0.941; figure 2). This finding was consistent with the adjusted analysis (intervention, AOR 1.37 (95% CI 0.99 to 1.88); control, AOR 1.00 (95% CI 0.72 to 1.41)).",3467590
2255,3467590,intensification of medications to control LDL,"web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group",baseline,No significant difference,"In the unadjusted analysis, intensification of medications to control LDL did not differ for patients cared for by physicians in either trial arm when comparing baseline and follow-up data (intervention, 10.6% vs 11.3%, p=0.726; control, 8.1% vs 8.4%, p=0.898; figure 2).",3467590
2256,3467590,haemogloblin A1c (%) among patients with worse glucose control - &gt;9%,"web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group",baseline,Significantly increased,"In the unadjusted analysis and among patients with worse glucose control (A1c &gt;9%), intensification of medications to control A1c increased in both trial arms between baseline and follow-up (intervention, pre 34.8% vs post 62.5%, p=0.002; control, pre 35.7% vs post 61.4%, p=0.008; figure 3 top panel).",3467590
2257,5223669, LDL value measured by ANCOVA and cLDA,Group Medical Clinics (GMC),usual care,Significantly decreased,"With complete data (n=195), 95% CI coverage are equivalent for ANCOVA and cLDA with an estimated 11.2â€…mg/dL (95% CI âˆ’19.2 to âˆ’3.3; p=0.006) lower mean low-density lipoprotein (LDL) cholesterol in GMC compared with usual care.",5223669
2258,5223669,LDL measured by cLDA,Group Medical Clinics (GMC),usual care,Significantly increased,cLDA*	Baseline (Y0)	233	98.0	98.0		12â€…months (Y12)		84.0	92.9	âˆ’8.9 (âˆ’16.7 to âˆ’1.0)	0.03,5223669
2259,5223669,LDL measured by LDA ,Group Medical Clinics (GMC),usual care,No significant difference,"The less efficient, LDA analysis yielded an LDL improvement of 7.2â€…mg/dL (95% CI âˆ’17.2 to 2.8; p=0.15) for GMC compared with usual care.",5223669
2260,4796902,Habituation,Silence condition,Noise condition,Significantly increased,"We compared the proportion of habituated and non-habituated infants in each condition: more infants failed to habituate in the Noise (35.1%) condition than in the Silence (7.7%) condition (Ï‡2(1)â€‰=â€‰6.34, pâ€‰=â€‰0.012).",4796902
2261,4796902,time and trials to attain the habituation criterion,Silence condition,Noise condition,Significantly increased,"Results revealed a significant effect of the condition for the total holding time occurring until the habituation criterion was reached (pâ€‰=â€‰0.024, Î·2pâ€‰=â€‰0.11) and for the mean number of trials conducted (pâ€‰=â€‰0.007, Î·2pâ€‰=â€‰0.15). Preterm infants in the Noise condition needed more time and trials to attain the habituation criterion than in the Silence condition.",4796902
2262,4379665,debris extrusion,"Group 1: WaveOne (primary) single reciprocating file (WO; Dentsply Maillefer, Ballaigues, Switzerland) (25/08), ","Group 2: Self-adjusting file (SAF; ReDent-Nova, Raâ€™anana, Israel) (1.5 mm) Group 3: ProTaper NEXT X1 and X2 (PTN; Dentsply Tulsa Dental, Tulsa, OK) (25/06)",Significantly increased,Post hoc tukey's test revealed Group 1 (WO) resulted in higher debris extrusion (P &lt; 0.001),4379665
2263,4379665,debris extrusion,"Group 2: Self-adjusting file (SAF; ReDent-Nova, Raâ€™anana, Israel) (1.5 mm) ","Group 1: WaveOne (primary) single reciprocating file (WO; Dentsply Maillefer, Ballaigues, Switzerland) (25/08)Ð± Group 3: ProTaper NEXT X1 and X2 (PTN; Dentsply Tulsa Dental, Tulsa, OK) (25/06)",Significantly decreased,Group 2 (SAF) resulted in least debris extrusion (P &lt; 0.001) in the three groups tested (SPSS software v16),4379665
2264,4379665,debris extrusion,"Group 3: ProTaper NEXT X1 and X2 (PTN; Dentsply Tulsa Dental, Tulsa, OK) (25/06)","Group 2: Self-adjusting file (SAF; ReDent-Nova, Raâ€™anana, Israel) (1.5 mm) ",Significantly increased,"Whereas, PTN group presented with an intermediate debris extrusion when compared to SAF it was higher (P &lt; 0.01)",4379665
2265,4379665,debris extrusion,"Group 1: WaveOne (primary) single reciprocating file (WO; Dentsply Maillefer, Ballaigues, Switzerland) (25/08),","Group 2: Self-adjusting file (SAF; ReDent-Nova, Raâ€™anana, Israel) (1.5 mm) ",Significantly decreased,"Whereas, PTN group presented with an intermediate debris extrusion when compared to SAF it was higher (P &lt; 0.01) and with WO it was lesser (P &lt; 0.01).",4379665
2266,5589093,intraoperative fluid balance,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,Significantly decreased,Median (IQR) intraoperative fluid balance was lower in the GDT group compared to the usual care group (p&lt;0.0001).,5589093
2267,5589093,Crystalloid,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,Significantly decreased,Crystalloid use was significantly lower in the GDT group (p&lt;0.0001).,5589093
2268,5589093,intraoperative colloid or blood products,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,No significant difference,There were no significant differences in the use of intraoperative colloid or blood products.,5589093
2269,5589093,intraoperative metaraminol,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,Significantly decreased,Three patients (12%) in the GDT group received intraoperative metaraminol vs. 23 patients (88%) in the usual care group (p&lt;0.0001).,5589093
2270,5589093,intraoperative noradrenaline,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,Significantly increased,Twenty-four patients (92%) in the GDT group received intraoperative noradrenaline vs. 8 patients (31%) in the usual care group (p&lt;0.0001).,5589093
2271,5589093,intraoperative ephedrine,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,No significant difference,Eleven patients (42%) received intraoperative ephedrine in the GDT group vs. 7 patients (27%) in the usual care (p = 0.125).,5589093
2272,5589093,dopamine and/or dobutamine,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,Significantly increased,"Similarly, the use of dopamine and/or dobutamine was significantly higher in the GDT group compared to the usual care group: 12 patients (46%) vs. 1 patient (4%) (p = 0.007).",5589093
2273,5589093,intraoperative beta-blockers,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,No significant difference,Use of intraoperative beta-blockers was similar between groups.,5589093
2274,5589093,volumes of crystalloid or colloid fluids on both postoperative Day 1 and Day 2,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,No significant difference,No statistically significant differences in the volumes of crystalloid or colloid fluids administered between the groups on both postoperative Day 1 and Day 2 were observed.,5589093
2275,5589093,Postoperative complications,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,No significant difference,Postoperative complications were common and occurred at similar frequencies amongst the GDT (73%) and usual care (81%) groups (p = 0.179).,5589093
2276,5589093,Total number of complications,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,Significantly decreased,"Total number of complications per patient were significantly lower in GDT group (44) than with usual care (92): IRR: 0.41 (95%CI 0.24, 0.69) p = 0.001 (Fig 3).",5589093
2277,5589093,most severe complications,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,No significant difference,Assessment of most severe complications demonstrated no significant differences between the GDT group and usual care group (p = 0.414).,5589093
2278,5589093,Postoperative pancreatic fistula,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,No significant difference,Postoperative pancreatic fistula occurred in 2 patients (8%) in the GDT group vs. 5 patients (19%) in the usual care group (p = 0.191).,5589093
2279,5589093,delayed gastric emptying,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,No significant difference,Three patients (12%) in the GDT group developed delayed gastric emptying vs. 6 patients (23%) in the usual care group (p = 0.213).,5589093
2280,5589093,blood transfusion,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,Significantly decreased,Patients in the usual care group were significantly more likely to receive blood transfusion: GDT (nil) vs. usual care (35%) (p = 0.0005).,5589093
2281,5589093,electrolyte derangements,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,Significantly decreased,Patients in the usual care group were significantly more likely to develop electrolyte derangements: GDT (27%) vs. usual care (62%) (p = 0.012).,5589093
2282,5589093,cardiorespiratory complications,pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT),pancreaticoduodenectomy,No significant difference,"A difference between the proportions of cardiorespiratory complications in the usual care group (54%) compared to GDT (27%) was noticed, which did not achieve statistical significance (p = 0.066).",5589093
2283,5337766,The number of ampoules of Follicle Stimulating Hormone (FSG),group D Human Follicle Stimulating Hormone/ Recombinant human follicle stimulating hormone (hFSH/rFSH),"groups A 	human menopausal gonadotropin (hMG), B Human Follicle Stimulating Hormone (hFSH), and C Recombinant Follicle Stimulating Hormone (rFSH)",Significantly decreased,"The number of ampoules or vials of gonadotropin administered was lower in group D than in the other groups; this difference was statistically significant compared to groups A, B, and C.",5337766
2284,5337766,The duration of stimulation,group C Human Follicle Stimulating Hormone (hFSH),groups A (hMG) and D (hFSH/rFSH),Significantly increased,The duration of stimulation was significantly longer in group C than in groups A and D (P=0.030).,5337766
2285,5337766,The serum estradiol level,group D Human Follicle Stimulating Hormone/  Recombinant human follicle stimulating hormone (hFSH/rFSH),groups B ( hFSH) and C(rFSH),Significantly increased,The serum estradiol level was significantly higher in group D than in groups B and C (P=0.005).,5337766
2286,5337766,number of large-sized follicles,group D Human Follicle Stimulating Hormone/ Recombinant human follicle stimulating hormone (hFSH/rFSH),groups B(hFSH) and C (rFSH),Significantly increased,The serum estradiol level was significantly higher in group D than in groups B and C (P=0.005).,5337766
2287,4392900,mean percent weight loss of subjects with prediabetes and/or MetS,intent-to-treat population using multiple imputation (ITT-MI)  ,placebo,Significantly increased,"After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P &lt; 0.0001 vs. placebo),",4392900
2288,4392900,incidence rate of type 2 diabetes,intent-to-treat population using multiple imputation (ITT-MI)  of subjects with prediabetes and/or MetS,placebo,Significantly decreased,"The annualized incidence rate of type 2 diabetes in this population was 6.1, 1.8, and 1.3 for placebo, 7.5/46, and 15/92 (reductions of 70.5% with 7.5/46 and 78.7% with 15/92; P &lt; 0.05 vs. placebo; ITT).",4392900
2289,5695666,weight  after 1 year,moderate-to-vigorous intensity physical activity (MVPA),baseline,Significantly decreased,"Year 1 PA was significantly associated with 1-year weight change (r=0.23, p&lt;0.0001), and this relationship was further strengthened after controlling for baseline PA and demographic factors (r=0.34, p&lt;0.0001).",5695666
2290,5695666,weight  after 1 year,moderate-to-vigorous intensity physical activity (MVPA) 50 - 150 min/week ,moderate-to-vigorous intensity physical activity (MVPA) &lt;50 min/week ,Significantly decreased,"Participants engaging in 150 to &lt;250 or â‰¥250 min/week of MVPA had significantly greater WL at 1-year compared to those engaging in &lt;50 or 50 to &lt;150 min/week. Similar findings were observed when the change in PA from baseline to 1-year was examined â€“ participants with greater improvements in PA also had better WL at Year 1 (adjusted r=0.34, p&lt;0.001).",5695666
2291,1971065,amount of remission of Seasonal Affective Disorder (SAD),efficient light-emitting diodes (LEDs),control treatment,Significantly increased,"The proportion of participants achieving remission was also significantly greater with active than control treatment in the OC analysis of all randomized participants: 57.1% versus 11.1%, p = 0.040 (Fisher's exact test; remission defined as SIGH-SAD score &lt;9).",1971065
2292,1971065,amount of remission of Seasonal Affective Disorder (SAD),efficient light-emitting diodes (LEDs),control treatment,No significant difference,"There was no significant correlation between expectation scores and therapeutic response measured as final %SIGH-SAD scores: for all participants, r2 = 0.00 (p = 0.86), for participants on active treatment, r2 = 0.07 (p = 0.35), and for participants on control treatment, r2 = 0.03 (p = 0.63).",1971065
2293,1971065,time of sleep end,efficient light-emitting diodes (LEDs) and control treatment,baseline,Significantly decreased,"The time of sleep end was earlier in the first week of treatment than in the baseline week in both active and control groups (within-group difference significant at p &lt; 0.0001 and p = 0.047, respectively, paired t test), presumably reflecting the need to complete treatment by 8 A.M. as required by the protocol.",1971065
2294,5337626,evidence of a treatment effect,"7Â·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1â€“21.","control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1â€“21.",No significant difference,"There was no evidence of a treatment effect of bevacizumab on either disease-free survival (HR 1Â·04, 95% CI 0Â·89â€“1Â·22; p=0Â·62) or progression-free survival (HR 1Â·05, 95% CI 0Â·89â€“1Â·23; p=0Â·56).",5337626
2295,5337626,patients achieving pathological tumour responses,"7Â·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1â€“21.","control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1â€“21.",No significant difference,The proportion of patients achieving pathological tumour responses were also similar between the groups (147 [33%] of 452 patients in the chemotherapy alone group vs 135 [30%] of 443 in the chemotherapy plus bevacizumab group; p=0Â·51).,5337626
2296,5337626,the proportions of R0 resections,"7Â·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1â€“21.","control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1â€“21.",No significant difference,"When the comparison was repeated including only patients who underwent a resection (R0 vs R1), the proportions of R0 resections were again similar between the groups (321 [75%] of 429 patients in the chemotherapy alone group vs 305 [75%] of 405 in the chemotherapy plus bevacizumab group).",5337626
2297,5509597,muscle activity,motor imagery training and neurodevelopmental treatment,baseline,Significantly increased,There were significant improvements in muscle activity in both the experimental and control groups after the intervention (p&lt;0.05).,5509597
2298,5509597,improvement in proprioception,motor imagery training ,baseline,Significantly increased,There was a significant improvement in proprioception in the experimental group after intervention (p&lt;0.05).,5509597
2299,5509597,improvement in proprioception,control group,baseline,No significant difference,"However, there was no significant difference in proprioception in the control group (p&gt;0.05).",5509597
2300,5509597,muscle activity and proprioception,motor imagery training ,neurodevelopmental treatment,Significantly increased,The experimental group showed significant improvements in the variations of muscle activity and proprioception compared to the control group (p&lt;0.05).,5509597
2301,4025600,reduction in absolute weight,traditional low-fat diet (LFD),low-carbohydrate diet (LCD),No significant difference,"Also, the reduction in absolute weight was similar between groups and maximal at 6 months: LFD âˆ’4.0 (4.1) kg, LCD âˆ’4.3 (3.6) kg.",4025600
2302,4025600,"HbA1c, Total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides ",traditional low-fat diet (LFD),low-carbohydrate diet (LCD),No significant difference,"LFD n = 30	LCD n = 29	P between groupsBMI, kg/m2 			â€ƒBaseline	34 (5.7)	32 (5.1)	NSâ€ƒ6 months	32 (5.5)	30 (5.1)	NSâ€ƒ P within group	&lt; 0.001	&lt; 0.001	HbA1c, mmol/mol			â€ƒBaseline	56 (8.0)	57 (8.6)	NSâ€ƒ6 months	55 (9.7)	53 (9.8)	NSâ€ƒ P within group	NS	&lt; 0.01	Total cholesterol, mmol/L			â€ƒBaseline	4.3 (1.0)	4.5 (1.0)	NSâ€ƒ6 months	4.2 (1.1)	4.4 (1.1)	NSâ€ƒ P within group	NS	NS	LDL cholesterol, mmol/L			â€ƒBaseline	2.4 (0.7)	2.7 (0.9)	NSâ€ƒ6 months	2.3 (0.8)	2.5 (0.8)	NSâ€ƒ P within group	NS	NS	HDL cholesterol, mmol/L			â€ƒBaseline	1.1 (0.3)	1.1 (0.3)	NSâ€ƒ6 months	1.1 (0.3)	1.2 (0.5)	NSâ€ƒ P within group	NS	&lt; 0.05	Triglycerides mmol/L			â€ƒBaseline	1.8 (0.8)	1.7 (1.4)	NSâ€ƒ6 months	1.8 (1.3)	1.5 (1.2)	NSâ€ƒ P within group	NS	NS",4025600
2303,4025600,IL-1Ra and IL-6 levels,low-carbohydrate diet (LCD), traditional low-fat diet (LFD),Significantly decreased,"After 6 months, the levels of IL-1Ra and IL-6 were significantly lower in the LCD group than in the LFD group, 978 (664â€“1385) versus 1216 (974â€“1822) pg/mL and 2.15 (1.65â€“4.27) versus 3.39 (2.25â€“4.79) pg/mL, both P &lt; 0.05.",4025600
2304,3747462,Serum glucose at the 3rd week.,glycyrrhizin-treated and vaccinated,control,Significantly decreased,"Before challenge, compared to normal control group (1), there is a significant hyperglycemia in vaccinated and treated and vaccinated groups at the 1st week, while significant hypoglycemia was noticed in treated and treated and vaccinated groups at the 3rd week.",3747462
2305,3747462,"RBCs count, PCV %, and Hb concentration",Vaccinated group,control,Significantly decreased,"Vaccinated group (3) showed significant decreases in the RBCs count, PCV %, and Hb concentration at the 1st and 2nd weeks.",3747462
2306,3747462,Serum Creatinine and Uric Acid,Vaccinated group,control,Significantly increased,"Before challenge, compared to normal control group (1), vaccinated group (3) showed significant increase in uric acid and creatinine at the 1st week and at the 1st and 2nd weeks, respectively.",3747462
2307,3747462,activities of AST and ALT,Vaccinated group,control,Significantly increased,"Before challenge, compared to normal control group (1), activities of AST and ALT showed significant increases in vaccinated groups (3) at the 1st and 2nd weeks.",3747462
2308,3747462,Serum Glucose,Vaccinated group,control,Significantly increased,"), there is a significant hyperglycemia in vaccinated and treated and vaccinated groups at the 1st week,",3747462
2309,3065646,"Glasgow outcome scale (GOS), Barthel index (BI), modified Rankin Scale (mRS)",minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) with a HV &lt;50 mL,conventional craniotomy (CC),Significantly increased,"Three parameters representing long-term outcome, the GOS (4.4 Â± 0.6), BI (82.6 Â± 9.5), and mRS (1.8 Â± 1.0) in the MISPTT group with a HV &lt;50 mL had significantly ameliorated compared to those in the CG group (GOS 3.4 Â± 1.1, BI 73.0 Â± 14.6, and mRS 2.7 Â± 1.3, respectively) (P = 0.000, P = 0.009, and P = 0.009, respectively).",3065646
2310,3065646,case fatality 1 year after stroke,minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT),conventional craniotomy (CC),No significant difference,"There were no sharp differences in case fatality between the MISPTT group and the CC group 1 year after stroke (17.2 and 25.9%, respectively, P = 0.243); however, on the whole, the results showed that the survival in the MISPTT group was significantly better than that of the CC group.",3065646
2311,3065646,"Glasgow outcome scale (GOS), Barthel index (BI), modified Rankin Scale (mRS)",minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) with a HV â‰¥50 mL,conventional craniotomy (CC),Significantly increased,"The GOS (3.3 Â± 1.6), BI (73.3 Â± 15.6), and mRS (2.2 Â± 1.2) in the MISPTT group with a HV â‰¥50 mL had significantly ameliorated compared to those in the CG group (GOS 2.5 Â± 1.5, BI 62.2 Â± 21.5, and mRS 3.0 Â± 1.6, respectively) (P = 0.040, P = 0.042, and P = 0.033, respectively).",3065646
2312,4051747,attitudes and behaviors related to Text4baby,Text4baby,attitudes and behaviors related to Usual care alone,Significantly increased,"there was a significant effect of intervention exposure on belief in the importance of visiting a health care provider to be a healthy new mother (OR 1.52, 95% CI 1.01-2.31, P=.046) and in the health risks of alcohol during pregnancy (OR 2.06, 95% CI 1.00-4.31, P=.05)",4051747
2313,4051747,attitudes and behaviors related to Text4baby,Text4baby,attitudes and behaviors related to Usual care alone,Significantly increased,"there was a significant effect of Text4baby intervention exposure on increased agreement with belief in the importance of taking prenatal vitamins (OR 1.91, 95% CI 1.08-3.34, P=.024)",4051747
2314,4051747," prenatal knowledge, attitudes,behaviors and beliefs related to text4baby",Text4baby mHealth program," prenatal knowledge, attitudes,behaviors beliefs in usual care",Significantly increased,"statistically significant percent reporting smoking in the last 30 days: 15.34%, (95% CI 12.08-18.58) in the control versus 9.64% (95% CI 6.95-12.32) in the treatment group, respectively. There was also a larger, statistically significant percent who reported consuming 3 or more vegetables per day in the control versus treatment group: 37.82% (95% CI 33.44-42.19) in control versus 29.98% (95% CI 25.81-34.15] in treatment, respectively.",4051747
2315,5031764,decrease in the levels of impulsivity and aggressiveness in experimental group,mindfulness training psycho-educative program,decrease in the levels of impulsivity and aggressiveness in control grup,Significantly increased,Statistical analyses showed a significant decrease in the levels of impulsivity and aggressiveness in the experimental group compared with the control group,5031764
2316,5031764,impulsivity and aggressiveness dimensions for experiemental group,Wilcoxon test,impulsivity and aggressiveness dimensions for control group,Significantly increased,statistically significant differences were observed when comparing the pre-test and post-test scores in all the dimensions of impulsivity and aggressiveness. No significant differences were found in such variables after the pre-test and post-test comparisons for the control group,5031764
2317,5031764,impulsivity and aggressiveness dimensions for experiemental group,Mann-Whitney U test,impulsivity and aggressiveness dimensions for control goup,Significantly increased,statistically significant differences did appear between the control and experimental groups at post-test in all the dimensions of impulsivity and aggressiveness,5031764
2318,3668955,Relief of plantar pain,real trigger point dry needling,sham trigger point dry needling,Significantly increased,"significant effects favored real dry needling over sham dry needling for pain (adjusted mean difference: VAS first-step pain -14.4 mm, 95% CI -23.5 to -5.2, p=0.002; FHSQ foot pain 10.0 points, 95% CI 1.0 to 19.1, p=0.029)",3668955
2319,3536989,effectiveness in posterior restoration.,Biodentine,composite Z100Â®,Significantly increased,"The following scores were statistically significantly different between Biodentine and Z100Â® restorations: for â€œanatomic formâ€� at each time point (pâ€‰=â€‰0.004 on D15, pâ€‰&lt;â€‰0.001 at M6 and M12); for â€œmarginal adaptationâ€� and â€œpoint of proximal contactâ€� at M6 and M12 (pâ€‰&lt;â€‰0.001).",3536989
2320,3536989,abrasion occurred,Biodentine,Biodentine covered with Z100Â®,Significantly increased,"This may constitute a therapeutic advantage for patients, especially for large cavities where the risk of secondary caries is increased [14]. This approach may help to preserve tooth structure and improve the longevity of the restoration. Importantly, this treatment resulted in very satisfactory restoration performance.",3536989
2321,5300822,reduce muscle damage.,pre-exercise vibration stimulation,post-exercise  vibration stimulation ,Significantly increased,Changes in the PPT with vibration stimulation before or after EIMD showed significant differences (p&lt;0.001) and significant interactions (p&lt;0.01) between the application times and groups.,5300822
2322,5300822,reduce muscle damage.,pre-exercise vibration stimulation,post-exercise  vibration stimulation ,Significantly increased,"Changes in the CK levels with vibration stimulation before or after EIMD showed significant differences between the application times and groups (p&lt;0.01), and significant interactions between the application times and groups (p&lt;0.001).",5300822
2323,5300822,reduce muscle damage.,pre-exercise vibration stimulation,post-exercise  vibration stimulation ,Significantly increased,Changes in the LDH levels with vibration stimulation before or after EIMD showed significant differences (p&lt;0.001) and significant interactions (p&lt;0.001) between the application times and groups.,5300822
2324,4348728,Urinary Retention relief,hot pack,water-soaked gauze,No significant difference,the difference between the two experimental groups was not statistically significant (P &gt; 0.05),4348728
2325,4348728,Urinary Retention relief,hot pack and water soaked gauze,control groups,Significantly increased,The results of the Chi-square test revealed that there was a significant difference among the three groups in terms of the percentage of patients who experienced UR relief (P &lt; 0.001).,4348728
2326,4348728,Urinary Retention relief,hot pack and water soaked gauze,control groups,No significant difference,The results of the one-way ANOVA test showed that the three study groups did not differ significantly in terms of the time to UR relief (P &gt; 0.05).,4348728
2327,4538249,reduce of glycaemic control.,RxING study first six month,Base line,Significantly decreased,"In the RxING study, HbA1c was reduced from 9.1% (SD 1) at baseline to 7.3% (SD 0.9) at 26â€…weeks, a change of 1.8% (95% CI 1.4 to 2, p&lt;0.001)",4538249
2328,4538249,Increase of glycaemic control.,RxING study first six month,A 1-year follow-up of the RxING study,Significantly increased,"Twelve months after completing the study, HbA1c increased from 7.3% (SD 0.9) at study end to 8.1% (SD 1.3), a change of 0.8% (95% CI âˆ’1.1 to âˆ’0.5, p&lt;0.001",4538249
2329,4538249,reduced cardiovascular risk.,RxING study first six month,base line,Significantly decreased,"risk of cardiovascular events in the next 10â€…years was reduced from 31% (SD 17.3) at baseline to 26.7% (SD 14.5) at study end, an absolute reduction of 4.3% (a 14% relative reduction) (95% CI 0.6 to 9.5, p=0.026).",4538249
2330,4538249,reduced cardiovascular risk.,RxING study first six month,A 1-year follow-up of the RxING study,Significantly increased,"Twelve months after completing the study, the risk of cardiovascular events in the next 10â€…years rose from 26.7% (SD 14.5) at study end to 30.75% (SD 15.5), an absolute increase of 4.05% (15% relative increase) (95% CI âˆ’0.09 to 0.005, p=0.083)",4538249
2331,4602159,Cough,topical lidocaine,intravenous lidocaine,Significantly increased,Incidence of cough in the pediatric patients was statistically higher in those who received topical lidocaine (P = 0.004).,4602159
2332,4602159,"apnea, laryngospasm, bronchospasm, vomiting",topical lidocaine,intravenous lidocaine,No significant difference,"Other variables including apnea, laryngospasm, bronchospasm, desaturation, and vomiting were not statistically different.",4602159
2333,1716162,"Change in haemoglobin, iron status indicators, and worm infection",iron fortification + mebenzadole,iron supplementation + mebendazole,Significantly decreased,Significant difference between group (one-way ANOVA): 1p &lt; 0.001;,1716162
2334,1716162,"Change in haemoglobin, iron status indicators, and worm infection",iron fortification + mebendazole,iron supplementation + mebendazole,Significantly decreased,Significant difference within group before and after intervention (t test); 2p &lt; 0.001;,1716162
2335,1716162,"Change in haemoglobin, iron status indicators, and worm infection",iron fortification + mebendazole,iron supplementation + mebendazole,Significantly decreased,Significant difference within group before and after intervention (McNemar); 3p &lt; 0.001; 4p &lt; 0.01;5p &lt; 0.05;,1716162
2336,5604419,neurodevelopment disorder in young children,vitamin-D deficiency,Vitamin D Non-deficient,No significant difference,The overall ASQ-3 score was not significantly lower in the vitamin-D deficient group [mean difference&nbsp;âˆ’&nbsp;6.54 (95% CI: -16.15 to 3.08)] compared to the vitamin-D non-deficient group.,5604419
2337,5604419,Growth retardation in young children,vitamin-D deficiency,Vitamin D Non-deficient,No significant difference,Vitamin-D deficiency was not associated with stunting nor wasting nor underweight at baseline or 6&nbsp;months later in this population,5604419
2338,4749757,Improvement in the 12-item MS Walking Scale (MSWS-12) Score during 24 weeks,Prolonged-release fampridine,Placebo,Significantly increased,"PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks.",4749757
2339,4749757,Improvement in Timed Up and Go (TUG) speed  during 24 weeks,Prolonged-release fampridine,Placebo,Significantly increased,"PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks.",4749757
2340,4749757,Improvement in Berg Balance Scale (BBS) Score  during 24 weeks,Prolonged-release fampridine,Placebo,Significantly increased,"PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks.",4749757
2341,4749757,Adverse Events,Prolonged-release fampridine,Placebo,No significant difference,The proportion of patients with any AE was similar in placebo-treated patients (49 (77%)) versus patients receiving PR-fampridine (51 (75%)).,4749757
2342,4749757,Improvement on PGIC,Prolonged-release fampridine,Placebo,Significantly increased,"In a post hoc analysis, a significantly greater proportion of patients (n (%)) treated with PR-fampridine (31 (46%)) versus placebo (16 (26%)) also reported improvement on PGIC at the week 2 visit (p = 0.023).",4749757
2343,4199615,Blood glucose concentrations over 7.5 hours,Hypoxic trials,Normoxic trials,No significant difference,The areas under the curves for blood glucose and serum insulin concentrations over 7.5 h did not differ among the four trials.,4199615
2344,4199615,Serum insuline concentrations over 7.5 hours,Hypoxic trials,Normoxic trials,No significant difference,The areas under the curves for blood glucose and serum insulin concentrations over 7.5 h did not differ among the four trials.,4199615
2345,4199615,%carbohydrate contribution,Exercise trial in hypoxia (HYP-Ex),Exercise trial in normoxia (NOR-Ex),Significantly increased,"Although exercise promoted carbohydrate oxidation in the NOR-Ex and HYP-Ex trials, %carbohydrate contribution during each exercise and post-exercise period were significantly higher in the HYP-Ex trial than in the NOR-Ex trial (P&lt;0.05).",4199615
2346,4199615,Serum FFA over 7.5 hours,Exercise trial in hypoxia (HYP-Ex),Exercise trial in normoxia (NOR-Ex),No significant difference,FFA responses did not differ significantly between the NOR-Ex and HYP-Ex trials over 7.5 h.,4199615
2347,4199615,Fasting blood lactate levels,Hypoxic trials,Normoxic trials,No significant difference,Fasting blood lactate concentrations did not differ significantly among the four trials.,4199615
2348,5331772,Density of type 1 monocytes chemo tactic protein (MCP-1),High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,No significant difference,"analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).",5331772
2349,5331772,Intercellular adhesion molecule-1 (ICAM-1),High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,No significant difference,"analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).",5331772
2350,5331772,Serum interleukin-10 (IL-10),High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,No significant difference,"analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).",5331772
2351,5331772,Baseline characteristics,High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,No significant difference,There was no significant difference between three groups regarding the baseline characteristics,5331772
2352,5331772,VO2max,High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,Significantly increased,"Tukey's post hoc test revealed increased VO2max in both â€œexercise + gingerâ€� (P &lt; 0.000) and â€œexercise + placeboâ€� (P &lt; 0.000) groups, in comparison to â€œgingerâ€� group.",5331772
2353,5331772,Density of type 1 monocytes chemo tactic protein (MCP-1),High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,No significant difference,"analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).",5331772
2354,5331772,Intercellular adhesion molecule-1 (ICAM-1),High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,No significant difference,"analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).",5331772
2355,5331772,Serum interleukin-10 (IL-10),High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,No significant difference,"analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).",5331772
2356,5331772,Baseline characteristics,High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,No significant difference,There was no significant difference between three groups regarding the baseline characteristics,5331772
2357,5331772,VO2max,High-intensity interval training (HIIT) plus either ginger or placebo,Ginger alone,Significantly increased,"Tukey's post hoc test revealed increased VO2max in both â€œexercise + gingerâ€� (P &lt; 0.000) and â€œexercise + placeboâ€� (P &lt; 0.000) groups, in comparison to â€œgingerâ€� group.",5331772
2358,4794540,Mean scores of anxiety and depression,Yogic intervention and medication,Prescribed medication without yogic intervention,Significantly decreased,"Significant improvement in domains of anxiety (P&lt;0.01), depression (P&lt;0.02), positive well-being (P&lt;0.01), general health (P&lt;0.04) and vitality (P&lt;0.02) in intervention group was noted after six months of yogic intervention when compared to control group (Table 3).",4794540
2359,4794540,General health,Yogic intervention and medication,Prescribed medication without yogic intervention,Significantly increased,"Significant improvement in domains of anxiety (P&lt;0.01), depression (P&lt;0.02), positive well-being (P&lt;0.01), general health (P&lt;0.04) and vitality (P&lt;0.02) in intervention group was noted after six months of yogic intervention when compared to control group (Table 3).",4794540
2360,4794540,Positive well-being and vitality scores,Yogic intervention and medication,Prescribed medication without yogic intervention,Significantly increased,"Significant improvement in domains of anxiety (P&lt;0.01), depression (P&lt;0.02), positive well-being (P&lt;0.01), general health (P&lt;0.04) and vitality (P&lt;0.02) in intervention group was noted after six months of yogic intervention when compared to control group (Table 3).",4794540
2361,4794540,Changes in hormonal levels,Yogic intervention and medication,Prescribed medication without yogic intervention,Significantly increased,"We found significant changes in thyroid-stimulating hormone (P&lt;0.02), follicle-stimulating hormone (P&lt;0.01), luteinizing hormone (P&lt;0.001) and prolactin (P&lt;0.03) in intervention group as compared to control group",4794540
2362,4794540, Self-control domain,Yogic intervention and medication,Prescribed medication without yogic intervention,No significant difference,There was no statistical difference in domain of self-control in intervention group when compared control group,4794540
2363,4763632,Demoscopic changes,All uncovered nevi,All covered nevi,Significantly increased,Overall demoscopic changes were observed in 34/37 (91.8%) of the uncovered nevi compared to 16/37 (43.2%) of the covered nevi (P value 0.0001).,4763632
2364,4763632,Demoscopic changes,Psoralen-ultraviolet A (PUVA),Narrowband ultraviolet B (NB-UVB),Significantly increased,"Compared to NB-UVB, dermoscopic changes were more frequent in both covered and uncovered nevi of the PUVA group. (P values 0.041 and 0.0172, respectively).",4763632
2365,4763632,Frequency of nevi enlargement,Psoralen-ultraviolet A (PUVA),Narrowband ultraviolet B (NB-UVB),No significant difference,No differences were found between the effects of the two types of UV therapy regarding the frequency of enlarging nevi and the amount of hyperpigmentation.,4763632
2366,4763632,Nevi hyperpigmentation,Psoralen-ultraviolet A (PUVA),Narrowband ultraviolet B (NB-UVB),No significant difference,No differences were found between the effects of the two types of UV therapy regarding the frequency of enlarging nevi and the amount of hyperpigmentation.,4763632
2367,4763632,Formation of new dot-globule ,Psoralen-ultraviolet A (PUVA),Narrowband ultraviolet B (NB-UVB),Significantly increased,new dot-globule formation was noted in all nevi (100%) exposed to PUVA compared to only 48.1% in the NB-UVB group (P value 0.0056),4763632
2368,5127177,Pedometer counts per week,Structured Booster Break program,Individual-based computer-prompt program and Usual-break control group,Significantly increased,Weekly pedometer counts increased among Booster Break (P &lt; .001) and decreased among computer-prompt (P &lt; .001) and usual-break (P &lt; .001) participants.,5127177
2369,5127177,Sedentary habits,Structured Booster Break program,Individual-based computer-prompt program and Usual-break control group,Significantly decreased,"Compared with the other groups, the consistent Booster Break attendees had greater weekly pedometer counts (P &lt; .001), significant decreases in sedentary behavior and self-reported leisure-time physical activity (P &lt; .001),",5127177
2370,5127177, Self-reported leisure-time physical activity ,Structured Booster Break program,Individual-based computer-prompt program and Usual-break control group,Significantly decreased,"Compared with the other groups, the consistent Booster Break attendees had greater weekly pedometer counts (P &lt; .001), significant decreases in sedentary behavior and self-reported leisure-time physical activity (P &lt; .001)",5127177
2371,5127177,Triglyceride levels,Structured Booster Break program,Individual-based computer-prompt program and Usual-break control group,Significantly decreased,"Compared with the other groups, the consistent Booster Break attendees had greater weekly pedometer counts (P &lt; .001), significant decreases in sedentary behavior and self-reported leisure-time physical activity (P &lt; .001), and a significant increase in triglyceride concentrations (P = .02)",5127177
2372,4760038,Score of needle visibility,Ultrasound-guided paravertebral block (Group I),ultrasound-guided paravertebral block using the needle guide (Group II),Significantly decreased,"Needle visibility score was better in group II (2.92 Â± 0.26 vs. 1.9 Â± 0.44, P &lt; 0.0001).",4760038
2373,4760038,Block performance time,Ultrasound-guided paravertebral block (Group I),ultrasound-guided paravertebral block using the needle guide (Group II),Significantly increased,"Block performance time was shorter in group II (90.92 Â± 15 vs. 128.25 Â± 16s, P &lt; 0.0001).",4760038
2374,4760038,Number of needle passes,Ultrasound-guided paravertebral block (Group I),ultrasound-guided paravertebral block using the needle guide (Group II),Significantly increased,"A number of needle passes were less in group II (1.27 Â± 0.45 vs. 2.2 Â± 0.68, P &lt; 0.0001).",4760038
2375,4760038,Complications,Ultrasound-guided paravertebral block (Group I),ultrasound-guided paravertebral block using the needle guide (Group II),No significant difference,"No differences were found regarding duration of the block (4.64 Â± 0.61 vs.4.62 Â± 0.63, P = 1.00). And incidence of complications (2 [2.5%] vs. 0, P = 0.49) between the two groups",4760038
2376,4760038,Satisfaction of the patients and physicians,Ultrasound-guided paravertebral block (Group I),ultrasound-guided paravertebral block using the needle guide (Group II),Significantly decreased,"Doctor and patient satisfaction were better in group II when compared to group I with a P &lt; 0.0001 and = 0.001, respectively.",4760038
2377,4652407,HbA1c levels,Commercially produced Scoparia dulcis porridge (SDC),Any other food,Significantly decreased,both test groups (1 and 2) elicited a decrease in HbA1c compared to respective control groups.,4652407
2378,4652407,Fasting blood glucose,Commercially produced Scoparia dulcis porridge (SDC),Any other food,No significant difference,Both test groups elicited a non significant decrease in FBG following the intervention (group 1 - from 174â€‰Â±â€‰14 to 160â€‰Â±â€‰10&nbsp;mg/dL; group 2 - from 183â€‰Â±â€‰13 to 160â€‰Â±â€‰7&nbsp;mg/dL).,4652407
2379,4652407,Insulin and cholesterol levels,Commercially produced Scoparia dulcis porridge (SDC),Any other food,No significant difference,"No significant differences (pâ€‰&gt;0.05) in insulin, cholesterol measurements (total cholesterol, LDL-C, HDL-C, triglycerides and cholesterol ratios) and atherogenic index between or within groups were observed.",4652407
2380,4652407,Atherogenic index,Commercially produced Scoparia dulcis porridge (SDC),Any other food,No significant difference,no significant difference (pâ€‰&gt;0.05) between or within the groups 1 and 2 was observed for AI at any study period of the study.,4652407
2381,4652407,Liver enzymes,Commercially produced Scoparia dulcis porridge (SDC),Any other food,No significant difference,A significant difference (pâ€‰&gt;0.05) was not observed between or within the two groups for all tested liver enzymes.,4652407
2382,2662857,mean physician Clinical Global Impression (CGI) scale - overall functioning ,40 hourly treatments of either hyperbaric treatment,baseline,Significantly increased,"After 40 sessions, the mean physician CGI score for change in overall functioning compared to baseline significantly improved (p = 0.0008) by 1.13 points in the treatment group (2.87 Â± 0.78, score of 4 = ""no change"") compared to 0.38 points in the control group (3.62 Â± 0.75), see Figure 2.",2662857
2383,2662857,mean physician Clinical Global Impression (CGI) scale - receptive language,40 hourly treatments of either hyperbaric treatment,control group,Significantly increased,"Examination of the physician CGI subscales demonstrated that more children improved in the treatment group compared to the control group in receptive language (p &lt; 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); a trend towards improvement was also observed in activity level (p = 0.0545).Figure 2",2662857
2384,2662857,mean physician Clinical Global Impression (CGI) scale - social interaction,40 hourly treatments of either hyperbaric treatment,control group,Significantly increased,"Examination of the physician CGI subscales demonstrated that more children improved in the treatment group compared to the control group in receptive language (p &lt; 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); a trend towards improvement was also observed in activity level (p = 0.0545).Figure 2",2662857
2385,2662857,mean physician Clinical Global Impression (CGI) scale - eye contact,40 hourly treatments of either hyperbaric treatment,control group,Significantly increased,"Examination of the physician CGI subscales demonstrated that more children improved in the treatment group compared to the control group in receptive language (p &lt; 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); a trend towards improvement was also observed in activity level (p = 0.0545).Figure 2",2662857
2386,2662857,Mean parental CGI scores - overall functioning ,40 hourly treatments of either hyperbaric treatment,control group,Significantly increased,"Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).",2662857
2387,2662857,Mean parental CGI scores - receptive language,40 hourly treatments of either hyperbaric treatment,control group,Significantly increased,"Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).",2662857
2388,2662857,Mean parental CGI scores - eye contact,40 hourly treatments of either hyperbaric treatment,control group,Significantly increased,"Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).",2662857
2389,2662857,sensory/cognitive awareness,40 hourly treatments of either hyperbaric treatment,control group,Significantly increased,"On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the treatment group compared to the control group.",2662857
2390,2662857,Aberrant Behavior Checklist (ABC) total score - irritability,40 hourly treatments of either hyperbaric treatment,control group,Significantly increased,"In the treatment group compared to the control group, mean changes on the ABC total score and subscales were similar except a greater number of children improved in irritability (p = 0.0311).",2662857
2391,2662857,"Aberrant Behavior Checklist (ABC) total score - irritability, stereotypy, hyperactivity, and speech",40 hourly treatments of either hyperbaric treatment,baseline and control group,Significantly increased,"On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p &lt; 0.03 for each), but not in the control group.",2662857
2392,2662857, Autism Treatment Evaluation Checklist (ATEC) - sensory/cognitive awareness,40 hourly treatments of either hyperbaric treatment,control group,Significantly increased,"On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the treatment group compared to the control group.",2662857
2393,5040779,intubation time,McGRATH MAC and C-MAC,Macintosh blade,Significantly decreased,"The overall mean intubation time of the three attempts decreased significantly with the McGRATH MAC and C-MAC compared to the Macintosh blade in the normal airway (P &lt; 0.001 and P = 0.017, resp.).",5040779
2394,5040779,"success rate of intubation on the first, second, and third attempts",McGRATH MAC and C-MAC,Macintosh blade,Significantly increased,"The success rate of intubation on the first, second, and third attempts increased significantly with the McGRATH MAC and C-MAC compared to the Macintosh blade in the normal airway (P &lt; 0.001 on the first attempt, P &lt; 0.001 on the second attempt, and P = 0.012 on the third attempt).",5040779
2395,5040779,The number of attempts,McGRATH MAC and C-MAC,Macintosh blade,Significantly decreased,The number of attempts decreased significantly with the McGRATH MAC and C-MAC compared to the Macintosh blade (P = 0.002).,5040779
2396,5040779,The difficulty score of using the device, Macintosh blade,McGRATH MAC and C-MAC,Significantly increased,The difficulty score of using the device was higher for the Macintosh blade compared to the McGRATH MAC and C-MAC (P = 0.002).,5040779
2397,5040779,The Cormack-Lehane grade,McGRATH MAC and C-MAC,Macintosh blade,Significantly increased,The Cormack-Lehane grade improved significantly with the McGRATH MAC and C-MAC compared to the Macintosh blade (P &lt; 0.001).,5040779
2398,3210361,accuracy in the timing task,ketamine (100&nbsp;ng/ml blood plasma level),placebo,Significantly decreased,"Post-hoc analysis with paired t tests indicated that ketamine, as compared to placebo, significantly reduced accuracy in the timing task (t (11)â€‰=â€‰3.35, pâ€‰&lt;â€‰0.01) but had no effect on performance of the colour task (t(11)â€‰=â€‰âˆ’0.44, ns) (Fig.&nbsp;3a).",3210361
2399,3210361,speeding of RTs at the long interval,ketamine (100ng/ml blood plasma level),placebo,Significantly decreased,"However, a significant treatment by onset interaction [F(1, 9)â€‰=â€‰5.83, pâ€‰&lt;â€‰0.05] revealed that, as compared to placebo, the relative speeding of RTs at the long interval was attenuated by administration of ketamine (Fig.&nbsp;4).",3210361
2400,3210361,colour task,ketamine (100ng/ml blood plasma level),placebo,No significant difference,"Post-hoc analysis with paired t tests indicated that ketamine, as compared to placebo, significantly reduced accuracy in the timing task (t (11)â€‰=â€‰3.35, pâ€‰&lt;â€‰0.01) but had no effect on performance of the colour task (t(11)â€‰=â€‰âˆ’0.44, ns) (Fig.&nbsp;3a).",3210361
2401,3210361,CADSS time perception subscale,ketamine (100ng/ml blood plasma level),placebo,Significantly increased,"More specifically, ketamine significantly [F(1, 10)â€‰=â€‰7.22, pâ€‰&lt;â€‰0.05] increased scores on the CADSS time perception subscale (see also Krystal et al. 1998), indicating a drug-induced distortion in the subjective experience of time.",3210361
2402,3210361, benefit of temporally valid cues at the short interval,ketamine (100ng/ml blood plasma level),placebo,Significantly increased,"Specifically, the benefit of temporally valid cues was significant at the short (t(10)â€‰=â€‰âˆ’4.71, pâ€‰=â€‰0.001) but not long (t(10)â€‰=â€‰âˆ’0.48, ns) interval (Table&nbsp;1): when a target does not appear after the short interval as expected it must, by process of elimination, appear at the longer one.",3210361
2403,3210361,incidence of overestimates,ketamine (100ng/ml blood plasma level),placebo,Significantly increased,"However, when data were broken down into trial type (probe shorter/equal to/longer than sample), a significant interaction between treatment, error type and trial type [F(2, 20)â€‰=â€‰7.34, pâ€‰&lt;â€‰0.005] indicated that ketamine, as compared to placebo, induced an increased incidence of overestimates, particularly when the probe was shorter than the sample (t(11)â€‰=â€‰4.14, pâ€‰&lt;â€‰0.005) (Fig.&nbsp;3b).",3210361
2404,3663169,"pigmentation,  vascularity, pliability, and height",silicone gel,control group,Significantly decreased,The final assessment at 8th week showed that differences observed between the two groups were statistically significant (P &lt; 0.05).,3663169
2405,3663169,"pigmentation, vascularity, pliability, and height of the scar",silicone gel,control group,Significantly decreased,"The differences were statistically significant in all parameters, including pigmentation (P = 0.001), Vascularity (P = 0.010), pliability (P = 0.001), and height (P = 0.010).",3663169
2406,2806387,The intensity of an unpleasant sensation,saline 9 mg/ml syringes,saline 9 mg/ml for injection in polyethylene package,Significantly increased,"The intensity of an unpleasant sensation after injection of BDs 10 ml over 5 seconds was rated significantly higher compared to rSaline, 10 ml over 5 seconds (p = 0.001), see figure 2.",2806387
2407,4842481,augmentation index,WBV training,control group,No significant difference,"However, a decrease in AIx@75 was displayed for WBV and the control illustrated an increase over time but this time effect was not significant (p = 0.225).",4842481
2408,4842481,systolic diameter,WBV training,control group,Significantly increased,There was a significant time effect post intervention for systolic (p = 0.039) and diastolic diameter (p = 0.040) (Table 2) but there was no interaction or intervention effect.,4842481
2409,4842481,diastolic diameter,WBV training,control group,Significantly increased,There was a significant time effect post intervention for systolic (p = 0.039) and diastolic diameter (p = 0.040) (Table 2) but there was no interaction or intervention effect.,4842481
2410,4842481,(PWV) pulse wave velocity,WBV training,control group,No significant difference,"Table 2 illustrates the interaction effect of PWV over time, demonstrating a decrease over time for both WBV and control but these measurements were not significant (p = 0.474).",4842481
2411,4842481,carotid to radial pulse transit time standard deviation,WBV training,control group,No significant difference,"Furthermore, there was no significant difference (p = 0.299) in carotid to radial pulse transit time standard deviation between WBV and control (Table 2).",4842481
2412,4842481,Arterial stiffness,WBV training,control group,No significant difference,"Arterial stiffness (Table 2) decreased over time for WBV. In contrast, arterial stiffness increased over time in the control group, but the interaction effect was not significant (p = 0.166).",4842481
2413,4842481,distensibility coefficient (DC),WBV training,control group,No significant difference,For the distensibility coefficient (DC) (Table 2) there was no significant interaction effect (p = 0.124) or main effect between the WBV and control groups (p = 0.431).,4842481
2414,4842481,compliance coefficient (CC),WBV training,control group,No significant difference,"Similarly, there was no significant interaction effect (p = 0.237) or main effect for compliance coefficient (CC) (Table 2) between the WBV and control groups (p = 0.496).",4842481
2415,4662683,recovery,early initiation group (3 days after stroke) with swallowing therapy , (2) medium group (2 weeks after stroke); and (3) late group (1-month after stroke) with swallowing therapy ,Significantly increased,"so that in first group patients, recovery was rather than other groups P &lt; 0.050, but between medium and late groups swallowing recovery was not differences P &gt; 0.050 (Table 3).",4662683
2416,4662683,number of patients experienced pneumonia,early initiation group (3 days after stroke) with swallowing therapy , (2) medium group (2 weeks after stroke); and (3) late group (1-month after stroke) with swallowing therapy ,Significantly decreased,"Furthermore, the frequency of pneumonia in the early group was less than other groups and in the early group no patients experienced pneumonia P = 0.002.",4662683
2417,4662683,recovery, (2) medium group (2 weeks after stroke) with swallowing therapy , (3) late group (1-month after stroke) with swallowing therapy ,No significant difference,"so that in first group patients, recovery was rather than other groups P &lt; 0.050, but between medium and late groups swallowing recovery was not differences P &gt; 0.050 (Table 3).",4662683
2418,3771300,index lesion cure rate after 6 months follow-up,Paromomycin Alone (15% paromomycin) for 20 days,"WR 279,396 (15% paromomycin + 0.5% gentamicin)",No significant difference,"The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099).",3771300
2419,3771300,final cure rate ," WR 279,396 (15% paromomycin + 0.5% gentamicin) for 20 days",Paromomycin Alone (15% paromomycin) for 20 days,Significantly increased,"When all treated lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for Paromomycin Alone-treated patients was 8 of 15 (53.3%; P = 0.046).",3771300
2420,3771300,the per-lesion cure rate for 20 cured patients,Paromomycin Alone (15% paromomycin) for 20 days ,"WR 279,396 (15% paromomycin + 0.5% gentamicin) for 20 days",Significantly increased,"Because there were a total of 30 presenting lesions of which 20 cured, the per-lesion cure rate was 66.7% (P = 0.005 versus the WR 279,396 group).",3771300
2421,3445058,electromyographic (EMG) activity of anterior deltoid muscle,The upright-assisted exercises,the gravity-minimized exercises,Significantly increased,"The upright-assisted exercises (95% CI, 23% to 42% MVIC) for the anterior deltoid generated more EMG activity than did the gravity-minimized exercises (95% CI, 9% to 21% MVIC) (P &lt; .05).",3445058
2422,3445058,electromyographic (EMG) activity of infraspinatus ,upright active forward elevation ,the dusting medial exercise,Significantly increased,"Post hoc analysis for the infraspinatus revealed that upright active forward elevation (21% Â± 15% MVIC) generated the most EMG activity but was significantly greater than only the dusting medial exercise (7% Â± 5% MVIC), which generated the least EMG activity (P = .00089) (Table 3).",3445058
2423,3445058,"The supraspinatus, infraspinatus, and anterior deltoid muscle electromyographic (EMG) activity",gravity-minimized exercises ,upright active forward exercises,Significantly increased,"Each muscle demonstrated significant differences between exercises (P &lt; .001), with upright active forward elevation producing the greatest EMG for all muscles (95% confidence interval [CI], 12% to 50% MVIC).",3445058
2424,3614647,Follicle Stimulating Hormone (FSH) level in group APMM,Pre-Gelatinized Organic Maca (Maca-GO) treatment,Placebo,Significantly decreased,"Results from hormone assays (Table 1) showed that, in comparison to placebo, out of four hormones studied, a significant (P&lt;0.05) decrease in FSH and a highly significant (P&lt;0.001) increase in E2 were observed in sequence group APMM only, without significant changes (P&gt;0.05) recorded in PRG and LH levels within the same sequence treatment.",3614647
2425,3614647,estradiol (E2) level  in group APMM,Pre-Gelatinized Organic Maca (Maca-GO) treatment,Placebo,Significantly increased,"Results from hormone assays (Table 1) showed that, in comparison to placebo, out of four hormones studied, a significant (P&lt;0.05) decrease in FSH and a highly significant (P&lt;0.001) increase in E2 were observed in sequence group APMM only, without significant changes (P&gt;0.05) recorded in PRG and LH levels within the same sequence treatment.",3614647
2426,3614647,Progesterone (PRG) and Luteinizing Hormone (LH) levels  in group APMM,Pre-Gelatinized Organic Maca (Maca-GO) treatment,Placebo,Significantly decreased,"Results from hormone assays (Table 1) showed that, in comparison to placebo, out of four hormones studied, a significant (P&lt;0.05) decrease in FSH and a highly significant (P&lt;0.001) increase in E2 were observed in sequence group APMM only, without significant changes (P&gt;0.05) recorded in PRG and LH levels within the same sequence treatment.",3614647
2427,3614647,High Density Lipoprotein (HDL) level ,Pre-Gelatinized Organic Maca (Maca-GO) treatment,Placebo,Significantly increased,"A total of 124 women concluded the study. Maca-GO significantly stimulated production of E2 (P&lt;0.001) with a simultaneous suppression (P&lt;0.05) of blood FSH, increase (P&lt;0.05) in HDL.",3614647
2428,3614647,severity of individual menopausal symptoms (hot flushes and night sweating in particular),Pre-Gelatinized Organic Maca (Maca-GO) treatment,Placebo,Significantly decreased,"Maca-GO significantly reduced both frequency and severity of individual menopausal symptoms (hot flushes and night sweating in particular) resulting in significant (P&lt;0.001) alleviation of KMI (from 22 to 10), thus, offering an attractive non-hormonal addition to the choices available to early-postmenopausal women in the form of a natural plant alternative to Hormone Replacement Therapy (HRT) â€“ hence, reducing dependence on hormone therapy programs.",3614647
2429,5054611,oropharyngeal seal pressure in extension,The Laryngeal Tube Suction Disposable (LTS-D),the Supreme Laryngeal Mask Airway (SLMA),Significantly increased,The oropharyngeal seal pressure of the LTS-D was higher that the SLMA in&nbsp;ï»¿extension (p=0.0150) and right positionï»¿ (p=0.0268ï»¿ at 60 cm H2O intracuff pressure,5054611
2430,5054611,oropharyngeal seal pressure in right position,The Laryngeal Tube Suction Disposable (LTS-D),the Supreme Laryngeal Mask Airway (SLMA),Significantly increased,The oropharyngeal seal pressure of the LTS-D was higher that the SLMA in&nbsp;ï»¿extension (p=0.0150) and right positionï»¿ (p=0.0268ï»¿ at 60 cm H2O intracuff pressure,5054611
2431,5054611, successfull insertion,The Laryngeal Tube Suction Disposable (LTS-D),the Supreme Laryngeal Mask Airway (SLMA),No significant difference,LTS-D and the SLMA were inserted successfully in all patients requiring one attempt in 87.5 and 86.2&nbsp;% of patients for SLMA and LTS-D respectively and a second attempt in 12.5 and 13.8&nbsp;% of patients for SLMA and LTS-D respectively (pâ€‰=â€‰0.8150).,5054611
2432,5054611,minor airway interventions,the Supreme Laryngeal Mask Airway (SLMA),The Laryngeal Tube Suction Disposable (LTS-D) ,Significantly decreased,Significantly less minor airway interventions were needed with the&nbsp;SLMA (pâ€‰=â€‰0.005).,5054611
2433,5054611,The oropharyngeal seal pressure during neck extension,The Laryngeal Tube Suction Disposable (LTS-D) ,the Supreme Laryngeal Mask Airway (SLMA),Significantly increased,The oropharyngeal seal pressure was significantly higher with the LTS-D during neck extension as compared to SLMA (p=â€‰0.015).,5054611
2434,5054611,The mean peak inspiratory pressure and plateau pressure,the Supreme Laryngeal Mask Airway (SLMA),The Laryngeal Tube Suction Disposable (LTS-D) ,Significantly decreased,The mean peak inspiratory pressure and plateau pressure in patients with SLMA was significantly lower than in patients with LTS-D (pâ€‰=â€‰0.006) and (pâ€‰=â€‰0.008).,5054611
2435,5054611,incidence of post-operative sore throat, The Laryngeal Tube Suction Disposable (LTS-D) ,the Supreme Laryngeal Mask Airway (SLMA),Significantly increased,A significantly higher incidence of post-operative sore throat was detected in patients with LTS-D (26.3&nbsp;%) (95&nbsp;% C.I.: Â±9.7) as compared to patients with SLMA (6.3&nbsp;%) (95&nbsp;% C.I.: Â±5.3) after 24&nbsp;h (pâ€‰=â€‰0.001).,5054611
2436,5808689,numbers of positively response to the following question about the hospitalization: â€œDid you get the nursing from the ward staff that you needed?â€�,comprehensive geriatric assessment (CGA) group,conventional care group,Significantly increased,"Significantly more patients in the intervention group responded positively to the following three questions: â€œDid you get the nursing from the ward staff that you needed?â€� (p=0.003), â€œAre you satisfied with the information you received on your diseases and medication?â€� (p=0.016), and â€œAre you satisfied with the planning before discharge from the hospital?â€� (p=0.032). There was no difference between the groups in response to the question â€œDid you get help from the doctors with the medical problems you came in for?â€� (p=0.120).",5808689
2437,5808689,numbers of positively response to the following question about the hospitalization: â€œAre you satisfied with the information you received on your diseases and medication?â€�,comprehensive geriatric assessment (CGA) group,conventional care group,Significantly increased,"Significantly more patients in the intervention group responded positively to the following three questions: â€œDid you get the nursing from the ward staff that you needed?â€� (p=0.003), â€œAre you satisfied with the information you received on your diseases and medication?â€� (p=0.016), and â€œAre you satisfied with the planning before discharge from the hospital?â€� (p=0.032). There was no difference between the groups in response to the question â€œDid you get help from the doctors with the medical problems you came in for?â€� (p=0.120).",5808689
2438,5808689,numbers of positively response to the following question about the hospitalization: â€œAre you satisfied with the planning before discharge from the hospital?â€� ,comprehensive geriatric assessment (CGA) group,conventional care group,Significantly increased,"Significantly more patients in the intervention group responded positively to the following three questions: â€œDid you get the nursing from the ward staff that you needed?â€� (p=0.003), â€œAre you satisfied with the information you received on your diseases and medication?â€� (p=0.016), and â€œAre you satisfied with the planning before discharge from the hospital?â€� (p=0.032). There was no difference between the groups in response to the question â€œDid you get help from the doctors with the medical problems you came in for?â€� (p=0.120).",5808689
2439,5808689,numbers of positively response to the following question: â€œDid you get help from the doctors with the medical problems you came in for?â€�,comprehensive geriatric assessment (CGA) group,conventional care group,Significantly increased,There was no difference between the groups in response to the question â€œDid you get help from the doctors with the medical problems you came in for?â€� (p=0.120).,5808689
2440,5808689,numbers of positively response to the following question," comprehensive geriatric assessment (CGA) group : ""Did you get the nursing from the ward staff that you needed?â€� ","questions: â€œAre you satisfied with the planning before discharge from the hospital?â€� , â€œAre you satisfied with the information you received on your diseases and medication?â€� in comprehensive geriatric assessment (CGA) group",Significantly increased,There was no difference between the groups in response to the question â€œDid you get help from the doctors with the medical problems you came in for?â€� (p=0.120).,5808689
2441,2001223,overall response rate,aromatase inhibitors (AIs) - letrozole,tamoxifen,Significantly increased,The ORR was 55% for letrozole versus 36% for tamoxifen (P&nbsp;&lt;&nbsp;0.001).,2001223
2442,2001223,numbers of breast-conserving surgery,aromatase inhibitors (AIs) - letrozole,tamoxifen,Significantly increased,"The proportion of patients able to undergo breast-conserving surgery was significantly higher in the letrozole group than in the tamoxifen group (45 vs. 35%, respectively; P&nbsp;=&nbsp;0.022).",2001223
2443,2001223,reducing tumor proliferation,aromatase inhibitors (AIs) - letrozole,tamoxifen,Significantly increased,"Furthermore, when analyzed by Ki67 immunohistochemistry, letrozole was significantly more effective than tamoxifen in reducing tumor proliferation (P&nbsp;=&nbsp;0.0009).",2001223
2444,4175258,mean peak torque (PT) and total work (TW),training with active ankle dorsiflxion,"training plantarflexion, and resting position",Significantly increased,The mean differences following training with active ankle dorsiflxion of both PT and TW were greater than those of ankle active plantarflexion and the resting position (p&lt;0.05).,4175258
2445,2639700,mean weekly steps during the first month,non-exercise control group,"groups with exercise energy expenditure of 4 , 8 , or 12 kcal/kg/week (KKW)",Significantly increased,"There were no significant differences in mean weekly steps during the first month among any of the exercise intervention groups, but the non-exercise control group (6098 (2065)) had significantly (P&lt;0.05 for each) more steps compared to all of the exercise groups.",2639700
2446,2639700,percent change in fitness,"groups with exercise energy expenditure of 4 , 8 , or 12 kcal/kg/week (KKW)",control group,Significantly increased,"Also similar to previous reports from the full study cohort there was a dose response in change in fitness (P-trend&lt;0.001) across the study groups with the 4, 8 and 12 KKW groups having a 3.7 (95% CI:1.9, 5.4), 6.9 (4.7, 9.2), and 8.0 (5.9, 10.2) percent change in fitness, respectively, each of which was statistically significant (p&lt;0.001) compared to the control group (âˆ’2.7 (âˆ’4.9, âˆ’0.6)). [15]",2639700
2447,2752772,incidence of the withdrawal movements,antihistamine group (Group A) were pre-medicated with 2 mL (45.5 mg) pheniramine maleate,control group (Group C) were premedicated with 2 mL normal saline,Significantly increased,Group C reveals lesser incidence than expected value in grade 3/4 withdrawal movement (P=0.008) (Table 3).,2752772
2448,4574984,postoperative in-hospital stay,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",No significant difference,"Fig 2 shows the postoperative in-hospital stay: Duration ranged from 0 to 139 days, with a median of 9 days (Interquartile Range, IQR: 7) for all patients. There was no significant difference between both groups (p = 0.99).",4574984
2449,4574984, Health-Related Quality of Life at 12 month - females,"intervention group, i.e. patient empowerment through information booklet and diary keeping - females","control group, which received standard care - females",No significant difference,The global HRQoL after 12 months of women in the intervention group was 61.07 (95% CI 55.42â€“66.71) compared to 63.27 (95% CI 58.28â€“68.25) in the control group (p = 0.54).,4574984
2450,4574984, Health-Related Quality of Life at 12 month - males,"intervention group, i.e. patient empowerment through information booklet and diary keeping - males","control group, which received standard care - males",No significant difference,Males in the intervention group had a mean global HRQoL after 12 months of 72.49 (CI95% 69.34â€“75.65) compared to 71.71 (95% CI 68.21â€“75.20) in the control group (p = 0.94).,4574984
2451,4574984,numbers overall complications,"intervention group, i.e. patient empowerment through information booklet and diary keeping ","control group, which received standard care",No significant difference,Overall complications occurred in 74% of the patients. There was no difference between intervention and control group (p = 0.79).,4574984
2452,4574984,level of postoperative pain,"intervention group, i.e. patient empowerment through information booklet and diary keeping ","control group, which received standard care",Significantly decreased,Patients in the intervention group reported significantly less postoperative pain (p = 0.03) than the control group.,4574984
2453,4574984,overall mortality,"intervention group, i.e. patient empowerment through information booklet and diary keeping ","control group, which received standard care",No significant difference,The overall mortality did not differ significantly between the two groups (Log-Rank-test p = 0.197) (Fig 7).,4574984
2454,5482825,systolic blood pressure,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Low AGE diets did not change systolic (pâ€‰=â€‰0.2) and diastolic blood pressure (pâ€‰=â€‰0.3), mean arterial pressure (pâ€‰=â€‰0.8) and pulse pressure (pâ€‰=â€‰0.2) compared to high AGE diets.",5482825
2455,5482825,Diastolic BP,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Low AGE diets did not change systolic (pâ€‰=â€‰0.2) and diastolic blood pressure (pâ€‰=â€‰0.3), mean arterial pressure (pâ€‰=â€‰0.8) and pulse pressure (pâ€‰=â€‰0.2) compared to high AGE diets.",5482825
2456,5482825,mean arterial pressure,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Low AGE diets did not change systolic (pâ€‰=â€‰0.2) and diastolic blood pressure (pâ€‰=â€‰0.3), mean arterial pressure (pâ€‰=â€‰0.8) and pulse pressure (pâ€‰=â€‰0.2) compared to high AGE diets.",5482825
2457,5482825,pulse pressure,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Low AGE diets did not change systolic (pâ€‰=â€‰0.2) and diastolic blood pressure (pâ€‰=â€‰0.3), mean arterial pressure (pâ€‰=â€‰0.8) and pulse pressure (pâ€‰=â€‰0.2) compared to high AGE diets.",5482825
2458,5482825,total cholesterol,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Change in total cholesterol (pâ€‰=â€‰0.3), low-density lipoprotein (pâ€‰=â€‰0.7), high-density&nbsp;lipoprotein (pâ€‰=â€‰0.2), and triglycerides (pâ€‰=â€‰0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ€‰=â€‰0.6), monocyte chemoattractant protein-1 (pâ€‰=â€‰0.9), tumour necrosis factor Î± (pâ€‰=â€‰0.2), C-reactive protein (pâ€‰=â€‰0.6) and nuclear factor kappa beta (pâ€‰=â€‰0.2).",5482825
2459,5482825,low-density lipoprotein,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Change in total cholesterol (pâ€‰=â€‰0.3), low-density lipoprotein (pâ€‰=â€‰0.7), high-density&nbsp;lipoprotein (pâ€‰=â€‰0.2), and triglycerides (pâ€‰=â€‰0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ€‰=â€‰0.6), monocyte chemoattractant protein-1 (pâ€‰=â€‰0.9), tumour necrosis factor Î± (pâ€‰=â€‰0.2), C-reactive protein (pâ€‰=â€‰0.6) and nuclear factor kappa beta (pâ€‰=â€‰0.2).",5482825
2460,5482825,high-density&nbsp;lipoprotein,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Change in total cholesterol (pâ€‰=â€‰0.3), low-density lipoprotein (pâ€‰=â€‰0.7), high-density&nbsp;lipoprotein (pâ€‰=â€‰0.2), and triglycerides (pâ€‰=â€‰0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ€‰=â€‰0.6), monocyte chemoattractant protein-1 (pâ€‰=â€‰0.9), tumour necrosis factor Î± (pâ€‰=â€‰0.2), C-reactive protein (pâ€‰=â€‰0.6) and nuclear factor kappa beta (pâ€‰=â€‰0.2).",5482825
2461,5482825,triglycerides,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Change in total cholesterol (pâ€‰=â€‰0.3), low-density lipoprotein (pâ€‰=â€‰0.7), high-density&nbsp;lipoprotein (pâ€‰=â€‰0.2), and triglycerides (pâ€‰=â€‰0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ€‰=â€‰0.6), monocyte chemoattractant protein-1 (pâ€‰=â€‰0.9), tumour necrosis factor Î± (pâ€‰=â€‰0.2), C-reactive protein (pâ€‰=â€‰0.6) and nuclear factor kappa beta (pâ€‰=â€‰0.2).",5482825
2462,5482825,interleukin-6,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Change in total cholesterol (pâ€‰=â€‰0.3), low-density lipoprotein (pâ€‰=â€‰0.7), high-density&nbsp;lipoprotein (pâ€‰=â€‰0.2), and triglycerides (pâ€‰=â€‰0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ€‰=â€‰0.6), monocyte chemoattractant protein-1 (pâ€‰=â€‰0.9), tumour necrosis factor Î± (pâ€‰=â€‰0.2), C-reactive protein (pâ€‰=â€‰0.6) and nuclear factor kappa beta (pâ€‰=â€‰0.2).",5482825
2463,5482825,monocyte chemoattractant protein-1,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Change in total cholesterol (pâ€‰=â€‰0.3), low-density lipoprotein (pâ€‰=â€‰0.7), high-density&nbsp;lipoprotein (pâ€‰=â€‰0.2), and triglycerides (pâ€‰=â€‰0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ€‰=â€‰0.6), monocyte chemoattractant protein-1 (pâ€‰=â€‰0.9), tumour necrosis factor Î± (pâ€‰=â€‰0.2), C-reactive protein (pâ€‰=â€‰0.6) and nuclear factor kappa beta (pâ€‰=â€‰0.2).",5482825
2464,5482825,tumour necrosis factor Î±,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Change in total cholesterol (pâ€‰=â€‰0.3), low-density lipoprotein (pâ€‰=â€‰0.7), high-density&nbsp;lipoprotein (pâ€‰=â€‰0.2), and triglycerides (pâ€‰=â€‰0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ€‰=â€‰0.6), monocyte chemoattractant protein-1 (pâ€‰=â€‰0.9), tumour necrosis factor Î± (pâ€‰=â€‰0.2), C-reactive protein (pâ€‰=â€‰0.6) and nuclear factor kappa beta (pâ€‰=â€‰0.2).",5482825
2465,5482825,C-reactive protein,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,"Change in total cholesterol (pâ€‰=â€‰0.3), low-density lipoprotein (pâ€‰=â€‰0.7), high-density&nbsp;lipoprotein (pâ€‰=â€‰0.2), and triglycerides (pâ€‰=â€‰0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ€‰=â€‰0.6), monocyte chemoattractant protein-1 (pâ€‰=â€‰0.9), tumour necrosis factor Î± (pâ€‰=â€‰0.2), C-reactive protein (pâ€‰=â€‰0.6) and nuclear factor kappa beta (pâ€‰=â€‰0.2).",5482825
2466,5482825,nuclear factor kappa beta,Low advanced glycation end products (AGEs) diet,high AGE diet,No significant difference,NFÎºB p65 activity (ng/Âµg protein)	âˆ’3.4â€‰Â±â€‰9.9	0.14	âˆ’1.3â€‰Â±â€‰11.4	0.61	âˆ’2.1â€‰Â±â€‰16.7	0.18,5482825
2467,5622764,coefficient of variation,StomacolÂ® tablets (1.53 g of Î²-glucan),placebo (Plac),Significantly increased,"Indeed, whereas glucose variability tended to increase between the first and last two CGM days on Plac (coefficient of variation from 34.3 Â± 1.9 to 39.1 Â± 3.0%; p &lt; 0.05), it remained unchanged on Î²-glucan (from 38.2 Â± 3.2 to 38.9 Â± 2.1%; p = ns (non-significant)), suggesting a time dependent positive effect in maintaining a stable glucose level.",5622764
2468,5622764,maximal glucose value,StomacolÂ® tablets (1.53 g of Î²-glucan),placebo (Plac),Significantly increased,"There was an increase in basic measures of glycaemic control (maximal glucose value 341 Â± 15 vs. 378 Â± 13 mg/dL for Plac and Î²-glucan, p = 0.004), and average daily risk range (62 Â± 5 vs. 79 Â± 4 mg/dL for Plac and Î²-glucan, p = 0.003) favouring Plac over Î²-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures.",5622764
2469,5622764,average daily risk range,StomacolÂ® tablets (1.53 g of Î²-glucan),placebo (Plac),Significantly increased,"There was an increase in basic measures of glycaemic control (maximal glucose value 341 Â± 15 vs. 378 Â± 13 mg/dL for Plac and Î²-glucan, p = 0.004), and average daily risk range (62 Â± 5 vs. 79 Â± 4 mg/dL for Plac and Î²-glucan, p = 0.003) favouring Plac over Î²-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures.",5622764
2470,4365008,"total cholesterol, LDL-c, and non-HDL-c levels",10 mg rosuvastatin over 4 months with zinc (30 mg/d) and selenium (150 Î¼g/d) supplementation.,10 mg rosuvastatin over 4 months,No significant difference,"Significant decreases in total cholesterol, LDL-c, and non-HDL-c levels were observed for all patients, regardless of group; however, there were no differences between the rosuvastatin + mineral-supplemented and rosuvastatin + placebo groups (P &gt; 0.21).",4365008
2471,4365008,Triglycerides concentrations,10 mg rosuvastatin over 4 months with zinc (30 mg/d) and selenium (150 Î¼g/d) supplementation.,10 mg rosuvastatin over 4 months,No significant difference,"Triglycerides concentrations dropped noticeably in both groups, though this pattern was significant only for the placebo group (P = 0.034); despite this, differences between the two groups were not significant (P = 0.76).",4365008
2472,4365008,glutathione peroxidase (GPx) and superoxide dismutase (SOD) levels,10 mg rosuvastatin over 4 months with zinc (30 mg/d) and selenium (150 Î¼g/d) supplementation.,10 mg rosuvastatin over 4 months,No significant difference,"Similarly, the activities of the antioxidant enzymes GPx and SOD were unchanged by treatments (P &gt; 0.42) and were similar in both groups (P &gt; 0.33).",4365008
2473,4365008,concentrations of zinc and selenium of studied groups.,10 mg rosuvastatin over 4 months with zinc (30 mg/d) supplementation.,10 mg rosuvastatin over 4 months with selenium (150 Î¼g/d) supplementation.,No significant difference,Neither treatment was associated with significant differences in concentrations of zinc (plasma: P &gt; 0.14; erythrocyte: P &gt; 0.14) or selenium (plasma: P &gt; 0.63; erythrocyte: P &gt; 0.07) of studied groups.,4365008
2474,4520847,grade of AGI,"CO2 pneumoperitoneum -10 mm Hg, 12 mm Hg and 15 mm Hg).",CO2 pneumoperitoneum - 15 mm Hg).,No significant difference,"Neither the incidence nor the grade of AGI showed a statistically significant difference between the 3 groups (p = 0.41, and p = 0.36 respectively).",4520847
2475,4520847,"Occurrense of postoperative ileus (POI), diarrhea","CO2 pneumoperitoneum -10 mm Hg, 12 mm Hg and 15 mm Hg).",CO2 pneumoperitoneum - 15 mm Hg).,No significant difference,"The level of IAP elevation was not related to increased occurrence of AGI symptoms, neither POI (p = 0.92) nor diarrhea (p = 0.67).",4520847
2476,4520847,Postoperative hospital stay,"CO2 pneumoperitoneum -10 mm Hg, 12 mm Hg and 15 mm Hg).",CO2 pneumoperitoneum - 15 mm Hg).,No significant difference,Postoperative hospital stay was similar in the 3 groups (p = 0.27) (Table II).,4520847
2477,4520847,increase in IL-6 levels,"CO2 pneumoperitoneum -10 mm Hg, 12 mm Hg and 15 mm Hg).",CO2 pneumoperitoneum - 15 mm Hg).,No significant difference,"However, the increase in IL-6 levels was not significantly different in the 3 groups (p = 0.27) (Table IV).",4520847
2478,5742427,perceived stress,deep breathing with essential oils,sleep without receiving the lavender aroma oil,Significantly decreased,"Lastly, there was a significant difference in the results of the reciprocal interaction of time based on the group (F = 60.11, p &lt; .001) (Table 2).",5742427
2479,5742427,objective stress index,deep breathing with essential oils,sleep without receiving the lavender aroma oil,Significantly decreased,"There was a significant difference in the results of the reciprocal interaction of time based on the group (F = 25.65, p &lt; .001) (Table 2).",5742427
2480,5742427,systolic blood pressure,deep breathing with essential oils,sleep without receiving the lavender aroma oil,Significantly decreased,"The results of the reciprocal interaction with time based on group also showed a significant difference (F = 9.09, p &lt; .001) (Table 3).",5742427
2481,5742427,diastolic blood pressure,deep breathing with essential oils,sleep without receiving the lavender aroma oil,No significant difference,"However, there was no significant difference between the diastolic blood pressure results between the groups (F = 0.076, p = .783) (Table 3).",5742427
2482,5742427, heart rate,deep breathing with essential oils,sleep without receiving the lavender aroma oil,Significantly decreased,"There was also a significant difference in the results of reciprocal interaction of time based on the group (F = 5.71, p &lt; .001) (Table 3).",5742427
2483,5742427,sleep quality,deep breathing with essential oils,sleep without receiving the lavender aroma oil,Significantly increased,"There was also a significant difference between the group and reciprocal interaction of time (F = 109.46, p &lt; .001) (Table 2).",5742427
2484,5391070,The rate of H. pylori eradication,"Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily,",Arm C triple therapy alone,Significantly increased,"The difference of H. pylori eradication rates between polaprezinc combined with triple therapy and triple therapy alone can further increase to reach 19.7% (Arm A vs. Arm C, P &lt; 0.01, 95% CI [7.7â€“31.8]) and 21.9% (Arm B vs Arm C, P &lt; 0.01, 95%CI [9.9â€“34.0]), respectively.",5391070
2485,5391070,"abdominal pain, acid reflux, belching, heartburn, bloating, nausea, and vomiting","Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily, Arm C triple therapy alone",baseline,Significantly decreased,"Symptoms included abdominal pain, acid reflux, belching, heartburn, bloating, nausea, and vomiting. All three groups exhibited significant symptom improvement at day 7, 14, and 28 after treatment compared to baseline (P &lt; 0.0001).",5391070
2486,5391070,The incidence of adverse events,"Arm B triple therapy plus polaprezinc 150 mg twice daily, ","Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily)  plus polaprezinc 75 mg twice daily; Arm C triple therapy alone",Significantly increased,The incidence of adverse events in Arm B was much higher than in Arms A (P = 0.04) and C (P = 0.02).,5391070
2487,3956949,stone expulsion rate,treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week),tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week),No significant difference,"Although the stone expulsion rate was on the higher side in group B, the difference was not statistically significant (p=0.349).",3956949
2488,3956949,mean expulsion time,treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week),tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week),No significant difference,"The mean expulsion time trended toward a lower value in group B (15.15Â±5.5 days) than in group A (18.9Â±8.7 days), but this difference was also not significant (p=0.074).",3956949
2489,3956949,The average number of hospital visits for colicky pain, tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week),treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week),Significantly decreased,"The average number of hospital visits for colicky pain were comparatively fewer in group B (0.45Â±0.67) than in group A (2.90Â±0.90), and this difference was highly significant (p=0.000).",3956949
2490,3956949,the mean analgesic requirement, tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week),treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week),Significantly decreased,"Also, the mean analgesic requirement was significantly less in group B (1.87Â±1.38 times) than in group A (2.90Â±0.90 times) (p&lt;0.0001).",3956949
2491,3956949,"side effects such as headache, dizziness, orthostatic hypotension, and backache", tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week),treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week),No significant difference,"Although side effects such as headache, dizziness, orthostatic hypotension, and backache occurred more often in group B patients (p&gt;0.05), these were not significant enough to exclude the patients from the study.",3956949
2492,3956949,Abnormal ejaculation, tamsulosin with tadalafil (group B) + 5-mg prednisolone once daily (maximum 1 week),treatment with tamsulosin (group A) + 5-mg prednisolone once daily (maximum 1 week),No significant difference,"Abnormal ejaculation was observed in 19.4% of patients in group A and 12.9% of patients in group B, which was not a significant difference (p=0.489).",3956949
2493,4296406,the mean of the gastric pH alteration,"treatment with omeprazole suspension 2 mg/ml (40 mg every day), pantoprazole suspension 2 mg/ml (40 mg every day) ",IV pantoprazole (40 mg every day) for up to 14 days,Significantly increased,On each of the 14 trial days the mean of the gastric pH alteration was significantly higher in omeprazole and pantoprazole suspension-treated patients than in IV pantoprazole-treated patients (P &lt; 0.001).,4296406
2494,4296406,Incidence of pneumonia,"treatment with omeprazole suspension 2 mg/ml (40 mg every day), pantoprazole suspension 2 mg/ml (40 mg every day) ",IV pantoprazole (40 mg every day) for up to 14 days,No significant difference,"Sixteen (88.9%) patients from IV pantoprazole treated group, 14 (77.8%) patients from omeprazole suspension-treated group and 17 (85%) patients who had received pantoprazole suspension were diagnosed as having nosocomial pneumonia.",4296406
2495,3661884,strength in the exercises for leg extension (LE) and Low Row (LR),the static stretching (SSG) or passive interval (PIG),baseline,Significantly increased,"Both groups showed significant increases in strength (SSGpre vs. SSGpost; PIGpre vs. PIGpost) in the same exercises for leg extension (LE) and Low Row (LR). Specifically, in the SSG group, the parameters for LE were (p = 0.0015 and ES = 2.28 - Large), and the parameters for LR were (p = 0.002 and ES = 1.95 - Large).",3661884
2496,3661884,strength in the exercises for leg extension (LE) and Low Row (LR),the static stretching (SSG) ,passive interval (PIG),No significant difference,No differences were found between the groups (SSGpost vs. PIGpost).,3661884
2497,3661884,flexibility of joints,the static stretching (SSG) or passive interval (PIG),baseline,Significantly increased,"Both groups showed significant increases in flexibility but in different joints (SSGpre vs. SSGpost; PIGpre vs. PIGpost). In the SSG group, only three joints showed significant increases in flexibility: shoulder extension (p = 0.004 and ES = 1.76 - Large), torso flexion (p = 0.002 and ES = 2.36 - Large), and hip flexion (p = 0.001 and ES = 1.79 -Large). In the PIG group, only three joints showed increases in flexibility: horizontal shoulder abduction (p = 0.003 and ES = 2.07 - Large), hip flexion (p = 0.001 and ES = 2.39 â€“ Large), and hip extension (p = 0.02 and ES = 1.79 - Large).",3661884
2498,3661884,cortisol secretion or growth hormone concentration,the static stretching (SSG) ,passive interval (PIG),No significant difference,The results showed no significant differences in the concentration of cortisol and growth hormone (Table 4 â€“ p &gt; 0.05).,3661884
2499,4266420,The subjective fatigue on day 3.,unstable shoes (Masai Barefoot Technology [MBT]),trail running shoes or control,Significantly decreased,"On day 3, the feeling of fatigue was significantly lower for the MBT group than for the CON group (P&lt;0.05) or the TR group (P&lt;0.05).",4266420
2500,4266420,The length of time spent wearing the assigned shoes,unstable shoes (Masai Barefoot Technology [MBT]),trail running shoes or control,No significant difference,The length of time spent wearing the assigned shoes in the MBT and TR groups did not statistically significantly differ (P=0.80).,4266420
2501,4266420,The subjective fatigue on day 3.,trail running shoes ,control,No significant difference,No difference between the CON and TR groups was found (P=0.64; Figure 2).,4266420
2502,5738810,change in dogsâ€™ body weight,"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)",an experimental diet (control),No significant difference,There was no significant change in dogsâ€™ body weight nor evidence of side effects over the duration of the study.,5738810
2503,5738810,PVF values for the most severely affected limb,"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)",an experimental diet (control),No significant difference,PVF values for the most severely affected limb were not significantly different between control and CCOT groups at T0 (pâ€‰=â€‰0.618) and T3 (pâ€‰=â€‰0.953).,5738810
2504,5738810,PVF change with time,"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)",an experimental diet (control),No significant difference,There was no significant PVF change with time in control group (T0: 69.65â€‰Â±â€‰4.33% BW; T3: 69.63â€‰Â±â€‰3.18% BW; pâ€‰=â€‰0.999) and in CCOT group (T0: 61.81â€‰Â±â€‰2.52% BW; T3: 67.44â€‰Â±â€‰3.32% BW; pâ€‰=â€‰0.283). The PVF change (Î” T3-T0) was not different between groups (pâ€‰=â€‰0.319) (Fig. 2).Fig. 2,5738810
2505,5738810,Pain at manipulation,"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)",an experimental diet (control),Significantly decreased,"Pain at manipulation was significantly decreased in the CCOT group (T0: 4.19â€‰Â±â€‰0.52; T3: 2.86â€‰Â±â€‰0.51; pâ€‰=â€‰0.037) but not in the control group (T0: 3.65â€‰Â±â€‰0.56; T3: 3.7â€‰Â±â€‰0.4, pâ€‰=â€‰0.999). Furthermore, the evolution for pain at manipulation depended on the diet (pâ€‰=â€‰0.036) (Fig. 4).",5738810
2506,5738810,"lameness, pain at palpation and joint mobility at T0 and T3","an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)",an experimental diet (control),No significant difference,"There was no significant difference between groups for lameness, pain at palpation and joint mobility at T0 and T3 (Table 4).Fig. 4",5738810
2507,5738810,Pain interference change,"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)",an experimental diet (control),No significant difference,There was no significant difference for PI change between CCOT (T0: 3.26â€‰Â±â€‰0.54; T3: 2.96â€‰Â±â€‰0.45; pâ€‰=â€‰0.101) and control groups (T0: 3.44â€‰Â±â€‰0.59; T3: 3.86â€‰Â±â€‰0.66; pâ€‰=â€‰0.633) (pâ€‰=â€‰0.063) (Fig. 5b).,5738810
2508,5738810,Coll2â€“1 and Coll2â€“1 NO2 serum concentrations,"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)",an experimental diet (control),No significant difference,Coll2â€“1 and Coll2â€“1 NO2 serum concentrations were not significantly different between control and CCOT groups at T0 and T3. No significant changes over time in Coll2â€“1 and Coll2â€“1 NO2 serum concentrations were observed in both groups.,5738810
2509,5738810,PI change (âˆ† T3-T0) on the ability to rise to standing,"an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT)",an experimental diet (control),Significantly increased,"However, when each question of the PI score was analyzed separately, PI change (âˆ† T3-T0) on the ability to rise to standing from lying down was significantly improved in CCOT group compared to control group (pâ€‰=â€‰0.029).Fig. 5",5738810
2510,4516063,bond strength values,All Bond 2 (Group III),"Group I, II and Group III (positive control)",Significantly increased,"Comparing the shear bond strength values of Group I, II and Group III (positive control), All Bond 2 (Group III) demonstrated fairly higher bond strength values at different levels of dentin (Graph 1) (P &lt; 0.05).",4516063
2511,3878739,proliferation index of Î³Î´-T cells,low calorie cranberry beverage (450&nbsp;ml),placebo beverage,Significantly increased,The proliferation index of Î³Î´-T cells in culture was almost five times higher after 10 wk of cranberry beverage consumption (p &lt;0.001).,3878739
2512,3878739,ability of PBMC to secrete interferon-Î³ (IFN-Î³),low calorie cranberry beverage (450&amp;nbsp;ml),placebo beverage,Significantly increased,The ability of PBMC to secrete interferon-Î³ (IFN-Î³) was significantly increased after CB consumption (pâ€‰=â€‰0.041).,3878739
2513,3878739,total number of symptoms of influenza,low calorie cranberry beverage (450&amp;amp;nbsp;ml),placebo beverage,Significantly decreased,"However, the proportion of the total number of symptoms was statistically lower in the CB drinking group (pâ€‰=â€‰0.031).",3878739
2514,5038569,central macular thickness (CMT) at 1 month and at 4 months,intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL),baseline,Significantly decreased,The mean CMT at baseline (603Â±199 Î¼m) decreased to 319Â±115 Î¼m (P=0.001) at 1 month and to 351Â±205 Î¼m (P=0.026) at 4 months.,5038569
2515,5038569,"The mean best-corrected visual acuity (BCVA) at 1 month, and at 4 months",intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL),baseline,No significant difference,The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits.,5038569
2516,3539990,Low-density lipoprotein cholesterol (LDL-C0 ,Counselling and Advisory Care for Health (COACH) programme,primary care physicians (PCP) alone,No significant difference,"The difference of mean change in the intervention group was 2.55% lower than the control group, however this was not significant (p=0.288).",3539990
2517,3539990,triglyceride (TG) levels at week 24 and 36 between the 2 study arms,primary care physicians (PCP) alone,primary care physicians assisted by nurse educators (PCP-NE),No significant difference,No significant difference was detected in triglyceride (TG) levels at week 24 and 36 between the 2 study arms.,3539990
2518,3539990,High density lipoprotein cholesterol (HDL-C),"primary care physicians (PCP) alone, primary care physicians assisted by nurse educators  (PCP-NE) groups",baseline,Significantly increased,"Significant difference in percentage change from baseline of HDL-C were observed between the PCP-NE and PCP groups, 3.01%, 95% CI 0.12-5.90, p=0.041, at week 24.",3539990
2519,4519544,Externalizing symptoms,An evidence-based treatment program called SNAP (Stop Now and Plan),baseline,Significantly decreased,"Externalizing symptoms generally decreased for the whole sample across the three sessions as shown by a one-way within-subjects ANOVA, F(2,34) = 21.60, p &lt; .001, partial Î· 2 = .56.",4519544
2520,4519544,internalizing symptomatology,An evidence-based treatment program called SNAP (Stop Now and Plan),baseline,Significantly decreased,"A similar pattern could be seen for internalizing symptomatology, F(2,34) = 7.82, p = .002, partial Î· 2.",4519544
2521,4519544,level of first theta power peak,long-term improvers (IMPs),long-term nonimprovers (NIMPs),Significantly decreased,"For the first theta power peak, a main effect of session was found, F(2,33) = 3.72, p = .035, partial Î· 2 = .18, showing a general decrease in theta power.",4519544
2522,4519544,level of second theta power peak,long-term improvers (IMPs),baseline,Significantly decreased,"For the second peak, a statistically significant session-by-group interaction effect was found, F(2,33) = 4.57, p = .018, partial Î· 2 = .19, showing decreases in theta power for IMPs from pretreatment to follow-up (p = .001) and from posttreatment to follow-up (p = .01).",4519544
2523,4759876,The total blood loss after Total knee arthroplasty (TKA),subcutaneous indwelling closed suction drainage method ,intraarticular indwelling closed suction drainage method,Significantly decreased,The total blood loss after TKA was significantly different between two groups (P = 0.04). The total blood loss (visible drained blood + hidden loss) was less in subcutaneous drainage group.,4759876
2524,4759876,The mean visible blood drainage during the first 24 h and between 24 and 48 h after TKA,subcutaneous indwelling closed suction drainage method ,intraarticular indwelling closed suction drainage method,Significantly decreased,"The mean visible blood drainage in subcutaneous drainage group was significantly less than intraarticular drainage group, both during the first 24 h and between 24 and 48 h (P &lt; 0.001).",4759876
2525,4759876,The hidden blood loss after TKA,subcutaneous indwelling closed suction drainage method ,intraarticular indwelling closed suction drainage method,Significantly increased,The hidden blood loss after TKA was significantly different between two groups (P &lt; 0.001) [Table 2]. There was more hidden blood loss in the subcutaneous group (Group A).,4759876
2526,4759876,Allogeneic transfusion requirements,subcutaneous indwelling closed suction drainage method ,intraarticular indwelling closed suction drainage method,Significantly decreased,"Allogeneic transfusion requirements between patients in the subcutaneous drainage and intraarticular drainage groups (6.4% versus 24.1%) were significantly different (P = 0.002, Table 3).",4759876
2527,4874073,The mean heart rate,Group D received a loading dose of dexmedetomidine 1 Î¼g/kg over 10 min followed by an infusion 0.5-1.0 Î¼g/kg/h,Group E received esmolol in a loading and maintenance dose of 1 mg/kg over 1 min and 0.5-1.0 mg/kg/h and group N received nitroglycerine infusion at a dose of 0.5-2 Î¼g/kg/min,Significantly decreased,The mean heart rate was significantly lower in group D compared to groups E and N at all times of measurement (P &lt; 0.05).,4874073
2528,4874073,mean arterial pressure (MAP),Group D received a loading dose of dexmedetomidine 1 Î¼g/kg over 10 min followed by an infusion 0.5-1.0 Î¼g/kg/h,Group E received esmolol in a loading and maintenance dose of 1 mg/kg over 1 min and 0.5-1.0 mg/kg/h and group N received nitroglycerine infusion at a dose of 0.5-2 Î¼g/kg/min,Significantly decreased,"The MAP was significantly lower in group D compared to groups N and E after infusion of study drugs, after induction of anesthesia, after intubation and 5 min after intubation (P &lt; 0.05) [Table 3].",4874073
2529,4874073,The Ramsay Sedation Scores,Group D received a loading dose of dexmedetomidine 1 Î¼g/kg over 10 min followed by an infusion 0.5-1.0 Î¼g/kg/h,Group E received esmolol in a loading and maintenance dose of 1 mg/kg over 1 min and 0.5-1.0 mg/kg/h and group N received nitroglycerine infusion at a dose of 0.5-2 Î¼g/kg/min,Significantly increased,The Ramsay Sedation Scores were significantly higher in group D (score 3 in 46%) when compared to group E (score 2 in 50%) and group N (score 2 in 54%) (P &lt; 0.001).,4874073
2530,3881871,Chromatic alterations,MTA Fillapex sealer,ZnOE-based sealer (Roth-811),Significantly decreased,"With regard to L*, a* and b* parameters, MTA Fillapex caused a statistically significant increase in a* (Î”a*to-t3=1.043, p&lt;0.001) and b* (Î”b* to-t3=2.292, p&lt;0.001) values. L* values remained stable. However, resultant Î”E values indicate that MTA Fillapex induced overall color changes below the human perceptibility threshold, ranging between 2.12-2.88 units. Roth 811 induced severe color changes exceeding the perceptibility threshold from the 1st week of evaluation (Î”E=5.65).",3881871
2531,3881871,Chromatic alterations,MTA Fillapex sealer,ZnOE-based sealer (Roth-811),Significantly decreased,"With regard to L*, a* and b* parameters, MTA Fillapex caused a statistically significant increase in a* (Î”a*to-t3=1.043, p&lt;0.001) and b* (Î”b* to-t3=2.292, p&lt;0.001) values. L* values remained stable. However, resultant Î”E values indicate that MTA Fillapex induced overall color changes below the human perceptibility threshold, ranging between 2.12-2.88 units. Roth 811 induced severe color changes exceeding the perceptibility threshold from the 1st week of evaluation (Î”E=5.65).",3881871
2532,4593658,Contrast-induced nephropathy,N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B),Only normal saline (Group C),No significant difference,This study showed that adding of NAC and AA have not any significant superior effect than traditionally used NS for preventing of CIN.,4593658
2533,4593658,Age and sex of the patients at baseline,N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B),Only normal saline (Group C),No significant difference,"The chi-square test did not show any significant difference between the distribution of sex in the groups (P = 0.313). The overall age of patients was from 38 to 81 years with the mean of 67.6 Â± 8.1 years. The mean age of patients in the Groups of A, B, and C was 67.5 Â± 7.5, 67.8 Â± 6.8 and 67.6 Â± 8.1 years respectively. The ANOVA test did not show any significant difference between the age of patients in the three groups (P = 0.127).",4593658
2534,4593658,Serum creatinine,N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B),Only normal saline (Group C),No significant difference,"The amount of serum Cr (P = 0.661) and GFR (P = 0.785) were equal in the three groups of patients at the beginning of the study. The serum Cr increased, and GFR decreased significantly during the intervention in three groups (Table 1). However, the amounts of these changes were equal between groups",4593658
2535,4593658,Glomerular filtration rate,N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B),Only normal saline (Group C),No significant difference,"The amount of serum Cr (P = 0.661) and GFR (P = 0.785) were equal in the three groups of patients at the beginning of the study. The serum Cr increased, and GFR decreased significantly during the intervention in three groups (Table 1). However, the amounts of these changes were equal between groups",4593658
2536,5057302,Improvement in symptom score,Sublingual immunotherapy (SLIT) 20 000 AUN/ml and 40 000 AUN/ml,Placebo,Significantly increased,"The improvement compared to placebo was shown to be significant for the 20 000 AUN/ml (P = 0.008) and 40 000 AUN/ml (P &lt; 0.001) groups, and no significance was demonstrated for the 10 000 AUN/ml group.",5057302
2537,5057302,Improvement in symptom score,Sublingual immunotherapy (SLIT) 10 000 AUN/ml,Placebo,No significant difference,"The improvement compared to placebo was shown to be significant for the 20 000 AUN/ml (P = 0.008) and 40 000 AUN/ml (P &lt; 0.001) groups, and no significance was demonstrated for the 10 000 AUN/ml group.",5057302
2538,5057302,Improvement in peak nasal inspiratory flow,Sublingual immunotherapy (SLIT) 40 000 AUN/ml,Placebo,Significantly increased,"In all active treatment groups, an increase in PNIF compared to placebo was observed, in patients treated with SB 40 000 AUN/ml, the improvement was significant",5057302
2539,5057302,Birchâ€�pollenâ€� and Bet v 1â€�specific immunoglobulin levels,Sublingual immunotherapy (SLIT) 40 000 AUN/ml,Placebo,Significantly increased,"for birchâ€�pollenâ€� and Bet v 1â€�specific IgG4, a significant increase compared to placebo was only observed in the 40 000 AUN/ml treatment group",5057302
2540,5057302,"Safety laboratory parameters, ECG, and physical exam.",Sublingual immunotherapy (SLIT) ,Placebo,No significant difference,"No clinically significant changes were observed in safety laboratory (haematology and blood chemistry) parameters, urinalysis, vital signs, physical examination and ECG.",5057302
2541,3376507,Body mass index,Standard version or enhanced version of commercial Web-based weight-loss program,Wait-list control group,Significantly decreased,"Intention-to-treat analysis showed that both intervention groups reduced their BMI compared with the controls (basic: â€“0.72, SD 1.1 kg/m2, enhanced: â€“1.0, SD 1.4, control: 0.15, SD 0.82; P &lt; .001)",3376507
2542,3376507,Weight loss,Standard version or enhanced version of commercial Web-based weight-loss program,Wait-list control group,Significantly increased,"Intention-to-treat analysis showed that both intervention groups reduced their BMI compared with the controls (basic: â€“0.72, SD 1.1 kg/m2, enhanced: â€“1.0, SD 1.4, control: 0.15, SD 0.82; P &lt; .001) and lost significant weight (basic: â€“2.1, SD 3.3 kg, enhanced: â€“3.0, SD 4.1, control: 0.4, SD 2.3; P &lt; .001)",3376507
2543,3376507,Changes in waist circumference,Standard version or enhanced version of commercial Web-based weight-loss program,Wait-list control group,Significantly increased,"Intention-to-treat analysis showed that both intervention groups reduced their BMI compared with the controls (basic: â€“0.72, SD 1.1 kg/m2, enhanced: â€“1.0, SD 1.4, control: 0.15, SD 0.82; P &lt; .001) and lost significant weight (basic: â€“2.1, SD 3.3 kg, enhanced: â€“3.0, SD 4.1, control: 0.4, SD 2.3; P &lt; .001) with changes in waist circumference (basic: â€“2.0, SD 3.5 cm, enhanced: â€“3.2, SD 4.7, control: 0.5, SD 3.0; P &lt; .001)",3376507
2544,3376507,Improvement in waist-to-height ratio,Standard version or enhanced version of commercial Web-based weight-loss program,Wait-list control group,Significantly increased,"Intention-to-treat analysis showed that both intervention groups reduced their BMI compared with the controls (basic: â€“0.72, SD 1.1 kg/m2, enhanced: â€“1.0, SD 1.4, control: 0.15, SD 0.82; P &lt; .001) and lost significant weight (basic: â€“2.1, SD 3.3 kg, enhanced: â€“3.0, SD 4.1, control: 0.4, SD 2.3; P &lt; .001) with changes in waist circumference (basic: â€“2.0, SD 3.5 cm, enhanced: â€“3.2, SD 4.7, control: 0.5, SD 3.0; P &lt; .001) and waist-to-height ratio (basic: â€“0.01, SD 0.02, enhanced: â€“0.02, SD 0.03, control: 0.0, SD 0.02; P &lt; .001), but no differences were observed between the basic and enhanced groups.",3376507
2545,3376507,Improvement in eating habits,Standard version or enhanced version of commercial Web-based weight-loss program,Wait-list control group,Significantly increased,Both basic and enhanced participants increased eating restraint and reduced uncontrolled eating compared with controls (P &lt; .001).,3376507
2546,2801838,Mean lutein concentration at baseline,Breastfed infants,Formula-fed infants,Significantly increased,Human milk-fed infants had higher mean serum lutein concentrations (81&nbsp;mcg/l) than all formula-fed infants (13&nbsp;mcg/l) at baseline.,2801838
2547,2801838,Mean lutein concentration at week 12,Breastfed infants,Unfortified formula group,Significantly increased,"At week 12, the human milk group had a sixfold higher geometric mean serum lutein (69.3&nbsp;mcg/l; 95% CI 40.3â€“119) than the unfortified formula group (11.3&nbsp;mcg/l; 95% CI 8.1â€“15.8).",2801838
2548,2801838,All adverse events,Breastfed infants,Formula-fed infants,No significant difference,There were no adverse events related to the formula and no serious adverse events reported.,2801838
2549,2801838,Mean lutein concentration at baseline,Breastfed infants,Formula-fed infants,Significantly increased,Human milk-fed infants had higher mean serum lutein concentrations (81&nbsp;mcg/l) than all formula-fed infants (13&nbsp;mcg/l) at baseline.,2801838
2550,2801838,Mean lutein concentration at week 12,Breastfed infants,Unfortified formula group,Significantly increased,"At week 12, the human milk group had a sixfold higher geometric mean serum lutein (69.3&nbsp;mcg/l; 95% CI 40.3â€“119) than the unfortified formula group (11.3&nbsp;mcg/l; 95% CI 8.1â€“15.8).",2801838
2551,2801838,All adverse events,Breastfed infants,Formula-fed infants,No significant difference,There were no adverse events related to the formula and no serious adverse events reported.,2801838
2552,4714728,mean scores of Constantâ€“Murley score,Group B with autogenous semitendinosus graft and endobutton technique,Group A was treated using a hook plate,Significantly increased,Results indicated that patients in Group B showed higher mean scores (90.3Â±5.4) than Group A (80.4Â±11.5) in terms of Constantâ€“Murley score (P=0.001).,4714728
2553,4714728,level of pain,Group B with autogenous semitendinosus graft and endobutton technique,Group A was treated using a hook plate,Significantly decreased,"Table 2 shows that patients treated with the autogenous semitendinosus graft and endobutton technique showed higher constant scores than the hook plate-treated patients with regard to pain (P=0.002), activities (P=0.02), range of motion (P&lt;0.001), and strength (P=0.004).",4714728
2554,4714728,activities,Group B with autogenous semitendinosus graft and endobutton technique,Group A was treated using a hook plate,Significantly increased,"Table 2 shows that patients treated with the autogenous semitendinosus graft and endobutton technique showed higher constant scores than the hook plate-treated patients with regard to pain (P=0.002), activities (P=0.02), range of motion (P&lt;0.001), and strength (P=0.004).",4714728
2555,4714728,range of motion,Group B with autogenous semitendinosus graft and endobutton technique,Group A was treated using a hook plate,Significantly increased,"Table 2 shows that patients treated with the autogenous semitendinosus graft and endobutton technique showed higher constant scores than the hook plate-treated patients with regard to pain (P=0.002), activities (P=0.02), range of motion (P&lt;0.001), and strength (P=0.004).",4714728
2556,4714728,strength,Group B with autogenous semitendinosus graft and endobutton technique,Group A was treated using a hook plate,Significantly increased,"Table 2 shows that patients treated with the autogenous semitendinosus graft and endobutton technique showed higher constant scores than the hook plate-treated patients with regard to pain (P=0.002), activities (P=0.02), range of motion (P&lt;0.001), and strength (P=0.004).",4714728
2557,4204994,percentages of migrated isoforms (PMI) on days 4 and 11,"high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13)",placebo on all days,Significantly decreased,"High-dose Epoetin beta decreased PMI on days 4 and 11 to 31.0 (4.2) % (p&lt;0.00001) and 45.2 (7.3) % (p&lt;0.00001), respectively.",4204994
2558,4204994,percentages of migrated isoforms (PMI) on days 4 and 11,"low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13)",placebo on all days,Significantly decreased,"Low-dose Epoetin beta decreased PMI on days 4 and 11 to 46.0 (12.8) % (p&lt;0.00001) and 46.1 (10.4) % (p&lt;0.00001), respectively.",4204994
2559,4204994,percentages of migrated isoforms (PMI) on day 25,"high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13) and low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13), ",placebo on all days,Significantly decreased,"In both rhEPO groups, PMI on day 25 was still decreased compared with placebo (Figure 3); high-dose Epoetin beta: 72.9 (19.4) (p&lt;0.029) %; low-dose Epoetin beta: 73.1 (17.8) % (p&lt;0.039).",4204994
2560,4814821,the time to first re-admission for COPD exacerbation,telemonitoring group,usual group,Significantly increased,"As shown in Fig. 2, the time to first re-admission for COPD exacerbation was increased in the telemonitoring group as compared with the usual care group (pâ€‰=â€‰0.026 by log-rank test).",4814821
2561,4814821,time to first COPD-related emergency room (ER) visit,telemonitoring group,usual group,Significantly increased,"In addition, telemonitoring intervention was associated with increased time to first COPD-related ER visit (Fig. 3), with an HR of 0.50 (95% CIâ€‰=â€‰0.24â€“1.04) over the six months of follow-up.",4814821
2562,4814821,the number of all-cause re-admissions over a period of six months,telemonitoring group,usual group,Significantly decreased,Telemonitoring intervention was associated with a significant reduction in the number of all-cause re-admissions from 0.68 to 0.23 per patient (pâ€‰=â€‰0.002) over a period of six months (Table 3).,4814821
2563,4814821,ER visits for all causes,telemonitoring group,usual group,Significantly decreased,"Similarly, patients in the telemonitoring intervention group had fewer ER visits for all causes than those in the usual care group (0.36â€‰vs. 0.91 per patient; pâ€‰=â€‰0.006).",4814821
2564,4814821,episodes of COPD-related re-admissions or ER visits per capita,telemonitoring group,usual group,Significantly decreased,"Moreover, the telemonitoring group patients tended to have fewer episodes of COPD-related re-admissions (0.19â€‰vs. 0.49; pâ€‰=â€‰0.11) or ER visits (0.23â€‰vs. 0.55; pâ€‰=â€‰0.16) per capita than did usual care group patients.",4814821
2565,3961219,The mean normalized area under the curve (AUC) values for the second phase,Bowman-Birk inhibitor concentrate (BBIC),placebo,No significant difference,"The mean normalized AUC values for the subjects treated with placebo or BBIC at doses of 800, 1,200, 1,600 or 2,000 CI units were 1.00Â±0.24, 0.91Â±0.39, 1.51Â±0.29, 1.39Â±0.12 and 1.49Â±0.33, respectively (Fig. 4), and the difference was not statistically significant (P=0.446 by one-way ANOVA).",3961219
2566,3961219,The mean normalized AUC values for the first phase,Bowman-Birk inhibitor concentrate (BBIC),baseline,Significantly increased,The difference among the treatment groups was statistically significant (P=0.006 by one-way ANOVA).,3961219
2567,3961219,The mean normalized AUC values for the first and second clinical trials,Bowman-Birk inhibitor concentrate (BBIC),placebo,Significantly increased,"The mean normalized AUC value for BBIC-treated subjects (all doses combined) was 1.808 and 1.325 for the first and second clinical trials, respectively, and the difference was statistically significant (P=0.031).",3961219
2568,4280425,duration of operation,laparoscopy within the group with American Society of Anesthesiologists  (ASA) 1â€“3 physical status,conventional surgery,Significantly decreased,Operating time [min]	85.1	61 0.0000000004	p &lt; 0.05,4280425
2569,4280425,duration of hospitalization,laparoscopy within the group with ASA 1â€“3,conventional surgery,Significantly decreased,Hospitalisation [days]	10.6	7.7	0.00013	p &lt; 0.05,4280425
2570,4280425,Total morbidity,laparoscopy within the group with ASA 4â€“5,conventional surgery,Significantly decreased,"Total morbidity was 27.5% in the case of patients with conventional surgery, vs. 10.9% with laparoscopic intervention (p &lt; 0.05). The sample of patients with ASA 4â€“5 suffered a high mortality of 82.7%.",4280425
2571,4280425,Complications,laparoscopy within the group with ASA 4â€“5,conventional surgery,Significantly decreased,Complications:	33 (27.5%)	12 (10.9%)	0.0015	p &lt; 0.05,4280425
2572,4884360,carbon monoxide-confirmed continuous abstinence rates (CAR),"standard nicotine patch (NRT), extended use of combined formulations of nicotine replacement therapy (NRT+)",varenicline (VR),No significant difference,"The CARs for weeks 5â€“52 were 10.0&nbsp;% (nâ€‰=â€‰24), 12.4&nbsp;% (nâ€‰=â€‰30), and 15.3&nbsp;% (nâ€‰=â€‰37) in the NRT, NRT+, and VR groups, respectively; they were not significantly different between groups (Pâ€‰&gt;â€‰0.025).",4884360
2573,4884360,Adverse events,"standard nicotine patch (NRT), extended use of combined formulations of nicotine replacement therapy (NRT+)",varenicline (VR),No significant difference,Adverse events resulting in treatment discontinuation by the qualified investigator were not significantly different between the groups (1.6&nbsp;% (nâ€‰=â€‰4) NRT group; 2&nbsp;% (nâ€‰=â€‰5) NRT+ group; and 2&nbsp;% (nâ€‰=â€‰5) VR group; Pâ€‰=â€‰0.93).,4884360
2574,4884360,The frequency of serious adverse events,"standard nicotine patch (NRT), extended use of combined formulations of nicotine replacement therapy (NRT+)",varenicline (VR),No significant difference,The frequency of serious adverse events did not differ between groups (3.7&nbsp;% (nâ€‰=â€‰9) in the NRT group; 2.4&nbsp;% (nâ€‰=â€‰6) in the NRT+ group; and 3.2&nbsp;% (nâ€‰=â€‰8) in the VR group; Pâ€‰=â€‰0.073);,4884360
2575,3400348, mean reduction in BP for both systolic blood pressure (SBP) and diastolic blood pressure (DBP) ,telmisartan 80â€‰mg combined with hydrochlorothiazide (HCTZ) 25â€‰mg,valsartan 160â€‰mg combined with hydrochlorothiazide (HCTZ) 25â€‰mg,Significantly increased,"Treatment with T80/H25 was associated with a significantly greater mean reduction in BP compared with V160/H25 for both SBP (adjusted mean difference âˆ’2.7â€‰mmâ€‰Hg; 95% confidence interval (CI), âˆ’5.1, âˆ’0.3; P = 0.0265) and DBP (adjusted mean difference âˆ’2.0â€‰mmâ€‰Hg; 95% CI, âˆ’3.4, âˆ’0.6; P = 0.0041).",3400348
2576,3400348,reduction in BP for systolic blood pressure (SBP) and diastolic blood pressure (DBP) ,telmisartan 80â€‰mg combined with hydrochlorothiazide (HCTZ) 25â€‰mg,valsartan 160â€‰mg combined with hydrochlorothiazide (HCTZ) 25â€‰mg,Significantly increased,"In patients aged &lt;65 years, T80/H25 resulted in significantly greater BP reductions from baseline (adjusted mean SBP/DBP change âˆ’31.6/âˆ’18.0â€‰mmâ€‰Hg) than V160/H25 (adjusted mean SBP/DBP change âˆ’28.0/âˆ’15.8â€‰mmâ€‰Hg; P = 0.0063 for difference in SBP and P = 0.0041 for DBP).",3400348
2577,3400348,DBP change among non-Black patients,telmisartan 80â€‰mg combined with hydrochlorothiazide (HCTZ) 25â€‰mg,valsartan 160â€‰mg combined with hydrochlorothiazide (HCTZ) 25â€‰mg,Significantly increased,"Among non-Black patients, T80/H25 resulted in significantly greater DBP reductions from baseline (adjusted mean DBP change âˆ’18.3â€‰mmâ€‰Hg) than V160/H25 (adjusted mean DBP change âˆ’16.5â€‰mmâ€‰Hg; P = 0.0229).",3400348
2578,5615289,The onset of tolerable and intolerable mucositis ,honey mitigates,povidone-iodine,Significantly decreased,The onset of tolerable and intolerable mucositis was delayed in the patients using honey and was significant for week 2 (p &lt; 0.0001) and 3 (p &lt; 0.003).,5615289
2579,5615289,signs of grade 1 mucositis at the end of the first week,honey mitigates,povidone-iodine,Significantly decreased,"At the end of the first week, 84% of the patients in the control and 24% in the honey group showed signs of grade 1 mucositis (p &lt; 0.05).",5615289
2580,5615289, the incidence of grade 2 mucositis at week 2,honey mitigates,povidone-iodine,Significantly decreased,"With continuation of the treatment, the incidence of grade 2 mucositis appeared only in the controls (32% (8/25) vs. 0% (0/25)) and was significant (p = 0.002) at week 2.",5615289
2581,5615289,The incidence of intolerable mucositis (only grade 3) at the end of week 7 ,honey mitigates,povidone-iodine,Significantly decreased,"The incidence of intolerable mucositis (only grade 3) were seen earlier and at the end of week 3 in controls (16% (4/24), p = 0.03) and reached a peak in both the groups at the end of week 7 (12/24 in controls vs. 8/25 in honey (p = 0.2)).",5615289
2582,5615289,weight loss,honey mitigates,povidone-iodine,Significantly decreased,"Additionally, it was observed that when compared to the povidone-iodine (4.86 Â± 1.73) group, the weight loss was less in the honey cohorts (2.77 Â± 0.85) and was statistically significant (p &lt; 0.001).",5615289
2583,4191553,the reduction in risk of 24-month incidence of new or worsening vertebral fracture,denosumab 60 mg sc every 6 months ,placebo,Significantly decreased,"The 24-month incidence of new or worsening vertebral fracture was 3.6% in the denosumab group and 10.3% in the placebo group, with the reduction in risk by 65.7% (P = .0001) (Figure 2A and Supplemental Table 1).",4191553
2584,4191553,risk of new or worsening vertebral fracture at 24 months among females,denosumab 60 mg sc every 6 months ,placebo,Significantly decreased,"In the subgroup analysis in women, the risk of new or worsening vertebral fracture at 24 months was reduced by 63.2% in the denosumab group compared with the placebo group (HR 0.368, 95% CI 0.207â€“0.653, P = .0004).",4191553
2585,4191553,"Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, and 6 months at the distal one third radius",denosumab 60 mg sc every 6 months,placebo,Significantly increased,"The difference between the two groups was significant as early as 3 months at the lumbar spine, total hip, and femoral neck (P &lt; .0001) and 6 months at the distal one third radius (P &lt; .0001).",4191553
2586,4191553,"Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, at 12 and 24 months at the femoral neck, and from 18 months at the distal one third radius",denosumab 60 mg sc every 6 months,oral alendronate 35 mg weekly,Significantly increased,"The difference between the denosumab and alendronate groups was significant as early as 3 months at the lumbar spine and total hip (P &lt; .05), at 12 and 24 months at the femoral neck (P &lt; .05), and from 18 months at the distal one third radius (P &lt; .05).",4191553
2587,4191553,"C-telopeptide of type 1 collagen (CTX-1), bone-specific alkaline phosphatase (BSAP)  at 1 month",denosumab 60 mg sc every 6 months,placebo,Significantly decreased,The difference in serum CTX-1 and BSAP between the denosumab and placebo groups was significant as early as 1 month (P &lt; .0001).,4191553
2588,4191553,"C-telopeptide of type 1 collagen (CTX-1) - at 1 month, bone-specific alkaline phosphatase (BSAP)  at 3 month",oral alendronate 35 mg weekly,placebo,Significantly decreased,"As the referential comparison, the difference between the alendronate and placebo groups was significant as early as 1 month in serum CTX-1 (P &lt; .01) and as early as 3 months in serum BSAP (P &lt; .05), respectively.",4191553
2589,3850342,percentage of excellent embryos,culture in ISM1 (MediCult),"routine lab culture medium (G-1TM v5; Vitrolife,",Significantly increased,"There were a significantly higher percentage of excellent embryos in the experimental group (42.7%; ISM1) compared to the control group (39%, p&lt;0.05).",3850342
2590,3850342," the length, weight babies born ",culture in ISM1 (MediCult),"routine lab culture medium (G-1TM v5; Vitrolife,",Significantly increased,"There was no significant difference in baby take home rates (BTHR) between both groups, however both the length [48.8 cm (experimental) vs. 46.0 cm (control)] and weight [3.03 kg (experimental) vs. 2.66 kg (control)] of babies born were significantly higher in the expreimental group (p&lt;0.001 for both parameters).",3850342
2591,4590407,The body mass index-for-age,10 mg Zn/day,sorbitol 10%,Significantly increased,The body mass index-for-age increased after oral zinc supplementation in the EG (p=0.005).,4590407
2592,4590407,The EG had increased in the soft tissue (primarily FFM),10 mg Zn/day,baseline,Significantly increased,The EG had increased in the soft tissue (primarily FFM) body composition after oral zinc supplementation compared with before supplementation (p&lt;0.0001).,4590407
2593,3263888,insulin sensitivity (IS),control,lifestyle intervention ,Significantly increased,Insulin sensitivity tended to increase more in the intervention than in the control group (P = 0.07).,3263888
2594,3263888,body weight and BMI,lifestyle intervention ,control ,No significant difference,"Participants in the intervention group had lower body weight and BMI during the follow-up than those in the control group, but the difference between the groups was not significant (P = 0.18 and P = 0.25, respectively).",3263888
2595,3263888,Matsuda index of insulin sensitivity (Matsuda ISI) during the 4-year follow-up,lifestyle intervention ,control ,Significantly increased,"the average Matsuda ISI was significantly higher in the intervention group than in the control group (4.24 [3.99â€“4.49] vs. 3.85 [3.60â€“4.11], P = 0.02).",3263888
2596,3263888,AIGR0â€“30 during the 4-year follow-up,lifestyle intervention ,control ,Significantly increased,"During the follow-up, although the average value (geometric mean [95% CI]) for the unadjusted AIGR0â€“30 tended to be lower in the intervention than in the control group (30.9 [28.7â€“33.0] vs. 33.0 [30.8â€“35.3], P = 0.08),",3263888
2597,3620559,The number of oocytes per the number of aspirated follicles,20 G/ 35 mm (thin) needle,17 G/ 35 mm (standard) needle,No significant difference,The number of oocytes per the number of aspirated follicles did not differ between the standard and thin needles (pâ€‰=â€‰0.23).,3620559
2598,3620559, Operating time,20 G/ 35 mm (thin) needle,17 G/ 35 mm (standard) needle,Significantly increased,"Operating time significantly increased, by an average of 3.3 minutes per ovary (pâ€‰=â€‰0.002) using the thin needle in comparison to the standard needle.",3620559
2599,3620559,Oocyte yield,20 G/ 35 mm (thin) needle,17 G/ 35 mm (standard) needle,No significant difference,Oocyte yield did not differ between the two needles (pâ€‰=â€‰0.50).,3620559
2600,3620559,oocyte yields among women with diminished ovarian reserve,20 G/ 35 mm (thin) needle,17 G/ 35 mm (standard) needle,No significant difference,"As indicated by the Wilcoxon Matched-Pairs Signed Ranks test, standard (Mâ€‰=â€‰9.2, SDâ€‰=â€‰4.5) and thin (Mâ€‰=â€‰6.8, SDâ€‰=â€‰4.1) needles resulted in similar oocyte yields among women with diminished ovarian reserve (pâ€‰=â€‰0.17).",3620559
2601,3620559, oocyte yield among women with normal ovarian reserve,20 G/ 35 mm (thin) needle,17 G/ 35 mm (standard) needle,No significant difference,"Likewise, among women with normal ovarian reserve, oocyte yield did not differ between standard (Mâ€‰=â€‰10.7, SDâ€‰=â€‰4.7) and thin (Mâ€‰=â€‰10.8, SDâ€‰=â€‰5.4) needles (pâ€‰=â€‰1.00; Figure&nbsp; 2a,b).",3620559
2602,5446455,"Visual Analog Scale (VAS), Pain Disability Index (PDI) and Headache Impact Tests (HIT)",Body Awareness Therapy (BAT) and aerobic exercise ,baseline,Significantly decreased,"While in individuals in BAT group and in aerobic exercise group, there was a difference found in VAS, PDI and HIT values prior to and after the treatment (p&lt;0.05);",5446455
2603,5446455,"Visual Analog Scale (VAS), Pain Disability Index (PDI) and Headache Impact Tests (HIT)",control,baseline,No significant difference,"While in individuals in BAT group and in aerobic exercise group, there was a difference found in VAS, PDI and HIT values prior to and after the treatment (p&lt;0.05); in individuals in control group, there was no difference found (p&gt;0.05).",5446455
2604,5446455,the average number of days of pain in individuals who had mild and severe pain,Body Awareness Therapy (BAT) and aerobic exercise ,control,No significant difference,"As the average number of days of pain in individuals who had mild and severe pain is concerned, statistically no difference was found among the individuals in each three groups (p&gt;0.05).",5446455
2605,5446455,the average number of days of pain in individuals who had moderate degree pain,Body Awareness Therapy (BAT) and aerobic exercise ,control,Significantly decreased,The average number of days which were noted in the pain diary in individuals who had moderate degree pain was found to be significantly high in control group (p&lt;0.05).,5446455
2606,5446455,"PF: Physical function, BP: Body perception,VT: Vitality, MH: Mental health", aerobic exercise ,baseline,Significantly increased,"While there was a difference found between PF, RP, VT, RE, MH, PCS, MCS values prior to and after the treatment of the individuals in BAT group; in individuals in aerobic exercise group, there was a difference found between PF, BP, VT, MH values (p&lt;0.05).",5446455
2607,5446455,RP: Role-physical, Body Awareness Therapy (BAT)  and aerobic exercise ,control,Significantly increased,"As for after the treatment, there was a difference found among the groups concerning RP and VT values (p&lt;0.05). RP values in BAT group and in aerobic exercise group were found to be significantly high,",5446455
2608,5446455,VT: Vitality,aerobic exercise ,control,Significantly increased,"As for after the treatment, there was a difference found among the groups concerning RP and VT values (p&lt;0.05). RP values in BAT group and in aerobic exercise group were found to be significantly high, VT values in aerobic exercise group were found to be significantly high (Table 4).",5446455
2609,5446455,VT: Vitality,aerobic exercise ,baseline,Significantly increased,"When the differentials of PF, RP, BP, GH, VT, SF, RE, MH, PCS, MCS among the groups prior to and after the treatment were taken, only the VT differential was found to be different for aerobic exercise group (p&lt;0.05) (Table 4).",5446455
2610,3549413,bone mineral density (BMD) At the 6-month time point,placebo,baseline,Significantly decreased,"At the 6-month time point, subjects supplemented with the GBB (n&nbsp;=&nbsp;30) maintained femoral neck BMD, whereas in the placebo group (n&nbsp;=&nbsp;28), BMD significantly decreased (p&nbsp;=&nbsp;0.007, Fig.&nbsp;2a), resulting in a 1.3% difference between groups (p&nbsp;&lt;&nbsp;0.05).",3549413
2611,3549413,bone mineral density (BMD),calcium only or the geniVidaâ„¢ bone blend (GBB),placebo,Significantly increased,"At the 6-month time point, subjects supplemented with the GBB (n&nbsp;=&nbsp;30) maintained femoral neck BMD, whereas in the placebo group (n&nbsp;=&nbsp;28), BMD significantly decreased (p&nbsp;=&nbsp;0.007, Fig.&nbsp;2a)",3549413
2612,3549413,Endometrial Thickness,calcium only or the geniVidaâ„¢ bone blend (GBB),baseline,Significantly decreased,"However, ET significantly decreased in the GBB group between screening and study end (2.3â€“1.8&nbsp;mm, p&nbsp;=&nbsp;0.007)",3549413
2613,3549413,estradiol (E2),calcium only or the geniVidaâ„¢ bone blend (GBB),placebo,Significantly increased,"Of note, E2 increased in the GBB group by 12.7% (p&nbsp;=&nbsp;0.044), but remained within the normal range (Table&nbsp;3).",3549413
2614,2887326,total equivalent amount (TEA),Hochu-ekki-to,placebo,Significantly decreased,The percent change of TEA at 24th week was significantly (P &lt; 0.05) lower in the Hochu-ekki-to group (closed circle) than in the placebo control group (open circle) (Fig. 3). Figure 2.,2887326
2615,2887326,The prominent efficacy rate,Hochu-ekki-to,placebo,No significant difference,"The prominent efficacy rate was indeed moderately higher in the Hochu-ekki-to group (19%; 7 of 37) than in the placebo group (5%; 2 of 40), although there was not a significant difference (P = 0.06).",2887326
2616,2887326,"the aggravated rate, defined as ratio of patients whose TEA had increased more than 50% at 24 weeks from the beginning of the study",Hochu-ekki-to,placebo,Significantly decreased,"Furthermore, the aggravated rate, defined as ratio of patients whose TEA had increased more than 50% at 24 weeks from the beginning of the study, was significantly lower in the Hochu-ekki-to group (3%; 1 of 37) than in the placebo group (18%; 7 of 39) (P &lt; 0.05).",2887326
2617,2409647,The mean skeletal morbidity period rate (SMPR) for all new bone events,oral ibandronate 50â€‰mg,placebo,Significantly decreased,The mean SMPR for all new bone events was significantly reduced with oral ibandronate 50â€‰mg compared with placebo (P=0.004) (Figure 1Figure 1,2409647
2618,2409647,bone events requiring radiotherapy,oral ibandronate 50â€‰mg,placebo,Significantly decreased,Analysis of the individual components revealed that this effect was due primarily to significant reductions in bone events requiring radiotherapy (P&lt;0.001) or surgery (P=0.037) (Figure 1).,2409647
2619,2409647,bone events requiring surgery,oral ibandronate 50â€‰mg,placebo,Significantly decreased,Analysis of the individual components revealed that this effect was due primarily to significant reductions in bone events requiring radiotherapy (P&lt;0.001) or surgery (P=0.037) (Figure 1).,2409647
2620,2409647,the number of skeletal fractures,oral ibandronate 50â€‰mg,placebo,Significantly decreased,There was no significant difference in the number of skeletal fractures with ibandronate compared with placebo (P=0.195).,2409647
2621,2409647,the mean number of measurement periods with events per patient,oral ibandronate 50â€‰mg,placebo,Significantly decreased,"Supportive analyses of new bone events demonstrated that the mean number of events and the mean number of measurement periods with events per patient were significantly reduced in the ibandronate group compared with placebo (P=0.008 and 0.015, respectively, Table 3 Table 3",2409647
2622,2409647,risk reduction for a skeletal event,oral ibandronate 50â€‰mg,placebo,Significantly decreased,"Multivariate Poisson's regression analysis showed that the risk reduction for a skeletal event in the ibandronate 50â€‰mg group was significantly lower than in the placebo group (hazard ratio 0.62, 95% CI=0.48, 0.79, P&lt;0.0001), translating to a 38% risk reduction for ibandronate vs placebo.",2409647
2623,2409647,the bone marker urinary CTx over the 96-week study period,oral ibandronate 50â€‰mg,placebo,Significantly decreased,"Patients receiving oral ibandronate 50â€‰mg showed a significant decrease from baseline in the bone marker urinary CTx over the 96-week study period compared with placebo (median change âˆ’77.3% and +11.0%, P&lt;0.001) (Figure 2Figure 2",2409647
2624,5446666,well-being at 4 weeks,Web-based self-guided app recommendation service (â€œThe Toolboxâ€�),control group,No significant difference,Results demonstrated no significant effect of â€œThe Toolboxâ€� intervention on participant well-being at 4 weeks compared with the control group (P=.66).,5446666
2625,5446666,Subscales of Mental Health Continuum-Short Form (MHC-SF),Web-based self-guided app recommendation service (â€œThe Toolboxâ€�),control group,No significant difference,"There were no significant differences between groups in any of the subdomain scores, psychological 0.57 (95% CI âˆ’0.67 to 1.81), P=.95, social 0.46 (95% CI âˆ’0.68 to 1.59), P=.42, and emotional âˆ’0.02 (95% CI âˆ’0.72 to 0.68), P=.95.",5446666
2626,5446666,"mood, energy, rest, and sleep",Web-based self-guided app recommendation service (â€œThe Toolboxâ€�),control group,No significant difference,"There was no evidence to suggest that a beneficial effect was associated with the number of logins in any of the measures, mood 0.15 (95% CI âˆ’0.58 to 0.87), P=.69, energy 0.08 (95% CI âˆ’0.56 to 0.72), P=.81, rest âˆ’0.13 (95% CI âˆ’0.91 to 0.64), P=.73, and sleep âˆ’5.29 (95% CI âˆ’11.96 to 1.54), P=.12.",5446666
2627,5556716,The mean surgical outcomes score and the mean patient dissatisfaction score,"ultrasound-guided reduction, Plane 1 and Plane 2 fractures",control group (blind reduction)  Plane I and  Plane II fracture,No significant difference,"The mean surgical outcomes score and the mean patient dissatisfaction score were found not to differ between the experimental and the control group in Plane I fracture (p=0.755, 0.578, respectively).",5556716
2628,5556716,surgeons graded outcomes for ultrasound-guided reduction,ultrasound-guided reduction Plane II fracture,control group (blind reduction) Plane II fracture,Significantly increased,"In a subgroup analysis consisting of Plane II fractures only, surgeons graded outcomes for ultrasound-guided reduction higher than that for the control group (p=0.007).",5556716
2629,5556716,level of patients dissatisfaction,ultrasound-guided reduction Plane II fracture,control group (blind reduction) Plane II fracture,Significantly decreased,"Likewise, among the Plane II fracture patients, those who underwent ultrasound-guided reduction were less dissatisfied than those who underwent blind reduction (p=0.043).",5556716
2630,5556716,amount of dissatisfaction for breathing difficulty during exercise,ultrasound-guided reduction Plane II fracture,control group (blind reduction) Plane II fracture,Significantly decreased,"As far as functional outcome was concerned, patients expressed highest amount of dissatisfaction for breathing difficulty during exercise (1.3 for the experimental group and 1.5 for the control group) (Table 4).",5556716
2631,5767990,probing depth (PD),Group A: scaling and root planing (SRP) with A. aspera gel,Group B: SRP with placebo gel,Significantly decreased,"The mean PDs in the test and control groups at baseline were 5.16 and 4.44, respectively, and after 3 months were 2.92 and 4.10, respectively, which showed statistically significant results (P &lt; 0.001).",5767990
2632,5767990,The mean GI after 3 months,Group A: scaling and root planing (SRP) with A. aspera gel,Group B: SRP with placebo gel,Significantly decreased,"The intergroup comparison between the groups results showed that the mean GIs in the test and control groups at baseline were 2.60 and 2.57, respectively, which were nonsignificant, and after 3 months were 1.35 and 2.32, respectively, which showed statistically significant results (P &lt; 0.001).",5767990
2633,5767990,The mean CALs after 3 months ,Group A: scaling and root planing (SRP) with A. aspera gel,Group B: SRP with placebo gel,Significantly decreased,"The mean CALs in the test and control groups at baseline were 1.03 and 0.61, respectively, which showed statistically significant results (P &lt; 0.045) and after 3 months were 0.30 and 0.41, respectively, which were statistically nonsignificant [Table 2].",5767990
2634,4802087,Forced Expiratory Volume in the first second (FEV1),"100,000 IU of oral vitamin D per month, for 6 months",placebo,Significantly increased,After	51.6Â±9.4	31.9Â±7.6	&lt;0.001,4802087
2635,4802087,COPD exacerbation,"100,000 IU of oral vitamin D per month, for 6 months",placebo,Significantly decreased,After	9.7Â±1.3	18.8Â±3.6	&lt;0.001,4802087
2636,3580611,The 30-day rate of stroke or death,percutaneous transluminal angioplasty and stenting (PTAS),medical-management group,Significantly increased,"The 30-day rate of stroke or death was 14.7% in the PTAS group (nonfatal stroke, 12.5%; fatal stroke, 2.2%) and 5.8% in the medical-management group (nonfatal stroke, 5.3%; non-stroke-related death, 0.4%) (P = 0.002).",3580611
2637,3580611,The probability of the occurrence of a primary end-point event,percutaneous transluminal angioplasty and stenting (PTAS),medical-management group,Significantly increased,"The probability of the occurrence of a primary end-point event over time differed significantly between the two treatment groups (P = 0.009), with 1-year rates of the primary end point of 20.0% in the PTAS group and 12.2% in the medical-management group.",3580611
2638,3580611,risk of death and stroke,percutaneous transluminal angioplasty and stenting (PTAS),medical-management group,Significantly increased,Treatment with the Wingspan stent system for patients with intracranial stenosis carries substantial risk of death and stroke and should be abandoned.,3580611
2639,5021260,The median coverage,high coverage rings,low vaccine coverage rings,Significantly increased,"The median coverage in the high coverage rings (coverage â‰¥ 30%) was 41% (interquartile range 34%â€“44%), compared to 0% (interquartile range 0%â€“6%) in the low vaccine coverage rings (coverage â‰¤ 12%).",5021260
2640,5101645,The sedation scores,the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL/kg) plus 2 Âµg/kg dexmedetomidine,the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL/kg) plus 2 Âµg/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml/kg),Significantly increased,"The lowest scores were observed in group B (0.35 Â± 0.49) and the highest were observed in group BD (1.65 Â± 0.67), whereas the scores in the BF group were intermediate (0.95 Â± 0.22) at the 30-min recovery time.",5101645
2641,5101645,The sedation scores,the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml/kg),the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL/kg) plus 2 Âµg/kg fentanyl and the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL/kg) plus 2 Âµg/kg dexmedetomidine,Significantly decreased,"The lowest scores were observed in group B (0.35 Â± 0.49) and the highest were observed in group BD (1.65 Â± 0.67), whereas the scores in the BF group were intermediate (0.95 Â± 0.22) at the 30-min recovery time.",5101645
2642,5101645,the mean pain scores, the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL/kg) plus 2 Âµg/kg dexmedetomidine,the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL/kg) plus 2 Âµg/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml/kg) ,Significantly decreased,"The lowest mean scores were observed in the BD group. In the 1st, 2nd and 4th h after the operation, the mean pain scores were significantly lower in the BD group than in the BF group (P &lt; 0.001).",5101645
2643,5831281,the mean intensity of pruritus,1 week with clemastine and levocetirizine,placebo,Significantly decreased,"A statistically significant decrease in mean VAS scoring was observed in clemastine and levocetirizine groups (p &lt; 0.001), but not in the placebo group.",5831281
2644,5831281,the mean intensity of pruritus,1 week with clemastine ,1 week with levocetirizine,Significantly increased,"The greatest improvement of VAS was seen in the clemastine group by 2.6 Â±3.1 points comparing to levocetirizine (by 2.0 Â±2.9 points, p = 0.56) and placebo (by 0.5 Â±2.3 points, p = 0.01) groups.",5831281
2645,4639339,The mean duration of a successful reduction,"Midazolam at the concentration of 1.0 mg/kg (up to 3 mg) was infused, and then barium reduction was performed under fluoroscopy guideline",placebo,No significant difference,"As far as the duration of the procedure in the successful reduction was concerned, the mean duration in the group receiving Midazolam, before reduction in intussusception was 11.35Â±34.8 minutes and in the group receiving distilled water prior to intussusception reduction was 19.2Â± 32.73 minutes. This difference in duration was not statistically significant (P=0.733).",4639339
2646,4639339,the possibility of manipulation,"Midazolam at the concentration of 1.0 mg/kg (up to 3 mg) was infused, and then barium reduction was performed under fluoroscopy guideline",placebo,Significantly increased,"In addition, there was the possibility of manipulation only on 12 (75%) patients receiving Midazolam, while among patients who received distilled water, it was possible to perform manipulation only on 3 (18.8%) patients. This difference was statistically significant (P&lt;0.001).",4639339
2647,4639339,reduction in intussusception,"Midazolam at the concentration of 1.0 mg/kg (up to 3 mg) was infused, and then barium reduction was performed under fluoroscopy guideline",placebo,No significant difference,"Of 16 patients that received Midazolam, 15 patients demonstrated successful reduction; and of 16 patients that received distilled water, only 11 patients showed successful reduction (P=0.07).",4639339
2648,4341495,Adjective Rating Scale for Withdrawal (ARSW) score,tramadol plus gabapentin ,methadone,No significant difference,The differences in the ARSW score between two groups were not significant (P value = 0.263).,4341495
2649,4341495,Clinical Opiate Withdrawal Scale (COWS) score,tramadol plus gabapentin ,methadone,No significant difference,The differences in the COWS score between two groups were not significant (P value = 0.862).,4341495
2650,4341495,VAS score,tramadol plus gabapentin ,methadone,No significant difference,"As demonstrated in Figure 3, the square of VAS score has been compared between two treatment groups at the first, second, fourth, sixth, and eight day of admission. The differences in the VAS score between two groups were nearly significant (P = 0.057).",4341495
2651,4341495,Mean (SD) age,tramadol plus gabapentin,methadone,Significantly decreased,"Mean (SD) age of the patients in methadone group and tramadol plus gabapentin group were 33.9 (7.1) and 32.4. (8.1), respectively (P = 0.462).",4341495
2652,4131263,Using of  Intention-to-treat (ITT) analysis for Beck Depression Inventory (BDI) scores,reboxetine,citalopram,No significant difference,"In ITT analysis, there was only weak evidence that those on reboxetine had a slightly worse outcome than those on citalopram [adjusted difference in mean Beck Depression Inventory (BDI) scores: 1.19, 95% confidence interval (CI) â€“0.52 to 2.90, p&nbsp;=&nbsp;0.17].",4131263
2653,4131263,Using structural mean modelling (SMM) approach for Beck Depression Inventory (BDI) scores,reboxetine,citalopram,No significant difference,"There was no evidence of a difference in efficacy when differential non-adherence was accounted for using the SMM approach for mean BDI (â€“0.29, 95% CI â€“3.04 to 2.46, p&nbsp;=&nbsp;0.84) or the other mental health outcomes.",4131263
2654,4131263,physical health (SF-12 physical subscale score),reboxetine,citalopram,No significant difference,There was little evidence for any difference in outcome in terms of physical health (SF-12 physical subscale score) between those randomized to receive reboxetine compared to citalopram (Table 2).,4131263
2655,3137994,Mortality rate,Surgical treatment,Medical treatment,No significant difference,There is no significant difference in the mortality rate between the â€œsurgicalâ€� and non-â€œsurgicalâ€� groups of Iranian patients with SAH.,3137994
2656,3137994,Rate of rebleeding,Surgical treatment,Medical treatment,No significant difference,"Difference of rebleeding rate in the two therapeutic groups was not significant; X2 = .014, P = .91. The effect of rebleeding on mortality was not significant; X2 = 2.54, P = .14.",3137994
2657,3219777,Verbal numerical rating scales after incision,Midazolam plus remifentanil plus ketamine,Midazolam plus remifentanil,Significantly decreased,"The VNRS values at 1, 3, and 5 min after incision and OAA/S scores at 5 min after remifentanil infusion, and 1, 3, and 5 min after incision were lower in the Ketamine group than in the Control group.",3219777
2658,3219777,Observer's Assessment of Alertness/Sedation scores after incision,Midazolam plus remifentanil plus ketamine,Midazolam plus remifentanil,Significantly decreased,"The VNRS values at 1, 3, and 5 min after incision and OAA/S scores at 5 min after remifentanil infusion, and 1, 3, and 5 min after incision were lower in the Ketamine group than in the Control group.",3219777
2659,3219777,Apnea,Midazolam plus remifentanil plus ketamine,Midazolam plus remifentanil,No significant difference,apnea after bolus (4 cases vs. 3 cases) were higher in the Control group but none of these differences were statistically significant,3219777
2660,3219777,Satisfaction scale of physicians and patients,Midazolam plus remifentanil plus ketamine,Midazolam plus remifentanil,No significant difference,The satisfaction scale (1 to 4) of the surgeons and the patients were high in both groups (4 vs. 4),3219777
2661,5777197,Risk of death in the first four months,High-dose continuous lenalidomide group,Sequential azacitidine and lenalidomide group and azacitidine only group,Significantly increased,"Subjects in the high-dose continuous lenalidomide cohort had a higher hazard of death than subjects in the azacitidine cohort [HR 5.73 (1.91, 17.20); P=0.002] or subjects in the sequential azacitidine and lenalidomide cohort [HR 2.19 (95%CI: 0.94, 5.13); P=0.071]",5777197
2662,5777197,Risk of death in the first four months,Sequential azacitidine and lenalidomide group,Zacitidine only group,Significantly increased,"Hazard of death was also higher in the sequential azacitidine and lenalidomide cohort compared with the azacitidine cohort [HR 2.51 (0.89, 7.05); P=0.081].",5777197
2663,5777197,Risk of death after 4 months,High-dose continuous lenalidomide group,Sequential azacitidine and lenalidomide group and azacitidine only group,No significant difference,Hazards of death &gt;4â€“12 months were similar in the 3 cohorts.,5777197
2664,2806530,Blood alcohol concentration,Alcohol,Placebo,No significant difference,"BAC values did not differ between males (mean Â± SD, 0.69â€‰Â±â€‰0.04) and females (mean Â± SD, 0.603â€‰Â±â€‰0.05; pâ€‰=â€‰0.17).",2806530
2665,2806530,Transcallosal inhibition in women,Alcohol,Placebo,Significantly decreased,"Post hoc analyses demonstrated that alcohol significantly reduced TCI in females (F(1, 11)â€‰=â€‰12.52; pâ€‰=â€‰0.005; Î·p2â€‰=â€‰0.53) but not in males (F(1, 9)â€‰=â€‰0.10; pâ€‰=â€‰0.76; Fig.&nbsp;1).",2806530
2666,2806530,Transcallosal inhibition in men,Alcohol,Placebo,No significant difference,"Post hoc analyses demonstrated that alcohol significantly reduced TCI in females (F(1, 11)â€‰=â€‰12.52; pâ€‰=â€‰0.005; Î·p2â€‰=â€‰0.53) but not in males (F(1, 9)â€‰=â€‰0.10; pâ€‰=â€‰0.76; Fig.&nbsp;1).",2806530
2667,4387644,Demographic characteristics,Stretching exercises group and walking group,Routine care group,No significant difference,No significant difference was found in the demographic characteristics of the three groups of women.,4387644
2668,4387644,Improvement of systolic and diastolic blood pressure,Stretching exercises group ,Routine care group and walking group,Significantly increased,Tukey's test showed significant improvement of systolic and diastolic blood pressure in stretching exercise group. Walking and control groups showed no change or significant reduction (P &lt; 0.05).,4387644
2669,4387644,Systolic and diastolic blood pressure,Walking group,Routine care group ,No significant difference,the difference between walking group and routine care (P &gt; 0.05) was not significant.,4387644
2670,4776564,Baseline characteristics,Hope-promoting interventions based on religious beliefs,No interventions,No significant difference,"In general, the results showed that the two groups were similar in terms of demographic characteristics and had no significant differences [Tables 1 and 2]. Independent t-test results showed no significant differences before the intervention between the two groups in terms of the mean QOL score in the performance and health, socioeconomic, psychological, spiritual, and familial dimensions and areas of satisfaction and importance.",4776564
2671,4776564,Quality of life score regarding satisfaction,Hope-promoting interventions based on religious beliefs,No interventions,Significantly increased,"The mean (standard deviation) overall QOL score in the area of satisfaction significantly increased in the study group, compared to the controls, immediately [70.7 (8.5) vs. 59.2 (12.5)] and 1 month after the intervention [75.2 (7.4) vs. 59.4 (12.9)] (P &lt; 0.05).",4776564
2672,4776564,Quality of life score regarding importance,Hope-promoting interventions based on religious beliefs,No interventions,Significantly increased,"The mean (standard deviation) overall QOL score in the area of satisfaction significantly increased in the study group, compared to the controls, immediately [70.7 (8.5) vs. 59.2 (12.5)] and 1 month after the intervention [75.2 (7.4) vs. 59.4 (12.9)] (P &lt; 0.05). There was also a similar difference between the two groups in the area of importance immediately [73.6 (5.8) vs. 65.7 (7.5)] and 1 month after the intervention [76.3 (8.1) vs. 66.8 (8.5)] (P &lt; 0.05).",4776564
2673,5385703,Vitiligo Area Scoring Index score,Betamethasone valerate cream plus oral simvastatin (Group B),Topical betamethasone valerate cream (Group A),No significant difference,"Despite a continuous reduction in VASI score in both groups, according to both physician (P = 0.13) and patient (P = 0.374) assessment oral simvastatin was not statistically more effective than conventional treatment of vitiligo.",5385703
2674,5385703,"Baseline characteristics such as age, sex, and distribution of vitiligo patches ",Betamethasone valerate cream plus oral simvastatin (Group B),Topical betamethasone valerate cream (Group A),No significant difference,"The difference in mean ages of the two groups was not statistically significant (P = 0.75). Group A included 24 (45%) female and 20 (54.5%) male patients. Group B included 21 (47.7%) female and 23 (52.3%) male patients. There was no significant difference between sex ratios in the two groups (P = 0.52).By Chi-square test, the distribution of vitiligo patches between two groups (P = 0.776) was not statistically significant between them",5385703
2675,5385703,Rate of side effects or laboratory abnormalities,Betamethasone valerate cream plus oral simvastatin (Group B),Topical betamethasone valerate cream (Group A),No significant difference,No side effect or any laboratory abnormality has been detected in both groups.,5385703
2676,4517027,Mental fatigue after exercise,Pre-exercise breakfast,No breakfast before exercise,Significantly increased,Energy intake at breakfast prior to exercise were significantly related to post-exercise mental fatigue (r (43) = âˆ’0.307; p = 0.043),4517027
2677,4517027,Thirst after exercise,Pre-exercise breakfast,No breakfast before exercise,Significantly increased,Energy intake at breakfast prior to exercise were significantly related to post-exercise mental fatigue (r (43) = âˆ’0.307; p = 0.043) and thirst (r (43) = âˆ’0.333; p = 0.027).,4517027
2678,4517027,Alertness after exercise,Pre-exercise breakfast,No breakfast before exercise,Significantly increased,Energy intake at breakfast prior to exercise was also significantly related to post-exercise alertness (r (43) = 0.315; p = 0.037),4517027
2679,4517027,RVIP false alarms at 1500 h,Pre-exercise breakfast,No breakfast before exercise,Significantly increased,"A significant breakfast Ã— repetition interaction was observed for RVIP false alarms (errors) [F (2, 16) = 4.86, p = 0.014] when completed on the mobile phone. Comparisons revealed that at 1500 h participants made significantly less false alarms in the no breakfast (NB) condition compared to the 40 g breakfast condition (p = 0.019, d = 0.37).",4517027
2680,4517027,Appetite control,Pre-exercise breakfast,No breakfast before exercise,Significantly increased,"Breakfast was also beneficial for appetite control before lunch irrespective of size (all p &lt; 0.05, d &gt; 0.43).",4517027
2681,5529957,Pulmonary vascular resistance,Riociguat group,Placebo group,Significantly decreased,Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n=189; least-squares mean difference: âˆ’285â€…dynâ€…s/cm5 (95% CI âˆ’357 to âˆ’213); p&lt;0.0001) and persistent/recurrent (n=72; âˆ’131 dynâ€…s/cm5 (95% CI âˆ’214 to âˆ’48); p=0.0025) patients.,5529957
2682,5529957,Improvement of cardiac index in inoperable patients,Riociguat group,Placebo group,Significantly increased,"Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6â€…L/min/m2 (95% CI 0.4 to 0.7; p&lt;0.0001),",5529957
2683,5529957,Improvement of cardiac index in persistent/recurrent patients,Riociguat group,Placebo group,No significant difference,"Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6â€…L/min/m2 (95% CI 0.4 to 0.7; p&lt;0.0001), while in persistent/recurrent patients the change was +0.2â€…L/min/m2 (95% CI âˆ’0.1 to 0.5; p=0.17)",5529957
2684,5529957,Mean pulmonary artery pressure,Riociguat group,Placebo group,Significantly decreased,"Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(âˆ’4.7â€…mmâ€…Hg (95% CI âˆ’6.9 to âˆ’2.6; p&lt;0.0001 and âˆ’4.8â€…mmâ€…Hg (â€“8.2 to âˆ’1.5; p=0.0055), respectively)",5529957
2685,5529957,Improvement in 6â€…min walk distance at week 16,Riociguat group,Placebo group,Significantly increased,"Riociguat significantly improved the primary end point, change from baseline in 6MWD at week 16, in the overall population by an LS mean difference versus placebo of +46â€…m (95% CI 25 to 67â€…m; p&lt;0.0001)",5529957
2686,5529957,Pulmonary vascular resistance,Riociguat group,Placebo group,Significantly decreased,Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n=189; least-squares mean difference: âˆ’285â€…dynâ€…s/cm5 (95% CI âˆ’357 to âˆ’213); p&lt;0.0001) and persistent/recurrent (n=72; âˆ’131 dynâ€…s/cm5 (95% CI âˆ’214 to âˆ’48); p=0.0025) patients.,5529957
2687,5529957,Improvement of cardiac index in inoperable patients,Riociguat group,Placebo group,Significantly increased,"Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6â€…L/min/m2 (95% CI 0.4 to 0.7; p&lt;0.0001),",5529957
2688,5529957,Improvement of cardiac index in persistent/recurrent patients,Riociguat group,Placebo group,No significant difference,"Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6â€…L/min/m2 (95% CI 0.4 to 0.7; p&lt;0.0001), while in persistent/recurrent patients the change was +0.2â€…L/min/m2 (95% CI âˆ’0.1 to 0.5; p=0.17)",5529957
2689,5529957,Mean pulmonary artery pressure,Riociguat group,Placebo group,Significantly decreased,"Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(âˆ’4.7â€…mmâ€…Hg (95% CI âˆ’6.9 to âˆ’2.6; p&lt;0.0001 and âˆ’4.8â€…mmâ€…Hg (â€“8.2 to âˆ’1.5; p=0.0055), respectively)",5529957
2690,5529957,Improvement in 6â€…min walk distance at week 16,Riociguat group,Placebo group,Significantly increased,"Riociguat significantly improved the primary end point, change from baseline in 6MWD at week 16, in the overall population by an LS mean difference versus placebo of +46â€…m (95% CI 25 to 67â€…m; p&lt;0.0001)",5529957
2691,1796543,Changes in gene expression,Imiquimod 5% cream,Placebo,Significantly increased,"The ontology analysis shows that imiquimod treatment of AK results in global gene expression changes impacting various cellular processes, with immune response and signal transduction being the 2 major processes represented.",1796543
2692,1796543,"Changes in TLR3, TLR7, TLR8, and IRF7",Imiquimod 5% cream,Placebo,Significantly increased,"The most statistically significant changes observed upon treatment with imiquimod were for TLR3, TLR7, TLR8, and IRF7, with good agreement between the Affymetrix and RT-PCR analysis both for the magnitude of change and for the p-values.",1796543
2693,1796543,Changes in TLR5 and TLR10,Imiquimod 5% cream,Placebo,No significant difference,There was no change in the expression levels of TLR5 and TLR10 upon treatment with imiquimod.,1796543
2694,1796543,CD8Î² expression,Imiquimod 5% cream,Placebo,Significantly increased,"treatment of AK lesions with imiquimod resulted in a small but significant increase in the expression of CD8Î², suggesting that there is an increase in CD8 T cells",1796543
2695,3019750,Enamel hardness,Saliva with fluoride (G2),Saliva in situ (G1),No significant difference,No significant differences were found between G1 and G2 for enamel hardness and wear.,3019750
2696,3019750,Enamel wear,Saliva with fluoride (G2),Saliva in situ (G1),No significant difference,The results reveal that the wear of blocks submitted to saliva (âˆ’0.0016) was similar to the wear of blocks submitted to saliva associated with fluoride (âˆ’0.0074) (P=0.6196).,3019750
2697,3919744,Sagittal and frontal planes COP path length values,"Exercises with whole-body vibration (Group I, II and III)",Exercises without the application of concurrent vibration (Group IV),No significant difference,"Both a single application of vibration and the 4-week whole-body vibration training had an effect on the COP path length values in the sagittal and frontal planes, but most changes were statistically insignificant (p&gt;0.05)",3919744
2698,3919744,COP path length in the AP plane,Exercises with whole-body vibration (Group I),Exercises with whole-body vibration (Groups II and III) and exercises without the application of concurrent vibration (Group IV),Significantly increased,Group I was the only group where the COP path length in the AP plane was significantly increased after the last session of the 4-week whole-body vibration training (pâ€Š=â€Š0.046),3919744
2699,3919744,Vibration frequency,Exercises with whole-body vibration (Group I),Exercises with whole-body vibration (Groups II and III) ,No significant difference,"To establish the impacts of different vibration frequency and amplitude parameters, test groups I-III were compared with each other. The Mann Whitney U test did not show a significant influence of vibration frequency and amplitude on the path length of the COP and rambling and trembling paths (p&gt;0.05) between the pre-test measurements and those made directly after the first session of whole-body vibration, immediately after the last set of exercises of the 4-week whole-body vibration training and one week after.",3919744
2700,3919744,Amplitude parameters,Exercises with whole-body vibration (Group I),Exercises with whole-body vibration (Groups II and III) ,No significant difference,"To establish the impacts of different vibration frequency and amplitude parameters, test groups I-III were compared with each other. The Mann Whitney U test did not show a significant influence of vibration frequency and amplitude on the path length of the COP and rambling and trembling paths (p&gt;0.05) between the pre-test measurements and those made directly after the first session of whole-body vibration, immediately after the last set of exercises of the 4-week whole-body vibration training and one week after.",3919744
2701,3919744,Sagittal and frontal planes COP path length values,"Exercises with whole-body vibration (Group I, II and III)",Exercises without the application of concurrent vibration (Group IV),No significant difference,"Both a single application of vibration and the 4-week whole-body vibration training had an effect on the COP path length values in the sagittal and frontal planes, but most changes were statistically insignificant (p&gt;0.05)",3919744
2702,3919744,COP path length in the AP plane,Exercises with whole-body vibration (Group I),Exercises with whole-body vibration (Groups II and III) and exercises without the application of concurrent vibration (Group IV),Significantly increased,Group I was the only group where the COP path length in the AP plane was significantly increased after the last session of the 4-week whole-body vibration training (pâ€Š=â€Š0.046),3919744
2703,3919744,Vibration frequency,Exercises with whole-body vibration (Group I),Exercises with whole-body vibration (Groups II and III) ,No significant difference,"To establish the impacts of different vibration frequency and amplitude parameters, test groups I-III were compared with each other. The Mann Whitney U test did not show a significant influence of vibration frequency and amplitude on the path length of the COP and rambling and trembling paths (p&gt;0.05) between the pre-test measurements and those made directly after the first session of whole-body vibration, immediately after the last set of exercises of the 4-week whole-body vibration training and one week after.",3919744
2704,3919744,Amplitude parameters,Exercises with whole-body vibration (Group I),Exercises with whole-body vibration (Groups II and III) ,No significant difference,"To establish the impacts of different vibration frequency and amplitude parameters, test groups I-III were compared with each other. The Mann Whitney U test did not show a significant influence of vibration frequency and amplitude on the path length of the COP and rambling and trembling paths (p&gt;0.05) between the pre-test measurements and those made directly after the first session of whole-body vibration, immediately after the last set of exercises of the 4-week whole-body vibration training and one week after.",3919744
2705,3599990,Differences between self-reported and measured weight,Informed group,Uninformed group,No significant difference,"Mean differences between self-reported and measured weight (pâ€‰=â€‰0.4004), height (pâ€‰=â€‰0.5342) and body mass index (BMI) (pâ€‰=â€‰0.4409) were not statistically different between the informed and uninformed group.",3599990
2706,3599990,Differences between self-reported and measured height,Informed group,Uninformed group,No significant difference,"Mean differences between self-reported and measured weight (pâ€‰=â€‰0.4004), height (pâ€‰=â€‰0.5342) and body mass index (BMI) (pâ€‰=â€‰0.4409) were not statistically different between the informed and uninformed group.",3599990
2707,3599990,Differences between self-reported and measured body mass index,Informed group,Uninformed group,No significant difference,"Mean differences between self-reported and measured weight (pâ€‰=â€‰0.4004), height (pâ€‰=â€‰0.5342) and body mass index (BMI) (pâ€‰=â€‰0.4409) were not statistically different between the informed and uninformed group.",3599990
2708,3599990,Patients who consented to be measured,Informed group,Uninformed group,No significant difference,"There was no significant difference in the proportion who consented to being measured between the informed (93%) and uninformed (92%) group (Ï‡2: 0.9213, dfâ€‰=â€‰1; pâ€‰=â€‰0.337).",3599990
2709,3452084,assessment of tolerability,naproxen sodium 550 mg (NAP),placebo (PLA),Significantly increased,"PCF and NAP were significantly better than placebo (P&nbsp;&lt;&nbsp;0.05), whilst no differences emerged between the two active treatments.Fig.&nbsp;1",3452084
2710,3452084,pain intensity difference (PID),"paracetamol 1,000mgâ€“caffeine 130mg (PCF)  ",naproxen sodium 550 mg (NAP),Significantly increased,"PCF and NAP were significantly better than placebo (P&nbsp;&lt;&nbsp;0.05), whilst no differences emerged between the two active treatments.Fig.&nbsp;1",3452084
2711,3452084,assessment of tolerability,"paracetamol 1,000mgâ€“caffeine 130mg (PCF)  ",naproxen sodium 550 mg (NAP),Significantly increased,"The evaluation was â€˜excellentâ€™ or â€˜very goodâ€™ in 45.7% of the patients after PCF, in 51.6% after NAP, and 41.7% after PLA. The difference was statistically significant (P&nbsp;&lt;&nbsp;0.05) between NAP and PLA.Table&nbsp;4",3452084
2712,3452084,Time course of total pain relief (TOTPAR),"paracetamol 1,000mgâ€“caffeine 130mg (PCF)  and naproxen sodium 550 mg (NAP)", placebo (PLA),Significantly decreased,"The time course of TOTPAR during the 4-h observation period is shown in Fig.&nbsp;2, whilst TOTPAR mean values with standard errors are displayed in Table&nbsp;5. Both PCF and NAP provided significantly more relief than placebo (P&nbsp;&lt;&nbsp;0.05), but were not significantly different from each other.Fig.&nbsp;2",3452084
2713,3843300,serum level of blood urea nitrogen (BUN) and creatinine (Cr),sham-operated group,control,Significantly decreased,The serum levels of BUN and Cr in the control group increased significantly when compared with the sham group (P &lt; 0.05),3843300
2714,3843300,serum level of blood urea nitrogen (BUN) ,N-acetylcysteine (NAC) (150 mg/kg),control group,No significant difference,"Administration of NAC (150 mg/kg) decreased the serum levels of Cr and BUN in comparison with the control group. However, only the serum level of Cr decreased significantly (P &lt; 0.05) [Figure 1].",3843300
2715,3843300,creatinine (Cr),N-acetylcysteine (NAC) (150 mg/kg),control group,Significantly decreased,"Administration of NAC (150 mg/kg) decreased the serum levels of Cr and BUN in comparison with the control group. However, only the serum level of Cr decreased significantly (P &lt; 0.05) [Figure 1].",3843300
2716,3843300,the lung injury score,N-acetylcysteine (NAC) (150 mg/kg),control group,Significantly decreased,"NAC did not improve kidney weight and damage; however, its low dose (150 mg/kg) attenuated the lung injury score (P &lt; 0.05) when compared with the control group.",3843300
2717,5740257,Global intellectual ability (IQ),4.5&nbsp;mg/m2 per day of oral everolimus once daily for 6 months,placebo,No significant difference,Full Scale IQ showed a wide range (55â€“122) and without detectable difference between placebo and treatment groups (P&nbsp;=&nbsp;0.80) (Table&nbsp;2).,5740257
2718,5740257,adverse events (AE): respiratory AE (cough),4.5mg/m2 per day of oral everolimus once daily for 6 months,placebo,Significantly decreased,"The only category to demonstrate significant difference between groups was respiratory AE (cough), which was significantly higher in the placebo group compared to everolimus group (P&nbsp;&lt;&nbsp;0.001).",5740257
2719,5740257,"adverse events (AE): gastrointestinal complaints, primarily stomatitis/aphthous ulcers",4.5mg/m2 per day of oral everolimus once daily for 6 months,placebo,No significant difference,"Gastrointestinal complaints, primarily stomatitis/aphthous ulcers, were the most common AE (28% overall) (Table&nbsp;4), although the frequency between treatment and placebo groups was not significant for gastrointestinal complaints in general (P&nbsp;=&nbsp;0.80) nor stomatitis/aphthous ulcers (P&nbsp;=&nbsp;0.25).",5740257
2720,5856914,The CANDEN spine inflammation score,adalimumab,placebo,Significantly decreased,CANDEN spine total inflammation score	10.2 (13)	âˆ’5.7 (9.2)	7.3 (10)	âˆ’0.8 (3.0)	0.03,5856914
2721,4362117,decline in the percentage of sites harboring Tannerella forsythia (Tf),One month after administeration systemic doxycycline after the completion of scaling and root planing (SRP),control group (CG) received only scaling and root planing (SRP),Significantly increased,"In the first month after administering doxycycline, a significantly higher decline in the percentage of sites harboring Tf was observed for TG compared with CG (p=0.02).",4362117
2722,4362117,percentage of Prevotella intermedia (Pi) and Porphyromonas gingivalis (Pg),One month after systemic doxycycline during the reevaluation visit 45 days after the completion of scaling and root planing (SRP),control group (CG) received only scaling and root planing (SRP),Significantly decreased,"The results showing the effect of systemic doxycycline on Pg and Pi are shown in Figures 1B &amp; 1C. One month after the administration of doxycycline, both Pg, and Pi showed significant reduction in the percentage of site for TG compared with CG (p&lt;0.01 and p=0.04).",4362117
2723,5268424,score on the general dimension scale of negative affects (referred to as NA from here onward),view a video featuring individuals that live in extreme poverty,control,Significantly increased,The average score of 21.036 in NA after watching the Poverty video is significantly larger than a typical baseline average of NA 14.8 reported by [13].,5268424
2724,5268424,"negative emotions such as fear, guilt, sadness, shame and upset.",view a video featuring individuals that live in extreme poverty,control,Significantly increased,"This finding is in agreement with the self-reported data, in that the Poverty treatment induces a more negative emotional state than the Neutral treatment. This difference is driven by the specific emotions of Scare (one sided t-test, p = .039) and Sadness (one sided t-test, p = .057). These patterns, coupled with the PANAS results, reveal that the Poverty video increases a number of negative emotions such as fear, guilt, sadness, shame and upset. Whether these differences in affects correlate with lower performance is addressed in the next section.10.1371/journal.pone.0170231.t004Table 4Emotion	Poverty	Neutral	DifferenceNeutral	-.0011	0.048	-.058(.213)	(0.294)	(.066)Happy	-.068	-0.051	.-017(.125)	(0.122)	(.033)Sad	0.037	-0.002	.039*(0.098)	(0.077)	(.024)Angry	0.002	-0.002	.004(0.091)	(0.062)	(.025)Surprised	0.007	0.027	-.020(0.097)	(0.090)	(.022)Scared	0.010	-0.006	.015**(0.036)	(0.019)	(.008)Disgusted	-0.003	-0.004	.001(0.016)	(0.010)	(.003)Valence	-0.111	-0.037	-.073*(0.185)	(0.134)	(.045)N	39	21	21",5268424
2725,5923799,Stork test of balance,Taekwondo (TKD) ,control,Significantly increased,Results of the Stork test of balance were significantly higher in the TKD group after intervention (p &lt; 0.05).,5923799
2726,5923799,vigor,Taekwondo (TKD) ,control,Significantly increased,"Furthermore, after the intervention, the TKD group had a significantly higher vigor score than did the control group (p &lt; 0.05).",5923799
2727,5923799,"tension, depression",Taekwondo (TKD) ,control,Significantly decreased,"Two-way repeated measures ANOVA for mood state revealed no significant interaction between intervention time (before and after) and group (control and TKD) for tension (F = 7.127, p = 0.012), depression (F = 6.964, p = 0.013), and vigor (F = 7.258, p = 0.012).",5923799
2728,5923799,"scores for anger, fatigue, or confusion",Taekwondo (TKD) ,control,No significant difference,"However, there were no significant differences in the scores for anger, fatigue, or confusion (p &gt; 0.05).3.3. Changes in Sociability",5923799
2729,5923799,sociability score,Taekwondo (TKD) ,control,Significantly increased,"Post-hoc tests showed no significant difference before and after the intervention in the control group. In contrast, the TKD group showed a significantly lower â€˜being left outâ€™ score after than before the intervention and a significantly higher sociability score (p &lt; 0.05).",5923799
2730,5923799,"cognitive function for the word , color, or color-word tests",Taekwondo (TKD) ,control,No significant difference,"Two-way repeated measures ANOVA for cognitive function showed no significant interaction for the word (F = 0.971, p = 0.333), color (F = 2.301, p = 0.140), or color-word (F = 0.260, p = 0.614) tests between the intervention time (before and after) and group (control and TKD).",5923799
2731,5307758,proliferation levels of RNA,RT-qPCR,qIHC of Ki-67 or vIHC of Ki-67,Significantly increased,"However, as illustrated in Fig. 4, statistically significant differences between groups were found for the RT-qPCR but not for IHC methods when patients were stratified according to proliferation and pCR (Mannâ€“Whitney pâ€‰=â€‰0.003 and pâ€‰=â€‰0,005 for RT-qPCR and pâ€‰=â€‰0.099 for qIHC and pâ€‰=â€‰0.133 for vIHC).",5307758
2732,3348688,"The bending stiffness anterior-posterior, medial-lateral and the torsional stiffness ",triple injection of 1 mL rhBMP-2/NaCl (4 mg rhBMP-2/ml) (A) ,no injection (B),Significantly increased,The comparison showed an increase in torsional stiffness of the treatment group of 248% to controls (P=0.012). The anterior-posterior bending stiffness revealed an increase of 210% (P=0.007) and the medial-lateral bending stiffness showed an increase of 239% (P=0.002).,3348688
2733,3348688,Connectivity and the compression strength and the maximum axial torque,triple injection of 1 mL rhBMP-2/NaCl (4 mg rhBMP-2/ml) (A) ,no injection (B),No significant difference,There was no significant relation between Connectivity and the compression strength and the maximum axial torque.,3348688
2734,3348688,The trabecular number,triple injection of 1 mL rhBMP-2/NaCl (4 mg rhBMP-2/ml) (A) ,no injection (B),Significantly increased,"The trabecular number (Tb.N.) in the treatment group (A) was significantly increased compared with the control group (B). The percentage difference was 46% (P=0.004), which corresponds to an absolute increase of the mean trabecular number (Tb.N.) by 5â€“6 trabeculae per millimeter",3348688
2735,3348688,"the trabecular spacing (Th.Sp.),",triple injection of 1 mL rhBMP-2/NaCl (4 mg rhBMP-2/ml) (A) ,no injection (B),Significantly decreased,"Regarding the trabecular spacing (Th.Sp.), there were significant differences between the treatment group (A) and the control group (B). Treatment group (A) compared with control group (B) had a lower mean trabecular spacing (Tb.Sp.) by 58% (P=0.022), representing an absolute difference of 0.25 mm.",3348688
2736,3348688,the trabecular thickness,triple injection of 1 mL rhBMP-2/NaCl (4 mg rhBMP-2/ml) (A) ,no injection (B),No significant difference,"For the trabecular thickness (Tb.Th.), there were no significant differences between the treatment group (A) and the control group (B). The maximum trabecular thickness (Tb.Th.) in treatment group (A) reached 0.39 mm compared to 0.35 mm in the control group (Figure 4).",3348688
2737,2797436,"AUCinf (ng h/mL), Cmax, t1/2 in Caucasian and Japanese",5 mg axitinib with 600 mg rifampin, 5 mg axitinib alone,Significantly decreased,Caucasian  AUCinf (ng h/mL)	187	38	20 (16â€“25)  Cmax (ng/mL)	51.1	14.6	28.6 (21.6â€“37.7)  t1/2 (h)a	9.4	1.6	N/AJapanese  AUCinf (ng h/mL)	193	41	21 (17â€“26)  Cmax (ng/mL)	49.2	14.5	29.4 (22.4â€“38.7)  t1/2 (h)a	6.0	3.3	N/A,2797436
2738,2212351,HbA1c levels after 12 months,diabetic meal delivery for 12 months (group M),no intervention,Significantly decreased,"In group M, HbA1c levels decreased significantly from 8.2 Â± 1.2% to 7.4 Â± 0.8% after 12 months (p&lt;0.05),",2212351
2739,2212351,HbA1c levels within 12 months,individual dietary counseling for 12 months (group D),no intervention,Significantly decreased,"n group D, HbA1c levels decreased significantly throughout the entire 12 month period, from 8.5 Â± 1.7% at baseline to 7.4 Â± 1.1% at the endpoint.",2212351
2740,2212351,fasting blood glucose (FBG),diabetic meal delivery for 12 months (group M),no intervention,Significantly decreased,"Similarly, fasting blood glucose (FBG) levels decreased significantly between 1 and 12 months in group M (p&lt;0.05),",2212351
2741,2212351,fasting blood glucose (FBG) levels,conventional dietary education (group C),no intervention,No significant difference,FBG levels decreased significantly from 167 Â± 30 to 128 Â± 26 mg/dl in group M (p&lt;0.05) and from 181 Â± 70 to 145 Â± 45 mg/dl in group D (p&lt;0.01). No significant change was observed in group C.,2212351
2742,2212351,fasting blood glucose (FBG) levels,individual dietary counseling for 12 months (group D),no intervention,Significantly decreased,"Similarly, fasting blood glucose (FBG) levels decreased significantly between 1 and 12 months in group M (p&lt;0.05), and decreased significantly during the entire 12 month period in group D (p&lt;0.01).",2212351
2743,2212351,BMI,individual dietary counseling for 12 months (group D) or diabetic meal delivery for 12 months (group M),conventional dietary education (group C),Significantly decreased,"BMI tended to decrease in groups M and D, but remained unchanged in group C.",2212351
2744,2212351,serum lipids,individual dietary counseling for 12 months (group D) or diabetic meal delivery for 12 months (group M),conventional dietary education (group C),No significant difference,"There were no significant changes in serum lipids levels in the three intervention groups, although serum TG levels were tended to decrease in groups M and D.",2212351
2745,3604854,The mean preoperative refraction and cylinder,low dose intraoperative MMC (LDMMC),standard dose MMC (SDMMC,No significant difference,The mean preoperative refraction in LDMMC eyes was âˆ’3.08 (SD 1.65) sphere and 0.92 (SD 0.88) cylinder. These values for SDMMC eyes were âˆ’3.25 (SD 1.80) sphere and 0.81 (SD 0.84) cylinder.,3604854
2746,3604854,Mean postoperative sphere in 3 and 6 months after PRK.,low dose intraoperative MMC (LDMMC),standard dose MMC (SDMMC,No significant difference,Mean postoperative sphere in LDMMC group was âˆ’0.132 (SD 0.503) and âˆ’0.138 (SD 0.484) in 3 and 6 months after PRK. These results was âˆ’0.041 (SD 0.501) and âˆ’0.076 (SD 0.489) for SDMMC group.,3604854
2747,3604854,Mean postoperative cylinder 3 and 6 month after PRK,low dose intraoperative MMC (LDMMC),standard dose MMC (SDMMC,No significant difference,Mean postoperative cylinder 3 and 6 month after PRK was 0.435 (SD 0.218) and 0.423 (SD 0.255) in LDMMC group and 0.435 (SD 0.247) and 0.426 (SD 0.261) in SDMMC group.,3604854
2748,3604854,haze formation rate,low dose intraoperative MMC (LDMMC),standard dose MMC (SDMMC,No significant difference,Comparison of haze formation rate in these two groups by Mann-Whitney test demonstrated no significant difference in results (P = 0.104 3rd month and P = 0.156 6th month after operation).,3604854
2749,3893543,The seizure recurrence rate over 24 months,listened to Mozart K.448 daily before bedtime for at least six months,control,Significantly decreased,"The seizure recurrence rate was estimated to be significantly lower in the treatment group than the control group over 24 months (37.2% vs. 76.8%, pâ€‰=â€‰0.0109).",3893543
2750,3893543,"epileptiform discharges after 1, 2, and 6 month",listened to Mozart K.448 daily before bedtime for at least six months,baseline,Significantly decreased,"Significant decreases in epileptiform discharges were found after 1, 2, and 6 months of listening to Mozart K.448 when compared with EEGs before listening to music (decreased by 79.4â€‰Â±â€‰20.0%, 71.2â€‰Â±â€‰40.3%, and 82.1â€‰Â±â€‰30.6% respectively, pâ€‰&lt;â€‰0.001).",3893543
2751,3893543,The seizure recurrence rate over 24 months,listened to Mozart K.448 daily before bedtime for at least six months,control,Significantly decreased,"The seizure recurrence rate was estimated to be significantly lower in the treatment group than the control group over 24 months (37.2% vs. 76.8%, pâ€‰=â€‰0.0109).",3893543
2752,3893543,"epileptiform discharges after 1, 2, and 6 month",listened to Mozart K.448 daily before bedtime for at least six months,baseline,Significantly decreased,"Significant decreases in epileptiform discharges were found after 1, 2, and 6 months of listening to Mozart K.448 when compared with EEGs before listening to music (decreased by 79.4â€‰Â±â€‰20.0%, 71.2â€‰Â±â€‰40.3%, and 82.1â€‰Â±â€‰30.6% respectively, pâ€‰&lt;â€‰0.001).",3893543
2753,5460737,Collagen III and IV,mesh repair for the various hernias,laparotomies for various reasons,Significantly increased,"Assessing the results in the case group we had 52.4% of the cases in Grade 4 and 35.7% of the cases in Grade 3 and 11.9% cases in Grade 2 which signifies that there is an increased presence of Collagen 3 in the patients which we have included in our study where as we had an 84.4% of patients in the control group with Grade 1, 4.4% of the patients with Grade 2 and 11.1% with Grade 0. Chi square test value is 81.279 and the p value &lt; 0.001 which is significant.Table 1",5460737
2754,5460737,intensity of staining,mesh repair for the various hernias,laparotomies for various reasons,Significantly increased,In the control group 95% of the slides were included in the mild group and 5% were not stained. Chi square test value was 57.64 and p value is &lt; 0.001 which was significant.,5460737
2755,4053826,pain scores at rest at 8 hours and at 16 hours ,the ropivacaine continuous infusion (the Ropi group),the 0.9% saline continuous infusion (the control group),Significantly decreased,Significant differences in pain scores at rest between the 2 groups were detected at 8 hours (NRS 1.5Â±0.51 for the Ropi group and 2.45Â±0.51 for the control group; P&lt;0.01) and at 16 hours (NRS 1.75Â±0.44 for the Ropi group and 2.1Â±0.31 for the control group; P&lt;0.01).,4053826
2756,4053826,pain score on movement,the ropivacaine continuous infusion (the Ropi group),the 0.9% saline continuous infusion (the control group),No significant difference,"However, there was no difference in pain score on movement between the 2 groups, as shown in Figure 2.",4053826
2757,4053826,The mean total sufentanil consumption at 48 hours ,the ropivacaine continuous infusion (the Ropi group),the 0.9% saline continuous infusion (the control group),Significantly decreased,The mean total sufentanil consumption by the control group at 48 hours was double that of the Ropi group (89.70Â±35.22 Î¼g for the control group vs. 41.50Â±21.80 Î¼g for the Ropi group; P&lt;0.01).,4053826
2758,4053826,"Time to bowel recovery, incidence of nausea/vomiting, mean length of hospitalization",the ropivacaine continuous infusion (the Ropi group),the 0.9% saline continuous infusion (the control group),Significantly decreased,"Time to bowel recovery (1.80Â±0.70 vs. 3.15Â±1.04 d; P&lt;0.01), incidence of nausea/vomiting (1.75Â±0.72 vs. 2.4Â±0.68; P&lt;0.05), and mean length of hospitalization (5.6Â±2.44 vs. 7.35Â±2.85 d; P&lt;0.01) were significantly reduced.",4053826
2759,4053826,patient satisfaction,the ropivacaine continuous infusion (the Ropi group),the 0.9% saline continuous infusion (the control group),No significant difference,"There was no difference with respect to patient satisfaction (Table 2, 3).",4053826
2760,3688436,Young Mania Rating Scale (YMRS) on the first day,donepezil in addition to lithium,placebo in addition to lithium,Significantly decreased,"On the first day, there was a difference of 1.97 units on the psychomotor symptoms scale of the YMRS in the donepezil group as compared to the placebo group (t = 2.39, P = 0.02).",3688436
2761,3688436,speech item and the sexual interest item,donepezil in addition to lithium,placebo in addition to lithium,Significantly decreased,"In the donepezil group, the speech items decreased by 0.57 units more than in the placebo group (t = 2.09, P = 0.04). The sexual interest items in the donepezil group decreased by 0.29 units more than in the placebo group (t = 2.11, P = 0.04).",3688436
2762,3688436,YMRS and the BPRS scale over the course of 4 weeks,donepezil in addition to lithium,placebo in addition to lithium,No significant difference,"Over the course of the 4 weeks, we failed to find that donepezil produced any significant difference in the YMRS as compared to placebo (see Table 3). Both the donepezil and placebo group produced a significant improvement in total scores on the YMRS from baseline to endpoint (donepezil group: t = 4.54, P &lt; 0.0001; placebo group: t = 9.06, P &lt; 0.0001).",3688436
2763,4715405,"mean level of blood glucose, 2 hours after lunch at 28 weeks of pregnancy",telephone intervention was performed for 10 weeks,three times of telephone call was established to record blood sugar levels,Significantly decreased,MeanÂ±SD level of blood glucose 2 hours after lunch at 28 weeks of pregnancy was 137.5Â±25.7 mg/dl in control and 123Â±18 mg/dl in intervention group (p=0.008).,4715405
2764,4715405,MeanÂ±SD level of blood glucose 2 hours after breakfast at 28 weeks of pregnancy,telephone intervention was performed for 10 weeks,three times of telephone call was established to record blood sugar levels,No significant difference,MeanÂ±SD level of blood glucose 2 hours after breakfast at 28 weeks of pregnancy was 131.2Â±20.9 mg/dl in control and 123.2Â±18.8 mg/dl in intervention group (p=0.058).,4715405
2765,4715405,MeanÂ±SD level of blood glucose before sleeping at 28 weeks of pregnancy,telephone intervention was performed for 10 weeks,three times of telephone call was established to record blood sugar levels,No significant difference,MeanÂ±SD level of blood glucose before sleeping at 28 weeks of pregnancy was 124.7Â±13.9 mg/dl in control and 113.2Â±15.8 mg/dl in intervention group (p=0.1).,4715405
2766,4715405,MeanÂ±SD of differences in levels of fasting blood glucose between 28 and 32 weeks and between 28 and 36 weeks of pregnancy,telephone intervention was performed for 10 weeks,three times of telephone call was established to record blood sugar levels,Significantly increased,MeanÂ±SD of differences in levels of fasting blood glucose between 28 and 32 weeks and between 28 and 36 weeks of pregnancy were significantly higher in the intervention than the control group (p&lt;0.05).,4715405
2767,4715405,Rate of postpartum glucose screening test,telephone intervention was performed for 10 weeks,three times of telephone call was established to record blood sugar levels,Significantly increased,Rate of postpartum glucose screening test was significantly higher in the intervention group (P&lt;0.001).,4715405
2768,5735486,number of patients and dosage of esmolol,Group F receiving preoperative flupirtine,Group C receiving identical-looking placebo,Significantly decreased,"Again to ensure induced hypotension, dose of esmolol and the number of patients treated with it were significantly higher (P &lt; 0.05) in Group C than F [Table 1].",5735486
2769,5735486,Nasal bleeding score and subsequently surgeon's satisfaction score,Group F receiving preoperative flupirtine,Group C receiving identical-looking placebo,Significantly increased,Nasal bleeding score and subsequently surgeon's satisfaction score both were significantly (P &lt; 0.05) better in flupirtine-treated group than control group [Table 5].,5735486
2770,5735486,Side effects ,Group F receiving preoperative flupirtine,Group C receiving identical-looking placebo,No significant difference,Side effects were all comparable between two groups (P &gt; 0.05) [Table 6].,5735486
2771,5735486,MAP and HR,Group F receiving preoperative flupirtine,Group C receiving identical-looking placebo,No significant difference,MAP and HR between two groups were found to be quite comparable among two groups (P &gt; 0.05) [Figures 1 and 2].,5735486
2772,4972969, number of patients per provider per month from Time 0 to Time 1,on-site support (OSS),Control,No significant difference,"As shown in Table&nbsp;3, pre/post change in the number of patients per provider per month from Time 0 to Time 1 among the IMID-MLP subgroup was higher in the Arm A (adjusted relative risk (aRR)â€‰=â€‰1.15, 99 % CIâ€‰=â€‰0.72-1.85, pâ€‰=â€‰0.437) than in Arm B (aRRâ€‰=â€‰0.96, 99 % CIâ€‰=â€‰0.57-1.62, pâ€‰=â€‰0.828), and the effect of OSS in this subgroup was not statistically significant (adjusted RRR (aRRR)â€‰=â€‰1.21; 99 % CIâ€‰=â€‰0.61-2.38, pâ€‰=â€‰0.478).",4972969
2773,4972969,estimated proportion of emergency patients who received at least one appropriate treatment,on-site support (OSS),Control,Significantly increased,"increases in the estimated proportion of emergency patients who received at least one appropriate treatment (Indicator 3, aRRRâ€‰=â€‰2.00; 99 % CIâ€‰=â€‰1.11-3.79, pâ€‰=â€‰0.003)",4972969
2774,4972969,proportion of patients with a negative malaria test result prescribed an antimalarial,on-site support (OSS),Control,Significantly decreased,"decrease in proportion of patients with a negative malaria test result prescribed an antimalarial (Indicator 6, aRRRâ€‰=â€‰0.65, 99 % CIâ€‰=â€‰0.44-0.98, pâ€‰=â€‰0.006).",4972969
2775,4972969,estimated proportion of malaria cases who received an appropriate antimalarial  in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group,on-site support (OSS),Control,Significantly increased,"Within the IMID-MLP, the incremental effect of OSS was statistically significant for three indicators; increases in estimated proportion of malaria cases who received an appropriate antimalarial (Indicator 5, aRRRâ€‰=â€‰1.26, 99 % CIâ€‰=â€‰1.02-1.56, pâ€‰=â€‰0.005)",4972969
2776,4972969,estimated proportion of patients with acid-fast bacilli (AFB) smear negative results who received empiric treatment for acute respiratory infection  in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group,on-site support (OSS),Control,Significantly increased,"estimated proportion of patients with acid-fast bacilli (AFB) smear negative results who received empiric treatment for acute respiratory infection (indicator 11, aRRRâ€‰=â€‰2.04, 99 % CIâ€‰=â€‰1.06-3.94, pâ€‰=â€‰0.005)",4972969
2777,4972969,proportion of patients with a negative malaria test result prescribed an antimalarial  in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group,on-site support (OSS),Control,Significantly decreased,"decrease in proportion of patients with a negative malaria test result prescribed an antimalarial (Indicator 6, aRRRâ€‰=â€‰0.49, 99 % CIâ€‰=â€‰0.26-0.92, pâ€‰=â€‰0.004).",4972969
2778,4972969,"Within the No-IMID subgroup - the proportion of emergency and priority patients admitted, detained or referred",on-site support (OSS),Control,Significantly increased,"Within the No-IMID subgroup, the incremental effect of OSS was statistically significant for only two indicators; increases in the proportion of emergency and priority patients admitted, detained or referred (Indicator 2, aRRRâ€‰=â€‰2.12, 99 % CIâ€‰=â€‰1.05-4.28, pâ€‰=â€‰0.006), and estimated proportion of emergency patients who received at least one appropriate treatment (Indicator 3, aRRRâ€‰=â€‰1.98, 99 % CIâ€‰=â€‰1.21-3.24, pâ€‰&lt;â€‰0.001).",4972969
2779,4972969,Within the No-IMID subgroup - estimated proportion of emergency patients who received at least one appropriate treatment,on-site support (OSS),Control,Significantly increased,"Within the No-IMID subgroup, the incremental effect of OSS was statistically significant for only two indicators; increases in the proportion of emergency and priority patients admitted, detained or referred (Indicator 2, aRRRâ€‰=â€‰2.12, 99 % CIâ€‰=â€‰1.05-4.28, pâ€‰=â€‰0.006), and estimated proportion of emergency patients who received at least one appropriate treatment (Indicator 3, aRRRâ€‰=â€‰1.98, 99 % CIâ€‰=â€‰1.21-3.24, pâ€‰&lt;â€‰0.001).",4972969
2780,5579675,fatty acid oxidation (FAO),2 g of YM,placebo (PLC),Significantly increased,"The YM treatment elicited significantly higher FAO compared with PLC during the 30-min steady-state exercise (ANOVA treatment effects, p = 0.037), (Figure 1).",5579675
2781,5579675,crossover point intensity (COP),2 g of YM,placebo (PLC),Significantly decreased,"However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p &lt; 0.001).",5579675
2782,5579675,total AUC for Total Energy Expenditure (TEE),2 g of YM,placebo (PLC),Significantly increased,"However, the total AUC for TEE was higher (85.60 vs. 82.13, p &lt; 0.001) in YM than PLC.",5579675
2783,5579675,HR,2 g of YM,placebo (PLC),No significant difference,"HR was not different between the treatments, but the time had significant effects (p &lt; 0.001), (Figure 4).",5579675
2784,5579675," Hunger, Prospective eating, desire to eat (Pre, immediately before, after, and 30 min post exercise).",2 g of YM,placebo (PLC),Significantly decreased,"There were significant treatment effects (YM vs. PLC) on VAS measures of Hunger (p = 0.019), Prospective eating (p = 0.022), and a trend towards a reduced desire to eat (p = 0.079) for exercise (Pre, immediately before, after, and 30 min post exercise).",5579675
2785,5579675,prospective eating score,2 g of YM,placebo (PLC),Significantly decreased,"When analyzing the resting data only (immediately pre-ingestion 0 to 120 min rest duration), only prospective eating score was slightly reduced (p = 0.046) at YM treatment compared with PLC",5579675
2786,2430617,HBeAg sero-conversion rate,60 Âµg of  immune complexes (YIC),placebo,Significantly decreased,"Statistical significance was not reached in primary endpoints four weeks after the end of treatment among three groups, however, at the end of follow-up, HBeAg sero-conversion rate was 21.8%(17/78) and 9% (7/78) in the 60 Âµg YIC and placebo groups respectively (pâ€Š=â€Š0.03), with 95% confidence intervals at 1.5% to 24.1%.",2430617
2787,2430617,adverse events,"30 Âµg YIC, 60 Âµg of YIC",placebo,No significant difference,"The occurrence of serious adverse events calculated according to the intent-to-treat principle was 5.1% (4/79), 3.6% (3/83), and 5.0% (4/80) in the placebo, 30 Âµg YIC and 60 Âµg YIC groups respectively (p&gt;0.05).",2430617
2788,4884260,analgesic requirement,Caudal Group received 1 ml/kg of 0.25% bupivacaine,Local Infiltration Group received 0.2 ml/kg 0.25% bupivacaine,Significantly decreased,Only one in 28 of the caudal group received acetaminophen on ward and neither one of 26 from the local group received acetaminophen on ward. The difference between groups for analgesic requirement is statistically significant p&lt;0.05.,4884260
2789,4884260,first analgesic administration,Caudal Group received 1 ml/kg of 0.25% bupivacaine,Local Infiltration Group received 0.2 ml/kg 0.25% bupivacaine,No significant difference,Time to first analgesic administration was not statistically significant p=0.40.,4884260
2790,5079604,Hyperglycemia relapse-free survival,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,Significantly increased,Hyperglycemia relapse-free survival was significantly higher in the metformin and sitagliptin groups than in the placebo group (P = 0.015) (Fig. 1).,5079604
2791,5079604,The 2-year failure rate,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,Significantly decreased,"The 2-year failure rate was higher in the placebo than in the sitagliptin (77% vs. 44%, P = 0.113) or metformin (77% vs. 34%, P = 0.013) groups.",5079604
2792,5079604, hyperglycemia relapse-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,No significant difference,"However, there was no difference in hyperglycemia relapse-free survival between metformin and sitagliptin (P = 0.75)",5079604
2793,5079604,The restricted mean time to hyperglycemia relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,Significantly increased,"The restricted mean time to hyperglycemia relapse in the combined metformin and sitagliptin groups was significantly higher than placebo (480 vs. 305 days, P = 0.004).",5079604
2794,5079604,Cox proportional hazards of failure-free survival,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,Significantly decreased,"Cox proportional hazards of failure-free survival among metformin, sitagliptin, and placebo in obese African American patients presenting with DKA and severe hyperglycemia. A significant difference was found among the placebo, metformin, and sitagliptin groups (P = 0.015), but no significant difference was found between the sitagliptin and metformin groups (P = 0.75).",5079604
2795,5079604,Cox proportional hazards of failure-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,No significant difference,"Cox proportional hazards of failure-free survival among metformin, sitagliptin, and placebo in obese African American patients presenting with DKA and severe hyperglycemia. A significant difference was found among the placebo, metformin, and sitagliptin groups (P = 0.015), but no significant difference was found between the sitagliptin and metformin groups (P = 0.75).",5079604
2796,5079604,The probability of relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,Significantly decreased,The probability of relapse was significantly lower for metformin (hazard ratio 0.28 [95% CI 0.10â€“0.81]) and sitagliptin (0.31 [0.10â€“0.98]) than for placebo.,5079604
2797,5079604,Disposition index (DI) and incremental area under the curve for insulin (AUCi) ,subjects who remained in remission,patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si),Significantly increased,Subjects who remained in remission had a higher DI (P = 0.02) and incremental AUCi (P &lt; 0.001) than those with hyperglycemia relapse without significant changes in Si.,5079604
2798,3329100,"volume of O2 maximum (VO2max), systolic blood pressure (SBP) , white blood cell (WBC) and diastolic blood pressure (DBP)",8-week interval training (60-79% HR max reserve) program of between 45 minutes to 60 minutes,the age-matched controls hypertensive  group,Significantly decreased,"The Table 2 ANCOVA test results indicated a significant reduction in the exercise groups over control in SBP (P=0.000), DBP (P=0.000), WBC (P=0.001), and VO2 max (P=0.000) at P&lt;0.05.",3329100
2799,4918317,The survival times,Long-chain omega-3 polyunsaturated fatty acids (PUFAs),placebo,Significantly increased,"The survival times were significantly different between the treatment groups, with a more rapid conversion time for the placebo group compared with the omega-3 PUFA group (log-rank test: Ï‡2=9.84, P=0.002) (Fig. 2).",4918317
2800,4918317,functioning  at longer-term follow-up,Long-chain omega-3 polyunsaturated fatty acids (PUFAs),placebo,Significantly increased,"The survival times were significantly different between the treatment groups, with a more rapid conversion time for the placebo group compared with the omega-3 PUFA group (log-rank test: Ï‡2=9.84, P=0.002) (Fig. 2).",4918317
2801,4918317,Positive and Negative Syndrome (PANS) Scale,Long-chain omega-3 polyunsaturated fatty acids (PUFAs),placebo,Significantly decreased,"For the PANSS measures, interactions between medication group and occasion were significant for positive (F4,133.6=4.48, P=0.002), general (F4,125.3=4.52, P=0.002) and total scores (F4,125.0=4.59, P=0.002), and were trending towards significance for the negative scores (F4,129.4=2.16, P=0.077).",4918317
2802,5781260,exercise-related loss of muscle strength,lemon verbena extract,placebo,Significantly decreased,"MVC was significantly less reduced after exercise in the lemon verbena group than in the placebo group (p&nbsp;=â€‰0.0311), with significant time effect (p&nbsp;=â€‰0.0051), (Fig.&nbsp;2, Table&nbsp;3).",5781260
2803,5781260,Movement induced pain (VAS),lemon verbena extract,placebo,No significant difference,"Movement induced pain (VAS) in the lemon verbena group was less pronounced by trend (p&nbsp;=â€‰0.0788) with a significant time effect (p&nbsp;&lt;â€‰0.0001) in comparison to the placebo group (Fig.&nbsp;3, Table 3).",5781260
2804,5781260,Exercise-induced Creatine kinase (CK),lemon verbena extract,placebo,No significant difference,"Exercise-induced CK was not significantly different between groups (p&nbsp;=â€‰0.9412 with significant time effect (pâ€‰&lt;â€‰0.0001) (Fig.&nbsp;5, Table 3).Fig. 5",5781260
2805,5781260,Glutathione peroxidase (GPxP),lemon verbena extract,placebo,No significant difference,"The GPxP activity within lemon verbena group was increased by trend compared to placebo group (p&nbsp;=â€‰0.0681), with time effect also by trend (p&nbsp;=â€‰0.0624), (Fig.&nbsp;6, Table 3).Fig. 6",5781260
2806,5781260,Interleukin 6,lemon verbena extract,placebo,No significant difference,"Only distinct increase of IL-6 could be observed after exercise, without significant differences but high inter-individual variability. Differences between groups were not significant (p&nbsp;=â€‰0.5824).",5781260
2807,5781260,adverse events,lemon verbena extract,placebo,No significant difference,There was no statistical difference between the two groups for adverse events (p&nbsp;=â€‰0.231).,5781260
2808,5491994,physicianâ€™s explanation of their treatment,"explanation of patients anatomy, disease state, and treatment options using the education model as an aid",control group,Significantly increased,"Statistically significant improvements in patient ratings of their physicianâ€™s explanation of their treatment options (p = 0.020), self-rated anatomical understanding (p = 0.043), self-rated understanding of disease state (p = 0.016), and effectiveness of the visualization (p = 0.007) were noted from the population that viewed the 3D education model, indicating it is an effective tool which ENT surgeons may use to educate and interact with patients.",5491994
2809,5491994,self-rated understanding of disease stat,"explanation of patients anatomy, disease state, and treatment options using the education model as an aid",control group,Significantly increased,"Statistically significant improvements in patient ratings of their physicianâ€™s explanation of their treatment options (p = 0.020), self-rated anatomical understanding (p = 0.043), self-rated understanding of disease state (p = 0.016), and effectiveness of the visualization (p = 0.007) were noted from the population that viewed the 3D education model, indicating it is an effective tool which ENT surgeons may use to educate and interact with patients.",5491994
2810,5491994,effectiveness of the visualization,"explanation of patients anatomy, disease state, and treatment options using the education model as an aid",control group,Significantly increased,"Statistically significant improvements in patient ratings of their physicianâ€™s explanation of their treatment options (p = 0.020), self-rated anatomical understanding (p = 0.043), self-rated understanding of disease state (p = 0.016), and effectiveness of the visualization (p = 0.007) were noted from the population that viewed the 3D education model, indicating it is an effective tool which ENT surgeons may use to educate and interact with patients.",5491994
2811,5491994,rating the quality of the physicianâ€™s explanation,"explanation of patients anatomy, disease state, and treatment options using the education model as an aid",control group,Significantly increased,"Patient responses in the 3D model group increased significantly when rating the quality of the physicianâ€™s explanation, their own understanding of their anatomy, their own understanding of their disease state, and their understanding of the proposed surgical treatment.",5491994
2812,4247720,the rate of memory retention,cognitive intervention through a training program for picture book reading for community-dwelling older adults.,control group,Significantly increased,Simple main effects showed that the rate of memory retention of the intervention group improved after the program completion (pâ€‰&lt;â€‰.05).,4247720
2813,4247720,rate of retention,cognitive intervention through a training program for picture book reading for In the participants with mild cognitive impairment (MCI),control group,Significantly increased,Simple main effects showed that the rate of retention of the intervention group improved after the program completion (p =0.012).,4247720
2814,3757993,The mean number of login attempts,multimedia intervention,control,Significantly increased,"The mean number of login attempts of the intervention group mean was 2.64 (SD 3.17, median 2.0) and the control group was 1.63 (SD 2.14, median 1.0). The difference between intervention and control groups login was statistically significant as expected since the intervention group was asked to set goals (Wilcoxon two-sample test, P=.0003).",3757993
2815,3757993,INTERHEART risk score (IHRS),multimedia intervention,control,Significantly decreased,"Comparing follow-up to baseline score change, the intervention group had a significant reduction in their IHRS score at follow-up (intervention group baseline IHRS: mean 13.4, SD 5.8; follow-up IHRS: mean 12.1, SD 5.9, P=.002), and a trend was seen in the control group (baseline IHRS: mean 12.6, SD 5.8; follow-up IHRS: mean 11.7, SD 5.9, P=.05) (see Table 2), though these results were not statistically significant.",3757993
2816,3757993,"changes in diet, physical activity, and weight loss",multimedia intervention,control,Significantly decreased,"Overall, more than 13.9% (51/367) of participants progressed from inactive (precontemplation, contemplation, and preparation) to the active (action, maintenance) stage in diet and physical activity, and 12.5% (46/367) progressed to the active stage in weight loss plans; however, no significant differences were observed between intervention and control groups (Table 6).",3757993
2817,4450208,pretestâ€“posttest change, a program of emotional intelligence (EI) 20 one-hour sessions,control,Significantly increased,"The results of the MANCOVA carried out with the pretestâ€“posttest differences in all the variables, with the pretest scores as covariates, revealed statistically significant differences between the experimental and control groups, Wilksâ€™ Lambda Î› = 0.345, F(15,117) = 14.81, p &lt; 0.001, with a large effect size (Î·2 = 0.655, r = 0.81).",4450208
2818,4450208,the effects of the program 1 year after completing the intervention, a program of emotional intelligence (EI) 20 one-hour sessions,control,Significantly increased,"The results of the MANCOVA on the pretest-follow-up differences in the set of assessed variables, with the pretest scores as covariates, showed statistically significant differences between the experimental and control groups, Wilksâ€™ Lambda Î› = 0.453, F(15,99) = 7.97, p &lt; 0.001, with a medium-high effect size (Î·2 = 0.547, r = 0.74).",4450208
2819,4450208,"attention, clarity, emotional repair, assertive cognitive social interaction strategies, internal control of anger and the cognitive ability to analyze negative feelings", a program of emotional intelligence (EI) 20 one-hour sessions,control,Significantly increased,"The pretestâ€“posttest ANCOVAs showed that the program significantly increased: (1) EI (attention, clarity, emotional repair); (2) assertive cognitive social interaction strategies; (3) internal control of anger; and (4) the cognitive ability to analyze negative feelings.",4450208
2820,4450208,the use of aggressive strategies as an interpersonal conflict-resolution technique, a program of emotional intelligence (EI) 20 one-hour sessions,control,Significantly decreased,"In the follow-up phase, the positive effects of the intervention were generally maintained and, moreover, the use of aggressive strategies as an interpersonal conflict-resolution technique was significantly reduced.",4450208
2821,4450208,"assertive social interaction strategies, attention, and emotional clarity", a program of emotional intelligence (EI) 20 one-hour sessions - boys, a program of emotional intelligence (EI) 20 one-hour sessions - girls,Significantly increased,"Regarding the effect of the program on both genders, the change was very similar, but the boys increased assertive social interaction strategies, attention, and emotional clarity significantly more than the girls.",4450208
2822,3831918,"retrograde shear rate, diastolic antegrade shear rate, and consequently mean shear rate","pneumatic cuff was applied to the calf and inflated to 0, 35, and 70 mmHg",baseline,Significantly decreased,"There were significant differences in retrograde shear rate, diastolic antegrade shear rate, and consequently mean shear rate across conditions (Table 3 and Fig. 1, P &lt; 0.05).",3831918
2823,3831918,retrograde shear,pneumatic cuff was applied to the calf and inflated to 70 mmHg,pneumatic cuff was applied to the calf and inflated to 0 mmHg,Significantly increased,"There were significant differences in retrograde shear rate, diastolic antegrade shear rate, and consequently mean shear rate across conditions (Table 3 and Fig. 1, P &lt; 0.05).",3831918
2824,3831918,diastolic antegrade and mean shear,pneumatic cuff was applied to the calf and inflated to 70 mmHg,pneumatic cuff was applied to the calf and inflated to 0 mmHg,Significantly decreased,"whereas diastolic antegrade and mean shear were lower during the 70-mmHg compression condition compared to the 0-mmHg compression condition (Table 3, P &lt; 0.05).",3831918
2825,3831918,"pulse wave velocit (PWV), elastic modulus (Ep),  forward expansion wave that decelerates flow and reduces pressure (W2), negative area (NA), and (RC) reflection coefficient ",pneumatic cuff was applied to the calf and inflated to 70 mmHg,pneumatic cuff was applied to the calf and inflated to 0 mmHg,Significantly increased,Post hoc pair-wise comparisons revealed significantly higher values for these parameters during the 70-mmHg compression condition compared with the 0-mmHg compression condition (P &lt; 0.05).,3831918
2826,3166670,numbers of positive proton pump inhibitor (PPI) test,"lansoprazole at a dose of 15 mg, 30 mg or 60 mg once daily - erosive reflux disease (ERD)","15 mg, 30 mg or 60 mg once daily - non-erosive reflux disease (ERD)",No significant difference,A positive PPI test was observed 93.2% of the ERD group and 87.2% of the NERD group during 2 weeks treatment (Table 2). There was no difference between two groups (p&gt;0.05).,3166670
2827,3166670,numbers of positive proton pump inhibitor (PPI) test,"lansoprazole at a dose of 15 mg, 30 mg once daily ",lansoprazole at a dose of  60 mg once daily ,No significant difference,"A positive PPI test by dosage of lansoprazole was noted 91.7% in 15 mg group, 89.7% in 30 mg group, and 87.2% in 60 mg of lansoprazole group (p&gt;0.05, Table 4, Fig. 3).",3166670
2828,5297995,coronal growth of approximal gingival margin on the neighboring teeth,zirconia implant abutments,stock,No significant difference,"There was no statistically significant difference between stock (0.24 mm; 95% CI [âˆ’0.09 mm; 0.57 mm]; SD 0.77 mm) and CAD/CAM customized abutments (0.40 mm; 95% CI [âˆ’0.01 mm; 0.81 mm] SD 0.99 mm, Table 3).",5297995
2829,5297995,"embarrassment and problems with taste, speech, gum color, tooth color and the visibility of the implant",followâ€�up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration,After the intake (T 0) and implant placement,Significantly increased,"Patients experienced significantly less embarrassment and problems with taste, speech, gum color, tooth color and the visibility of the implant at T 1 (pâ€‰&lt;â€‰.01) and T 12 (pâ€‰&lt;â€‰.05) than they had expected at T 0.",5297995
2830,5297995,bone apposition,zirconia implant abutments,stock,No significant difference,"The difference in bone apposition between the 2 groups (stock: 0.06 mm, 95% CI [âˆ’0.05 mm; 0.16 mm], standard deviation 0.23mm versus CAD/CAM customized: 0.11 mm, 95% CI [0.02 mm; 0.20 mm]; standard deviation 0.20 mm) was not statistically significant.",5297995
2831,5297995,coronal growth of approximal gingival margin on the neighboring teeth,followâ€�up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration,After the intake (T 0) and implant placement,Significantly increased,"Clinical examination revealed a significant (Tâ€‰=â€‰24; pâ€‰&lt;â€‰.05) coronal growth of approximal gingival margin (0.32 mm; 95% CI [0,06 mm; 0,58mm]; SD 0.88 mm) on the neighboring teeth after 12 months.",5297995
2832,5483302,Small dense low-density lipoprotein cholesterol (sd-LDL-C) level at 52wks,ezetimibe (10&nbsp;mg) add-on statin (EAT),double-dose statin (DST) ,Significantly decreased,This sd-LDL outcome (36.1&nbsp;Â±&nbsp;14.9&nbsp;mg/dl at 52&nbsp;weeks) was significantly lower than those in the DST Group (45.6&nbsp;Â±&nbsp;13.4&nbsp;mg/dl at 52wk). The sd-LDL-C level at 52wks were significantly different (p&nbsp;=&nbsp;0.0035). (Fig. 3C),5483302
2833,3626705,The median progression-free survival (PFS),oral trametinib (2&nbsp;mg once daily),"intravenous chemotherapy consisting of either dacarbazine (1000&nbsp;mg/m2) or paclitaxel (175&nbsp;mg/m2), every 3&nbsp;weeks",Significantly increased,The median progression-free survival (PFS) of patients who received trametinib (4.8&nbsp;months) was significantly longer than that of patients who received chemotherapy (1.5&nbsp;months) (hazard ratio [HR] 0.45; Pâ€‰&lt;â€‰0.001).,3626705
2834,3626705,"At 6 months, the rate of overall survival",oral trametinib (2&amp;nbsp;mg once daily),"intravenous chemotherapy consisting of either dacarbazine (1000mg/m2) or paclitaxel (175mg/m2), every 3weeks",Significantly increased,"At 6&nbsp;months, the rate of overall survival was 81% in the trametinib group versus 67% in the chemotherapy group (HR 0.54; Pâ€‰=â€‰0.01).",3626705
2835,3626705,Median overall survival (OS),docetaxel plus selumetinib (75mg twice daily q21 days),docetaxel plus placebo,No significant difference,"Median OS was 9.4&nbsp;months (m) in selumetinib arm vs 5.2&nbsp;m in control arm, yet the difference was statistically non-significant (HR 0.8, 80% CI 0.56-1.14, pâ€‰=â€‰0.21).",3626705
2836,4888158,The antimicrobial activity,2% CHX,baseline,Significantly increased,Statistical analyses showed a significant relationship between the filling material and residual antimicrobial activity of CHX (P&lt;0.05).,4888158
2837,4888158,residual antimicrobial activity of CHX at one week and at three and six weeks,gutta-percha/AH26 , Resilon/RealSeal SE samples,Significantly increased,"The results showed that residual antimicrobial activity of CHX was significantly higher in gutta-percha/AH26 samples than in Resilon/RealSeal SE samples (P=0.02 at one week and P=0.003 at three and six weeks, respectively).",4888158
2838,4888158,Residual antimicrobial activity,gutta-percha/AH26 negative control - one week	,baseline -  three weeks and six weeks,Significantly increased,"In gutta-percha/AH26 negative control, the differences between one week and two other time points were statistically significant (P&lt;0.001).",4888158
2839,4888158,Residual antimicrobial activity,Resilon/RealSeal SE negative control - one week,Resilon/RealSeal SE negative control - six weeks,Significantly increased,"In Resilon/RealSeal SE negative control, only the difference between one week and six weeks was statistically significant (P=0.02).",4888158
2840,5722109,success rate of inferior alveolar nerve block (IANB) in posterior mandible teeth with symptomatic irreversible pulpitis.,3.2 mL 4% articaine with epinephrine 1:200000 and 0.4 mL 50 mg/mL ketamine hydrochloride (A-ketamine group),epinephrine 1:200000 and 0.4 mL normal saline (A-saline group),No significant difference,There was no statistically significant difference in success rates between the two groups (P=0.437).,5722109
2841,5422432,Story recall improved at post-intervention,Active experiencing (AE),control,Significantly increased,"Story recall improved at post-intervention (mean = 0.32, p &lt; 0.001, Î±â€™ = 0.01; BS 95% CI: 0.21/0.42)",5422432
2842,5422432,thematic recall,Active experiencing (AE),control,Significantly increased,"as did thematic recall (mean = 0.18, p = 0.03, Î±â€™ = 0.01; BS 95% CI: 0.04/0.32)",5422432
2843,5422432,nominal gains at post-intervention,Active experiencing (AE),control,Significantly increased,"Task switching also showed nominal gains at post-intervention (mean = 0.14, p = 0.04, Î±â€™ = 0.01)",5422432
2844,5422432,nominal gains at follow-up,Active experiencing (AE),control,Significantly increased,"Task switching also showed nominal gains at post-intervention (mean = 0.14, p = 0.04, Î±â€™ = 0.01) and follow-up (mean = 0.16, p = 0.04, Î±â€™ = 0.01)",5422432
2845,5422432,category fluency at follow-up,Active experiencing (AE),control,Significantly increased,"whereas category fluency only improved at follow-up (0.21, p = 0.005, Î±â€™ = 0.01; BS 95% CI: 0.09/0.36).",5422432
2846,5422432,gains in episodic memory,Active experiencing (AE),control,Significantly increased,"The AE intervention produced greater gains in episodic memory than Active Control. Grouped models of episodic memory had excellent fit (story and thematic recall, respectively): Ï‡(62)2 = 78.51 and 65.78, p = 0.08 and 0.35 (AE = 39.49 and 43.23; Active Control = 39.02 and 22.55); CFI = 0.97 and 0.99; RMSEA = 0.06 and 0.03; SRMR = 0.06.",5422432
2847,5422432,story recall at post-intervention,Active experiencing (AE),baseline,Significantly increased,"The AE condition experienced significant improvement in story recall at post-intervention (0.44, p &lt; 0.001; BS 95% CI: 0.31/0.59)",5422432
2848,5422432,story recall at post-intervention,Active Control,baseline,No significant difference,"The AE condition experienced significant improvement in story recall at post-intervention (0.44, p &lt; 0.001; BS 95% CI: 0.31/0.59) and a trend for the same at follow-up (0.20, p = 0.05, BS 95% CI: 0.04/0.37) whereas the Active Control group showed no significant change in performance over the study (Table 3).",5422432
2849,5586978,Anal exsufflation time,The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A,conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B,Significantly decreased,"Anal exsufflation time in group A and group B were 1.21Â±0.48 day and 2.12Â±0.82 day, respectively, and there were significant differences between the two groups (p&lt;0.05).",5586978
2850,5586978,The visual analog scale (VAS) scores,The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A,baseline,Significantly increased,The VAS scores had significant differences between one week after surgery and before surgery in group A (p&lt;0.05),5586978
2851,5586978,The visual analog scale (VAS) scores,conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B,baseline,No significant difference,but the difference was not significant in group B (p&gt;0.05).,5586978
2852,5586978, the VAS scores after surgery,The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A,conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B,Significantly increased,"After surgery, the VAS scores in group A were better than that in group B (P&lt;0.05), while the Cobb angle and ESR of the two groups showed no difference.",5586978
2853,5586978,Postoperative nerve compression symptoms ,The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A,conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B,No significant difference,But there were no significant differences between group A and group B (p&gt;0.05).,5586978
2854,4631853,"systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP) and saturation levels","propofol (1.5â€‰mg/kg) in Group Î™, remifentanil (0.05â€‰Î¼g/kg) + propofol (1.5â€‰mg/kg) combination in Group II",fentanyl (1â€‰Î¼g/kg) + propofol (1.5â€‰mg/kg) combination in Group III,No significant difference,"No statistically significant differences were detected between the groups in terms of changes in SAP, DAP, MAP, and saturation levels throughout the follow-up (monitorization) (p &gt; 0.05).",4631853
2855,4631853,changes in Ramsey scores,"propofol (1.5â€‰mg/kg) in Group Î™, remifentanil (0.05â€‰Î¼g/kg) + propofol (1.5â€‰mg/kg) combination in Group II",fentanyl (1â€‰Î¼g/kg) + propofol (1.5â€‰mg/kg) combination in Group III,Significantly increased,The differences between the groups in terms of the changes in Ramsey scores were not statistically significant either (p &gt; 0.0033) (Table 2).,4631853
2856,4631853,total propofol doses,"propofol (1.5â€‰mg/kg) in Group Î™, remifentanil (0.05â€‰Î¼g/kg) + propofol (1.5â€‰mg/kg) combination in Group II",fentanyl (1â€‰Î¼g/kg) + propofol (1.5â€‰mg/kg) combination in Group III,Significantly increased,"In terms of total propofol doses administered during the follow-up (monitorization), the difference between Group I and Group II and between Group I and Group III and Groups II and III was statistically significant (p &lt; 0.001) (p &lt; 0.003).",4631853
2857,4631853,pain level,"propofol (1.5â€‰mg/kg) in Group Î™, remifentanil (0.05â€‰Î¼g/kg), fentanyl (1â€‰Î¼g/kg) + propofol (1.5â€‰mg/kg) combination in Group III",propofol (1.5â€‰mg/kg) combination in Group II ,Significantly increased,"Also there was statistically significant difference between the groups during the follow-up (monitorization) period in terms of pain levels (p &lt; 0.05). The patients in Group I suffered from the pain most, whereas the patients in Group II had the least pain (Table 3).",4631853
2858,4631853,pain level,"propofol (1.5â€‰mg/kg) in Group Î™, remifentanil (0.05â€‰Î¼g/kg)",propofol (1.5â€‰mg/kg) combination in Group II ,Significantly increased,Comparison of severe pain levels during the follow-up (monitorization) period indicated a statistically significant difference between Group I and Group II (p &lt; 0.05).,4631853
2859,5870330,fracture resistance,G4 was prepared with the occlusal extension of 1mm in depth and width. G5: The occlusal extension was 1mm in depth and 2 mm in width,G3 was prepared with an occlusal extension that extended one-third of buccolingual width and 2 mm in depth,Significantly increased,"Furthermore, the results of this study showed that the fracture resistance of G4 and G5 (MOD1 and MOD2) was significantly higher than G3 (standard MOD)(P &lt; 0.05), where in both groups, the preparation of the occlusal extension mostly remained in the enamel layer [Table 2].",5870330
2860,5870330,fracture resistance,G4 was prepared with the occlusal extension of 1mm in depth and width. G5: The occlusal extension was 1mm in depth and 2 mm in width,G6: The occlusal extension was 2 mm in depth and 1 mm in width.,Significantly increased,"In addition, the fracture resistance of G4 and G5 (MOD1, MOD2) was significantly higher G6 (MOD3) where the preparation of the occlusal extension was 2 mm in the depth and the width (P &lt; 0.05) [Table 2].",5870330
2861,5870330,fracture resistance,G3 was prepared with an occlusal extension that extended one-third of buccolingual width and 2 mm in depth,G6: The occlusal extension was 2 mm in depth and 1 mm in width.,No significant difference,"However, there was no significant difference between G3 and G6 (MOD3) where both groups had the lowest fracture resistance meansâ€™ values (522 N and 628 N), respectively, among all the groups (P &gt; 0.05) [Table 2].",5870330
2862,5126155,The effective pacing rate immediately after the procedure,"pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)","pacemaker Talos DR (Biotronik, Berlin, Germany)",No significant difference,"The effective pacing rate immediately after the procedure was no significant difference in the two groups (trial: 100% vs. control: 99.1%, P = 1.000).",5126155
2863,5126155,The effective sensitivity rate,"pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)","pacemaker Talos DR (Biotronik, Berlin, Germany)",No significant difference,"The effective sensitivity rate immediately after the procedure was 94.8% and 93.6% in the trial and control groups, respectively, with no significant difference (P = 0.716).",5126155
2864,5126155,The stability of pacing during follow-up,"pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)","pacemaker Talos DR (Biotronik, Berlin, Germany)",No significant difference,"The stability of pacing during follow-up was very high (99.0% in trial and 98.1% in control groups), and the difference was not significant (P = 0.621).",5126155
2865,5126155,The rate of adverse event,"pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)","pacemaker Talos DR (Biotronik, Berlin, Germany)",No significant difference,"The rate of adverse event was 3.53% in the trial group and 2.67% in the control group, with no significant difference (P = 1.000).",5126155
2866,4112748,the time to maximum concentration,frovatriptan,rizatriptan,Significantly increased,"Although the time to maximum concentration was similar for both drugs (2.7 versus 2.3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29.3 versus 3.2 hours, P&lt;0.0001).",4112748
2867,4112748,The proportion of patients who were pain-free at 4 hours without rescue medication,frovatriptan,rizatriptan,Significantly increased,"The proportion of patients who were pain-free at 4 hours without rescue medication was higher in the frovatriptan-treated group, (38.9 versus 5.6%, P=0.045).",4112748
2868,4112748,cumulative hazard of migraine recurrence,frovatriptan,rizatriptan,Significantly decreased,This finding was confirmed by the observation of a significantly lower cumulative hazard of migraine recurrence (P=0.04) over 72 hours in patients treated with frovatriptan (Figure 3).,4112748
2869,4112748,"nausea, photophobia , and phonophobia",frovatriptan and rizatriptan,baseline,Significantly decreased,"A significant reduction in patients experiencing nausea (P=0.045), photophobia (P&lt;0.001), and phonophobia (P&lt;0.001) was observed at 72 hours for both drugs compared to baseline (Figure 5Bâ€“D).",4112748
2870,4112748,The frequency of rescue medication,frovatriptan and rizatriptan,baseline,No significant difference,"The frequency of rescue medication was lower in patients during frovatriptan treatment (seven of 20) compared to rizatriptan treatment (13 of 20), this difference just failing to reach statistical significance (P=0.058).",4112748
2871,4112748,adverse events,frovatriptan and rizatriptan,baseline,Significantly decreased,"Fewer adverse events were observed for frovatriptan compared to rizatriptan (one versus eight, P=0.021).",4112748
2872,4776123,  improving of level laterality cofactor (LCF) in cerebellum network included bilateral cerebellum hemispheres (CereN),right- and left- frontoparietal networks (FPNs) and control,baseline,Significantly increased,"After the Fisher r-to-z translation, a repeated measure ANOVA revealed that both groups improved their LCFs in CereN as indicated by a significant main effect of time (F = 6.903, p = 0.015).",4776123
2873,4776123,  improving of level laterality cofactor (LCF) ,right lateral  frontoparietal networks (rFPN) left lateral  frontoparietal networks (lFPN),baseline,Significantly increased,"In addition, a significant training main effect on the LCF in rFPN (F = 5.897, p = 0.021) and lFPN (F = 7.641, p = 0.01), as well as interactions of LCF of lFPN (F = 8.908, p = 0.006), were observed.",4776123
2874,4776123,global LCF of CereN,conrtol after scanning,control before scanning,Significantly increased,"Paired-sample t-tests revealed that the global LCF of CereN (T = 2.30, p = 0.03) was significantly increased after the training scan compared with the before-training scan in the control group but not in the training group.",4776123
2875,4776123,LCF ,lFPN in the training group,control ,Significantly decreased,"Post hoc analysis showed significantly increased LCF of lFPN in the training group compared with the control group at the second scan (T = 3.48, p = 0.001).",4776123
2876,4776123,LCF of lFPN ,control after scanning,control before scanning,Significantly decreased,"Similarly, compared with the before-training scan, the after-training scan showed the decreased LCF of lFPN (T = 2.21, p = 0.04) in the control group, whereas a marginal significant increase (T = 2.02, p = 0.06) was observed in the training group.",4776123
2877,5106877,serums Vit D level,Vit D as 50 000 IU/week,placebo,Significantly increased,"However at the end of the study mean serum level of Vit D was 89.44Â±34.35 (nmol/L) and 38.02Â±23.90 (nmol/L) in the case and control groups, respectively (P=0.0001).",5106877
2878,5106877,mean level of proteinuria,Vit D as 50 000 IU/week,placebo,Significantly decreased,"Difference of proteinuria before and after the study in the case and control groups were 70.38Â±553.71 and 215.89Â±451.44, respectively (P=0.028), which revealed a significant difference among them.",5106877
2879,5106877,"fasting blood sugar (FBS), glycosylated hemoglobin (HbA1C), erythrocyte sedimentation rate (ESR) and C-Reactive Protein (CRP) levels",Vit D as 50 000 IU/week,placebo,No significant difference,"There were no significant difference between two groups of the patients based on FBS, HbA1C, ESR and CRP levels (P&gt;0.05).",5106877
2880,5129820,Trial Outcome Index (TOI),olaparib 400â€‰mg b.i.d. (capsules),placebo,No significant difference,"In the overall population, there was no statistically significant difference in median time to TOI worsening with olaparib vs placebo, although the median time to worsening was numerically shorter with olaparib (3.8 vs 4.6 months, respectively; hazard ratio (HR) 1.08; 95% CI 0.75, 1.55; P=0.7).",5129820
2881,5129820,The Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Ovarian Symptom Index (FOSI),olaparib 400â€‰mg b.i.d. (capsules),placebo,No significant difference,"In the overall population, the percentage of patients with a best response of â€˜improved' in FOSI was similar between treatment groups (17% vs 15% for olaparib vs placebo; Table 2), with no significant differences (OR 1.22; 95% CI 0.60, 2.51; P=0.59).",5129820
2882,5129820, Functional Assessment of Cancer Therapy Ovarian (FACT-O) questionnaire,olaparib 400â€‰mg b.i.d. (capsules),placebo,No significant difference,"No statistically significant differences were observed between treatment groups (21% vs 19% for olaparib vs placebo) for improvement in the FACT-O score in the overall population (OR 1.17; 95% CI 0.60, 2.27; P=0.65).",5129820
2883,4249579,magnitude of QTc interval prolongation,primaquine phosphate ,dihydroartemisinin-piperaquine,No significant difference,The addition of primaquine to dihydroartemisinin-piperaquine did not affect the magnitude of QTc prolongation (P = 0.5695) (Table 3).,4249579
2884,4249579,oral clearance (CL/F) and V/F  values,primaquine phosphate and dihydroartemisinin-piperaquine,primaquine phosphate,Significantly decreased,"Combined administration with dihydroartemisinin-piperaquine resulted in significantly lower primaquine CL/F (P = 0.0229) and V/F (P = 0.0013) values than administration alone, leading to significantly higher Cmax (P = 0.0019) and AUC0â€“last (P = 0.0200) values. This also resulted in a shorter primaquine t1/2 (P = 0.0005) than with administration alone.",4249579
2885,4249579,maximum observed plasma concentration after oral administration (Cmax) and predicted area under the plasma concentration time curve after the last dose from zero time to infinity (AUC0â€“last)values,primaquine phosphate and dihydroartemisinin-piperaquine,primaquine phosphate,Significantly increased,"Combined administration with dihydroartemisinin-piperaquine resulted in significantly lower primaquine CL/F (P = 0.0229) and V/F (P = 0.0013) values than administration alone, leading to significantly higher Cmax (P = 0.0019) and AUC0â€“last (P = 0.0200) values. This also resulted in a shorter primaquine t1/2 (P = 0.0005) than with administration alone.",4249579
2886,4249579,primaquine terminal elimination half-life; (t1/2),primaquine phosphate and dihydroartemisinin-piperaquine,primaquine phosphate,Significantly decreased,"Combined administration with dihydroartemisinin-piperaquine resulted in significantly lower primaquine CL/F (P = 0.0229) and V/F (P = 0.0013) values than administration alone, leading to significantly higher Cmax (P = 0.0019) and AUC0â€“last (P = 0.0200) values. This also resulted in a shorter primaquine t1/2 (P = 0.0005) than with administration alone.",4249579
2887,4249579,carboxyprimaquine exposures,primaquine phosphate and dihydroartemisinin-piperaquine,primaquine phosphate,Significantly increased,"Similarly, when primaquine was administered in combination with dihydroartemisinin-piperaquine, there were also significantly higher carboxyprimaquine exposures (Cmax, P = 0.0032; AUC0- last, P = 0.0262) and lower V/F (P = 0.0019) and shorter t1/2 (P = 0.0084) values than with administration alone.",4249579
2888,4249579,V/F,primaquine phosphate and dihydroartemisinin-piperaquine,primaquine phosphate,Significantly decreased,"Similarly, when primaquine was administered in combination with dihydroartemisinin-piperaquine, there were also significantly higher carboxyprimaquine exposures (Cmax, P = 0.0032; AUC0- last, P = 0.0262) and lower V/F (P = 0.0019) and shorter t1/2 (P = 0.0084) values than with administration alone.",4249579
2889,4249579,t1/2,primaquine phosphate and dihydroartemisinin-piperaquine,primaquine phosphate,Significantly decreased,"Similarly, when primaquine was administered in combination with dihydroartemisinin-piperaquine, there were also significantly higher carboxyprimaquine exposures (Cmax, P = 0.0032; AUC0- last, P = 0.0262) and lower V/F (P = 0.0019) and shorter t1/2 (P = 0.0084) values than with administration alone.",4249579
2890,3267052,mean probing pocket depth (PPD)," fruit/vegetable (FV), fruit/vegetable/berry (FVB)",placebo,Significantly increased,"Clinical outcomes improved in all groups at 2 months, with additional improvement in PPD versus placebo for FV (p &lt; 0.03).",3267052
2891,3267052,Gingival crevicular fluid volumes,"fruit/vegetable (FV), fruit/vegetable/berry (FVB)",placebo,Significantly decreased,"Gingival crevicular fluid volumes diminished more in supplement groups than placebo (FVB; p &lt; 0.05) at 2 months, but not at later times.",3267052
2892,3267052,bleeding on probing (% BOP) and cumulative plaque scores ,fruit/vegetable (FV),"fruit/vegetable/berry (FVB), placebo",Significantly decreased,The % BOP (5 months) and cumulative plaque scores (8 months) were lowered more in the FV group (p &lt; 0.05).,3267052
2893,3267052,clinical attachment level (CAL),fruit/vegetable (FV) and FVB,placebo,Significantly increased,Significant post-treatment CAL gains were detected at all time points in both FV (p &lt; 0.05) and FVB (p &lt; 0.02) supplement groups (Fig. 3c),3267052
2894,3267052,Gingival crevicular fluid (GCF) volumes,fruit/vegetable (FV) and FVB,placebo,Significantly decreased,"In contrast, GCF volumes at deep sites were significantly reduced at all time points in all groups post-therapy, with reductions being consistently greater in supplementation groups (p &lt; 0.002; Fig. 4b).",3267052
2895,3267052,cumulative plaque scores,fruit/vegetable (FV),placebo,Significantly decreased,"No differences were evident between groups until month 8, when the reduction in plaque scores relative to baseline were significantly higher in the FV group (p &lt; 0.05) compared with the placebo group.",3267052
2896,4729786,"the three-way interaction of probe location, picture type, and group","negative training (NT) (pull negative, push positive pictures)",positive training (PT) (vice versa),No significant difference,"Because of the similar effects observed for trained and untrained pictures, the three-way interaction of probe location, picture type, and group was not significant, F(1, 139)&nbsp;=&nbsp;.10, p&nbsp;&gt;&nbsp;.7, Î·p2&nbsp;=&nbsp;.001.",4729786
2897,4729786,"mood scales, stress scales","negative training (pull negative, push positive pictures)",positive training (vice versa),No significant difference,The analyses revealed neither an immediate training effect on the mood scales nor on the stress scales (p&nbsp;&gt;&nbsp;.398),4729786
2898,4729786,compatibility effect,dysphoric,non-dysphoric,Significantly increased,"Additionally, one-sample t-tests revealed that in both groups, the compatibility effect was significantly positive (non-dysphoric: t(35)&nbsp;=&nbsp;2.71, p&nbsp;=&nbsp;.01, d&nbsp;=&nbsp;.92; dysphoric: t(24)&nbsp;=&nbsp;3.30, p&nbsp;=&nbsp;.003, d&nbsp;=&nbsp;1.35).",4729786
2899,4729786,compatibility effect,"PT groups (dysphoric, non-dysphoric)","sham-training (dysphoric, non-dysphoric)",No significant difference,"This indicates an increase of the compatibility effects after training in the PT groups (dysphoric: t(9)&nbsp;=&nbsp;5.29, p&nbsp;&lt;&nbsp;.001, d&nbsp;=&nbsp;1.67; non-dysphoric: t(17)&nbsp;=&nbsp;2.62, p&nbsp;=&nbsp;.018, d&nbsp;=&nbsp;.62), compared to the sham-training groups (dysphoric: t(14)&nbsp;=&nbsp;1.13, p&nbsp;&gt;&nbsp;.2, d&nbsp;=&nbsp;.29; non-dysphoric: t(17)&nbsp;=&nbsp;.12, p&nbsp;&gt;&nbsp;.9, d&nbsp;=&nbsp;.03).",4729786
2900,4729786,main effect of training on the stress ratings,"PT groups (dysphoric, non-dysphoric)","sham-training (dysphoric, non-dysphoric)",No significant difference,"For the group of non-dysphoric students, no significant main effect of training on the stress ratings was found, F(3, 29)&nbsp;=&nbsp;.95, p&nbsp;&gt;&nbsp;.4, Î·p2&nbsp;=&nbsp;.09.",4729786
2901,4729786,tension,"PT groups (dysphoric, non-dysphoric)","sham-training (dysphoric, non-dysphoric)",Significantly decreased,"Univariate ANCOVAs indicated that the training was particularly associated with less tension after the anagram task, F(1, 20)&nbsp;=&nbsp;6.81, p&nbsp;=&nbsp;.017, Î·p2&nbsp;=&nbsp;.25, in that participants in the training group showed lower scores on the stress subscale than those in the control group (M&nbsp;=&nbsp;2.8, SD&nbsp;=&nbsp;1.1 vs. M&nbsp;=&nbsp;4.1, SD&nbsp;=&nbsp;.9)",4729786
2902,4155124, plasma cathepsin S levels,healthy Nordic diet (ND),baseline,No significant difference,"However, adjusting for baseline cathepsin S levels attenuated the difference between groups (pâ€‰=â€‰0.06), as well as adjustments for differences in systolic and diastolic blood pressure (pâ€‰=â€‰0.06).",4155124
2903,4155124,insulin sensitivity,healthy Nordic diet (ND),baseline,Significantly increased,"These differences remained after adjusting for sex (pâ€‰=â€‰0.03) and insulin sensitivity (Pâ€‰=â€‰0.03), whereas adjusting for weight change (Pâ€‰=â€‰0.22), LDL-C (Pâ€‰=â€‰0.36) and total cholesterol (Pâ€‰=â€‰0.48) abolished the significant difference between groups.",4155124
2904,4155124," weight change, LDL-C and total cholesterol",healthy Nordic diet (ND),baseline,Significantly increased,"These differences remained after adjusting for sex (pâ€‰=â€‰0.03) and insulin sensitivity (Pâ€‰=â€‰0.03), whereas adjusting for weight change (Pâ€‰=â€‰0.22), LDL-C (Pâ€‰=â€‰0.36) and total cholesterol (Pâ€‰=â€‰0.48) abolished the significant difference between groups.",4155124
2905,4069273,HbA1c and FPG and BMI,"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction",received a routine program,No significant difference,"There were statistically significant differences of both HbA1c and FPG between the intervention and the control groups at 3 month follow up (pâ€‰=â€‰0.003 and &lt;0.001, respectively). However, there was no statistically significant difference in BMI between the intervention and the control groups at 3 month follow up (pâ€‰=â€‰0.057) (Table 2).",4069273
2906,4069273,the plaque index score and gingival index score,"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction",received a routine program,Significantly decreased,"mong the 130 participants (65 intervention and 65 control), the plaque index score and gingival index score decreased from baseline to 3 month follow up in both the intervention and the control groups with statistically significant differences between the intervention and the control groups at 3 month follow up (pâ€‰=â€‰0.006 and 0.001, respectively).",4069273
2907,4069273,"The average score of overall attitude, oral health attitude, and diabetes attitude","attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction",received a routine program,Significantly increased,"The average score of overall attitude, oral health attitude, and diabetes attitude increased from baseline to 3 month follow up only in the intervention group with statistically significant differences between the intervention and the control groups at 3 month follow up (pâ€‰&lt;â€‰0.001, &lt;0.001 and &lt;0.001, respectively) (Table 2).",4069273
2908,4069273,"pocket depth, clinical attachment level (CAL), and percentage of bleeding on probing (BOP)","attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction",received a routine program,Significantly decreased,"There were statistically significant differences between the intervention and the control groups at 3 month follow up of pocket depth, CAL, and BOP (pâ€‰&lt;â€‰0.001, 0.001 and, &lt;0.001, respectively) (Table 2).",4069273
2909,4069273,Exercise,"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction",received a routine program,Significantly increased,Exercise had a statistically significant difference between the intervention and the control groups (pâ€‰&lt;â€‰0.001).,4069273
2910,4069273,The percentage of participants who modified diet,"attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction",received a routine program,Significantly increased,The percentage of participants in the intervention group (93.8%) who modified diet was higher than the control group (70.8%) with a statistically significant difference (pâ€‰=â€‰0.001).,4069273
2911,4069273,"The percentage of participants who received foot examination, always wore covered shoes, and participated in screening of feet","attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction",received a routine program,Significantly increased,"The percentage of participants in the intervention group who received foot examination, always wore covered shoes, and participated in screening of feet were higher than the control group with statistically significant differences (p &lt;0.001, &lt;0.001, 0.044) (Table 3).",4069273
2912,5459456,"surgery time, blood loss, recovery time, and time before eating",ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),No significant difference,"No significant differences were found in surgery time, blood loss, recovery time, and time before eating among ACVC, ACVC-HA, and ACCF groups. These findings indicate that ACVC or ACVC-HA implantation did not increase surgery time, blood loss, recovery time, and time before eating compared with the ACCF group.",5459456
2913,5459456,"inflexion-extension and lateral bending for the C2-C6, C2-C4, C4-C5, and C5-C6 segments",ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,No significant difference,"There were no significant differences among the control, ACVC, and ACVC-HA groups inflexion-extension and lateral bending for the C2-C6, C2-C4, C4-C5, and C5-C6 segments.",5459456
2914,5459456,The stiffness,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),Significantly decreased,"The stiffness was significantly decreased in all directions for the ACVC and ACVC-HA groups, while it was increased for the ACCF group.",5459456
2915,5459456,new bone formation around the screws and bone-implant contact (BIC) in both sections,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating,ACVC,Significantly increased,"In the sections located at the self-drilling fixation screw level (Fig 8E and 8G), we found significantly more new bone formation around the screws for the ACVC-HA group (Fig 8G) than for the ACVC group (Fig 8E). Moreover, the ACVC group had much more fibrous tissue around the screws than the ACVC-HA group. These findings indicate that, compared with the ACVC group, the ACVC-HA group had a significantly higher bone-implant contact (BIC) in both sections respectively located at the vertebral body component and screw level (Fig 8I), which is an appropriate index for measuring bone ingrowth into the implant.",5459456
2916,4021263,APTB adequate specimens collection ,sputum induction with 7% saline nebulization in clinic (SI) ,self-expectoration (ES),Significantly increased,"Among the APTB, more adequate specimens were collected from SI (41/65, 63.1%) than ES (34/80, 42.5%) (p=0.01).",4021263
2917,4021263,Bacteriological confirmation,sputum induction with 7% saline nebulization in clinic (SI) ,self-expectoration (ES),No significant difference,"Bacteriological confirmation was achieved in 14 (58.3%) patients in SI, and 13 (48.1%) in ES (p=0.46).",4021263
2918,4021263,M. tuberculosis or nontuberculous mycobacteria detection,sputum induction with 7% saline nebulization in clinic (SI) ,self-expectoration (ES),No significant difference,"M. tuberculosis or nontuberculous mycobacteria was detected in at least one of microscopy or PCR, 9 patients from the SI group and 7 from the ES group (37.5% and 25.9%, respectively; p=0.37) (Figure 3).",4021263
2919,5771895,the number of women with improved sleep quality,"transdermal 17Î²-estradiol (t-E2; 50â€ŠÎ¼g/d) plus cyclic progesterone (Prometrium, 200â€Šmg) ", oral conjugated equine estrogens (o-CEE; 0.45â€Šmg/d)  or placebo (PBO),Significantly increased,"When compared with PBO, the reduction in the percentage of women with poor sleep quality (ie, the number of women with improved sleep quality) was significantly greater in the t-E2 group (Pâ€Š=â€Š0.003) and modestly but not significantly greater in the o-CEE group (Pâ€Š=â€Š0.07).",5771895
2920,5771895,"domain scores pertaining to sleep efficiency, sleep duration, or daytime dysfunction","transdermal 17Î²-estradiol (t-E2; 50â€ŠÎ¼g/d) plus cyclic progesterone (Prometrium, 200â€Šmg) ", oral conjugated equine estrogens (o-CEE; 0.45â€Šmg/d) ,No significant difference,"There were no significant differences between groups for the changes in domain scores pertaining to sleep efficiency (Pâ€Š=â€Š0.45), sleep duration (Pâ€Š=â€Š0.38), or daytime dysfunction (Pâ€Š=â€Š0.26) across follow-up.",5771895
2921,5771895,sleep disturbances,"transdermal 17Î²-estradiol (t-E2; 50â€ŠÎ¼g/d) plus cyclic progesterone (Prometrium, 200â€Šmg) ", oral conjugated equine estrogens (o-CEE; 0.45â€Šmg/d)  ,Significantly decreased,"Among the three domains, only sleep disturbances showed a statistically significant difference between the two HT formulations (Pâ€Š=â€Š0.029), with t-E2 improving more during follow-up than o-CEE (Table 2).",5771895
2922,5771895,average severity scores of hot flashes and night sweats,"transdermal 17Î²-estradiol (t-E2; 50â€ŠÎ¼g/d) plus cyclic progesterone (Prometrium, 200â€Šmg)  or  oral conjugated equine estrogens (o-CEE; 0.45â€Šmg/d)  ",placebo,Significantly decreased,"As reported previously for the entire KEEPS cohort,27 the average severity scores of hot flashes and night sweats were significantly reduced by both HT formulations when compared with PBO (Pâ€Š&lt;â€Š0.001 for both), with no difference between the o-CEE and t-E2 groups (Pâ€Š=â€Š0.343 and Pâ€Š=â€Š0.919, respectively; Table 2)",5771895
2923,5771895,average severity scores of hot flashes and night sweats,"transdermal 17Î²-estradiol (t-E2; 50â€ŠÎ¼g/d) plus cyclic progesterone (Prometrium, 200â€Šmg)  ",oral conjugated equine estrogens (o-CEE; 0.45â€Šmg/d)  ,No significant difference,"with no difference between the o-CEE and t-E2 groups (Pâ€Š=â€Š0.343 and Pâ€Š=â€Š0.919, respectively; Table 2).",5771895
2924,4286912,Immune response,PHiD-CV Phase III Clinical (Clin group),PHiD-CV Commercial lot (Com group),No significant difference,"In the primary vaccination phase, immune responses induced by the PHiD-CV Commercial lot were shown to be non-inferior to those induced by the Phase III Clinical lot",4286912
2925,4286912,Antigens of co-administered vaccines,PHiD-CV Phase III Clinical (Clin group),PHiD-CV Commercial lot (Com group),No significant difference,"One month post-primary and post-booster vaccination, all children were seroprotected against diphtheria, tetanus and poliovirus types 1, 2 and 3, and all infants were seropositive for antibodies against the three pertussis antigens and polyribosylribitol phosphate from Hib. All infants except one were seroprotected against hepatitis B surface antigen (HBs) at one month post-primary vaccination.",4286912
2926,4286912,Serious adverse events,PHiD-CV Phase III Clinical (Clin group),PHiD-CV Commercial lot (Com group),No significant difference,No serious adverse events considered causally related to vaccination were reported throughout the study.,4286912
2927,4286912,Reactogenicity and safety profiles,PHiD-CV Phase III Clinical (Clin group),PHiD-CV Commercial lot (Com group),No significant difference,"The reactogenicity and safety profiles of the Commercial and the Phase III Clinical lots of PHiD-CV were comparable and clinically acceptable, in line with previous studies",4286912
2928,3476139,Cephalea relief at 2 hours,Rizatriptan,Ibuprofen and placebo,Significantly increased,Rizatriptan was superior to ibuprofen and placebo in relieving headache at 2 h but not at 24 h.,3476139
2929,3476139,Cephalea relief at 24 hours,Rizatriptan,Ibuprofen and placebo,No significant difference,Rizatriptan was superior to ibuprofen and placebo in relieving headache at 2 h but not at 24 h.,3476139
2930,3476139,Side effects,Rizatriptan,Ibuprofen and placebo,No significant difference,"Side effects were noted in 9 patients in rizatriptan, 8 in ibuprofen and 3 in placebo, all of which were nonsignificant.",3476139
2931,3476139,Overall cephalea relief and improvement of associated symptoms,Rizatriptan,Ibuprofen ,Significantly increased,"Rizatriptan is superior to ibuprofen in relieving headache, associated symptoms and functional disability.",3476139
2932,2963843,Rates of discontinuation,Imipramine 150 mg,Fluoxetine 20 mg and imipramine 75 mg,Significantly increased,discontinuation rates are higher in subjects on imipramine 150 mg as compared to the other groups,2963843
2933,5601935,Number of follicles,Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH),Human menopausal gonadotropin (HMG) plus r-FSH,No significant difference,"Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p&gt;0.05).",5601935
2934,5601935,Number of oocytes or M2 oocytes,Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH),Human menopausal gonadotropin (HMG) plus r-FSH,No significant difference,"Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p&gt;0.05).",5601935
2935,5601935,Quality of fetuses,Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH),Human menopausal gonadotropin (HMG) plus r-FSH,No significant difference,"Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p&gt;0.05).",5601935
2936,5601935,Total number of fetuses,Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH),Human menopausal gonadotropin (HMG) plus r-FSH,Significantly decreased,total number of fetuses was significantly higher in patients who received rFSH and HMG,5601935
2937,5601935,Fertility outcomes,Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH),Human menopausal gonadotropin (HMG) plus r-FSH,Significantly decreased,"Fertility outcomes consisted of: live birth rate, chemical pregnancy and clinical pregnancy rate were higher in rFSH + HMG group in comparison to rFSH +r-LH group (p&lt;0.05).",5601935
2938,2744923,Adequate clinical and parasitological response rates at days 28 and 42,Artemether-lumefantrine (AL),Sulphadoxine-pyrimethamine (SP) or chlorproguanil-dapsone (CPD),Significantly increased,ACPR rates with AL were significantly higher than the rates in either of the other groups on days 28 and 42 (p â‰¤ 0.002 for all comparisons).,2744923
2939,2744923,Effectiveness at day 28,Chlorproguanil-dapsone (CPD),Sulphadoxine-pyrimethamine (SP) ,Significantly increased,"CPD was more effective than SP on day-28 (p = 0.01), but not day-42.",2744923
2940,2744923,Effectiveness at day 42,Chlorproguanil-dapsone (CPD),Sulphadoxine-pyrimethamine (SP) ,No significant difference,"CPD was more effective than SP on day-28 (p = 0.01), but not day-42.",2744923
2941,2744923,"Hemoglobin levels at days 7, 14, and 28",Chlorproguanil-dapsone (CPD),Sulphadoxine-pyrimethamine (SP) ,No significant difference,No differences in mean Hb level were observed after treatment with CPD or SP.,2744923
2942,2744923,Hemoglobin levels at days 14 and 28,Artemether-lumefantrine (AL),Sulphadoxine-pyrimethamine (SP) ,Significantly increased,"After treatment with AL, the Hb rose by day-14 and 28; this rise was significantly greater than the change after SP.",2744923
2943,4993942,Subfoveal choroidal thickness,Panretinal photocoagulation (PRP) with green laser,Panretinal photocoagulation (PRP) with red laser,No significant difference,"There was no difference between red and green laser considering subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increase after PRP (P values: 0.184, 0.404, and 0.726, resp.).",4993942
2944,4993942,Central retinal thickness,Panretinal photocoagulation (PRP) with green laser,Panretinal photocoagulation (PRP) with red laser,No significant difference,"There was no difference between red and green laser considering subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increase after PRP (P values: 0.184, 0.404, and 0.726, resp.).",4993942
2945,4993942,Peripapillary nerve fiber layer thickness,Panretinal photocoagulation (PRP) with green laser,Panretinal photocoagulation (PRP) with red laser,No significant difference,"There was no difference between red and green laser considering subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increase after PRP (P values: 0.184, 0.404, and 0.726, resp.).",4993942
2946,4993942,Complications,Panretinal photocoagulation (PRP) with green laser,Panretinal photocoagulation (PRP) with red laser,No significant difference,No complication occurred in both groups during laser and in follow-up period.,4993942
2947,5600923,Tumor size before or after surgery,Alginate oligosaccharide (AOS; AG group),Placebo (CG group),No significant difference,"Before surgery and the outcome of primary end point after surgery, no significant differences were observed for clinical data and tumor size between the AG and CG groups (P &gt; 0.05).",5600923
2948,5600923,Tumor volume after 2 years of therapy,Alginate oligosaccharide (AOS; AG group),Placebo (CG group),Significantly decreased,"No statistical significance was observed for tumor volume between the AG and CG (658.4 Â± 167.2 c.c. and 629.8 Â± 198.5 c.c., P = 0.35) before surgery, and tumor volumes were all &lt; 50 c.c. at the primary end point after surgery (P = 0.17).",5600923
2949,5600923,Rate of local recurrence,Alginate oligosaccharide (AOS; AG group),Placebo (CG group),Significantly decreased,"The rate of local recurrence was 44.9 and 68.7% in AG and CG, respectively (P &lt; 0.01).",5600923
2950,5600923,Lipid profile improvement after 8 months,Alginate oligosaccharide (AOS; AG group),Placebo (CG group),No significant difference,"In AG, serum levels of TG, TC, LDL-C, and MDA were reduced, whereas the serum level of HDL-C was increased after 8 months; however, no statistically significant difference was observed between the two groups (P &gt; 0.05, Table 2)",5600923
2951,5600923,Lipid profile improvement after 16 months and 24 months,Alginate oligosaccharide (AOS; AG group),Placebo (CG group),Significantly increased,"Lipid pattern was improved further in AG after 16 months, and statistically significant difference was observed between the two groups (P &lt; 0.05, Table 2). Similarly, the lipid pattern was improved significantly in AG after 24 months, and statistically significant difference was observed between the two groups (P &lt; 0.05; Table 2).",5600923
2952,2928344,"A1C levels at 6, 12, and 24 months",Calcitriol,Placebo,No significant difference,"At 6, 12, and 24 months follow-up, A1C and insulin requirement in the calcitriol group did not differ from the placebo group.",2928344
2953,2928344,"Insulin requirements at 6, 12, and 24 months",Calcitriol,Placebo,No significant difference,"At 6, 12, and 24 months follow-up, A1C and insulin requirement in the calcitriol group did not differ from the placebo group.",2928344
2954,2928344,C-peptide response,Calcitriol,Placebo,No significant difference,The area under the curve of C-peptide response (AUC0â€“120 min) was not significantly different in the calcitriol versus placebo group at baseline (calcitriol group: 69.9 Â± 24.8 nmol/l Ã— 120 min; placebo group: 72.5 Â± 37.7; P = 0.658) or after 12 months (calcitriol group: 49.7 Â± 30.4 nmol/l Ã— 120 min; placebo group: 56.2 Â± 39.7; P = 0.845).,2928344
2955,2928344,Levels of calcium and phosphate,Calcitriol,Placebo,No significant difference,Calcium and phosphate levels remained within normal limits throughout the follow-up,2928344
2956,2928344,Adverse events,Calcitriol,Placebo,No significant difference,no adverse events were reported in any patient.,2928344
2957,3597059,Hypotension,Crystalloid (RS group) and colloid (HES group),Control (C group),No significant difference,"Hypotension occurred in 3 patients in the C group and one each in the RS and HES group, respectively (P = 0.362).",3597059
2958,3597059,Baseline characteristics,Crystalloid (RS group) and colloid (HES group),Control (C group),No significant difference,"Patient demographic characteristics were similar among the groups (P &gt; 0.05). The main comorbid disease was hypertension in 9 patients in the control group, 6 in the RS group and 8 in the HES group (P &gt; 0.05, Table 1)",3597059
2959,3597059,Cardiac output during spinal anesthesia,Colloid (HES group),Crystalloid (RS group) and control (C group),Significantly increased,"Intergroup comparison showed that the CO in the HES group was significantly higher than that in the RS and C groups at the corresponding time point during spinal anesthesia, but no significant difference existed between the RS and C groups",3597059
2960,3597059,Cardiac output during spinal anesthesia,Crystalloid (RS group),Control (C group),No significant difference,"Intergroup comparison showed that the CO in the HES group was significantly higher than that in the RS and C groups at the corresponding time point during spinal anesthesia, but no significant difference existed between the RS and C groups",3597059
2961,3597059,Heart rate,Crystalloid (RS group) and colloid (HES group),Control (C group),No significant difference,"there was a nonsignificant trend toward decrease in the heart rate after spinal anesthesia in all patients, with no significant difference among the three groups",3597059
2962,4770250,CFU/g reduction in bacterial density of Pseudomona aeruginosa ,Dual release ciprofloxacin for inhalation (DRCFI),Placebo,Significantly increased,"DRCFI resulted in a mean (SD) 4.2 (3.7) log10 CFU/g reduction in P aeruginosa bacterial density at day 28 (vs âˆ’0.08 (3.8) with placebo, p=0.002).",4770250
2963,4770250,Time to first pulmonary exacerbation,Dual release ciprofloxacin for inhalation (DRCFI),Placebo,Significantly increased,"The median time to pulmonary exacerbation by Kaplanâ€“Meier analysis was 134â€…days for the DRCFI group and 58â€…days for the placebo group, although this achieved conventional statistical significance only on the per protocol population (p=0.057 mITT, p=0.046 per protocol, by log-rank test; see figure 3).",4770250
2964,4770250,Systemic adverse events,Dual release ciprofloxacin for inhalation (DRCFI),Placebo,No significant difference,DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group,4770250
2965,4770250,Requirement of antibiotics for pulmonary exacerbation,Dual release ciprofloxacin for inhalation (DRCFI),Placebo,Significantly decreased,"Post hoc analysis revealed that the overall proportion of subjects requiring antibiotics for pulmonary exacerbation was lower in the DRCFI group (8 (40%) vs 17 (77%), OR 0.2, 95% CI 0.04 to 0.89, p=0.027 by Fisher's exact test).",4770250
2966,4770250,"FEV1, SGRQ total score, and 6MWT distance",Dual release ciprofloxacin for inhalation (DRCFI),Placebo,No significant difference,"No significant differences were seen between the two treatment groups for changes to day 28 for other outcome measures including FEV1 (DRCFI âˆ’0.05Â±0.12 vs placebo 0.00Â±0.10 L, p=0.18), SGRQ total score (DRCFI âˆ’1.3Â±7.16 vs placebo âˆ’6.4Â±9.8, p=0.08) or 6MWT distance (DRCFI 0.6Â±71.6 vs placebo âˆ’7.6Â±92.3â€…m, p=0.54).",4770250
2967,4152682,Pulse rate during surgery,Transversus abdominis plane block with 0.25% bupivacaine (Group B),Normal saline followed by general anesthesia (Group N),Significantly decreased,"From the analysis of the intraoperative hemodynamic parameters it was found that pulse rate was significantly higher in patients receiving placebo (95.9 Â± 11.2 bpm vs. 102.9 Â± 8.8 bpm, mean the difference 7.0 s, P = 0.001) after surgical skin incision.",4152682
2968,4152682,Pulse rate and blood pressure after surgery,Transversus abdominis plane block with 0.25% bupivacaine (Group B),Normal saline followed by general anesthesia (Group N),No significant difference,"There was no statistically significant difference between the two groups in terms of median values of immediate postoperative pulse rate, systolic blood pressure and diastolic blood pressure (Mannâ€“Whitney U-test",4152682
2969,4152682, Requirement of fentanyl during surgery,Transversus abdominis plane block with 0.25% bupivacaine (Group B),Normal saline followed by general anesthesia (Group N),Significantly decreased,"Median intraoperative fentanyl requirement was significantly higher in Group N (81 mcg vs. 114 mcg, P = 0.000).",4152682
2970,4152682,Visual analog scale scores,Transversus abdominis plane block with 0.25% bupivacaine (Group B),Normal saline followed by general anesthesia (Group N),Significantly decreased,"VAS scores on emergence at rest (median VAS 3 mm vs 27 mm), with activity (median 8 mm vs. 35 mm) were significantly lower in Group B.",4152682
2971,4152682,Analgesia duration ,Transversus abdominis plane block with 0.25% bupivacaine (Group B),Normal saline followed by general anesthesia (Group N),Significantly increased,"Median duration of analgesia was significantly higher in Group B (290 min vs. 16 min, P = 0.000).",4152682
2972,5452353,Level of VO2 max after 5 minutes into cycling time trial to exhaustion at 100%VO2max,Exercise at 1657 m of altitude plus Pomegranate extract (ALTPOMx),Exercise at 1657 m of altitude plus Placebo (ALTPLAC),Significantly increased,"O2 measured at five minutes into the TTE100% was significantly increased in ALTPOMx vs. ALTPLAC (+3.8&nbsp;ml.minâˆ’1kgâˆ’1, 95% CI, âˆ’5.7, 9.5, F1,7â€‰=â€‰29.2, pâ€‰=â€‰0.001, ESâ€‰=â€‰0.6)",5452353
2973,5452353,Level of VO2 max after 5 minutes into cycling time trial to exhaustion at 100%VO2max,Exercise at sea-level plus Pomegranate extract (SEAPOMx),Exercise at sea-level plus Placebo (SEAPLAC),No significant difference,"VO2 measured at five minutes into the TTE100% was significantly increased in ALTPOMx vs. ALTPLAC (+3.8&nbsp;ml.minâˆ’1kgâˆ’1, 95% CI, âˆ’5.7, 9.5, F1,7â€‰=â€‰29.2, pâ€‰=â€‰0.001, ESâ€‰=â€‰0.6) but unchanged in SEAPOMx vs. SEAPLAC (pâ€‰&gt;â€‰0.05).",5452353
2974,5452353,Levels of NO3 âˆ’ in plasma,Pomegranate extract (POMx),Placebo (PLAC),Significantly increased,"Plasma NO3 âˆ’ was greater following POMx compared to PLAC (+10.3&nbsp;Î¼mol, 95% CI, 0.8, 19.7, F 1,7â€‰=â€‰7.83, pâ€‰&lt;â€‰0.04, ESâ€‰=â€‰0.9).",5452353
2975,5452353,Performance,Cycling time trial to exhaustion at 100%VO2max at sea-level (SEA),Cycling time trial to exhaustion at 100%VO2max at 1657 m of altitude (ALT),Significantly increased,"Performance was significantly decreased at ALT compared to SEA (âˆ’4.1&nbsp;min, 95% CI, âˆ’6.9, âˆ’1.3, F 1,7â€‰=â€‰12.3, pâ€‰&lt;â€‰0.02, ESâ€‰=â€‰0.8).",5452353
2976,5452353,Systolic blood pressure,Pomegranate extract (POMx),Placebo (PLAC),No significant difference,"SBP was not significantly affected by POMx or ALT (pâ€‰&gt;â€‰0.05). However, there was a trend towards an increase in SBP with POMx vs. PLAC (+3.9&nbsp;bpm, 95% CI, âˆ’0.6, 8.5, F 1,7â€‰=â€‰4.28, pâ€‰=â€‰0.08, ESâ€‰=â€‰0.3).",5452353
2977,2762969,Overall outcomes,Advanced Quality Improvement Program (AQIP),Usual Quality Improvement Program (UQIP),No significant difference,"After 18 months of intervention a significant improvement in all variables was noted (p &lt; 0.0001), irrespective of the intervention arm. When comparing the two intervention arms (AQIP and UQIP) no significant differences in outcomes were noted after 18 months of intervention.",2762969
2978,2762969,Use of the  interdisciplinary diabetes care teams in primary care physicians and patients,Advanced Quality Improvement Program (AQIP),Usual Quality Improvement Program (UQIP),Significantly increased,"When comparing the two intervention arms the use of the IDCT in PCPs and patients was significantly higher in the AQIP compared to the UQIP (AQIP = 61 PCPs (91%); UQIP = 40 PCPs (75%); p = 0.02) and (AQIP = 226 patients (14.3%), vs. UQIP = 87 patients (9,4%); p = 0.03), respectively.",2762969
2979,2762969,Improvements in levels of HbA1c and LDL-cholesterol at 18 months,Use of the interdisciplinary diabetes care teams (IDCT),No- users  of IDCT,Significantly increased,After 18 months of intervention the use of the IDCT was significantly associated with improvements in HbA1c (p = 0.00001) and LDL-cholesterol (p = 0.00039),2762969
2980,2762969,Use of statins and anti-platelet therapy at 18 months,Use of the interdisciplinary diabetes care teams (IDCT),No- users  of IDCT,Significantly increased,After 18 months of intervention the use of the IDCT was significantly associated with improvements in HbA1c (p = 0.00001) and LDL-cholesterol (p = 0.00039) and an increase in both the use of statins (p = 0.04308; OR: 1.902) and anti-platelet therapy (p = 0.00544; OR: 2.213).,2762969
2981,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Mild-cooling,No cooling,Significantly increased,"the analysis at 6 months post-trauma disclosed mild-cooling-treated patients did better than no cooling (70% vs. 15.4% attained good GOS, P = 0.013)",4323894
2982,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,Mild-cooling,No significant difference,the deep-cooling-treated patients failed to be better than either no cooling (P = 0.074) or mild cooling group (P = 0.650).,4323894
2983,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,No cooling,No significant difference,the deep-cooling-treated patients failed to be better than either no cooling (P = 0.074) or mild cooling group (P = 0.650).,4323894
2984,4323894,Rate of complications,Mild-cooling or deep-cooling,No cooling,No significant difference,"Kruskal Wallis non-parametric statistical test comparing the three groups for complication disclosed insignificant difference with P = 0.405. In conclusion, no significant difference is found in the incidence of complication among the three groups.",4323894
2985,2836298,Continued abstinence at 1 year,Intensive individual intervention (III),Minimal intervention (MI),No significant difference,"Continued abstinence at 12 months confirmed through CO was 7.4% in the III, 5.4% in the IGI, and 1% in the MI. No significant differences were noted between III and MI on the one hand, and between IGI and MI on the other [RR 7.04 (0.9-7.2) and RR 5.1 (0.6-41.9), respectively].",2836298
2986,2836298,Continued abstinence at 1 year,Intensive group intervention (IGI),Minimal intervention (MI),No significant difference,"Continued abstinence at 12 months confirmed through CO was 7.4% in the III, 5.4% in the IGI, and 1% in the MI. No significant differences were noted between III and MI on the one hand, and between IGI and MI on the other [RR 7.04 (0.9-7.2) and RR 5.1 (0.6-41.9), respectively].",2836298
2987,2836298,Continued abstinence at 1 year,Intensive group intervention (IGI),Intensive individual intervention (III),No significant difference,"No differences were observed between the IGI and the III for continued abstinence confirmed by CO [RR 0.7 (0.2-2.2)] or for any of the other secondary outcome measures: self-reported continued abstinence [RR 0.8 (0.3-2.2)]; point abstinence confirmed by CO [RR 0.5 (0.2-1.1)], and self-reported point abstinence [RR 0.8 (0.4-1.8)].",2836298
2988,5423967,weight loss,intensive lifestyle intervention (ILI),diabetes support and education (DSE),Significantly decreased,"However, at 1&nbsp;year, when the ILI group had achieved maximum weight loss (8.6&nbsp;Â±&nbsp;6.9% vs 0.7&nbsp;Â±&nbsp;4.8% in the DSE group [17]), the MNSI questionnaire score had decreased to 1.7&nbsp;Â±&nbsp;0.04 and was significantly lower than the DSE group score of 2.0&nbsp;Â±&nbsp;0.04 (p&nbsp;&lt;&nbsp;0.001).",5423967
2989,5423967,light touch sensation in the feet,intensive lifestyle intervention (ILI),diabetes support and education (DSE),Significantly increased,"In an additional post hoc analysis the data were analysed as a reading of &lt;8 perceived pricks on either the right or the left foot. This was present in 34.5% of the participants in the DSE group and 30.4% of the participants in the ILI group (p&nbsp;=&nbsp;0.008), suggesting that the ILI group participants may have maintained slightly better light touch sensation in the feet than did the DSE group participants.Table 1",5423967
2990,5423967,triacylglycerol:HDL-cholesterol ratio the MNSI score,"intensive lifestyle intervention (ILI), diabetes support and education (DSE)",baseline,Significantly increased,For each unit increase in the triacylglycerol:HDL-cholesterol ratio the MNSI score increased by 0.02 (p&nbsp;&lt;&nbsp;0.001) in both the DSE and ILI groups.,5423967
2991,3214395,"laryngoscopy duration, laryngospasm, bronchospasm, laryngoscopy failure, extremity movement, awakening","group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 50",group 3 involved bispectral index (BIS) of 40,No significant difference,"There were no significant differences in laryngoscopy duration, laryngospasm, bronchospasm, laryngoscopy failure, extremity movement, awakening time among three groups. (p&lt;0.05) (Tables 1 and 2).",3214395
2992,3671204,pain scores after six weeks, physical activity (PA) program for patients with knee and/or hip osteoarthritis (OA),baseline,Significantly increased,"After six weeks, pain scores increased from 5.3 to 6.6 (p=0.04).",3671204
2993,3671204,pain scores after 12 weeks,PA program for patients with knee and/or hip OA,baseline,No significant difference,After 12 weeks this difference disappeared (p=0.5).,3671204
2994,3671204,total time spent on PA ,PA program for patients with knee and/or hip OA,baseline,No significant difference,"These results, did not however, attain statistical significance (p= 0.3 and p=0.43, respectively).",3671204
2995,5980459,pH of abomasal outflow fluid for 4 hours,famotidine administered at 0.4 mg/kg,saline control,Significantly increased,A single dose of famotidine at 0.4 mg/kg significantly increased the pH of abomasal outflow fluid for 4 hours (P &lt; .05) compared with saline control (Figure 3).,5980459
2996,5980459,Least square means and standard deviation pH of abomasal outflow fluid,famotidine administered at 0.4 mg/kg,saline control,Significantly increased,"Least square means and standard deviation pH of abomasal outflow fluid from adult cattle (nâ€‰=â€‰4) administered multiple intravenous doses of 0.4 mg/kg famotidine (circles) every 8 hours (time 0, 8, 16 hours) compared with adult cattle (nâ€‰=â€‰4) administered an equivalent volume of saline (squares). *Denotes statistical significance (Pâ€‰&lt;â€‰.05)",5980459
2997,4586379,aorta wall thicknesses,Hydroxychloroquine (HCQ),control,Significantly decreased,HCQ significantly reduced the area of atherosclerosis as evidenced on en face Sudan IV staining of the whole aorta (Figs 3 and 4) in the CKD treatment group (20.75 Â± 3.3%) compared to CKD control mice (47.48 Â± 4.1%) (P&lt;0.001).,4586379
2998,4586379,"The elasticity of the major vessels, i.e., the movement of vessel wall between the systole and diastole, as well as blood velocity within these vessels",Hydroxychloroquine (HCQ),control,Significantly increased,"The elasticity of the major vessels, i.e., the movement of vessel wall between the systole and diastole, as well as blood velocity within these vessels were significantly better in CKD mice treated with HCQ. *P &lt; 0.05 compared with CKD placebo mice.",4586379
2999,3220859,glucose infusion rate (GIR), detemir,"glargine, NPH insuline",Significantly decreased,"On the basis of BMI status, with all three basal insulins, GIR was lower in people with BMI &gt;29 kg/m2 compared with people with BMI &lt;29 kg/m2 (Fig. 1), but statistical significance was achieved with detemir treatment only (598 Â± 604 and 1,564 Â± 649 mg/kg, respectively; P = 0.03) and not with NPH (1,058 Â± 859 and 1,282 Â± 532 mg/kg) and glargine (1,408 Â± 563 and 1,668 Â± 807 mg/kg) (both P &gt; 0.2).",3220859
3000,3220859,endogenous glucose production (EGP), detemir,"glargine, NPH insuline",Significantly decreased,"In addition, residual EGP was greater in people with BMI &gt;29 vs. &lt;29 kg/m2, although significance was achieved with detemir (7.8 Â± 1.8 vs. 4.1 Â± 2.1 Î¼mol/kg/min, P = 0.001) but not with glargine (5.3 Â± 1.3 vs. 3.8 Â± 2.7 Î¼mol/kg/min, P = 0.231) and tended to be different with NPH (6.6 Â± 2.2 vs. 4.0 Â± 2.1 Î¼mol/kg/min, P = 0.068).",3220859
3001,4730432,intention to seek information about clinical trials,church-based educational intervention,baseline,Significantly increased,"Control group participants did not see a significant increase or decrease in intention to seek information about clinical trials, on average, between any pair of time points. There were no significant changes in the average intention to join between any pair of time points for either group.",4730432
3002,4730432,intention to seek information about clinical trials,control,baseline,Significantly increased,"Control group participants did not see a significant increase or decrease in intention to seek information about clinical trials, on average, between any pair of time points. There were no significant changes in the average intention to join between any pair of time points for either group.",4730432
3003,4347450,self-reported Music performance anxiety (MPA),cognitive behavioral (CB) group-delivered intervention,waitlist condition,Significantly decreased,"The intervention group (post-intervention) showed significantly less self-reported MPA than the wait-list control group (pre-intervention) at time 2 [t(60) = âˆ’2.4, p &lt; 0.05].",4347450
3004,4347450,Judge 1's ratings of PQ,cognitive behavioral (CB) group-delivered intervention,waitlist condition,Significantly increased,"There was a statistically significant increase in Judge 1's ratings of PQ for the intervention group between time 1 and 3 [t(29) = âˆ’2.53, p &lt; 0.05] (see Figure 5), indicating that, despite the intervention having had no immediate significant therapeutic benefit in terms of Judge 1's ratings of PQ, there was a significant increase in PQ over the five and half month period of the study.",4347450
3005,4347450,Judge 2's performance quality ratings between time 2 and 3,cognitive behavioral (CB) group-delivered intervention,waitlist condition,Significantly increased,"While a paired-samples t-test indicated a statistically significant increase in Judge 2's ratings of PQ for the intervention group between time 2 and 3 [t(29) = âˆ’2.09, p &lt; 0.05],",4347450
3006,4347450,Judge 2's performance quality ratings between time 1 and 3,cognitive behavioral (CB) group-delivered intervention,waitlist condition,No significant difference,"While a paired-samples t-test indicated a statistically significant increase in Judge 2's ratings of PQ for the intervention group between time 2 and 3 [t(29) = âˆ’2.09, p &lt; 0.05], ratings of PQ at time 1 and 3 were equivalent [t(29) = âˆ’0.21, p &gt; 0.05] (see Figure 6).",4347450
3007,3263747,mean number of attacks per day,plant extract St. John's Wort (SJW),placebo,No significant difference,"The decrease in mean number of attacks per day was 0.75 with SJW and 1.01 with placebo, P = 0.06.",3263747
3008,3263747," levels of  vascular cell adhesion molecule-1 (sVCAM-1), Soluble intercellular adhesion molecule-1 (sICAM-1), The monocyte chemoattractant protein-1 (MCP-1)",plant extract St. John's Wort (SJW),placebo,Significantly increased,"A â‰¥50% improvement in severity of attacks corresponded to a significant increase in levels of sVCAM-1 (P = 0.003), sICAM-1 (P = 0.007), and MCP-1 (P = 0.004).",3263747
3009,3263747,"E-selectin, metalloproteinase-9 (MMP-9),  Granulocyte colony-stimulating factor (G-CSF) , and Vascular endothelial growth factor (VEGF)",plant extract St. John's Wort (SJW),placebo,Significantly increased,"Comparing subjects who improved by at least 50% to those who did not with respect to the frequency of RP attacks demonstrated significant changes in E-selectin (P = 0.049), MMP-9 (P = 0.011), G-CSF (P = 0.02), and VEGF (P = 0.012) (Table 2).",3263747
3010,5900060,hypoventilation symptoms,noninvasive ventilation (NIV),baseline,No significant difference,NIV was able to relieve hypoventilation symptoms in 95 (89.49%) patients with no or moderate bulbar dysfunction and in 14 (82.86%) patients with severe bulbar dysfunction (p=0.720).,5900060
3011,5900060,Survival from NIV months,noninvasive ventilation (NIV),no NIV,Significantly increased,"When patients were compared in terms of site of ALS onset, all patients who agreed to receive NIV presented longer survival from NIV than those who refused NIV: spinal onset and NIV, median 24.00â€…months (95% CI 17.03â€“30.96â€…months); spinal onset without NIV, median 2.00â€…months (95% CI 0.23â€“3.76â€…months) (p=0.001); bulbar onset and NIV, median 12.00â€…months (95% CI 9.60 to 14.40â€…months); bulbar onset without NIV, median 4.00â€…months (95%CI 2.04â€“5.95â€…months) (p&lt;0.001).",5900060
3012,5043523,folate intakes,knowledge of MTHFR 677Câ€‰â†’â€‰T genotype,control or not at risk,No significant difference,"lthough both intervention groups (risk and non-risk) increased their folate intakes in comparison with the control, there were no significant differences between the groups (pâ€‰=â€‰0.131). There were no significant differences between the risk, non-risk or control with respect to changes in reported intakes of food groups high in folate (Table 2).",5043523
3013,3636767,"patients, who achieve the BP target of systolic/diastolic BP &lt; 140/90 mmHg",telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25),telmisartan 80 mg ,Significantly increased,"Across the entire study population, at week 7, single-pill T80/H25 combination therapy significantly reduced the adjusted mean Â± standard error seated trough cuff systolic/diastolic BP from baseline (âˆ’37.0 Â± 0.62/âˆ’18.6 Â± 0.38 mmHg) as compared with T80 monotherapy (âˆ’28.5 Â± 0.88/âˆ’15.4 Â± 0.55 mmHg [adjusted mean difference âˆ’8.5/âˆ’3.2 mmHg; 95% CI âˆ’10.6, âˆ’6.4/âˆ’4.5, âˆ’1.9; P &lt; 0.0001]) and allowed more patients to achieve the BP target of systolic/diastolic BP &lt; 140/90 mmHg (55.5% versus 34.7%; OR, 2.39; 95% CI 1.76, 3.26; P &lt; 0.0001).9",3636767
3014,4630743,Baseline cervical dilatation,400 Î¼g of misoprostol,400 mg of metronidazole tablets (as a placebo),Significantly increased,The primary outcome of misoprostol administration is presented in Table 3. Baseline cervical dilatation of 4.6 Â± 0.96 mm in the study group was significantly (P &lt; 0.0001) higher than the control group (3.6 Â± 0.82 mm).,4630743
3015,4630743,Meantime needed for further cervical dilatation,400 Î¼g of misoprostol,400 mg of metronidazole tablets (as a placebo),Significantly decreased,Meantime needed for further cervical dilatation was significantly (P &lt; 0.0001) delayed in the control group (study: 46.6 Â± 14.57 s vs. control: 68.6 Â± 14.3 s).,4630743
3016,4630743,Pain on cervical dilatation,400 Î¼g of misoprostol,400 mg of metronidazole tablets (as a placebo),Significantly decreased,Pain on cervical dilatation was significantly less in the study group (P &lt; 0.05) [Table 4 and Figure 1].,4630743
3017,4630743,Perioperative side effects of which preoperative abdominal cramp and nausea vomiting,400 Î¼g of misoprostol,400 mg of metronidazole tablets (as a placebo),Significantly increased,Perioperative side effects of which preoperative abdominal cramp and nausea vomiting were significantly higher in study group although these effects did not lead to any prolonged hospital stay [Table 5].,4630743
3018,3152513,Montgomery-Asberg Depression Rating Scale (MADRS) total score changes in patients with baseline MADRS total scores â‰¥20 on day on day 7 and 21,flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter),"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks",Significantly increased,"In patients with baseline MADRS total scores â‰¥20, LS mean Â± SE changes from baseline in MADRS total score with asenapine were significantly greater than placebo on days 7 (-11.3 Â± 1.5 vs -4.5 Â± 1.6; P = 0.002) and 21 (-13.6 Â± 1.6 vs-7.0 Â± 1.8; P = 0.009) and were greater than olanzapine on day 7 (-11.3 Â± 1.5 vs -6.9 Â± 1.2; P = 0.020).",3152513
3019,3152513,LS mean Â± SE changes in MADRS total score in patients with a mixed episode at baseline,flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter),"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks",Significantly increased,"In patients with a mixed episode at baseline, LS mean Â± SE changes in MADRS total score were significantly greater with asenapine than placebo on days 7 (-6.7 Â± 0.7 vs -3.6 Â± 1.0; P = 0.011) and 21 (-8.5 Â± 0.8 vs -5.8 Â± 1.1; P = 0.040), with the difference from olanzapine showing a trend towards statistical significance on day 7 (-6.7 Â± 0.7 vs -5.0 Â± 0.7; P = 0.076).",3152513
3020,3152513,MADRS remission rates in patients with baseline MADRS total scores â‰¥20,flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter),"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks",Significantly increased,"In patients with baseline MADRS total scores â‰¥20, MADRS remission rates (defined as MADRS total score â‰¤12) with asenapine were significantly greater than placebo on days 7 (57% vs 17%; P = 0.004) and 21 (70% vs 33%; P = 0.012); remission rate with asenapine on day 7 was significantly greater than olanzapine (57% vs 25%; P = 0.006) and showed a trend towards statistical significance on day 21 (70% vs 48%; P = 0.066).",3152513
3021,3152513,"In patients with baseline CGI-BP-D severity score â‰¥4, MADRS remission rates",flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter),"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks",Significantly increased,"In patients with baseline CGI-BP-D severity score â‰¥4, MADRS remission rates with asenapine were significantly greater than placebo on day 7 (68% vs 35%; P = 0.014) and showed a trend towards statistical significance on day 21 (68% vs 41%; P = 0.05); the remission rate with asenapine on day 7 was significantly greater than olanzapine (68% vs 45%; P = 0.031).",3152513
3022,3152513,"In patients with a mixed episode at baseline, MADRS remission rates",flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter),"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks",Significantly increased,"In patients with a mixed episode at baseline, MADRS remission rates with asenapine were significantly greater than placebo on days 7 (76% vs 44%; P &lt; 0.001) and 21 (78% vs 56%; P = 0.019); the remission rate with asenapine on day 7 was significantly greater than olanzapine (76% vs 55%; P = 0.007).",3152513
3023,3152513,Clinical Global Impression for Bipolar Disorder-Depression (CGI-BP-D) score,flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter),"placebo, or oral olanzapine 5-20 mg once daily for 3 weeks",Significantly decreased,Decreases in CGI-BP-D score were significantly greater with asenapine versus placebo at day 7 in all categories and day 21 in population 1; CGI-BP-D score reductions were significantly greater with olanzapine versus placebo at day 21 in population 1 and day 7 in populations 2 and 3.,3152513
3024,4240932,Brief International Cognitive Assessment for MS (BICAMS) test,"B. papyrifera (capsule 300 mg, twice a day)",placebo,Significantly increased,"regarding BVMT-R, our findings were statistically significant (P &lt; 0.001).",4240932
3025,4240932,"California verbal learning test (CVLT), and symbol digit modality test (SDMT)","B. papyrifera (capsule 300 mg, twice a day)",placebo,No significant difference,"Although the number of patients who improved after receiving the drug in the treatment group was more than the placebo group in CVLT and SDMT, such a difference was not statistically significant (P = 0.2000 for SDMT, P = 0.1700 for CVLT); r",4240932
3026,5156617,the myopic refractive error,myopia of -0.75 to -6.0 diopters (D),baseline,Significantly decreased,"The mean myopic refractive error changed from -3.65 Â± 1.62 to -1.05 Â± 1.64 D after wearing the lenses for 4 weeks, which constituted a statistically significant decrease of 2.60 Â± 2.21 D (p &lt; 0.001).",5156617
3027,5156617,The mean astigmatic refractive error,astigmatism of 1.25 to 4.0 D,baseline,Significantly decreased,"The mean astigmatic refractive error changed from 2.07 Â± 0.83 to 1.44 Â± 0.99 D after wearing the lenses for 4 weeks, which constituted a statistically significant decrease of 0.63 Â± 0.98 D (p = 0.001).",5156617
3028,5156617,The mean uncorrected and corrected visual acuities,myopia of -0.75 to -6.0 diopters (D) and astigmatism of 1.25 to 4.0 D,baseline,Significantly decreased,"The mean uncorrected and corrected visual acuities before wearing the lenses were 2.14 Â± 0.80 logarithm of the logMAR (logMAR) and 0.05 Â± 0.13 logMAR, respectively, which changed to 0.12 Â± 0.30 logarithm of the logMAR (p &lt; 0.001) and 0.01 Â± 0.04 logMAR (p = 0.156) after 4 weeks.",5156617
3029,5156617,"The mean corneal endothelial cell count, the difference in hexagonality, the coefficient of variation before and after wearing the lenses",myopia of -0.75 to -6.0 diopters (D) and astigmatism of 1.25 to 4.0 D,baseline,No significant difference,"The mean corneal endothelial cell count at the screening visit was 3,196.55 Â± 237.80 cells/mm2, which increased by 40.72 Â± 207.67 cells/mm2 to 3,237.28 Â± 277.25 cells/mm2 after 4 weeks of toric orthokeratology lens use. However, this difference was not statistically significant (p = 0.300). The difference in hexagonality was -0.07 Â± 12.07, which was also not statistically significant (p = 0.976). The coefficient of variation before and after wearing the lenses was 0.31 Â± 0.05 and 0.33 Â± 0.07. The difference of 0.02 Â± 0.06 was statistically significant (p = 0.027) (Table 4).",5156617
3030,5156617,The Efron grading scale scores,myopia of -0.75 to -6.0 diopters (D) and astigmatism of 1.25 to 4.0 D,baseline,No significant difference,"After 4 weeks of lens use, 25 eyes (80.65%) were normal, four eyes (12.90%) were graded as trace, and two eyes (6.45%) were graded as mild. The difference in grading before and after lens use was not statistically significant (p = 0.815).",5156617
3031,4483405,pain or  range of motion (ROM) improvement,Maitland mobilization,Kaltenborn mobilization,No significant difference,"However, there were no significant differences between the MM and KM groups with respect to pain or ROM improvement in FS patients (p &gt; 0.05) (Table 2).",4483405
3032,5864139,Cases of pancreatic cancer,"sitagliptin, 23 (0.3%)",placebo,No significant difference,"Cases of pancreatic cancer were numerically fewer with sitagliptin (9 [0.1%]) versus placebo (14 [0.2%]) (hazard ratio 0.66 [95% CI 0.28â€“1.51], P = 0.32; 0.042 vs. 0.066 events/100 patient-years).",5864139
3033,5864139,risk for acute pancreatitis,DPP-4i therapy,placebo,Significantly increased,"Meta-analysis of the data from the three cardiovascular outcome trials with DPP-4i reported to date (Fig. 2) shows a statistically significant increased risk of acute pancreatitis for DPP-4i therapy (risk ratio 1.78 [95% CI 1.13â€“2.81], P = 0.01) without evidence of heterogeneity.",5864139
3034,5864139,Cases of pancreatic cancer,DPP-4i therapy,placebo,No significant difference,"Meta-analysis for pancreatic cancer showed a nonsignificant effect of DPP-4i (risk ratio 0.54 [95% CI 0.28â€“1.04], P = 0.07) without evidence of heterogeneity.",5864139
3035,3506580,mean pain intensity,Transcranial direct current stimulation (tDCS),baseline,No significant difference,"There was no significant difference of the perceived mean pain intensity before and after tDCS stimulation for the factors time (PREPOST: F(1,13)â€Š=â€Š0.85; pâ€Š=â€Š0.374) and stimulation modality (STIM: F(2,26)â€Š=â€Š0.93; pâ€Š=â€Š0.379) and no interaction between STIM*PREPOST (F(2,26)â€Š=â€Š1.18; pâ€Š=â€Š0.323).",3506580
3036,3506580,heat pain thresholds (HPT),Transcranial direct current stimulation (tDCS),baseline,No significant difference,"There were no significant differences of HPT before and after tDCS (PREPOST: F(1,9)â€Š=â€Š0.82; pâ€Š=â€Š0.389) and between treatment modalities (STIM: F(2,18)â€Š=â€Š1.27; pâ€Š=â€Š0.306).",3506580
3037,3506580,Individual patient responses,Transcranial direct current stimulation (tDCS),baseline,No significant difference,Individual patient responses are shown in Table 3. There were no significant distribution differences (Pâ€Š=â€Š0.762) for a 30% cut-off.,3506580
3038,3506580," PREPOST, STIM and BLOCK ",Transcranial direct current stimulation (tDCS),baseline,No significant difference,"Likewise, a three factor repeated measures ANOVA using non-normalized data across all 10 blocks did not yield significant results for the factors PREPOST: F(1,11)â€Š=â€Š1.67; pâ€Š=â€Š0.222) STIM (F(2,22)â€Š=â€Š0.56; pâ€Š=â€Š0.509) and BLOCK (F(9,99)â€Š=â€Š2.87; pâ€Š=â€Š0.103) and the corresponding interactions (STIM*PREPOST: F(2,22)â€Š=â€Š0.13; pâ€Š=â€Š0.767; STIM*BLOCK: F(18,198)â€Š=â€Š0.70; pâ€Š=â€Š0.554; PREPOST*BLOCK: F(9,99)â€Š=â€Š1.86; pâ€Š=â€Š0.188; STIM*PREPOST*BLOCK: F(18,198)â€Š=â€Š1.1; pâ€Š=â€Š0.363).",3506580
3039,3671234,VAS score,"bupivacaine in 0 (immediately in the postoperative recovery room), 1st, 2nd, 3rd, and 4th hours in the postoperative period",Baseline,Significantly increased,"VAS score was found to be significantly higher (P &lt; 0.05) among the patients who received only bupivacaine in 0 (immediately in the postoperative recovery room), 1st, 2nd, 3rd, and 4th hours in the postoperative period. A",3671234
3040,3671234,The duration of analgesia,12.5â€‰mg hyperbaric bupivacaine along with preservative free midazolam 0.4â€‰mL (2â€‰mg),hyperbaric bupivacaine 12.5â€‰mg along with 0.4â€‰mL of normal saline in the subarachnoid block,Significantly increased,The duration of analgesia was significantly higher in patients receiving bupivacaine and midazolam in comparison to bupivacaine alone (median 320â€‰min versus 220â€‰min) (Figure 1).,3671234
3041,3321528,"wrist flexion, hip flexion, knee extension, and ankle dorsiflexion",electrical muscle stimulation (EMS),control,Significantly increased,"Twenty four patients in the EMS group and 28 patients in the control group were finally evaluated. EMS patients achieved higher MRC scores than controls (P â‰¤ 0.05) in wrist flexion, hip flexion, knee extension, and ankle dorsiflexion.",3321528
3042,3321528,the total MRC score of the legs,electrical muscle stimulation (EMS),control,Significantly increased,"Collectively, the EMS group performed higher (P &lt; 0.01) in the legs and overall.",3321528
3043,3321528,handgrip strength,Intensive Care Unit acquired weakness (ICU-AW),without an ICU-AW diagnosis,No significant difference,"No difference was observed between the EMS and the control group in handgrip strength either in absolute (21.4 Â± 10.8 versus 14.8 Â± 10.7â€‰kg, resp., P = 0.18) or relative (60.2 Â± 27.3% predicted versus 49.1 Â± 28.5% predicted, resp., P = 0.38) values.",3321528
3044,3321528,handgrip strength,dominant hand,non-dominant hand,No significant difference,"In concern to between-sides comparison, patients tended to perform better with the dominant rather than the non-dominant hand (16.2 Â± 11.1 versus 14.2 Â± 9.9â€‰kg, resp., P = 0.09).",3321528
3045,5735476,The onset time of sensory block, Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î¼g (0.5 ml),"Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î¼g (0.5 ml), Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î¼g (0.5 ml)",Significantly increased,"The onset time of sensory block in Group D5-2.76 Â± 1.32, Group D10-2.45 Â± 1.50, and Group D15-1.86Â±0.93, which is statistically significant (P = 0.025).",5735476
3046,5735476,The time taken for two-segment sensory regression,Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î¼g (0.5 ml),"Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î¼g (0.5 ml)",Significantly increased,"The onset time of sensory block in Group D5-2.76 Â± 1.32, Group D10-2.45 Â± 1.50, and Group D15-1.86Â±0.93, which is statistically significant (P = 0.025).",5735476
3047,5735476,The time taken for complete sensory recovery,Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î¼g (0.5 ml),"Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î¼g (0.5 ml)",Significantly increased,"The time taken for complete sensory recovery in Group D5-319.83 Â± 61.41, Group D10-336.13 Â± 61.38, and Group D15-415.20 Â± 96.6, which is statistically highly significant (P = 0.000).",5735476
3048,5735476,Time for rescue analgesia,Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î¼g (0.5 ml),"Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î¼g (0.5 ml)",Significantly increased,"Time for rescue analgesia in Group D5-377.46 Â± 60.05, in Group D10-401.60 Â± 61.11, and in Group D15-517.96 Â± 97.30, which is statistically highly significant (P &lt; 0.000).",5735476
3049,5735476,Heart rate falls,"Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î¼g (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î¼g (0.5 ml)",baseline,Significantly increased,"The HR fall significantly at 105 and 120 min from basal rate within groups, we noticed bradycardia in 3 (10.0%) patients among Group D5, 4 (13.3%) patients in Group D10, 10 (33.3%) patients in Group D15, which is statistically significant (P = 0.044).",5735476
3050,5735476,mean arterial pressure (MAP) falls,"Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î¼g (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î¼g (0.5 ml)",baseline,Significantly increased,"MAP falls significantly at 30th, 45th, and 60th min from basal rate within the groups, we have noticed hypotension in 4 (13.3%) patients in Group D5, 6 (20.0%) patients in Group D10, 13 (43.3%) patients in Group D15, which is statistically significant (P = 0.020) [Table 3].",5735476
3051,3177395,dental plaque on smooth and approximal tooth surfaces after 14 days,received herbal extract dentifrices or used a conventional dentifrice,baseline,Significantly decreased,"After 14 days, significant reduction of dental plaque on smooth and approximal tooth surfaces compared to baseline was observed in all groups (P &lt;60; 0.001).",3177395
3052,3177395,mean values of plaque indices after 14 days,received herbal extract dentifrices ,used a conventional dentifrice,Significantly decreased,"However, in the conventional group, mean values of plaque indices were significantly higher than in the herbal groups.",3177395
3053,3177395,reduction in gingival inflammation after 42 days,received herbal extract dentifrices ,used a conventional dentifrice,Significantly increased,"After 42 days, the reduction in gingival inflammation (as assessed by GI) was 68.0% in herbal test group 1, 70.6% in herbal test group 2, and 40.5% in the conventional group.",3177395
3054,3177395,Mean values of the SBI after 42 days,received herbal extract dentifrices ,used a conventional dentifrice,Significantly decreased,"Mean values of the SBI decreased by 79.5%, 81.2%, and 42.1%, respectively.",3177395
3055,1968469,appetite between weeks 0 (pre-study) and 3 and 0 and 6,MPA (100 mg tds orally) ,placebo,Significantly increased,here was a significant improvement in appetite in the MPA group between weeks 0 (pre-study) and 3 (P = 0.0002) and 0 and 6 (P = 0.015). There was no significant improvement in appetite in the placebo group.,1968469
3056,1968469,serum thyroid binding pre-albumin and retinol binding protein,MPA (100 mg tds orally) ,placebo,Significantly increased,Supporting this finding was the significant increase in serum thyroid binding pre-albumin and retinol binding protein in the MPA group between weeks 0 and 3 and 0 and 6 (P = 0.023 and P = 0.039 respectively). These two parameters showed no significant change in the placebo group.,1968469
3057,1968469,"change in anthropometric measurements, weight, performance status, energy, mood or pain",MPA (100 mg tds orally) ,placebo,No significant difference,"here was no change in anthropometric measurements, weight, performance status, energy, mood or pain in either group.",1968469
3058,1968469,only abstarct,1,2,No significant difference,TitleArticle TitleA double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.,1968469
3059,5140822,static and dynamic balance and cadence,"climbed onto a horse riding simulator, and performed the horse riding simulation exercise",took part in the horse riding exercises without a blindfold,Significantly increased,Significant differences in the post-training gains in static and dynamic balance and cadence were observed between experimental and control groups (p&lt;0.05).,5140822
3060,5140822,"static balance, dynamic balance, velocity, and cadence","climbed onto a horse riding simulator, and performed the horse riding simulation exercise or took part in the horse riding exercises without a blindfold",baseline,Significantly increased,"The experimental group showed significant improvement in static balance, dynamic balance, velocity, and cadence compared to the pre-intervention results (p&lt;0.05). In addition, the control group showed significant improvement in static and dynamic balance, single support, and cadence compared to the pre-intervention results (p&lt;0.05).",5140822
3061,4726501,The annual change in eGFR,"receive aspirin (81 mg or 100 mg daily,",no aspirin,No significant difference,"The annual change in eGFR was âˆ’0.8 Â± 2.9 ml/min/1.73m2/year in the aspirin group, and âˆ’0.9 Â± 2.5 ml/min/1.73m2/year in the no aspirin group. There was no significant difference in the both group (P = 0.2).",4726501
3062,4726501,the incidence of positive urine dipstick albumin,"receive aspirin (81 mg or 100 mg daily,",no aspirin,No significant difference,"The multivariable analyses showed that low-dose aspirin was not associated with the incidence of positive urine dipstick albumin in the intension-to-treat analysis (HR, 1.12; 95% CI, 0.95 to 1.32) and the on-treatment analysis (HR, 1.08; 95% CI, 0.92 to 1.27) (Table 2).",4726501
3063,5377263,Th1 and Th1/Th2,"HBD-3 (standard, 10 Âµg:50 Âµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.",injected with placebo saline solution in the articular cavity,Significantly increased,"Th1 and Th1/Th2 of observation group was increased significantly comparing with that of control group, while Th2 decreased, the difference was statistically significant (P&lt;0.05) (Table I and Fig. 1).",5377263
3064,5377263,IL-2 and TNF-Î±,"HBD-3 (standard, 10 Âµg:50 Âµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.",injected with placebo saline solution in the articular cavity,Significantly increased,"IL-2 and TNF-Î± levels increased significantly comparing with that of control group, while IL-10 level decreased, the differences were statistically significant (P&lt;0.05) (Table II).",5377263
3065,5377263,IL-10 level,"HBD-3 (standard, 10 Âµg:50 Âµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.",injected with placebo saline solution in the articular cavity,Significantly decreased,"while IL-10 level decreased, the differences were statistically significant (P&lt;0.05) (Table II).",5377263
3066,5377263,TLR-4 and ALP levels,"HBD-3 (standard, 10 Âµg:50 Âµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.",injected with placebo saline solution in the articular cavity,Significantly increased,"TLR-4 and ALP levels of observation group were significantly higher than that of control group, the difference was statistically significant (P&lt;0.05) (Table III).",5377263
3067,5377263,implant infection,"HBD-3 (standard, 10 Âµg:50 Âµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days.",injected with placebo saline solution in the articular cavity,No significant difference,"There were 3 cases of implant infection in control group (9.4%), 1 case in observation group (3.1%), there was no statistical significance (P=0.306, unilateral) by Fisher's exact probability method.",5377263
3068,2762767,"the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Minnesota Living with Heart Failure Questionnaire (MLHFQ), and the Self-Care Heart Failure Index (SCHFI)",Internet administration,pen-and-paper administration,No significant difference,KCCQ								Overall Summary Score	18	4.0	9.1	16	-2.0	9.2	.07	Clinical Summary Score	18	2.9	12.5	16	-3.5	14.5	.18MLHFQ								Overall	18	0.9	14.0	16	7.5	26.4	.38	Physical	18	3.3	6.3	16	4.3	10.9	.76	Emotional	18	-2.2	5.5	16	0.6	6.3	.17SCHFI								Overall	17a	15.8	30.9	14	3.3	26.8	.24	Maintenance	18	3.3	8.0	16	2.2	8.8	.69	Management	17 a	7.1	17.2	14	3.9	21.9	.66	Confidence	18	4.9	19.0	14	-3.1	8.4	.12,2762767
3069,5870915,The number of days with AF detectable excretion and the number of piglets that excreted AF detectable oocysts,45 mg toltrazuril + 200 mg gleptoferron (ForcerisÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÂ® 5%),untreated,Significantly decreased,The number of days with AF detectable excretion and the number of piglets that excreted AF detectable oocysts were significantly reduced in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Table 2).Table 1,5870915
3070,5870915,the number of piglets that excreted countable oocyst numbers,45 mg toltrazuril + 200 mg gleptoferron (ForcerisÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÂ® 5%),untreated,Significantly decreased,"The area under the curve for OpG, the number of days with McMaster countable excretion and the number of piglets that excreted countable oocyst numbers were significantly reduced in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Table 2).",5870915
3071,5870915,the number of days with diarrhoea and the number of piglets that had diarrhoea,45 mg toltrazuril + 200 mg gleptoferron (ForcerisÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÂ® 5%),untreated,Significantly decreased,"he area under the curve for the FS, the number of days with diarrhoea and the number of piglets that had diarrhoea were significantly reduced in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Table 2).Fig. 3",5870915
3072,5870915,The daily body weight gain from SD 1 to SD 29,45 mg toltrazuril + 200 mg gleptoferron (ForcerisÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÂ® 5%),untreated,Significantly increased,The daily body weight gain from SD 1 to SD 29 was significantly higher in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Fig. 5).,5870915
3073,3650212,The maxillary molars movement,using the FA alone,a combination of the FA with high-pull headgear worn at night,No significant difference,"The maxillary molars moved distally by 5.51 Â± 2.56 mm and 5.93 Â± 1.46 mm in groups 1 and 2, respectively. The change was significant in each of the 2 groups (pre-versus post-treatment), but there was no significant difference between the 2 groups.",3650212
3074,3650212,The tipping,using the FA alone,a combination of the FA with high-pull headgear worn at night,Significantly increased,"The tipping was only significant in group 1, and it was significantly larger in this group than in group 2 (p &lt; 0.001).",3650212
3075,3650212,Mesial movement of the second premolars,using the FA alone,a combination of the FA with high-pull headgear worn at night,Significantly increased,"Mesial movement of the second premolars was 2.70 Â± 1.37 mm and 0.90 Â± 1.38 mm in groups 1 and 2, respectively. Although the change was significant in each of the 2 groups, mesial movement was significantly higher in group 1 than in group 2 (p = 0.008).",3650212
3076,3650212,Treatment time,using the FA alone,a combination of the FA with high-pull headgear worn at night,Significantly increased,Treatment time was significantly greater in group 1 than in group 2 (7.44 Â± 1.30 months versus 6.27 Â± 1.11 months; p &lt; 0.001).,3650212
3077,3650212,The speed of maxillary molar distalization,using the FA alone,a combination of the FA with high-pull headgear worn at night,Significantly decreased,The speed of maxillary molar distalization was also significantly lower in group 1 than in group 2 (0.68 Â± 0.40 mm/month versus 0.86 Â± 0.32 mm/month; p &lt; 0.001).,3650212
3078,3650212,the ratio of the maxillary molar distalization movement relative to the overall opening space between the molars and second premolars,using the FA alone,a combination of the FA with high-pull headgear worn at night,Significantly decreased,"Finally, the ratio of the maxillary molar distalization movement relative to the overall opening space between the molars and second premolars was significantly lower in group 1 than in group 2 (70.74% Â± 7.25% versus 90.97% Â± 5.51%; p &lt; 0.001).",3650212
3079,3967502,healthy eating behaviour,completed internet intention questions,completed the word jumble,No significant difference,"The non-significant effect of control condition indicates that there was no difference in healthy eating behaviour between participants who completed internet intention questions (M = .20, SD = .34) and participants who completed the word jumble (M = .27, SD = .38).",3967502
3080,3967502,"the proportion of healthy items in total items chosen,",completed questions,control,Significantly increased,"Consistent with a QBE, participants in the healthy eating intentions condition chose a greater proportion of healthy food (M = .38, SD = .42) relative to participants in the control conditions (M = .24, SD = .36) (see Figure 1).1",3967502
3081,5148913,adjusted mean change of PEF,BDP/FF 200/6 Î¼g pMDI extrafine (two puffs twice a day),BDP 100 Î¼g (four puffs twice a day),Significantly increased,"The difference in the adjusted mean change from baseline between the two treatment groups was statistically significant in favour of the BDP/FF group (19 L/min, 95% CI: 10, 27; pâ€‰&lt;â€‰0.001), indicating superiority of BDP/FF treatment vs. BDP (Table 2).",5148913
3082,5148913,pre-dose morning FEV1,BDP/FF 200/6 Î¼g pMDI extrafine (two puffs twice a day),BDP 100 Î¼g (four puffs twice a day),Significantly increased,"Both treatments showed a statistically significant increase in pre-dose morning FEV1 from baseline to each clinic visit and over the entire treatment period (pâ€‰&lt;â€‰0.001) with a difference of 0.071 L in favour of BDP/FF group (pâ€‰=â€‰0.058). When reversibility test results were added as covariate (post-hoc analysis), the magnitude of the FEV1 difference between groups were even larger 0.087 L (pâ€‰=â€‰0.016) in favour of BDP/FF (Fig. 3).Fig. 3",5148913
3083,5148913,The mean average use of rescue medication,BDP/FF 200/6 Î¼g pMDI extrafine (two puffs twice a day),BDP 100 Î¼g (four puffs twice a day),No significant difference,The mean average use of rescue medication was similar in the BDP/FF and BDP groups at baseline (2.7 and 2.9 puffs/day respectively) and decreased significantly in both groups at the end of the treatment period (1.4 and 1.7 puffs/day respectively; pâ€‰&lt;â€‰0.001 vs baseline). There were no statistically significant differences between the adjusted mean changes in use of rescue medication across treatment groups at each inter-visit period (p-value ranging from 0.051 to 0.586) and over the entire treatment period (pâ€‰=â€‰0.143).,5148913
3084,5148913,abnormalities in haematology or blood chemistry parameters,BDP/FF 200/6 Î¼g pMDI extrafine (two puffs twice a day),BDP 100 Î¼g (four puffs twice a day),No significant difference,No clinically significant abnormalities in haematology or blood chemistry parameters were reported during the study.,5148913
3085,5148913,The ACQ scores,BDP/FF 200/6 Î¼g pMDI extrafine (two puffs twice a day),BDP 100 Î¼g (four puffs twice a day),No significant difference,"he ACQ scores were similar in the BDP/FF and BDP at baseline (2.12 and 2.16, respectively). Both treatments resulted in a statistically significant reduction in ACQ score from baseline to Week12 (pâ€‰&lt;â€‰0.001), above the minimal clinical difference of 0.5 points. The extent of the reduction was similar across treatments.",5148913
3086,4530661,BMI and waist to hip ratio,consumed 200 ml/day of probiotic soy milk containing Lactobacillus planetarium A7  for 8 weeks,consumed 200 ml/day of soy milk for 8 weeks,No significant difference,"There were not any significant differences in terms of BMI (P = 0.920) and waist to hip ratio (WHR) (P = 0.610) at the beginning of study between two groups, but after intervention in probiotic soy milk a significant within group reduction was found in BMI (P &lt; 0.010) and WHR (P &lt; 0.050). But we did not find a significant difference between two groups after adjusting by baseline values, confounding factors with ANCOVA (Table 3).",4530661
3087,4530661,systolic and diastolic BP,consumed 200 ml/day of probiotic soy milk containing Lactobacillus planetarium A7  for 8 weeks,consumed 200 ml/day of soy milk for 8 weeks,Significantly decreased,"However, probiotic soy milk significantly reduced systolic (P &lt; 0.001) and diastolic BP (P &lt; 0.050) even after adjusting by cofounding factors and baseline values with ANCOVA (P &lt; 0.001), but systolic and diastolic BP didnâ€™t show any significant changes in soy milk group (P = 0.120 and 0.670, respectively).",4530661
3088,4950806,The percentage changes in lumbar BMD,alendronate (AD) ,alfacalcidol (AC),Significantly increased,"The percentage changes in lumbar BMD from baseline to the end of one year of therapy were âˆ’0.4Â±4.0% for the AC group and 6.8Â±6.3% for the AD group, with significantly effective lumbar BMD findings identified in the AD group (P=0.015; Fig. 1).",4950806
3089,4950806,"BAP (U/l),NTX (nmol BCE/l)",alendronate (AD) ,alfacalcidol (AC),No significant difference,"When comparing the percentage change between baseline and the end of one year of treatment, the AC group demonstrated less of a change over time in BAP (âˆ’12.1Â±25.5%) compared with the AD group (âˆ’32.7Â±21.7%) (P=0.103), and less of a change over time in NTX (+2.4Â±25.7%) compared with the AD group (âˆ’15.9Â±21.3%) (P=0.143); although the difference was not statistically significant (Figs. 2 and 3).",4950806
3090,4950806,FSSG score,alendronate (AD) ,alfacalcidol (AC),No significant difference,"The change from baseline FSSG scores to the end of one year of treatment was not significantly different in either group (AC group, P=0.556; AD group, P=0.723), respectively (Fig. 4).",4950806
3091,5800451,final irrigant solutions of root canal,3 mL of 5.25% Sodium hypoclorite  with ultrasonic for 30 sec.,3 mL of 5.25% Sodium hypoclorite  with 808 nm Diode laser for 30 sec,Significantly decreased,Statistical analysis showed significant difference between groups (P&lt;0.05). There was a significant difference between groups 1 and 2 in terms of protein leakage.,5800451
3092,5800451,final irrigant solutions of root canal,3 mL of 17% EDTA  with ultrasonic for 30 sec.,3 mL of 17% EDTA  with 808 nm Diode laser for 30 sec,Significantly decreased,Statistical analysis showed significant difference between groups (P&lt;0.05),5800451
3093,5800451,Final irrigant solutions of root canal,3 mL of 5.25% sodio hypoclorite  with ultrasonic for 30 sec.,3 mL of 17% EDTA  with 808 nm Diode laser for 30 sec,No significant difference,here was no significant difference among the effects of solutions on the apical seal (P&gt;0.05),5800451
3094,5800451,Final irrigant solutions of root canal,3 mL of 5.25% sodio hypoclorite with 808 nm Diode laser for 30 sec,3 mL of 17% EDTA  with ultrasonic for 30 sec.,No significant difference,here was no significant difference among the effects of solutions on the apical seal (P&gt;0.05),5800451
3095,5091897,household smoking bans follow up 3 and 6 months ,Intervention group,Control Group,Significantly decreased,intervention participants had significantly less self-reported SHS exposure compared to those in the control group,5091897
3096,5091897,Household smoking bans ,Intervention group,Control Group,No significant difference,"There were no statistically significant differences in changes in smoking status over time between the two groups,",5091897
3097,5306984,subacute stroke patients,ArmAssist (AA group),conventional arm training (control group),Significantly decreased,AA robotic device is safe and able to reduce motor deficits more effectively than matched conventional arm training,5306984
3098,5306984,subacute stroke patients,ArmAssist AA group,conventional arm training (control group),Significantly increased,"The AA group, in comparison to the Control group, showed significantly greater increases in FMA-UE score (18.0 Â± 9.4 versus 7.5 Â± 5.5, p = 0.002) and WMFT-FAS score (14.1 Â± 7.9 versus 6.7 Â± 7.8, p = 0.025) after 3 weeks of treatment",5306984
3099,4830045,Fertilization characteristics,patients in the 3&nbsp;h group,patients in the 20&nbsp;h group,No significant difference,"did not find a significant difference between the rates of normal fertilization in the 3&nbsp;h and 20&nbsp;h groups, suggesting that normal fertilization was not affected by early cumulus cell removal.",4830045
3100,4830045,Embryo quality,Patients in the 3h group,Patients in the 20h group,Significantly increased,significantly higher polyspermy rate and percentage of optimal embryos.,4830045
3101,4830045,Birth status,Patients in the 3h group,Patients in the 20h group,No significant difference,low birth weight infants were more common in the 3&nbsp;h group,4830045
3102,4450164,ureteropelvic junction obstruction,internal drainage group,"stentless cases,",No significant difference,"there was no significant difference between groups, concerning extravasation and anastomosis complications, such as leakage, stenosis, urinoma formation, evidence of obstruction at postoperative IVP or DTPA scan",4450164
3103,4450164,ureteropelvic junction obstruction,internal drainage group,stentless cases,Significantly increased,"significant incidence of catheter related symptoms, such as irritative urinary symptoms and flank pain was reported",4450164
3104,3994428,Hematoma enlargement,ICP monitoring,control group,No significant difference,Hematoma enlargement and secondary brain hernia,3994428
3105,3994428,Secondary brain herniation.,ICP monitoring,control group,Significantly decreased,"in the ICP monitoring group was significantly lower compared with the control group (10.9% vs. 20.5%, Pâ€‰=â€‰0.04).",3994428
3106,3994428,neurological status,ICP monitoring,control group,No significant difference,neurological outcome was better in the ICP group compared with the control group (Pâ€‰&lt;â€‰0.05).,3994428
3107,3994428,Mortality,ICP monitoring,control group,No significant difference,6.5% in the ICP group and 9.1% in the control group (Pâ€‰&lt;â€‰0.05),3994428
3108,3132864,restriction,derivation group,validation group,No significant difference,". The discriminative formula was thus applied to this â€œvalidation groupâ€�. When our formula was applied to this group, we found that our formula significantly predicted the absence of restriction (p&lt; 0.0001)",3132864
3109,3132864,diagnose restriction,formula,Gladyâ€™s algorithm,Significantly decreased,Using Gladyâ€™s algorithm we would avoid about the same number of tests (39%) but would only diagnose 136 of the 154 (89%) patients with restriction,3132864
3110,3132864,discriminative formula,derivation group,validation group,Significantly decreased,our formula significantly predicted the absence of restriction (p&lt; 0.0001),3132864
3111,3132864,discriminative formula,"VALIDATION GROUP  the sensitivity, specificity, PPV, NPV were 95%, 44%, 22%, and 98%"," DERIVATION GROUP sensitivity, specificity, PPV, NPV were 95%, 42%, 25%, and 98% ",Significantly increased,"both in our derivation and validation groups, our formula had a NPV of 98%",3132864
3112,5516192,The time taken to complete the approach,electrosurgical device,traditional cold instruments (scalpel and scissors),No significant difference,"The time taken to complete the approach was not significantly different between dogs receiving cold or electroincision; cold 3.9 (3.1) minutes, electroincision 3.3 (1.6) minutes, 95% CI âˆ’3.6â€�1.4, Pâ€‰=â€‰.23.",5516192
3113,5516192,The incision length,electrosurgical device,traditional cold instruments (scalpel and scissors),No significant difference,"The incision length was not significantly different; cold 15.7 (5.2) cm, electroincision 15.6 (4.2) cm, 95% CI âˆ’1.6â€�1.8, Pâ€‰=â€‰.91.",5516192
3114,5516192,blood lost,electrosurgical device,traditional cold instruments (scalpel and scissors),Significantly decreased,"There was significantly less blood lost for electroincision than cold incision; cold 3.0 (4.3) mL, electroincision 0.7 (1.7) mL, 95% CI 1.1â€�3.4, Pâ€‰&lt;â€‰.0001.",5516192
3115,5516192,The pain score or swelling 24 hours postoperative,electrosurgical device,traditional cold instruments (scalpel and scissors),No significant difference,"The pain score or swelling 24 hours postoperative was not significantly different between dogs receiving cold or electroincision; pain score cold 1 (0â€�8), electroincision 1.5 (0â€�7), Pâ€‰=â€‰.55; swelling cold 0 (0â€�3), electroincision 0 (0â€�1), Pâ€‰=â€‰.12.",5516192
3116,5516192,The incision redness and discharge,electrosurgical device,traditional cold instruments (scalpel and scissors),Significantly decreased,"The incision redness and discharge were significantly less for electroincision; redness cold 1 (0â€�3), electroincision 0 (0â€�2), Pâ€‰=â€‰.02; discharge cold 0.5 (0â€�3), electroincision 0 (0â€�1), Pâ€‰=â€‰.006.",5516192
3117,5516192,"The pain score, swelling, incision redness, and discharge  at 48 hours postoperative",electrosurgical device,traditional cold instruments (scalpel and scissors),Significantly decreased,"The incision redness and discharge were significantly less for electroincision; redness cold 1 (0â€�3), electroincision 0 (0â€�2), Pâ€‰=â€‰.02; discharge cold 0.5 (0â€�3), electroincision 0 (0â€�1), Pâ€‰=â€‰.006.",5516192
3118,5516192,"incision redness, swelling, or discharge at 10 days postoperative",electrosurgical device,traditional cold instruments (scalpel and scissors),No significant difference,"There was no significant difference in incision redness (Pâ€‰=â€‰.77), swelling (Pâ€‰=â€‰.33), or discharge (Pâ€‰=â€‰.78) at 10 days postoperative between dogs receiving cold or electroincision.",5516192
3119,4188585,The maximum difference in summed pain intensity differences (SPID),capsaicin,placebo,Significantly decreased,"The maximum difference in SPID, between capsaicin and placebo treatments, was observed at 1 month after patch application, but the pain reduction was not significant (NRS, mean difference [95% CI]: 5.0 [0.09 to 9.9]; Pâ€Š=â€Š0.046).",4188585
3120,4188585, skin reactions,capsaicin,placebo,Significantly increased,"Seventeen of 23 (74%) capsaicin treated patients and 6 of 20 (30%) placebo treated patients reported one or more skin reactions on the application site (Pâ€Š=â€Š0.006, Fischerâ€™s exact test, table 5).",4188585
3121,4188585,intraepidermal nerve fiber density (IENFD) to 1 month,capsaicin,placebo,Significantly increased,"Changes in IENFD, from baseline to 1 month after patch application on the pain side, did not differ between capsaicin and placebo treated patients (Pâ€Š=â€Š0.32, table 4).",4188585
3122,3775615,virological response (VR) rates,lamivudine (LAM) (100 mg/day,adefovir (ADV) (10 mg/day),No significant difference,"There were no significant differences in the virological response (VR) rates between LAM+ADV and ETV cohorts at 24, 52, and 104 weeks (P&gt;0.05).",3775615
3123,3775615, HBeAg levels,lamivudine (LAM) (100 mg/day,adefovir (ADV) (10 mg/day),No significant difference,"There were no statistically significant differences between these 2 groups (P=0.668, 0.729, 0.614, and 0.955 at weeks 12, 24, 52, and 104, respectively).",3775615
3124,4815378,Mean hospitalization time, palady,cup,Significantly decreased,Independent t-test showed that mean length of hospitalization and the time interval to reach full oral feeding were significantly lower in palady group compared to the cup group (P &lt; 0.001) [Table 1].,4815378
3125,4815378,Mean weight changes of neonates 7 weeks, palady,cup,Significantly increased,Mean weight changes of neonates 7 weeks after the intervention compared to those in the beginning of the intervention were significantly more in palady group compared to the cup group (cup = 146.7 and palady = 198.8; P &lt; 0.001).,4815378
3126,5200917,reaction time in simple speeded response task ,tolcapone,placebo,No significant difference,"Moreover, in a simple speeded response task, no difference was seen in reaction time for either visual or auditory responding on tolcapone compared to placebo (all T(14)&nbsp;â‰¤&nbsp;1.1, p&nbsp;â‰¥&nbsp;0.3),",5200917
3127,5200917,blood pressure,tolcapone,placebo,No significant difference,"Finally, no differential changes in blood pressure were seen on tolcapone versus placebo (T(15)&nbsp;=&nbsp;1.31, p&nbsp;=&nbsp;0.21),",5200917
3128,4078065,mRNA stability,3.2&nbsp;g/day citrulline,placebo,Significantly increased,"Further, ABCA1 and ABCG1 mRNA decay induced by ActD were inhibited in the presence of the citrulline (Fig.&nbsp;2C and D), thus indicating they enhanced mRNA stability of ABCA1 by 44.5&nbsp;Â±&nbsp;7.0% (p&lt;0.05) and ABCG1 by 39.1&nbsp;Â±&nbsp;5.5% (p&lt;0.05).",4078065
3129,4078065,apoA-I- and HDL-mediated cholesterol efflux,3.2&amp;nbsp;g/day citrulline,placebo,Significantly increased,"Citrulline enhanced both apoA-I- and HDL-mediated cholesterol efflux from THP-1 macrophages by 96.1&nbsp;Â±&nbsp;26.1% (p&lt;0.05) and 14.4&nbsp;Â±&nbsp;2.5% (p&lt;0.05), respectively, compared to control (Fig.&nbsp;3A and B).",4078065
3130,4078065,arginine and ornithine,3.2&amp;amp;nbsp;g/day citrulline,placebo,Significantly increased,"Further, arginine and ornithine, which are metabolically linked with citrulline through the Krebs-Henseleit cycle,(33) were also increased, by 44.7% (p&lt;0.05) and 12.4%, respectively.",4078065
3131,4078065,ABCA1 and ABCG1 protein levels in MDM cultured,3.2 g/day citrulline,placebo,Significantly increased,"ABCA1 and ABCG1 protein levels in MDM cultured under post-citrulline sera were significantly increased, by 85.7&nbsp;Â±&nbsp;24.1% (p&lt;0.05) and 34.7&nbsp;Â± 10.5% (p&lt;0.05), respectively (Fig.&nbsp;6C and D).",4078065
3132,4078065,ApoA-I and HDL-mediated cholesterol effluxes,3.2 g/day citrulline,placebo,Significantly increased,"Consistent with the increased ABCA1/G1 expressions observed above, ApoA-I and HDL-mediated cholesterol effluxes were also significantly increased, by 78.0% (p&lt;0.05) and 11.0% (p&lt;0.05), respectively, in MDM cultured under post-citrulline sera, as compared to pre-citrulline cells and sera (Fig.&nbsp;7A and B).",4078065
3133,5156970,weekly consistency relief,azithromycin,baseline,Significantly increased,"The proportion of weekly consistency relief was greater in azithromycin group for all weeks except for week 8; however, this difference was not significant. According to the Chi-square test's results, the proportion of weekly relief for consistency was significantly greater in azithromycin group only in week 2 (P = 0.028).",5156970
3134,5156970,daily bloating and gas in all 12 weeks,azithromycin,placebo,Significantly decreased,More patients in azithromycin felt the relief of daily bloating and gas in all 12 weeks. Relief differences were significant for both bloating (except for 1st week) and gas in 12 weeks (P &lt; 0.0001).,5156970
3135,5156970,relief of overall symptoms,azithromycin,baseline,Significantly decreased,"Onset of relief for subjects was considered as the 1st week that each patient had relief of overall symptoms. According to the explanation, lower values are more suitable. As it is depicted in Table 1, onset of relief occurred significantly sooner in patients in azithromycin group (P = 0.001).",5156970
3136,3845560,Grade 1/2 anemia,2 cycles of sinusoidal chronomodulated infusion (Arm A),flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy,Significantly decreased,Grade 1/2 anemia was more common in Arm B than in Arm A (P = 0.05).,3845560
3137,3845560,"neutropenia , leucopenia , thrombocytopenia , and anemia",2 cycles of sinusoidal chronomodulated infusion (Arm A),flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy,No significant difference,"During radiotherapy, the most frequent serious hematologic toxicities were neutropenia (15.9% in Arm A and 13.1% in Arm B, P = 0.896), leucopenia (11.1% in Arm A and 8.2% in Arm B, P = 0.481), thrombocytopenia (9.5% in Arm A and 4.9% in Arm B, P = 0.289), and anemia (4.8% in Arm A and 1.6% in Arm B, P = 0.508).",3845560
3138,3845560,grade 3 stomatitis,2 cycles of sinusoidal chronomodulated infusion (Arm A),flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy,Significantly decreased,"The severe non-hematologic toxicities observed were grade 3 stomatitis (38.1% in Arm A and 59.0% in Arm B, P = 0.020), vomiting (15.9% in Arm A and 9.8% in Arm B, P = 0.316), diarrhea (1.6% in Arm A and 4.9% in Arm B, P = 0.583), anorexia (1.6% in Arm A and 6.6% in Arm B, P = 0.446), weight loss (9.5% in Arm A and 16.4% in Arm B, P = 0.313), and skin (irradiation field) toxicity (14.3% in Arm A and 26.2% in Arm B, P = 0.097).",3845560
3139,3845560,"vomiting, diarrhea, anorexia, weight loss, and skin (irradiation field) toxicity",2 cycles of sinusoidal chronomodulated infusion (Arm A),flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy,No significant difference,"The severe non-hematologic toxicities observed were grade 3 stomatitis (38.1% in Arm A and 59.0% in Arm B, P = 0.020), vomiting (15.9% in Arm A and 9.8% in Arm B, P = 0.316), diarrhea (1.6% in Arm A and 4.9% in Arm B, P = 0.583), anorexia (1.6% in Arm A and 6.6% in Arm B, P = 0.446), weight loss (9.5% in Arm A and 16.4% in Arm B, P = 0.313), and skin (irradiation field) toxicity (14.3% in Arm A and 26.2% in Arm B, P = 0.097).",3845560
3140,3845560,Locoregional,2 cycles of sinusoidal chronomodulated infusion (Arm A),flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy,No significant difference,Locoregional recurrence occurred in 16 (12.1%) patients: 9 (14.3%) in Arm A and 7 (11.5%) in Arm B (P = 0.539).,3845560
3141,3845560,Distant metastasis,2 cycles of sinusoidal chronomodulated infusion (Arm A),flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy,No significant difference,Distant metastasis represented the major failure pattern and occurred in 27 (21.8%) patients: 16 (25.4%) in Arm A and 11 (18.0%) in Arm B (P = 0.597) (Table 4).,3845560
3142,5014878,Mean antibody reactivity against the associated HPV,quadrivalent HPV vaccine (GardasilÂ®),baseline,Significantly increased,"The mean post-vaccination antibody reactivity was 4690 MFI (SD 727). All individual antibody reactivities increased after vaccination, with a median rise of 3766 MFI (range 1199â€“4670). The mean MFI per patient rose significantly after vaccination (p&nbsp;&lt;&nbsp;0.001).",5014878
3143,5790265,positive rate of HUTT (Head-up tilt testing (HUTT)  after 30 days,Valsalva maneuver (MVM),conventional treatment group (NVM),Significantly decreased,"After 30 days treatment, the positive rate of HUTT was 9.7% in MVM group and 79.4% in NVM group (P&lt;0.01, Fig 3A).",5790265
3144,5790265,Incidence of recurrent syncope after 12 months,Valsalva maneuver (MVM),conventional treatment group (NVM),Significantly decreased,"Incidence of recurrent syncope after 12 months (6.5% vs. 41.2%, P&lt;0.01) and rate of positive HUTT after 30 days (9.7% vs.79.4%, P&lt;0.01) were significantly lower in MVM group than in NVM group.",5790265
3145,4435250,"relationship control, gender norms supporting female autonomy in relationships",Couples Health CoOp [CHC],Menâ€™s Health CoOp/Womenâ€™s Health CoOp [MHC/WHC],Significantly increased,"Following the intervention, women in the CHC arm compared with those in the WHC arm were more likely to report an increase in relationship control (Î²=0.92, 95% confidence interval [CI]: 0.02, 1.83, P=0.045) and gender norms supporting female autonomy in relationships (Î²=0.99, 95% CI: 0.07, 1.91, P=0.035).",4435250
3146,4435250,relationship equity, females in group Menâ€™s Health CoOp/Womenâ€™s Health CoOp [MHC/WHC],Couples Health CoOp [CHC],Significantly increased,"Women in the MHC/WHC arm were more likely to report increases in relationship equity, relative to those in the CHC arm, and had a higher odds of reporting no victimization during the previous 3 months (MHC/WHC vs WHC: odds ratio =3.05, 95% CI: 1.55, 6.0, P=0.001; CHC vs MHC/WHC: odds ratio =0.38, 95% CI: 0.20, 0.74, P=0.004).",4435250
3147,4435250, partner victimization, females in group Menâ€™s Health CoOp/Womenâ€™s Health CoOp [MHC/WHC],"Couples Health CoOp [CHC], Womenâ€™s Health CoOp",Significantly decreased,"At follow-up, the proportion of women reporting no partner victimization varied significantly by intervention arm (Table 2): 78.6% of women in the MHC/WHC arm, compared with approximately 60% of women in the other two arms, reported no partner victimization (P=0.008).",4435250
3148,4083640,postoperative pain on day 5,neurovascular bundle preservation (NBP),conventional thoracotomy (CT),Significantly decreased,"Although postoperative pain intensity on postoperative days 1, 3, and 5 was lower in the NBP group than in the conventional thoracotomy group, the difference was significant only on postoperative day 5 (p = 0.04; Table 3).",4083640
3149,4083640,The mean consumption of tramadol hydrochloride,neurovascular bundle preservation (NBP),conventional thoracotomy (CT),No significant difference,"The mean consumption of tramadol hydrochloride was 1,025 Â± 464 mg in the conventional thoracotomy group and 834 Â± 568 mg in the NBP group (p = 0.22).",4083640
3150,4083640,The mean consumption of dipyrone,neurovascular bundle preservation (NBP),conventional thoracotomy (CT),No significant difference,The mean consumption of dipyrone was 16.67 Â± 12.06 g in the former and 15.71 Â± 11.73 g in the latter (p = 0.98).,4083640
3151,4083640,postoperative complications,neurovascular bundle preservation (NBP),conventional thoracotomy (CT),No significant difference,"Regarding the occurrence of postoperative complications, there were no significant differences between the conventional thoracotomy and NBP groups (28.18% vs. 30.77%; p = 0.58).",4083640
3152,5094682,urinary albumin-to-creatinine ratio (UACR),acarbose,pioglitazone,No significant difference,"After 6 months of treatment, the mean changes in UACR were âˆ’18 Â± 104 and 12 Â± 85 (p = 0.25, between groups) for the acarbose and pioglitazone groups, respectively.",5094682
3153,5094682,glomerular filtration rate (eGFR),acarbose,pioglitazone,No significant difference,"The mean changes in eGFR were 0 Â± 14 and âˆ’7 Â± 16 mL/min/1.73 m2 (p = 0.09, between groups) for the acarbose and pioglitazone groups, respectively.",5094682
3154,5094682,rates of minor to moderate hypoglycemia,acarbose,pioglitazone,No significant difference,"The overall rates of minor to moderate hypoglycemia showed no significant difference between two groups (Acarbose vs. Pioglitazone: 1.37 Â± 1.16 vs. 1.87 Â± 1.48 episodes, p = 0.51).",5094682
3155,5094682,side-effect,acarbose,pioglitazone,Significantly increased,"The most common side-effect was mild to moderate gastrointestinal symptoms in those given acarbose than in those given pioglitazone (Acarbose vs. Pioglitazone: 83% vs. 60%, p &lt;0.001).",5094682
3156,5094682,edema, pioglitazone,acarbose,Significantly increased,"However in the pioglitazone group, more patients had edema (Acarbose vs. Pioglitazone: 3.3% vs. 36.7%, p &lt;0.001)",5094682
3157,5094682,body weight, pioglitazone,acarbose,Significantly increased,"body weight increase (Acarbose vs. Pioglitazone: âˆ’0.6 Â± 1.5 kg vs. 1.3 Â± 2.8 kg, p = 0.002).",5094682
3158,5842771,The Mini Mental State Examination (MMSE),"Î²-asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5â€“20 mg/d",memantine 5â€“20 mg/d,Significantly increased,"However, the result of ANCOVA showed that the average MMSE score in the experiment group was significantly higher compared to the control group (p&lt;0.00001, Figure 1).",5842771
3159,5842771,Activities of Daily Living (ADL) score,"Î²-asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5â€“20 mg/d",memantine 5â€“20 mg/d,Significantly increased,"However, the result of ANCOVA showed that the average ADL score in the experiment group was significantly higher compared to the control group (p=0.00002, Figure 2).",5842771
3160,5842771,Clinical Dementia Rating Scale (CDR) score,"Î²-asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5â€“20 mg/d",memantine 5â€“20 mg/d,Significantly increased,"However, the result of ANCOVA showed that the average CDR score in the experiment group was significantly higher compared to the control group (p=0.030, Figure 3).",5842771
3161,3652505,positive evaluation,"question: 100 patients taking one kind of medicine, 70 patients became better. How would you evaluate the drug effect?","question:  100 patients taking one kind of medicine, 30 patients didnâ€™t become better. How would you evaluate the drug effect?",Significantly increased,"As shown in Table 1, the results revealed that if drug effect was described respectively in a therapeutically effective rate or ineffective rate, the participants gave the former a more positive evaluation (t = 3.34, P = 0.01).",3652505
3162,3652505,better compliance,"question:  Doctor tells you that although you particularly like to eat bacon, if you stop eating, your body cholesterol content would be significantly reduced, and thus the possibility of suffering from cardiovascular disease would be greatly reduced. Would you continue to eat bacon?","question:  Doctors tells you that although you particularly like to eat bacon, if you continue to eat, your body cholesterol content will significantly rise, and thus the possibility of suffering from cardiovascular disease would be greatly increased. Would you continue to eat bacon?",Significantly increased,"As shown in Table 2 that if the doctorâ€™ advise was respectively described in the benefit of compliance and the aftermath of violation, the former one lead to a better compliance (t = 2.14, P = 0.035).",3652505
3163,3652505,risk seeking,"There are 600 critically ill patients in one hospital. Two rescue programs are under consideration. If program A is adopted, 200 patients will be saved; If program B is adopted, there is a 1\3 chance that all patients will be saved and there is 2/3 chance that none will be saved. Which program will you choose?","There are 600 critically ill patients in one hospital. Two rescue programs are under consideration. If program A is adopted, 400 patients will die; If program B is adopted, there is a 1/3 chance that none of the patients will die and there is 2/3 chance that all will die Which program will you choose?",Significantly increased,"Table 3 presented the classic Asia Disease Problem which we used as an example of risky choice framing of options equivalent. The results revealed that in a positive frame, people tend to be risk seeking, while in a negative frame, people tend to be risk avoiding. The framing effect was significant (t = -2.72, P = 0.007).",3652505
3164,3652505,preferred the risky option,"Imagine one of your relatives was diagnosed with a cancer that must be treated. His choices are as follows: Surgery: Of 100 people having surgery, 50 live through the operation, and 40 are alive at the end of five years. Radiation therapy: Of 100 people having radiation therapy, all live through the treatment, and 20 are alive at the end of five years. Which treatment would you advise him to choose?","Imagine one of your relatives was diagnosed with a cancer that must be treated. His choices are as follows: Surgery: Of 100 people having surgery, 50 die because of the operation and 10 of the 50 survivals die by the end of five years. Radiation therapy: Of 100 people having radiation therapy, none die during the treatment, and 80 die by the end of five years. Which treatment would you advise him to choose?",Significantly increased,"Table 4 described the risky choice framing effect when the candidate options were not equivalent. As the results revealed, if treatment options were described in survival rates, people more preferred the risky option, compared with described in mortality rates (t = 2.09, P = 0.039).",3652505
3165,3652505,number size framing effect,"Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ€™ medical records revealed that: Doctor A: Of 200 patients, 191 were not found postoperative visual acuity declined but 3 suffered from keratitis; Doctor B: Of 200 patients, 198 were not found postoperative visual acuity declined but 10 suffered from keratitis. Which doctor you will choose?","Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ€™ medical records revealed that: Doctor A: Of 200 patients, 197 didnâ€™t suffer from keratitis but 9 were found visual acuity declined. Doctor B: Of 200 patients, 190 didnâ€™t suffer from keratitis but 2 were found visual acuity declined. Which doctor you will choose?",Significantly decreased,"Table 5 described the effect of number size framing. The results revealed that the number size framing effect was significant in medical situation (t = -7.5, P &lt; 0.001).",3652505
3166,3536709,Energy intake,low-protein vegetarian diet (LPVD), normally diet (ND),Significantly decreased,"Energy intake was significantly lower during LPVD compared to ND (2400 Â± 338 kcal vs. 2793 Â± 554 kcal, p=0.033).",3536709
3167,3536709,intake of protein,low-protein vegetarian diet (LPVD), normally diet (ND),Significantly decreased,"During LPVD, the intake of protein was 10.1 Â± 0.26% and during ND 17.6 Â± 3.0% of the total energy intake (p=0.000).",3536709
3168,3536709,The intake of carbohydrates,low-protein vegetarian diet (LPVD), normally diet (ND),Significantly increased,"The intake of carbohydrates was significantly higher during LPVD compared to ND (58.7 Â± 2.4% vs. 49.8 Â± 5.4%, p=0.003).",3536709
3169,3536709, the amount of fat,low-protein vegetarian diet (LPVD), normally diet (ND),Significantly decreased,"As well, the amount of fat differed between LPVD and ND (24.7 Â± 2.3% vs. 28.1 Â± 3.1%, p=0.015).",3536709
3170,3536709,difference in the weight,low-protein vegetarian diet (LPVD), normally diet (ND),No significant difference,In spite of lower energy intake during LPVD there was no difference in the weight of the subjects compared to ND (75.6 Â± 7.9 kg vs. 76.2 Â± 7.6 kg).,3536709
3171,3536709,strong ion difference (SID),low-protein vegetarian diet (LPVD), normally diet (ND),Significantly increased,"In the LPVD group, at rest SID significantly increased over the diet period (38.6 Â± 1.8 vs. 39.8 Â± 0.9, p=0.009).",3536709
3172,3536709,"VO2  at 40, 60 and 80% of VO2max",low-protein vegetarian diet (LPVD), normally diet (ND),Significantly increased,"Diet had no significant effect on exercise time to exhaustion, but VO2 was significantly higher at 40, 60 and 80% of VO2max after LPVD compared to ND (2.03 Â± 0.25 vs. 1.82 Â± 0.21 l/min, p=0.035; 2.86 Â± 0.36 vs. 2.52 Â± 0.33 l/min, p&lt;0.001 and 4.03 Â± 0.50 vs. 3.54 Â± 0.58 l/min, p&lt;0.001; respectively).",3536709
3173,3503942,pain threshold (lb/cm2),trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS),extracorporeal shock wave therapy (ESWT),Significantly decreased,"The changes in pain threshold (lb/cm2) showed the values of 6.86Â±1.35 before first therapy, 11.43Â±0.27 after first therapy, and 12.57Â±0.72 after third therapy, while TPI+TENS group showed the values of 6.20Â±1.92 before first therapy, 8.80Â±0.48 after first therapy, and 9.60Â±2.19 after third therapy, and the changes between the groups were significantly different (p=0.045).",3503942
3174,3503942,The changes in visual analog scale,extracorporeal shock wave therapy (ESWT), trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS),Significantly decreased,"The changes in visual analog scale were estimated to be 6.86Â±0.90 before first therapy, 2.86Â±0.90 after first therapy, and 1.86Â±0.69 after third therapy in case of ESWT group, whereas the figures were estimated to be 7.20Â±1.30 before first therapy, 4.60Â±0.55 after first therapy, and 2.80Â±0.84 after third therapy in case of TPI+TENS group, and the changes between the groups were significantly different (p=0.010).",3503942
3175,3503942,The changes in McGill pain questionnaire,extracorporeal shock wave therapy (ESWT), trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS),No significant difference,The changes in McGill pain questionnaire (p=0.816) and pain rating scale (p=0.644) between the groups were not significantly different.,3503942
3176,3503942,neck range of motion,extracorporeal shock wave therapy (ESWT), trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS),No significant difference,"As a result of the Repeated Measure ANOVA carried out on neck range of motion, there was no significant difference between the groups (p&gt;0.05) but also no reciprocal action effect (p&gt;0.05) in all the category, and, in all the categories excluding extension, time (p&lt;0.05) effect was found to be significant.",3503942
3177,4563303,Anterior (cm),visual feedback group (VFG),visual disuse group (VDG),Significantly increased,Anterior (cm)	2.83Â±0.83	3.75Â±1.29â€ 	2.03Â±0.67	3.47Â±0.83â€ ,4563303
3178,4563303,Posterior (cm)â€¡,visual feedback group (VFG),visual disuse group (VDG),Significantly increased,Posterior (cm)â€¡	2.51Â±0.87	4.07Â±1.99â€ 	1.90Â±0.79	2.97Â±0.62â€ ,4563303
3179,4563303,Left (cm)â€¡,visual feedback group (VFG),visual disuse group (VDG),Significantly increased,Left (cm)â€¡	2.81Â±1.57	4.36Â±1.33â€ 	2.07Â±1.25	3.20Â±1.43â€ ,4563303
3180,4563303,Right (cm)â€¡,visual feedback group (VFG),visual disuse group (VDG),Significantly increased,Right (cm)â€¡	3.40Â±1.58	4.11Â±2.35â€ 	1.95Â±0.92	3.16Â±1.15â€ ,4563303
3181,4563303,Timed Up and Go (TUG) (sec)â€¡,visual feedback group (VFG),visual disuse group (VDG),Significantly decreased,TUG (sec)â€¡	15.62Â±4.89	9.93Â±3.93â€ 	21.84Â±12.61 19.33Â±12.07â€ ,4563303
3182,4563303,BBS: Berg Balance Scale,visual feedback group (VFG),visual disuse group (VDG),Significantly increased,BBS (score)â€¡	44.89Â±3.73	52.00Â±3.87â€ 	44.68Â±3.26	46.54Â±4.27â€ ,4563303
3183,5633216,plaque index and gingival index,"Group I (CHX/thymol mouthwash-Vi-one), Group II (CHX mouthwash-Behsa)",baseline,Significantly decreased,The results showed that plaque index and gingival index significantly reduced in two groups (p&lt;0.001).,5633216
3184,5633216,plaque index and gingival index,Group I (CHX/thymol mouthwash-Vi-one), Group II (CHX mouthwash-Behsa),Significantly increased,"However, group I was significantly more efficient than group II (p&lt;0.001, p=0.021 respectively)",5633216
3185,5633216,terms of bleeding index,Group I (CHX/thymol mouthwash-Vi-one), Group II (CHX mouthwash-Behsa),No significant difference,"Analysis of this data show that the mean BI in the Vi-one group decreased more than that in the Behsa group, but there were no significant differences between the two groups (p=0.879).",5633216
3186,4836241,KMI and hot flash/sweating score,"Kuntai, Tibolone, Control",baseline,Significantly increased,"For all the three groups, the hot flash/sweating scores increased significantly after GnRH-a therapy in comparison to the pretherapeutic level respectively (P &lt; 0.05).",4836241
3187,4836241,KMI and hot flash/sweating score, Control,"Kuntai, Tibolone",Significantly decreased,"At the 4th week after GnRH-a therapy, the hot flash/sweating score result was as follows: Control group &gt; Kuntai group &gt; Tibolone group (P &lt; 0.05); while at the 8th and 12th week after GnRH-a therapy, the hot flash/sweating score in control group was significantly higher than the other two groups (P &lt; 0.05), but no significant difference was identified between Kuntai and Tibolone groups (P &gt; 0.05). The results were shown in Figure 2.",4836241
3188,4836241,KMI and hot flash/sweating score,Kuntai,Tibolone,No significant difference,but no significant difference was identified between Kuntai and Tibolone groups (P &gt; 0.05). The results were shown in Figure 2.,4836241
3189,4836241,"follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) level and endometrial thickness","Kuntai, Tibolone, Control",baseline,Significantly decreased,"The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) level and endometrial thickness decreased significantly in all the three groups (P &lt; 0.05).",4836241
3190,4836241,estradiol (E2) leve,"Tibolone, ","Kuntai, Control",Significantly increased,"After therapy, serum E2 level in Tibolone group was obviously higher than the other two groups (P &lt; 0.05),",4836241
3191,4836241,"follicle-stimulating hormone (FSH), luteinizing hormone (LH)","Tibolone, ","Kuntai, Control",Significantly decreased,"After therapy, serum E2 level in Tibolone group was obviously higher than the other two groups (P &lt; 0.05), while FSH and LH levels were obviously lower (P &lt; 0.05). (5)",4836241
3192,4836241,"incidence of vaginal bleeding, breast distending pain","Tibolone, ",Kuntai,Significantly increased,"The incidence of vaginal bleeding, breast distending pain in Tibolne group was obviously higher than Kuntai group (P &lt; 0. 05).",4836241
3193,3446145,The state anxiety score,preoperative preparation program on children's anxiety,control,Significantly decreased,Children in experimental group reported significantly lower level anxiety score in preoperative period (P=0.000).,3446145
3194,3661337,falls,surface perturbation treadmill training (SPTT),baseline,No significant difference,"Over a period of 3&nbsp;months, 5 of 26 (19.2%) subjects in the SPTT group and 11 of 33 (33.3%) subjects in the Standard PT group had fallen at least once (Chi2â€‰=â€‰1.46; pâ€‰&lt;â€‰0.23);",3661337
3195,3661337, fewer having an injurious fall,surface perturbation treadmill training (SPTT),baseline,No significant difference,2 of 26 (7.7%) in the SPTT group and 6 of 33 (18.2%) in the Standard PT group had an injurious fall (Chi2â€‰=â€‰1.37; pâ€‰&lt;â€‰0.25) (see Figure&nbsp;2).,3661337
3196,4568196, total cholesterol (TC),hypocaloric diet without legumes (HDWL),baseline,Significantly increased,HDWL significantly increased TC in 6 weeks as much as 6.3% (P = 0.000);,4568196
3197,4568196,low-density lipoprotein-cholesterol (LDL-C),hypocaloric diet without legumes (HDWL),baseline,Significantly increased,"HDWL marginally increased LDL-C in the first 3 weeks (8.4%, P = 0.060)",4568196
3198,4568196,high-sensitive-C-reactive protein (hs-CRP) after 3 weeks,"hypocaloric diet without legumes (HDWL), hypocaloric diet enriched with legumes (HDEL)",baseline,Significantly decreased,Both hypocaloric diets reduced hs-CRP in 3 weeks and returned it to basal values after 6 weeks (P = 0.004).,4568196
3199,4568196, total antioxidant capacity (TAC), hypocaloric diet enriched with legumes (HDEL),baseline,Significantly increased,"(4) and HDEL increased TAC in 3 weeks (4%, P = 0.050).",4568196
3200,4568196,high-sensitive-C-reactive protein (hs-CRP) after 6 weeks,"hypocaloric diet without legumes (HDWL), hypocaloric diet enriched with legumes (HDEL)",baseline,Significantly decreased,Both hypocaloric diets reduced hs-CRP in 3 weeks and returned it to basal values after 6 weeks (P = 0.004).,4568196
3201,4787139,heart rate (HR),"MDZ:FEN, DEX 0.25 Î¼g/kg (DEX half)",baseline,Significantly decreased,HR values in â€˜DEX fullâ€™ group were significantly lower than in MDZ:FEN and â€˜DEX halfâ€™ group at 10 min (P = 0.001).,4787139
3202,4787139,systolic blood pressure (SBP),"â€˜DEX fullâ€™  at 10 min, 90, 120, 150, 180 and 210 min",MDZ: FEN and â€˜DEX halfâ€™,Significantly decreased,"â€˜DEX fullâ€™ group patients had significantly lower SBP values at 10 min (P = 0.018), 90, 120, 150, 180 and 210 min (P = 0.001) as compared to patients in MDZ: FEN and â€˜DEX halfâ€™ group.",4787139
3203,4787139,rate pressure product (RPP),DEX full,MDZ:FEN and DEX half,Significantly decreased,"â€˜DEX fullâ€™ group patients had significantly lower SBP values at 10 min (P = 0.018), 90, 120, 150, 180 and 210 min (P = 0.001) as compared to patients in MDZ: FEN and â€˜DEX halfâ€™ group.",4787139
3204,4787139,"bradycardia, hypotension and level 4 sedation",DEX full,baseline,Significantly increased,"DEX full group patients had statistically significant bradycardia (P &lt; 0.001), hypotension (P = 0.008) and level 4 sedation (P = âˆ’0.001).",4787139
3205,4787139,nausea and vomiting,MDZ:FEN,baseline,Significantly increased,MDZ:FEN group patients had significantly higher incidence of nausea (P = 0.001) and vomiting (P = 0.002).,4787139
3206,5295074,serum 25(OH)D from baseline to study, 800 IU vitamin D3,200 IU vitamin D3,Significantly increased,The primary endpoint defined as the increase in 25(OH)D from baseline to study end was significantly higher in the 800 IU group compared to the 200 IU group (p &lt; 0.001; see Figure 2).,5295074
3207,5295074,serum 25(OH)D at 4 weeks, 800 IU vitamin D3,200 IU vitamin D3,Significantly increased,"At 4 weeks, there was already a significant between group difference for the increase in 25(OH)D (p &lt; 0.001).",5295074
3208,2784386,treatment success in non-ICU subjects,micafungin (100 mg/day for subjects &gt; 40 kg; 2 mg/kg/day for subjects â‰¤ 40 kg),liposomal amphotericin B (3 mg/kg/day),Significantly increased,"In non-ICU subjects, the treatment success rate was significantly higher among subjects receiving micafungin than liposomal amphotericin B (85% versus 72.1%; P = 0.0113).",2784386
3209,2784386,treatment success in ICU subjects,micafungin (100 mg/day for subjects &amp;gt; 40 kg; 2 mg/kg/day for subjects â‰¤ 40 kg),liposomal amphotericin B (3 mg/kg/day),No significant difference,"However, for ICU subjects, treatment success rates for micafungin versus liposomal amphotericin B were similar (62.5% (n = 75/120) versus 66.4% (n = 73/110); P = 0.5828).",2784386
3210,2784386,renal function in ICU and non-ICU subjects,micafungin (100 mg/day for subjects 40 kg; 2 mg/kg/day for subjects â‰¤ 40 kg),liposomal amphotericin B (3 mg/kg/day),Significantly increased,"Renal function was significantly better in micafungin versus liposomal amphotericin B subjects: a difference (liposomal amphotericin B - micafungin in mean peak change in estimated glomerular filtration rate (ml/minute/1.73 m2) of -18.2 (P &lt; 0.0001) and -17.7 (P = 0.0124) in non-ICU and ICU subjects, respectively.",2784386
3211,3977448,Relative and absolute  flow-mediated dilation (FMD) ,16 weeks of aerobic (5â€‰d/wk) and resistance training (2â€‰d/wk) (combined: â‰¥250â€‰kcal/d) and caloric restriction (âˆ’500â€‰kcal/d versus requirement),baseline,Significantly increased,"Relative and absolute FMD increased (before: 4.0â€‰Â±â€‰0.5% versus after: 6.9â€‰Â±â€‰0.6%, P &lt; 0.05, and before: 0.14â€‰Â±â€‰0.02â€‰mm versus after: 0.23â€‰Â±â€‰0.02â€‰mm, P &lt; 0.05, resp.), while body mass decreased (before: 86.9â€‰Â±â€‰2.4â€‰kg versus after: 81.1â€‰Â±â€‰2.4â€‰kg, P &lt; 0.05) following the intervention.",3977448
3212,3977448,"IL-6, ET-1 levels",16 weeks of aerobic (5â€‰d/wk) and resistance training (2â€‰d/wk) (combined: â‰¥250â€‰kcal/d) and caloric restriction (âˆ’500â€‰kcal/d versus requirement),baseline,No significant difference,"There was no change in either of the serum markers (IL-6: before = 1.5 Â± 0.2â€‰pg/mL and after = 1.5 Â± 0.1â€‰pg/mL, P = 0.58, and ET-1: before = 0.55 Â± 0.05â€‰pg/mL and after = 0.59 Â± 0.09â€‰pg/mL, P = 0.73; N = 19, as one participant had undetectable ET-1 values).",3977448
3213,4495314,Baseline age and level of education of the mothers,"Extended postpartum care (Intervention group, IG)","Standard care (Control group, CG)",Significantly decreased,"There was a small but significant difference in socio-demographic characteristics between IG and CG mothers [F(3,313)â€‰=â€‰3.562, pâ€‰=â€‰0.015; Wilksâ€™ Î›â€‰=â€‰0.967; Î·p2=0.033], such that CG mothers were significantly older [F(1,315)â€‰=â€‰7.227, pâ€‰=â€‰0.008; Î·p2=0.022] and had a higher level of education [F(1,315)â€‰=â€‰4.348, pâ€‰=â€‰0.038; Î·p2=0.014].",4495314
3214,4495314,Use of midwife contacts,"Extended postpartum care (Intervention group, IG)","Standard care (Control group, CG)",Significantly increased,IG mothers used significantly more midwife contacts than CG mothers,4495314
3215,4495314,Edinburgh postnatal depression scale (EPDS) scores,"Extended postpartum care (Intervention group, IG)","Standard care (Control group, CG)",No significant difference,"ANOVAs revealed no group differences in EPDS scores for mothers [F(1,315)â€‰=â€‰0.278, pâ€‰=â€‰0.592; Î·p2=0.001] or fathers [F(1,274)â€‰=â€‰0.377, pâ€‰=â€‰0.540; Î·p2=0.001].",4495314
3216,4495314,Mean age and work experience of the midwives,"Extended postpartum care (Intervention group, IG)","Standard care (Control group, CG)",No significant difference,"The mean age of the midwives was 40.33 (SDâ€‰=â€‰9.06) years and their mean work experience (years they have been working in their profession) was 15.68 (SDâ€‰=â€‰8.73) years, with no significant differences between IG and CG [age: F(1,84)â€‰=â€‰0.432, pâ€‰=â€‰0.513; Î·p2=0.005; work experience: F(1,75)â€‰=â€‰0.009, pâ€‰=â€‰0.926; Î·p2&lt;0.001].",4495314
3217,4495314,Proportion of emotionally distressed parents at 6 months,"Extended postpartum care (Intervention group, IG)","Standard care (Control group, CG)",No significant difference,Midwives identified 20% of mothers and 9% of fathers as highly distressed at 6â€‰months postpartum. There was no difference between groups regarding the proportion of emotionally distressed mothers and fathers.,4495314
3218,3994324,Adherence,Novel glaucoma education and motivational support package using behaviour change counselling,Standard clinical care,No significant difference,"No significant difference in mean adherence over the monitoring period was identified with 77.2% (CI, 73.0, 81.4) for the control group and 74.8% (CI, 69.7, 79.9) for the intervention group (pâ€‰=â€‰0.47).",3994324
3219,3994324,Decrease in intraocular pressure,Novel glaucoma education and motivational support package using behaviour change counselling,Standard clinical care,No significant difference,"there was no significant difference in percentage intraocular pressure reduction; 27.6% (CI, 23.5, 31.7) for the control group and 25.3% (CI, 21.06, 29.54) for the intervention group (pâ€‰=â€‰0.45).",3994324
3220,3994324,Satisfaction with information given about travoprost,Novel glaucoma education and motivational support package using behaviour change counselling,Standard clinical care,Significantly increased,"Participants in the intervention group were more satisfied with information about glaucoma medication with a mean score of 14.47/17 (CI, 13.85, 15.0) compared with control group which was 8.51 (CI, 7.72, 9.30).",3994324
3221,3994324,Baseline intraocular pressure,Novel glaucoma education and motivational support package using behaviour change counselling,Standard clinical care,No significant difference,"The mean IOP at baseline for subsequently treated right and/or left eyes was 23.7&nbsp;mmHg (95% CI, 22.6, 24.8) for the control group and 22.4&nbsp;mmHg (95% CI, 21.3, 23.5) for the intervention group which was not statistically different (pâ€‰=â€‰0.096, 1.3, CI âˆ’0.2, 2.9).",3994324
3222,5847600,Change in rates of alcohol consumption per week,Enhanced version of the app,Minimal version of the app,No significant difference,There were no significant main effects of the intervention modules on change in weekly alcohol consumption or AUDIT score.,5847600
3223,5847600,Score of Alcohol Use Disorders Identification Test ,Enhanced version of the app,Minimal version of the app,No significant difference,There were no significant main effects of the intervention modules on change in weekly alcohol consumption or AUDIT score.,5847600
3224,5847600,"Usage and positive rates of Normative Feedback, Cognitive Bias Re-training, Identity Change or Action Planning",Enhanced version of the app,Minimal version of the app,No significant difference,"There were no significant main effects of Normative Feedback, Cognitive Bias Re-training, Identity Change or Action Planning on usability ratings",5847600
3225,5847600,"Usage and positive rates for Enhanced Self-monitoring and Feedback for helpfulness, satisfaction and recommendation to others than the minimal version.",Enhanced version of the app,Minimal version of the app,Significantly increased,"Enhanced Self-monitoring and Feedback was used significantly more often and rated significantly more positively for helpfulness, satisfaction and recommendation to others than the minimal version",5847600
3226,3089991,Inhibition of food cravings,Prefrontal rTMS,Sham rTMS,No significant difference,"With an improved sham control condition, prefrontal rTMS inhibited food cravings no better than sham rTMS.",3089991
3227,3089991,Face and scalp sensations,Prefrontal rTMS,Sham rTMS,No significant difference,"At the end of the study, participants were asked to guess which rTMS session was real and which was sham. Only 40% of participants guessed correctly (p =â€‰0.27), suggesting that the sham condition was reasonably matched to real TMS with respect to face and scalp sensations.",3089991
3228,3089991,Hours elapsed since the participant's last meal,Prefrontal rTMS,Sham rTMS,No significant difference,"There was no significant difference in hours since last ate between sham and real TMS conditions [t(9) =â€‰0.52, ns], but when we controlled for hours since participants last ate, no effects were observed for time [F(1,8) =â€‰2.97, ns], condition [F(1,8) =â€‰1.94, ns], or the time by condition interaction [F(1,8) =â€‰2.07, ns].",3089991
3229,3346674,Improvement of rash sites,Aloe cream,Calendula ointment,Significantly decreased,patients receiving Calendula ointment had significantly fewer rash sites compared to Aloe group (P = 0.001).,3346674
3230,3346674,Adverse effect,Aloe cream,Calendula ointment,No significant difference,No adverse effect was reported from either of the medications.,3346674
3231,3346674,Baseline characteristics,Aloe cream,Calendula ointment,No significant difference,"There was no statistically significant difference between the groups regarding age, gender, and daily frequencies of diaper change and washing diaper area.",3346674
3232,3346674,History of diseases or disorders that might influence the development of diaper dermatitis ,Aloe cream,Calendula ointment,No significant difference,"Table 2 indicates data regarding the past history of diseases that might influence the development of DD. These diseases included diarrhea, immunodeficiency, renal deficiency, powdered milk, food or drug hypersensitivity, hematochezia, chest wheezing, facial eczema, oral thrush, and anemia. No significant difference in the prevalence of the aforementioned disorders was observed between the groups (P &gt; 0.05).",3346674
3233,5720557,"Plan preference, planner, or planning institution",Pinnacle plan,Perspecta plans,No significant difference,No statistically significant association was found between plan preference and planning institution (p=0.43) or planner (p=0.44).,5720557
3234,5720557,Use of nonâ€�coplanar beams,Pinnacle plan,Perspecta plans,Significantly decreased,The use of nonâ€�coplanar beams was more frequent with Perspecta (p&lt;0.001).,5720557
3235,5720557,Number of iterations,Pinnacle plan,Perspecta plans,No significant difference,the number of iterations did not significantly differ between the two planning techniques.,5720557
3236,5720557,Hot spot located inside or outside the target,Pinnacle plan,Perspecta plans,No significant difference,"Perspecta plans were more likely to have the hot spot located inside the target (43% vs. 33%), although the difference was not statistically significant (p=0.61). Conversely, 30% of the Pinnacle plans had the hot spot outside the target compared with 18% for Perspecta plans (p=0.34).",5720557
3237,5720557,Dose delivered to normal tissues,Pinnacle plan,Perspecta plans,No significant difference,"A total of 161 normal structures were contoured for patients in the study. Of those structures, 92 showed lower doses with the Perspecta plan (57%). The difference, however, was not statistically significant (p=0.07).",5720557
3238,3958613,P2Y12 reaction unit (PRU) values at baseline,Clopidogrel 75 mg or prasugrel 5 mg ,Prasugrel 10 mg,No significant difference,No differences in baseline PRU values were observed among the three groups.,3958613
3239,3958613,P2Y12 reaction unit (PRU) values at 30 days,Prasugrel 5 mg ,Clopidogrel 75 mg,Significantly decreased,"The prasugrel (5 mg) group had a significantly lower PRU value compared with that of 75 mg clopidogrel (174.6Â±60.2 vs. 223.4Â±72.9, p=0.022) group at 30 days",3958613
3240,3958613,P2Y12 reaction unit (PRU) values at 30 days,Prasugrel 5 mg ,Prasugrel 10 mg,Significantly increased,the 10 mg prasugrel group showed a lower PRU value (71.9Â±34.4) compared with that of the 5 mg prasugrel (p&lt;0.001).,3958613
3241,3958613,P2Y12 reaction unit (PRU) values higher than 235,Prasugrel 5 mg ,Clopidogrel 75 mg,Significantly decreased,"The rate of high on-treatment platelet reactivity (PRU &gt;235) was significant lower in the 5 mg prasugrel group than that in the 75 mg clopidogrel group (15.0% vs. 56.5%, p=0.010).",3958613
3242,3958613,Life threatening bleeding events,Clopidogrel 75 mg or prasugrel 5 mg ,Prasugrel 10 mg,No significant difference,Thrombolysis in Myocardial Infarction major bleeding or life threatening bleeding events did not occur during the study period in any of the treatment groups.,3958613
3243,2972614,Severity of pain,Laser therapy (Group I),Placebo laser therapy (Group II),No significant difference,"In group I, statistically significant improvements in pain severity, range of motion except internal and external rotation and SPADI scores were observed compared to baseline scores after the therapy (p&lt;0.05). In Group II, all parameters except range of motion of external rotation were improved (p&lt;0.05). However, no significant differences were recorded between the groups (p&gt;0.05).",2972614
3244,2972614,Motion range,Laser therapy (Group I),Placebo laser therapy (Group II),No significant difference,"In group I, statistically significant improvements in pain severity, range of motion except internal and external rotation and SPADI scores were observed compared to baseline scores after the therapy (p&lt;0.05). In Group II, all parameters except range of motion of external rotation were improved (p&lt;0.05). However, no significant differences were recorded between the groups (p&gt;0.05).",2972614
3245,2972614,Shoulder Pain and Disability Index score,Laser therapy (Group I),Placebo laser therapy (Group II),No significant difference,"In group I, statistically significant improvements in pain severity, range of motion except internal and external rotation and SPADI scores were observed compared to baseline scores after the therapy (p&lt;0.05). In Group II, all parameters except range of motion of external rotation were improved (p&lt;0.05). However, no significant differences were recorded between the groups (p&gt;0.05).",2972614
3246,2972614,Adverse effects,Laser therapy (Group I),Placebo laser therapy (Group II),No significant difference,All patients were able to complete the therapy program without any adverse effects.,2972614
3247,2972614,Laboratory parameters,Laser therapy (Group I),Placebo laser therapy (Group II),No significant difference,"The results of complete blood count, biochemical markers, erythrocyte sedimentation rate and Câ€�reactive protein of the patients were found to be normal.",2972614
3248,5851532,Sensitivity and specificity,Self-collected vaginal specimens,Provider-collected cervical swabs,No significant difference,"Compared to provider-collected cervical specimens (gold standard), hrHPV DNA hybridization assay via self-collected vaginal specimen had a sensitivity of 71.4% (95% CI: 0.52, 0.91) and a specificity of 98.2% (95% CI: 0.96, 1.00). There was substantial concordance between the sampling methods (Îº = 0.75; 95% CI = 0.59, 0.92; p&lt;0.0001).",5851532
3249,5851532,Positive Predictive Value or Negative Predictive Value,Self-collected vaginal specimens,Provider-collected cervical swabs,No significant difference,"There were no statistically significant differences in sensitivity, specificity, PPV, or NPV for provider-collected cervical vs. self-collected vaginal hrHPV DNA specimens by randomization order.",5851532
3250,5457851,Self-reported pain intensity,"2% lidocaine with 1:80,000 epinephrine ","2% lidocaine with 1:200,000 epinephrine ",No significant difference,"Although the participants in the L200 group reported having experienced more intense pain than those in the L80 group (Pâ€Š=â€Š.055), the upper limit of the 1-sided confidence interval was 12.9â€Šmm, which is lower than the noninferiority tolerance of 15â€Šmm (Table 2). Therefore, the pain control of L200 was noninferior to that of L80",5457851
3251,5457851,Time of onset of anesthesia,"2% lidocaine with 1:80,000 epinephrine ","2% lidocaine with 1:200,000 epinephrine ",No significant difference,"The secondary efficacy analysis was carried out to compare the time of onset of anesthesia for the 2 concentrations of epinephrine. The meanâ€ŠÂ±â€ŠSD time of onset was 4.9â€ŠÂ±â€Š4.1â€Šminutes in the L80 group and 5.2â€ŠÂ±â€Š4.1â€Šminutes in the L200 group, with no significant difference between the groups (Pâ€Š=â€Š.447)",5457851
3252,5457851,Time of anesthesia action,"2% lidocaine with 1:80,000 epinephrine ","2% lidocaine with 1:200,000 epinephrine ",No significant difference,"The meanâ€ŠÂ±â€ŠSD duration of action of anesthesia was 183.5â€ŠÂ±â€Š5.0â€Šminutes in the L80 group and 182.2â€ŠÂ±â€Š5.4â€Šminutes in the L200 group, with no significant difference between the groups (Pâ€Š=â€Š.758)",5457851
3253,5457851,Bleeding tendency,"2% lidocaine with 1:80,000 epinephrine ","2% lidocaine with 1:200,000 epinephrine ",No significant difference,"The meanâ€ŠÂ±â€ŠSD bleeding tendency was 2.0â€ŠÂ±â€Š0.1 in the L80 group and 2.2â€ŠÂ±â€Š0.1 in the L200 group, with no significant difference between the groups (Pâ€Š=â€Š.206)",5457851
3254,5457851,Overall satisfaction score of the participants and operators,"2% lidocaine with 1:80,000 epinephrine ","2% lidocaine with 1:200,000 epinephrine ",No significant difference,"The meanâ€ŠÂ±â€ŠSD overall satisfaction score of the operators was 3.9â€ŠÂ±â€Š0.9 in the L80 group and 3.8â€ŠÂ±â€Š1.0 in the L200 group, with no significant difference between the groups (Pâ€Š=â€Š.548) (Table 3). The meanâ€ŠÂ±â€ŠSD overall satisfaction score of the participants was 3.6â€ŠÂ±â€Š0.1 in the L80 group and 3.7â€ŠÂ±â€Š0.1 in the L200 group, with no significant difference between the groups (Pâ€Š=â€Š.693)",5457851
3255,4285787,Glycosuria,Canagliflozin,Placebo,Significantly increased,"Canagliflozin increased urinary glucose excretion in a dose-dependent manner and produced statistically significant reductions in body weight compared with placebo (least squares mean percent changes from baseline of âˆ’2.2%, âˆ’2.9%, âˆ’2.7%, and âˆ’1.3% with canagliflozin 50, 100, and 300 mg and placebo; Pâ€‰&lt;â€‰0.05 for all comparisons).",4285787
3256,4285787,Body weight reduction,Canagliflozin,Placebo,Significantly increased,"Canagliflozin increased urinary glucose excretion in a dose-dependent manner and produced statistically significant reductions in body weight compared with placebo (least squares mean percent changes from baseline of âˆ’2.2%, âˆ’2.9%, âˆ’2.7%, and âˆ’1.3% with canagliflozin 50, 100, and 300 mg and placebo; Pâ€‰&lt;â€‰0.05 for all comparisons).",4285787
3257,4285787,Adverse events,Canagliflozin,Placebo,No significant difference,Overall adverse event (AE) rates were similar across groups.,4285787
3258,4285787,Genital mycotic infections in women,Canagliflozin,Placebo,Significantly increased,The incidence of genital mycotic infections was higher in women treated with canagliflozin compared to those who received placebo,4285787
3259,4285787,Triglycerides and HDL-C levels,Canagliflozin,Placebo,No significant difference,"At Week 12 compared to placebo, canagliflozin produced no clinically meaningful changes from baseline in triglycerides and HDL-C levels",4285787
3260,3475525,Correct selection of  the healthier product,MTL+caloric intake group and choices group,No label group and TL+SNL group,Significantly increased,"The MTL+caloric intake group (mean [standard deviation], 73.3% [6.9%]) and Choices group (72.5% [13.2%]) significantly outperformed the no label group (67.8% [10.3%]) and the TL+SNL group (65.8% [7.3%]) in selecting the more healthful product on the healthier product quiz.",3475525
3261,3475525,"Scores on the saturated fat, sugar, and sodium quizzes",MTL group and MTL+caloric intake group,No label group and choices group,Significantly increased,"The MTL and MTL+caloric intake groups achieved average scores of more than 90% on the saturated fat, sugar, and sodium quizzes, which were significantly better than the no label and Choices group average scores, which were between 34% and 47%.",3475525
3262,3475525,Taste perception and intent of purchase,MTL group and MTL+caloric intake group,No label group and choices group,No significant difference,Perceptions of taste and purchase intent did not significantly differ across label groups.,3475525
3263,4464926,Rates of pain,Hermetical closure of the wound,Partial closure of the wound,No significant difference,No statistically significant differences were found to be related to pain (p&lt;0.06) at 48 hours and 7 days between the different suture techniques in group A and B,4464926
3264,4464926,Trismus,Hermetical closure of the wound,Partial closure of the wound,No significant difference,"There were no significant differences for trismus between none of them by measuring the mouth opening (p&lt;0.71) before surgery, at 48 hours and at 7 days after surgery",4464926
3265,4464926,Swelling,Hermetical closure of the wound,Partial closure of the wound,No significant difference,"Regarding swelling, there were no significant differences for horizontal (p&lt;0.73), vertical (p&lt;0.37) and oblique (p&lt;0.83) facial measurements taken prior, at 48 hours and at 7 days after surgery, between the distinct suture techniques in both groups",4464926
3266,3712888,Recurrence of bacterial vaginosis after 6 months,Vaginal vitamin C,Placebo,Significantly decreased,"Considering a 6-month treatment period, the recurrence rate in the vitamin C group (16.2%) was significantly lower (P = 0.024) than in the placebo group (32.4%).",3712888
3267,3712888,Baseline characteristics ,Vaginal vitamin C,Placebo,No significant difference,"The two groups were homogeneous for age, height and weight distribution.",3712888
3268,3712888,Signs and symptoms of bacterial vaginosis,Vaginal vitamin C,Placebo,No significant difference,"BV signs and symptoms (itching, burning, dysuria, odour, erythema, oedema and fissures) were fairly similar across treatment groups",3712888
3269,3712888,Recurrence of bacterial vaginosis after 3 months,Vaginal vitamin C,Placebo,No significant difference,"The proportion of women having a BV recurrence in the ITT population during the first 3 months was 6.8% in the vitamin C group (5/74) and 14.7% (10/68) in the placebo group, but the difference between the groups was not statistically significant.",3712888
3270,3712888,Probability of being free of BV relapse (survival analysis of Kaplan Meyer),Vaginal vitamin C,Placebo,Significantly increased,the survival analysis of Kaplan Meyer was significant in favour of the vitamin C group compared with the placebo group (P = 0.029).,3712888
3271,4619975,Endogenous opioids,Asymptomatic inflammation group (EXPg),Control group (CTRg),No significant difference,none of the endogenous opioids showed statistically significant differences (P &gt; 0.05),4619975
3272,4619975,Expression of substance P (SP) and calcitonin gene-related peptide (CGRP),Asymptomatic inflammation group (EXPg),Control group (CTRg),Significantly increased,"In CTRg basal levels of both neuropeptides and endogenous opioids were observed. In the EXPg, SP and CGRP exhibited statistically significant different levels (P &lt; 0.05)",4619975
3273,5682159,Overall satisfaction of the patients,Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26),Vycross 20 mg/ml HA (VYC-20),No significant difference,"In this first direct comparison of CPM-26 and VYC-20, the majority of subjects were satisfied with both treatments throughout the study. Patient-reported outcome measures identified a trend in favor of CPM-26.",5682159
3274,5682159,GAIS Scores,Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26),Vycross 20 mg/ml HA (VYC-20),No significant difference,"At M3 and M12 after treatment, GAIS scores indicated that the majority of subjects were at least improved compared with baseline whether treated with CPM-26 or VYC-20.",5682159
3275,5682159,Improvement according to the patients at the M12 and M18 visits,Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26),Vycross 20 mg/ml HA (VYC-20),Significantly increased,"At both the M12 and M18 visits, more CPM-26-treated subjects considered themselves much improved or very much improved compared with VYC-20-treated subjects.",5682159
3276,4276527,Postprandial triglycerides,Short-term estradiol (E2),Placebo,Significantly decreased,Short-term E2 reduced postprandial TG and insulin,4276527
3277,4276527,Insulin,Short-term estradiol (E2),Placebo,Significantly decreased,Short-term E2 reduced postprandial TG and insulin,4276527
3278,4276527,Storage of dietary fatty acids (FA),Short-term estradiol (E2),Placebo,No significant difference,"Short-term E2 reduced postprandial TG and insulin, but had no effect on oxidation or storage of dietary FA.",4276527
3279,4276527,Adipocytes in femoral subcutaneous adipose tissue,Short-term estradiol (E2),Placebo,Significantly increased,E2 increased the proportion of small adipocytes in femoral (but not abdominal) SAT.,4276527
3280,4276527,Serum leptin,Short-term estradiol (E2),Placebo,Significantly increased,"Compared with placebo, 2 weeks of E2 increased serum leptin",4276527
3281,4519214,Visual search performance,Training with visual functions,Control group,Significantly increased,The results of this experiment proved that an 8-week long perceptual training program significantly differentiated the plot of visual detecting time.,4519214
3282,4519214,Visual detection time,Training with visual functions,Control group,Significantly increased,"The visual detection time improved during and after training stimulation in comparison to the baseline (Sig_0 vs. Sig_2: F(1.22)=24.44, p&lt;0.001).",4519214
3283,4610927,Demographic and anesthetic parameters,Remifentanil 0.05 (Group RL) or remifentanil 0.3 (group RH),Remifentanil 0.3 + ketamine 0.5 (group KRH),No significant difference,"There were no significant differences among the three groups related to demographic and anesthetic parameters, such as age, body weight, baseline blood pressure (systolic, diastolic, mean), baseline heart rate, duration of anesthesia, input, output, or time to extubation after surgery.",4610927
3284,4610927,Consumption of additional analgesics,Remifentanil 0.3 (group RH),Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL) ,Significantly increased,"Additional analgesic consumption, numerical rating scale scores at 6 and 24 h, and cumulative fentanyl dose were significantly higher in group RH than in the other two groups.",4610927
3285,4610927,Cumulative fentanyl dose,Remifentanil 0.3 (group RH),Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL) ,Significantly increased,"Additional analgesic consumption, numerical rating scale scores at 6 and 24 h, and cumulative fentanyl dose were significantly higher in group RH than in the other two groups.",4610927
3286,4610927,Pain scores as measured by the NRS at 6 hours and 24 hours after surgery,Remifentanil 0.3 (group RH),Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL) ,Significantly increased,"Additional analgesic consumption, numerical rating scale scores at 6 and 24 h, and cumulative fentanyl dose were significantly higher in group RH than in the other two groups.",4610927
3287,4610927,Value of the Touch-Test sensory evaluation after surgery,Remifentanil 0.3 (group RH),Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL) ,Significantly decreased,The postoperative value of the Touch-Test sensory evaluation was significantly lower in group RH than in the other two groups.,4610927
3288,3427491,Hepatic disorders and asthenia,TOMOX,FOLFOX4,No significant difference,"Hepatic disorders (25.0 vs. 14.3&nbsp;%) and asthenia (19.6 vs. 11.0&nbsp;%) had a numerically higher incidence in the TOMOX group than the FOLFOX4 group, but the differences did not reach statistical significance.",3427491
3289,3427491,Progression-free survival,TOMOX,FOLFOX4,No significant difference,"No statistically significant differences were observed in overall survival (15.6 and 17.2&nbsp;months; p&nbsp;=&nbsp;0.475); progression-free survival (7.7 and 8.7&nbsp;months; p&nbsp;=&nbsp;0.292), and response duration (6.4 and 7.6&nbsp;months; p&nbsp;=&nbsp;0.372) for TOMOX and FOLFOX4, respectively",3427491
3290,3427491,Survival rate,TOMOX,FOLFOX4,No significant difference,"No statistically significant differences were observed in overall survival (15.6 and 17.2&nbsp;months; p&nbsp;=&nbsp;0.475); progression-free survival (7.7 and 8.7&nbsp;months; p&nbsp;=&nbsp;0.292), and response duration (6.4 and 7.6&nbsp;months; p&nbsp;=&nbsp;0.372) for TOMOX and FOLFOX4, respectively",3427491
3291,3427491,Response duration,TOMOX,FOLFOX4,No significant difference,"No statistically significant differences were observed in overall survival (15.6 and 17.2&nbsp;months; p&nbsp;=&nbsp;0.475); progression-free survival (7.7 and 8.7&nbsp;months; p&nbsp;=&nbsp;0.292), and response duration (6.4 and 7.6&nbsp;months; p&nbsp;=&nbsp;0.372) for TOMOX and FOLFOX4, respectively",3427491
3292,3427491,Neutropenia and leukopenia,TOMOX,FOLFOX4,Significantly decreased,Grades 3 and 4 neutropenia (p&nbsp;&lt;&nbsp;0.0001) and leukopenia (p&nbsp;=&nbsp;0.028) were more common with the FOLFOX4 regimen,3427491
3293,3504074, Improvement in Psoriasis Area and Severity Index â‰¥75% after 24 weeks,Etanercept plus methotrexate,Eetanercept alone,Significantly increased,PASI 75 was significantly higher at week 24 for the combination therapy group compared with the monotherapy group (77Â·3% vs. 60Â·3%; P &lt; 0Â·0001).,3504074
3294,3504074, Improvement in Psoriasis Area and Severity Index â‰¥50% and â‰¥90% after 24 weeks,Etanercept plus methotrexate,Eetanercept alone,Significantly increased,"Other PASI improvement scores at week 12 [PASI 75, 70Â·2% vs. 54Â·3% (P = 0Â·01); PASI 50, 92Â·4% vs. 83Â·8% (P = 0Â·01); and PASI 90, 34Â·0% vs. 23Â·1% (P = 0Â·03)] showed similar results as did week 24 PASI 50 (91Â·6% vs. 84Â·6%; P = 0Â·01) and PASI 90 (53Â·8% vs. 34Â·2%; P = 0Â·01).",3504074
3295,3504074," Improvement in Psoriasis Area and Severity Index â‰¥50%, â‰¥ 75%, and â‰¥90% after 12 weeks",Etanercept plus methotrexate,Eetanercept alone,Significantly increased,"Other PASI improvement scores at week 12 [PASI 75, 70Â·2% vs. 54Â·3% (P = 0Â·01); PASI 50, 92Â·4% vs. 83Â·8% (P = 0Â·01); and PASI 90, 34Â·0% vs. 23Â·1% (P = 0Â·03)] showed similar results",3504074
3296,3504074,Physicianâ€™s Global Assessment of clear/almost clear,Etanercept plus methotrexate,Eetanercept alone,Significantly increased,Significantly more patients in the combination group than the monotherapy group had sPGA of clear or almost clear at week 12 (65Â·5% vs. 47Â·0%; P = 0Â·01) and week 24 (71Â·8% vs. 54Â·3%; P = 0Â·01) (Fig. 5).,3504074
3297,4594140,Anaerobic power after 12 weeks,Interval training combined with Judo training (IJ) or Resistance training combined with Judo training (RJ),Only Judo training (CG),Significantly increased,VO2max and anaerobic mean power in IJ (P &lt; 0.05) and anaerobic power in RJ (P &lt; 0.05) were significantly increased after 12-week training compared to CG.,4594140
3298,4594140,"Decrease in body weight, VO2max, and % fat",Interval training combined with Judo training (IJ),Only Judo training (CG),Significantly increased,"After 12-week training, there was a significant decrease in body weight (P = 0.003), % fat (P = 0.009), VO2max (P = 0.03), and HRmax (P = 0.01) of IJ compared to CG.",4594140
3299,4594140,Changes in epinephrine at 30-minute recovery,Resistance training combined with Judo training (RJ),Interval training combined with Judo training (IJ),Significantly increased,There was significantly higher changes in epinephrine of RJ compared to IJ at 30-minute recovery (P = 0.045).,4594140
3300,4594140,Decrease in IgA levels,Interval training combined with Judo training (IJ) or Resistance training combined with Judo training (RJ),Only Judo training (CG),No significant difference,"all groups showed reduced trend of IgA; however, there was no group difference based on different training methods.",4594140
3301,4594140,"Changes in % fat, VO2max, and HRmax",Resistance training combined with Judo training (RJ),Only Judo training (CG),No significant difference,"there were no significant changes in % fat, VO2max, and HRmax of RJ compared to CG after 12-week training",4594140
3302,4450462,Reduction in body weight after 20 weeks,Prescribed diet plus vitamin B12 supplement,Only vitamin B12 supplement,Significantly increased,"Body weight declined by a mean of 7.0â€‰kg over 20 weeks in the intervention group, as compared with 0.6â€‰kg in the control group (P&lt;0.001, Table 2).",4450462
3303,4450462,Changes in electrochemical skin conductance in the foot,Prescribed diet plus vitamin B12 supplement,Only vitamin B12 supplement,Significantly increased,"Electrochemical skin conductance in the foot improved by an average of 12.4 microseimens (95% CI 1.2â€“23.6, P=0.03) with the intervention in an effect size analysis.",4450462
3304,4450462,Improvement in pain score,Prescribed diet plus vitamin B12 supplement,Only vitamin B12 supplement,Significantly increased,"The between-group difference in change in pain, as measured by the McGill pain questionnaire, was âˆ’8.2 points (95% CI âˆ’16.1 to âˆ’0.3, P=0.04).",4450462
3305,4450462,Lipid profile,Prescribed diet plus vitamin B12 supplement,Only vitamin B12 supplement,No significant difference,"Total cholesterol declined 12.1â€‰mgâ€‰dlâˆ’1 in the intervention group and 2.2â€‰mgâ€‰dlâˆ’1 in the control group (P=0.20). Low density lipoprotein cholesterol declined 7.8â€‰mgâ€‰dlâˆ’1 in the intervention group, but increased by 0.4â€‰mgâ€‰dlâˆ’1 in the control group (P=0.35).",4450462
3306,4450462,Blood pressure,Prescribed diet plus vitamin B12 supplement,Only vitamin B12 supplement,No significant difference,"Systolic and diastolic blood pressure fell in both groups, without a significant between-group difference.",4450462
3307,3662597,Cardiovascular health parameters ,Multi-ingredient performance supplement (MIPS) group,Placebo group,No significant difference,"There was no groupâ€‰Ã—â€‰time interaction for HR, BP, blood glucose, lipids, NOx, hs-CRP, cortisol concentrations or body fat.",3662597
3308,3662597,Lipid parameters,Multi-ingredient performance supplement (MIPS) group,Placebo group,No significant difference,"There was no groupâ€‰Ã—â€‰time interaction for HR, BP, blood glucose, lipids, NOx, hs-CRP, cortisol concentrations or body fat.",3662597
3309,3662597,"Levels of nitrate/nitrite (NOx), cortisol, and high sensitivity C-reactive protein (hs-CRP)",Multi-ingredient performance supplement (MIPS) group,Placebo group,No significant difference,"There was no groupâ€‰Ã—â€‰time interaction for HR, BP, blood glucose, lipids, NOx, hs-CRP, cortisol concentrations or body fat.",3662597
3310,3662597,Body fat,Multi-ingredient performance supplement (MIPS) group,Placebo group,No significant difference,"There was no groupâ€‰Ã—â€‰time interaction for HR, BP, blood glucose, lipids, NOx, hs-CRP, cortisol concentrations or body fat.",3662597
3311,3662597,Total body mass and fat-free mass ,Multi-ingredient performance supplement (MIPS) group,Placebo group,Significantly increased,"Total body mass (Table&nbsp;3) was increased in both groups (pâ€‰&lt;â€‰0.0001) but more so in MIPS than Placebo (pâ€‰=â€‰0.024). FFM (Table&nbsp;3) was increased in both groups (pâ€‰&lt;â€‰0.0001); however, the increases were significantly greater with MIPS (pâ€‰=â€‰0.025).",3662597
3312,3321403,Voiding symptoms,Hydrodistension plus intravesical resiniferatoxin (RTX),Hydrodistension only,No significant difference,"Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale.",3321403
3313,3321403,Uroflowmetry,Hydrodistension plus intravesical resiniferatoxin (RTX),Hydrodistension only,No significant difference,"Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale.",3321403
3314,3321403,Improvement in pain scores,Hydrodistension plus intravesical resiniferatoxin (RTX),Hydrodistension only,Significantly increased,"Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale.",3321403
3315,3321403,Severity of IC symptoms at baseline,Hydrodistension plus intravesical resiniferatoxin (RTX),Hydrodistension only,No significant difference,There were no clinically meaningful differences among the two groups in the severity of IC symptoms.,3321403
3316,5219826,High contrast visual acuity at 40 cms,Extended depth-of-focus (EDOF),Center-near lens (AOMF),Significantly increased,"EDOF was significantly better than AOMF for HCVA at 40&nbsp;cm (0.42&nbsp;Â±&nbsp;0.18 vs. 0.48&nbsp;Â±&nbsp;0.22, p&nbsp;=&nbsp;0.024),",5219826
3317,5219826,Intermediate and near clarity-of-vision,Extended depth-of-focus (EDOF),Center-near lens (AOMF),Significantly increased,"Clarity-of-vision at intermediate and near were rated significantly higher with EDOF (Fig. 2, p&nbsp;=&nbsp;0.006, p&nbsp;=&nbsp;0.005 respectively).",5219826
3318,5219826,Stereopsis and lack-of-ghosting,Extended depth-of-focus (EDOF),Center-near lens (AOMF),Significantly increased,"EDOF was significantly better than AOMF for HCVA at 40&nbsp;cm (0.42&nbsp;Â±&nbsp;0.18 vs. 0.48&nbsp;Â±&nbsp;0.22, p&nbsp;=&nbsp;0.024), stereopsis (98&nbsp;Â±&nbsp;88 vs. 141&nbsp;Â±&nbsp;114, p&nbsp;&lt;&nbsp;0.001), clarity-of-vision at intermediate (8.5&nbsp;Â±&nbsp;1.6 vs. 7.7&nbsp;Â±&nbsp;1.9, p&nbsp;=&nbsp;0.006) and near (7.3&nbsp;Â±&nbsp;2.5 vs. 6.2&nbsp;Â±&nbsp;2.5, p&nbsp;=&nbsp;0.005), lack-of-ghosting (p&nbsp;=&nbsp;0.012),",5219826
3319,5219826,Overall vision satisfaction and ocular comfort,Extended depth-of-focus (EDOF),Center-near lens (AOMF),Significantly increased,Overall vision satisfaction and ocular comfort were rated significantly higher with EDOF,5219826
3320,5219826,Purchase preferance,Extended depth-of-focus (EDOF),Center-near lens (AOMF),Significantly increased,"Significantly more participants chose to only-purchase EDOF (33% vs. 6%, p&nbsp;=&nbsp;0.003).",5219826
3321,5295657,HDL-C rate,40 mg/day of Lovastatin plus 2 g/day powder of Kelussia odoratissima,40 mg/day of lovastatin,Significantly increased,The HDL-C rate was higher in intervention group compared to control group (P &lt; 0.05).,5295657
3322,5295657,The mean LDL/HDL ratio,"40 mg/day of Lovastatin plus 2 g/day powder of Kelussia odoratissima, 40 mg/day of lovastatin",baseline,Significantly decreased,The mean LDL/HDL ratio decreased during the study (P &lt; 0.001),5295657
3323,5295657,fasting blood sugar (FBS),40 mg/day of Lovastatin plus 2 g/day powder of Kelussia odoratissima,40 mg/day of lovastatin,No significant difference,The mean of FBS did not change and the two groups had no significant difference (P&gt;0.05; Table 1).,5295657
3324,5295657,The mean LDL/HDL ratio,40 mg/day of Lovastatin plus 2 g/day powder of Kelussia odoratissima,40 mg/day of lovastatin,No significant difference,"The mean LDL/HDL ratio decreased during the study (P&lt;0.001); however, there was not any significant difference between the two groups (P&gt;0.05).",5295657
3325,5149084,mean pain scores,"Group II  - 2 mg Amlexanox paste respectively, group III received diode laser",Group I -  herbal combination of Acacia nilotica and Licorice (A and L),Significantly decreased,"At day 5 both Amlexanox and Laser groups demonstrated statistically significantly lower mean pain scores than A and L group (p &lt; 0.001), where the mean pain score results for the Amlexanox group was 3.2+1.6 and for the laser group 2.9 +1.1 while that of A and L group was 5.6+1.3 ( Table 1, Fig. 1A).",5149084
3326,5149084,mean ulcer size,Group I -  herbal combination of Acacia nilotica and Licorice (A and L),control,Significantly decreased,"At day 5, A and L group showed statistically significantly lower mean ulcer size than the control group (p&lt;0.001), while Amlexanox and Laser groups; both showed the lowest mean ulcer sizes with no statistically significant difference between them.",5149084
3327,4832354,"informed about the treatment choice,  aware of options,  knowledgeable about treatment benefits, and knowledgeable about treatment risks/side effects ",Patient decision aids (Pâ€�DAs),control,Significantly increased,"Pâ€�DA users perceived themselves to be significantly more 1) informed about the treatment choice (Pâ€‰=â€‰.008), 2) aware of options (Pâ€‰=â€‰.009), 3) knowledgeable about treatment benefits (Pâ€‰=â€‰.020), and 4) knowledgeable about treatment risks/side effects (Pâ€‰=â€‰.001) in comparison with controls.",4832354
3328,4832354,"decision satisfaction, decision regret, cancerâ€�related worry (Assessment of Survivor Concerns), mood, and trust in the treating physician, subscale measures of cancer worry or health worry of the Assessment of Survivor Concerns questionnairerespective anxiety, worry , interest, or depression measures of the Patient Health Questionnaire for Depression and Anxiety 4 mood screening questionnaire.",Patient decision aids (Pâ€�DAs),control,No significant difference,"There were no significant differences between the Pâ€�DA and noâ€“Pâ€�DA groups in the following outcomes: decision satisfaction (Pâ€‰=â€‰.142), decision regret (Pâ€‰=â€‰.199), cancerâ€�related worry (Assessment of Survivor Concerns; Pâ€‰=â€‰.645), mood (Pâ€‰=â€‰.211), and trust in the treating physician (Pâ€‰=â€‰.764; Table 2). Furthermore, there was no significant difference between groups for any of the respective subscale measures of cancer worry (Pâ€‰=â€‰.718) or health worry (0.191) of the Assessment of Survivor Concerns questionnaire. Also, there was no significant difference between groups for any of the respective anxiety (Pâ€‰=â€‰.107), worry (Pâ€‰=â€‰.251), interest (Pâ€‰=â€‰.912), or depression measures (Pâ€‰=â€‰.286) of the Patient Health Questionnaire for Depression and Anxiety 4 mood screening questionnaire.",4832354
3329,5410668,colloidal stability,"D1 (Colgate Sensitive Pro-ReliefÂ®), dentifrice D3 (Sensodyne Repair &amp; ProtectÂ®)","D2 (Sensodyne Rapid ReliefÂ®), D4 (Colgate Maximum Cavity ProtectionÂ®)",Significantly increased,Zeta potential analysis shows better colloidal stability in solution for dentifrice D1 (Colgate Sensitive Pro-ReliefÂ®) and dentifrice D3 (Sensodyne Repair &amp; ProtectÂ®) (p &lt;0.05) when compared to D2 and D4. D2 and D4 are statistically similar with regards to this parameter.,5410668
3330,5410668,"carbon, calcium, nitrogen, phosphorus and magnesium",D1 (Colgate Sensitive Pro-ReliefÂ®),control,Significantly increased,"In the analysis of the chemical composition of Group 1 samples, a statistically significant difference (p &lt;0.05) was verified between the controlâ€™s and experimentalâ€™s surfaces, mainly with respect to carbon, calcium, nitrogen, phosphorus and magnesium.",5410668
3331,5410668,"carbon, calcium, nitrogen, phosphorus and strontium",G2- brushing with SensodyneÂ®Rapid Relief;,control,Significantly increased,"Evaluation regarding the chemical elements present in the specimen from Group 2 shows a statistically significant difference (p &lt;0.05) in the experimental faces when comparing to the positive control faces for carbon, calcium, nitrogen, phosphorus and strontium.",5410668
3332,5410668,oxygen; carbon; calcium; nitrogen; phosphorus; silicon and sodium,G3- brushing with SensodyneÂ®Repair &amp; Protect;,control,Significantly increased,"By checking the chemical elements of specimens from Group 3, a statistically significant difference (p&lt;0.05) between the positive and the experimental control regions for all chemical elements present in oxygen; carbon; calcium; nitrogen; phosphorus; silicon and sodium, samples was noticed, which is solidified by the dentifrice chemical composition (5% calcium phosphosilicate and sodium and 1426 ppm fluoride) and by the reduction in the diameter of dentinal tubules in the experimental part when compared to the control, besides the formation of a layer over the dentin, as verified in the SEM images from Group 3.",5410668
3333,5410668,"oxygen, nitrogen, carbon, phosphorus and sodium",G4- brushing with ColgateÂ®Maximum Cavity Protection,control,Significantly increased,"Analysis of the chemical elements of specimens from Group 4 (brushing with Colgate Maximum Cavity ProtectionÂ® - negative control) showed a statistically significant difference (p &lt;0.05) in the experimental faces when compared to the positive controls as for oxygen, nitrogen, carbon, phosphorus and sodium, whose results are based on the dentifrice formulation (calcium carbonate and 1,450 ppm fluoride) and slight differences were noticed in the experimental areas when compared to the surfaces of the positive control in the SEM images from Group 4.",5410668
3334,4069535,Pulse pressure variation (PPV) ,propofol SD2,propofol SD1,Significantly increased,"At the increasing dose of propofol, both PPV and SVV significantly increased in SD1 versus SD0 (P &lt; 0.01) and SD2 versus SD0 (P &lt; 0.001), but only PPV in SD2 versus SD1 (P = 0.024)",4069535
3335,4069535,Pulse pressure variation (PPV) and stroke volume variation (SVV),propofol SD1 and SD2,fluid resuscitation and norepinephrine infusion (SD0),Significantly increased,"At the increasing dose of propofol, both PPV and SVV significantly increased in SD1 versus SD0 (P &lt; 0.01) and SD2 versus SD0 (P &lt; 0.001),",4069535
3336,4069535,Pulse pressure variation (PPV) and stroke volume variation (SVV),propofol SD1 and SD2,Dexmedetomidine ,Significantly increased,"At SD1 and SD2, PPV and SVV were higher in PROP with respect to DEX (P &lt; 0.001).",4069535
3337,4069535,Pulse pressure variation (PPV) and stroke volume variation (SVV),Dexmedetomidine, fluid resuscitation and norepinephrine infusion (SD0),No significant difference,Dexmedetomidine infusion did not affect PPV and SVV.,4069535
3338,4893393,intensity of pain,lidocaine (5â€‰mgs/kg),placebo,Significantly decreased,"Both lidocaine and placebo reduced the intensity of pain, at the end of each session; however, lidocaine achieved a greater reduction compared to placebo (76.4% versus 40.1%, P &lt; 0.001).",4893393
3339,4297469, follow-up (FU) visits,Home Monitoring facilitated FU (HM ON),regular in-office FU (HM OFF),Significantly decreased,"Despite a significantly higher number of unscheduled in-office FU visits in the HM ON group, the total number of FU visits was still significantly lower with HM ON (3.79 Â± 1.67 vs. 5.53 Â± 2.32, P &lt; 0.001).",4297469
3340,4297469,clinically relevant finding/action (â€˜actionable visitsâ€™),Home Monitoring facilitated FU (HM ON),regular in-office FU (HM OFF),Significantly increased,"In the HM ON group, 32.0% of in-office FU visits (193/603) resulted in a clinically relevant finding/action (â€˜actionable visitsâ€™) compared with 26.8% (213/795) in the HM OFF group (P &lt; 0.05).",4297469
3341,4297469,unscheduled visits,Home Monitoring facilitated FU (HM ON),regular in-office FU (HM OFF),Significantly increased,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P &lt; 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P &lt; 0.005),",4297469
3342,4297469,non-office-based contacts,Home Monitoring facilitated FU (HM ON),regular in-office FU (HM OFF),Significantly increased,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P &lt; 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P &lt; 0.005), more non-office-based contacts (1.95 Â± 3.29 vs. 1.01 Â± 2.64; P &lt; 0.001),",4297469
3343,4297469,Internet sessions,Home Monitoring facilitated FU (HM ON),regular in-office FU (HM OFF),Significantly increased,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P &lt; 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P &lt; 0.005), more non-office-based contacts (1.95 Â± 3.29 vs. 1.01 Â± 2.64; P &lt; 0.001), more Internet sessions (11.02 Â± 15.28 vs. 0.06 Â± 0.31; P &lt; 0.001)",4297469
3344,4297469,in-clinic discussions,Home Monitoring facilitated FU (HM ON),regular in-office FU (HM OFF),Significantly increased,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P &lt; 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P &lt; 0.005), more non-office-based contacts (1.95 Â± 3.29 vs. 1.01 Â± 2.64; P &lt; 0.001), more Internet sessions (11.02 Â± 15.28 vs. 0.06 Â± 0.31; P &lt; 0.001) and more in-clinic discussions (1.84 Â± 4.20 vs. 1.28 Â± 2.92; P &lt; 0.03)",4297469
3345,4297469,"hospitalizations,  shorter length-of-stay",Home Monitoring facilitated FU (HM ON),regular in-office FU (HM OFF),No significant difference,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P &lt; 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P &lt; 0.005), more non-office-based contacts (1.95 Â± 3.29 vs. 1.01 Â± 2.64; P &lt; 0.001), more Internet sessions (11.02 Â± 15.28 vs. 0.06 Â± 0.31; P &lt; 0.001) and more in-clinic discussions (1.84 Â± 4.20 vs. 1.28 Â± 2.92; P &lt; 0.03), but with numerically fewer hospitalizations (0.67 Â± 1.18 vs. 0.85 Â± 1.43, P = 0.23) and shorter length-of-stay (6.31 Â± 15.5 vs. 8.26 Â± 18.6; P = 0.27), although not significant. For the whole study population,",4297469
3346,4297469, total FU cost for providers,Home Monitoring facilitated FU (HM ON),regular in-office FU (HM OFF),No significant difference,"For the whole study population, the total FU cost for providers was not different for HM ON vs. OFF [mean (95% CI): â‚¬204 (169â€“238) vs. â‚¬213 (182â€“243); range for difference (â‚¬âˆ’36 to 54), NS].",4297469
3347,4502126,dentinal defects,"ProTaper, K3 SybronEndo, and Easy RaCe rotary",hand instrumentation,Significantly increased,"Significant difference was seen between groups. No defects were found in unprepared roots and those prepared with hand files. ProTaper, K3 rotary, and Easy RaCe preparations resulted in dentinal defects in 23.3%, 10%, and 16.7% of teeth, respectively.",4502126
3348,4389977,mean number of terminal hairs,oral marine protein supplement (MPS),placebo,Significantly increased,"Among the MPS-treated subjects, there was a significant increase in the mean number of terminal hairs from 178.3 (7.8) at baseline to 235.8 (18.4) at Visit 2 (f (1,29) = 362.0, P &lt; 0.0001) but not among placebotreated subjects from 178.2 (9.6) to 180.9 (18.8) (f (1,29) = 1.25, P = 0.273)",4389977
3349,4389977,the number of vellus hairs,oral marine protein supplement (MPS),placebo,Significantly increased,"Similarly, there was a significant increase in the number of vellus hairs in MPS-treated subjects (f (1,29) = 54.1, P &lt; 0.0001) but not among the placebotreated subjects (f (1,29) = 0.67, P = 0.420) (Table 1).",4389977
3350,4389977,hair shedding counts following hair washing,oral marine protein supplement (MPS),placebo,Significantly decreased,"The two groups were significantly different in the hair shedding counts following hair washing (f (1,58) = 4.51, P = 0.038) due to significant decrease among the MPS-treated subjects (MPS: D0: 27.13 Â± 27; D90:16.47 Â± 14; placebo: D0:23.4 Â± 25, D90:21.87 Â± 21).",4389977
3351,4389977,terminal hair diameter,oral marine protein supplement (MPS),placebo,No significant difference,"There was no significant increase in terminal hair diameter among MPS-treated subjects (f (1,29) = 11.42, P = 0.434) or placebotreated subjects (f (1,29) = 0.29, P = 0.725) and the two groups were not significantly different from one another with respect to terminal hair diameter (f (1,58) = 0.674, P = 0.415).",4389977
3352,4389977,Self-Assessment Questionnaire score at Visit 2,oral marine protein supplement (MPS),placebo,Significantly increased,"Subjects treated with MPS obtained significantly higher total scores on the Self-Assessment Questionnaire at Visit 2 (f (1,58) = 8.27, P = 0.006; MPS: 61.20 Â± 7; placebo: 55.57 Â± 8) with significant differences between the two groups on 7 of 13 items including overall hair growth, overall hair volume, scalp coverage, thickness of hair body, hair strength, growth of eyebrow hair, and overall skin health (Table 2).",4389977
3353,4389977,total scores on the Quality of Life Questionnaire,oral marine protein supplement (MPS),placebo,Significantly increased,"The MPS-treated subjects also obtained significantly higher total scores on the Quality of Life Questionnaire (f (1,58) = 4.61, P = 0.035; MPS: D0:33.9 Â± 10; D90:26.9 Â± 8; placebo: D0:34.0 Â± 11, D90:30.6 + 11).",4389977
3354,5919699,moderate physical activity,6-week home-based exercise program,usual care,Significantly increased,"A total of 57 participants (79.2%) completed the trial. Intention-to-treat analysis indicated that moderate physical activity level increased significantly by 269.4 Â± 260.6 minutes per week in the exercise group (mean between-group difference, 254.6 minutes; 95% confidence interval, 172.7â€“434.7; p &lt; 0.001).",5919699
3355,5919699,the step test and  push-up test,6-week home-based exercise program,usual care,Significantly increased,"Participants in the exercise group demonstrated significant improvement in the step test (exercise group, -3.9 vs. usual care group, 2.6; p = 0.012) and push-up test (exercise group, 3.0 vs. usual care group, -1.2; p = 0.012).",5919699
3356,5919699,"6-minute walk test, change in chair-to-standing repetitions",6-week home-based exercise program,usual care,No significant difference,"No significant difference between groups was observed for changes in the 6-minute walk test (p = 0.754), but there was a trend toward a change in chair-to-standing repetitions (exercise group, 0.2 vs. usual care group, -2.2; p = 0.137).",5919699
3357,3215167,NaHCO3 condition,"750 mL of water with either 9 g of EG (manufacturer recommendations), 0.1 gÂ·kg-1 of NaHCO3",placebo (plain flour),Significantly increased,"Represented are the acid-base responses for Energised Greensâ„¢ (9 g) (EG), 0.1 gÂ·kg-1BW sodium bicarbonate (NaHCO3) or flour placebo (Placebo) conditions over 120 min post ingestion. For all three acid-base variables, only the NaHCO3 condition resulted in significant elevation (*) in blood alkalosis between 15 and 120 min (p &lt; 0.01) when compared to both Placebo and EG.",3215167
3358,3215167,"pH, HCO3-, &amp; BE","750 mL of water with either 9 g of EG (manufacturer recommendations), 0.1 gÂ·kg-1 of NaHCO3",placebo (plain flour),Significantly increased,"There were significant interactions (p &lt; 0.01) and main effects for condition (p &lt; 0.001) and time (p &lt; 0.001) for all acid-base variables (pH, HCO3-, &amp; BE).",3215167
3359,3215167,incidence and severity of GI discomfort,"750 mL of water with either 9 g of EG (manufacturer recommendations), 0.1 gÂ·kg-1 of NaHCO3",placebo (plain flour),No significant difference,There were no significant interactions (p &gt; 0.98) or main effects for condition (p &gt; 0.80) or time (p &gt; 0.57) for either incidence or severity.,3215167
3360,2788265,Progression-free survival,"5-fluorouracil (350â€‰mgâ€‰mâˆ’2 per day on each day of radiotherapy, RT-5-FU arm)","gemcitabine (300â€‰mgâ€‰mâˆ’2), and cisplatin (30â€‰mgâ€‰mâˆ’2) on days 1, 8, 22, and 29 (RT-GC arm), or the same concurrent treatment followed by sequential full-dose gemcitabine (1000â€‰mgâ€‰mâˆ’2) and cisplatin (50â€‰mgâ€‰mâˆ’2) every 2 weeks (RT-GC+GC arm)",No significant difference,"Progression-free survival: after a median follow-up of 8.6. months (range, 1.4â€“39.5), the median PFS was estimated with 4.0 months in the RT-5-FU arm, 5.6 months in the RT-GC arm, and 6.0 months in the RT-GC+GC arm (P=0.21; Table 3). The Kaplanâ€“Meier plot for PFS is shown in Figure 2A.",2788265
3361,2788265,Overall survival,"5-fluorouracil (350â€‰mgâ€‰mâˆ’2 per day on each day of radiotherapy, RT-5-FU arm)","gemcitabine (300â€‰mgâ€‰mâˆ’2), and cisplatin (30â€‰mgâ€‰mâˆ’2) on days 1, 8, 22, and 29 (RT-GC arm), or the same concurrent treatment followed by sequential full-dose gemcitabine (1000â€‰mgâ€‰mâˆ’2) and cisplatin (50â€‰mgâ€‰mâˆ’2) every 2 weeks (RT-GC+GC arm)",No significant difference,"The corresponding 9-month OS rates were 58% (RT-5-FU), 52% (RT-GC), and 45% (RT-GC+GC) respectively (P=0.61).",2788265
3362,2527839,The median relative dose intensity per patient, S-1 40â€“60â€‰mg two times daily according to body surface area on days 1â€“28 every 6 weeks,capecitabine 1250â€‰mgâ€‰mâˆ’2 two times daily on days 1â€“14 every 3 weeks,Significantly increased,"The median relative dose intensity per patient was 87.6% (range, 32.3â€“102.4%) for capecitabine and 96.3% (range, 16.1â€“102.5%) for S-1 (P=0.003).",2527839
3363,5167461,forced expiratory volume in one second (FEV1),IND/GLY 110 Î¼g/50 Î¼g,twice-daily SFC 50 Î¼g/500 Î¼g,Significantly increased,"Pre-dose trough FEV1 improved significantly with IND/GLY versus SFC in the overall population (treatment difference, 0.10 L; P&lt;0.0001) as well as in the GOLD B (treatment difference, 0.10 L; P&lt;0.0001) and GOLD D (treatment difference, 0.08 L; P&lt;0.0001) subgroups of patients (Figure 1).",5167461
3364,5167461,standardized area under the curve for FEV1 from 0 to 12 hours (FEV1 AUC0â€“12 hours),IND/GLY 110 Î¼g/50 Î¼g,twice-daily SFC 50 Î¼g/500 Î¼g,Significantly increased,"Significant improvements in lung function in terms of FEV1 AUC0â€“12 hours were observed with IND/GLY versus SFC in the overall population (treatment difference, 0.13 L; P&lt;0.0001) and also in the GOLD B (treatment difference, 0.14 L; P&lt;0.0001) and GOLD D (treatment difference, 0.11 L; P&lt;0.005) subgroups (Figure 2).",5167461
3365,5167461,rate of moderate or severe exacerbations,IND/GLY 110 Î¼g/50 Î¼g,twice-daily SFC 50 Î¼g/500 Î¼g,Significantly decreased,"In the overall pooled population, the annualized rate of moderate or severe exacerbations was significantly lower with IND/GLY versus SFC (incidence rate ratio [IRR], 0.67; P=0.02; Figure 3).",5167461
3366,5167461,The incidence of pneumonia,IND/GLY 110 Î¼g/50 Î¼g,twice-daily SFC 50 Î¼g/500 Î¼g,Significantly decreased,"The incidence of pneumonia was lower with IND/GLY (IND/GLY, 3 patients; SFC, 14 patients). In a post hoc analysis, the difference in the incidence of pneumonia was found to be statistically significant (P=0.0074).",5167461
3367,3150240,Total Points (TP) score,Group A subjects receiving active treatmen,baseline,Significantly decreased,"In Group A, the TP scores decreased significantly from 122.3 to 96.01, Figure 1 (Wilcoxon Signed Rank Test Z = -22,735, Asymp. Sig (2-tailed) = 0,000);",3150240
3368,3150240,Total Points (TP) score,Group B subjects receiving placebo,baseline,No significant difference,"in Group B, the decrease of TP scores from 122.96 to 122.11, was not statistically significant (Wilcoxon Signed Rank Test Z=-0,914, Asymp. Sig (2-tailed) = 0,361), Figure 2, Table 3.",3150240
3369,5374834,severity of postoperative catheter-related bladder discomfort (CRBD),ketamine group,hyoscine group,Significantly increased,"There was a significant difference between the two groups in the severity of CRBD measured by visual analog scale score only 30 min after drug administration where it was higher in ketamine group (44.50 Â± 7.70) compared to hyoscine group (36.00 Â± 8.55) (P &lt; 0.001), otherwise there was no significant difference at other time points between the two groups, also there was a significant rise in heart rate in hyoscine group but no significant difference in mean arterial pressure.",5374834
3370,5374834,rise in heart rate (HR), hyoscine group,ketamine group,Significantly increased,"There was a statistically significant rise in HR in hyoscine group patients compared to ketamine group over time (P &lt; 0.001), whereas no difference was observed in mean arterial pressure [Figures 2 and 3].",5374834
3371,5374834,the level of sedation, ketamine group, hyoscine group,Significantly decreased,"Moreover, there was a significant difference between the two groups regarding the level of sedation where it was lower in ketamine group compared to hyoscine group (P &lt; 0.001), which was assessed by modified observer's assessment of alertness/sedation score [Figure 4].",5374834
3372,4768887,use of right-sided approach ,Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT),computed tomography (CT),No significant difference,"Compared to the CT group, the right-sided approach was more frequently used (42.6% versus 25.5%, P=0.065) in the PET/CT group in order to allow surgical access to radiographically suspicious lymph nodes inaccessible from the left, thus enabling the removal of more involved lymph nodes (2.83 versus 1.76; P=0.039) as well as their stations (1.65 versus 1.08; P=0.042).",4768887
3373,4768887,"removal of more involved lymph nodes, their stations",Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT),computed tomography (CT),Significantly increased,"Compared to the CT group, the right-sided approach was more frequently used (42.6% versus 25.5%, P=0.065) in the PET/CT group in order to allow surgical access to radiographically suspicious lymph nodes inaccessible from the left, thus enabling the removal of more involved lymph nodes (2.83 versus 1.76; P=0.039) as well as their stations (1.65 versus 1.08; P=0.042).",4768887
3374,4768887,overall sensitivity and an accuracy in the detection of the metastasis,Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT),computed tomography (CT),Significantly increased,"On a station-based analysis, PET/CT displayed an overall sensitivity of 86.5% and an accuracy of 92.2% in the detection of the metastasis. CT showed a lower sensitivity of 67.3% (P=0.006) and an accuracy of 87.2% (P=0.024).",4768887
3375,4768887,Overall survival (OS),Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT),computed tomography (CT),No significant difference,The estimated mean OS for the PET/CT group (28.4 months; 95% CI: 24.1â€“32.7 months) was slightly higher than that for the CT group (25.7 months; 95% CI: 21.7â€“29.6 months) but did not achieve statistical significance (P=0.38).,4768887
3376,4768887,Disease-free survival (DFS),Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT),computed tomography (CT),Significantly increased,Subgroup analysis of node-positive patients indicates that the PET/CT group again demonstrates longer mean DFS (22.5 months; 95% CI: 17.4â€“27.6 months versus 13.5 months; 95% CI: 9.6â€“17.5 months) (P=0.02; Figure 3).,4768887
3377,3564767,Attitudes Towards Nicotine Replacement Therapy Scale (ANRT-12),two sessions of 1.5â€‰hours each of the Pick-Klop game or two sessions of 1.5â€‰hours each of psychoeducation,nothing (waiting list group),Significantly increased,"Both intervention groups compared to the control group significantly increased their mean between T0 and T1 (F(2,235)â€‰=â€‰16.7, pâ€‰&lt;â€‰0.0005). This mean difference was still significant between T1 and T2 (F(2,235)â€‰=â€‰3.3, pâ€‰=â€‰0.04). Finally, a main group effect was observed (F(2,235)â€‰=â€‰6.0, pâ€‰=â€‰0.003). This translates higher overall means on the dependent variable for Pick-Klop and psychoeducation groups compared to the waiting list group.",3564767
3378,3564767,Attitudes Towards Smoking Scale (ATS-18),two sessions of 1.5â€‰hours each of the Pick-Klop game or two sessions of 1.5â€‰hours each of psychoeducation,nothing (waiting list group),Significantly decreased,"Between T0 and T1, the mean scores for the two treatment groups decreased while they increased for the waiting list (F(2, 235)â€‰=â€‰5.7, pâ€‰=â€‰0.004).",3564767
3379,3564767,Smoking Self-Efficacy Questionnaire (SEQ-12),two sessions of 1.5â€‰hours each of the Pick-Klop game,nothing (waiting list group)  or two sessions of 1.5â€‰hours each of psychoeducation,Significantly increased,"It was shown that this effect occurred mainly between T1 and T2 (F(1, 235)â€‰=â€‰10.4, pâ€‰=â€‰0.001). A treatment groupâ€‰Ã—â€‰time interaction was observed as well (F(4, 470)â€‰=â€‰3.5, pâ€‰=â€‰0.008). This effect occurred mainly between T1 and T2 (F(2, 235)â€‰=â€‰4.2, pâ€‰=â€‰0.02). The scores were significantly higher for the Pick-Klop group compared with the psychoeducation and the waiting list groups between these times.",3564767
3380,3564767,Number of cigarettes smoked per day,two sessions of 1.5â€‰hours each of the Pick-Klop game,nothing (waiting list group)  or two sessions of 1.5â€‰hours each of psychoeducation,Significantly decreased,"The Pick-Klop group significantly decreased the number of cigarette smoked per day compared to the psychoeducation and the waiting list groups mainly between T1 and T2 (F(2, 230)â€‰=â€‰3.5, pâ€‰=â€‰0.03).",3564767
3381,3564767,Smoking status,two sessions of 1.5â€‰hours each of the Pick-Klop game or two sessions of 1.5â€‰hours each of psychoeducation,nothing (waiting list group)  ,Significantly decreased,"Compared with the participants in the waiting-list group, those in the Pick-Klop group were less likely to be smokers (pâ€‰=â€‰0.04, ORâ€‰=â€‰0.32, and CIâ€‰=â€‰[0.11; 0.96]). There was no significant difference between the psychoeducation and the waiting-list groups as the confidence interval includes the â€œ1â€� value.",3564767
3382,4310883,length of stay (LOS),alvimopan,control,Significantly decreased,"Patients who received alvimopan experienced a shorter length of stay (LOS) versus those in who did not receive alvimopan (10.5 vs. 8.6 days, p = 0.005, 95% CI 0.6â€“3.3).",4310883
3383,4310883,Costs,alvimopan,control,Significantly decreased,"Costs were significantly lower in the alvimopan group than the control groups (2012 USD 32,443 vs. 40,604 p &lt;0.001).",4310883
3384,4310883,disposition of patients from the OR to the intensive care unit,alvimopan,preâ€“alvimopan,Significantly increased,"There was increased disposition of patients from the OR to the intensive care unit in the alvimopan group (44% vs. 66%, p = 0.048).",4310883
3385,4310883,use of robotic technique,alvimopan,preâ€“alvimopan,Significantly increased,"Additionally, use of robotic technique increased markedly in the alvimopan group (8% vs. 25%, p = 0.030).",4310883
3386,4310883,Utilization of total parenteral nutrition,alvimopan,preâ€“alvimopan,Significantly decreased,"Utilization of total parenteral nutrition was higher in the preâ€“alvimopan group (38.8% preâ€“alvimopan 20.6% vs. alvimopan, p = 0.010).",4310883
3387,4310883,Time to regular diet,alvimopan,preâ€“alvimopan,Significantly decreased,Time to regular diet was significantly longer in the preâ€“alvimopan cohort at 7.1 days compared to 4.8 days in the treatment group (p = 0.020).,4310883
3388,3206382,percentage of reticulocytes at day 7,Iron polymaltose complex (IPC),"ferrous sulfate twice daily, (both 5â€‰mg iron/kg/day)",No significant difference,The percentage of reticulocytes at day 7 was similar with IPC (1.41 Â± 1.31%) and ferrous sulfate (1.57 Â± 1.29%; P = 0.905).,3206382
3389,3206382,improvement in Hb by month 1,"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5â€‰mg iron/kg/day)",baseline,Significantly increased,"A significant improvement in Hb was observed by month 1 in the IPC group (9.5 Â± 1.1â€‰g/dL to 10.6 Â± 1.0â€‰g/dL, P = 0.001) and the ferrous sulfate group (9.4 Â± 1.6â€‰g/dL to 11.2 Â± 0.9â€‰g/dL, P = 0.001),",3206382
3390,3206382,improvement in Hb by month 4,"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5â€‰mg iron/kg/day)",baseline,Significantly increased,"with an increase of more than 2â€‰g/dL in both treatment arms by month 4 (IPC 11.7 Â± 0.8â€‰g/dL, ferrous sulfate 12.4 Â± 1.0â€‰g/dL; both P = 0.001 versus baseline).",3206382
3391,3206382,Hb and Hct levels by months 1 and 4,"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5â€‰mg iron/kg/day)",baseline,No significant difference,"Hb and Hct levels from baseline to months 1 and 4 were not significantly different between treatment groups, although at month 1 there was a nonsignificant trend to a greater increase in Hb in the ferrous sulfate group (IPC 1.2 Â± 0.9â€‰g/dL versus 1.8 Â± 1.7â€‰g/dL, P = 0.060).",3206382
3392,3206382, transferrin saturation (TSAT),"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5â€‰mg iron/kg/day)",baseline,No significant difference,"In terms of iron status parameters, TSAT improved from approximately 5% in each group at baseline to &gt;20% at month 4 (IPC 5.1 Â± 3.3% to 20.2 Â± 15.5%, P = 0.001; ferrous sulfate 5.4 Â± 3.5% to 22.4 Â± 13.2%, P = 0.001) with no significant difference between the groups.",3206382
3393,3206382,serum ferritin level by month 4,"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5â€‰mg iron/kg/day)",baseline,Significantly increased,"The increase in serum ferritin level from baseline to month 4 was almost twofold lower in the IPC group versus ferrous sulfate (22.7 Â± 26.1â€‰Î¼g/mL versus 42.5 Â± 62.0â€‰Î¼g/mL, P = 0.001).",3206382
3394,3206382,gastrointestinal adverse event,"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5â€‰mg iron/kg/day)",baseline,Significantly decreased,"Overall, 38.8% patients (40/103) reported one or more gastrointestinal adverse event typical for oral iron supplementation, with a significantly lower frequency of events in the IPC group (26.9% [14/52]) compared to the ferrous sulfate group (50.9% [26/51], P = 0.012) (Table 3).",3206382
3395,3206382,mean facial expression score on the five-point Wong-Baker scale,"Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5â€‰mg iron/kg/day)",baseline,Significantly decreased,"At the end of the four-month study period, the mean facial expression score on the five-point Wong-Baker scale was 0.51 points lower in the IPC group compared to the ferrous sulfate group (1.63 Â± 0.56 versus 2.14 Â± 0.75, P = 0.001).",3206382
3396,5623480,"Primary outcome: the proportion of patients who did not have 70% resolution of ST-segment elevation and did not meet the criteria for Thrombolysis In Myocardial Infarction (TIMI) flow 3 at initial angiography. Secondary outcome: the composite of death, MI, stent thrombosis, stroke or urgent revascularisation and major or minor bleeding at 30 days.",in-hospital administration of ticagrelor,Prehospital administration of ticagrelor,No significant difference,"Prehospital administration of ticagrelor compared with in-hospital administration resulted in a non-significant difference in the primary, secondary and safety outcomes.",5623480
3397,4320136,Ferritin concentration, 500 g/day of cooked banana for 4 days,480 g/day of raw banana for 6 days,Significantly increased,Ferritin concentration was significantly higher in the group that received the cooked banana compared to the group that received the raw banana with added iron (p&lt;0.05).,4320136
3398,4320136,Percent iron absorption, 480 g/day of raw banana for 6 days, 500 g/day of cooked banana for 4 days,Significantly increased,Percent iron absorption was significantly higher in the group consuming raw (49.3Â±21.4%) compared to the group consuming uncooked bananas (33.9Â±31.4%; p=0.035) (Fig. 2).,4320136
3399,4320136,Total amount of absorbed iron , 480 g/day of raw banana for 6 days, 500 g/day of cooked banana for 4 days,No significant difference,"Total amount of iron absorbed in the cooked bananas and raw bananas was similar (0.86Â±0.41 mg vs. 0.77Â±0.33 mg, respectively; p=0.525) (Fig. 3).",4320136
3400,4320136,Iron content, 480 g/day of raw banana for 6 days, 500 g/day of cooked banana for 4 days,Significantly increased,"Iron content in cooked bananas was significantly higher than raw bananas (0.53 mg/100 g bananas vs. 0.33 mg/100 mg bananas, respectively) (p&lt;0.001).",4320136
3401,3877023,quantitative contour sharpness,short-bore MR scanner,high-field horizontal open MR scanner,Significantly increased,"Regarding all sequences, the relative differences were 39% for the mean overall qualitative image quality, 53% for the mean SNR values, and 34â€“37% for the quantitative contour sharpness (P&lt;0.0001).",3877023
3402,3877023,contrast-to-noise ratios (CNR) ,short-bore MR scanner,high-field horizontal open MR scanner,Significantly increased,The CNR values were also higher for images obtained with the short-bore MR scanner.,3877023
3403,3877023,Scanning times, high-field horizontal open MR scanner,short-bore MR scanner,Significantly increased,Scanning times were significantly longer for examinations performed on the open MR scanner (mean: 32Â±22 min versus 20Â±9 min; P&lt;0.0001).,3877023
3404,3877023,The mean signal-to-noise (SNR) values,short-bore MR scanner,  high-field horizontal open MR scanner,Significantly increased,"The mean SNR values of all available sequences were significantly higher for short-bore MR images than for open MR images (17.97 [SD, 6.58] versus 11.28 [SD, 4.35]; P&lt;0.0001).",3877023
3405,4544133,CRP levels,"atorvastatin 40 mg daily,  rosuvastatin 20 mg daily for 4 weeks",baseline,Significantly decreased,"CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P &lt; 0.001).",4544133
3406,4544133,CRP levels, rosuvastatin 20 mg daily for 4 weeks,atorvastatin 40 mg daily ,Significantly decreased,"However, there was significant difference between the levels of CRP in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 Â± 6.32 vs 23.07 Â± 7.47, P &lt; 0.05).",4544133
3407,4544133,Erythrocyte sedimentation rate (ESR), rosuvastatin 20 mg daily for 4 weeks,atorvastatin 40 mg daily ,No significant difference,There was no statistically significant difference between the levels of ESR in the patients of both groups.,4544133
3408,4544133,lipid profile, rosuvastatin 20 mg daily for 4 weeks,atorvastatin 40 mg daily ,Significantly increased,There was no statistically significant difference between the changes in lipid profile in both groups. All P values were &gt; 0.05.,4544133
3409,4544133,Adverse effect, rosuvastatin 20 mg daily for 4 weeks,atorvastatin 40 mg daily ,Significantly increased,There was no statistically significant difference between the two groups on account of incidence of adverse effects.,4544133
3410,4302388,whole-blood Se concentration,"Brazil nuts, consuming more than two seafood portions per week",baseline,Significantly increased,"After adjustment, whole-blood Se concentration was higher in women consuming Brazil nuts (P=&nbsp;0Â·040) and in those consuming more than two seafood portions per week (P=&nbsp;0Â·054).",4302388
3411,4302388,developing pre-eclampsia and pregnancy-induced hypertension (PE/PIH),"Brazil nuts, consuming more than two seafood portions per week",non-consumers,Significantly increased,"The median toenail Se concentration in women who developed PE/PIH was significantly lower than that in other women (0Â·57, range 0Â·46â€“0Â·64 v. 0Â·61, range 0Â·46â€“1Â·11; P=&nbsp;0Â·004).",4302388
3412,4067355,"the risk of stroke, all-cause mortality",non vitamin K antagonist oral anticoagulant (NOAC),placebo,Significantly decreased,"Compared to imputed placebo, all NOACs reduced the risk of stroke (ORs between 0.24 and 0.42, all p&lt;0.001) and all-cause mortality (ORs between 0.55 and 0.59, all p&lt;0.05).",4067355
3413,4067355,The risk of major bleedings,edoxaban 30,any other NOAC,Significantly decreased,"The risk of major bleedings was lower with edoxaban 30 mg than any other NOAC, odds ratios (ORs) ranging between 0.45 and 0.67 (all p&lt;0.001).",4067355
3414,4067355,"major bleedings, intracranial bleedings, and death from any cause",non vitamin K antagonist oral anticoagulant (NOAC), warfarin,Significantly decreased,"On the safety side, NOACs reduced the risk of major bleedings (by 15%; p&lt;0.001), intracranial bleedings (by 52%; p&lt;0.001) and death from any cause (by 10%; pâ€Š=â€Š0.001).",4067355
3415,4067355,"the risk of stroke/systemic embolism , stroke, hemorrhagic stroke and systemic embolism",non vitamin K antagonist oral anticoagulant (NOAC), warfarin,Significantly decreased,"NOACs as a whole reduced the risk of stroke/systemic embolism (by 21%; p&lt;0.001), stroke (by 20%; p&lt;0.001), hemorrhagic stroke (by 50%; p&lt;0.001) and systemic embolism (by 40%; pâ€Š=â€Š0.006).",4067355
3416,4067355,"gastrointestinal bleeding, myocardial infarction",non vitamin K antagonist oral anticoagulant (NOAC), warfarin,No significant difference,"On the safety side, NOACs reduced the risk of major bleedings (by 27%; p&lt;0.001), intracranial bleedings (by 59%; p&lt;0.001) and all-cause death (by 91%; p&lt;0.001), whereas gastrointestinal bleedings (pâ€Š=â€Š0.688) and myocardial infarction (pâ€Š=â€Š0.640) did not differ between NOACs and warfarin.",4067355
3417,4067355, risk of stroke,edoxaban , rivaroxaban,Significantly increased,"There were no significant differences between the higher dose of edoxaban (60 mg) and any other NOAC in the efficacy outcomes, apart from a slightly higher risk of stroke with edoxaban than rivaroxaban (pâ€Š=â€Š0.032).",4067355
3418,5768344,anemia (AN),adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC),docetaxel-doxorubicin-cyclophosphamide (TAC),Significantly increased,"Whereas AN was more frequent after ddAC (P &lt; 0.001),",5768344
3419,5768344,peripheral neuropathy (PNP),docetaxel-doxorubicin-cyclophosphamide (TAC),adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) ,Significantly increased,TAC treated patients more often had PNP (P &lt; 0.001).,5768344
3420,5768344,Dose reductions,docetaxel-doxorubicin-cyclophosphamide (TAC),adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) ,Significantly increased,"Dose reductions of more than 10% occurred more frequently for TAC (39 out of 1817 cycles, 2.1%) than for ddAC (13 out of 1914 cycles, 0.7%, P &lt; 0.001).",5768344
3421,5768344,"hand-foot syndrome, cough and phlebitis",adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC),docetaxel-doxorubicin-cyclophosphamide (TAC),Significantly increased,"Also, hand-foot syndrome (4.3% vs 0.6%, P = 0.004), cough (5.8% vs 2.2%, P = 0.019) and phlebitis (4.3% vs 1.3%, P = 0.029) were observed more often in the ddAC treated patients.",5768344
3422,5768344,Peripheral neuropathy,docetaxel-doxorubicin-cyclophosphamide (TAC),adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) ,Significantly increased,Peripheral neuropathy was seen in 46 out of 319 patients (14.4%) in the TAC treatment group and in 15 out of 327 ddAC treated patients (4.6%; P &lt; 0.001).,5768344
3423,5768344,"diarrhea, edema of the limbs",docetaxel-doxorubicin-cyclophosphamide (TAC),adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) ,Significantly increased,"In addition, diarrhea was observed more often in patients treated with TAC (16.6%) than in patients treated with ddAC (6.4%; P &lt; 0.001), as was edema of the limbs (4.7% vs 0.3%; P &lt; 0.001).",5768344
3424,5768344,"Serious adverse events (SAEs),  Admission to the hospital due to a SAE",adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC),docetaxel-doxorubicin-cyclophosphamide (TAC),No significant difference,"In total, 130 out of 646 patients (20.1%) experienced at least one SAE: 60 out of 327 patients (18.3%) in the ddAC treated group and 70 out of 319 patients (21.9%) in the TAC treated group (P = 0.255).",5768344
3425,4183082,sore throat 2 hours postâ€“operation,Succinylcholine group,Cisatracurium group,Significantly increased,hese numbers decreased at 2 hours postâ€“operation (42% in the Succinylcholine group and 17.5% in the Cisatracurium group) but the difference was still statistically significant (P = 0.027).,4183082
3426,4183082,At 12 and 24 hours post operation,Succinylcholine group,Cisatracurium group,No significant difference,"At 12 and 24 hours post operation, the difference was no longer significant (Figure 2).",4183082
3427,4183082,developing hoarseness,Succinylcholine group,Cisatracurium group,No significant difference,"At 12 and 24 hours post operation, the difference was no longer significant (P = 0.35 and P = 0.19 respectively)",4183082
3428,4183082,dryness of the throat,Succinylcholine group,Cisatracurium group,No significant difference,The difference was no longer significant at 12 (P = 0.22) and 24 (P = 0.063) hours post-operation (Figure 4).,4183082
3429,4183082,visual analogue score (VAS),Succinylcholine group,Cisatracurium group,No significant difference,"At 12 (P = 0.077) and 24 (P = 0.14) hours post operation, the difference was no longer significant (Figure 5).",4183082
3430,4183082,developed fasciculation,Succinylcholine group,Cisatracurium group,Significantly increased,"97.5% of the patients who had received Succinylcholine developed fasciculation, while none of the patients in the Cisatraciruim arm showed similar problem (P &lt; 0.001).",4183082
3431,4183082,Muscle ache and fasciculation,Succinylcholine group,Cisatracurium group,Significantly increased,Muscle ache and fasciculation was experienced in 85% of the patients in Succinylcholine group and 27.5% of the Cisatracurium group (P = 0.002).,4183082
3432,4234827,number of procedures performed,late tracheotomy,early tracheotomy ,Significantly increased,"Of 245 patients randomized to the early group, the procedure was performed for 167 patients (68.2%) whereas in the 244 patients randomized to the late group was performed for 135 patients (55.3%) (P &lt;0.004).",4234827
3433,4234827,Mortality at day 90,late tracheotomy,early tracheotomy ,No significant difference,Mortality at day 90 was similar in the early and the late group: 25.7% (63 of 245 participants) versus 29.9% (73 of 244) (P = 0.2996).,4234827
3434,4234827,The duration of sedation, early tracheotomy ,late tracheotomy,Significantly decreased,"The duration of sedation was shorter in the early group with a median (range) of 11 (2 to 92) days, compared to 14 (0 to 79) days in the late group (P &lt;0.02).",4234827
3435,4234827,procedure-related complications, early tracheotomy ,late tracheotomy,Significantly decreased,"For the 302 patients receiving tracheotomy, procedure-related complications were reported for a total of 11 patients (3.6%; 95% CI 1.8%, 6.4%): 2 of 167 patients (1.2%) in the early group (95% CI 0.2%, 4.3%) and 9 of 135 patients (6.7%) in the late group (95% CI, 3.1%, 12.3%) (P &lt;0.05).",4234827
3436,4234827,dead without tracheotomy, early tracheotomy ,late tracheotomy,Significantly decreased,"Two cases randomized to early group (2%; 95% CI 0.2%, 7%) dead without tracheotomy, whereas 15 cases in the late group died without tracheotomy (14.4%; 95% CI 8%, 23%) (P &lt;0.002).",4234827
3437,4234827,The crude 90-day mortality, early tracheotomy ,late tracheotomy,No significant difference,"The crude 90-day mortality was 29.7% (95% CI, 21%, 40%) in the early group and 42.3% (95% CI, 33%, 52%) in the late group (P = 0.0603).",4234827
3438,3704267,The rates of continuous abstinence from month 24 to the end of month 30,behavioral intervention,control group,Significantly increased,The rates of continuous abstinence from month 24 to the end of month 30 was higher in the intervention group than that in the control group ( 46.4% vs 3.4% p&lt;0.001). 639 out of 1377 (46.4% ) participants receiving behavioral intervention remained abstinent compared with 42 out of 1230 (3.4%) receiving usual care.,3704267
3439,3704267,The rates of continuous abstinence at the 48 month follow-up,behavioral intervention,control group,Significantly increased,"At the 48&nbsp;month follow-up, more participants receiving behavioral intervention remained abstinent than those receiving usual care (44.3% vs 5.1% , p&lt;0.001).",3704267
3440,3704267,The mean exhaled CO,sustained quitters,continuous smokers,Significantly decreased,"The mean exhaled CO in sustained quitters was significantly lower (meanâ€‰=â€‰3.7&nbsp;ppm, SDâ€‰=â€‰1.5) compared with continuous smokers (meanâ€‰=â€‰15.7&nbsp;ppm, SDâ€‰=â€‰5.1, p&lt;0.001).",3704267
3441,3517846,Fasting plasma glucose,"Group 1: all types of carbohydrates (CHO), Group 2: low GI foods",baseline,Significantly decreased,"Fasting plasma glucose decreased significantly in Group 1 and Group 2 throughout the intervention (P &lt; 0.003 and P &lt; 0.004, resp.),",3517846
3442,3517846,Fasting plasma glucose,Group 1: all types of CHO,Group 2: low GI foods,No significant difference,"Fasting plasma glucose decreased significantly in Group 1 and Group 2 throughout the intervention (P &lt; 0.003 and P &lt; 0.004, resp.), but no significant differences were observed between groups.",3517846
3443,3517846,The proportion of women who started using insulin during the intervention,Group 1: all types of CHO,Group 2: low GI foods,No significant difference,"The proportion of women who started using insulin during the intervention was similar between study groups in both types of DM (P â‰¥ 0.40), without differences in insulin doses (Group 1: 42.7 Â± 26.4â€‰u/d and Group 2: 35.5 Â± 21.5â€‰u/d) (P = 0.18).",3517846
3444,3517846,gaining weight,type 2 DM,gestational diabetes mellitus (GDM),No significant difference,Women with type 2 DM gained more weight during pregnancy (7.5 Â± 7.41â€‰kg) when compared to women with GDM (4.35 Â± 6.59â€‰kg) (P = 0.023); no differences were observed by study groups.,3517846
3445,3517846, glycemic index (GI) ,Group 2,baseline,Significantly decreased,"There was a significant decrease in the GI of the diet throughout the intervention period only in Group 2 (51.29 Â± 7.28 to 47.18 Â± 6.93, P = 0.001).",3517846
3446,3517846,clinical outcomes,GDM,2 DM,No significant difference,No differences were found in these clinical outcomes between women with GDM and type 2 DM within each study group (P &gt; 0.05).,3517846
3447,3517846,"risk of preeclampsia, intrauterine, and neonatal death",Group 1: all types of CHO	,Group 2: low GI foods,No significant difference,"Multivariate analysis showed the same risk of preeclampsia, intrauterine, and neonatal death in women from both study groups, but a higher risk of prematurity in women in Group 2 (RR: 4.74, 95% CI: 1.08 to 20.84, P = 0.03).",3517846
3448,4685630,Clinically meaningful symptom,Pre-School Autism Communication Trial (PACT)+  treatment as usual (TAU),treatment as usual (TAU),No significant difference,"A clinically meaningful improvement was in evidence for 53&nbsp;% of the PACTâ€‰+â€‰TAU group compared to 41&nbsp;% for TAU (odds ratio 1.91, 95&nbsp;% CI 0.94 to 3.87, pâ€‰=â€‰0.074).",4685630
3449,4685630,Service costs,Pre-School Autism Communication Trial (PACT)+  treatment as usual (TAU),treatment as usual (TAU),Significantly increased,"Service costs were significantly higher for PACTâ€‰+â€‰TAU (mean difference Â£4,489, pâ€‰&lt;â€‰0.001)",4685630
3450,4685630,Service costs,Pre-School Autism Communication Trial (PACT)+  treatment as usual (TAU),societal costs,No significant difference,"Service costs were significantly higher for PACTâ€‰+â€‰TAU (mean difference Â£4,489, pâ€‰&lt;â€‰0.001), but the difference in societal costs was smaller and non-significant (mean difference Â£1,385, pâ€‰=â€‰0.788) due to lower informal care rates for PACTâ€‰+â€‰TAU.",4685630
3451,3702153,precise Fischer tests 48 hours after treatment  -  reduction of redness,position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore,control,Significantly decreased,"According to precise Fischer tests, the difference between the two group was totally significant (p &lt; 0.001) 48 hours after treatment intervention, 23 people (76.7%) of the treating group who had received fish oil had reduction in redness, although none of the patients in placebo group showed such recovery.",3702153
3452,3702153,Chi-square test - reduction of redness 2 days after treatment,position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore,control,Significantly decreased,Chi-square test also showed 2 days after treatment that the redness changes were significant in the two groups. (p &lt; 0.001),3702153
3453,3702153,Chi-square test - frequency distribution of the redness,position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore,control,Significantly decreased,"Chi-square test showed that the frequency distribution of the redness changes, 96 hours after intervention, has significant difference for both groups (p &lt; 0.001).",3702153
3454,3702153,recovery of the bed wound,position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore,control,Significantly increased,Doing the precise Fischer test on the data showed that the recovery of the bed wound in the two groups under study had a significant difference (p &lt; 0.002) (Table 1).,3702153
3455,3702153,recovery time,position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore,control,Significantly decreased,"According to the obtained results, the average period of bed wound recovery in treating patients with fish oil (12.6) 71.2 hours 30 patients and (27.3) 131.2 hours 25 patients in placebo group and according to t-standard test, the recovery time in the two groups was significant (p &lt; 0.001) in other words, according to this test, fish oil could shorten the recovery time of bed wound (Table 2).",3702153
3456,4449043,Vibriocidal responses to O1 Ogawa in the percentage seroconversion,re-immunization with 2 booster doses in previously immunized,two doses of vaccine,No significant difference,Vibriocidal responses to O1 Ogawa demonstrated no significant difference in the percentage seroconversion in the boosting or primary arms following two doses of OCV (66% [95% CI 55%-74%] vs 72% [95% CI 62%-80%] in the 6â€“14 year age group and 41% [95% CI 31%-51%] vs 53% [95% CI 43%-63%] in â‰¥15 years age group).,4449043
3457,4842387,Subjective hypomnesis/memory loss (SML),BrainPower Advanced capsules,placebo,Significantly decreased,"Ridit scoring test shows a significant and differential reduction in the SML (mean Â± s.d. = 0.418 Â± 0.236 versus 0.575 Â± 0.299, P &lt; 0.01)",4842387
3458,4842387,subjective attention/concentration deficits (SAD),BrainPower Advanced capsules,placebo,Significantly decreased,"Ridit scoring test shows a significant and differential reduction in the SML (mean Â± s.d. = 0.418 Â± 0.236 versus 0.575 Â± 0.299, P &lt; 0.01) and SAD symptom severity (means = 0.424 Â± 0.229 versus 0.612 Â± 0.283, P &lt; 0.01) after BrainPower Advanced and placebo treatment.",4842387
3459,4842387,"audio/visual memory, abstract thinking, memory retrieval, and combined total function test scores",BrainPower Advanced capsules ,placebo,Significantly increased,"Both the BrainPower Advanced and the placebo groups produced significant improvements (129%â€“150%) (P &lt; 0.01, each) of the subtests and combined total scores in the older adults, with the BrainPower Advanced group producing better improvements (1.50-, 1.35-, 1.43-, and 1.29-fold relative to the baseline values of audio/visual memory, abstract thinking, memory retrieval, and combined total function test scores) than the placebo group (1.35-, 1.27-, 1.13-, and 1.27-fold, resp.) (Tables 6(a) and 6(b)).",4842387
3460,4842387,combined total scores of the memory function,BrainPower Advanced capsules,placebo,Significantly increased,Ridit scoring test showed that the improvement in the combined total scores of the memory function subtests was significantly better after the BrainPower Advanced intervention (mean = 0.56 Â± 0.287) than after the placebo intervention (0.445 Â± 0.276) (P &lt; 0.05) (Table 6(c)).,4842387
3461,5898527,CRC screening frequency,network A,network B,Significantly increased,Participants at network A were also more likely to have ever been screened for CRC using any test,5898527
3462,3441250,Frequency of nausea,crystalloid,colloid,Significantly decreased,"At 2 hours the proportion of the patients experiencing nausea (38.2 vs 17.9%, Pâ€‰=â€‰0.03) (Figure 2, Panel A) and the mean nausea score (1.49â€‰Â±â€‰0.3 vs 0.68â€‰Â±â€‰0.2, Pâ€‰=â€‰0.028) (Figure 2, Panel B) and were increased in the colloid group compared to crystalloid respectively.",3441250
3463,5158040,Presence of diastolic dysfunction during hospitalization,Metformin,Placebo,No significant difference,Diastolic dysfunction was present in 11 (9%) of patients on metformin and 11 (9%) patients on placebo treatment (P = 0.98) during hospitalization.,5158040
3464,5158040,Presence of diastolic dysfunction after 4 months ,Metformin,Placebo,No significant difference,After 4 months 22 (19%) of patients with metformin and 18 (15%) patients with placebo (P = 0.47) had diastolic dysfunction.,5158040
3465,5158040,Improvement of diastolic function echocardiographic markers ,Metformin,Placebo,No significant difference,metformin did not improve any of the individual echocardiographic markers of diastolic function.,5158040
3466,5158040,Measurements of cardiac structure and function during hospitalization,Metformin,Placebo,No significant difference,"During hospitalization, measurements of cardiac structure and function for patients treated with metformin (n = 118) or placebo (n = 119) were similar",5158040
3467,3914427,Satisfaction with sexual relationship,Physta plus Polygonum minus,Placebo,Significantly decreased,Sexual relationship satisfaction was significantly lower in the active group compared to the placebo group at baseline and at 12 weeks (P &lt; 0.0001).,3914427
3468,3914427,Improvement in Sexual Intercourse Attempt diary scores,Physta plus Polygonum minus,Placebo,Significantly increased,"Significant improvements were noted in scores for the Sexual Intercourse Attempt diary, Erection Hardness Scale, Sexual Health Inventory of Men, and Aging Male Symptom scale (P &lt; 0.05 for all).",3914427
3469,3914427,Improvement in erectile hardness,Physta plus Polygonum minus,Placebo,Significantly increased,"Significant improvements were noted in scores for the Sexual Intercourse Attempt diary, Erection Hardness Scale, Sexual Health Inventory of Men, and Aging Male Symptom scale (P &lt; 0.05 for all).",3914427
3470,3914427,Improvement in Sexual Health Inventory of Men,Physta plus Polygonum minus,Placebo,Significantly increased,The SHIM score demonstrated a significant improvement from baseline to week 12 in the active group only (P &lt; 0.005),3914427
3471,3914427,Improvement in Aging Male Symptom scale,Physta plus Polygonum minus,Placebo,Significantly increased,"Significant improvements were noted in scores for the Sexual Intercourse Attempt diary, Erection Hardness Scale, Sexual Health Inventory of Men, and Aging Male Symptom scale (P &lt; 0.05 for all).",3914427
3472,4569275,Estimated infection hazard ratios for men,Vaccine group,Placebo group,Significantly increased,"the estimated HR over Phambili and HVTN 503-S follow-up was 1.52 (95% CI 1.08â€“2.15, p = 0.02, 82 vaccine/54 placebo infections). The HR was significant for men (HR = 2.75, 95% CI 1.49, 5.06, p = 0.001) but not for women (HR = 1.12, 95% CI 0.73, 1.72, p = 0.62).",4569275
3473,4569275,Estimated infection hazard ratios for women,Vaccine group,Placebo group,No significant difference,"the estimated HR over Phambili and HVTN 503-S follow-up was 1.52 (95% CI 1.08â€“2.15, p = 0.02, 82 vaccine/54 placebo infections). The HR was significant for men (HR = 2.75, 95% CI 1.49, 5.06, p = 0.001) but not for women (HR = 1.12, 95% CI 0.73, 1.72, p = 0.62).",4569275
3474,4569275,Infections detected,Vaccine group,Placebo group,Significantly increased,"In the combined Phambili and HVTN 503-S follow-up periods, significantly more HIV-1 infections were detected amongst vaccinees (n = 82) as compared to placebo (n = 54)",4569275
3475,4569275,Annualized HIV-1 incidence rate,Vaccine group,Placebo group,Significantly increased,"the annualized HIV-1 incidence rate was 4.7% (95% CI 3.7%-5.8%) for vaccinees and 3.0% (95% CI 2.3%-3.9%) for placebo recipients (p = 0.01, Fig 1, table 2).",4569275
3476,4569275,Reported use of condom or increase in number of sexual partners,Vaccine group,Placebo group,No significant difference,"There were no differences in these self-reported risk behaviors by Phambili treatment group (table 5) or follow-up status (data not shown). Women were more likely than men to report no change (table 5). Borderline differences between treatment groups were seen for men with number of partners (p = 0.054), with placebo recipients more likely to report an increase in number of partners (16.4%) than vaccinees (6.9%) and for women, placebo recipients more likely to report a decrease in condom use (17.0%) than vaccinees (6.1%) (p = 0.052).",4569275
3477,5593355,Risk of cardiovascular death,ASV group,Control group,Significantly increased,"On-treatment analysis showed similar results to the SERVE-HF intention-to-treat analysis, with an increased risk of cardiovascular death in heart failure with reduced ejection fraction patients with predominant central sleep apnoea treated with adaptive servo ventilation. Bias is inevitable and needs to be taken into account in any kind of on-treatment analysis in positive airway pressure studies.",5593355
3478,5593355,Dose-dependency for the effect of ASV on cardiovascular risk,ASV group,Control group,No significant difference,No dose-dependency for the effect of ASV on cardiovascular risk was observed in either the adjusted or unadjusted analyses,5593355
3479,4223943,Means scores of expectations and childbirth self-efficacy,Training-based strategies (experimental group),No intervention (control group),Significantly increased,mean scores of childbirth in intervention group was reduced and expectation and childbirth self-efficacy had a significant increase after intervention (P &lt; 0.05),4223943
3480,4223943,Delivery by C-section,Training-based strategies (experimental group),No intervention (control group),Significantly increased,Most of intervention group mothers desired to deliver through cesarean and had more fear (P &lt; 0.001),4223943
3481,4223943,Fear of childbirth,Training-based strategies (experimental group),No intervention (control group),Significantly increased,Most of intervention group mothers desired to deliver through cesarean and had more fear (P &lt; 0.001),4223943
3482,4223943,Baseline characteristics,Training-based strategies (experimental group),No intervention (control group),No significant difference,"The mean marriage age, pregnancy number and gestational age in intervention group were 22.57 Â± 4.31 year, 1.38 Â± 0.65 times and 28.04 Â± 2.91 week, respectively. The figures in control group were 22.35 Â± 3.91 year, 1.45 Â± 0.77 times and 29.03 Â± 2.89 week, respectively, with no significant difference (P &gt; 0.05).",4223943
3483,5498715,Physical activity and physical fitness ,Motivational interviewing through self-determination theory sessions,Standard education session,Significantly increased,"Four months after the intervention, an increase in the mean scores of total PA (p&lt;0.001, ES=4.77), physical fitness tests including flexibility (p&lt;0.001, ES=1.59), muscular endurance (p&lt;0.001, ES=2.0), cardiorespiratory endurance (p&lt;0.001, ES=0.51), and a decrease in mean scores of agility test (p&lt;0.001, ES= âˆ’ 0.51) and sedentary behavior (p&lt;0.01, ES=âˆ’ 0.74) was observed in the intervention group compared to the control group.",5498715
3484,5498715,Sedentary behavior and agility test,Motivational interviewing through self-determination theory sessions,Standard education session,Significantly decreased,"Four months after the intervention, an increase in the mean scores of total PA (p&lt;0.001, ES=4.77), physical fitness tests including flexibility (p&lt;0.001, ES=1.59), muscular endurance (p&lt;0.001, ES=2.0), cardiorespiratory endurance (p&lt;0.001, ES=0.51), and a decrease in mean scores of agility test (p&lt;0.001, ES= âˆ’ 0.51) and sedentary behavior (p&lt;0.01, ES=âˆ’ 0.74) was observed in the intervention group compared to the control group.",5498715
3485,5498715,"Scores of intrinsic motivation, perception of competence and autonomy, enjoyment, and health care climate",Motivational interviewing through self-determination theory sessions,Standard education session,Significantly increased,"The intervention group reported an increase in the scores of intrinsic motivation (p&lt;0.001, ES=3.34), identified regulation (p&lt;0.001, ES= 1.28), perceptions of competence (p&lt;0.001, ES=0.81) and autonomy (p&lt;0.001, ES=2.01), enjoyment (p&lt;0.001, ES=0.98) and health motives (p&lt;0.01, ES=0.19), health care climate (p&lt;0.001, ES=4.6), and a decreased score of external regulation (p&lt;0.01, ES=âˆ’0.55) and amotivation (p&lt;0.01, ES= âˆ’0.56) over time, compared to the control group.",5498715
3486,5498715,Scores of external regulation and amotivation,Motivational interviewing through self-determination theory sessions,Standard education session,Significantly decreased,"The intervention group reported an increase in the scores of intrinsic motivation (p&lt;0.001, ES=3.34), identified regulation (p&lt;0.001, ES= 1.28), perceptions of competence (p&lt;0.001, ES=0.81) and autonomy (p&lt;0.001, ES=2.01), enjoyment (p&lt;0.001, ES=0.98) and health motives (p&lt;0.01, ES=0.19), health care climate (p&lt;0.001, ES=4.6), and a decreased score of external regulation (p&lt;0.01, ES=âˆ’0.55) and amotivation (p&lt;0.01, ES= âˆ’0.56) over time, compared to the control group.",5498715
3487,5498715,Body mass index,Motivational interviewing through self-determination theory sessions,Standard education session,Significantly decreased,"In the intervention group, the repeated measures tests showed a significant reduction in body mass index",5498715
3488,3936610,"Baseline ranges of HR, MAP, and QTc intervals",Group D (dexmedetomidine),Group C (control),No significant difference,"All patients had normal baseline ranges of HR, MAP, and QTc intervals at rest, and there were no statistically significant differences in baseline HR, MAP, QTc, and Tp-e value between the two groups.",3936610
3489,3936610,Tp-e interval,Group D (dexmedetomidine),Group C (control),No significant difference,No significant changes in the Tp-e interval from baseline were observed in either group at any measurement time,3936610
3490,3936610,Change of MAP,Group D (dexmedetomidine),Group C (control),No significant difference,"There was no significant change of MAP in either group among patients, who did not require administration of ephedrine",3936610
3491,3936610,Rate of complications,Group D (dexmedetomidine),Group C (control),No significant difference,"We did not observe any complications, such as significant changes in MAP or arrhythmias, in either group in the post-anesthetic care unit.",3936610
3492,3936610,QTc interval values,Group D (dexmedetomidine),Group C (control),Significantly decreased,The QTc interval values after dexmedetomidine administration were significantly shorter compared to the QTc interval values just before dexmedetomidine administration.,3936610
3493,3422059,Shear bond strength,Conventional etching with 37% phosphoric acid (group 1),Irradiation with Er:YAG laser at 1 W (group 2) and irradiation with Er:YAG laser at 1.5 W (group 3),No significant difference,The mean SBS obtained with an Er:YAG laser operated at 1W or 1.5W is approximately similar to that of conventional etching.,3422059
3494,3422059,ARI degrees,Conventional etching with 37% phosphoric acid (group 1),Irradiation with Er:YAG laser at 1 W (group 2) and irradiation with Er:YAG laser at 1.5 W (group 3),No significant difference,"Table 2 shows the frequency distribution of ARI degrees in the three groups. According to the Kruskal-Wallis test, there was no significant difference between the three groups (p=0.918).",3422059
3495,3410988,Test scores on measures of episodic and spatial memory,Memantine,Placebo,No significant difference,no significant differences were observed between the memantine and placebo groups on the two primary outcome measures,3410988
3496,3410988,"Baseline characteristics regarding the patient's age, gender, or educational level of the parents",Memantine,Placebo,No significant difference,"There were no differences expected between the placebo and memantine groups on age or gender, given the matched-pair design. In each group, 62% of the participants were female. The mean age of the participants in the placebo group (22 years and 7 months, range 18â€“31) did not differ from the mean age of the participants in the memantine group (23 years and 3 months; range 18â€“30; t(36)=âˆ’0.552, P=0.59). Parent's years of education was used to index the socioeconomic status. There were no significant differences between the placebo and memantine groups on the years of education of the mothers or fathers (mother: t(36)=1.43, P=0.16; father: t(36)=âˆ’0.43, P=0.67).",3410988
3497,3410988,Overall adverse events,Memantine,Placebo,No significant difference,There were no laboratory adverse events and no serious adverse events.,3410988
3498,3410988,CVLT-II Free Recall Total Score,Memantine,Placebo,Significantly increased,"Pre/post difference scores on the CVLT-II Free Recall Total Score were 5.84 (90% CI=3.47â€“8.21) for the memantine group and 2.53 (90% CI=0.33â€“4.72) for the placebo group, showing that the memantine group scored disproportionately better than the placebo group at 16 weeks.",3410988
3499,3410988,DAS-II Recall of Digits score,Memantine,Placebo,No significant difference,"Finally, a contrast effect bordering statistical significance was found for the DAS-II Recall of Digits score (F(1,â€‰34)=2.83, P=0.051). The memantine pre/post difference score was 5.39 (90% CI=âˆ’3.88 to 14.66), whereas the pre/post difference score for the placebo group was âˆ’7.47 (90% CI=âˆ’16.50 to 1.55).",3410988
3500,5684963,Glycemic response after breakfast,High glycemic index intervention,Low glycemic index intervention,Significantly increased,"Compared to the high GI intervention, the low GI intervention significantly reduced the GR following breakfast (p&nbsp;=&nbsp;0.02)",5684963
3501,5684963,Glycemic response after lunch,High glycemic index intervention,Low glycemic index intervention,Significantly increased,"Compared to the high GI intervention, the low GI intervention significantly reduced the GR following breakfast (p&nbsp;=&nbsp;0.02), lunch (p&nbsp;=&nbsp;0.02)",5684963
3502,5684963,Glycemic response after dinner,High glycemic index intervention,Low glycemic index intervention,No significant difference,"Compared to the high GI intervention, the low GI intervention significantly reduced the GR following breakfast (p&nbsp;=&nbsp;0.02), lunch (p&nbsp;=&nbsp;0.02) and dinner (p&nbsp;=&nbsp;0.05).",5684963
3503,5684963,Area under the curve (AUC),High glycemic index intervention,Low glycemic index intervention,Significantly increased,The daily total AUC was significantly higher for the HGI compared to the LGI intervention over the 48&nbsp;h period (p&nbsp;=&nbsp;0.03). The daily total AUC also reduced on day 2 of the LGI treatment (p&nbsp;=&nbsp;0.03).,5684963
3504,5684963,Mean amplitude of glycemic excursion,High glycemic index intervention,Low glycemic index intervention,Significantly increased,The MAGE was significantly lower during the entire low GI treatment (p&nbsp;=&nbsp;0.03).,5684963
3505,2710065,Microbiological and clinical parameters,Single-dose intravenous antibiotic prophylaxis,No prophylaxis,No significant difference,No statistically significant difference was observed between these groups based on the microbiological and clinical parameters.,2710065
3506,2710065,Baseline characteristics,Single-dose intravenous antibiotic prophylaxis,No prophylaxis,No significant difference,No statistical difference was detected regarding age and gender between the groups.,2710065
3507,3441250,Nausea at 2 hours,Intravenous colloid,Intravenous crystalloid,Significantly increased,"At 2 hours the proportion of the patients experiencing nausea (38.2 vs 17.9%, Pâ€‰=â€‰0.03) (Figure 2, Panel A) and the mean nausea score (1.49â€‰Â±â€‰0.3 vs 0.68â€‰Â±â€‰0.2, Pâ€‰=â€‰0.028) (Figure 2, Panel B) and were increased in the colloid group compared to crystalloid respectively.",3441250
3508,3441250,Incidence of vomiting,Intravenous colloid,Intravenous crystalloid,No significant difference,The incidence of vomiting and anti-emetic usage was low and did not differ between the groups.,3441250
3509,3441250,"Sore throat, dizziness, cephalea, and general well being",Intravenous colloid,Intravenous crystalloid,No significant difference,"Sore throat, dizziness, headache and general well being were not different between the groups",3441250
3510,3441250,Use of anti-emetic drugs,Intravenous colloid,Intravenous crystalloid,No significant difference,The incidence of vomiting and anti-emetic usage was low and did not differ between the groups.,3441250
3511,3441250,"Reduction in FVC, FEV-1, and PEFR after surgery",Intravenous colloid,Intravenous crystalloid,No significant difference,A comparable reduction on post-operative FVC and FEV-1 and PEFR was observed in both groups.,3441250
3512,4616107,Maximum voluntary isometric contraction or endurance,"Active myofascial trigger point group, or Latent myofascial trigger point group",Control group,No significant difference,No significant differences in MVIC or endurance were revealed among the three groups.,4616107
3513,4616107,"Median frequency (MDF), and muscle fatigue index",Active myofascial trigger point group,Control group,Significantly increased,"the active trigger point group had significantly different MDF and muscle fatigue index compared with the control group. [Conclusion] Given that muscles with active myofascial trigger points had an increased MDF and suffered muscle fatigue more easily, increased recruitment of motor unit action potential of type II fibers was evident.",4616107
3514,3661239,Post-test scores,group A,group B,Significantly increased,Post-test scores of groups A and B differed significantly.,3661239
3515,5176312,T2-T1,WSTP,EC,No significant difference,There were no significant T2-T1 or T3-T2 differences in the CHART scores between the WSTP and EC groups based on the t tests or repeated-measures ANOVAs.,5176312
3516,4263705,a,b,c,Significantly increased,"Table 2 shows the success of the randomization at the facility level in the baseline characteristics. There were no statistically significant differences in any of variables, except for the professional title. In the intervention group, the proportion of entry-level professionals was higher and that of middle and above level lower than in the control group. The composition of the groups also differed slightly in relation to occupation type (pâ€Š=â€Š0.07) and income gap group (pâ€Š=â€Š0.10).",4263705
3517,5061809,fluency,Free-walking,Rectangular-walking or Free-generation or Random-experienced ,Significantly increased,"The Scheffe test for the three components of creativity showed that the participants in the free-walking group performed better than the rectangular-walking group (p = 0.001), free-generation group (p = 0.003), and random-experienced group (p = 0.002) in fluency.",5061809
3518,5061809,flexibility,Free-walking,Rectangular-walking or Random-experienced ,Significantly increased,Participants in the free-walking group performed better than the rectangular-walking group (p = 0.019) and the random-experienced group (p = 0.049) in flexibility;,5061809
3519,5061809,originality,Free-walking,Rectangular-walking or Free-generation or Random-experienced ,Significantly increased,"Participants in the free-walking group performed better than the rectangular-walking group (p &lt; 0.001), the free-generation group (p &lt; 0.001), and the random-experienced group (p &lt; 0.001) in originality.",5061809
3520,5061809,"fluency, flexibility, originality in patients over 65 years old",Free-walking,Rectangular-walking,Significantly increased,"The results showed a significant effect of groups among three components, F(1,30) = 16.77, p &lt; 0.001, Î·p2 = 0.36 for fluency, F(1,30) = 12.74, p = 0.001, Î·p2 = 0.30 for flexibility, F(1,30) = 15.74, p &lt; 0.001, Î·p2 = 0.34 for originality.",5061809
3521,4050230,The plaque index (PI) and the gingival index (GI),rinse their mouths with 0.2% chlorhexidine or  triphala mouthwash  for 1 minute twice daily for two weeks,rinse their mouths with 10 mL of distilled water  for 1 minute twice daily for two weeks ,Significantly decreased,"The intergroup comparison of the mean differences in the PI and GI calculated using ANOVA showed no statistically significant difference between group B and group C, but when group B and group C were compared with group A, there was a statistically significant difference (P&lt;0.05) (Table 1) (Fig. 2).",4050230
3522,4050230,periodontal disease,rinse their mouths with 0.2% chlorhexidine  for 1 minute twice daily for two weeks,rinse their mouths with  triphala mouthwash for 1 minute twice daily for two weeks ,No significant difference,"However, a statistically significant difference was observed in PI and GI when both group B and group C were compared with group A and also within groups B and C, after 15 days (P&lt;0.05).",4050230
3523,3026127,the cured rate,supervision by tuberculosis health visitors (TBHVs),supervision by non-TBHVs,Significantly increased,"there was a significant difference (risk ratio 1.53, CI 1.15-2.03) in the cured rate which was 71.74% (66/92) with TBHVs and 60% (39/65) with non-TBHVs.",3026127
3524,3026127,treatment success rate,supervision by tuberculosis health visitors (TBHVs),supervision by non-TBHVs,No significant difference,"However, no significant difference was observed in the treatment success rate (risk ratio 0.87, CI 0.76-0.99) between TBHVs (80/105) and non-TBHVs (83/95).",3026127
3525,2464595,overall complications,received intraoperative application of a fibrin sealant following inguino-femoral lymph node dissection,received only inguino-femoral lymph node dissection,No significant difference,"the median time to drain removal in the control group (n = 14) was 30 days (range, 13â€“74) compared to 29 days (range, 11â€“45) in the fibrin sealant group (n = 16; P = 0.6).",2464595
3526,2464595,the time to drain removal,received intraoperative application of a fibrin sealant following inguino-femoral lymph node dissection,received only inguino-femoral lymph node dissection,No significant difference,"Postoperatively, there was no statistically significant difference in the time to drain removal between the two groups: the fibrin sealant group required drains for a median of 31 days (range, 11â€“45 days), compared to 26 days (range, 13â€“74 days) in the control group (P = 0.6).",2464595
3527,4598931,apnea-hypopnea index (AHI),mandibular advancement device (MAD),Placebo device,Significantly decreased,"When both splints were compared, the use of MAD reduced significantly the AHI (p = 0.000).",4598931
3528,4425923,treat the patients with cancer among oncologists and general practitioners,smoking,non-smoking,Significantly decreased,"When subgrouping according to medical specialities, we found the above-mentioned disinclination to treat the smoker compared to the non-smoker among oncologists and GPs only (Chi-2â€‰=â€‰6.1; dfâ€‰=â€‰1, pâ€‰=â€‰0.013 and Chi-2â€‰=â€‰4.9; dfâ€‰=â€‰1, pâ€‰=â€‰0.026 respectively). Among pulmonologists, there was no significant difference in the inclination to treat depending upon the patientâ€™s smoking status (Chi-2â€‰=â€‰0.49, dfâ€‰=â€‰1 and pâ€‰=â€‰0.48). See Table 2.",4425923
3529,4425923,receiving the treatment for cancer among oncologists and pulmonologists ,smoking,non-smoking,Significantly decreased,"Among oncologists and pulmonologists, 78% (95% CI: 72-85) would offer the treatment to the non-smoker and 66% (95% CI: 58-74) to the smoker (Chi-2â€‰=â€‰5.4, dfâ€‰=â€‰1, pâ€‰=â€‰0.019).",4425923
3530,5976501,self-perception of effort spent ,5-aminolevulinic acid (5-ALA),baseline,Significantly increased,"In the analysis of the association of 5-ALA on responses to the PDS Questionnaire, only the outcome â€œeffortâ€� was found to be significant (p = 0.002).",5976501
3531,5976501,coping ability,5-aminolevulinic acid (5-ALA),baseline,Significantly increased,"In the analysis of the effect of 5-ALA on responses to the PSS Questionnaire, only the outcome â€œcopeâ€� was found to be significant (p = 0.004).",5976501
3532,5976501,"effort, loneliness, and coping ability",5-aminolevulinic acid (5-ALA) 50 mg ,5-aminolevulinic acid (5-ALA) 15 mg,Significantly increased,"Finally, we found a significant dose-dependent relationship for the association of 5-ALA intake on measures of effort (p = 0.003), loneliness (p = 0.006), and coping ability (p = 0.003).",5976501
3533,5957406,gastrointestinal (GI) side effects,150 mgâˆ™kg-1 of Sodium bicarbonate (SB) for 10 days,placebo,No significant difference,No gastrointestinal (GI) side effects were reported during the entire protocol.,5957406
3534,5957406,The overall Fight Gone Bad (FGB),150 mgâˆ™kg-1 of SB for 10 days,placebo,Significantly increased,The overall FGB performance improved under SB by ~6.1% (p&lt;0.001) and it was ~3.1% higher compared to post placebo (PLApost) (p = 0.040).,5957406
3535,5957406,"time to ventilatory threshold (VT), workload at VT  and heart rate at VT in incremental cycling (ICT)",150 mgâˆ™kg-1 of SB for 10 days,placebo,Significantly increased,"Moreover, in ICT, the time to ventilatory threshold (VT) (~8:25 min SBpost vs. ~8:00 min PLApost, p = 0.020), workload at VT (~218 W SBpost vs. ~208 W PLApost, p = 0.037) and heart rate at VT (~165 bpm SBpost vs. ~161 bpm PLApost, p = 0.030) showed higher SBpost than PLApost.",5957406
3536,5957406,maximum carbon dioxide production,150 mgâˆ™kg-1 of SB for 10 days,baseline,Significantly increased,"Furthermore, the maximum carbon dioxide production increased under SB by ~4.8% (from ~3604 mLâˆ™min-1 to ~3776 mLâˆ™min-1, p = 0.049).",5957406
3537,5957406,Pyruvate concentration and creatine kinase activity before incremental cycling (ICT),150 mgâˆ™kg-1 of SB for 10 days,placebo,Significantly increased,"Before the onset of ICT, pre exercise [Pa] increased from 0.25 Â± 0.06 mmolâˆ™L-1 SBpre to 0.32 Â± 0.11 mmolâˆ™L-1 SBpost (p = 0.001) and was significantly higher compared to that after placebo treatment (0.32 Â± 0.11 mmolâˆ™L-1 SBpost vs. 0.26 Â± 0.09 mmolâˆ™L-1 PLApost). Furthermore, CK activity before the onset of ICT decreased after both trials (SB and PLA).",5957406
3538,3434899,duration of the disease, NBUVB -  9 J/cm2 for 6 weeks,prednisolon 0.3 mg/kg for 6 weeks,No significant difference,"In addition, before initiation of the treatment, ANOVA did not show significant differences regarding duration of the disease between the two groups (p = 0.910).",3434899
3539,3434899,effectiveness according to chi-square test, NBUVB -  9 J/cm2 for 6 weeks,prednisolon 0.3 mg/kg for 6 weeks,Significantly increased,"There was a significant difference in efficacy of treatment between the two groups. According to chi-square test, NBUVB was significantly more effective than systemic steroid in treatment of generalized lichen planus (p = 0.008) (Table 2).",3434899
3540,3434899,Patient satisfaction, NBUVB -  9 J/cm2 for 6 weeks,prednisolon 0.3 mg/kg for 6 weeks,Significantly increased,Patient satisfaction was also significantly higher in the group treated with NBUVB as compared with the systemic corticosteroids (p = 0.012) (Table 3).,3434899
3541,3434899,side effects, NBUVB -  9 J/cm2 for 6 weeks,prednisolon 0.3 mg/kg for 6 weeks,No significant difference,No significant side effects were observed in either group.,3434899
3542,3963555,recurrent episodes of bronchiolitis in the first year,fraction of exhaled nitric oxide (FeNO group),control,Significantly decreased,"Infants born to mothers from the FeNO group were significantly less likely to have recurrent episodes of bronchiolitis in the first year of life (OR 0.08, 95% CI 0.01 to 0.62; p=0.016) as compared with the clinical group.",3963555
3543,3963555,"wheezing and coughing frequency, triggers and severity",fraction of exhaled nitric oxide (FeNO group),control,No significant difference,"There was also no difference in wheezing and coughing frequency, triggers and severity between groups as evaluated by the specific domains of the standardised questionnaire.4",3963555
3544,5698802,Scale for the Assessment and Rating of Ataxia (SARA) after 16 weeks,docosahexaenoic acid (DHA),placebo,Significantly increased,"After 16 weeks, we showed a significant preâ€“post clinical improvement in the DHA group versus placebo, using the Scale for the Assessment and Rating of Ataxia (SARA; mean difference [MD]â€‰=â€‰+2.70, 95% confidence interval [CI]â€‰=â€‰+0.13 toâ€‰+â€‰5.27, pâ€‰=â€‰0.042).",5698802
3545,5698802,Scale for the Assessment and Rating of Ataxia (SARA) after 40 weeks,docosahexaenoic acid (DHA),baseline,Significantly increased,"At 40â€�week treatment, clinical improvement was found significant by both SARA (MDâ€‰=â€‰+2.2, 95% CIâ€‰=â€‰+0.93 toâ€‰+â€‰3.46, pâ€‰=â€‰0.008)",5698802
3546,5698802,International Cooperative Ataxia Rating Scale,docosahexaenoic acid (DHA),baseline,Significantly increased,"International Cooperative Ataxia Rating Scale (MDâ€‰=â€‰+3.8, 95% CIâ€‰=â€‰+1.39 toâ€‰+â€‰6.41, pâ€‰=â€‰0.02) scores; clinical data were corroborated by significant improvement of cerebellar hypometabolism (statistical parametric mapping analyses, false discovery rate corrected).",5698802
3547,4206016,ated patients compared to control group (p&lt;0.05). There were no significant changes in glycosylated hemoglobin and FBS between the two groups.,"ts three times a day for three months. The fasting blood sugar (FBS) and 2 hours postprandial (2hpp) glucose were checked at the beginning and every 2 weeks, for three months Glycosylated hemoglobin (HbA1c), lipid profile, liver and kidney function tests were also measured at the beginning and at the end of trial and compared in two mentioned groups.Results: The 2hpp blood sugar and cholesterol levels were significantly decreased in Salvia officinalis treated patients compared to control group (p&lt;0.05). There were no significant changes in glycosylated hemoglobin and FBS between the two groups.Conclusion: Results showed that Salvia officinalis might be beneficial in diabetic patients to reduce 2hpp and cholesterol. However higher doses might be needed to decrease fasting blood glucose and glycosylated hemoglobin.Outcome 	Intervention 	Comparator 	Answer 	Reasoning","eal control of the disease. Patients were randomly divided into two equal groups of case and control. The case group received Salvia officinalis and the control group received placebo tablets three times a day for three months. The fasting blood sugar (FBS) and 2 hours postprandial (2hpp) glucose were checked at the beginning and every 2 weeks, for three months Glycosylated hemoglobin (HbA1c), lipid profile, liver and kidney function tests were also measured at the beginning and at the end of trial and compared in two mentioned groups.Results: The 2hpp blood sugar and cholesterol levels were significantly decreased in Salvia officinalis treated patients compared to control group (p&lt;0.05). There were no significant changes in glycosylated hemoglobin and FBS between the two groups.Conclusion: Results showed that Salvia officinalis might be beneficial in diabetic patients to reduce 2hpp and cholesterol. However higher doses might be needed to decrease fasting blood glucose and glycosylated hemoglobin.Outcome 	Intervention 	Comparator 	Answer 	Reasoning",Significantly decreased,"had not reached the ideal control of the disease. Patients were randomly divided into two equal groups of case and control. The case group received Salvia officinalis and the control group received placebo tablets three times a day for three months. The fasting blood sugar (FBS) and 2 hours postprandial (2hpp) glucose were checked at the beginning and every 2 weeks, for three months Glycosylated hemoglobin (HbA1c), lipid profile, liver and kidney function tests were also measured at the beginning and at the end of trial and compared in two mentioned groups.Results: The 2hpp blood sugar and cholesterol levels were significantly decreased in Salvia officinalis treated patients compared to control group (p&lt;0.05). There were no significant changes in glycosylated hemoglobin and FBS between the two groups.Conclusion: Results showed that Salvia officinalis might be beneficial in diabetic patients to reduce 2hpp and cholesterol. However higher doses might be needed to decrease fasting blood glucose and glycosylated hemoglobin.Outcome 	Intervention 	Comparator 	Answer 	Reasoning",4206016
3548,4255428,alcohol use in pregnancy,screening method with Screening and Brief Intervention (SBI) program,screening with the help of clinical staff,Significantly increased,"The prenatal alcohol use rate obtained by our program was 20.6% (60 of 290). This rate was significantly higher than the highest rate of 15.2% (Ï‡2â€‰=â€‰6.78, pâ€‰&lt;â€‰.01) and the average rate of 13.3% (Ï‡2â€‰=â€‰13.73, pâ€‰&lt;â€‰.001) in the WIC data for the same time period.",4255428
3549,522822,"serum total cholesterol, LDL, HDL and triglycerides",12.7 g of psyllium hydrophilic mucilloid,baseline,No significant difference,"Data for changes from baseline for total, LDL and HDL cholesterol and triglycerides are listed in table 5. Changes from baseline were not significant for any parameter.",522822
3550,4298817,The International Prostate Symptom Score (IPSS),levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML) for six weeks,"levofloxacin (500 mg/d) (group L, 40 patients) for 6 weeks",Significantly increased,"Mirodenafil significantly improved the mean change in IPSS from baseline at six weeks (group L, -1.1 vs. group ML, -4.3; p&lt;0.05) (Table 2).",4298817
3551,4298817,The International Prostate Symptom Score (IPSS),levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML) for six weeks," levofloxacin (500 mg/d) (group L, 40 patients) for 6 weeks",Significantly increased,"Significant improvements were also seen in the IPSS voiding subscore (group L, -0.7 vs. group ML, -3.0; p&lt;0.05).",4298817
3552,4298817,National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI),levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML) for six weeks,"levofloxacin (500 mg/d) (group L, 40 patients) for 6 weeks",Significantly increased,"Changes from baseline in the NIH-CPSI at six weeks observed in group ML were greater than those in group L (group L, -3.2 vs. group ML, -7.2; p&lt;0.05).",4298817
3553,4298817,NIH-CPSI voiding score and the quality of life (QoL) domains,levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML) for six weeks,"levofloxacin (500 mg/d) (group L, 40 patients) for 6 weeks",Significantly increased,"Significant improvements were also seen in the NIH-CPSI voiding score (group L, -0.5 vs. group ML, -1.7; p&lt;0.05) and the quality of life (QoL) domains (group L, -1.0 vs. group ML, -1.8; p&lt;0.05) (Table 3).",4298817
3554,4298817,International Index of Erectile Function (IIEF) questionnaire,levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML) for six weeks,"levofloxacin (500 mg/d) (group L, 40 patients) for 6 weeks",Significantly increased,"Group ML showed a significantly greater increase in the IIEF-EF score than group L (group L, +0.2 vs. group ML, +7.8; p&lt;0.05) (Table 4).",4298817
3555,4298817,maximum urinary flow rate or mean residual urine volume,levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML) for six weeks,"levofloxacin (500 mg/d) (group L, 40 patients) for 6 weeks",No significant difference,"No significant change from baseline to the end of treatment and no significant difference in maximum urinary flow rate or mean residual urine volume were observed between the two groups (Table 5, 6).",4298817
3556,2755038,history of peripheral vascular disease,endovascular arm,angioplasty alone,Significantly decreased,"In the endovascular arm, patients who were treated with stenting were less likely to have a history of peripheral vascular disease than were patients treated with angioplasty alone (4 of 50 [8%] vs 38 of 145 [26%]; p=0Â·005).",2755038
3557,2755038,(â‰¥70% restenosis,endovascular arm,angioplasty alone,Significantly increased,"The primary outcome (â‰¥70% restenosis) occurred significantly more often in patients who had endovascular treatment than in patients who had endarterectomy (53 vs 20 patients [adjusted HR 3Â·17, 95% CI 1Â·89â€“5Â·32; p&lt;0Â·0001]; table 3, figure 2).",2755038
3558,2755038,â‰¥50% restenosis,endovascular arm,angioplasty alone,Significantly increased,"The secondary outcome (â‰¥50% restenosis) also occurred more frequently in the endovascular arm than in the surgery arm (109 vs 59; adjusted HR 2Â·58, 95% CI 1Â·87â€“3Â·55; p&lt;0Â·0001).",2755038
3559,2755038, the risks of 50% or more restenosis,endovascular arm,angioplasty alone,Significantly decreased,"Of the patients who were assigned to endovascular treatment, the risks of 70% or more restenosis (adjusted HR 0Â·43, 0Â·19â€“0Â·97; p=0Â·04) and 50% or more restenosis (0Â·37, 0Â·21â€“0Â·62; p=0Â·0003) were significantly lower in those patients treated with a stent than in those treated by angioplasty alone (table 4, figure 2).",2755038
3560,2755038,The incidence of ipsilateral non-perioperative stroke or transient ischaemic attack,patients with 70% or more restenosis in the first year,less than 70% restenosis in the first year,No significant difference,"There was a higher incidence of ipsilateral stroke in patients with 70% or more restenosis (four patients [9Â·7%]) compared with patients without 70% or more restenosis (17 patients [5Â·4%]) but the difference was not statistically significant (1Â·67, 0Â·54â€“5Â·11; p=0Â·4).",2755038
3561,2755038,risks of 70% restenosis,endovascular arm,angioplasty alone,No significant difference,"Of the patients who were assigned to endovascular treatment, the risks of 70% or more restenosis (adjusted HR 0Â·43, 0Â·19â€“0Â·97; p=0Â·04) and 50% or more restenosis (0Â·37, 0Â·21â€“0Â·62; p=0Â·0003) were significantly lower in those patients treated with a stent than in those treated by angioplasty alone (table 4, figure 2).",2755038
3562,4284021, high-density lipoprotein-cholesterol (HDL-C),evacetrapib (10â€“600â€‰mg),placebo,Significantly increased,"At the highest dose tested (600â€‰mg), evacetrapib increased HDL-C by 86.8% (Pâ€‰&lt;â€‰0.001 vs placebo)",4284021
3563,4284021, low-density lipoprotein cholesterol (LDL-C),evacetrapib (10â€“600â€‰mg),placebo,Significantly decreased,decreased LDL by 28.6% (Pâ€‰&lt;â€‰0.001 vs placebo) from baseline to Day 14.,4284021
3564,4284021,systolic blood pressure (SBP) and diastolic blood pressure (DBP),evacetrapib (10â€“600â€‰mg),placebo,No significant difference,No significant differences in either SBP or DBP were observed with evacetrapib 600â€‰mg compared with placebo (Tableâ€‰3).,4284021
3565,4284021,cholesteryl ester transfer protein (CETP),evacetrapib (10â€“600â€‰mg),placebo,Significantly decreased,"At the highest dose (600â€‰mg), evacetrapib significantly inhibited CETP activity (91%)",4284021
3566,4284021,Apolipoprotein AI (apo AI),evacetrapib (10â€“600â€‰mg),placebo,Significantly decreased,"At the highest dose (600â€‰mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.",4284021
3567,4284021,Apolipoprotein B-100 (apo B),evacetrapib (10â€“600â€‰mg),placebo,Significantly decreased,"At the highest dose (600â€‰mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.",4284021
3568,3661239,z-test,patient-oriented problem-solving (POPS) system,traditional lectures,Significantly increased,"The z-test was done to determine the significance between performance of group A (POPS) and group B (lecture) methods. The z test value was 16.62 (P &lt; 0.0001) (Table 1a, b).",3661239
3569,5176312,The median interquartile range (IQR) latencies - post-training and 1 year follow-up,Wheelchair Skills Training Program (WSTP),Educational Control (EC),No significant difference,The median (IQR) latencies for T2-T3 were 307 (290â€“320) days and 321 (301â€“357) days for the WSTP and EC groups (p = 0.052).,5176312
3570,5176312,"Wheelchair Skills Test - baseline,  post-training",Wheelchair Skills Training Program (WSTP),Educational Control (EC),Significantly increased,The same pattern of significant differences between the groups was seen when using the multivariate models for T2 vs T1 that included the baseline demographic and clinical characteristics except that the magnitudes of the differences were slightly higherâ€”the mean (SD) total WST T2-T1 change scores were 5.9% (1.3) and 1.5% (1.2) for the WSTP and EC groups (p &lt; 0.001);,5176312
3571,5176312,"the Advanced-level subtotal Wheelchair Skills Test (WST) - baseline,  post-training",Wheelchair Skills Training Program (WSTP),Educational Control (EC),Significantly increased,the Advanced-level subtotal WST T2-T1 change scores were 15.6% (3.1) and 4.4% (3.0) (p &lt; 0.001).,5176312
3572,5176312,scores for the Mobility subscale,Wheelchair Skills Training Program (WSTP),Educational Control (EC),Significantly increased,only one of the six parameters was different to a statistically significant extentâ€”the mean (SD) change scores for the Mobility subscale were 3.0 (1.8) and -0.7 (1.7) for the WSTP and EC groups (p = 0.021).,5176312
3573,4263705,"scores of WSC total scale, horizontal and vertical dimensions",workplace social capital intervention among those lost to follow-up,remaining participants,Significantly increased,"In the intervention group, the scores of WSC total scale, horizontal and vertical dimensions among those lost to follow-up were respectively 2.9, 1.9 and 0.9 points higher than the remaining participants (all p&lt;0.01).",4263705
3574,4263705,"scores of WSC total scale, horizontal and vertical dimensions",control group - those who lost to follow-up,control group - remaining participants,Significantly increased,"In the control group, the percent with more than 40 weekly work hours among those lost to follow-up was 12.3% higher (pâ€Š=â€Š0.046) than that among the remaining participants.",4263705
3575,3782468,"eye strain, and blurred vision","bright white light (10,000 lux)",dim red light (&lt; 500 lux),Significantly decreased,"Analysis of variance (ANOVA) showed a significant main effect of time on eye strain, F(1, 211) = 32.36, p &lt; .001, d = .47, and blurred vision, F(1, 211) = 7.60, p = .006, d = .19.",3782468
3576,3782468,eye strain severity," bright white light (10,000 lux), dim red light (&amp;lt; 500 lux) post-treatment","bright white light (10,000 lux), dim red light (&amp;lt; 500 lux) pre-treatment ",Significantly increased,"Across both groups, the average post-treatment eye strain severity (M = .4, SD = 1.0) was greater than pre-treatment severity (M = .1, SD = .5); likewise, average post-treatment blurred vision severity (M = .2, SD = .5) was greater than the pre-treatment mean (M = .1, SD = .4).",3782468
3577,3782468, blurred vision severity," bright white light (10,000 lux), dim red light (&amp;amp;lt; 500 lux) post-treatment","bright white light (10,000 lux), dim red light (&amp;amp;lt; 500 lux) pre-treatment ",Significantly increased,"Across both groups, the average post-treatment eye strain severity (M = .4, SD = 1.0) was greater than pre-treatment severity (M = .1, SD = .5); likewise, average post-treatment blurred vision severity (M = .2, SD = .5) was greater than the pre-treatment mean (M = .1, SD = .4).",3782468
3578,3782468,"nervousness, muscle twitching, and sweating"," bright white light (10,000 lux), dim red light (&amp;amp;amp;lt; 500 lux) post-treatment","bright white light (10,000 lux), dim red light (&amp;amp;amp;lt; 500 lux) pre-treatment ",Significantly decreased,"Across both groups, the average post-treatment eye strain severity (M = .4, SD = 1.0) was greater than pre-treatment severity (M = .1, SD = .5); likewise, average post-treatment blurred vision severity (M = .2, SD = .5) was greater than the pre-treatment mean (M = .1, SD = .4).",3782468
3579,3782468,"headache, or nausea"," bright white light (10,000 lux), dim red light (&amp;amp;amp;amp;lt; 500 lux) post-treatment","bright white light (10,000 lux), dim red light (&amp;amp;amp;amp;lt; 500 lux) pre-treatment ",No significant difference,"There was no significant main effect for headache, F(1, 211) = 2.41, p = .12, or nausea, F(1, 211) = .61, p = .43.",3782468
3580,3782468,total side effect intensity," bright white light (10,000 lux), dim red light (&amp;amp;amp;amp;amp;lt; 500 lux) post-treatment","bright white light (10,000 lux), dim red light (&amp;amp;amp;amp;amp;lt; 500 lux) pre-treatment ",No significant difference,"Similarly, there was no significant main effect for total side effect intensity, F(1, 211) = .07, p = .80.",3782468
3581,4731690,6-month outcome (Oxford Handicap Scale [OHS]),more extensive hyperdense artery sign (HAS),less extensive hyperdense artery sign (HAS),Significantly decreased,"Outcome was worse in patients with more (vs less) extensive HAS (OR 0.61, p = 0.027) but not in proximal (vs distal) HAS (p = 0.420).",4731690
3582,4731690,6-month outcome (Oxford Handicap Scale [OHS]),proximal extensive HAS,distal extensive HAS,No significant difference,"Outcome was worse in patients with more (vs less) extensive HAS (OR 0.61, p = 0.027) but not in proximal (vs distal) HAS (p = 0.420).",4731690
3583,4731690,HAS shrinkage/disappearance with alteplase at follow-up, HAS,baseline,No significant difference,"Treatment with alteplase increased HAS shrinkage/disappearance at follow-up (OR 0.77, p = 0.006).",4731690
3584,4731690,HAS shrinkage and alteplase effect,proximal extensive HAS,distal extensive HAS,No significant difference,"There was no significant difference in HAS shrinkage with alteplase in proximal (vs distal) or more (vs less) extensive HAS (p = 0.516 and p = 0.580, respectively).",4731690
3585,4731690, HAS shrinkage and alteplase effect,more extensive hyperdense artery sign (HAS),less extensive hyperdense artery sign (HAS),No significant difference,"Nevertheless, there was no evidence of an interaction between HAS extent and alteplase effect (p = 0.580) (figure 2).",4731690
3586,3712961,HIV RNA &lt;50 copies/mL,directly administered antiretroviral therapy (DAART),self-administered therapy (SAT),No significant difference,"Average proportion with HIV RNA &lt;50 copies/mL during interventionb	0.40	0.51	0.11 (âˆ’0.02, 0.24)	0.087",3712961
3587,2570683,the proportions of malaria cases among all health facility attendance (all causes diseases),Home Management of Malaria (HMM),control,Significantly decreased,"During the study period, the proportions of malaria cases among all health facility attendance (all causes diseases) were 21.0%, (445/2,111, 95% CI [19.3%â€“22.7%]) and 70.7% (2,595/3,671, 95% CI 68.5%â€“71.5%), respectively in the intervention and control arms (p &lt;&lt; 0.0001).",2570683
3588,2570683,incidence of disease episodes,Home Management of Malaria (HMM),control,Significantly decreased,"From August to October 2006, 2,111 episodes of disease (all causes) in children under the age of five were treated in HF of the intervention arm, and 3,671 in HF of the control arm; this corresponds to an incidence of disease episodes of 27.7% (2,111/7,621) and 48.3% (3,671/7605), respectively (95% CI 26.7%â€“28.7% and 47.2%â€“49.4%).",2570683
3589,2570683,Non-malaria diseases treated at the health facility level,Home Management of Malaria (HMM),control,Significantly increased,"Non-malaria diseases treated at the health facility level have represented 29.3% in the control arm (1,076/3,671) versus 78.9% (1,666/2,111) in the intervention arm (P &lt;&lt; 0.0001). (Figure 2)",2570683
3590,4560512,IOP-lowering effect,fixed-combination bimatoprost 0.03%/timolol 0.5% (FCBT PF) in treatment-naÃ¯ve patients,fixed-combination bimatoprost 0.03%/timolol 0.5% (FCBT PF) in previously treated patients,Significantly decreased,"After adjusting for these factors, FCBT PF demonstrated a 0.8â€“1.7 mmHg greater IOP-lowering effect in treatment-naÃ¯ve patients than in previously treated patients, and these differences were statistically significant at seven of nine time points (P&lt;0.05; Figure 2).",4560512
3591,4560512, incidence of eye pain and influenza,fixed-combination bimatoprost 0.03%/timolol 0.5% (FCBT PF) in treatment-naÃ¯ve patients,fixed-combination bimatoprost 0.03%/timolol 0.5% (FCBT PF) in previously treated patients,Significantly increased,"For patients who received FCBT PF, only the incidence of eye pain and influenza was higher in treatment-naÃ¯ve patients (P=0.022 and P=0.032, respectively) than in previously treated patients (Table 2).",4560512
3592,4757976,"eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma, Red Blood Cell Count (RBC), and PBMC (	Purified Blood Mononuclear Cells)",echium oil (EO) , linseed oil (LO),Significantly increased,". Final EPA and DPA in plasma, RBC, and PBMC were consistently higher (15â€“35&nbsp;%) compared to LO, respectively (Pâ€‰&lt;â€‰0.05; Table&nbsp;4).",4757976
3593,4757976,DHA,echium oil (EO) , linseed oil (LO),Significantly increased,"The final plasma DHA was higher with EO compared to LO, but lower in PBMC (Pâ€‰&lt;â€‰0.01; Table&nbsp;4).Table 3",4757976
3594,4757976,PBMC,echium oil (EO) , linseed oil (LO),Significantly decreased,"The final plasma DHA was higher with EO compared to LO, but lower in PBMC (Pâ€‰&lt;â€‰0.01; Table&nbsp;4).Table 3",4757976
3595,4757976,"RBC, and PBMC of EPA",fish oil (FO)," linseed oil (LO), echium oil (EO),  olive oil (OO)",Significantly increased,"Overall, final EPA and DPA in plasma, RBC and PBMC were in similar order: FOâ€‰&gt;â€‰EOâ€‰&gt;â€‰LOâ€‰&gt;â€‰OO (Pâ€‰â‰¤â€‰0.001; not for DPA in RBC; Table&nbsp;4). In plasma and PBMC, DHA was highest following FO, but was not different in RBC compared to EO or LO (Table&nbsp;4).",4757976
3596,4757976,insulin concentration in serum,echium oil (EO) , linseed oil (LO),Significantly decreased,"The insulin concentration in serum decreased most with EO vs. LO (Pâ€‰&lt;â€‰0.001), while OO remained unchanged (Table&nbsp;5).",4757976
3597,2998470, Benign Prostatic Hyperplasia Impact Index (BII),subjects reporting improvement,subjects reporting no improvement,Significantly increased,"There was a significant difference between improved and not improved subjects for both studies (Study 1: Wilcoxin two-sample test z = 5.03, P &lt; .0001, t-test (df = 256) = 5.16, P &lt; .0001; Study 2: Wilcoxin two-sample test z = 10.24, P &lt; .0001, t-test (df = 469) = 10.64, P &lt; .0001).",2998470
3598,2998470,Benign Prostatic Hyperplasia Impact Index (BII),subjects taking tadalafil,subjects taking placebo,Significantly increased,"There were significant differences in BII at the End-of-Study Visit between subjects reporting improvement versus subjects reporting no improvement (Studies 1 and 2, P &lt; .0001) and subjects taking tadalafil versus subjects taking placebo (Study 1, P = .0045; Study 2, P = .0064)",2998470
3599,4489004,"(Disease Activity Score in 28 joints, Health Assessment Questionnaire Disability Index and 36-item Short Form Health Survey scores","abatacept, rituximab",different TNFi,No significant difference,There were no significant differences between the three groups with respect to multiple measures of RA outcomes.,4489004
3600,4489004,cost,abatacept,rituximab,Significantly decreased,"The uncorrected difference in cost was significant between the abatacept and rituximab groups (mean differenceâ€‰=â€‰â‚¬5,586, 95% CIâ€‰=â€‰â‚¬3,681 to â‚¬7,491, P &lt;0.001) and between the TNFi and rituximab groups (mean differenceâ€‰=â€‰â‚¬3,758, 95% CIâ€‰=â€‰â‚¬1,661 to â‚¬5,856, Pâ€‰=â€‰0.001), but not between the TNFi and abatacept groups (mean differenceâ€‰=â€‰â‚¬1,828, 95% CIâ€‰=â€‰âˆ’â‚¬294 to â‚¬3,950, Pâ€‰=â€‰0.090).Figure 4",4489004
3601,4489004,cost,TNFi,rituximab,Significantly decreased,"The uncorrected difference in cost was significant between the abatacept and rituximab groups (mean differenceâ€‰=â€‰â‚¬5,586, 95% CIâ€‰=â€‰â‚¬3,681 to â‚¬7,491, P &lt;0.001) and between the TNFi and rituximab groups (mean differenceâ€‰=â€‰â‚¬3,758, 95% CIâ€‰=â€‰â‚¬1,661 to â‚¬5,856, Pâ€‰=â€‰0.001), but not between the TNFi and abatacept groups (mean differenceâ€‰=â€‰â‚¬1,828, 95% CIâ€‰=â€‰âˆ’â‚¬294 to â‚¬3,950, Pâ€‰=â€‰0.090).Figure 4",4489004
3602,4489004,cost,TNFi,abatacept,No significant difference,"The uncorrected difference in cost was significant between the abatacept and rituximab groups (mean differenceâ€‰=â€‰â‚¬5,586, 95% CIâ€‰=â€‰â‚¬3,681 to â‚¬7,491, P &lt;0.001) and between the TNFi and rituximab groups (mean differenceâ€‰=â€‰â‚¬3,758, 95% CIâ€‰=â€‰â‚¬1,661 to â‚¬5,856, Pâ€‰=â€‰0.001), but not between the TNFi and abatacept groups (mean differenceâ€‰=â€‰â‚¬1,828, 95% CIâ€‰=â€‰âˆ’â‚¬294 to â‚¬3,950, Pâ€‰=â€‰0.090).Figure 4",4489004
3603,5370326,mean blood pressure,"peribulbuar block with 5ml lignocaine 2% +3 ml bupivacaine 0.5% +1 ml hyaluronidase (250 IU) + 1 ml normal saline - Group S, ","peribulbuar block with 5ml lignocaine 2% +3 ml bupivacaine 0.5% +1 ml hyaluronidase (250 IU) + 25 Î¼g fentanyl to Group F, peribulbuar block with 5ml lignocaine 2% +3 ml bupivacaine 0.5% +1 ml hyaluronidase (250 IU) + 25 Î¼g clonidine to Group C",No significant difference,"Figure 1 shows the mean blood pressure changes during the surgery. In group S, mean blood pressure ranges from 90.9 Â± 6.12 to 88.6 Â± 15.5, in group F from 90.1 Â± 4.92 to 88.3 Â± 3.49, and in group C, it ranges from 92.2 Â± 2.48 to 90.2 Â± 4.34. There is no statistically significant difference in mean blood pressure of the patients between the three groups (P â‰¥ 0.05).",5370326
3604,4831612,cleanliness,Reciproc,K-file,Significantly increased,"Considering cleanliness, at coronal third Reciproc was better than K-file (P &lt; 0.001)",4831612
3605,4831612,cleanliness,Reciproc,Mtwo,No significant difference,"Considering cleanliness, at coronal third Reciproc was better than K-file (P &lt; 0.001), but not more effective than Mtwo (P = 0.080).",4831612
3606,4831612,leaving the canal,Mtwo, K-file,Significantly increased,"Furthermore, Mtwo leaved the canal cleaner than K-file (P = 0.001).",4831612
3607,4831612,cleaning efficacy in the middle third,Reciproc, K-file,Significantly increased,"In the middle third, only Reciproc exhibited better cleaning efficacy than K-file (P = 0.005).",4831612
3608,4831612,cleaning efficacy in the coronal third,Reciproc, K-file,No significant difference,"However, in the coronal third, despite the same performance of Reciproc and Mtwo files (P = 0.080),",4831612
3609,4831612,shaping ability,Reciproc,Mtwo,No significant difference,"Regarding shaping ability, no differences were found between Reciproc and Mtwo (P = 1.00).",4831612
3610,4831612,shaping ability,"Reciproc, Mtwo",K-file ,Significantly increased,"Meanwhile, both displayed better shaping efficacy than K-file (P &lt; 0.05).",4831612
3611,4831612,preparation time,Reciproc,"K-file, Mtwo",Significantly increased,"Between each two groups, there were differences in preparation time (P &lt; 0.05), with Reciproc being the fastest.",4831612
3612,4128673,biopsy-proven acute rejection (BPAR),standard dose ATG (total dose 3.75 mg/kg)(sATG),lower dose 2.25 mg/kg (lowATG),No significant difference,The rate of acute rejection in the lowATG group was 10% compared to 17% in the sATG group (pâ€Š=â€Š0.66) (Table 2).,4128673
3613,4128673,Patient survival at 1 year,standard dose ATG (total dose 3.75 mg/kg)(sATG),lower dose 2.25 mg/kg (lowATG),No significant difference,Patient survival at 1 year in the lowATG group was 85% compared with 100% in the sATG (pâ€Š=â€Š0.11) (Table 2).,4128673
3614,4128673,Delayed graft function,standard dose ATG (total dose 3.75 mg/kg)(sATG),lower dose 2.25 mg/kg (lowATG),Significantly decreased,Delayed graft function occurred in 40% of patients in the lowATG group compared with 14.3% in the sATG group (pâ€Š=â€Š0.05).,4128673
3615,4128673, the serum creatinine at 12 months post-transplant,standard dose ATG (total dose 3.75 mg/kg)(sATG),lower dose 2.25 mg/kg (lowATG),No significant difference,"At 12 months post-transplant, the serum creatinine in the lowATG was 1.4Â±0.44 mg/dl compared with 1.33Â±0.0.36 in the sATG group (pâ€Š=â€Š0.56).",4128673
3616,4128673,leukopenia,standard dose ATG (total dose 3.75 mg/kg)(sATG),lower dose 2.25 mg/kg (lowATG),No significant difference,"We observed more leukopenia in the sATG group compared with the lowATG group (43% vs. 30%, pâ€Š=â€Š0.34) (Table 2).",4128673
3617,4128673,The incidence of severe infection requiring hospital admission,standard dose ATG (total dose 3.75 mg/kg)(sATG),lower dose 2.25 mg/kg (lowATG),No significant difference,The incidence of severe infection requiring hospital admission was 13% in the sATG group compared to 10% in the lowATG group (pâ€Š=â€Š0.55).,4128673
3618,2211287,overall effect of BMI,overweight group,"normal weight group, underweight group.",Significantly increased,"Similarly, when energy expenditure was expressed as the change in kcal/min/ffm, the overall effect of BMI was significant (p = 0.0034), with the values for the overweight group significantly greater than the normal weight group which was significantly greater than the underweight group.",2211287
3619,2211287, change in energy expenditure,"normal weight group following consumption of the high protein, high fat meal","normal weight group following consumption of the high protein, low fat meal",Significantly increased,"While there was not an effect of meal type in the overweight or underweight groups, the change in energy expenditure was significantly (p = 0.0014) greater in the normal weight group following consumption of the high protein, high fat meal versus following consumption of the high protein, low fat meal.",2211287
3620,2211287,Changes in metabolic rate (MR) (kcal/min and kcal/min/kg ffm),underweight,overweight,No significant difference,Changes in MR (kcal/min and kcal/min/kg ffm) from the baseline rate did not significantly differ in the underweight (n = 3) or in the overweight subjects (n = 5) following consumption of either meal at any time.,2211287
3621,2211287,Changes in metabolic rate (MR) (kcal/min and kcal/min/kg ffm),"normal weight group -  high protein, high fat meal","normal weight group -  high protein, low fat meal",Significantly increased,"While there was not an effect of meal type in the overweight or underweight groups, the change in energy expenditure was significantly (p = 0.0014) greater in the normal weight group following consumption of the high protein, high fat meal versus following consumption of the high protein, low fat meal.",2211287
3622,3290117,mean BMI,NC with supervised bootcamp (NC + BC),Neoadjuvant chemotherapy (NC) alone,Significantly decreased,"BMI in the control group was 35.8 (35.8 Â± 2.7), versus 28.0 (28.0 Â± 1.0) in the bootcamp group after neoadjuvant chemotherapy, which was a statistically significant difference (P = 0.03, Table 2).",3290117
3623,3290117,Final tumor size,NC with supervised bootcamp (NC + BC),Neoadjuvant chemotherapy (NC) alone,No significant difference,Final tumor size was 2.59 cm in the NC + BC group versus 3.16 cm for NC (P = 0.76),3290117
3624,3290117,Mean Ki-67,NC with supervised bootcamp (NC + BC),Neoadjuvant chemotherapy (NC) alone,No significant difference,Mean Ki-67 for NC + BC was 7% versus 29% with NC (P = 0.14).,3290117
3625,3290117,C-peptide (ng/mL),NC with supervised bootcamp (NC + BC),Neoadjuvant chemotherapy (NC) alone,No significant difference,"C-peptide (ng/mL) was equivalent between the two groups (4.55 NC + BC versus 4.74 NC, P = 0.85).",3290117
3626,2194675,fasting and postprandial triglyceride concentrations,plant sterol (PS)  from fish oil (FO),PS-sunflower oil (SO) and PS-olive oil (OO),Significantly increased,"However, PS-FO consumption resulted in markedly lower (P &lt; 0.0001) fasting and postprandial triglyceride concentrations compared with PS-SO and PS-OO.",2194675
3627,2194675,"total cholesterol, LDL-cholesterol, or high-density lipoprotein (HDL)-cholesterol levels",plant sterol (PS)  from fish oil (FO),PS-sunflower oil (SO) and PS-olive oil (OO),No significant difference,"There were no differences between PS-containing diet effects on total cholesterol, LDL-cholesterol, or high-density lipoprotein (HDL)-cholesterol levels.",2194675
3628,2194675,retinol concentrations,plant sterol (PS)  from fish oil (FO), PS-olive oil (OO),Significantly increased,"Specifically, the PS-FO-fed group exhibited higher retinol concentrations as compared with the PS-OO (P = 0.0425) but not the PS-SO (P = 0.0638) groups.",2194675
3629,2194675,retinol concentrations,plant sterol (PS)  from fish oil (FO),PS-sunflower oil (SO),No significant difference,"Specifically, the PS-FO-fed group exhibited higher retinol concentrations as compared with the PS-OO (P = 0.0425) but not the PS-SO (P = 0.0638) groups.",2194675
3630,2194675,plasma Î²-carotene concentrations,plant sterol (PS)  from fish oil (FO),PS-sunflower oil (SO) ,Significantly increased,"In addition, plasma Î²-carotene concentrations following PS-FO feeding were elevated in comparison with PS-SO (P = 0.0139), but not PS-OO (P = 0.2376).",2194675
3631,2194675,plasma Î²-carotene concentrations,plant sterol (PS)  from fish oil (FO), PS-olive oil (OO),No significant difference,"In addition, plasma Î²-carotene concentrations following PS-FO feeding were elevated in comparison with PS-SO (P = 0.0139), but not PS-OO (P = 0.2376).",2194675
3632,2194675,plasminogen activator inhibitor 1 (PAI-1) concentrations,plant sterol (PS)  from fish oil (FO),PS-sunflower oil (SO) ,Significantly decreased,"However, the consumption of PS-FO resulted in lowered plasminogen activator inhibitor 1 (PAI-1) concentrations compared with PS-SO (P = 0.0282), but not PS-OO (P = 0.7487).",2194675
3633,2194675,plasminogen activator inhibitor 1 (PAI-1) concentrations,plant sterol (PS)  from fish oil (FO),PS-olive oil (OO),No significant difference,"However, the consumption of PS-FO resulted in lowered plasminogen activator inhibitor 1 (PAI-1) concentrations compared with PS-SO (P = 0.0282), but not PS-OO (P = 0.7487).",2194675
3634,4558976,extinction learning in a novel context (ABA condition),tiapride,placebo,Significantly increased,"When considering only extinction learning in a novel context (ABA condition), the TIA group was significantly impaired compared to PLAC [t(38) = 1.989 p = 0.027; TIA 24.00% Â± 3.81; PLAC 15.00% Â± 2.43], while there was no significant difference in AAA extinction learning between groups [t(38) = 0.673 p = 0.252; TIA 18.25% Â± 2.93; PLAC 16.00% Â± 1.59â€”all t-tests one-tailed]. (See Figure 2A)",4558976
3635,4558976,AAA extinction learning,tiapride,placebo,No significant difference,"When considering only extinction learning in a novel context (ABA condition), the TIA group was significantly impaired compared to PLAC [t(38) = 1.989 p = 0.027; TIA 24.00% Â± 3.81; PLAC 15.00% Â± 2.43], while there was no significant difference in AAA extinction learning between groups [t(38) = 0.673 p = 0.252; TIA 18.25% Â± 2.93; PLAC 16.00% Â± 1.59â€”all t-tests one-tailed]. (See Figure 2A)",4558976
3636,4558976,"activation during ABA and AAA extinction in bilateral dlPFC (BA 9) and OFC (BA 10), fusiform gyrus and temporal pole, right hippocampus and left lingual gyrus",tiapride (TIA),placebo,Significantly decreased,"A two-sample t-test showed reduced activation of the TIA group compared to PLAC during ABA and AAA extinction in bilateral dlPFC (BA 9) and OFC (BA 10), fusiform gyrus and temporal pole, as well as in right hippocampus and left lingual gyrus. Moreover, there was reduced activation in right lingual gyrus exclusively in ABA extinction, as well as reduced activation in left vmPFC (BA 10) and hippocampus, and in bilateral insula exclusively in AAA extinction (see Table 3 and Figure 4).",4558976
3637,4744284,"shoulder abduction, external rotation, internal rotation range of movements &amp; Shoulder Pain and Disability Index (SPDI) after 5 weeks",exercise and manual therapy group,exercise only,Significantly increased,After 5 weeks of intervention both groups made significant improvements in all outcome measures (p &lt; 0.001).,4744284
3638,4744284,"shoulder abduction, external rotation, internal rotation range of movements &amp;amp; Shoulder Pain and Disability Index (SPDI)",exercise and manual therapy group,exercise only,No significant difference,Intra-group analysis showed no statistically significant difference between the two groups in all outcome measures (p-value &gt;0.05).,4744284
3639,3664086,The objective response rate,"neoadjuvant DE (docetaxel: 75&nbsp;mg/m2, d1, epirubicin: 75&nbsp;mg/m2, d1, every 3&nbsp;weeks)","neoadjuvant DE combined with rh-endostatin (7.5&nbsp;mg/m2, d1-d14, every 3&nbsp;weeks)",Significantly increased,The objective response rate was 67.7% for chemotherapy (nâ€‰=â€‰31) and 90.9% for rh-endostatin plus chemotherapy (nâ€‰=â€‰33) (Pâ€‰=â€‰0.021).,3664086
3640,3664086,effectiveness in premenopausal patients and patients with ECOG score of zero,"neoadjuvant DE (docetaxel: 75&amp;nbsp;mg/m2, d1, epirubicin: 75&amp;nbsp;mg/m2, d1, every 3&amp;nbsp;weeks)","neoadjuvant DE combined with rh-endostatin (7.5&amp;nbsp;mg/m2, d1-d14, every 3&amp;nbsp;weeks)",Significantly increased,"However, premenopausal women and those with ECOG score of zero demonstrated a significantly higher ORR (100% vs 46.3%, Pâ€‰=â€‰0.002, and 94.4% vs 66.7%, Pâ€‰=â€‰0.049, respectively).",3664086
3641,3664086,achieving pathologic complete response,"neoadjuvant DE (docetaxel: 75&amp;amp;nbsp;mg/m2, d1, epirubicin: 75&amp;amp;nbsp;mg/m2, d1, every 3&amp;amp;nbsp;weeks)","neoadjuvant DE combined with rh-endostatin (7.5&amp;amp;nbsp;mg/m2, d1-d14, every 3&amp;amp;nbsp;weeks)",No significant difference,Five patients in the rh-endostatin plus chemotherapy arm achieved pathologic complete response compared with 2 in the chemotherapy arm (Pâ€‰=â€‰0.428).,3664086
3642,3664086,quality of life score and side effects,"neoadjuvant DE (docetaxel: 75&amp;amp;amp;nbsp;mg/m2, d1, epirubicin: 75&amp;amp;amp;nbsp;mg/m2, d1, every 3&amp;amp;amp;nbsp;weeks)","neoadjuvant DE combined with rh-endostatin (7.5&amp;amp;amp;nbsp;mg/m2, d1-d14, every 3&amp;amp;amp;nbsp;weeks)",No significant difference,No significant difference was identified in quality of life score and side effects (Pâ€‰&gt;â€‰0.05).,3664086
3643,4467206,"SF-36 mental component summary (MCS),  sense of coherence (SOC)","therapeutic acupuncture (TA) , salutogenic dialogue (IT)", conventional treatment (CT),Significantly increased,Significant differences were found between treatment groups on the SF-36 MCS (pâ€‰=â€‰.001) and the SOC (pâ€‰=â€‰.001) (Table&nbsp;2).,4467206
3644,4467206,"SF-36 mental component summary (MCS),  sense of coherence (SOC)",conventional treatment (CT),"salutogenic dialogue (IT), therapeutic acupuncture ",Significantly decreased,Pairwise comparisons between treatment groups showed that CT had significantly worse MCS and SOC values than did IT and TA (all pâ€‰=â€‰.001).,4467206
3645,4467206,"SF-36 mental component summary (MCS),  sense of coherence (SOC)",therapeutic acupuncture (TA),salutogenic dialogue (IT),No significant difference,No differences were found between IT and TA on any variable.,4467206
3646,3716527,deciding about medication and referrals,"intervention group (where mood, stress and daily activities were monitored with program mobiletype)",attention-comparison group (where only daily activities were monitored),Significantly increased,"Moreover, GPs reported that the mobiletype program was significantly more helpful in deciding about medication (pâ€‰=â€‰.013, dâ€‰=â€‰0.55) and referrals (pâ€‰=â€‰.012, dâ€‰=â€‰0.56) compared to the attention comparison.",3716527
3647,3716527,"helping to diagnosed and communication, specific medical and mental health problems","intervention group (where mood, stress and daily activities were monitored with program mobiletype)",attention-comparison group (where only daily activities were monitored),Significantly increased,"Finally, GPs indicated that the mobiletype program helped in their diagnosis (pâ€‰=â€‰.002, dâ€‰=â€‰0.69) and communication (pâ€‰=â€‰.031, dâ€‰=â€‰0.47), as well as their patientâ€™s specific medical (pâ€‰=â€‰.023, dâ€‰=â€‰0.52) and mental health problems (pâ€‰=â€‰.011, dâ€‰=â€‰0.56), significantly more than when using the attention comparison.",3716527
3648,3716527,post-test in the GP Confidence scale,"intervention group (where mood, stress and daily activities were monitored with program mobiletype)",attention-comparison group (where only daily activities were monitored),No significant difference,"After adjusting for baseline values, the difference between intervention and comparison groupâ€™s doctors confidence was not significant (Î²â€‰=â€‰1.05, pâ€‰=â€‰.131).",3716527
3649,4398439,body weight," a protein gel, and a multi-vitamin (SUP), the high-protein diet with isocaloric placebo supplements (PLA)",baseline,Significantly decreased,"SUP and PLA significantly decreased body weight (SUP: PRE, 70.47 Â± 8.01 kg to POST, 67.51 Â± 8.10 kg; PLA: PRE, 67.88 Â± 12.28 kg vs. POST, 66.38 Â± 11.94 kg; p â‰¤ 0.05) with a greater (p â‰¤ 0.05) decrease in SUP than PLA or CON.",4398439
3650,4398439,body weight," a protein gel, and a multi-vitamin (SUP)","the high-protein diet with isocaloric placebo supplements (PLA), no change in diet (CON)",Significantly decreased,"SUP and PLA significantly decreased body weight (SUP: PRE, 70.47 Â± 8.01 kg to POST, 67.51 Â± 8.10 kg; PLA: PRE, 67.88 Â± 12.28 kg vs. POST, 66.38 Â± 11.94 kg; p â‰¤ 0.05) with a greater (p â‰¤ 0.05) decrease in SUP than PLA or CON.",4398439
3651,4398439, % Fat according to DXA," a protein gel, and a multi-vitamin (SUP)",the high-protein diet with isocaloric placebo supplements (PLA),No significant difference,"PLA	34.22 Â± 6.36	32.69 Â± 5.84	-1.53 Â± 1.46 a , bSUP	34.98 Â± 7.05	32.99 Â± 6.89	-1.99 Â± 2.10 a , b",4398439
3652,4398439,%Fat according to skinfolds," a protein gel, and a multi-vitamin (SUP)",baseline,Significantly decreased,"SUP and PLA significantly decreased %Fat according to DXA (SUP: PRE, 34.98 Â± 7.05% to POST, 32.99 Â± 6.89%; PLA: PRE, 34.22 Â± 6.36% vs. POST, 32.69 Â± 5.84%; p â‰¤ 0.05), whereas only SUP significantly decreased %Fat according to skinfolds (SUP: PRE, 27.40 Â± 4.09% to POST, 24.08 Â± 4.31%; p â‰¤ 0.05).",4398439
3653,4398439,"%Fat according to skinfolds (chest, waist, hip, subscapular, and tricep)"," a protein gel, and a multi-vitamin (SUP)",PLA,Significantly decreased,"SUP significantly (p â‰¤ 0.05) decreased thicknesses at five skinfolds (chest, waist, hip, subscapular, and tricep) compared to PLA, but not at two skinfolds (axilla and thigh).",4398439
3654,4283612,terms of the duration of therapy,iPad-based software platform,control,No significant difference,"The two groups did not differ in terms of the duration of therapy: control participants had an average of 11 weeks (SD = 2.2) in therapy and experimental participants had an average 11.5 weeks (SD = 2.5) in therapy (t = 1.12, p = 0.78, Figure 5)6.",4283612
3655,4283612, Revised-Western Aphasia Battery (R-WAB),iPad-based software platform,control,Significantly increased,"On the R-WAB they showed an improvement of 2.15 points on the CQ subtest (t = âˆ’2.16, p &lt; 0.05) and an improvement of 3.18 points on the AQ subtest (t = âˆ’2.89, p &lt; 0.01).",4283612
3656,4283612,"Cognitive Linguistic Quick Test (CLQT),  executive function subtest, visuospatial skill subtest, Composite Severity score",iPad-based software platform,control,Significantly increased,"On the CLQT, the experimental participants showed an improvement of 10.92 percentage points on the attention subtest (t = âˆ’1.93, p &lt; 0.05), an improvement of 5.06 percentage points on the executive function subtest (t = âˆ’2.74, p &lt; 0.01), an improvement of 6.89 percentage points on the visuospatial skill subtest (t = âˆ’3.45, p &lt; 0.001), and an improvement of 5.26 percentage points on the Composite Severity score (t = âˆ’3.10, p &lt; 0.01).",4283612
3657,3532974,BP readings,â€˜Florenceâ€™- interactive mobile phone texting service,baseline,Significantly increased,"Intervention patients had significantly greater SBP and diastolic BP readings at recruitment and for the year prior to recruitment, see table 2.",3532974
3658,3532974,changes in medication usage ,â€˜Florenceâ€™- interactive mobile phone texting service,baseline,Significantly increased,"Significantly more changes, 0.31 vs 0.08 (p&lt;0.05; CI for difference 0.16 to 0.32) were made to the medications of intervention patients, compared with control patients over the 3-month programme, respectively.",3532974
3659,2956327,"Age, education.",weight loss program -in the consistent user group,"weight loss program  in the some, and minimal user group",Significantly increased,"Participants in the consistent user group (n = 212) were more likely to be older (P = .002), other than African American (P = .02), and more educated (P = .01).",2956327
3660,2956327,attending Phase I sessions,weight loss program - minimal user group,"weight loss program  in the consistent , and some user group",Significantly increased,"While there was no significant difference between website use categories in the amount of Phase I change in body weight (P = .45) or income (P = .78), minimal website users (n = 75) were significantly more likely to have attended fewer Phase I sessions (P = .001) and had a higher initial body mass index (BMI) (P &lt; .001).",2956327
3661,2956327,initial body mass index (BMI),weight loss program - minimal user group,"weight loss program  in the consistent , and some user group",Significantly increased,"While there was no significant difference between website use categories in the amount of Phase I change in body weight (P = .45) or income (P = .78), minimal website users (n = 75) were significantly more likely to have attended fewer Phase I sessions (P = .001) and had a higher initial body mass index (BMI) (P &lt; .001).",2956327
3662,2956327,initial weight loss regained,weight loss program -in the consistent user group,"weight loss program  in the some, and minimal user group",Significantly decreased,"Mean weight change in Phase II, both absolute weight and proportion of initial weight loss regained, was significantly lower (less weight regained) in the consistent website-use category (P = .003 [Figure 2] and P = .001 [Figure 3]).",2956327
3663,2956327,patients that maintained a clinically important weight loss,weight loss program -in the consistent user group,"weight loss program  in the some, and minimal user group",Significantly increased,"Likewise, significantly more consistent users, 107 out of 212 (51%), maintained a clinically important weight loss of 4 kg compared with 16 out of 61 (27%) and 18 out of 75 (24%) in the other two categories (P = .002)",2956327
3664,5687903,Vertigo after intervention,promethazine intramuscularly at a dose of 25 mg (group A),8 mg betahistine tablets (group B),No significant difference,Vertigo after intervention (h)	1.7 Â± 0.59	1.6 Â± 0.39	NS,5687903
3665,5687903,nausea and vomiting, 8 mg betahistine tablets (group B),promethazine intramuscularly at a dose of 25 mg (group A),Significantly increased,Nausea and vomiting	3 (3.7%)	11 (13.8%),5687903
3666,5687903,drowsiness,promethazine intramuscularly at a dose of 25 mg (group A),8 mg betahistine tablets (group B),Significantly increased,Drowsiness	51 (62.2%)	0,5687903
3667,5753687," corticosteroid dosage,  Crohnâ€™s disease activity index (CDAI), Harvey-Bradshaw index (HBI)","umbilical cord mesenchymal stem cells (UC-MSCs) 1Ã—106 UC-MSCs/kg, with one infusion per week",control,Significantly decreased,"In the UC-MSC group, the pretreatment CDAI, HBI, and corticosteroid dosage were 281.5Â±75.2, 12.7Â±3.2 and 13.6Â±2.8 mg/day, respectively; 12 months after treatment, the CDAI, HBI, and corticosteroid dosage were 219.0Â±67.6, 9.3Â±2.9, and 9.4Â±3.1, respectively, representing respective decreases of 62.5Â±23.2, 3.4Â±1.2, and 4.2Â±0.84 mg/day. In the control group, the CDAI, HBI, and corticosteroid dosage were 293.2Â±68.4, 11.9Â±3.5, and 12.8Â±2.5, respectively; 12 months after treatment, the CDAI, HBI, and corticosteroid dosage were 269.6Â±62.5, 10.7Â±3.3, and 11.6Â±2.4, respectively, representing respective decreases of 23.6Â±12.4, 1.2Â±0.58, and 1.2Â±0.35 mg/day (p&lt;0.01, p&lt;0.05, and p&lt;0.05; UC-MSC vs control; respectively) (Fig. 2Aâ€“C).",5753687
3668,5753687,CD endoscopic index of severity (CDEIS) after Colonoscopy ,"umbilical cord mesenchymal stem cells (UC-MSCs) 1Ã—106 UC-MSCs/kg, with one infusion per week",control,Significantly decreased,"Colonoscopy showed that the CDEIS in the UC-MSC group was 9.2Â±1.5 and 3.4Â±1.2 before treatment and at the 12-month follow-up, respectively (Fig. 3). The values were 8.7Â±2.3 at the start of the study and 7.2Â±1.9 at the 12-month follow-up in the control group, which indicates significant differences in the two groups (p&lt;0.01, UC-MSC vs control) (Fig. 2D).",5753687
3669,4185107,overall rate of early postoperative complications,gentamicin collagen implant (GCI),control,No significant difference,"There were no statistically significant differences in the overall rate of early postoperative complications between the study and control group: 25.6 and 34.1&nbsp;% respectively; p&nbsp;=&nbsp;0.245, relative risk (RR) 0.750 [95&nbsp;% confidence interval (CI) 0.471â€“1.195].",4185107
3670,4185107,The reoperation rate,gentamicin collagen implant (GCI),control,No significant difference,The reoperation rate was similar in both groups: 12.8 versus 9.4&nbsp;%; p&nbsp;=&nbsp;0.628; RR 1.359; (95&nbsp;% CI 0.575â€“3.212).,4185107
3671,4185107,The total rate of SSI and organ space surgical site infections (SSI),gentamicin collagen implant (GCI),control,Significantly decreased,"However, if there was no leakage, the risk of organ space SSI was significantly reduced in patients who received GCI: 2.6&nbsp;% (95&nbsp;%CI 0â€“6.2) versus 13.8&nbsp;% (95&nbsp;% CI 6.2â€“21.4); p&nbsp;=&nbsp;0.018 (Table&nbsp;2).",4185107
3672,4251531,The sum of target lesions, intramuscular injections of 0.035 mg/kg of body weight BP-C1, placebo,Significantly increased,The difference between the groups in sum lesion increase was significant in favor of BP-C1 (P=0.04).,4251531
3673,4251531,Response Evaluation Criteria In Solid Tumors (RECIST) classification, intramuscular injections of 0.035 mg/kg of body weight BP-C1, placebo,Significantly increased,There was a significant difference (P=0.026) in favor of BP-C1 regarding Response Evaluation Criteria In Solid Tumors (RECIST) classification.,4251531
3674,4251531,The sum CTC-NCI toxicity score, intramuscular injections of 0.035 mg/kg of body weight BP-C1,baseline,No significant difference,The sum CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group but significantly in the placebo group (P=0.05).,4251531
3675,4251531,The sum CTC-NCI toxicity score,placebo,baseline,Significantly increased,The sum CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group but significantly in the placebo group (P=0.05).,4251531
3676,4251531,The sum CTC-NCI toxicity score, intramuscular injections of 0.035 mg/kg of body weight BP-C1,placebo,No significant difference,The difference in increase between groups did not meet the level of significance (P=0.12).,4251531
3677,4251531,â€œBreast cancer-related pain and discomfortâ€� and â€œBreast cancer treatment problem last weekâ€�, intramuscular injections of 0.035 mg/kg of body weight BP-C1,baseline,Significantly decreased,â€œBreast cancer-related pain and discomfortâ€� and â€œBreast cancer treatment problem last weekâ€� were significantly reduced (P=0.02) in the BP-C1 group but increased slightly in the placebo group; between-group differences were significant in favor of BP-C1 (P=0.05).,4251531
3678,4251531,â€œBreast cancer-related pain and discomfortâ€� and â€œBreast cancer treatment problem last weekâ€�,placebo,baseline,Significantly increased,â€œBreast cancer-related pain and discomfortâ€� and â€œBreast cancer treatment problem last weekâ€� were significantly reduced (P=0.02) in the BP-C1 group but increased slightly in the placebo group; between-group differences were significant in favor of BP-C1 (P=0.05).,4251531
3679,4251531,â€œBreast cancer-related pain and discomfortâ€� and â€œBreast cancer treatment problem last weekâ€�, intramuscular injections of 0.035 mg/kg of body weight BP-C1,placebo,Significantly decreased,â€œBreast cancer-related pain and discomfortâ€� and â€œBreast cancer treatment problem last weekâ€� were significantly reduced (P=0.02) in the BP-C1 group but increased slightly in the placebo group; between-group differences were significant in favor of BP-C1 (P=0.05).,4251531
3680,4251531,"â€œBreast cancer related pain and discomfortâ€�, â€œBreast cancer treatment problem last week,â€� and â€œPhysical activity problemâ€�", intramuscular injections of 0.035 mg/kg of body weight during the 64 days of BP-C1 treatment,baseline,Significantly decreased,"â€œBreast cancer related pain and discomfortâ€�, â€œBreast cancer treatment problem last week,â€� and â€œPhysical activity problemâ€� were significantly reduced during the 64 days of BP-C1 treatment (Pâ‰¤0.05).",4251531
3681,3780629,primary measures of depressive symptoms and distress,cognitive behavioral therapy (iCBT),baseline,Significantly decreased,Intent-to-treat marginal models using restricted maximum likelihood estimation demonstrated significant reductions in primary measures of depressive symptoms and distress corresponding to medium-large effect sizes (Cohenâ€™s d = 0.62â€“2.40) following CBM-I and the combined (CBM-I + iCBT) intervention.,3780629
3682,3780629,primary measures of depressive symptoms and distress,CBM-I (cognitive-bias modification (CBM) + Internet-based cognitive behavioral therapy (iCBT),baseline,Significantly decreased,Intent-to-treat marginal models using restricted maximum likelihood estimation demonstrated significant reductions in primary measures of depressive symptoms and distress corresponding to medium-large effect sizes (Cohenâ€™s d = 0.62â€“2.40) following CBM-I and the combined (CBM-I + iCBT) intervention.,3780629
3683,3780629,"disability, anxiety, and repetitive negative thinking",CBM-I (cognitive-bias modification (CBM) + Internet-based cognitive behavioral therapy (iCBT),baseline,Significantly decreased,Intent-to-treat marginal models using restricted maximum likelihood estimation demonstrated significant reductions in primary measures of depressive symptoms and distress corresponding to medium-large effect sizes (Cohenâ€™s d = 0.62â€“2.40) following CBM-I and the combined (CBM-I + iCBT) intervention.,3780629
3684,3780629,"The Beck Depression Inventoryâ€“2nd edition (BDI-II), nine-item Depression Scale of the Patient Health Questionnaire (PHQ-9), and The 10-item Kessler Psychological Distress Scale (K10)",CBM-I ,baseline,Significantly decreased,"Following CBM-I, the reductions in BDI-II, PHQ-9, and K10 scores in the intervention group were all significant and corresponded to medium-large effects.",3780629
3685,4871571,The median titers in vaccinees who had received three HIV-DNA and two HIV-MVA immunizations followed by two CN54rgp140/GLA-AF immunizations, two CN54rgp140/GLA-AF immunizations,baseline,No significant difference,The median titers in vaccinees who had received three HIV-DNA and two HIV-MVA immunizations followed by two CN54rgp140/GLA-AF immunizations were not significantly different from the median titer in those who were not primed before receipt of two CN54rgp140/GLA-AF immunizations (p = 0.077).,4871571
3686,4871571,The concentration of CN54rgp140 antibodies,two CN54rgp140/GLA-AF immunizations,baseline,Significantly increased,The concentration of CN54rgp140 antibodies increased significantly from a median of 0.861 (range 0.197â€“4.449 Î¼g/ml) after the HIV-DNA and HIV-MVA vaccinations to a median of 9.866 (range 0.134â€“129.6 Î¼g/ml) after the first dose of CN54rgp140/GLA-AF (p&lt;0.001) and then increased further to a median of 17.75 Î¼g/ml (range 0.277 to 219.8 Î¼g/ml) after the second Env protein immunization (p&lt;0.001).,4871571
3687,4871571,ADCC-mediating antibody response,two CN54rgp140/GLA-AF immunizations,baseline,No significant difference,The magnitude of the ADCC-mediating antibody response against CM235 CRF01_AE did not differ significantly between the two time points (Fig 3).,4871571
3688,4871571,adverse events,two CN54rgp140/GLA-AF immunizations,baseline,No significant difference,"All of these were mild or moderate and included infectious diseases in four cases (malaria, tonsillitis or flu like illness), headache in two cases and musculo-skeletal problems in another two cases. None was considered related to the vaccinations. No HIV infection occured.",4871571
3689,3511949, visual analog scale (VAS) scores at every visit over 12 weeks,"Group M - morphine plus bupivacaine intra-articularly, ",Group T - triamcinolone plus bupivacaine intra-articularly ,No significant difference,The morphine and steroid groups had significantly decreased VAS scores at every visit over 12 weeks.,3511949
3690,3511949, visual analog scale (VAS) scores at the end of 12th week,"Group M - morphine plus bupivacaine intra-articularly, Group T - triamcinolone plus bupivacaine intra-articularly ",Group C received saline plus bupivacaine intra-articularly,Significantly decreased,"Variance analysis of repeated measurements revealed decreased VAS scores of both morphine and steroid groups than the control group and this decrease continued until the end of 12th week [P &lt; 0.001, Figure 1].",3511949
3691,3511949,Patients who needed NSAID supplementation,"Group M - morphine plus bupivacaine intra-articularly,  Group T - triamcinolone plus bupivacaine intra-articularly ",Group C received saline plus bupivacaine intra-articularly,Significantly decreased,Patients in the morphine and steroid groups needed significantly lesser NSAID supplementation than patients in the control group.,3511949
3692,3511949,"WOMAC pain, stiffness and, function scores",Group M - morphine plus bupivacaine intra-articularly, Group T - triamcinolone plus bupivacaine intra-articularly ,No significant difference,"Morphine and steroid groups were compared with each other using variance analysis of repeated measurements, and their WOMAC scores were also similar in 2nd, 4th, 6th, and 12th weeks [P &gt; 0.05, Figure 2].",3511949
3693,3511949,"WOMAC pain, stiffness and, function scores","Group M - morphine plus bupivacaine intra-articularly,  Group T - triamcinolone plus bupivacaine intra-articularly ",Group C - saline plus bupivacaine intra-articularly,No significant difference,"In three groups, there was a significant different compared in terms of the WOMAC baseline values (P &gt; 0.05).",3511949
3694,3511949,Patients who needed NSAID supplementation,Group M - morphine plus bupivacaine intra-articularly,Group T - triamcinolone plus bupivacaine intra-articularly ,Significantly decreased,The morphine group had significantly lower NSAID consumption than steroid group (P = 0.036).,3511949
3695,3511949,side effect,"Group M - morphine plus bupivacaine intra-articularly,  Group T - triamcinolone plus bupivacaine intra-articularly ",Group C - saline plus bupivacaine intra-articularly,No significant difference,No side effect was recorded for any patient during the conduct of this study.,3511949
3696,4839526,8 in the digit symbol substitution test (DSST),duloxetine 60â€‰mg,placebo,No significant difference,"The difference from placebo was not significant for the duloxetine group (Î” +1.21, 95% CI: âˆ’0.23, 2.65; P=0.099), with a standardized effect size of 0.176.",4839526
3697,4839526,8 in the digit symbol substitution test (DSST),vortioxetine (10â€“20â€‰mg),placebo,Significantly increased,"The difference from placebo was significant for vortioxetine (Î” +1.75, 95% CI: 0.28, 3.21; P=0.019; ANCOVA, OC), with a standardized effect size of 0.254 (Table 2 and Figure 3).",4839526
3698,4839526, CGI-I score,vortioxetine (10â€“20â€‰mg),placebo,Significantly decreased,"Vortioxetine produced a statistically significant improvement in disease severity compared with placebo in reducing the CGI-I score at week 8 (Î” âˆ’0.29, 95% CI: âˆ’0.53, âˆ’0.05; P&lt;0.05) (Figure 4b).",4839526
3699,4839526,The patient-reported perceived deficits questionnaire (PDQ),duloxetine 60â€‰mg,placebo,Significantly decreased,"Treatment with duloxetine also demonstrated a statistically significant improvement on the CGI-I compared with placebo at week 8 (Î” âˆ’0.40, 95% CI: âˆ’0.64, âˆ’0.17; P&lt;0.001; MMRM, FAS).",4839526
3700,4839526,Trail Making Test B Total Time,vortioxetine (10â€“20â€‰mg),placebo,Significantly decreased,"Trail Making Test B Total Time (Î” âˆ’9.67, 95% CI: âˆ’15.38, âˆ’3.96; P&lt;0.001; ANCOVA, OC) was significantly improved with vortioxetine compared with placebo.",4839526
3701,4839526,Trail Making Test B Total Time,duloxetine 60â€‰mg,placebo,No significant difference,No significant benefit was found with duloxetine compared with placebo on any of the secondary measures of cognitive function.,4839526
3702,4839526,8 in the digit symbol substitution test (DSST),vortioxetine (10â€“20â€‰mg),duloxetine 60â€‰mg,No significant difference,"An additional analysis of the comparative effects of vortioxetine and duloxetine was conducted on the change from baseline on DSST total number of correct symbols at week 8. The effect of vortioxetine was not significantly different from duloxetine (Î” +0.54, 95% CI: âˆ’0.89, 1.96; P=0.46; ANCOVA, OC).",4839526
3703,4839526,"The patient-reported perceived deficits questionnaire (PDQ),physician-assessed clinical global impression (CGI) , and Montgomeryâ€“Ã…sberg Depression Rating Scale (MADRS)",duloxetine 60â€‰mg,placebo,Significantly increased,"Duloxetine was not significantly different from placebo on the DSST or UPSA, but was superior to placebo on the PDQ, CGI-I, and MADRS.",4839526
3704,5972262,"bispectral index (BIS)  at sputum suction (T5), extubation (T6) and 1 min (T7), 5 min (T8),",creatine phosphate sodium (1.0 g/100 ml 0.9% saline; group P),100 ml 0.9% saline (group C),Significantly increased,"Compared with group C, the BIS values at T5, T6, T7, and T8 in group P were significantly higher (Pâ€‰&lt;â€‰0.001 for all comparisons; one-way ANOVA).",5972262
3705,5972262,The Steward recovery scores at T7 and T8,creatine phosphate sodium (1.0 g/100 ml 0.9% saline; group P),100 ml 0.9% saline (group C),Significantly increased,The Steward recovery scores at T7 and T8 were significantly higher in group P than in group C (Pâ€‰&lt;â€‰0.001 for both comparisons; one-way ANOVA) (Table 5).,5972262
3706,5972262,"The time of waking, extubation, recovery of consciousness and time in the PACU",creatine phosphate sodium (1.0 g/100 ml 0.9% saline; group P),100 ml 0.9% saline (group C),Significantly decreased,"The time of waking, extubation, recovery of consciousness and time in the PACU were significantly shorter in group P compared with group C (Pâ€‰&lt;â€‰0.001 for all comparisons; one-way ANOVA).",5972262
3707,3781545,weight loss,liraglutide 1.8 mg,placebo,Significantly increased,Subjects who continued to use liraglutide (n = 24) lost twice as much weight as those using placebo (n = 27; 6.8 vs. 3.3 kg; P &lt; 0.001).,3781545
3708,3781545,steady-state plasma glucose (SSPG) concentration,liraglutide 1.8 mg,baseline,Significantly increased,SSPG concentration declined by 29% in the liraglutide group compared with no change in the placebo group (P &lt; 0.001 for difference between groups).,3781545
3709,3781545,steady-state plasma glucose (SSPG) concentration,liraglutide 1.8 mg,placebo,No significant difference,Changes in steady-state plasma insulin concentrations were not significantly different between groups (P = 0.25 for difference between groups).,3781545
3710,3781545," systolic blood pressure, fasting glucose , and triglyceride",liraglutide 1.8 mg,baseline,Significantly decreased,"Liraglutide-treated subjects also had a significant improvement in SSPG concentration (âˆ’3.2 vs. 0.2 mmol/L; P &lt; 0.001) and significantly (P â‰¤ 0.04) greater lowering of systolic blood pressure (âˆ’8.1 vs. âˆ’2.6 mmHg), fasting glucose (âˆ’0.5 vs. 0 mmol/L), and triglyceride (âˆ’0.4 vs. âˆ’0.1 mmol/L) concentration.",3781545
3711,3781545,Inflammatory markers,liraglutide 1.8 mg,placebo,No significant difference,"Inflammatory markers did not differ between the two groups, but pulse increased after liraglutide treatment (6.4 vs. âˆ’0.9 bpm; P = 0.001).",3781545
3712,3781545,pulse,liraglutide 1.8 mg,placebo,Significantly increased,"Inflammatory markers did not differ between the two groups, but pulse increased after liraglutide treatment (6.4 vs. âˆ’0.9 bpm; P = 0.001).",3781545
3713,3781545,gastrointestinal side effect,liraglutide 1.8 mg,placebo,Significantly increased,he majority of individuals (79%) treated with liraglutide experienced at least one gastrointestinal side effect compared with 46% treated with placebo (P = 0.02).,3781545
3714,3781545,nausea,liraglutide 1.8 mg,placebo,Significantly increased,"The most common side effect was nausea, with 67% treated with liraglutide experiencing nausea compared with 26% treated with placebo (P = 0.005).",3781545
3715,3781545,"systolic blood pressure, fasting glucose , and triglyceride",liraglutide 1.8 mg,placebo,Significantly decreased,"Liraglutide-treated subjects had significant decreases in systolic blood pressure, fasting glucose, and triglyceride concentration as compared with placebo.",3781545
3716,4772687,treatment success,Cal/BD aerosol foam,Cal/BD ointment,Significantly increased,"By treatment end (week 4), a significantly larger proportion of patients using Cal/BD aerosol foam achieved treatment success compared with those using Cal/BD ointment (54.6% [nâ€‰=â€‰77/141] vs. 43.0% [nâ€‰=â€‰58/135]; mean difference 11.6%; odds ratio (OR) 1.7; 95% CI 1.1, 2.8; pâ€‰=â€‰0.025; Figure 3).",4772687
3717,4772687,mean modified psoriasis area and severity index (mPASI) score,Cal/BD aerosol foam at week 1 and week 4,Cal/BD ointment at week 1 and week 4,Significantly decreased,"There was a significant difference in adjusted mean mPASI score between Cal/BD aerosol foam and Cal/BD ointment at week 1 (mean difference â€“0.7; 95% CI â€“1.1, â€“0.3; pâ€‰=â€‰0.001) and week 4 (mean difference â€“0.6; 95% CI â€“1.1, â€“0.2; pâ€‰=â€‰0.005; Figure 4).",4772687
3718,4772687,mean modified psoriasis area and severity index (mPASI) score at week 4,Cal/BD aerosol foam at week 1 and week 4,Cal/BD ointment at week 1 and week 4,No significant difference,"Furthermore, at week 4; a greater proportion of patients using Cal/BD aerosol foam achieved PASI75 or PASI50 compared with ointment-treated patients although the difference was not statistically significant (PASI75: 50.4 versus 40.7%; OR 1.7; 95% CI 1.0, 2.7; pâ€‰=â€‰0.052; PASI50: 80.9 versus 74.8%; OR 1.5; 95% CI 0.8, 2.8; pâ€‰=â€‰0.17). Figure 4.",4772687
3719,4776542, postanesthesia care unit (PACU) time, saline 0.90% in group S,"midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, midazolam 0.75 mg/kg and ondansetron 4 mg in group MO",Significantly increased,Time to oral intake was significantly higher in group S (P &lt; 0.001) than to the other groups.,4776542
3720,4776542,postoperative nausea and vomiting (PONV),midazolam 0.75 mg/kg and ondansetron 4 mg in group MO,"midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O,  and saline 0.90% in group S",Significantly decreased,PONV was significantly less in those patients who received a combination of midazolam and ondansetron as compared to the other groups [Table 3].,4776542
3721,4776542,postoperative nausea and vomiting (PONV),ondansetron 4 mg in group O,midazolam 0.75 mg/kg in group M,No significant difference,"Subsequently, the difference was not significant between group M and group O.",4776542
3722,4776542,postoperative nausea and vomiting (PONV),"midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O",saline 0.90% in group S,Significantly decreased,"However, PONV in both of them were significantly less as compared to group S [Table 3].",4776542
3723,4776542,The overall patient satisfaction,midazolam 0.75 mg/kg and ondansetron 4 mg in group MO,"midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S",Significantly increased,"The overall patient satisfaction was significantly higher in the group MO compared the other groups [P &lt; 0.001, Table 2].",4776542
3724,4776542, visual analog scale (VAS) of nausea,midazolam 0.75 mg/kg and ondansetron 4 mg in group MO,"midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S",Significantly decreased,VAS of nausea in group MO was significantly less than other groups (P &lt; 0.001).,4776542
3725,4776542,VAS of pain,midazolam 0.75 mg/kg and ondansetron 4 mg in group MO,"midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S",No significant difference,There was no significant difference between VAS of pain in four groups [Table 4].,4776542
3726,4776542,dizziness and headache,midazolam 0.75 mg/kg and ondansetron 4 mg in group MO,"midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S",No significant difference,No significant difference was found between groups in terms of side effects such as dizziness and headache [Table 5].,4776542
3727,3034877,mean serum 25(OH)D,"D3 supplementation (daily 800&nbsp;IU or 100,000&nbsp;IU/3&nbsp;months)",sunlight exposure,Significantly increased,"After 6&nbsp;months, mean serum 25(OH)D increased to 53&nbsp;nmol/l with 800&nbsp;IU/day, to 50.5&nbsp;nmol/l with 100,000&nbsp;IU/3&nbsp;months, and to 29.1&nbsp;nmol/l with advised sunlight exposure (supplementation vs sunshine pâ€‰&lt;â€‰0.001).",3034877
3728,3034877,parathyroid hormone (PTH) concentrations,"vitamin D 800&nbsp;IU/day or 100,000&nbsp;IU/3&nbsp;months",sunlight exposure,Significantly decreased,"Serum PTH decreased significantly in all groups after 3&nbsp;months, more in the supplementation groups than in the advised sunlight group (pâ€‰&lt;â€‰0.05).",3034877
3729,3034877,"demographic and prognostic variables, and baseline values of outcome measurements","vitamin D 800IU/day or 100,000IU/3months",sunlight exposure,No significant difference,"The three intervention groups were similar in demographic and prognostic variables, and baseline values of outcome measurements.",3034877
3730,3577896,osteoclacin (OC) and Î²-CrossLaps levels,0.25 Âµg calcitriol per day  for one year,placebo,No significant difference,No significant differences were observed between calcitriol and placebo groups for OC (37.2Â±11.8 ng/ml vs 25.8Â±7.4 ng/ml; Pâ€Š=â€Š0.39) and Î²-CrossLaps (0.33Â±0.07 ng/ml vs 0.50Â±0.12 ng/ml; Pâ€Š=â€Š0.29) (table 2).,3577896
3731,3382694,The mean stone size,"Extracorporeal Shock Wave Lithotripsy (ESWL) in group A, stone size â‰¤10 mm; - success group", failure group,Significantly increased,"The mean stone size in the success and failure groups, respectively, was 5.9Â±1.27 mm vs. 7.5Â±1.43 mm in group A (p&lt;0.001) and 12.2Â±2.15 mm vs. 19.1Â±4.15 mm in group B (p&lt;0.001).",3382694
3732,3382694,The mean stone size,"Extracorporeal Shock Wave Lithotripsy (ESWL) group B, stone size10 mm - success group", failure group,Significantly increased,"The mean stone size in the success and failure groups, respectively, was 5.9Â±1.27 mm vs. 7.5Â±1.43 mm in group A (p&lt;0.001) and 12.2Â±2.15 mm vs. 19.1Â±4.15 mm in group B (p&lt;0.001).",3382694
3733,3382694,skin-to-stone distance (SSD),"Extracorporeal Shock Wave Lithotripsy (ESWL) group B, stone size10 mm -  success  group", failure group,Significantly increased,"The mean SSD in the success and failure groups, respectively, was 102.4Â±12.88 mm vs. 110.8Â±5.66 mm in group A (p=0.043) and 97.8Â±12.97 mm vs. 107.9Â±13.02 mm in group B (p=0.013) (Table 3).",3382694
3734,3382694,skin-to-stone distance (SSD),"Extracorporeal Shock Wave Lithotripsy (ESWL) in group A, stone size â‰¤10 mm - success group", failure group,Significantly increased,"The mean SSD in the success and failure groups, respectively, was 102.4Â±12.88 mm vs. 110.8Â±5.66 mm in group A (p=0.043) and 97.8Â±12.97 mm vs. 107.9Â±13.02 mm in group B (p=0.013) (Table 3).",3382694
3735,4115605,Improvement  Orthostatic Hypotension Questionnaire (OHQ),droxidopa dose optimization (100â€“600 mg 3 times daily),placebo,Significantly increased,"Improvement in OHQ symptom subscore favored droxidopa by 0.73 units (p = 0.010), with maximum change in â€œdizziness/lightheadedness.â€�",4115605
3736,4115605,Improvement in symptom-impact subscore,droxidopa dose optimization (100â€“600 mg 3 times daily),placebo,Significantly increased,"For symptom-impact composite score, mean (SD) change was âˆ’1.98 (2.31) vs âˆ’0.92 (1.82) units, favoring droxidopa by 1.06 units (95% CI 0.41â€“1.71; p = 0.003), with statistically significant differences from placebo on all symptom-impact items (figure 2).",4115605
3737,4115605,"Mean standing systolic blood pressure (BP), mean supine systolic BP",droxidopa dose optimization (100â€“600 mg 3 times daily),placebo,Significantly increased,"From randomization to end of study, standing systolic BP increased by a mean (SD) of 11.2 (22.9) mm Hg in droxidopa recipients vs 3.9 (16.3) in placebo recipients, a difference of 7.3 mm Hg (95% CI 1.1â€“13.5; p &lt; 0.001).",4115605
3738,4115605,systolic BP while supine,droxidopa dose optimization (100â€“600 mg 3 times daily),placebo,Significantly increased,"From randomization to end of study, systolic BP while supine increased by 7.6 (19.2) mm Hg in droxidopa recipients vs 0.8 (14.5) in placebo recipients, a difference of 6.8 mm Hg (95% CI 1.53â€“12.07; p &lt; 0.001), to mean (SD) values of 133.7 (23.3) and 125.9 (22.2) mm Hg, respectively.",4115605
3739,4115605,adverse events,droxidopa dose optimization (100â€“600 mg 3 times daily),placebo,No significant difference,No patients discontinued double-blind treatment because of adverse events.,4115605
3740,3546023,tocopherol and tocotrienol levels,"200â€‰mg/day palmvitee smokers , 200â€‰mg/day palmvitee nonsmokers",baseline,Significantly increased,"After palmvitee supplementation, both plasma tocopherol and tocotrienol concentration were increased in smokers and nonsmokers (pâ€‰&lt;â€‰0.05) starting from 12â€‰weeks until the end of the experiment.",3546023
3741,3546023,Urine cotinine levels ,200â€‰mg/day palmvitee smokers ,200â€‰mg/day palmvitee  nonsmokers,Significantly increased,Urinary cotinine and serum Î±1-antitrypsin of smokers were significantly higher (pâ€‰&lt;â€‰0.05) compared to nonsmokers (Tableâ€‰ 1),3546023
3742,3546023, serum Î±1-antitrypsin,200â€‰mg/day palmvitee smokers ,200â€‰mg/day palmvitee  nonsmokers,Significantly increased,Urinary cotinine and serum Î±1-antitrypsin of smokers were significantly higher (pâ€‰&lt;â€‰0.05) compared to nonsmokers (Tableâ€‰ 1),3546023
3743,3546023,The percentage of B cells,200â€‰mg/day palmvitee nonsmokers ,baseline,Significantly increased,"After palmvitee supplementation, B cells percentage was significantly increased in nonsmokers at 24â€‰weeks (pâ€‰&lt;â€‰0.05) but not in the smokers (Tableâ€‰ 6). In S1 and S3 palmvitee-supplemented groups there was a trend of increment in B cells percentage.",3546023
3744,3546023,The percentage of B cells,200â€‰mg/day palmvitee smokers ,baseline,No significant difference,"After palmvitee supplementation, B cells percentage was significantly increased in nonsmokers at 24â€‰weeks (pâ€‰&lt;â€‰0.05) but not in the smokers (Tableâ€‰ 6).",3546023
3745,3546023,CD4+/CD8+ ratio,200â€‰mg/day palmvitee smokers ,200â€‰mg/day palmvitee nonsmokers,No significant difference,"CD4+/CD8+ ratio was found to be significantly increased (pâ€‰&lt;â€‰0.001) in smokers compared to nonsmokers at baseline (Tableâ€‰ 5) and also in S2. However, no significant changes were observed after palmvitee supplementation for both smokers and nonsmokers (Tableâ€‰ 9).",3546023
3746,3546023,The percentage of NK cells,200â€‰mg/day palmvitee smokers ,200â€‰mg/day palmvitee nonsmokers,Significantly decreased,"The percentage of NK cells were lower in smokers compared to nonsmokers (pâ€‰&lt;â€‰0.0001) at baseline (S1: pâ€‰&lt;â€‰0.05, S2: pâ€‰&lt;â€‰0.005, S3: pâ€‰&lt;â€‰0.01) and after palmvitee supplementation (Tableâ€‰ 8 and Tableâ€‰ 9).",3546023
3747,3529678,minutes moderate-vigorous physical activity (MVPA),telephone-delivered multiple health behaviour change intervention,baseline,Significantly increased,"MVPA, mins/week	66.6 (21.1)	217.3 (34.7)	150.7 (22.7 110.5)	&lt;0.01",3529678
3748,3529678,"Processed meat, serves/week",telephone-delivered multiple health behaviour change intervention,baseline,Significantly decreased,"Processed meat, serves/week	2.0 (1.8)	0.9(1.2)	-1.2 (-1.8 -0.5)	&lt;0.01",3529678
3749,3529678,"Vegetables, serves/day",telephone-delivered multiple health behaviour change intervention,baseline,Significantly increased,"Vegetables, serves/day	2.5 (1.3)	3.5 (1.1)	1.0 (0.4 1.6)	&lt;0.01",3529678
3750,3529678,"Body mass index, kg/m2",telephone-delivered multiple health behaviour change intervention,baseline,Significantly decreased,"Body mass index, kg/m2	30.4 (7.4)	29.0 (6.1)	-1.4 (-2.3 -0.5)	&lt;0.01",3529678
3751,3529678,"Waist circumference, cm",telephone-delivered multiple health behaviour change intervention,baseline,Significantly decreased,"Waist circumference, cm	97.5 (18.4)	92.4 (15.7)	-5.1 (-8.3 -2.0)	&lt;0.01",3529678
3752,3529678,Physical Functioning,telephone-delivered multiple health behaviour change intervention,baseline,Significantly increased,Physical Functioning	50.6 (6.5)	52.8 (4.4)	2.2 (0.9 3.5)	&lt;0.01,3529678
3753,3529678,Bodily Pain,telephone-delivered multiple health behaviour change intervention,baseline,Significantly increased,Bodily Pain	45.0 (11.4)	50.7 (9.7)	5.8 (1.4 10.1)	0.01,3529678
3754,3529678,General Health,telephone-delivered multiple health behaviour change intervention,baseline,Significantly increased,General Health	48.4 (29.6)	52.1 (8.6)	3.7 (0.3 7.1)	0.03,3529678
3755,3529678,Vitality,telephone-delivered multiple health behaviour change intervention,baseline,Significantly increased,Vitality	47.3 (42.7)	52.0 (49.3)	4.8 (1.4 8.2)	0.01,3529678
3756,3529678,Physical HRQoL,telephone-delivered multiple health behaviour change intervention,baseline,Significantly increased,Physical HRQoL	48.6 (1.6)	51.9 (6.6)	3.3 (03 6.3)	0.03,3529678
3757,3179931,returned fecal occult blood test (FOBT) cards,FOBT plus a mailed reminder,FOBT alone,Significantly increased,The FOBT card return rate after 6 months was 64.6% in the intervention group compared to 48.4% in the usual care group (p &lt; 0.001).,3179931
3758,3395326,hidden blood loss,epoetin-Î±,control,No significant difference,There was no difference in average hidden blood loss (1643 versus 1578) (P = 0.7459).,3395326
3759,3395326,average total blood loss,epoetin-Î±,control,No significant difference,There was no difference in average total blood loss between groups (1737 versus 1670) (P = 0.725).,3395326
3760,3395326,mean hemoglobin level at admission,epoetin-Î±,control,Significantly increased,"At admission, the mean hemoglobin level was higher in the epoetin-Î± group (13.8â€‰g/dL versus 12.2â€‰g/dL) (P = 0.001);",3395326
3761,3395326,mean hemoglobin level at admission at the discharge,epoetin-Î±,control,Significantly increased,the discharge hemoglobin level was higher in the epoetin-Î± group (10.6â€‰g/dL versus 9.69â€‰g/dL) (P &lt; 0.001).,3395326
3762,3395326,mean duration of surgery,epoetin-Î±,control,No significant difference,There was no difference in mean duration of surgery between cohorts (epoetin-Î± versus control: 85.4 minutes versus 92.66 minutes) (P = 0.276) (Table 2).,3395326
3763,3395326,patients required blood transfusion,epoetin-Î±,control,Significantly decreased,"In the epoetin-Î± group, 0% of the patients (0 of 28) required blood transfusion. This was significantly lower than the control group where 53% of the patients (28 of 53) received at least one unit of blood transfusion (P = 0.0001).",3395326
3764,3395326,hospital stay,epoetin-Î±,control,Significantly decreased,"The epoetin-Î± cohort had a shorter hospital stay (3 versus 3.67, P = 0.042) (Table 2).",3395326
3765,5117579,The incidence of hypotension,"Group A, 1&nbsp;Î¼g/kg of dexmedetomidine was intravenously 10&nbsp;min, followed by the maintenance infusion of dexmedetomidine 0.2&nbsp;Î¼g/kg/hr after 5&nbsp;min of intrathecal bupivacaine injection",Group B received same dose of dexmedetomidine by intravenous administration before 5&nbsp;min of intrathecal bupivacaine injection,Significantly decreased,The incidence of hypotension was significantly lower in Group A (16.1%) than in Group B (48.4%) during infusion of dexmedetomidine (pâ€‰=â€‰0.01).,5117579
3766,5117579,The incidence of bradycardia and desaturation,"Group A, 1Î¼g/kg of dexmedetomidine was intravenously 10min, followed by the maintenance infusion of dexmedetomidine 0.2Î¼g/kg/hr after 5min of intrathecal bupivacaine injection",Group B received same dose of dexmedetomidine by intravenous administration before 5min of intrathecal bupivacaine injection,No significant difference,The incidence of bradycardia and desaturation did not significantly differ between the two groups (Table&nbsp;2).,5117579
3767,5117579,The mean HR and  mean blood pressure (MBP),"Group A, 1Î¼g/kg of dexmedetomidine was intravenously 10min, followed by the maintenance infusion of dexmedetomidine 0.2Î¼g/kg/hr after 5min of intrathecal bupivacaine injection",Group B received same dose of dexmedetomidine by intravenous administration before 5min of intrathecal bupivacaine injection,No significant difference,"The mean HR (Group A vs. Group B, 57.88â€‰Â±â€‰6.16 vs. 59.49â€‰Â±â€‰8.13, pâ€‰=â€‰0.133) and MBP (Group A vs. Group B, 80.07â€‰Â±â€‰12.48 vs. 77.49â€‰Â±â€‰9.36, pâ€‰=â€‰0.121) were not significantly different.",5117579
3768,5117579,The need for treatment of hypotension,"Group A, 1 Î¼g/kg of dexmedetomidine was intravenously 10min, followed by the maintenance infusion of dexmedetomidine 0.2Î¼g/kg/hr after 5min of intrathecal bupivacaine injection",Group B received same dose of dexmedetomidine by intravenous administration before 5min of intrathecal bupivacaine injection,Significantly decreased,The need for treatment of hypotension is higher in Group B than Group A (pâ€‰=â€‰0.02).,5117579
3769,5732563,rate of pain relief (VRS/minute),10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle,"catheter, given in 5 mL increments spaced 2 minutes apart",No significant difference,"The estimated difference in rate of pain relief (slope) from the time of medication dosing, reported as VRS pain score/minute, between the epidural needle and epidural catheter groups was 0.04 (95% CI: âˆ’0.01 to 0.11) and not statistically significant (p=0.109; Figure 1 and Table 2).",5732563
3770,5732563,analgesic spread (spinal level/minute),10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle,"catheter, given in 5 mL increments spaced 2 minutes apart",No significant difference,"The estimated difference in analgesic spread (spinal level/minute), as defined by loss of sharpness of pinprick, was 0.63 (95% CI: âˆ’0.12 to 0.19) and did not significantly differ between groups (p=0.166; Figure 2 and Table 2).",5732563
3771,5732563,The time to VRS â‰¤3 and level of sensory block 20 minutes after dosing,10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle,"catheter, given in 5 mL increments spaced 2 minutes apart",No significant difference,The time to VRS â‰¤3 and level of sensory block 20 minutes after dosing were also similar between groups.,5732563
3772,5732563,maternal mean arterial blood pressure or maternal heart rate,10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle,"catheter, given in 5 mL increments spaced 2 minutes apart",No significant difference,"No significant difference was observed in the estimated slope differences of maternal mean arterial blood pressure (0.25, p=0.188; Figure 3) or maternal heart rate (0.03, p=0.807; Figure 4).",5732563
3773,5732563,adverse events,10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle,"catheter, given in 5 mL increments spaced 2 minutes apart",No significant difference,No adverse events occurred in either study group.,5732563
3774,5958330,C-peptide levels,BV juice (480 mL/day,"BV juice placebo at the same time (480 mL/day,",No significant difference,"Serum C-peptide decreased by 8% after treatment with BV relative to placebo, whereas these changes were not statistically significant (Table 3).",5958330
3775,5958330,(HOMA-B)  homeostasis model assessment of Î²-cell function ,BV juice (480 mL/day),placebo,Significantly increased,HOMA-B increased by 44% relative to placebo after 8 weeks treatment of the BV group (Table 3).,5958330
3776,5958330,homeostasis model assessment of insulin resistance index (HOMA-IR),BV juice (480 mL/day),placebo,No significant difference,"HOMA-IR showed 16% decrease in BV group relative to the placebo, but it was not statistically significant (Table 3).",5958330
3777,2655271,Apoptosis rates of CL187 cancer cells,125I seeds,60Co Î³ ray,Significantly increased,"Apoptosis rates of CL187 cancer cells were 13.74% Â± 1.63%, 32.58% Â± 3.61%, and 46.27% Â± 3.82% after 2 Gy, 5 Gy, and 10 Gy irradiation, respectively; however, the control group apoptosis rate was 1.67% Â± 0.19%.",2655271
3778,2655271,G2/M cell cycle arrests of CL187 cancer cells,125I seeds,60Co Î³ ray,Significantly increased,"G2/M cell cycle arrests of CL187 cancer cells were 42.59% Â± 3.21%, 59.84% Â± 4.96%, and 34.61% Â± 2.79% after 2 Gy, 5 Gy, and 10 Gy irradiation, respectively; however, the control group apoptosis rate was 26.44% Â± 2.53%. P &lt; 0.05 vs. control groups by Student's t-test were found in every treated group both in apoptosis and in G2/M cell cycle arrest.",2655271
3779,2655271,Expression of EGFR and Raf in CL187 cells,125I seeds,60Co Î³ ray,Significantly increased,"Under low dose rate irradiation, expression of EGFR (74.27 Â± 5.63%) and Raf (53.84 Â± 2.31%) was significantly higher than in the control group (Fig. 5 and Table 3).",2655271
3780,2655271,Expression of EGFR and Raf in CL187 cells after irradiation and/or EGFR monoclonal antibody treatment,125I seeds,60Co Î³ ray,No significant difference,"fter signal transduction was blocked, expression of EGFR (2.07 Â± 0.31%) and Raf (13.74 Â± 1.82%) did not show detectable change after low dose rate irradiation (Fig. 5 and Table 3).",2655271
3781,5789513, incidence of clinical cure,"Group II -IV amikacin 20 mg/kg/24 h and meropenem 2 g over 30 min/8 h in addition to nebulized amikacin 25 mg/kg/day every 8 h. Group III received IV amikacin 20 mg/kg/24 h, nebulized amikacin 25 mg/kg/day every 8 h, and meropenem 2 g diluted in 240 ml normal saline over 3 h/8 h ",  Group I - IV amikacin 20 mg/kg/24 h and meropenem 2 g over 30 min/8 h.,Significantly increased,"At the end of therapy, nebulized AB group (Group II) and nebulized + extended infusion AB group (Group III) compared to control group (Group I) showed higher incidence of clinical cure (53.33% patients in Group II and 66.67% patients in Group III vs. 26.67% patients in Group I; P = 0.007); the results were statistically significant.",5789513
3782,5789513, ventilator days,Group II -IV amikacin 20 mg/kg/24 h and meropenem 2 g over 30 min/8 h in addition to nebulized amikacin 25 mg/kg/day every 8 h. ,Group I - IV amikacin 20 mg/kg/24 h and meropenem 2 g over 30 min/8 h.,Significantly decreased,"Group II compared to Group I showed significant reduction in ventilator days (5.32 Â± 1.86 vs. 7.3 Â± 2.1 days, respectively, P &lt; 0.001) and reduction in ICU days (11.87 Â± 2.6 vs. 15.3 Â± 3.1 days, respectively, P &lt; 0.001).",5789513
3783,5789513, ventilator days,"Group III received IV amikacin 20 mg/kg/24 h, nebulized amikacin 25 mg/kg/day every 8 h, and meropenem 2 g diluted in 240 ml normal saline over 3 h/8 h",Group II -IV amikacin 20 mg/kg/24 h and meropenem 2 g over 30 min/8 h in addition to nebulized amikacin 25 mg/kg/day every 8 h.,Significantly decreased,"Group III compared to Group II showed significant reduction in ventilator days (4.22 Â± 1.32 vs. 5.32 Â± 1.86, respectively, P = 0.011)",5789513
3784,5789513,ICU days,"Group III received IV amikacin 20 mg/kg/24 h, nebulized amikacin 25 mg/kg/day every 8 h, and meropenem 2 g diluted in 240 ml normal saline over 3 h/8 h",Group II -IV amikacin 20 mg/kg/24 h and meropenem 2 g over 30 min/8 h in addition to nebulized amikacin 25 mg/kg/day every 8 h.,Significantly decreased,"Group III compared to Group II showed significant reduction in ventilator days (4.22 Â± 1.32 vs. 5.32 Â± 1.86, respectively, P = 0.011) and highly significant reduction in ICU days (9.21 Â± 1.17 vs. 11.87 Â± 2.6, respectively, P &lt; 0.001).",5789513
3785,3432828,Equol concentrations,Isoflavone + Fructooligosaccharides diet (GIF),Isoflavone diet (GI),Significantly increased,"Concentrations of equol, a metabolite of daidzein, were significantly higher in rats fed the GIF diet than in those fed GI diet (Fig.&nbsp;2C; p&lt;0.05).",3432828
3786,3432828,Calcium absorption,Fructooligosaccharides diet (GF) and Isoflavone + Fructooligosaccharides diet (GIF),Control diet (GC),Significantly increased,the absorption in rats fed the FOS diet (GF and GIF) was significantly higher than that in rats fed the control diet (GC) (p&lt;0.05),3432828
3787,3432828,Bone strength of femur,Fructooligosaccharides diet (GF) and Isoflavone + Fructooligosaccharides diet (GIF),Isoflavone diet (GI),Significantly increased,the 2 FOS diets (GF and GIF) prevented bone fragility (Fig.&nbsp;2C; p&lt;0.05). Isoflavone did not have any effect on the decreased breaking force.,3432828
3788,3432828,Bone strength of femur,Fructooligosaccharides diet (GF) and Isoflavone + Fructooligosaccharides diet (GIF),Control diet (GC),Significantly increased,"Bone breaking force significantly decreased after GX; however, the 2 FOS diets (GF and GIF) prevented bone fragility (Fig.&nbsp;2C; p&lt;0.05).",3432828
3789,3432828,Calcium absorption,Isoflavone diet (GI),Control diet (GC),No significant difference,there was no significant difference in the Ca absorption between the GC and GI groups (Table&nbsp;2).,3432828
3790,5550381,Loss of Brain volume,Teriflunomide 14 mg (1 year),Placebo,Significantly decreased,"BVL was lower for teriflunomide 14 mg vs placebo at year 1 (36.9% relative reduction, p = 0.0001) and year 2 (30.6% relative reduction, p = 0.0001)",5550381
3791,5550381,Loss of Brain volume,Teriflunomide 14 mg (2 years),Placebo,Significantly decreased,"BVL was lower for teriflunomide 14 mg vs placebo at year 1 (36.9% relative reduction, p = 0.0001) and year 2 (30.6% relative reduction, p = 0.0001)",5550381
3792,5550381,Loss of Brain volume,Teriflunomide 7 mg (1 year),Placebo,Significantly decreased,"At both time points analyzed, teriflunomide 7 and 14 mg significantly slowed BVL compared with placebo (figure 1A)",5550381
3793,5550381,Loss of Brain volume,Teriflunomide 7 mg (2 years),Placebo,Significantly decreased,Teriflunomide 7 mg was also associated with significant reduction in BVL vs placebo over the 2-year study.,5550381
3794,5550381,Loss of Brain volume,Teriflunomide 14 mg (1 year) + presence of on-study disability worsening,Placebo,Significantly decreased,"BVL remained statistically significantly lower in patients treated with teriflunomide 14 mg than in placebo-treated patients, regardless of the presence or absence of on-study disability worsening at both years 1 and 2",5550381
3795,4554233,Self-adhesive resin cement strength,Tannic acid,Distilled water ,Significantly decreased,There was significant difference in the shear bond strength of control and tannic acid contaminated group (p&lt;0.05),4554233
3796,4554233,Self-adhesive resin cement strength,Aluminium chloride,Distilled water ,No significant difference,there was no significant differences between the shear bond strength between control and aluminium chloride and ferric sulphate groups (p&gt;0.05).,4554233
3797,4554233,Self-adhesive resin cement strength,Ferric sulphate,Distilled water ,No significant difference,"Even though Group II (Aluminium chloride) [9.83Â±1.50] and Group III (Ferric sulphate) [8.27Â±4.36] showed reduced SBS as compared to the control, there was no statistically significant difference.",4554233
3798,3890270,VO2max,Aerobic interval training (ITT),Walking,Significantly increased,"relative to WALK VO2max (L/min) (see also the subgroup comparisons used in Table 5), there was a significant difference favouring AIT on both ITT analysis (pâ€Š=â€Š0.01) and also on PP analysis (pâ€Š=â€Š0.04).",3890270
3799,3890270,VO2max,Aerobic interval training (PP),Walking,Significantly increased,"relative to WALK VO2max (L/min) (see also the subgroup comparisons used in Table 5), there was a significant difference favouring AIT on both ITT analysis (pâ€Š=â€Š0.01) and also on PP analysis (pâ€Š=â€Š0.04).",3890270
3800,3890270,VO2max,Maximal volitional interval training,Walking,No significant difference,Comparison of MVIT with WALK continued to show non-significant changes.,3890270
3801,3890270,Body mass,Aerobic interval training ,Baseline (No exercise),No significant difference,Although there was no significant change in body mass and only a small non-significant fall in self-reported calorie intake,3890270
3802,3890270,Reported calorie intake,Aerobic interval training ,Baseline (No exercise),No significant difference,Although there was no significant change in body mass and only a small non-significant fall in self-reported calorie intake,3890270
3803,3734718,CD4 reduction,Polyherbal formulation,Highly active antiretroviral treatment,Significantly decreased,"The slow kinetics of the CD4 cell reduction in the PHF arm, 14.3 Â± 6.1 cells/Î¼l lost per year (R2 = 0.029, P=0.021), contrasted that of the HAART and the difference between the two arms was statistically significant at all the time points (P&lt;0.001) subsequent to the baseline.",3734718
3804,3734718,CD4 reduction,Polyherbal formulation,No treatment,Significantly decreased,"In contrast, the PHF arm showed a profile of CD4 cell loss at remarkably slower kinetics (14.3 cells/Î¼l/year, P=0.021)",3734718
3805,3734718,Viral load,Polyherbal formulation,No treatment,No significant difference,"In contrast, the PHF arm showed a profile of CD4 cell loss at remarkably slower kinetics (14.3 cells/Î¼l/year, P=0.021) and insignificant reduction in the viral load.",3734718
3806,3734718,CD4 count,Highly active antiretroviral treatment,No treatment,Significantly increased,"The HAART arm was characterized by significant improvements in CD4 cell count (154.4 cells/Î¼l/year, P&lt;0.001) and reduction in plasma viral load within 3 to 6 months (-0.431+ 0.004 log10 IU/month, P&lt;0.001).",3734718
3807,3734718,Viral load,Highly active antiretroviral treatment,No treatment,Significantly decreased,"The HAART arm was characterized by significant improvements in CD4 cell count (154.4 cells/Î¼l/year, P&lt;0.001) and reduction in plasma viral load within 3 to 6 months (-0.431+ 0.004 log10 IU/month, P&lt;0.001).",3734718
3808,3864139,Epistaxis (Overall),Laryngeal mask ,Endotracheal tube,No significant difference,"Overall, 40 of 66 (60.6%) patients in the LMA group and 36 of 68 (52.9%) patients in the ETT group experienced nasal bleeding within the whole study period. There was no significant difference between two groups (RD = âˆ’7.7%; 95% CI: âˆ’24.4% to 9.1%; P = 0.371).",3864139
3809,3864139,Epistaxis (inside OR),Laryngeal mask ,Endotracheal tube,Significantly decreased,"In the OR, the incidence of nasal bleeding in the ETT group was significantly higher than that in the LMA group (RD = 18.8%, 95% CI: 5.7% to 31.9%; P = 0.007; Table 2).",3864139
3810,3864139,Epistaxis insidence (outside OR),Laryngeal mask ,Endotracheal tube,No significant difference,"Outside the OR, there were no statistically significant differences in the incidence, episodes, and intensity of nasal bleeding between the two groups (Table 3).",3864139
3811,3864139,Epistaxis episodes (outside OR),Laryngeal mask ,Endotracheal tube,No significant difference,"Outside the OR, there were no statistically significant differences in the incidence, episodes, and intensity of nasal bleeding between the two groups (Table 3).",3864139
3812,3864139,Epistaxis intensity(outside OR),Laryngeal mask ,Endotracheal tube,No significant difference,"Outside the OR, there were no statistically significant differences in the incidence, episodes, and intensity of nasal bleeding between the two groups (Table 3).",3864139
3813,3864139,Epistaxis first episode (outside OR),Endotracheal tube, Laryngeal mask ,Significantly decreased,"Thus, outside the OR, the incidence of the first episode of epistaxis in the ETT group was lower than that in the LMA group (RD: âˆ’26.5%; 95% CI: âˆ’42.2% to âˆ’10.7%; P &lt; 0.001; Table 3)",3864139
3814,5153686,Time in PACU ,Ropivacaine (0.33%) 30ml,Ropivacaine (0.5%) 20ml,No significant difference,"There was a 50-min longer PACU stay in group B compared to group A (49.76, 4.72 to 94.8).",5153686
3815,5153686,Opioid usage,Ropivacaine (0.33%) 30ml,Ropivacaine (0.5%) 20ml,No significant difference,"Total postoperative opioid use in group A was slightly higher. Group B used 26&nbsp;mg less morphine than group A (âˆ’26.1, âˆ’75.9 to 23.8), while group C used 23&nbsp;mg less than group A (âˆ’22.7, âˆ’74.72 to 29.34).",5153686
3816,5153686,Opioid usage,Ropivacaine (0.25%) 40ml,Ropivacaine (0.5%) 20ml,No significant difference,"Total postoperative opioid use in group A was slightly higher. Group B used 26&nbsp;mg less morphine than group A (âˆ’26.1, âˆ’75.9 to 23.8), while group C used 23&nbsp;mg less than group A (âˆ’22.7, âˆ’74.72 to 29.34).",5153686
3817,5153686,Pain score,Ropivacaine (0.33%) 30ml,Ropivacaine (0.5%) 20ml,No significant difference,"With regard to pain scores at rest and with knee flexion, no meaningful difference was observed between the groups.",5153686
3818,5153686,Pain scores,Ropivacaine (0.25%) 40ml,Ropivacaine (0.5%) 20ml,No significant difference,"With regard to pain scores at rest and with knee flexion, no meaningful difference was observed between the groups",5153686
3819,3952602,Viral load suppression after 96 weeks,Nevirapine,Abacavir,Significantly increased,"Consistent with previously reported week 48 data [6], the distribution of viral load at week 96 differed between the 2 arms (P &lt; .001; Table 1), with a greater proportion of participants in the NVP arm achieving viral load suppression &lt;1000 copies/mL.",3952602
3820,3952602,Viral load suppression maintenance (from week 48 to week 96),Nevirapine,Abacavir,Significantly increased,"Participants with viral load &lt;1000 copies/mL at week 48 were likely to remain &lt;1000 copies/mL at 96 weeks, although more so in the NVP arm (96% [149/156]) than in the ABC arm (82% [148/180]) (P = .003).",3952602
3821,3952602,Resuppression ,Nevirapine,Abacavir,No significant difference,"Nineteen of 70 (27%) of individuals (12/46 ABC vs 7/24 NVP; P = .82) with viral load &gt;1000 copies/mL at week 48 experienced resuppression by week 96,",3952602
3822,3952602,Viral load &lt;200 copies/mL,Nevirapine,Abacavir,No significant difference,"The viral load in the majority of participants with suppression was &lt;200 copies/mL in both arms (91% and 95% of those &lt;1000 copies/mL in the ABC and NVP arms, respectively)",3952602
3823,3952602,Thymidine analogue mutations â‰¥3 ,Nevirapine,Abacavir,No significant difference,The proportion of participants with â‰¥3 thymidine analogue mutations (TAMs) at week 96 was similar between the ABC group (49%) and the NVP group (42%) (P = .79).,3952602
3824,5461594,Waist circumference,Omega-3,Placebo (Olive oil),Significantly decreased,"After 6 monthsâ€™ intervention, WC was significantly lower in omega-3 group (81.18 Â± 2.87) as compared to control group (84.22 Â± 2.61) (P &lt; 0.0001).",5461594
3825,5461594,High density lipoprotein (HDL),Omega-3,Placebo (Olive oil),Significantly increased,"High-density lipoprotein was increased (47.2 Â± 1.37 vs. 41.56 Â± 1.34 mg/dl, respectively, P &lt; 0.0001)",5461594
3826,5461594,Low density lipoprotein (LDL),Omega-3,Placebo (Olive oil),Significantly decreased,"LDL was significantly lower in omega-3 group than control group (107.79 Â± 1.68 mg/dl versus 117.4 Â± 1.57 mg/dl, respectively, P &lt; 0.0001)",5461594
3827,5461594,Triglycerides ,Omega-3,Placebo (Olive oil),Significantly decreased,"Also, TG (116.02 mg/dl in omega-3 group vs. 125.06 mg/dl in control group, P &lt; 0.0001) and cholesterol (180.34 mg/dl in omega-3 group vs. 189.56 mg/dl in control group, P &lt; 0.0001) in omega-3 group were significantly lower than control group.",5461594
3828,5461594,Cholesterol,Omega-3,Placebo (Olive oil),Significantly decreased,"Also, TG (116.02 mg/dl in omega-3 group vs. 125.06 mg/dl in control group, P &lt; 0.0001) and cholesterol (180.34 mg/dl in omega-3 group vs. 189.56 mg/dl in control group, P &lt; 0.0001) in omega-3 group were significantly lower than control group.",5461594
3829,5461594,Time between menstrual cycles ,Omega-3,Placebo (Olive oil),Significantly decreased,"The interval between periods in omega-3 was significantly shorter than control (29.83 Â± 4.68 vs. 47.11 Â± 8.72 days, respectively, P &lt; 0.001).",5461594
3830,5461594,Body mass index,Omega-3,Placebo (Olive oil),Significantly decreased,BMI was significantly lower in omega-3 group than control group (P = 0.044),5461594
3831,3144183,"Meet all criteria for ""being cured""",Ivermectin,thiabendazole,No significant difference,"Based on the primary endpoint (all criteria fulfilled), the subjects cured were 60/106 (56.6%) and 48/92 (52.2%) in ivermectin and thiabendazole arm, respectively (pâ€Š=â€Š0.53)",3144183
3832,3144183,Negative stool culture + One IFAT title decreased,Ivermectin,Thiabendazole,No significant difference,"If we considered as cured, with less stringent criteria, also the subjects with a partial response (negative stool culture and decrease of only one IFAT titer), efficacy would rise to 75/106 (70.8%) and to 67/92 (72.8%), respectively (pâ€Š=â€Š0.75).",3144183
3833,3144183,Negative culture after having had positve culture,Ivermectin,Thiabendazole,No significant difference,"If we considered as criteria of cure the direct methods only (negative stool culture at follow-up in subjects who were positive at microscopy and/or culture on recruitment), efficacy would be 30/35 (85.7%) and 35/37 (94.6%), respectively (pâ€Š=â€Š0.21).",3144183
3834,3144183,Side effects (grade 1 to 2),Ivermectin,Thiabendazole,Significantly decreased,"Overall, 103/223 patients complained of any side effect, grade 1 to 2 (Table 5). In ivermectin arm, side effects were observed in 24/115 patients (20.9%), versus 79/108 (73.1%) in thiabendazole arm (pâ€Š=â€Š0.00).",3144183
3835,3144183,Side effects (grade 2),Ivermectin,Thiabendazole,Significantly decreased,"Only 5/115 (4.3%) patients in the ivermectin arm presented effects of grade 2 (requiring medication), while in thiabendazole arm 43/108 patients (39.8) presented effects of grade 2 (pâ€Š=â€Š0.00).",3144183
3836,5832511,CD4 count,ARV,Lipid based nutrient,Significantly increased,Significant differences were only observed for the CD4 counts with higher counts for the groups that received ARV.,5832511
3837,5832511,Iron levels (at 2 weeks),ARV,Lipid based nutrients,No significant difference,"For iron, no interactions by treatment (ARV and LNS) or with treatment and TP and/or FTP were significant indicating that the effects of ARV and LNS at 2, 6, and 24&nbsp;weeks were not different from each other (Table S2).",5832511
3838,5832511,Copper levels (at 2 weeks),ARV,Lipid based nutrients,Significantly decreased,"ARV by TP by FTP interactions were significant for copper (p&nbsp;=&nbsp;.034), whereas ARV by FTP interactions were significant for zinc (p&nbsp;=&nbsp;.031).",5832511
3839,5832511,Copper levels (at 6 weeks),ARV,Lipid based nutrients,No significant difference,"The mixed model analysis for copper and zinc at 2, 6, and 24&nbsp;weeks showed that ARV treatment significantly and negatively affected milk copper and zinc concentrations (p&nbsp;=&nbsp;.044 and p&nbsp;=&nbsp;.014) but only at the initial 2&nbsp;weeks TP.",5832511
3840,5832511,Zinc levels (at 2 weeks),ARV,Lipid based nutrients,Significantly decreased,"ARV by TP by FTP interactions were significant for copper (p&nbsp;=&nbsp;.034), whereas ARV by FTP interactions were significant for zinc (p&nbsp;=&nbsp;.031).",5832511
3841,3160381,Vital capacity (after 3 months),Pirfenidone (high-dose) ,Placebo,Significantly increased,"Significant differences in the distributions of the ratings were consistently observed between high-dose pirfenidone and placebo groups (p = 0.0136, 0.0447, 0.0166, and 0.0053",3160381
3842,3160381,Vital capacity (after 12 months),Pirfenidone (high-dose) ,Placebo,Significantly increased,"Significant differences in the distributions of the ratings were consistently observed between high-dose pirfenidone and placebo groups (p = 0.0136, 0.0447, 0.0166, and 0.0053",3160381
3843,3160381,Vital capacity (after 3 months),Pirfenidone (high and low dose) ,Placebo,Significantly increased,"Significant differences were also seen between high- and low- dose pirfenidone and placebo groups (p = 0.0064, 0.0381, 0.0091, and 0.0010",3160381
3844,3160381,Vital capacity (after 12 months),Pirfenidone (high and low dose) ,Placebo,Significantly increased,"Significant differences were also seen between high- and low- dose pirfenidone and placebo groups (p = 0.0064, 0.0381, 0.0091, and 0.0010",3160381
3845,3160381,Vital capacity (after 3 months),Pirfenidone (low-dose) ,Placebo,Significantly increased,"Significant differences were also seen between high- and low- dose pirfenidone and placebo groups (p = 0.0064, 0.0381, 0.0091, and 0.0010, Risk ratio; 0.561, 0.652, 0.674, and 0.642 at months 3, 6, 9, and 12, respectively) (Figure 1-b), and between low-dose pirfenidone and placebo groups",3160381
3846,4402460,IL-8.,Bevacizumab (1 dose),No treatment,No significant difference,None of these markers showed significant changes in circulating levels between T0 and T1,4402460
3847,4402460, PDGF-AA level,Bevacizumab (2 doses),No treatment,Significantly decreased,"However, small but significant treatment-induced changes between T0 and T2 were observed for PDGF-AA, PDGF-BB, thrombospondin-1, angiopietin-2 and IL-8.",4402460
3848,4402460,IL-8,Bevacizumab (2 doses),No treatment,Significantly decreased,"However, small but significant treatment-induced changes between T0 and T2 were observed for PDGF-AA, PDGF-BB, thrombospondin-1, angiopietin-2 and IL-8.",4402460
3849,4402460,Microvessel density,Bevacizumab (1 dose),No Bevacizumab,Significantly decreased,The MVD shifted from 74 blood vessels per mm2 (36â€“126 blood vessels per mm2) to 62 blood vessels per mm2 (22â€“151 blood vessels per mm2; P=0.02),4402460
3850,4402460,Mature vessels ,Bevacizumab (1 dose),No Bevacizumab,Significantly decreased,the proportion of mature vessels declined from 87% (20â€“98%) before treatment to 73% (35â€“91%) afterwards (T1; P&lt;0.0001).,4402460
3851,4402460,Hypoxia,Bevacizumab (1 dose),No Bevacizumab,No significant difference,"Hypoxia, measured by CA-IX expression, showed a small but nonsignificant increase during bevacizumab treatment from 10 to 20% (P=0.08)",4402460
3852,4141382,Isoflurane consumption,IV Sufentanil ,Caudal Sufentanil + neostigmine,No significant difference,"The isoflurane consumption (ml/kg/h) was similar among the patients from Group IVSu, Group CSuNeo, and Group CSuNeoAdr (P &gt; 0.05)",4141382
3853,4141382,Anesthetics during surgery,Caudal Sufentanil + neostigmine,Caudal Sufentanil + Adrenaline,Significantly decreased,Their intraoperative anesthetic consumption was lesser when compared to patients who received caudal sufentanil alone or in combination with adrenaline (Group CSu = Group CSuAdr) (P &lt; 0.02),4141382
3854,4141382,VAS sedation,Caudal Sufentanil + neostigmine,Caudal Sufentanil + Adrenaline,Significantly decreased,"However, patients who received caudal neostigmine had lower VAS sedation and were classified as more awake at the reversal time (P &lt; 0.005)",4141382
3855,4141382,Time needed for rescue analgesics ,Caudal Sufentanil + neostigmine + Adrenaline,Caudal Sufentanil ,Significantly increased,"The time to first administration of rescue analgesics for patients who received caudal sufentanil plus neostigmine (Group CSuNeo and Group CSuNeoAdr) was similar, but higher when compared to the other groups (10-11 h, P &lt; 0.05)",4141382
3856,4141382,Dipyrone needed,Caudal Sufentanil + neostigmine ,Caudal Sufentanil ,Significantly decreased,"However, patients who received caudal sufentanil and caudal neostigmine (Group CSuNeo and Group CSuNeoAdr) needed lesser doses in 24 h evaluation (P &lt; 0.005)",4141382
3857,3383212,Plasma concentration,Brand-name desogestrel ,Generic desogestrel ,No significant difference,"Plasma concentration-time curves of 3-ketodesogestrel are shown in Figure 1, exhibiting the evident similarity of the plasma level profiles of both formulations.",3383212
3858,3383212, C max,Brand-name desogestrel ,Generic desogestrel ,No significant difference,The 90% CI for the ratio of Cmax (96.14â€“114.53%) and AUC0â€“t (105.73â€“123.83%) values for the test and reference formulations fell within the specified bioequivalent interval (80â€“125%).,3383212
3859,3383212,AUC 0â€“t,Brand-name desogestrel ,Generic desogestrel ,No significant difference,The 90% CI for the ratio of Cmax (96.14â€“114.53%) and AUC0â€“t (105.73â€“123.83%) values for the test and reference formulations fell within the specified bioequivalent interval (80â€“125%).,3383212
3860,3383212,Adverse reactions,Brand-name desogestrel ,Generic desogestrel ,No significant difference,Events were recorded in 28 of the subjects with the test formulation and 31 with the reference formulation.,3383212
3861,3383212,Biological half-life,Brand-name desogestrel ,Generic desogestrel ,No significant difference,Calculated pharmacokinetic parameters of 3-ketodesogestrel for the test and reference formulations are shown in Table 1.,3383212
3862,3383212,T max,Brand-name desogestrel ,Generic desogestrel ,No significant difference,Calculated pharmacokinetic parameters of 3-ketodesogestrel for the test and reference formulations are shown in Table 1.,3383212
3863,4280721,severity of pain in primary dysmenorrhea,extracts of fennelin,placebo,Significantly decreased,"There was no significant difference in the mean of severity of dysmenorrhea during one cycle before the intervention between the four groups, but the difference was significant during two cycles after the intervention. Fennelin had similar effects as vitagnus on dysmenorrhea. Mefenamic acid had less effect than both the drugs (P &lt;0.05).",4280721
3864,4280721,severity of pain in primary dysmenorrhea,extracts of vitagnus,placebo,Significantly decreased,"There was no significant difference in the mean of severity of dysmenorrhea during one cycle before the intervention between the four groups, but the difference was significant during two cycles after the intervention. Fennelin had similar effects as vitagnus on dysmenorrhea. Mefenamic acid had less effect than both the drugs (P &lt;0.05).",4280721
3865,4280721,severity of pain in primary dysmenorrhea,extracts of vitagnus or fennelin,mefenamic acid,Significantly decreased,The effects of the two herbal drugs were the same but higher than that of mefenamic acid.,4280721
3866,4280721,severity of pain in primary dysmenorrhea,mefenamic acid,placebo,Significantly decreased,"There was no significant difference in the mean of severity of dysmenorrhea during one cycle before the intervention between the four groups, but the difference was significant during two cycles after the intervention. Fennelin had similar effects as vitagnus on dysmenorrhea. Mefenamic acid had less effect than both the drugs (P &lt;0.05).",4280721
3867,3637600,Chronic diseases prevention and management,patient-centered care,Preliminary clinical evaluation,Significantly increased,the integration of CDPM services in primary health care practices is a promising care delivery innovation,3637600
3868,3637600,Chronic diseases prevention and management,Practical training,Preliminary clinical evaluation,Significantly increased,the integration of CDPM services in primary health care practices is a promising care delivery innovation,3637600
3869,3637600,Chronic diseases prevention and management,Self-management support,Preliminary clinical evaluation,Significantly increased,the integration of CDPM services in primary health care practices is a promising care delivery innovation,3637600
3870,3637600,Chronic diseases prevention and management,"Education on diseases (diabetes, COPD, asthma, cardiovascular)",Preliminary clinical evaluation,Significantly increased,the integration of CDPM services in primary health care practices is a promising care delivery innovation,3637600
3871,3637600,Chronic diseases prevention and management,"Education on risk factors (pre-diabetes, high blood pressure, dyslipidemias, obesity, physical inactivity, smoking)",Preliminary clinical evaluation,Significantly increased,the integration of CDPM services in primary health care practices is a promising care delivery innovation,3637600
3872,4683729,effectiveness of preventive interventions on Latinos with mental disorders,universal prevention,no prevention,Significantly increased,"Studies have consistently shown that increased physical activity effectively reduces symptoms of depression and anxiety as well as physical functioning risk factors in older adults [24â€“27]. Similarly, increasing pleasant events has been shown to be an effective intervention for geriatric depression [28].",4683729
3873,4683729,effectiveness of preventive interventions on Latinos with mental disorders,selective prevention,no prevention,Significantly increased,"Studies have consistently shown that increased physical activity effectively reduces symptoms of depression and anxiety as well as physical functioning risk factors in older adults [24â€“27]. Similarly, increasing pleasant events has been shown to be an effective intervention for geriatric depression [28].",4683729
3874,4683729,effectiveness of preventive interventions on Latinos with mental disorders,indicated prevention,no prevention,Significantly increased,"Studies have consistently shown that increased physical activity effectively reduces symptoms of depression and anxiety as well as physical functioning risk factors in older adults [24â€“27]. Similarly, increasing pleasant events has been shown to be an effective intervention for geriatric depression [28].",4683729
3875,4683729,effectiveness of preventive interventions on Latinos with mental disorders,the newly refined HOLA,enhanced psychoeducation,Significantly increased,"Studies have consistently shown that increased physical activity effectively reduces symptoms of depression and anxiety as well as physical functioning risk factors in older adults [24â€“27]. Similarly, increasing pleasant events has been shown to be an effective intervention for geriatric depression [28].",4683729
3876,4226329,decrease on attention deficit hyperactivity disorder symptoms,methylphenidate,placebo,Significantly decreased,"In the MPH group, 17 patients (65%, n = 26) decreased symptoms of inattention or hyperactivity by at least 30%, considered as a clinically relevant reduction, compared to seven patients (27%, n = 26) in the placebo group (P = 0.012).",4226329
3877,4226329,reduction of the risk for relapse to substance use in criminal offenders,Methylphenidate treatment,placebo,Significantly decreased,"The ITT analysis of the primary efficacy variable (Fig. 3a) showed a significant difference in the proportion of drug-negative urines in the MPH group (Md = 23%, n = 27) compared to the placebo group (Md = 16%, n = 27) (U = 250, Z = âˆ’1.985, P = 0.047, r = 0.27)",4226329
3878,4357072,improvement in symptom scores,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,Significantly increased,there was a statistically highly significant improvement in reduction of clinical scoring (P &lt; 0.01%),4357072
3879,4357072,reduction in burning sensation,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,No significant difference,there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18),4357072
3880,4357072,reduction in erythematous area,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,No significant difference,there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18) and erythematous area (P = 0.07),4357072
3881,4357072,sustained remission of symptoms,pimecrolimus,triamcinolone acetonide,Significantly increased,"Following the termination of the treatment, sustained remission of symptoms and long-lasting therapeutic effects was detected in 93.3% of the patients treated with pimecrolimus.",4357072
3882,4357072,reappearance of erythematous areas after 2 months posttreatment,pimecrolimus,triamcinolone acetate,No significant difference,"After the posttreatment follow-up of 2 months, the erythematous areas reappeared in 6.7% and 33.3% subjects in the pimecrolimus and triamcinolone acetonide groups, respectively, but no statistical difference was found (P = 0.07)",4357072
3883,5564101,increase on the effect of an elevated concentration of lidocaine hydrochloride in the surgical removal of an impacted lower third molar,"4% lidocaine along with 1:100,000 epinephrine","2% lidocaine along with 1:100,000 epinephrine",No significant difference,"the extent of pulpal anesthesia, surgical duration, and duration of soft tissue anesthesia were not significantly different.",5564101
3884,5564101,the duration of anesthesia,"4% lidocaine along with 1:100,000 epinephrine","2% lidocaine along with 1:100,000 epinephrine",No significant difference,"the duration of anesthesia with 4% lidocaine was longer than that with 2% (228 Â± 55 min vs. 207 Â± 54 min), although this was not significantly different.",5564101
3885,5564101,The onset speed of anesthesia,"4% lidocaine along with 1:100,000 epinephrine","2% lidocaine along with 1:100,000 epinephrine",Significantly increased,"The onset of anesthesia was significantly more rapid with 4% lidocaine than 2% lidocaine (subjective onset: 113 Â± 63 and 159 Â± 57 min, respectively, after administration; objective onset: 5.46 Â± 2.02 and 8.19 Â± 4.24 min, respectively).",5564101
3886,5564101,the intensity of intra-operative pain during the administration of the drug,"4% lidocaine along with 1:100,000 epinephrine","2% lidocaine along with 1:100,000 epinephrine",No significant difference,"the 4% lidocaine group experienced more pain (20.77 Â± 23.3 mm) than the 2% group (16.51 Â± 14.21 mm), but the difference was not statistically significant.",5564101
3887,5564101,The number of cases requiring additional anesthetic,"2% lidocaine along with 1:100,000 epinephrine","4% lidocaine along with 1:100,000 epinephrine",Significantly increased,The proportion of cases requiring additional anesthetic was significantly greater in the 2% lidocaine group than in the 4% group (26/36 vs. 16/31; P = 0.006).,5564101
3888,5797014,"the prognostic value of CEA, CA19-9, CA72-4 combined on gastric cancer",three-tumor marker classifier,"CEA, CA19-9 and CA72-4 alone",Significantly increased,"As demonstrated in previous literature, when used as a combination, these markers had the ability to increase the sensitivity and accuracy for survival prediction",5797014
3889,5797014,cancer specific survival,three-tumor marker classifier,"CEA, CA19-9 and CA72-4 alone",Significantly increased,"As demonstrated in previous literature, when used as a combination, these markers had the ability to increase the sensitivity and accuracy for survival prediction",5797014
3890,3984270,primary dysfunction after kidney transplant,Î±-melanocyte stimulating hormone (Î±-MSH),control group,Significantly increased,Î±-MSH treatment reduced urine flow and impaired recovery of glomerular filtration rate (GFR) compared to controls.,3984270
3891,3984270,inflammation after kidney transplant,Î±-melanocyte stimulating hormone (Î±-MSH),control group,No significant difference,Î±-MSH did not affect expression of inflammatory markers.,3984270
3892,3984270,short-term graft function,Î±-melanocyte stimulating hormone (Î±-MSH),control group,No significant difference,in a porcine experimental model Î±-MSH did not reduce renal inflammation and did not improve short-term graft function following DBD kidney transplantation.,3984270
3893,3984270,Urine flow,Î±-MSH,controls,Significantly decreased,"During ten hours follow-up, urine output was significantly lower in the Î±-MSH group compared to the controls (Figure 2, p&lt;0.05)",3984270
3894,3984270,time of recovery,Î±-MSH group,controls,Significantly increased,Î±-MSH treatment tended to impair recovery of GFR (Figure 3A) during ten hours follow-up compared to controls.,3984270
3895,3846267,Baseline characteristics,Mitomycine C,Acetic acid,No significant difference,"The number of men and women in both groups were similar. The time period, the long-lasting Otorrhea and the degree of involvement of disease were similar in both groups.",3846267
3896,3846267,Dry cavity after 1 month of treatment,Mitomycine C,Acetic acid,Significantly increased,"one month later, this percentage (complete dry mastoid) in the MMC group was 72% and for Acid group was 20% that was statistically significant (P&lt;0.05).",3846267
3897,3846267,Involvement with granulation tissue in the mastoid cavity at the third phase of treatment,Mitomycine C,Acetic acid,Significantly decreased,"In the third phase of treatment of topical MMC only 7 patients (28%) had involvement with granulation tissue in the mastoid cavity and this is less than 25% involvement but the percentage of patients in acetic acid group that involved in more than 25% mastoid involvement was 17 patients (68%), which was again statistically signi- ficant (P&lt;0.05).",3846267
3898,3846267,Dry cavity after 3 months of treatment,Mitomycine C,Acetic acid,Significantly increased,"After three months of follow up, the final result of using topical MMC and acetic acid was evaluated and the incidence of dry cavity with no granulation tissue was 92% in MMC group whereas it was 24% in Acid group, which was statistically significant (P&lt;0.05).",3846267
3899,3846267,Patients with 25% involvement with granulation tissue in the mastoid cavity after three months,Mitomycine C,Acetic acid,Significantly decreased,"At the same time the percentage of patients with 25% involvement mastoid cavity with granulation was 8% in the MMC group (two patients) and 19 patients (76%) in Acid group, which was again statistically significant difference.",3846267
3900,4709811,Improvement in urinary incontinence,Hyaluronic acid,Conjugated estrogen (Premarin),Significantly increased,Urinary incontinence only showed improvement in the hyaluronic acid group (P&lt;0.05),4709811
3901,4709811,Improvement in vaginal dryness,Hyaluronic acid,Conjugated estrogen (Premarin),Significantly increased,"Improvement in urinary incontinence, dryness, maturation index (P&lt;0.05) and composite score of vaginal symptoms (P&lt;0.001) in the hyaluronic acid group was better than those in the Premarin group.",4709811
3902,4709811,Improvement in the composite score of vaginal symptoms,Hyaluronic acid,Conjugated estrogen (Premarin),Significantly increased,"Improvement in urinary incontinence, dryness, maturation index (P&lt;0.05) and composite score of vaginal symptoms (P&lt;0.001) in the hyaluronic acid group was better than those in the Premarin group.",4709811
3903,4709811,Vaginal pH,Hyaluronic acid,Conjugated estrogen (Premarin),No significant difference,"studies showed that comparing the results of intra-group (before and after treatment), the amount of PH of both groups reduced, moving towards acidity (P&lt;0.001) and no significant difference was obtained when the results of both groups were compared (P&gt;0.05)",4709811
3904,4709811,Baseline characteristics,Hyaluronic acid,Conjugated estrogen (Premarin),No significant difference,"from the view point of age, menarche, age of menopause beginning, number of pregnancies, occupation, education, disease history and drug consumption both therapeutic groups were similar and the Chi-square test did not show any statistical significant difference (P&gt;0.05)",4709811
3905,3694465,Placement of hands in the abdominal region,Specific instructions,General instructions,Significantly decreased,None in the intervention group placed their hands in the abdominal region vs. 5/18 in the control group (pâ€‰=â€‰0.045),3694465
3906,4231047,Minimal mean hepatic threshold dose 6 weeks after radiotherapy,"Pentoxifylline, ursodeoxycholic acid, and low-dose low molecular weight heparin.",No medication,Significantly increased,"The minimal mean hepatic threshold dose at 6 weeks after BT (primary endpoint) was significantly higher in the study treatment group than the control (19.1 Gy versus 14.6 Gy, pâ€Š=â€Š0.011",4231047
3907,4231047,Focal radiation-induced liver injury at 12 weeks,"Pentoxifylline, ursodeoxycholic acid, and low-dose low molecular weight heparin.",No medication,No significant difference,Qualitative evidence of fRILI by MRI at 6 weeks was observed in 45.5% of patients in the treatment versus 90.9% of the control group. No significant differences between the groups were observed at the 12-week follow-up.,4231047
3908,4231047,EQ5D and distribution of ECOG performance status,"Pentoxifylline, ursodeoxycholic acid, and low-dose low molecular weight heparin.",No medication,No significant difference,EQ5D (as a descriptor of quality of life) and distribution of ECOG performance status were not significantly different at baseline (Table 2) or at any follow-up visit (Table S1).,4231047
3909,4231047,Median overall survival after radiotherapy,"Pentoxifylline, ursodeoxycholic acid, and low-dose low molecular weight heparin.",No medication,No significant difference,Median overall survival from time of BT on was not different between the groups with 30.0 months (95%CI: 8.7â€“51.3) in the treatment group and 39.5 months (27.5â€“51.5) in the control group (pâ€Š=â€Š0.430).,4231047
3910,5103331,Improvement of Rhinoconjunctivitis Quality of Life Questionnaire score after 4 weeks,Active catgut implantation group,Sham catgut implantation group,No significant difference,"the RQLQ scores significantly differed between the two groups after 4&nbsp;weeks of treatment completion (tâ€‰=â€‰âˆ’2.045, Pâ€‰=â€‰0.05)",5103331
3911,5103331,Improvement of Rhinoconjunctivitis Quality of Life Questionnaire score after 8 weeks,Active catgut implantation group,Sham catgut implantation group,Significantly increased,"the RQLQ scores significantly differed between the two groups after 4&nbsp;weeks of treatment completion (tâ€‰=â€‰âˆ’2.045, Pâ€‰=â€‰0.05) and this difference lasted until the end of 8-week follow-up (tâ€‰=â€‰âˆ’2.246, Pâ€‰=â€‰0.033).",5103331
3912,5103331,Intake of relief medication,Active catgut implantation group,Sham catgut implantation group,No significant difference,"Throughout the treatment regimen, none of the participants took any relief medication",5103331
3913,5103331,Rate of adverse events,Active catgut implantation group,Sham catgut implantation group,No significant difference,no severe adverse events occurred.,5103331
3914,5103331,Improvement in visual analogue scale scores after 8 weeks,Active catgut implantation group,Sham catgut implantation group,Significantly increased,"For the analysis based on VAS scores, the difference between the treatment group and the sham-controlled group was not significant until 8&nbsp;weeks after the 2-week treatment regimen (tâ€‰=â€‰âˆ’2.424, Pâ€‰=â€‰0.017; Table&nbsp;4)",5103331
3915,3914313,Mean heart rate ,Shensong Yangxin,Placebo,Significantly increased,"Results showed that the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the control group at the end of treatment (P &lt; 0.05 or 0.01, resp.)",3914313
3916,3914313,Fastest heart rate ,Shensong Yangxin,Placebo,Significantly increased,"Results showed that the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the control group at the end of treatment (P &lt; 0.05 or 0.01, resp.)",3914313
3917,3914313,Lowest heart rate ,Shensong Yangxin,Placebo,Significantly increased,"Results showed that the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the control group at the end of treatment (P &lt; 0.05 or 0.01, resp.)",3914313
3918,3914313,Improvement of symptom scores,Shensong Yangxin,Placebo,Significantly increased,"ompared with the control group, the symptom score in the trial group was significantly lower (P &lt; 0.01).",3914313
3919,3914313,Severe adverse effects,Shensong Yangxin,Placebo,No significant difference,No severe adverse effects were reported.,3914313
3920,4697245,Changes in diastolic blood pressure 1 minute after induction of anaesthesia,Alfentanil,Placebo,Significantly decreased,"Changes in diastolic blood pressure were significantly less in alfentanil group, 1 min after induction of anaesthesia and 1 min after endotracheal intubation.",4697245
3921,4697245,Changes in diastolic blood pressure 1 minute after endotracheal extubation,Alfentanil,Placebo,Significantly decreased,"Changes in diastolic blood pressure were significantly less in alfentanil group, 1 min after induction of anaesthesia and 1 min after endotracheal intubation.",4697245
3922,4697245,Baseline characteristics,Alfentanil,Placebo,No significant difference,Mean of age (years) of patients was 28.4 Â± 5.77 in alfentanil group and 27.12 Â± 5.79 in placebo group. Average weight (kg) of patients was 75.8 Â± 10.4 in alfentanil group and 80.4 Â± 7.5 in placebo group. The two groups were comparable with respect to pre-operative haemodynamic parameters and BISÂ®,4697245
3923,4697245,Neonatal Apgar scores at 1 and 5 min,Alfentanil,Placebo,No significant difference,Mean of neonatal Apgar scores at 1 and 5 min and neonatal SpO2 were not significantly differerent between the two groups [,4697245
3924,4697245,Heart rate at 1 minute after induction of anesthesia and intubation,Alfentanil,Placebo,Significantly decreased,"There were significant statistical differences between the two groups in regard to mean heart rate 1 min after induction of anaesthesia (P = 0.01), 1 min after endotracheal intubation (P = 0.000) and 5 min after endotracheal intubation (P = 0.04)",4697245
3925,5220753,Mortality rate,Eptifibatide,Control,No significant difference,"The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; P &gt; 0.05 considered significant for all comparisons.",5220753
3926,5220753,Stent thrombosis or Myocardial Infarction,Eptifibatide,Control,No significant difference,"The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; P &gt; 0.05 considered significant for all comparisons.",5220753
3927,5220753,Target lesion revascularization and target vessel revascularization,Eptifibatide,Control,No significant difference,"The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; P &gt; 0.05 considered significant for all comparisons.",5220753
3928,5220753,Emergency CABG,Eptifibatide,Control,No significant difference,"In this study we did not find any significant to statistical differences between the eptifibatide group and the control group in clinical outcomes such as cardiac and noncardiac death, ST, MI, TLR, TVR, CVA, and emergency CABG (P &gt; 0.05).",5220753
3929,5220753,Cerebral vascular accident,Eptifibatide,Control,No significant difference,"The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; P &gt; 0.05 considered significant for all comparisons.",5220753
3930,4793655,Sway in the A/P direction,Attractive cuing,Repulsive cuing,Significantly increased,Sway in the A/P direction (A/P RMS) was significantly smaller (~1Â°) for repulsive versus attractive cues (pâ€‰&lt;â€‰0.001),4793655
3931,4793655,Rate of improvement,Attractive cuing,Repulsive cuing,Significantly increased,the rate of improvement was greater for attractive versus repulsive cuing.,4793655
3932,4793655,Time spent in the no feedback zone,Attractive cuing,Repulsive cuing,Significantly decreased,Subjects spent slightly more time (~1&nbsp;%) in the no feedback zone (Time-in-Zone) when using repulsive cues (pâ€‰&lt;â€‰0.001),4793655
3933,4793655,Peak A/P tilts for the MCT and ADT perturbations,Attractive cuing,Repulsive cuing,Significantly increased,Peak A/P tilts for the MCT and ADT perturbations (Fig.&nbsp;3) were significantly smaller for all conditions with repulsive cuing (pâ€‰=â€‰0.001).,4793655
3934,4793655,Rate of return to the feedback zone after the perturbation,Attractive cuing,Repulsive cuing,Significantly decreased,"the percentage of trials in which subjects returned to the no feedback zone after the perturbation was significantly larger for repulsive cuing versus attractive cuing (Fig 3,&nbsp;pâ€‰=â€‰0.01).",4793655
3935,4960789,Peripheral intravenous catheter failure rates per 1000 hours,0.9&nbsp;% sodium chloride 10&nbsp;mL flush,0.9&nbsp;% sodium chloride 3&nbsp;mL flush,No significant difference,"PIVC failure rates per 1000&nbsp;hours were not significantly different for the volume intervention (4.84 [3&nbsp;mL] versus 7.44 [10&nbsp;mL], pâ€‰=â€‰0.06, log-rank).",4960789
3936,4960789,Peripheral intravenous catheter failure rates per 1000 hours,Flush frequency every 24 hours,Flush frequency every 6 hours,No significant difference,"PIVC failure rates per 1000&nbsp;hours were also not significantly different for the frequency intervention (5.06 [24&nbsp;hour] versus 7.34 [6&nbsp;hour], pâ€‰=â€‰0.05, log-rank).",4960789
3937,4960789,Peripheral intravenous catheter failure rates per 1000 hours,Flush frequency,Flush volume,No significant difference,"There was no significant interaction between the two study interventions (pâ€‰=â€‰0.21, Cox, Table&nbsp;3); i.e. the results for comparison of the two volumes were not affected by the frequency, and the results for comparison between the two frequencies were also not affected by the volume.",4960789
3938,5560591,Postoperative numerical rating scale at 30 min and 2 hours,2 Hertz EA stimulation,Control group,Significantly decreased,The mean NRS was 2.75 (SD = 2.34) at 30 minutes and 2.25 (SD = 1.80) at 2 hours postoperatively in the EA group that was significantly lower than the mean NRS in the control group as 4.50 (SD = 2.37) at 30 minutes and 3.88 (SD = 2.21) at 2 hours.,5560591
3939,5560591,Mean patient-controlled analgesia morphine demand,2 Hertz EA stimulation,Control group,Significantly decreased,"The mean PCA morphine demand was 27.28 (SD = 21.61) times pressed in the EA group and 55.25 (SD = 46.85) times pressed in the control group within 24 hours postoperatively, which showed a significant reduction in the EA group than the control group.",5560591
3940,5560591,Total need of morphine ,2 Hertz EA stimulation,Control group,Significantly decreased,total morphine requirement was significantly lower in the EA group with the value of 21.38 (SD = 14.38) mg compared to the control group with the value of 33.94 (SD = 20.24) mg within 24 hours postoperatively.,5560591
3941,5560591,Incidence of nausea 30 min after surgery,2 Hertz EA stimulation,Control group,Significantly decreased,Incidence of postoperative nausea significantly reduced in EA group at 30 minutes compared to control group (P value &lt; 0.05),5560591
3942,5560591,Mean pain score at 30 mins and 2 hours after surgery,2 Hertz EA stimulation,Control group,Significantly decreased,"In this study, the mean pain score was significantly lower in the EA group than the control group at 30 minutes and 2 hours (P value &lt; 0.05).",5560591
3943,5593668,Metastasis and relapse rates,Adjuvant S-1 therapy after sugery,Surgery alone,Significantly decreased,Rates of metastasis and relapse were lower in the S-1 than in the surgery-only group for all sites,5593668
3944,5593668,"Expression of GGH, PECAM1, or TOP2A ",Adjuvant S-1 therapy after sugery,Surgery alone,No significant difference,"There were no statistically significant interactions between GGH, PECAM1, or TOP2A expression and S-1 treatment at the respective recurrence sites",5593668
3945,5593668,Peritoneal recurrence related to PECAM1 expression,Adjuvant S-1 therapy after sugery,Surgery alone,No significant difference,PECAM1 showed a significant correlation to peritoneal recurrence in both surgery alone (FDR P = 0.005) and S-1 treated patients (FDR P = 0.031).,5593668
3946,5593668,Hematogenous recurrence related to TOP2A expression,Adjuvant S-1 therapy after sugery,Surgery alone,Significantly decreased,TOP2A expression correlated significantly with hematogenous recurrence in the surgery alone group but not in S-1 treated patients.,5593668
3947,4824463,Proportion of patients with fever receiving ACT,Rapid diagnostic tests,Clinical judgement,Significantly decreased,The proportion of fever cases receiving ACT was lower in the RDT arm (72% vs 81%; p = 0.02).,4824463
3948,4824463,Incidence of moderate or severe anaemia after the first episode of fever,Rapid diagnostic tests,Clinical judgement,No significant difference,"After the first episode of febrile illness, the incidence of severe anaemia was the same in both arms (0.11 per child per year) and that of moderate anaemia was 0.16 (0.13â€“0.21) vs. 0.17 (0.14â€“0.21) per child year respectively.",4824463
3949,4824463,Incidence of the overall episodes of malaria,Rapid diagnostic tests,Clinical judgement,No significant difference,"The incidence of all episodes (first or repeat) of malaria was 0.99 per child per year (95% CI 0.78, 1.27) in the RDT arm compared to 1.05 per child per year (95% CI 0.87, 1.29) in the CJ arm. There was no significant difference in the incidence of all episodes of malaria following the first episode of febrile illness (adjusted rate Ratio 1.13, 0.82â€“1.55)",4824463
3950,4824463,Incidence of severe febrile illness per child and year,Rapid diagnostic tests,Clinical judgement,No significant difference,The incidence of severe febrile illness after a first episode was 0.15 (0.09â€“0.24) per child per year in the RDT arm compared with 0.17 (0.11â€“0.28) among children in the CJ arm (p = 0.78).,4824463
3951,4824463,Rates of mortality,Rapid diagnostic tests,Clinical judgement,No significant difference,There were 21 (1.4%) deaths in the CJ arm compared with 15(1.0%) deaths in the RDT-arm. The difference was not statistically significant (p = 0.31).,4824463
3952,4844154,Tinnitus suppression,Tinnitus Implant,Cochlear Implant,No significant difference,No significant difference in tinnitus suppression was found between the standard clinical CI and the TI.,4844154
3953,4844154,Depression,Tinnitus Implant ,Cochlear Implant,No significant difference,"no statistically significant differences on tinnitus related outcomes, depression and quality-of-life between TI and CI could be found",4844154
3954,4844154,Tinnitus related outcomes,Tinnitus Implant ,Cochlear Implant,No significant difference,"no statistically significant differences on tinnitus related outcomes, depression and quality-of-life between TI and CI could be found",4844154
3955,4844154,Quality-of-life scores,Tinnitus Implant ,Cochlear Implant,No significant difference,"no statistically significant differences on tinnitus related outcomes, depression and quality-of-life between TI and CI could be found",4844154
3956,4440033,Overall reduction in serum interleukin-6 after 12 weeks,Vitamin D + Calcium,Calcium ,No significant difference,"At week 12, serum IL-6 was reduced in both groups (p = 0.001)",4440033
3957,4440033,Serum interleukin-10,Vitamin D + Calcium,Calcium ,Significantly increased,serum IL-10 was maintained in the Vitamin D + C group (p = 0.06) and was reduced in the Calcium group (p = 0.001).,4440033
3958,4440033, Serum interleukin-6 in non-diabetic patients,Vitamin D + Calcium,Calcium ,Significantly decreased,serum IL-6 only reduced in the Vitamin D + C arm in non diabetic subgroup,4440033
3959,4440033,Serum hs-CRP,Vitamin D + Calcium,Calcium ,No significant difference,Calcium supplementation with or without calcitriol in our study had no effect on hs-CRP levels independent of their diabetic's status and is consistent with previous studies,4440033
3960,4440033,Serum 25-OHD after 12 weeks,Vitamin D + Calcium,Calcium ,Significantly increased,In our patients both treatment arms had an increment in their median serum 25-OHD levels at 12 weeks but the increment was higher in the Vitamin D + C group.,4440033
3961,4808543,Improvement of Total Nasal Symptom Score,Aromatherapy oil inhalation,Almond oil inhalation,Significantly increased,"Compared with the placebo, the experimental group showed significant improvement in TNSS, especially in nasal obstruction.",4808543
3962,4808543,Improvement of Rhinoconjunctivitis Quality of Life Questionnaire scores,Aromatherapy oil inhalation,Almond oil inhalation,Significantly increased,The aromatherapy group also showed significantly higher improvements in total score of RQLQ and CFS.,4808543
3963,4808543,Improvement of fatigue level by Chalder Fatigue Scale,Aromatherapy oil inhalation,Almond oil inhalation,Significantly increased,The aromatherapy group also showed significantly higher improvements in total score of RQLQ and CFS.,4808543
3964,4808543,Baseline characteristics,Aromatherapy oil inhalation,Almond oil inhalation,No significant difference,"There were no significant differences among the two groups in general characteristics and baseline outcome measures, indicating statistical homogeneity",4808543
3965,4412792,Glomerulosclerosis at day 14,Enalapril,Hydralazine,Significantly decreased,Both glomerulosclerosis and urinary albumin-to-creatinine ratio were less in the ACE-inhibition arm at day 14.,4412792
3966,4412792,Urinary albumin-to-creatinine ratio at day 14,Enalapril,Hydralazine,Significantly decreased,Both glomerulosclerosis and urinary albumin-to-creatinine ratio were less in the ACE-inhibition arm at day 14.,4412792
3967,4412792,Podocyte proliferation,Enalapril,Hydralazine,No significant difference,Podocyte proliferation did not occur at any time in any group.,4412792
3968,4412792,Decrease in blood pressure ,Enalapril,Hydralazine,No significant difference,"The decrease in systolic BP and diastolic BP was similar in FSGS mice treated with hydralazine and enalapril on day 4 (111/66 mmHg, enalapril; 118/75 mmHg, hydralazine, p &gt; 0.05), day 6 (101/63 mmHg, enalapril; 114/77 mmHg, hydralazine, p &gt; 0.05) and day 13 (90/58 mmHg, enalapril; 97/66 mmHg, hydralazine, p &gt; 0.05).",4412792
3969,4412792,Amount of PAX2+/p-ERK+-positive cells,Enalapril,Hydralazine,Significantly increased,"Enalapril further increased the number of PAX2+/p-ERK+-positive cells approximately two-fold at day 7 (1.40Â±0.16, p &lt; 0.01 vs. hydralazine-treated FSGS mice) (Figure 8(f)).At day 14 of FSGS, the number of PAX2+/p-ERK+ cells increased along Bowmanâ€™s capsule in untreated mice (1.04Â±0.16 per Bowmanâ€™s capsule cross section, p &lt; 0.001 vs. normal) and hydralazine treated mice with FSGS (1.03Â±0.13, p &lt; 0.001 vs. normal) (Figure 8(f)). This was further increased by enalapril (1.46Â±0.19, p &lt; 0.05, vs. hydralazine).",4412792
3970,2748711,Matrix metalloproteinases in cerebrospinal fluid in early treatment,Dexamethasone,Placebo,Significantly decreased,Dexamethasone significantly reduced CSF MMP-9 concentrations in early follow up samples (median 5 days (range 3â€“8) of treatment),2748711
3971,2748711,Baseline TIMP-2,Dexamethasone,Placebo,Significantly decreased,"Baseline pre-treatment concentrations of MMPs and TIMPs are summarized in table 2 and are similar between the two groups with the exception of TIMP-2, which was significantly higher in the patients give placebo.",2748711
3972,2748711,Matrix metalloproteinases in cerebrospinal fluid in late treatment,Dexamethasone,Placebo,No significant difference,MMP-9 concentrations at later time points were not statistically different between the two groups.,2748711
3973,5307611,Mean scores of the constructs of the Protection Motivation Theory at baseline,Theory-based educational intervention,Control group,No significant difference,"Before the intervention, no significant difference in mean (SD) scores of the constructs of the Protection Motivation Theory was found between the two groups (p&gt;0.05)",5307611
3974,5307611,SCPBs,Theory-based educational intervention,Control group,Significantly increased,"The comparison of SCPBs (use of sunscreen or sun block lotion, long-sleeved shirts, wide-brimmed hats, and stay in shade) in the intervention and control groups before and after the intervention is presented in Tables 3 and 4 (p&lt;0.05).",5307611
3975,5307611,Perceived susceptibility,Theory-based educational intervention,Control group,Significantly increased,"The findings showed that perceived susceptibility in the intervention group increased significantly compared to the control group 3 months after the intervention, showing that the educational program has been effective on perceived susceptibility among the rural farmers in the intervention group",5307611
3976,4260664,Beck Depression Inventory-II score,Internet-based cognitive behavior therapy,Treatment-as-usual,No significant difference,"The analyses revealed no significant difference between the two groups at post treatment, neither on BDI-II, MADRS-S, nor BAI.",4260664
3977,4260664,Montgomery Ã…sberg Depression Rating Scale score,Internet-based cognitive behavior therapy,Treatment-as-usual,No significant difference,"The analyses revealed no significant difference between the two groups at post treatment, neither on BDI-II, MADRS-S, nor BAI.",4260664
3978,4260664,Beck Anxiety Inventory,Internet-based cognitive behavior therapy,Treatment-as-usual,No significant difference,"The analyses revealed no significant difference between the two groups at post treatment, neither on BDI-II, MADRS-S, nor BAI.",4260664
3979,4260664,Baseline characteristics,Internet-based cognitive behavior therapy,Treatment-as-usual,No significant difference,A comparison of baseline scores revealed no significant difference between treatment groups and the randomization as expected produced a similar distribution across conditions (see Table 1). Ï‡2 tests failed to reveal any significant between-group differences in demographic characteristics.,4260664
3980,3376478,Open communication,Parental monitoring,Control group,No significant difference,Similar effects were found in both the intervention and control group models regarding open communication.,3376478
3981,3376478,Association of parental beliefs with change in parental monitoring,Parental monitoring,Control group,Significantly increased,"In contrast to models predicting patterns of open communication, associations between parental attitudes, and teen-reported parental monitoring differed between intervention and control group models. Within the intervention group model but not the control group model, parental beliefs about the normative nature of teen risk taking behavior were positively associated with longitudinal change in parental monitoring.",3376478
3982,3738485,Increase in fat free body mass,Spirulina Platensis,Soya Beans,Significantly increased,"when compared between the two groups at the end of the trial, FFM was significantly higher in the spirulina group (42.2 vs. 39.0 Kg, P = 0.01).",3738485
3983,3738485,Increment of the haemoglobin level,Spirulina Platensis,Soya Beans,No significant difference,The haemoglobin level rose significantly within groups (P &lt; 0.001 for each group) with no difference between groups (P = 0.77).,3738485
3984,3738485,Increase in serum albumin levels,Spirulina Platensis,Soya Beans,No significant difference,Serum albumin level did not increase significantly within groups (P &lt; 0.90 vs. P &lt; 0.82) with no difference between groups (P = 0.39).,3738485
3985,3738485,Increase in CD4 T lymphocyte count,Spirulina Platensis,Soya Beans,Significantly increased,"The increase in CD4 cell count within groups was significant (P &lt; 0.01 in both groups), with a significantly higher CD4 count in the spirulina group compared to subjects on soya beans at the end of the study (P = 0.02).",3738485
3986,3738485,Decrease in HIV viral load,Spirulina Platensis,Soya Beans,Significantly decreased,"The variation of viral load is reported in table 7: in patients receiving spirulina, the viral load significantly decreased at the end of the study as opposed to the subjects on soya (P = 0.02).",3738485
3987,4222660,Decrease in average Sugar Sweetened Beverages Consumption,The water campaign,Their regular health promotion programme,Significantly decreased,"Average SSB consumption in the intervention group was significantly lower than that in the control group (B -0.19 litres per day, 95% CI -0.28;-0.10, pâ€‰&lt;â€‰0.001).",4222660
3988,4222660,Decrease in the number of Sugar Sweetened Beverages servings,The water campaign,Their regular health promotion programme,Significantly decreased,"The decrease in the number of SSB servings was also significantly higher in the intervention group than in the control group (B -0.54 servings per day, 95% CI -0.82;-0.26, pâ€‰&lt;â€‰0.001).",4222660
3989,5486467,Decrease in serum phosphorus levels,PA21,Placebo,Significantly decreased,The change in serum phosphorus level was significantly greater in each PA21 group than in the placebo group (analysis of covariance: P&nbsp;&lt;&nbsp;0.001 for all groups).,5486467
3990,5486467,Cumulative achievement rates of target serum phosphorus levels,PA21,placebo,Significantly increased,"The cumulative achievement rates were significantly higher in all the PA21 groups than in the placebo group (all *&nbsp;P&nbsp;&lt;&nbsp;0.001, Fisherâ€™s exact test)",5486467
3991,5486467,Time course of mean serum phosphorus levels,PA21,placebo,Significantly increased,"Time course of mean serum phosphorus levels (full analysis set). The mean serum phosphorus levels were significantly higher in all the PA21 groups in all the time-points after administering the PA21 dose (all P&nbsp;&lt;&nbsp;0.001, one-sample t test)",5486467
3992,3972946,the score of the Visual Analog Scale at rest (VASr),Preemptive Thoracic Epidural Analgesia (Group P),Conventional Postoperative Epidural Analgesia (Group C),Significantly decreased,"Both VASr and VASc scores in Group P were lower than in Group C at postoperative 1st, 2nd, and 4th hours (P &lt; 0.01)",3972946
3993,3972946,the score of the Visual Analog Scale while coughing (VASc),Preemptive Thoracic Epidural Analgesia (Group P),Conventional Postoperative Epidural Analgesia (Group C),Significantly decreased,"Both VASr and VASc scores in Group P were lower than in Group C at postoperative 1st, 2nd, and 4th hours (P &lt; 0.01)",3972946
3994,3972946,Patient's demand and pump's delivery count for bolus dose,Preemptive Thoracic Epidural Analgesia (Group P),Conventional Postoperative Epidural Analgesia (Group C),Significantly decreased,"When PCEA pump was examined, patient's demand and pump's delivery count for bolus dose in Group P were lower than in Group C on all measurement times (P &lt; 0.01)",3972946
3995,3972946,Total analgesic requirements on postoperative 1st and 24th hours,Preemptive Thoracic Epidural Analgesia (Group P),Conventional Postoperative Epidural Analgesia (Group C),Significantly decreased,"When the additional analgesic requirement was compared, total tramadol amount on postoperative 1st and 24th hours in Group P was lower than in Group C (postoperative 1st hour: 17.5 Â± 14.4, 45.0 Â± 22.3, postoperative 24th hour: 75.0 Â± 63.8, 130.0 Â± 89.4, resp.) (P &lt; 0.01 and P &lt; 0.05, resp.)",3972946
3996,3972946,Side effects,Preemptive Thoracic Epidural Analgesia (Group P),Conventional Postoperative Epidural Analgesia (Group C),No significant difference,There were no differences between the groups with respect to side effects.,3972946
3997,5504600,Incidence of constipation,perioperative oral extended-release tapentadol,extended-release oxycodone/naloxone,No significant difference,The incidence of constipation was 35% in the tapentadol vs. 30% in the oxycodone/naloxone group (pâ€‰=â€‰0.33).,5504600
3998,5504600,Total score of side effect events,perioperative oral extended-release tapentadol,extended-release oxycodone/naloxone,No significant difference,"The sum score of side effect events was 51% in the tapentadol vs. 49% in the oxycodone/naloxone group; risk difference 3% [95% CI, âˆ’8 to 14%]; pâ€‰=â€‰0.6).",5504600
3999,5504600,Incidence of Vomiting on day 1,perioperative oral extended-release tapentadol,extended-release oxycodone/naloxone,No significant difference,Vomiting on day 1 occurred in 11% of the tapentadol and in 16% of the oxycodone/naloxone patients (pâ€‰=â€‰0.60).,5504600
4000,5504600,Pain intensity during exercise in the first 24h of post operatory,perioperative oral extended-release tapentadol,extended-release oxycodone/naloxone,No significant difference,"Mean maximum pain intensity during exercise in the first 24&nbsp;h after surgery was 3.8â€‰Â±â€‰1.9 (tapentadol) and 3.8â€‰Â±â€‰2.1 (oxycodone/naloxone; difference in means âˆ’0.06 [95% CI, âˆ’0.54 to 0.42]; pâ€‰=â€‰0.8).",5504600
4001,4879328,weight loss,"Get Healthy, Stay Healthyâ€™ (GHSH)",no continued contact,Significantly increased,"Intervention group improvements were significantly greater than controls for weight loss (âˆ’1.35 kg, 95% CI: âˆ’2.24, âˆ’0.46, P=.003), but not for waist circumference ( P=.115; Table 3).",4879328
4002,4879328,waist circumference,"Get Healthy, Stay Healthyâ€™ (GHSH)",no continued contact,No significant difference,"Intervention group improvements were significantly greater than controls for weight loss (âˆ’1.35 kg, 95% CI: âˆ’2.24, âˆ’0.46, P=.003), but not for waist circumference ( P=.115; Table 3).",4879328
4003,4879328,effects for walking and vigorous activity,"Get Healthy, Stay Healthyâ€™ (GHSH)",no continued contact,No significant difference,Intervention effects for walking and vigorous activity were not significant (Table 3).,4879328
4004,4879328,FFBQ Total Index Score,"Get Healthy, Stay Healthyâ€™ (GHSH)",no continued contact,Significantly increased,"In the intervention group, small, but statistically significant improvements in dietary outcomes were observed for the FFBQ Fiber and Total Indices, while remaining dietary outcomes, except takeaway meals per week, were all maintained (Table 2).",4879328
4005,4879328,weekly moderate physical activity sessions,"Get Healthy, Stay Healthyâ€™ (GHSH)",no continued contact,Significantly increased,"Significant intervention effects, all favoring the intervention group, were observed at 6-months for change in weight (-1.35 kg, 95% confidence interval (CI): -2.24, -0.46, P=.003), weekly moderate physical activity sessions (0.56 sessions/week, 95% CI: 0.15, 0.96, P=.008) and accelerometer-assessed MVPA (24.16 minutes/week, 95% CI: 5.07, 43.25, P=.007).",4879328
4006,4879328,accelerometer-assessed moderate to vigorous physical activity (MVPA)	,"Get Healthy, Stay Healthyâ€™ (GHSH)",no continued contact,Significantly increased,"Significant intervention effects, all favoring the intervention group, were observed at 6-months for change in weight (-1.35 kg, 95% confidence interval (CI): -2.24, -0.46, P=.003), weekly moderate physical activity sessions (0.56 sessions/week, 95% CI: 0.15, 0.96, P=.008) and accelerometer-assessed MVPA (24.16 minutes/week, 95% CI: 5.07, 43.25, P=.007).",4879328
4007,5515187,self-efficacy,"6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring",routine care from health-care center,Significantly increased,"As shown in table 2, a significant difference is in the mean of self-efficacy between the groups (P &lt; 0.001) and follow-up time (P &lt; 0.001). So that the mean of self-efficacy improve immediately after intervention and 6 months later in comparison to control group after adjusting for baseline.",5515187
4008,5515187,"LDL, and cholesterol","6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring",routine care from health-care center,No significant difference,"After adjusting for age, LDL, and cholesterol showed there is not significant difference in the mean of healthy nutrition between two groups (P = 0.250).",5515187
4009,5515187,average of physical activity,"6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring",routine care from health-care center,Significantly increased,So that the intervention group immediately after intervention have a higher average of physical activity than the control group (P &lt; 0.001). Although there is not any significant differences between immediately after intervention and 6 months later in terms of physical activity in the intervention group (P = 0.120) (Table 2).,5515187
4010,5515187,systolic and diastolic BP,"6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring",routine care from health-care center,Significantly decreased,"After 6 months, there was a significant reduction in systolic (P &lt; 0.001) and diastolic BP (P = 0.010) in the intervention group.",5515187
4011,5153622, International Prostate Symptom Score (IPSS-T (total),onabotulinumtoxinA (100â€‰U), placebo ,Significantly increased,"Interestingly, there was a significantly greater reduction in IPSS-T in the placebo group than in the onabotulinumtoxinA group (pâ€‰=â€‰0.026).",5153622
4012,5153622,detrusor pressure,onabotulinumtoxinA (100â€‰U),baseline,Significantly decreased,"Nevertheless, significant improvements in videourodynamic parameters including detrusor pressure (from 40.3â€‰Â±â€‰23.0 to 31.6â€‰Â±â€‰22.3 cmH2O), maximum flow rate (from 6.4â€‰Â±â€‰5.4 to 11.1â€‰Â±â€‰10.1â€‰mL/s) and voided volume (from 119.9â€‰Â±â€‰82.2 to 191.0â€‰Â±â€‰140.1â€‰mL) were only found in the onabotulinumtoxinA group.",5153622
4013,5153622,maximum flow rate,onabotulinumtoxinA (100â€‰U) ,baseline,Significantly increased,"Nevertheless, significant improvements in videourodynamic parameters including detrusor pressure (from 40.3â€‰Â±â€‰23.0 to 31.6â€‰Â±â€‰22.3 cmH2O), maximum flow rate (from 6.4â€‰Â±â€‰5.4 to 11.1â€‰Â±â€‰10.1â€‰mL/s) and voided volume (from 119.9â€‰Â±â€‰82.2 to 191.0â€‰Â±â€‰140.1â€‰mL) were only found in the onabotulinumtoxinA group.",5153622
4014,5153622,voided volume,onabotulinumtoxinA (100â€‰U) ,baseline,Significantly increased,"Nevertheless, significant improvements in videourodynamic parameters including detrusor pressure (from 40.3â€‰Â±â€‰23.0 to 31.6â€‰Â±â€‰22.3 cmH2O), maximum flow rate (from 6.4â€‰Â±â€‰5.4 to 11.1â€‰Â±â€‰10.1â€‰mL/s) and voided volume (from 119.9â€‰Â±â€‰82.2 to 191.0â€‰Â±â€‰140.1â€‰mL) were only found in the onabotulinumtoxinA group.",5153622
4015,5153622,post-void residual volume,  placebo,onabotulinumtoxinA (100â€‰U),Significantly increased,"Reduction in post-void residual volume, however, was significantly greater in the placebo group (from 415.0â€‰Â±â€‰304.0 to 131â€‰Â±â€‰169.1â€‰mL) than in the onabotulinumtoxinA group (from 350.0â€‰Â±â€‰174.6 to 293â€‰Â±â€‰233.1â€‰mL) (pâ€‰=â€‰0.046).",5153622
4016,5153622, Patient perception of Bladder Condition, onabotulinumtoxinA (100â€‰U),  placebo,No significant difference,"There were no significant differences in subjective or objective parameters between patients who received onabotulinumtoxinA and those who received saline injection therapy, and the overall success rate was 43.5% (reduction in Patient perception of Bladder Condition by â‰¥2: onabotulinumtoxinA 36.8% vs placebo 54.2%, pâ€‰=â€‰0.114).",5153622
4017,3420321,IKET hold-time,Î²-alanine (nâ€‰=â€‰7; 6.4â€‰gÂ·d-1 over 4â€‰weeks),placebo,Significantly increased,"IKET hold times, pre- and post-supplementation are shown in Table 2. The 9.7â€‰Â±â€‰9.4â€‰s gain (+13.2%) in the Î²-alanine group was significantly higher (t(11)â€‰=â€‰2.9, pâ€‰&lt;â€‰0.05) than the corresponding change in the placebo group (âˆ’2.6â€‰Â±â€‰4.3â€‰s).",3420321
4018,3420321,Impulse values,Î²-alanine (nâ€‰=â€‰7; 6.4â€‰gÂ·d-1 over 4â€‰weeks),placebo,Significantly increased,"Impulse values pre- and post-supplementation are shown in Table 3. The 3.7â€‰Â±â€‰1.3 kNÂ·s-1 gain (+13.9%) in the Î²-alanine group was significantly different (tâ€‰=â€‰(11) 3.1, pâ€‰&lt;â€‰0.05) to the change in the placebo group (âˆ’1.1â€‰Â±â€‰1.5 kNÂ·s-1).",3420321
4019,3420321,maximal voluntary isometric contraction (MVIC),Î²-alanine (nâ€‰=â€‰7; 6.4â€‰gÂ·d-1 over 4â€‰weeks),placebo,No significant difference,There were no significant changes in MVIC force in either group.,3420321
4020,4414618,weakness,low frequency transcutaneous electrical nerve stimulation (TENS),non-  low frequency transcutaneous electrical nerve stimulation (TENS),Significantly increased,"On the other hand, the two groups had different force values in the final (p = 0.014), but not in the baseline (p = 0.430) and manipulation (p = 0.077) sessions (Fig 2A and 2B).",4414618
4021,4414618,force of pressure on the piston,low frequency transcutaneous electrical nerve stimulation (TENS),baseline,Significantly decreased,"On the other hand, the two groups had different force values in the final (p = 0.014), but not in the baseline (p = 0.430) and manipulation (p = 0.077) sessions (Fig 2A and 2B).",4414618
4022,4414618,force of pressure on the piston,non- low frequency transcutaneous electrical nerve stimulation (TENS),baseline,No significant difference,"No difference was found in the control group between the final (40.54 Â± 9.25%), the manipulation (34.27 Â± 7.05%) and the baseline (45.94 Â± 1.6%) sessions (for all comparisons, p &gt; 0.391).",4414618
4023,4414618,force of pressure on the piston, low frequency transcutaneous electrical nerve stimulation (TENS),non- low frequency transcutaneous electrical nerve stimulation (TENS),Significantly decreased,"Moreover, in the final session the experimental group had significantly lower values than the control group (p = 0.035).",4414618
4024,4414618,CSP duration, low frequency transcutaneous electrical nerve stimulation (TENS),baseline,No significant difference,"Duration of the CSP was shorter in the final than in the baseline session in the experimental group (red line), whereas there was a slight increase, although not significant, in the control group (green line).",4414618
4025,4414618,CSP duration,non- low frequency transcutaneous electrical nerve stimulation (TENS),baseline,No significant difference,"Duration of the CSP was shorter in the final than in the baseline session in the experimental group (red line), whereas there was a slight increase, although not significant, in the control group (green line).",4414618
4026,4414618,motor evoked potentials (MEP),non- low frequency transcutaneous electrical nerve stimulation (TENS),baseline,No significant difference,"This analysis disclosed, no effect of session (FDI: F(2,60) = 1.05, p = 0.357; ADM: F(2,60) = 0.13, p = 0.874), no effect of group (FDI: F(1,30) = 2.47, p = 0.127; ADM: F(1,30) = 0.33, p = 0.568) and no session Ã— group interaction (FDI: F(2,60) = 0.017, p = 0.983; ADM: F(2,60) = 0.31, p = 0.738), suggesting that EMG background activity was similar in both groups and all the sessions and therefore the MEP amplitude was not influenced by differences in preceding EMG activity (Fig 5C and 5D).",4414618
4027,2887151,"Median peak (4 hours after administration), aFXa levels",60 mg SC enoxaparin for a period of 24 hours,40 SC enoxaparin for a period of 24 hours,Significantly increased,"Median peak (4 hours after administration) aFXa levels increased significantly with an increase in enoxaparin dose, from 0.13 IU/ml at 40 mg, to 0.14 IU/ml at 50 mg, 0.27 IU/ml at 60 mg, and 0.29 IU/ml at 70 mg (P = 0.002).",2887151
4028,2887151,"prothrombin time (PT),  Activated Partial Thromboplastin Time (APTT), activity, antithrombin (AT), platelet count, fibrinogen, thrombin-antithrombin complexes (TAT) complexes, or D-dimer levels",70 mg SC enoxaparin for a period of 24 hours,"40, 50, 60 mg SC enoxaparin for a period of 24 hours",No significant difference,"No significant difference was found in the PT, aPTT, AT, platelet count, fibrinogen, TAT complexes, or D-dimer levels between the four groups. No significant change from baseline was noted in these coagulation parameters within each group over the 24-hour study period (Table 2).",2887151
4029,3813772,Mu rhythm desynchronization of hand area of cortex in child,adult reach towards and touch an object using her hand , no touching,Significantly increased,"Consistent with the prediction of neural somatotopy, a 2Ã—2 ANOVA showed a significant interaction between electrode position (hand area vs. foot area) and group (Observe-Hand vs. Observe-Foot), F (1, 30)â€Š=â€Š6.21, pâ€Š=â€Š.018.",3813772
4030,3813772,Mu rhythm desynchronization of foot area of cortex in child,adult reach towards and touch an object using her foot, no touching,Significantly increased,"Consistent with the prediction of neural somatotopy, a 2Ã—2 ANOVA showed a significant interaction between electrode position (hand area vs. foot area) and group (Observe-Hand vs. Observe-Foot), F (1, 30)â€Š=â€Š6.21, pâ€Š=â€Š.018.",3813772
4031,5429471,bond strength,No irrigant,"Smear Clear, 2.5% sodium hypochlorite (NaOCl), 2% chlorhexidine (CHX) and saline",Significantly increased,The control group showed the highest bond strength with significant differences with other groups (P&lt;0.05).,5429471
4032,5429471,bond strength,saline,Smear Clear,Significantly increased,"Also, significant differences were noted in bond strength between saline and Smear Clear (P=0.007) and saline and sodium hypochlorite (P=0.001) groups.",5429471
4033,5429471,bond strength,saline,sodium hypochlorite,Significantly increased,"Also, significant differences were noted in bond strength between saline and Smear Clear (P=0.007) and saline and sodium hypochlorite (P=0.001) groups.",5429471
4034,5429471,bond strength,saline,chlorhexidine (CHX),No significant difference,Other pairwise comparisons did not show statistically significant differences (P&gt;0.05).,5429471
4035,5747102,The Assessment Scale-Cognitive (ADAS-cog) scores at 12-week follow-up period (T2),acupuncture three times per week,donepezil hydrochloride once daily (5&nbsp;mg/day for the first 4&nbsp;weeks and 10&nbsp;mg/day thereafter),Significantly decreased,"The ADAS-cog scores for AG group showed obvious decreases at T2 and âˆ†(T2-T0)when compared with DG group, and significant between-group differences were detected (all p&nbsp;&lt;â€‰0.05).",5747102
4036,5747102,Clinicianâ€™s Interview-Based Impression of Change-Plus (CIBIC-Plus) values at 12-week treatment phase (T1) and 12-week follow-up period (T2),acupuncture three times per week,donepezil hydrochloride once daily (5mg/day for the first 4weeks and 10mg/day thereafter),Significantly decreased,"The mean CIBIC-Plus values were 3.07 (1.03) and 4.08 (0.81) for the AG group at T1 and T2, which were much lower than that for the DG group. The CIBIC-Plus scores showed obvious decreases for AG group when compared with DG group, and significantly statistical differences were observed between the two groups (P&lt;0.05) (Fig.&nbsp;2b).",5747102
4037,5747102,Activities of Daily Living Scales (ADAS-ADL23) and Neuropsychiatric Index (NPI),acupuncture three times per week,donepezil hydrochloride once daily (5mg/day for the first 4weeks and 10mg/day thereafter),No significant difference,There were no significant between-group differences in the scores of ADAS-ADL23 and NPI during the study period.,5747102
4038,5409664,The Disease Activity Score 28 (DAS 28 score),"12 week supplementation with fish oil (group I), fish oil with primrose evening oil (group II)",baseline,Significantly decreased,"The Disease Activity Score 28 (DAS 28 score), number of tender joints and visual analogue scale (VAS) score decreased notably after supplementation in groups I and II (p &lt; 0.001).",5409664
4039,5409664,phospholipids the n-6/n-3 fatty acids ratio,"12 week supplementation with fish oil (group I), fish oil with primrose evening oil (group II)",baseline,Significantly decreased,"In plasma phospholipids the n-6/n-3 fatty acids ratio declined from 15.47 Â± 5.51 to 10.62 Â± 5.07 (p = 0.005), and from 18.15 Â± 5.04 to 13.50 Â± 4.81 (p = 0.005) in groups I and II respectively.",5409664
4040,5409664,"eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), n-3 polyunsaturated fatty acids (PUFA) and total PUFA",12 week supplementation with fish oil (group I),baseline,Significantly increased,"Because of the high fish oil intake, EPA, DHA, n-3 PUFA and total PUFA increased significantly (p â‰¤ 0.05, Table 3) in plasma of the group I.",5409664
4041,3733287,Quality of life (QOL),psycho-educational intervention,did not receive the intervention,Significantly increased,Also the result showed that there was a statistically significant difference between two groups in all aspects of QOL (P &lt; .0.001) [Table 3].,3733287
4042,4319305,amount of debris,The WaveOne group,Reciproc Group,No significant difference,"The WaveOne group presented larger amount of debris than the Reciproc Group, however, without statistically significant difference (P &gt; 0.05).",4319305
4043,4319305,amount of debris,"The WaveOne group,  Reciproc Group",no instrumentation was performed,Significantly decreased,"Whereas, specimens in the control group, in which no instrumentation was performed, a larger amount of debris was observed with statistically significant difference from the Reciproc and WaveOne Groups (P &lt; 0.05).",4319305
4044,2741450,steps/day,record the number of steps on a daily basis for 12 weeks,baseline,Significantly increased,"At week twelve, the pedometer group was taking an average of 3461 steps per day more (36% increase) than at baseline.",2741450
4045,2741450,steps/day,was not able to record their steps daily,baseline,No significant difference,The control group remained unchanged in the number of steps during the 12-week intervention.,2741450
4046,2741450,"waist, BMI, waist/hip ratio, HR or % body fat",record the number of steps on a daily basis for 12 weeks,was not able to record their steps daily,No significant difference,"There was no significant differences within groups or between groups in waist, BMI, waist/hip ratio, HR or % body fat at 12 weeks.",2741450
4047,2741450,Systolic blood pressure,record the number of steps on a daily basis for 12 weeks,baseline,Significantly decreased,Systolic blood pressure decreased significantly by 4.7% at week 12 compared with baseline in the pedometer group (p = 0.018).,2741450
4048,2741450,Systolic blood pressure,record the number of steps on a daily basis for 12 weeks,was not able to record their steps daily,Significantly decreased,The pedometer group was found to have a significantly lower systolic blood pressure (112.8 Â± 2.44 mm Hg) at 12 weeks compared to the control group (117.3 Â± 2.03 mm Hg) (p = 0.003).,2741450
4049,2741450,diastolic blood pressure,"record the number of steps on a daily basis for 12 weeks, was not able to record their steps daily",baseline,No significant difference,There were no significant changes to diastolic blood pressure (baseline versus 12 weeks) or between groups at 12 weeks.,2741450
4050,2741450,moderate or vigorous physical activity,record the number of steps on a daily basis for 12 weeks,was not able to record their steps daily,No significant difference,Table 4 shows that time doing moderate or vigorous physical activity was not significantly different between the control and pedometer groups.,2741450
4051,5458653,"mean plasma glucose level, HbA1c",vildagliptin (50 mg twice daily) for 12weeks,baseline,No significant difference,Vildagliptin did not significantly alter the mean plasma glucose level (175.5 Â± 54.4 mg/dL vs. 179.1 Â± 73.4 mg/dL) or HbA1c (8.01% vs. 8.02%) after 12 weeks.,5458653
4052,5458653,"mean plasma glucose level, HbA1c",alogliptin (25 mg once daily),baseline,Significantly increased,"With alogliptin, mean plasma glucose increased from 175.4 Â± 50.9 mg/dL to 195.3 Â± 55.0 mg/dL after 12 weeks and HbA1c increased significantly from 8.0% to 8.3% (P &lt; 0.05).",5458653
4053,5458653,"mean plasma glucose level, HbA1c",switching from vildagliptin to high-dose sitagliptin (100 mg daily),baseline,Significantly increased,"At 12 weeks after switching from vildagliptin to high-dose sitagliptin (100 mg daily), HbA1c was increased to 8.3%, but it was significantly (P &lt; 0.05) reduced to the baseline level of 8.0% after switching from alogliptin.",5458653
4054,5458653,HbA1c,vildagliptin (50 mg twice daily) for 12weeks,alogliptin (25 mg once daily),Significantly decreased,Comparison between the vildagliptin and alogliptin groups showed that the reduction of HbA1c was significantly greater with vildagliptin (P = 0.008).,5458653
4055,4755968,measure of mean overall balance (OLB),"Biodex Balance System (BBS)  balance training, virtual-reality (VR) balance training",baseline,No significant difference,"The main effect of the two types of intervention was not significant: (p&gt; 0.05), F (1, 28) = 0.016, p = 0.9, partial eta squared (Æžp2) = 0.001.",4755968
4056,4755968,dynamic limit-of-stability balance test (DLOS),"Biodex Balance System (BBS)  balance training, ",virtual-reality (VR) balance training,No significant difference,"The main effect of the two types of intervention effect on the DLOS test time was not significant: (p&gt; 0.05), F (1, 28) = 1.9, p = 0.18, partial eta squared (Æžp2) = 0.07.",4755968
4057,4755968,The sense of balance improvement,"Biodex Balance System (BBS)  balance training, ",virtual-reality (VR) balance training,No significant difference,"The sense of balance improvement also did not differ significantly between the groups (p&gt;0.05),",4755968
4058,4755968,fatigue after the training session,"Biodex Balance System (BBS)  balance training, ",virtual-reality (VR) balance training,Significantly increased,There was a significant difference between the groups regarding the participantsâ€™ sense of fatigue after the training session (p&lt; 0.05) with higher fatigue reported by of the BBSG.,4755968
4059,4755968,enjoyment attribute,"Biodex Balance System (BBS)  balance training, ",virtual-reality (VR) balance training,Significantly decreased,"There was a significant difference between the groups in the enjoyment attribute (p&lt; 0.05), with higher enjoyment reported by the VRG.",4755968
4060,4717319,"Positive and Negative Syndrome Scale total score ,  Clinical Global Impression-Severity (CGI-S) scores","(40â€“80 mg/d, flexibly dosed) for an additional 28-week treatment period",placebo,Significantly decreased,Least squares mean change (ANCOVA at week 28 LOCF) was +12.4 in the placebo group versus +8.3 in the lurasidone group on the PANSS (p=0.029) and +0.7 versus +0.4 on the CGI-S (p=0.015) (Figure 4).,4717319
4061,4717319,time to relapse,"(40â€“80 mg/d, flexibly dosed) for an additional 28-week treatment period",placebo,Significantly increased,"In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447â€“0.983); p=0.041).",4717319
4062,4717319,risk of relapse,"(40â€“80 mg/d, flexibly dosed) for an additional 28-week treatment period",placebo,Significantly decreased,"In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447â€“0.983); p=0.041).",4717319
4063,4717319,adverse event and  extrapyramidal symptoms (EPS)-related adverse events,"(40â€“80 mg/d, flexibly dosed) for an additional 28-week treatment period",placebo,No significant difference,"In the double-blind phase, the percentage of patients reporting any adverse event was similar for the lurasidone (53.5%) and placebo (54.6%) groups; the incidence of EPS-related adverse events in the double-blind phase was low (4%) and comparable between the groups.",4717319
4064,2429977,Bleeding complications,group A (â€˜non-selectiveâ€™â€”clopidogrel 600 mg &gt;6 h before CAG;,"group B (â€˜selectiveâ€™â€”clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI;",Significantly increased,Bleeding complications (Table&nbsp;4) occurred in 3.5% of group A patients vs. 1.4% of group B patients (P = 0.025) (Figure&nbsp;3).,2429977
4065,2429977,risk of bleeding complications,group A (â€˜non-selectiveâ€™â€”clopidogrel 600 mg &amp;gt;6 h before CAG;,"group B (â€˜selectiveâ€™â€”clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI;",Significantly increased,"After adjustment for specified covariates and factors that may influence the bleeding risk (see Methods section), patients in group A were shown to have more likely bleeding complications when compared with group B (OR = 3.03; 95% CI 1.14â€“8.10; P = 0.027).",2429977
4066,2429977,death/periprocedural MI/stroke or transient ischaemic attack/re-intervention within 7 days,group A (â€˜non-selectiveâ€™â€”clopidogrel 600 mg &amp;amp;gt;6 h before CAG;,"group B (â€˜selectiveâ€™â€”clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI;",No significant difference,Primary endpoint occurred in 0.8% of group A patients vs. 1% of group B patients (P = 0.749; 90% CI for difference in percentages âˆ’1.2â€“0.8) (Table&nbsp;3).,2429977
4067,2429977,Periprocedural troponin elevation,group A (â€˜non-selectiveâ€™â€”clopidogrel 600 mg &amp;amp;amp;gt;6 h before CAG;,"group B (â€˜selectiveâ€™â€”clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI;",No significant difference,Periprocedural troponin elevation (&gt;3Ã— ULN) was detected in 2.6% of patients in group A vs. 3.3% in group B (P = 0.475; 90% CI âˆ’2.5â€“1.0) (Figure&nbsp;2).,2429977
4068,2429977,death/periprocedural MI/stroke or transient ischaemic attack/re-intervention within 7 days,group A (â€˜non-selectiveâ€™â€”clopidogrel 600 mg 6 h before CAG; in subgroup of patients who underwent PCI,"group B (â€˜selectiveâ€™â€”clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; in  subgroup of patients who underwent PCI",No significant difference,"When only the subgroup of patients who underwent PCI was analysed, primary endpoint occurred in 1.3% group A vs. 2.8% group B (P = 0.432; 90% CI âˆ’4.1â€“1.2).",2429977
4069,2429977,TIMI-flow &lt;3 after PCI,group A (â€˜non-selectiveâ€™â€”clopidogrel 600 mg 6 h before CAG; in subgroup of patients who underwent PCI,"group B (â€˜selectiveâ€™â€”clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; in  subgroup of patients who underwent PCI",No significant difference,TIMI-flow &lt;3 after PCI was in 1.3% group A vs. 0% group B (P = 0.499).,2429977
4070,2429977,Bleeding complications,group A (â€˜non-selectiveâ€™â€”clopidogrel 600 mg 6 h before CAG; in subgroup of patients who underwent PCI,"group B (â€˜selectiveâ€™â€”clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; in  subgroup of patients who underwent PCI",Significantly increased,"Bleeding complications occurred in 7.1% (group A) vs. 0.7% (group B, P = 0.006) and re-intervention within 7 days in 0.7% group A vs. 1.4% group B (P = 0.515).",2429977
4071,2429977,Periprocedural troponin elevation,group A (â€˜non-selectiveâ€™â€”clopidogrel 600 mg 6 h before CAG; in subgroup of patients who underwent PCI,"group B (â€˜selectiveâ€™â€”clopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; in  subgroup of patients who underwent PCI",No significant difference,Periprocedural troponin elevation (&gt;3Ã— ULN) was detected in 2.6% of patients in group A vs. 3.3% in group B (P = 0.475; 90% CI âˆ’2.5â€“1.0) (Figure&nbsp;2).,2429977
4072,3346068,The median time to first postsurgical use of rescue opioid medication,liposome bupivacaine,bupivacaine HCl  and placebo,Significantly decreased,The median time to first postsurgical use of rescue opioid medication was significantly longer with liposome bupivacaine (9.3 hours) compared with bupivacaine HCl (6.4 hours; P = 0.013) and placebo (3.6 hours; P &lt; 0.0001).,3346068
4073,3346068,the proportion of patients avoiding rescue medication through 72 hours after surgery,liposome bupivacaine 266 mg, placebo,Significantly decreased,"In study 9 (hemorrhoidectomy), the proportion of patients avoiding rescue medication through 72 hours after surgery was significantly lower in favor of liposome bupivacaine 266 mg (28% avoided use of rescue opioids) compared with placebo (10% avoided use of rescue opioids; P = 0.0007).",3346068
4074,3346068,patient satisfaction scores,liposome bupivacaine 266 mg, placebo,Significantly increased,"In the studies that included assessment of patient ratings of postsurgical analgesia (studies 1, 6, 7, 8, 9, and 10), the liposome bupivacaine group in study 9 showed statistically significantly better patient satisfaction scores than the comparator.",3346068
4075,3346068,â€œsatisfiedâ€� or â€œextremely satisfiedâ€� with their postoperative analgesia at 24 hours after surgery,liposome bupivacaine 266 mg , placebo,Significantly increased,"At 24 hours after surgery in this study, 95% of patients in the liposome bupivacaine 266 mg group were â€œsatisfiedâ€� or â€œextremely satisfiedâ€� with their postoperative analgesia compared with 72% in the placebo group (P = 0.0007).",3346068
4076,3346068,â€œsatisfiedâ€� or â€œextremely satisfiedâ€� with their postoperative analgesia at 72 hours after surgery,liposome bupivacaine 266 mg  , placebo,Significantly increased,"At 72 hours after surgery, percentages were 95% and 73%, respectively (P = 0.0007).",3346068
4077,3346068,"mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied)",liposome bupivacaine 532 mg at day 8,bupivacaine HCl 150 mg group at day 8,Significantly increased,"Statistically significant differences in favor of liposome bupivacaine were also observed in study 3, where mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied), were 9.2 in the liposome bupivacaine 532 mg group and 8.3 in the bupivacaine HCl 150 mg group (P = 0.045) at day 8, and in study 4 where mean ratings in the liposome bupivacaine 266 mg and bupivacaine HCl 75 mg groups were 7.4 and 6.0, respectively (P = 0.03) at 96 hours.",3346068
4078,3346068,"mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied) at 96 hours", liposome bupivacaine 266 mg ,bupivacaine HCl 75 mg,Significantly increased,"Statistically significant differences in favor of liposome bupivacaine were also observed in study 3, where mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied), were 9.2 in the liposome bupivacaine 532 mg group and 8.3 in the bupivacaine HCl 150 mg group (P = 0.045) at day 8, and in study 4 where mean ratings in the liposome bupivacaine 266 mg and bupivacaine HCl 75 mg groups were 7.4 and 6.0, respectively (P = 0.03) at 96 hours.",3346068
4079,3346068,cumulative pain,liposome bupivacaine,bupivacaine HCl,Significantly decreased,Between-group differences were statistically significant in favor of liposome bupivacaine in six of these treatment arms through 24 hours and in five treatment arms through 72 hours (P &lt; 0.05).,3346068
4080,4369830,overall survival (OS)  in patients with metastatic colorectal cancer (mCRC),Regorafenib (RE),placebo,Significantly increased,"The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HRâ€‰=â€‰0.77, pâ€‰=â€‰0.0052, median OS: 6.4&nbsp;months vs. 5.0&nbsp;months for the placebo group) in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after approved standard therapies.",4369830
4081,4369830,progression-free survival (PFS)  in patients with metastatic colorectal cancer (mCRC),Regorafenib (RE),placebo,Significantly increased,"Additionally, findings from the secondary endpoints of the CORRECT study showed statistically significant improvement in progression-free survival (PFS) (HRâ€‰=â€‰0.49, pâ€‰&lt;â€‰0.000001, median PFS: 1.9&nbsp;months vs. 1.7&nbsp;months) and an improvement in disease control rate (44.8% vs. 15.3%) in patients treated with regorafenib compared to those treated with placebo.",4369830
4082,4301837,plasma cortisol,LCI699,placebo,Significantly decreased,a single dose of LCI699 200&nbsp;mg caused a 19% decrease in plasma cortisol 24&nbsp;h post-dose (Pâ€‰=â€‰0.029 vs placebo).,4301837
4083,4301837,24-h urinary cortisol,LCI699,placebo,Significantly decreased,"Significant reductions in 24-h urinary cortisol (34â€“42%) were observed following single LCI699 doses of 30, 100 or 200&nbsp;mg (vs 33% increase with placebo relative to time-matched baseline; Pâ€‰â‰¤â€‰0.001), but with no clear dose-dependence (results not shown).",4301837
4084,4301837,Levels of the cortisol precursor 11-deoxycortisol,LCI699,placebo,Significantly increased,"Levels of the cortisol precursor 11-deoxycortisol increased with LCI699 at dosesâ€‰â‰¥â€‰100&nbsp;mg (942% and 584% with 100&nbsp;mg and 200&nbsp;mg, respectively; Pâ€‰&lt;â€‰0.001 vs placebo), likely due to off-target inhibition of 11-Î² hydroxylase (results not shown).",4301837
4085,4301837,plasma aldosterone concentration at 12&nbsp;h,LCI699,placebo,Significantly decreased,"LCI699 reduced plasma aldosterone concentration at 12&nbsp;h on Day 1 (0.5&nbsp;mg, â€“49%; 1&nbsp;mg, â€“47%; 3&nbsp;mg, â€“63%; all Pâ€‰&lt;â€‰0.001 vs placebo);",4301837
4086,4301837,24&nbsp;h urinary aldosterone levels,LCI699,placebo,Significantly decreased,"On Day 1, all three doses of LCI699 reduced 24&nbsp;h urinary aldosterone levels from baseline (0.5&nbsp;mg, â€“39%; 1&nbsp;mg, â€“39%; 3&nbsp;mg, â€“66%; all Pâ€‰&lt;â€‰0.001 vs placebo; Figure&nbsp;6A).",4301837
4087,4301837,ACTH-stimulated aldosterone levels,LCI699,placebo,Significantly decreased,"For ACTH-stimulated aldosterone levels (Figure&nbsp;7A), LCI699 0.5â€“3&nbsp;mg resulted in peak inhibition of 41â€“64% from baseline (Day âˆ’2) on Day 6 (vs 7% reduction with placebo; Pâ€‰&lt;â€‰0.001).",4301837
4088,4301837,ACTH-stimulated aldosterone levels,eplerenon,placebo,Significantly increased,"By contrast, treatment with eplerenone 100&nbsp;mg caused a progressive increase in pre-ACTH aldosterone levels 2&nbsp;h post-dose (increase vs Day âˆ’2 pre-ACTH levels; Day 6, 29%; Pâ€‰â‰¤â€‰0.01 vs placebo) (Figure&nbsp;7A). In eplerenone-treated subjects, ACTH stimulation on Day 6 resulted in a 63% increase in peak aldosterone levels.Figure 7",4301837
4089,4301837,Levels of the cortisol precursor 11-deoxycortisol,eplerenon,placebo,No significant difference,Eplerenone and lower doses of LCI699 had no significant effect on cortisol precursors on Day 6 or Day 13.,4301837
4090,5137281,level of perfusion left middle and right superior prefrontal cortex and left caudate nucleus and at the border of left posterior part of the putamen and insular cortex,quetiapine (dopamine receptor antagonist),placebo,Significantly increased,QT increased perfusion relative to placebo in the left middle and right superior prefrontal cortex and left caudate nucleus and at the border of left posterior part of the putamen and insular cortex (4% CBF change).,5137281
4091,5137281,"cerebral blood flow (CBF) bilateral visual cortex, but also in the bilateral cerebellum",quetiapine (QT),placebo,Significantly decreased,"QT reduced CBF relative to placebo, particularly pronounced in the bilateral visual cortex (19.05% CBF change), but also in the bilateral cerebellum (Crus 2) with a right hemispheric dominance.",5137281
4092,5137281,"cerebral blood flow (CBF) of the right cerebellum, thalamus, and fusiform cortex",pramipexole (PX) (dopamine agonist of the nonergoline class) ,placebo,Significantly decreased,"PX reduced CBF in the right cerebellum, thalamus, and fusiform cortex relative to placebo.",5137281
4093,5137281,global CBF,pramipexole (PX),placebo,No significant difference,"If global CBF was included as confounding variable in the analysis, we found further decreases in CBF in the left fusiform gyrus, right cuneus, and superior temporal gyrus (global CBF was not significantly different between the treatments, all P&gt;.5).",5137281
4094,5137281,perfusion of the left middle and right superior prefrontal cortex and left caudate nucleus and at the border of left posterior part of the putamen and insular cortex,quetiapine (QT),placebo,Significantly increased,QT increased perfusion relative to placebo in the left middle and right superior prefrontal cortex and left caudate nucleus and at the border of left posterior part of the putamen and insular cortex (4% CBF change).,5137281
4095,5137281,CBF,pramipexole (PX),quetiapine (QT),No significant difference,No CBF increases were detected when comparing QT with PX at P&lt;.001 or P&lt;.005.,5137281
4096,5137281,"CBF  in the bilateral caudate nuclei, left brainstem (including substantia nigra), and the left SMA and middle frontal gyrus",pramipexole (PX),placebo,Significantly increased,"PX increased CBF relative to placebo in the bilateral caudate nuclei, left brainstem (including substantia nigra, 7% CBF change), and the left SMA and middle frontal gyrus (BA 11) if global CBF was included in the GLM.",5137281
4097,5137281,CBF in the left cerebellum and brainstem (including substantia nigra) and right hypothalamus,pramipexole (PX),quetiapine (QT),Significantly increased,"PX showed elevated CBF compared with QT in the left cerebellum and brainstem (including substantia nigra, 8% CBF change) and right hypothalamus.",5137281
4098,4140238,ocular itching,bepotastine besilate ophthalmic solution (BBOS) 1.5%,placebo,Significantly decreased,"For the PP population, the differences in mean ocular itching scores between the BBOS 1.5% and the placebo group were found to be statistically significant (P&lt;0.001) at all visits and time points by the Wilcoxon rank-sum test and across all time points at a study visit by ANCOVA assessments (Table 3).",4140238
4099,5440738,attending of sessions, CBT for depression  with the addition of a text messaging adjunct,standard group CBT for depression standard group,No significant difference,"Patients assigned to the text messaging adjunct also generally attended more sessions (median=6 sessions) during this period than patients assigned to the control condition (median =2.5 sessions), but the effect was not significant (Wilcoxon-Mann-Whitney z=âˆ’1.65, P=.10).",5440738
4100,5440738,time staying in therapy, CBT for depression  with the addition of a text messaging adjunct,standard group CBT for depression standard group,No significant difference,"Patients assigned to the texting condition stayed in therapy for a median of 13.5 weeks before dropping out, whereas patients in the control conditions stayed in therapy for a median of only 3 weeks before dropping out (Figure 5).",5440738
4101,5440738,depressive symptom severity, CBT for depression  with the addition of a text messaging adjunct,baseline,Significantly decreased,"Both patients assigned to the text messaging adjunct (B=âˆ’.29, 95% CI âˆ’0.38 to âˆ’0.19, z=âˆ’5.80, P&lt;.001) and patients assigned to the control conditions (B=âˆ’.20, 95% CI âˆ’0.32 to âˆ’0.07, z=âˆ’3.12, P=.002) experienced significant decreases in depressive symptom severity over the course of treatment; however, the conditions did not significantly differ in their degree of symptom reduction.",5440738
4102,5440738,depressive symptom severity,standard group CBT for depression standard group,baseline,Significantly decreased,"Both patients assigned to the text messaging adjunct (B=âˆ’.29, 95% CI âˆ’0.38 to âˆ’0.19, z=âˆ’5.80, P&lt;.001) and patients assigned to the control conditions (B=âˆ’.20, 95% CI âˆ’0.32 to âˆ’0.07, z=âˆ’3.12, P=.002) experienced significant decreases in depressive symptom severity over the course of treatment; however, the conditions did not significantly differ in their degree of symptom reduction.",5440738
4103,5440738,the degree of symptom reduction,standard group CBT for depression standard group,CBT for depression with the addition of a text messaging adjunct,No significant difference,"Both patients assigned to the text messaging adjunct (B=âˆ’.29, 95% CI âˆ’0.38 to âˆ’0.19, z=âˆ’5.80, P&lt;.001) and patients assigned to the control conditions (B=âˆ’.20, 95% CI âˆ’0.32 to âˆ’0.07, z=âˆ’3.12, P=.002) experienced significant decreases in depressive symptom severity over the course of treatment; however, the conditions did not significantly differ in their degree of symptom reduction.",5440738
4104,4161265,activity of the anterior cingulate cortex,Acetylsalicylic acid,saline,Significantly increased,"As shown in Figure&nbsp;1, we found an increased activation in the left ACC [x = -6, y = 20, z = 32; T(18) = 4.13, p = 0.029 (FWE corrected)) as well as in the right SII [x = 54, y = -28, z = 4, T(18) = 4.4 p = 0.047 (FWE corrected)] regarding the contrast [Placebo (Ammonia &gt; air puffs) &gt; ASS (Ammonia &gt; air puffs)] replicating the trend found in a previous study [26].",4161265
4105,4161265,activity of the secondary somatosensory cortex (SII),Acetylsalicylic acid,saline,Significantly increased,"As shown in Figure&nbsp;1, we found an increased activation in the left ACC [x = -6, y = 20, z = 32; T(18) = 4.13, p = 0.029 (FWE corrected)) as well as in the right SII [x = 54, y = -28, z = 4, T(18) = 4.4 p = 0.047 (FWE corrected)] regarding the contrast [Placebo (Ammonia &gt; air puffs) &gt; ASS (Ammonia &gt; air puffs)] replicating the trend found in a previous study [26].",4161265
4106,4161265,Mean Pain intensity rating,Acetylsalicylic acid,saline,No significant difference,Mean Pain intensity rating (Â±SEM) for the ASA session was 61.7â€‰Â±â€‰2.73 and for the saline session 62.1â€‰Â±â€‰2.71. A paired t-test comparing the average pain ratings of both sessions failed to reach significance (pâ€‰&gt;â€‰0.05).,4161265
4107,4161265,activity of the hypothalamic area or the trigeminal nuclei,Acetylsalicylic acid,saline,No significant difference,"Additionally, no increased activation for placebo compared to ASA condition could be revealed regarding the hypothalamic area or the trigeminal nuclei. No significant differences could be revealed for the opposite contrast (ASA &gt; Saline).",4161265
4108,3382640,standard deviation of lateral position (SDLP) in the first and second hour after the break,a single cup of coffee (80 mg caffeine),decaffeinated coffee,Significantly decreased,"However, both in the first (F(1,23)â€‰=â€‰5.8; pâ€‰=â€‰0.024) and in the second hour (F(1,23)â€‰=â€‰6.4; pâ€‰=â€‰0.019) after the break, caffeinated coffee significantly reduced SDLP.Fig. 1",3382640
4109,3382640,"the standard deviation of speed, mental effort, and subjective sleepiness ",a single cup of coffee (80 mg caffeine),decaffeinated coffee,Significantly decreased,"Similarly, the standard deviation of speed (pâ€‰=â€‰0.024; pâ€‰=â€‰0.001), mental effort (pâ€‰=â€‰0.003; pâ€‰=â€‰0.023), and subjective sleepiness (pâ€‰=â€‰0.001; pâ€‰=â€‰0.002) were reduced in both the first and second hour after consuming caffeinated coffee.",3382640
4110,3382640,Subjective driving quality,a single cup of coffee (80 mg caffeine),decaffeinated coffee,Significantly increased,Subjective driving quality was significantly improved in the first hour after consuming caffeinated coffee (pâ€‰=â€‰0.004).,3382640
4111,5399146,"circadian variation of F1+2, a marker of thrombin generation, and D-dimer, a marker of activated coagulation and fibrinolysis",2â€‰mg of melatonin given 4 days for tetraplegic patients,placebo for  tetraplegic patients,No significant difference,"The circadian patterns of the F1+2, a marker of thrombin generation, and D-dimer, a marker of activated coagulation and fibrinolysis, were apparently similar (P&gt;0.05) between the tetraplegic groups, that is, irrespective of whether they were given melatonin (Figures 2a and c).",5399146
4112,5399146,The absolute plasma concentration of activated FVII,able-bodied men without any intervention,2â€‰mg of melatonin given 4 days for tetraplegic patients and placebo for tetraplegic patients,Significantly increased,The absolute plasma concentration of activated FVII was higher (P&lt;0.05) among the able-bodied compared with the tetraplegic groups.,5399146
4113,5399146,circadian variation of F1+2,  2â€‰mg of melatonin given 4 days for tetraplegic patients and  placebo for  tetraplegic patients,able-bodied men without any intervention,Significantly increased,"Compared with the able-bodied group, the tetraplegic groups with or without melatonin supplementation showed an apparent increase in the circadian variation of F1+2 (P=0.01 and P&lt;0.001, respectively), whereas the circadian pattern for D-dimer was similar (P&gt;0.05) across the three study groups.",5399146
4114,5399146,circadian pattern for D-dimer,  2â€‰mg of melatonin given 4 days for tetraplegic patients and  placebo for  tetraplegic patients,able-bodied men without any intervention,No significant difference,"Compared with the able-bodied group, the tetraplegic groups with or without melatonin supplementation showed an apparent increase in the circadian variation of F1+2 (P=0.01 and P&lt;0.001, respectively), whereas the circadian pattern for D-dimer was similar (P&gt;0.05) across the three study groups.",5399146
4115,5399146,"the plasma concentrations of PAI-1, a fibrinolytic inhibitor",  2â€‰mg of melatonin given 4 days for tetraplegic patients and  placebo for  tetraplegic patients,able-bodied men without any intervention,No significant difference,"Similarly, the plasma concentrations of PAI-1, a fibrinolytic inhibitor, did not differ (P&gt;0.05) among the three study groups, with regard to circadian variations (Figure 3e) or absolute plasma concentration (Figure 3f).",5399146
4116,5529983,"improvements in physical limitation , angina frequency  and quality of life",standard care plus CT coronary angiography (CTCA),standard care,Significantly increased,"Compared with standard care alone, CTCA was associated with less marked improvements in physical limitation (difference âˆ’1.74 (95% CIs, âˆ’3.34 to âˆ’0.14), p=0.0329), angina frequency (difference âˆ’1.55 (âˆ’2.85 to âˆ’0.25), p=0.0198) and quality of life (difference âˆ’3.48 (âˆ’4.95 to âˆ’2.01), p&lt;0.0001) at 6â€…months.",5529983
4117,5529983,Treatment satisfaction,"standard care plus CT coronary angiography (CTCA), standard care",baseline,Significantly increased,Treatment satisfaction was excellent at baseline and fell slightly across all groups.,5529983
4118,4274545,incidence of suspected Necrotizing enterocolitis (NEC),prebiotic mixture (SCGOS/LCFOS; 9:1),not receive any prebiotic,Significantly decreased,"Only one neonate (4.0%), in the prebiotic group developed NEC, as compared to 11 infants (22.0%) who had not received SCGOS/LCFOS mixture [HR: 0.49 (95% confidence interval [CI]: 0.29-0.84); P - 0.002; Table 2].",4274545
4119,4274545,Hospitalization time,prebiotic mixture (SCGOS/LCFOS; 9:1),not receive any prebiotic,Significantly decreased,The median (range) of hospital stay time was 16 (9-45) days (95% CI: 15.34-24.09) and 25 (11-80) days (95% CI: 25.52-34.39) in group P and C respectively (P - 0.004; Table 1].,4274545
4120,4274545,sepsis,prebiotic mixture (SCGOS/LCFOS; 9:1),not receive any prebiotic,No significant difference,"Four neonates (16%) in the prebiotic group suffered from sepsis, but 17 infants (34%) who had not received SCGOS/LCFOS mixture developed sepsis, although the difference was not statistically significant [HR: 0.60 (95% CI: 0.27-2.72); P = 0.79; Table 2].",4274545
4121,4274545,time of reaching full volume of milk,prebiotic mixture (SCGOS/LCFOS; 9:1),not receive any prebiotic,Significantly decreased,"The median (range) time of reaching full enteral feeds (150 ml/kg/day) in group P was 11 (7-21) days (95% CI: 10.69-13.14) and in group C, 14 (8-36) days (95% CI: 13.17-16.50) [P - 0.02; Table 1].",4274545
4122,4274545,Mortality,prebiotic mixture (SCGOS/LCFOS; 9:1),not receive any prebiotic,No significant difference,Mortality was similar between the two groups; only one neonate died in each group [P - 0.66; Table 1].,4274545
4123,5846302,Median time to hemostasis,Verisetâ„¢ hemostatic patch,TachoSilÂ® (control),Significantly decreased,"The median time to hemostasis at the TBS was 1.5 min in patients treated with Verisetâ„¢ hemostatic patch and 3.0 min in patients treated with TachoSilÂ® (p&lt;0.0001), which was the minimum time based on instructions for use (Table 7).",5846302
4124,5846302,Serious adverse events within 30 days post-surgery,Verisetâ„¢ hemostatic patch,TachoSilÂ® (control),No significant difference,Serious adverse events within 30 days post-surgery were experienced by 12/44 (27.3%) patients treated with Verisetâ„¢ hemostatic patch and 10/45 (22.2%) in the TachoSilÂ® group (p=0.6295).,5846302
4125,5846302,difference in any surgical procedure or  target bleeding site (TBS) characteristic,Verisetâ„¢ hemostatic patch,TachoSilÂ® (control),No significant difference,There was no significant difference between the two treatment groups in any surgical procedure or TBS characteristic;,5846302
4126,4093188,half carcasses,"group C, indoor with no supplement; S, indoor with supplement,","G, outdoor with no supplement",No significant difference,"A comparison of half carcasses across the groups has shown no difference between the control group and the one with supplements, while the weight of half carcasses in the grazing group was smaller in comparison with groups C and S (p&lt;0.001).",4093188
4127,4093188,the weight of half carcasses,"group C, indoor with no supplement; S, indoor with supplement,","G, outdoor with no supplement",Significantly increased,"A comparison of half carcasses across the groups has shown no difference between the control group and the one with supplements, while the weight of half carcasses in the grazing group was smaller in comparison with groups C and S (p&lt;0.001).",4093188
4128,4093188,fat content,"group C, indoor with no supplement; S, indoor with supplement,","G, outdoor with no supplement",Significantly increased,"The lack of differences in meat content of the pelvic limb between the groups, and, at the same time, the lower fat content (p&lt;0.001) in group G, plus the better parameters of pelvic limb tightness in groups C and S, are evidence of their higher fatness.",4093188
4129,4093188,internal fat depot  -  kidney with pelvic fat,"G, outdoor with no supplement",baseline,Significantly decreased,"Grazing had a lesser effect on internal fat depot (kidney with pelvic fat; p&lt;0.05) than on intermuscular (p&lt;0.001) and on subcutaneous (p&lt;0.001) fat, in keeping with the findings of other authors (KuÅºnicka, 2006; Joy et al., 2008; Carrasco et al., 2009b).",4093188
4130,4093188,internal fat depot  -   intermuscular  and on subcutaneous  fat,"G, outdoor with no supplement",baseline,Significantly increased,"Grazing had a lesser effect on internal fat depot (kidney with pelvic fat; p&lt;0.05) than on intermuscular (p&lt;0.001) and on subcutaneous (p&lt;0.001) fat, in keeping with the findings of other authors (KuÅºnicka, 2006; Joy et al., 2008; Carrasco et al., 2009b).",4093188
4131,4093188,The fat of pelvic limb  ,"group C, indoor with no supplement; S, indoor with supplement,","G, outdoor with no supplement",Significantly increased,The pelvic limb of grazing lambs contained less fat compared to the control and supplemented groups (p&lt;0.001).,4093188
4132,4093188,The concentrations of Se and Zn in the blood plasma of ram-lambs,"S, indoor with supplement,","G, outdoor with no supplement, group C, indoor with no supplement; ",Significantly increased,The concentrations of Se and Zn in the blood plasma of ram-lambs from the supplemented group were significantly higher than for the control and grazing lambs.,4093188
4133,5704449,Low density lipoprotein,Aerobic and resistance exercice + prenatal care,Prenatal care only,Significantly decreased,"At the end of the intervention programme, the multivariable analysis, which we adjusted for baseline levels, showed a difference between groups in LDL-c (-8&nbsp;mg/dL, 95%CI -3 to âˆ’29; Pâ€‰&lt;â€‰0.001) and TG (âˆ’6&nbsp;mg/dL, 95%CI 1 to 11; Pâ€‰=â€‰0.03).",5704449
4134,5704449,Triglycerides ,Aerobic and resistance exercice + prenatal care,Prenatal care only,Significantly decreased,"At the end of the intervention programme, the multivariable analysis, which we adjusted for baseline levels, showed a difference between groups in LDL-c (-8&nbsp;mg/dL, 95%CI -3 to âˆ’29; Pâ€‰&lt;â€‰0.001) and TG (âˆ’6&nbsp;mg/dL, 95%CI 1 to 11; Pâ€‰=â€‰0.03).",5704449
4135,5704449,Weight gained,Aerobic and resistance exercice + prenatal care,Prenatal care only,No significant difference,There were no significant differences between the groups regarding maternal weight gain and BMI during the exercise programme period,5704449
4136,5704449,Preterm birth,Aerobic and resistance exercice + prenatal care,Prenatal care only,No significant difference,"In the same vein, the percentage of preterm deliveries did not differ between the exercise and control group (Pâ€‰=â€‰0.64).",5704449
4137,5704449,Baby's weight at birth,Aerobic and resistance exercice + prenatal care,Prenatal care only,No significant difference,"There was no significant difference between the experimental and control groups regarding mean birth weight (3133â€‰Â±â€‰406&nbsp;g versus 3013â€‰Â±â€‰494&nbsp;g, Pâ€‰=â€‰0.34), low birth weight (&lt; 2500&nbsp;g; (nâ€‰=â€‰3 versus nâ€‰=â€‰2) or high birth weight (&gt; 4000&nbsp;g; nâ€‰=â€‰1 versus nâ€‰=â€‰0)",5704449
4138,5704449,Need for C-section,Aerobic and resistance exercice + prenatal care,Prenatal care only,No significant difference,"The experimental group showed a higher percentage in of Caesarean sections in comparison to the control group without significant differences (27% compared with 13%, Pâ€‰=â€‰0.89).",5704449
4139,3713866,Salivary secretion,Pilocarpine,No treatment,Significantly increased,Comparisons between the rate of secretion showed no significant differences in bromhexine users (P=0.35) but there were significant differences in pilocarpine users (P=0.0001).,3713866
4140,3713866,Salivary secretion,Bromhexine,No treatment,No significant difference,Comparisons between the rate of secretion showed no significant differences in bromhexine users (P=0.35) but there were significant differences in pilocarpine users (P=0.0001).,3713866
4141,3713866,Xerostomia ,Pilocarpine,No treatment,Significantly decreased,"Furthermore, 28% and 100% of bromhexine and pilocarpine users showed improvement of xerostomia after fourteen days, respectively. Statistical analysis showed significant differences in improvement of xerostomia for users of both medications (P=0.0001).",3713866
4142,3713866,Xerostomia ,Bromhexine,No treatment,Significantly decreased,"Furthermore, 28% and 100% of bromhexine and pilocarpine users showed improvement of xerostomia after fourteen days, respectively. Statistical analysis showed significant differences in improvement of xerostomia for users of both medications (P=0.0001).",3713866
4143,3713866,Difficulties with chewing,Policarpine,No treatment,Significantly decreased,All the (100%) pilocarpine users and 14.3% of bromhexine users demonstrated improvement of chewing difficulties,3713866
4144,4636858,Multiple sclerosis plaques,Mitoxantrone + methylprednisolone,Mitoxantrone only,No significant difference,MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782).,4636858
4145,4636858,Multiple sclerosis plaques ,Mitoxantrone + methylprednisolone,No treatment,Significantly decreased,The mean number of MRI plaques showed significant reduction in the both groups after the treatment (P value &lt; 0.05),4636858
4146,4636858,Multiple sclerosis plaques after 6 months,Mitoxantrone + methylprednisolone,Mitoxantrone only,No significant difference,"Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611).",4636858
4147,4636858,Expanded disability status scale,Mitoxantrone + methylprednisolone,Mitoxantrone only,No significant difference,The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953),4636858
4148,4636858,Expanded disability status scale,Mitoxantrone only,No treatment,Significantly decreased,EDSS reduced significantly in the both groups at the end of treatment completion (P value &lt; 0.05),4636858
4149,4164149,Pregnancy rate,Subcutaneous progesterone,Vaginal progesterone,No significant difference,"the ongoing pregnancy rate per retrieval for subcutaneous versus vaginal progesterone was 41.6 versus 44.4%, with a difference between groups of âˆ’2.8% (95% CI âˆ’9.7, 4.2), consistent with the non-inferiority of subcutaneous progesterone for luteal phase support.",4164149
4150,4164149,Positive Î²-hCG at start,Subcutaneous progesterone,Vaginal progesterone,No significant difference,"In addition, rates of initial positive Î²-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% CI âˆ’9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% CI âˆ’10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% CI âˆ’7.6, 4.0), live birth (41.1 versus 43.1%; 95% CI âˆ’8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% CI âˆ’8.4, 5.4) were comparable.",4164149
4151,4164149,Pregnancy with fetal cardiac activity (in uterus),Subcutaneous progesterone,Vaginal progesterone,No significant difference,"In addition, rates of initial positive Î²-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% CI âˆ’9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% CI âˆ’10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% CI âˆ’7.6, 4.0), live birth (41.1 versus 43.1%; 95% CI âˆ’8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% CI âˆ’8.4, 5.4) were comparable.",4164149
4152,4164149,Implantation,Subcutaneous progesterone,Vaginal progesterone,No significant difference,"In addition, rates of initial positive Î²-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% CI âˆ’9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% CI âˆ’10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% CI âˆ’7.6, 4.0), live birth (41.1 versus 43.1%; 95% CI âˆ’8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% CI âˆ’8.4, 5.4) were comparable.",4164149
4153,4164149,Babies born alive,Subcutaneous progesterone,Vaginal progesterone,No significant difference,"In addition, rates of initial positive Î²-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% CI âˆ’9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% CI âˆ’10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% CI âˆ’7.6, 4.0), live birth (41.1 versus 43.1%; 95% CI âˆ’8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% CI âˆ’8.4, 5.4) were comparable.",4164149
4154,4164149,Babies taken home,Subcutaneous progesterone,Vaginal progesterone,No significant difference,The take-home baby rate per embryo transfer (the most important outcome measure from the patient's perspective) for Prolutex versus Endometrin was 41.1 versus 42.6% (P = 0.72),4164149
4155,3984795,Fasting blood glucose,Probiotic (VSL#3),Placebo,Significantly decreased,"Fasting blood glucose (FBG) rose slightly in the placebo group but reduced significantly (P &lt; 0.05) in the probiotic, omega-3, and probiotic + omega-3 combination groups.",3984795
4156,3984795,Fasting blood glucose,Omega-3,Placebo,Significantly decreased,"Fasting blood glucose (FBG) rose slightly in the placebo group but reduced significantly (P &lt; 0.05) in the probiotic, omega-3, and probiotic + omega-3 combination groups.",3984795
4157,3984795,Lipid profile improvement,Probiotic (VSL#3),Placebo,Significantly increased,"In the probiotic group HDL increased by 18.5% (P &lt; 0.01); LDL (P &lt; 0.05), triglycerides, and VLDL (P &lt; 0.01) decreased by 7.04%, 5.8%, and 12.98%, respectively",3984795
4158,3984795,Lipid profile improvement,Omega-3,Placebo,Significantly increased,"In the omega-3 group, total cholesterol, triglycerides, LDL, and VLDL decreased and HDL increased significantly by 6.7% (P &lt; 0.01)",3984795
4159,3984795,Atherogenic Index,Probiotic (VSL#3),Placebo,Significantly decreased,"Atherogenic index was significantly (P &lt; 0.01) decreased in the probiotic, omega-3, and combination groups.",3984795
4160,3984795,Atherogenic Index,Omega-3,Placebo,Significantly decreased,"Atherogenic index was significantly (P &lt; 0.01) decreased in the probiotic, omega-3, and combination groups.",3984795
4161,4758401,Elevation of glucose and glucagon after 1 hour,Insulin + Pramlintide (all doses),Insulin alone,Significantly decreased,"Compared with placebo/insulin, all three pramlintide/insulin ratios produced marked and statistically equivalent reductions of increments of glucose and glucagon in the first hour, with levels subsequently increasing",4758401
4162,4758401,Elevation of glucose and glucagon after 1 hour,Insulin + Pramlintide (6 mcg/U),Insulin + Pramlintide (12 mcg/U),No significant difference,"Compared with placebo/insulin, all three pramlintide/insulin ratios produced marked and statistically equivalent reductions of increments of glucose and glucagon in the first hour, with levels subsequently increasing.",4758401
4163,4758401,Glucose AUC 0â€“3 h,Insulin + Pramlintide (all doses),Insulin alone,Significantly decreased,"The AUC0â€“3 h for glucose was reduced by 60, 58 and 72% for the 6, 9 and 12 mcg/U ratios (Table 1; all doses vs placebo: p &lt; 0.001)",4758401
4164,4758401,Glucagon AUC 0â€“3 h,Insulin + Pramlintide (all doses),Insulin alone,Significantly decreased,"Reductions of AUC0â€“3 h for glucagon for the 6, 9 and 12 mcg/U were 57, 59 and 55% (Table 1; all doses vs placebo: p &lt; 0.05)",4758401
4165,4758401,Hypoglycemia after 24 hours,Insulin + Pramlintide (all doses),Insulin alone,No significant difference,No symptomatic hypoglycaemia occurred during the 24â€�h period after pramlintide administration.,4758401
4166,4632405,Incidence of Diabetes,JQJT tablets,Placebo,Significantly decreased,Jinqi&nbsp;Jiangtang&nbsp;tablet&nbsp;effectively&nbsp;reduced&nbsp;the&nbsp;incidence&nbsp;of&nbsp;diabetes mellitus&nbsp;and enhanced reversion&nbsp;rate.&nbsp;compared&nbsp;with&nbsp;the&nbsp;control&nbsp;group (p&lt; 0.05),4632405
4167,4632405,SF-36 questionnaire,JQJT tablets,Placebo,No significant difference,compared&nbsp;with&nbsp;the&nbsp;control&nbsp;group (p&lt; 0.05); the&nbsp;scores&nbsp;of&nbsp;SF-36&nbsp;of&nbsp;two&nbsp;groups&nbsp;had&nbsp;no&nbsp;significant&nbsp;difference P&gt; 0.05);,4632405
4168,4632405,Patient compliance,JQJT tablets,Placebo,No significant difference,and the compliance of participants showed no significant difference between the two groups.,4632405
4169,4632405,Baseline values,JQJT tablets,Placebo,No significant difference,Jinqi&nbsp;Jiangtang&nbsp;tablet&nbsp;effectively&nbsp;reduced&nbsp;the&nbsp;incidence&nbsp;of&nbsp;diabetes mellitus&nbsp;and enhanced reversion&nbsp;rate.&nbsp;compared&nbsp;with&nbsp;the&nbsp;control&nbsp;group (p&lt; 0.05),4632405
4170,4632405,Pre-diabetes reversion,JQJT tablets,Placebo,Significantly increased,The JinQi Jiangtang tablet effectively reduced the incidence of diabetes mellitus and enhanced the reversion rate.,4632405
4171,3314673,Perceived stress scale,Second Life program,No program,No significant difference,PSS	15.7Â±5.9	15Â±6.7	âˆ’0.7	0.501,3314673
4172,3314673,Global Severity Index of the SCL 90-r,Second Life program,No program,Significantly decreased,Change on the Global Severity Index of the SCL 90-r reached statistical significance as shown in Table 5,3314673
4173,3314673,Depression index of the SCL-90-r,Second Life program,No program,No significant difference,DEP	57.6Â±9.4	57.0Â±10.4	âˆ’0.6	0.683,3314673
4174,3314673,Anxiety Index of the SCL-90-r,Second Life program,No program,No significant difference,ANX	56.8Â±10.2	54.8Â±11.4	âˆ’2.0	0.126,3314673
4175,4292865,Pancreatitis,E-mode Endoscopic sphincterotomy,C-mode Endoscopic sphincterotomy,No significant difference,There were 6 (3.4%) patients with pancreatitis in the E-mode group (5 mild and 1 moderate pancreatitis) versus 7 (3.9%) patients with pancreatitis (7 mild pancreatitis) in the conventional blended C-mode group. There was no significant difference of the frequency of pancreatitis between both groups.,4292865
4176,4292865,Evident bleeding,E-mode Endoscopic sphincterotomy,C-mode Endoscopic sphincterotomy,No significant difference,There were 14 (7.8%) patients with endoscopically evident bleeding in the E-mode group versus 18 (9.9%) patients with endoscopically evident bleeding in the conventional blended C-mode group. The frequency of endoscopically evident bleeding was not significantly different.,4292865
4177,4292865,Hemorrhage ,E-mode Endoscopic sphincterotomy,C-mode Endoscopic sphincterotomy,No significant difference,"There was no case of clinically evident hemorrhage in either group at the time of EST, 24 hours after EST, or within 7 days of randomization.",4292865
4178,4292865,Amylase levels,E-mode Endoscopic sphincterotomy,C-mode Endoscopic sphincterotomy,No significant difference,"Thus, there was no significant clinical difference of the serum total amylase levels after EST between both groups.",4292865
4179,4292865,Perforation,E-mode Endoscopic sphincterotomy,C-mode Endoscopic sphincterotomy,No significant difference,No patients experienced perforation.,4292865
4180,3926947,Responsiveness,Interactive Voice Response,Questionnaire sent by post,Significantly increased,The response rate for complete answers was 65% in the IVR group and 38% in the postal survey group (pâ€‰=â€‰0.014).,3926947
4181,3926947,Need for reminders,Interactive Voice Response,Questionnaire sent by post,Significantly decreased,There was less need for reminders in the IVR group (pâ€‰=â€‰0.000),3926947
4182,3926947,This is not a prompt. I just need to use prompts from different Sections to move to next article but no results are displayed in the Results section,Interactive Voice Response,Questionnaire sent by post,No significant difference,Results,3926947
4183,2723123,Dentin mineral loss,Fluoride toothpaste (5000 ppm) ,Fluoride mouth rinse (250 ppm) ,Significantly decreased,The mean mineral loss from dentin was significantly lower in the group treated with 5000 ppm fluoride compared to the 250 ppm fluoride group and the control group.,2723123
4184,2723123,Dentin mineral loss,Fluoride toothpaste (5000 ppm) ,Control (distilled water),Significantly decreased,The mean mineral loss from dentin was significantly lower in the group treated with 5000 ppm fluoride compared to the 250 ppm fluoride group and the control group.,2723123
4185,2723123,Dentin mineral loss,Fluoride mouth rinse (250 ppm) ,Control ,No significant difference,Mineral loss was not statistically significantly different between the 250 ppm fluoride and control group.,2723123
4186,2723123,Depth of the lesion,Fluoride toothpaste (5000 ppm) ,Fluoride mouth rinse (250 ppm) ,Significantly decreased,The lesion depth in dentin of the 5000 ppm fluoride group was significantly lesser than in the 250 ppm fluoride group and the control group.,2723123
4187,2723123,Depth of the lesion,Fluoride toothpaste (5000 ppm) ,Control (distilled water),Significantly decreased,The lesion depth in dentin of the 5000 ppm fluoride group was significantly lesser than in the 250 ppm fluoride group and the control group.,2723123
4188,5022334,Surgery time,Thyroidectomy via BABA,Conventional open thyroidectomy ,Significantly increased,"The mean operative time of the robotic group was longer than that of the conventional open approach group (118.8 Â± 16.5 min vs. 90.7 Â± 10.3 min, P &lt; 0.05)",5022334
4189,5022334,Visual analogue scale,Thyroidectomy via BABA,Conventional open thyroidectomy ,Significantly decreased,"The study showed significant differences between the two groups in terms of the VASs (2.1 Â± 1.0 vs. 3.8 Â± 1.2, P &lt; 0.05) and NSS (8.9 Â± 0.8 vs. 4.8 Â± 1.7, P &lt; 0.05).",5022334
4190,5022334,Numerical scoring system,Thyroidectomy via BABA,Conventional open thyroidectomy ,Significantly increased,"The study showed significant differences between the two groups in terms of the VASs (2.1 Â± 1.0 vs. 3.8 Â± 1.2, P &lt; 0.05) and NSS (8.9 Â± 0.8 vs. 4.8 Â± 1.7, P &lt; 0.05).",5022334
4191,5022334,Amount of blood lost,Thyroidectomy via BABA,Conventional open thyroidectomy ,No significant difference,"The differences between the two groups in the estimated intraoperative blood loss, postoperative hospital stay time, numbers of lymph node removed, postoperative thyroglobulin levels, and complications were not statistically significant (all P &gt; 0.05).",5022334
4192,5022334,Amount of lymph nodes removed,Thyroidectomy via BABA,Conventional open thyroidectomy ,No significant difference,"The differences between the two groups in the estimated intraoperative blood loss, postoperative hospital stay time, numbers of lymph node removed, postoperative thyroglobulin levels, and complications were not statistically significant (all P &gt; 0.05).",5022334
4193,5022334,Complications,Thyroidectomy via BABA,Conventional open thyroidectomy ,No significant difference,"The complications in both groups, such as hypoparathyroidism (temporary), RLN paralysis (temporary), seroma, skin burn, flap necrosis, hematoma, wound infection, chyle leakage, and postoperative Tg levels, were not statistically different (all P &gt; 0.05)",5022334
4194,5728078,25-hydroxyvitamin D levels,Vitamin D supplementation,No Vitamin D supplementation,Significantly increased,"In the VitD group serum 25(OH)VitD levels significantly increased by 91% (from 16.0 (3.0â€“35.0) to 30.6 (8.4â€“67.0) ng/ml, p &lt; 0.001), while in the control group no significant change was observed (from 10.0 (4.0â€“39.6) to 13.0 (3.5â€“37.0) ng/ml)",5728078
4195,5728078,Triglycerides level,Vitamin D supplementation,No Vitamin D supplementation,No significant difference,"In both groups TCHOL, TGs, HDL-C, LDL-C, ApoA1, ApoB, fasting glucose, fasting insulin, HbA1c, HOMA index and diastolic blood pressure did not significantly change.",5728078
4196,5728078,High-density lipoprotein cholesterol,Vitamin D supplementation,No Vitamin D supplementation,No significant difference,"In both groups TCHOL, TGs, HDL-C, LDL-C, ApoA1, ApoB, fasting glucose, fasting insulin, HbA1c, HOMA index and diastolic blood pressure did not significantly change.",5728078
4197,5728078,Low-density lipoprotein cholesterol,Vitamin D supplementation,No Vitamin D supplementation,No significant difference,"In both groups TCHOL, TGs, HDL-C, LDL-C, ApoA1, ApoB, fasting glucose, fasting insulin, HbA1c, HOMA index and diastolic blood pressure did not significantly change.",5728078
4198,5728078,Fasting glucose levels,Vitamin D supplementation,No Vitamin D supplementation,No significant difference,"In both groups TCHOL, TGs, HDL-C, LDL-C, ApoA1, ApoB, fasting glucose, fasting insulin, HbA1c, HOMA index and diastolic blood pressure did not significantly change.",5728078
4199,5728078,Systolic blood pressure,Vitamin D supplementation,No Vitamin D supplementation,No significant difference,"Systolic blood pressure (SBP) decreased by 3.7% (from 134 Â±14 to 129 Â±13 mm Hg, p = 0.05) in the VitD group, while it decreased by 1.5% in the control group (from 132 Â±13 to 130 Â±16 mm Hg, p = NS)",5728078
4200,5124283,CXCL7,Purified anthocyanins,Placebo,Significantly decreased,"Anthocyanin supplementation for 24&nbsp;weeks significantly decreased the plasma CXCL7 (â€“12.32% vs. 4.22%, Pâ€‰=â€‰0.001), CXCL5 (â€“9.95% vs. 1.93%, Pâ€‰=â€‰0.011), CXCL8 (â€“6.07% vs. 0.66%, Pâ€‰=â€‰0.004), CXCL12 (â€“8.11% vs. 5.43%, Pâ€‰=â€‰0.023) and CCL2 levels (â€“11.63% vs. 12.84%, Pâ€‰=â€‰0.001) compared with the placebo.",5124283
4201,5124283,CXCL12 ,Purified anthocyanins,Placebo,Significantly decreased,"Anthocyanin supplementation for 24&nbsp;weeks significantly decreased the plasma CXCL7 (â€“12.32% vs. 4.22%, Pâ€‰=â€‰0.001), CXCL5 (â€“9.95% vs. 1.93%, Pâ€‰=â€‰0.011), CXCL8 (â€“6.07% vs. 0.66%, Pâ€‰=â€‰0.004), CXCL12 (â€“8.11% vs. 5.43%, Pâ€‰=â€‰0.023) and CCL2 levels (â€“11.63% vs. 12.84%, Pâ€‰=â€‰0.001) compared with the placebo.",5124283
4202,5124283,Macrophage migration inhibitory factor ,Purified anthocyanins,Placebo,No significant difference,"Although the plasma CXCL4L1, CXCL1, MIF and PAI-1 concentrations also exhibited trends toward slight decreases during the treatment period, no significant changes were detected between the two groups.",5124283
4203,5124283,Plasminogen activator inhibitor 1,Purified anthocyanins,Placebo,No significant difference,"Although the plasma CXCL4L1, CXCL1, MIF and PAI-1 concentrations also exhibited trends toward slight decreases during the treatment period, no significant changes were detected between the two groups",5124283
4204,5124283,High-sensitivity C-reactive protein,Purified anthocyanins,Placebo,Significantly decreased,"Further, anthocyanin supplementation for 24&nbsp;weeks led to significant decreases in the plasma hsCRP [â€“21.6% (95% CI,&nbsp;â€“37.5 to â€“5.7%)], IL-1Î² [â€“12.8% (95% CI, â€“24.4 to â€“1.2%)], and sP-selectin levels [â€“5.9% (95% CI, â€“17.7 to 6.0%)] compared with the placebo.",5124283
4205,4253794,Time needed to intubate,GlideScope video-laryngoscope,Macintosh direct laryngoscope,Significantly increased,Intubation time was longer in the GVL group (9.80 Â± 1.27 s) than in the MDL group (8.20 Â± 1.17 s) (P &lt; 0.05).,4253794
4206,4253794,Increase in Rate pressure product (First 3 minutes),GlideScope video-laryngoscope,Macintosh direct laryngoscope,Significantly decreased,"MAP, pulse rate, and RPP were lower in the GVL than the MDL group after endotracheal intubation (P &lt; 0.05)",4253794
4207,4253794,Mean arterial blood pressure (first 3 minutes),GlideScope video-laryngoscope,Macintosh direct laryngoscope,Significantly decreased,MAP increase after intubation was significantly higher in the MDL than the GVL group in the first 3 minutes after intubation,4253794
4208,4253794,Mean arterial blood pressure (after 5 minutes),GlideScope video-laryngoscope,Macintosh direct laryngoscope,No significant difference,"However, the values returned to pre-intubation levels after 5 minutes in both groups",4253794
4209,4253794,Drop in pulse rate (first 3 minutes),GlideScope video-laryngoscope,Macintosh direct laryngoscope,Significantly decreased,"PR showed a significant drop after induction in both groups. Nevertheless, this was similar in both groups (Table 3). In contrast, after intubation, the changes were more significant in the MDL than the GVL group in the first 3 minutes",4253794
4210,4610679,Physical activity,Health risk assessment (HRA),No HRA,Significantly increased,"70% compared to 62% were physically active (odds ratio 1.43, 95% CI 1.16â€“1.77, p = 0.001)",4610679
4211,4610679,Influenza vaccinations,Health risk assessment (HRA),No HRA,Significantly increased,"66% compared to 59% had influenza vaccinations in the past year (odds ratio 1.35, 95% CI 1.09â€“1.66, p = 0.005)",4610679
4212,4610679,Mortality rate (after 8 years),Health risk assessment (HRA),No HRA,Significantly decreased,"the estimated proportion alive was 77.9% in the intervention and 72.8% in the control group, for an absolute mortality difference of 4.9% (95% CI 1.3%â€“8.5%, p = 0.009; based on z-test for risk difference)",4610679
4213,4610679,Glucose measurement frequency,Health risk assessment (HRA),No HRA,Significantly increased,"Glucose measurement in past 3 y	670 (81.0)	1,014 (76.8)	1.29 (1.03â€“1.62)	0.03",4610679
4214,4610679,Pneumococcal vaccination,Health risk assessment (HRA),No HRA,Significantly increased,Pneumococcal vaccination (ever)	259 (31.3)	266 (20.2)	1.90 (1.52â€“2.37)	&lt;0.001,4610679
4215,4950066,Glycated hemoglobin,Vitamin D3 (cholecalciferol) supplementation,Placebo,No significant difference,"There was no effect of vitamin D supplementation on HbA1c: D2 versus placebo: âˆ’0.05% [95% confidence interval (CI) âˆ’0.11, 0.02] or âˆ’0.51 mmol/mol (95% CI âˆ’1.16, 0.14; p = 0.13); D3 versus placebo: 0.02% (95% CI âˆ’0.04, 0.08) or 0.19 mmol/mol (95% CI âˆ’0.46, 0.83; p = 0.57).",4950066
4216,4950066,Glycated hemoglobin,Vitamin D2 (ergocalciferol) supplementation ,Placebo,No significant difference,"There was no effect of vitamin D supplementation on HbA1c: D2 versus placebo: âˆ’0.05% [95% confidence interval (CI) âˆ’0.11, 0.02] or âˆ’0.51 mmol/mol (95% CI âˆ’1.16, 0.14; p = 0.13); D3 versus placebo: 0.02% (95% CI âˆ’0.04, 0.08) or 0.19 mmol/mol (95% CI âˆ’0.46, 0.83; p = 0.57).",4950066
4217,4950066,Liver function markers,Vitamin D3 (cholecalciferol) supplementation,Placebo,No significant difference,"Among the secondary outcomes, there were no differences comparing D2 with placebo (Figure 4A) or D3 with placebo (Figure 4B) for anthropometric measures, blood pressure, hsCRP, CVD risk, assessed by UKPDS risk engine, hepatic markers, or fructosamine",4950066
4218,4950066,Blood pressure ,Vitamin D3 (cholecalciferol) supplementation,Placebo,No significant difference,"Among the secondary outcomes, there were no differences comparing D2 with placebo (Figure 4A) or D3 with placebo (Figure 4B) for anthropometric measures, blood pressure, hsCRP, CVD risk, assessed by UKPDS risk engine, hepatic markers, or fructosamine",4950066
4219,4950066,Arterial Stiffness (Pulse Wave Velocity),Vitamin D2 (ergocalciferol) supplementation ,Placebo,Significantly decreased,"There was a reduction from baseline in PWV in both the D2 [mean (s.d.) âˆ’0.17 (2.5) m/s] and D3 [mean (s.d.) âˆ’0.75 (2.1) m/s] groups, relative to placebo [treatment difference D2 vs placebo: âˆ’0.68 (95% CI âˆ’1.31,âˆ’0.05) m/s; D3 vs placebo: âˆ’0.73 (95% CI âˆ’1.42, âˆ’0.03) m/s",4950066
4220,4950066,Arterial Stiffness (Pulse Wave Velocity),Vitamin D3 (cholecalciferol) supplementation,Placebo,Significantly decreased,"There was a reduction from baseline in PWV in both the D2 [mean (s.d.) âˆ’0.17 (2.5) m/s] and D3 [mean (s.d.) âˆ’0.75 (2.1) m/s] groups, relative to placebo [treatment difference D2 vs placebo: âˆ’0.68 (95% CI âˆ’1.31,âˆ’0.05) m/s; D3 vs placebo: âˆ’0.73 (95% CI âˆ’1.42, âˆ’0.03) m/s;",4950066
4221,3633335,Vomiting,Sevoflurane + Ondansetron,Sevoflurane alone,Significantly decreased,"We found that the incidence of vomiting was lower in group II (17.5%), group IV (7.5%), and group VI (10%) compared with group I (55%), group III (27.5%), and group V (30%), respectively (P &lt; 0.05).",3633335
4222,3633335,Vomiting,Propofol + Ondansetron,Propofol alone,Significantly decreased,"We found that the incidence of vomiting was lower in group II (17.5%), group IV (7.5%), and group VI (10%) compared with group I (55%), group III (27.5%), and group V (30%), respectively (P &lt; 0.05).",3633335
4223,3633335,Vomiting,Propofol alone,Sevoflurane alone,Significantly decreased,The incidence of vomiting was also lower in group III (27.5%) and group V (30%) when compared with group I (55%) (P &lt; 0.05).,3633335
4224,3633335,Nausea,Sevoflurane + Ondansetron,Sevoflurane alone,No significant difference,"No statistically significant difference was noted in incidence of nausea in groups II, IV, and VI. The same was true regarding incidence of nausea when comparing group II versus group I, group IV versus group III, and group VI versus group V",3633335
4225,3633335,Nausea,Propofol + Ondansetron,Propofol alone,No significant difference,"No statistically significant difference was noted in incidence of nausea in groups II, IV, and VI. The same was true regarding incidence of nausea when comparing group II versus group I, group IV versus group III, and group VI versus group V",3633335
4226,3633335,Nausea,Propofol alone,Sevoflurane alone,Significantly decreased,Groups III and V had a lower incidence of nausea than group I (P &lt; 0.05).,3633335
4227,2361515,Overall response rate,Oxaliplatin + Raltitrexed,Irinotecan + Raltitrexed,No significant difference,"According to the ITT analysis, the overall response rate was 46% (95% CI 29.5â€“57.7%) for arm A (oxaliplatin/raltitrexed) and 34% (95% CI, 19.8â€“48.4%) for arm B (irinotecan/raltitrexed). These differences were not significant (P&gt;0.05)",2361515
4228,2361515,Duration of response,Oxaliplatin + Raltitrexed,Irinotecan + Raltitrexed,No significant difference,"Median duration of response was 7.9 and 9.2 months, respectively (P=0.696",2361515
4229,2361515,Time to tumor progression,Oxaliplatin + Raltitrexed,Irinotecan + Raltitrexed,No significant difference,The median TTP was 8.2 months for arm A and 8.8 months for arm B (P=0.565,2361515
4230,2361515,Diarrhoea of some grade,Oxaliplatin + Raltitrexed,Irinotecan + Raltitrexed,Significantly decreased,"It should be noted that 14 patients (31%) from arm A had some grade of diarrhoea, while it was observed in 24 patients (52%) from arm B (P&lt;0.05).",2361515
4231,2361515,Asthenia ,Oxaliplatin + Raltitrexed,Irinotecan + Raltitrexed,No significant difference,"Overall, asthenia was detected in 17 patients (35%) in arm A and in 24 patients (52%) in arm B. However, these differences were not significant from a statistical point of view (P=NS)",2361515
4232,5846971,Quality of life after 3 months,Resistance training (Once a week),No training,Significantly increased,"After 3 months, there was an intervention effect on environmental quality of life (groupâ€‰Ã—â€‰time pâ€‰=â€‰.048)",5846971
4233,5846971,Quality of life after 3 months,Resistance training (Twice a week),No training,Significantly increased,RT2 had significant differences compared to CG (pâ€‰=â€‰.001),5846971
4234,5846971,Quality of life 3-9 months,Resistance training (Once a week),Resistance training (Twice a week),Significantly decreased,"Between 3 and 9 months, environmental quality of life decreased among RT1 compared to RT2 and RT3 (groupâ€‰Ã—â€‰time pâ€‰=â€‰.025)",5846971
4235,5846971,Quality of life 0-9 months,Resistance training (Twice a week),Resistance training (Three times a week),Significantly increased,"Between baseline and 9 months, environmental quality of life increased in RT2 compared to all other groups (groupâ€‰Ã—â€‰time pâ€‰=â€‰.011)",5846971
4236,5846971,Sense of coherence,Resistance training (Twice a week),Resistance training (Three times a week),Significantly increased,Sense of coherence increased in RT2 compared to the control group and RT3 (groupâ€‰Ã—â€‰time pâ€‰=â€‰.032),5846971
4237,5947263,AUC (FEV1)/h,Procaterol hydrochloride inhaler,Approved inhaler,No significant difference,"Results of ANOVA showed no significant group or carryover effects for either AUC (FEV1)/h and maximum FEV1 (P = .50 and P = .59, respectively)",5947263
4238,5947263,FEV1 Max,Procaterol hydrochloride inhaler,Approved inhaler,No significant difference,"Results of ANOVA showed no significant group or carryover effects for either AUC (FEV1)/h and maximum FEV1 (P = .50 and P = .59, respectively)",5947263
4239,5947263,Period effects for AUC (FEV1)/h,Procaterol hydrochloride inhaler,Approved inhaler,No significant difference,"no significant period effects for either AUC (FEV1)/h and maximum FEV1 (P = .19 and P = .42, respectively)",5947263
4240,5947263,Period effects for FEV1 Max,Procaterol hydrochloride inhaler,Approved inhaler,No significant difference,"no significant period effects for either AUC (FEV1)/h and maximum FEV1 (P = .19 and P = .42, respectively)",5947263
4241,5947263,Mortality or significant adverse events,Procaterol hydrochloride inhaler,Approved inhaler,No significant difference,There were no deaths or other significant adverse events.,5947263
4242,5350209,Speed of alcohol consumption,Visual warning (image),No warning,Significantly decreased,where consumption was significantly faster in the â€˜no health warningâ€™ compared to both the text and pictorial conditions (pâ€‰&lt;â€‰.001),5350209
4243,5350209,Speed of alcohol consumption,Visual warning (text),No warning,Significantly decreased,where consumption was significantly faster in the â€˜no health warningâ€™ compared to both the text and pictorial conditions (pâ€‰&lt;â€‰.001),5350209
4244,5350209,Speed of alcohol consumption,Visual warning (image),Visual warning (text),No significant difference,"where consumption was significantly faster in the â€˜no health warningâ€™ compared to both the text and pictorial conditions (pâ€‰&lt;â€‰.001), with the latter two not differing significantly (pâ€‰=â€‰.76",5350209
4245,5350209,Acceptance of alcohol,Visual warning (image),No warning,Significantly decreased,"A significant effect of health-warning label was found, F(2, 42)â€‰=â€‰7.01, pâ€‰=â€‰.002, Î· p 2â€‰=â€‰.25, with as expected, significantly lower ratings in the pictorial condition versus the â€˜no health warningâ€™ condition (pâ€‰=â€‰.002)",5350209
4246,5350209,Acceptance of alcohol,Visual warning (text),No warning,No significant difference,"A significant effect of health-warning label was found, F(2, 42)â€‰=â€‰7.01, pâ€‰=â€‰.002, Î· p 2â€‰=â€‰.25, with as expected, significantly lower ratings in the pictorial condition versus the â€˜no health warningâ€™ condition (pâ€‰=â€‰.002), but more surprisingly, there was no difference between the latter and the text condition (pâ€‰=â€‰.10)",5350209
4247,5350209,Acceptance of alcohol,Visual warning (image),Visual warning (text),No significant difference,There were also no differences between the text and pictorial conditions (pâ€‰=â€‰.41).,5350209
4248,5015408,OAC candidates rates,Electronic alert system,No system,No significant difference,There was no difference in the proportion of OAC candidates based on the CHA2DS2â€�VASC score between the alert (443; 97.4%) and the control (413; 95.2%) groups (P=0.083),5015408
4249,5015408,HASBLED score of â‰¥3,Electronic alert system,No system,No significant difference,There was no difference in the proportion of patients with HASBLED score of â‰¥3 between the alert (208; 45.7%) and the control (183; 42.2%) groups (P=0.287),5015408
4250,5015408,HASBLED score of â‰¥5,Electronic alert system,No system,No significant difference,There was no difference in the proportion of patients with HASBLED score of â‰¥5 between the alert (16; 3.5%) and the control (16; 3.7%) groups (P=0.892).,5015408
4251,5015408,Probability for adequate OAC prescription,Electronic alert system,No system,Significantly increased,"Overall, 100 (22.0%) patients from the alert group versus 69 (15.9%) from the control group received an adequate OAC prescription (Table&nbsp; 3) (relative risk 1.38; P=0.021)",5015408
4252,5015408,Dual antiplatelet therapy prescribed,Electronic alert system,No system,No significant difference,"dual antiplatelet therapy was ordered in 55 (15.5%) and 63 (17.3%), respectively (P=0.51)",5015408
4253,3897026,Recovery time,Ketamine,Control,No significant difference,There were no differences in the recovery time (17.3 Â± 3.4 in the case group vs. 16.3 Â± 3 in the control group,3897026
4254,3897026,Post-Surgical Pain,Ketamine,Control,No significant difference,postoperative pain scores (5 Â± 1 in the case group vs. 5.6 Â± 2 in the control group,3897026
4255,3897026,Anesthetic usage,Ketamine,Control,No significant difference,"the consumption of anesthetic (9376.9 Â± 1245.8 in the case group vs. 9012.9 Â± 1620 in the control group,",3897026
4256,3897026,Usage of analgesics,Ketamine,Control,No significant difference,the analgesic requirements (1000 in the case group vs. 940.9 Â± 135.6 in the control group,3897026
4257,3897026,Time for extubation ,Ketamine,Control,Significantly decreased,"The extubation time in the case group was significantly shorter than in the control group (P = 0.01, Table 1)",3897026
4258,4648234,Agreement between  Experts and Sponsors,New law criteria (Concept),Intuitive approach (ad hoc),No significant difference,Chance-corrected agreement between the Expert Group and Sponsors was low within the concept arm (kappa: 0.27; 95% CI = 0.06â€“0.50) and the ad hoc arm (0.34; 95% CI = 0.10â€“0.58),4648234
4259,4648234,Kappa values,New law criteria (Concept),Intuitive approach (ad hoc),No significant difference,The difference between kappa values was 0.07 in favour of the ad hoc procedure (p-value: 0.67),4648234
4260,4648234,Agreement between  Experts and Sponsors,Commercial sponsor,Academic sponsor,No significant difference,"Neither the type of sponsor, whether commercial or academic (p-value for interaction: 0.74), nor the type of intervention (p-value for interaction: 0.85) affected the degree of agreement between assessors",4648234
4261,5471755,Mini-Mental State Examination improvement,MLC601,Control,Significantly increased,The cognition changes based on both MMSE and ADAS-cog scores were statistically significant between the placebo and the MLC601 group (p &lt; 0.001),5471755
4262,5471755,ADAS-cog score improvement,MLC601,Control,Significantly increased,The cognition changes based on both MMSE and ADAS-cog scores were statistically significant between the placebo and the MLC601 group (p &lt; 0.001),5471755
4263,5471755,Abdominal discomfort,MLC601,Control,No significant difference,"Only 5 patients (14.7%) reported AEs in the MLC601 group, including nausea (8.8%), diarrhea (8.8%), constipation (5.8%), abdominal discomfort (2.9%), and anorexia",5471755
4264,5471755,Changes in blood count,MLC601,Control,No significant difference,"Also, we did not find any abnormalities in blood count and in liver and renal function.",5471755
4265,5471755,Renal function,MLC601,Control,No significant difference,"Also, we did not find any abnormalities in blood count and in liver and renal function.",5471755
4266,2360030,Response rate,Irinotecan,Oxaliplatin,No significant difference,"Six CR and 19 PR were recorded in the TEGAFIRI arm, for an overall response rate of 41.7% (95% CL, from 29.1 to 55.1%). In the TEGAFOX arm, six CR and 22 PR were recorded, corresponding to an overall response rate of 38.9% (95% CL, from 27.6 to 51.1).",2360030
4267,2360030,Response duration,Irinotecan,Oxaliplatin,No significant difference,The median duration of response was 6 (range: 3â€“15) for TEGAFIRI and 6 months (range: 3â€“23) for TEGAFOX group.,2360030
4268,2360030,Diarrhoea,Irinotecan,Oxaliplatin,Significantly increased,Diarrhoea was prevalent in the TEGAFIRI arm (16%) vs TEGAFOX (4%),2360030
4269,2360030,Hand-foot syndrome,Irinotecan,Oxaliplatin,Significantly decreased,No HFS was reported in the TEGAFIRI group whereas grade 1â€“2 HFS was evident in 10% of the TEGAFOX group,2360030
4270,2360030,Grade 3â€“4 toxicity,Irinotecan,Oxaliplatin,No significant difference,"Sequential grade 3â€“4 toxicity (as defined in the Materials and methods section) was recorded in four (5.9, 95% CL, from 1.6 to 14.4%) TEGAFIRI patients and three (4.1, 95% CL, from 0.9 to 11.5%) TEGAFOX patients.",2360030
4271,4984795,Overall survival,Low  Ang-2 + bevacizumab,High  Ang-2 + bevacizumab,Significantly decreased,Low Ang-2 levels were associated with prolonged OS in both treatment armes analysed separately.,4984795
4272,4984795,Liver metastasis,Low  Ang-2 ,High  Ang-2 ,Significantly decreased,Logistic regression analysis confirmed that Ang-2 levels were strongly correlated with the frequency of liver metastasis at any time,4984795
4273,1913602,Systolic blood pressure ,Improved cookstove,Control,Significantly decreased,"After adjustment, the plancha improved stove was associated with 3.7 mm Hg lower SBP [95% confidence interval (CI), âˆ’8.1 to 0.6] and 3.0 mm Hg lower DBP (95% CI, âˆ’5.7 to âˆ’0.4)",1913602
4274,1913602,Diastolic blood pressure ,Improved cookstove,Control,Significantly decreased,"After adjustment, the plancha improved stove was associated with 3.7 mm Hg lower SBP [95% confidence interval (CI), âˆ’8.1 to 0.6] and 3.0 mm Hg lower DBP (95% CI, âˆ’5.7 to âˆ’0.4)",1913602
4275,1913602,Systolic blood pressure ,Improved cookstove + smoking,Improved cookstove + No smoking,No significant difference,"Excluding smokers did not alter the results, and there was no significant interaction between intervention and ever smoking nor intervention and SHS exposure for either BP measure (all p &gt; 0.25).",1913602
4276,1913602,Diastolic blood pressure ,Improved cookstove + smoking,Improved cookstove + No smoking,No significant difference,"Excluding smokers did not alter the results, and there was no significant interaction between intervention and ever smoking nor intervention and SHS exposure for either BP measure (all p &gt; 0.25).",1913602
4277,1913602,Personal PM 2.5,Improved cookstove,Control,Significantly decreased,Personal PM2.5 was about 61% lower on average and had a narrower distribution among the plancha improved stove group compared with the open fire group.,1913602
4278,3678237,Consciousness Commands improvement,Erythropoietin,Control,Significantly increased,"This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).",3678237
4279,3678237,Facial palsy score improvement,Erythropoietin,Control,Significantly increased,"This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).",3678237
4280,3678237,Motor arm Score improvement,Erythropoietin,Control,Significantly increased,"This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).",3678237
4281,3678237,Best language score improvement,Erythropoietin,Control,Significantly increased,"This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).",3678237
4282,3678237,Sensory score improvement,Erythropoietin,Control,Significantly increased,"it was 0.00 Â± 0.000 in erythropoietin group and 0.28 Â± 0.666 in control group, which had significant difference (P = 0.009).",3678237
4283,3678237,Motor leg Score improvement,Erythropoietin,Control,Significantly increased,"After 4 weeks, they reached to 0.65 Â± 0.588 in erythropoietin and 1.74 Â± 1.236 in control groups, which had significant difference (P = 0.0001).",3678237
4284,3557008,Heart rate,Ephedrine,Control (nothing),No significant difference,No significant change in PR was detected in normal saline group (93.9 Â± 18.3 vs. 93.8 Â± 17.2 beats/min; P = 0.938) or the Ephedrine group (100.1 Â± 20.9 vs. 97.6 Â± 12.9; P = 0.341).,3557008
4285,3557008,Heart rate,Saline,Control (nothing),No significant difference,No significant change in PR was detected in normal saline group (93.9 Â± 18.3 vs. 93.8 Â± 17.2 beats/min; P = 0.938) or the Ephedrine group (100.1 Â± 20.9 vs. 97.6 Â± 12.9; P = 0.341).,3557008
4286,3557008,Systolic blood preasure,Ephedrine,Control (nothing),No significant difference,No significant differences were found in the two groups in SBP before and after hospitalization in the ICU (P &gt; 0.05),3557008
4287,3557008,Central venous pressure,Saline,Control (nothing),Significantly decreased,The mean CVP was also reduced significantly (10.7 Â± 2.9 vs. 8.2 Â± 3.4; P &lt; 0.001),3557008
4288,3557008,Diastolic blood pressure,Ephedrine,Control (nothing),Significantly decreased,DBP also showed a significant reduction in the ephedrine group (65.6 Â± 12.7 vs. 61.4 Â± 11.8; P &lt; 0.001),3557008
4289,3557008,Diastolic blood pressure,Saline,Control (nothing),Significantly decreased,"In addition, a significant reduction in mean DBP was observed in the normal saline group (68.5 Â± 11.8 vs. 61.5 Â± 12.1 mmHg; P &lt; 0.001)",3557008
4290,4558453,Heart Rate in virtual immersive environment,Exercise of moderate intensity,No exercise,Significantly increased,"Heart rates showed significant increases from rest to No-Exercise and Exercise trials (F (3,51) = 39.63, p &lt; 0.05), and these changes were consistent across the three levels of virtual environment exposure",4558453
4291,4558453,Sense of presence in virtual immersive environment,Exercise of moderate intensity,No exercise,Significantly increased,"Furthermore, these changes indicated that exercise augments the demands of virtual environment exposures and this likely contributed to an enhanced sense of presence",4558453
4292,4558453,Assessment of Mental State - PEPS and PSYCH,Exercise of moderate intensity,No exercise,Significantly increased,"There were significant main effects where mental state differed between Exercise and No-Exercise trials and between the different levels of virtual environment exposure (F (4,68) = 3.37, p &lt; 0.05). Post hoc analysis revealed increases in PEPS and PSYCH from Control to OSM and TSM during the Exercise trial, whereas MOT increased from Control to OSM and TSM in the No-Exercise trial",4558453
4293,4704894,Intervention engagement for all groups over time,TTM based posts (beginning),TTM based posts (later),Significantly decreased,"As can be seen in Figure 1, intervention engagement with TTM posts decreased over time in each of the seven Facebook groups (range of correlation coefficients from -.81 to -.55; all P&lt;.001) and the number of comments varied by group (F 6,505=29.7; P&lt;.001).",4704894
4294,4704894,Engagement in Precontemplation and Contemplation groups,TTM Decisional Balance posts,Other intervention content based on the TTM,Significantly increased,"In Precontemplation and Contemplation groups, Decisional Balance posts generated above average engagement (P=.01 and P&lt;.001).",4704894
4295,4704894,Engagement in Contemplation group,TTM posts Dramatic Relief and Self-Liberation,Other intervention content based on the TTM,Significantly decreased,"n Contemplation groups, posts based on the TTM processes Dramatic Relief and Self-Liberation resulted in below average engagement (P=.01 and P=.005).",4704894
4296,4704894,Engagement in Preparation group,TTM posts based on Consciousness Raising,Other intervention content based on the TTM,Significantly increased,"In Preparation groups, posts based on Consciousness Raising generated above average engagement (P=.009).",4704894
4297,4823408,"Laryngeal, pharyngeal and oral axes alignment",8 cm pillow during tracheal intubation,4 cm pillow during tracheal intubation,No significant difference,"The alignment of laryngeal, pharyngeal and oral axes were not different between the two degrees of head elevation.",4823408
4298,4823408,View of Larynx,8 cm pillow during tracheal intubation,4 cm pillow during tracheal intubation,No significant difference,There were no differences in the laryngeal view and success rate for tracheal intubation between the two groups.,4823408
4299,4823408,Tracheal intubation success rate,8 cm pillow during tracheal intubation,4 cm pillow during tracheal intubation,No significant difference,There were no differences in the laryngeal view and success rate for tracheal intubation between the two groups.,4823408
4300,4823408,Discomfort score for tracheal intubation,8 cm pillow during tracheal intubation,4 cm pillow during tracheal intubation,Significantly increased,The discomfort score during tracheal intubation was higher in the 8 cm group that was performed in sequence I (Table 2).,4823408
4301,165418,improvement in GHbA1c,paroxetine,placebo,Significantly increased,An improvement in GHbA1c was observed after only ten weeks of treatment with paroxetine.,165418
4302,165418,glycemic control,paroxetine,placebo,No significant difference,A trend towards a superior improvement in glycemic control was found in the paroxetine group (p = 0.08).,165418
4303,165418,Quality of life,paroxetine,placebo,No significant difference,no significant difference between groups in improvement of quality of life was found,165418
4304,165418,investigator-rated aspects of mental health,paroxetine,placebo,No significant difference,"The paroxetine-treated women showed improvements in investigator-rated aspects of mental health, but again statistical superiority when compared with the control group was not reached.",165418
4305,165418,Insulin sensitivity,paroxetine,placebo,Significantly increased,Paroxetine has a beneficial effect on measures of insulin sensitivity and may improve glycemic control.,165418
4306,3937058,"documentation for the previously given, â€˜historicalâ€™ vaccine doses",webinar consultations,in-person,Significantly increased,"more webinar clinics reported improving documentation of previously administered, â€˜historicalâ€™ vaccine doses.",3937058
4307,3937058,participantsâ€™ confidence for giving reminder/recalls,post-consultation,pre-consultation,Significantly increased,"On a five-point response scale, participantsâ€™ mean confidence in running reminder/recalls increased from 2.7 (SDâ€‰=â€‰1.5) at pre-consultation to 4.4 (SDâ€‰=â€‰0.8) at post-consultation (pâ€‰&lt;â€‰0.001).",3937058
4308,3937058,cost of intervention ,$99.95 for the webinar,$152.45 for the in-person,Significantly decreased,The intervention cost per clinic was $152.45 for the in-person condition and $99.95 for the webinar condition (Table&nbsp;3).,3937058
4309,3937058,confidence to use reminder/recall systems,webinar consultations,in-person,No significant difference,Both in-person and webinar clinics showed sustained improvement in confidence to use reminder/recall systems (both pâ€‰&lt;â€‰0.05).,3937058
